,compound_id,standard_inchi_key,compound_name,synonym,target_id,target_pref_name,gene_names,wildtype_or_mutant,mutation_info,pubmed_id,standard_type,standard_relation,standard_value,standard_units,activity_comment,ep_action_mode,assay_format,assaytype,assay_subtype,inhibitor_type,detection_tech,assay_cell_line,compound_concentration_value,compound_concentration_value_unit,substrate_type,substrate_relation,substrate_value,substrate_units,assay_description,title,journal,doc_type,annotation_comments,SMILES,pDTC_Value,base_rdkit_smiles
3,CHEMBL1232461,AAAQFGUYHFJNHI-SFHVURJKSA-N,GSK525762A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24015967.0,IC50,>=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,J. Med. Chem.,PUBLICATION,,CCNC(=O)C[C@H]1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C,4.481486060122112,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21
15,CHEMBL2158292,AADUJBXZMSDOOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)C4=CC=[N+](C=C4)[O-])NC(=O)C5=NC=C(N5)C#N,5.0,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)c4cc[n+]([O-])cc4)CC3)cc2C2=CCCCC2)[nH]1
56,CHEMBL1086377,AATCBLYHOUOCTO-UHFFFAOYSA-N,KU-0060648,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23855836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.",J. Med. Chem.,PUBLICATION,,CCN1CCN(CC1)CC(=O)NC2=C3C4=CC=CC=C4SC3=C(C=C2)C5=CC=CC6=C5OC(=CC6=O)N7CCOCC7,5.0,CCN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1
59,CHEMBL2017279,AAVAYKQPRIQKRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4N5CCOCC5)C(=O)N)OC,5.823908740944319,COc1cc2c(Nc3ccccc3N3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C
67,CHEMBL490153,ABACVOXFUHDKNZ-UHFFFAOYSA-N,A-867744,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19419141.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.,J. Med. Chem.,PUBLICATION,,CCC(=O)C1=C(N(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)S(=O)(=O)N)C,5.0,CCC(=O)c1cc(-c2ccc(Cl)cc2)n(-c2ccc(S(N)(=O)=O)cc2)c1C
75,CHEMBL1090526,ABDWUBPDHWDFCV-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CN=C3OC,5.0,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(F)ccc21
76,CHEMBL1090526,ABDWUBPDHWDFCV-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20800486.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CN=C3OC,5.0,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(F)ccc21
94,CHEMBL489094,ABKBSWVRNXDREE-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,5.309803919971486,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CCN1
95,CHEMBL489094,ABKBSWVRNXDREE-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,4.853871964321762,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CCN1
99,CHEMBL1097358,ABLYXLXBJMBVQN-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C,5.455931955649724,Cc1cc(N2CCN(C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
100,CHEMBL1097358,ABLYXLXBJMBVQN-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C,5.455931955649724,Cc1cc(N2CCN(C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
116,CHEMBL523752,ABOWEPDTQXMFNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC=CC(=C1CNC2=CC=CN3C2=NC(=C3C)C)C,5.327902142064283,CCc1cccc(C)c1CNc1cccn2c(C)c(C)nc12
117,CHEMBL523752,ABOWEPDTQXMFNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC=CC(=C1CNC2=CC=CN3C2=NC(=C3C)C)C,5.200659450546418,CCc1cccc(C)c1CNc1cccn2c(C)c(C)nc12
123,CHEMBL476568,ABQNMOMAPSGPLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccccc1
129,CHEMBL3114722,ABUAEJMNHRQEPP-NGCAANIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC[C@@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.853871964321762,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
130,CHEMBL3114713,ABUAEJMNHRQEPP-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.886056647693163,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
133,CHEMBL1215664,ABUNZHUAYBOXCN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,3210.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1C2=CC=C(C=C2)O)C(C3=CC=NC=C3)O,5.493494967595128,Oc1ccc(-c2ccc(C(O)c3ccncc3)cc2)cc1
147,CHEMBL1951338,ABZRQOXZIBNTTA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,47.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)C(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,7.327902142064283,CCN(CC)C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
465,CHEMBL3601377,ACBKFGPDANWBLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26105194.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)CN(C)C)C(=O)CN2C(=O)C=C(C=N2)OCC3=NC=C(C=C3)OC,4.7447274948966935,COc1ccc(COc2cnn(CC(=O)c3ccc(CN(C)C)cc3C)c(=O)c2)nc1
471,CHEMBL2029678,ACDVIHRBYWUYPZ-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in absence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,CC1=NSC(=C1)N2C=CC3=C(C2=O)N(N=N3)[C@@H](C)C4=CC5=CC(=CN=C5C=C4)OCCOC,5.823908740944319,COCCOc1cnc2ccc([C@H](C)n3nnc4ccn(-c5cc(C)ns5)c(=O)c43)cc2c1
472,CHEMBL2029678,ACDVIHRBYWUYPZ-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,CC1=NSC(=C1)N2C=CC3=C(C2=O)N(N=N3)[C@@H](C)C4=CC5=CC(=CN=C5C=C4)OCCOC,4.6777807052660805,COCCOc1cnc2ccc([C@H](C)n3nnc4ccn(-c5cc(C)ns5)c(=O)c43)cc2c1
474,CHEMBL208155,ACFQJABFUNOOOS-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,580.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)[C@H](C)[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3,6.236572006437063,CCN(CC)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
496,CHEMBL3359018,ACIYUYIAZNHVED-QKDCVEJESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25210858.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,PUBLICATION,,COC1=CC(=C(C=C1)NC(=O)N2C[C@H]3CC(C[C@H]3C2)C4=CC=CC=C4C(F)(F)F)C(=O)O,5.096910013008056,COc1ccc(NC(=O)N2C[C@H]3CC(c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)c1
520,CHEMBL2086754,ACSSIWPJCYCXGD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=C3C(=C4N=C5C=CC=CC5=N4)C6=CC=C(C=C6)C)O,4.920818753952375,CCN1CCC(Nc2ccc3[nH]c(O)c(C(=C4N=c5ccccc5=N4)c4ccc(C)cc4)c3c2)CC1
525,CHEMBL2018573,ACUYMTWKMROFBQ-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,C1[C@H](CN([C@@H]1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CN4N=CC=N4)CC5=CC=C(C=C5)F,4.698970004336019,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1nccn1
538,CHEMBL559531,ACXQPBJHXILGLA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC(=NO2)C3=CC=C(C=C3)C(=O)O)C(=O)NC4CC4C5=CC=CC=C5,5.0,O=C(O)c1ccc(-c2noc(C3CCN(C(=O)NC4CC4c4ccccc4)CC3)n2)cc1
539,CHEMBL1911822,ACYMETHQFZHOBR-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)C(=O)[C@@H](COCC2=CC(=NC=C2)Cl)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,4.958607314841775,CN1CCN(C(=O)[C@@H](COCc2ccnc(Cl)c2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
541,CHEMBL3699326,ACZMHYDTZOAQBH-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2420.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC=C(C=C8)N,5.616184634019569,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
542,CHEMBL1081693,ACZVADNXZFAFAJ-UIOOFZCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,274.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CO2)C[C@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CO4,6.562249437179612,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cnco1)C[C@H](Cc1ccccc1)NC(=O)OCc1ncco1
558,CHEMBL502,ADEBPBSSDYVVLD-UHFFFAOYSA-N,DONEPEZIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25499431.0,IC50,=,54680.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay,Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,4.262171494104216,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2
576,CHEMBL482233,ADGULOHTKSMBCP-PXAQALGRSA-N,"(8R,8'R,9'S)-5-METHOXYCLUSIN",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,830.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,COC1=CC(=CC2=C1OCO2)C[C@H]3CO[C@@H]([C@@H]3CC4=CC(=C(C(=C4)OC)OC)OC)O,6.080921907623926,COc1cc(C[C@H]2[C@@H](O)OC[C@@H]2Cc2cc(OC)c3c(c2)OCO3)cc(OC)c1OC
584,CHEMBL1669412,ADLLYWYUHVDQBH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C1)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,5.0,c1ccc2c(c1)CC(CCN1CCC1)=C2Cc1cnccn1
585,CHEMBL2004290,ADLPKFFMGIJZIM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 µL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 µg/mL) were incubated with 5 concentrations of test compound (from 0.1 µM to 10 µM), 1 mM NADPH (Sigma), and 2 µM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,CC(C)(CN1C=C(C=N1)C2=CN=C(C3=C2SC=C3C4=CC=C(C=C4)NC(=O)NC5=CC=C(C=C5)OC)N)O,5.0,COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1
586,CHEMBL3112601,ADMREWYBXXZUMI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24447850.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)OC)C2CCCC(=O)N2CC3=NC4=CC=CC=C4C=C3,4.522878745280337,COc1cccc(OC)c1C1CCCC(=O)N1Cc1ccc2ccccc2n1
594,CHEMBL115769,ADQZGIYHFQQPRB-UHFFFAOYSA-N,RWJ-68354,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,COC1=CC(=NC2=C1C(=C(N2)C3=CC=C(C=C3)F)C4=CC=NC=C4)N,6.0,COc1cc(N)nc2[nH]c(-c3ccc(F)cc3)c(-c3ccncc3)c12
600,CHEMBL1934523,ADRZQEOBUFIYAZ-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22172695.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of biaryl sulfone derivatives as antagonists of the histamine H3 receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCC2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)CCCOC,4.3979400086720375,COCCCS(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1
601,CHEMBL3417505,ADTARRIQWGUIIA-BULQSVBWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25827402.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,C[C@@H]1CCCN1C[C@H](C)COC2=CC=C(C=C2)C3=NNC(=O)C4C3C4,4.522878745280337,C[C@H](COc1ccc(C2=NNC(=O)C3CC23)cc1)CN1CCC[C@H]1C
608,CHEMBL3673982,ADVBAMJDBQBHCU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320658,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=C(C=C(C=N1)F)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)C#N)F,5.0,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C#N)cc23)c(F)n1
609,CHEMBL3673982,ADVBAMJDBQBHCU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320701,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=C(C=C(C=N1)F)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)C#N)F,5.0,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C#N)cc23)c(F)n1
614,CHEMBL2022571,ADYPGEBADRLHCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NN1)C(=O)O)CC2=CC3=CC=CC=C3S2,5.0,Cc1[nH]nc(C(=O)O)c1Cc1cc2ccccc2s1
620,CHEMBL3218856,ADYZVNMLQOHYDE-BAYWULLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,14200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,COC1=C(C=CC(=C1)N2CCC(CC2)N3CCOCC3)C4=NC5=NC=C(C(=C5N4)N[C@@H]6[C@@H]7C[C@H]([C@@H]6C(=O)N)C=C7)Cl,4.847711655616943,COc1cc(N2CCC(N3CCOCC3)CC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
621,CHEMBL3218856,ADYZVNMLQOHYDE-BAYWULLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,COC1=C(C=CC(=C1)N2CCC(CC2)N3CCOCC3)C4=NC5=NC=C(C(=C5N4)N[C@@H]6[C@@H]7C[C@H]([C@@H]6C(=O)N)C=C7)Cl,4.522878745280337,COc1cc(N2CCC(N3CCOCC3)CC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
634,CHEMBL241064,AEBNQBMNALVGPB-LJQANCHMSA-N,SR-706,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)[C@@H](C4=CC=CC=C4)O,6.0,O=C([C@H](O)c1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
637,CHEMBL1951321,AEEXIWXDMCZBGH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=C3C(=NC=C2)N=CN3)NC(=O)NC4=CC=C(C=C4)Br,6.6777807052660805,O=C(Nc1ccc(Br)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
638,CHEMBL2041182,AEFKPNYWNAAZGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=NC(=C4)C)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,Cc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
641,CHEMBL3235265,AEIYXQGHBFFFPX-CTNGQTDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24630562.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CC[C@H](CN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C#CC4=CC=CC(=C4)CO,5.3979400086720375,Cc1ccc(-n2nccn2)c(C(=O)N2C[C@H](C#Cc3cccc(CO)c3)CC[C@H]2C)c1
647,CHEMBL570403,AELBOLRAJBHJSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C2CN(CCC2=C1)C(=O)C34CC5CC(C3)CC(C5)(C4)C6=CC=C(C=C6)OCC(=O)NC7=CC=CC(=C7)C#N)OC,5.301029995663981,COc1cc2c(cc1OC)CN(C(=O)C13CC4CC(C1)CC(c1ccc(OCC(=O)Nc5cccc(C#N)c5)cc1)(C4)C3)CC2
659,CHEMBL231509,AENCTNCRKXVXOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=O)N(C)C,5.657577319177793,Cc1cc(C(=O)N(C)C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
663,CHEMBL468551,AEOBYHAZFRJFPZ-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,230.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)N)C4=C(C(=CC=C4)OC)F,6.638272163982407,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F
678,CHEMBL561788,AEUILRDAXLSTHQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC(=NO2)C3=CC=CC=C3C(F)(F)F)C(=O)NC4CC4C5=CC=CC=C5,5.0,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccc3C(F)(F)F)no2)CC1
680,CHEMBL2010872,AEULIVPVIDOLIN-UHFFFAOYSA-N,CEP-11981,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22148921.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.",J. Med. Chem.,PUBLICATION,,CC(C)CN1C2=C(C=C(C=C2)NC3=NC=CC=N3)C4=C1C5=C(C6=CN(N=C6CC5)C)C7=C4CNC7=O,4.522878745280337,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
704,CHEMBL252817,AFANGSZMNLRLKU-SJLPKXTDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,16900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NOC(=N4)C,4.772113295386326,CC[C@@H]1CCC[C@H](C2(Cc3noc(C)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
728,CHEMBL412023,AFKWCSONBYVREL-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)[C@H](CC(C)C)NC(=O)CNC,5.443697499232713,CNCC(=O)N[C@@H](CC(C)C)c1cc(C)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
729,CHEMBL2057787,AFLLEMMCAWXUGY-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,38.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C#CCNC1=NC2=C(O1)C=C(C=C2)C(=O)N(CC#C)C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,7.42021640338319,C#CCNc1nc2ccc(C(=O)N(CC#C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
730,CHEMBL269915,AFNDEYWFNPXTKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=CC=N5,4.886056647693163,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccccn5)cccc4c3)c2cc1OC
738,CHEMBL1221,AFNXATANNDIXLG-UHFFFAOYSA-N,SULCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,70.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,7.154901959985743,Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
746,CHEMBL3422082,AFPQNJFINOFINI-BTOOTBGFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,240.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1CC1[C@H](C2=CC=CC=C2F)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6COC7,6.619788758288394,O=C(N[C@@H](c1ccccc1F)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
747,CHEMBL3358923,AFQIBZSGVWHLSI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=C(N2)C=NC(=C3)C)(C(F)(F)F)O,6.221848749616356,Cc1cc2cc(CC(O)(CC(C)(C)c3cc(F)ccc3C)C(F)(F)F)[nH]c2cn1
758,CHEMBL2059116,AFUJORLTHMNOKI-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CN=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=CS4,7.045757490560675,CC(C)CN(C[C@@H](O)[C@H](Cc1cccnc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncsc2c1
760,CHEMBL1643880,AFUWQWYPPZFWCO-LBPRGKRZSA-N,PUMOSETRAG,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21146988.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@H](C2)NC(=O)C3=CNC4=C(C3=O)SC=C4,5.031517051446065,O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O
765,CHEMBL2069579,AFWNZGMHIZENTJ-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22884988.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@@H](C(=O)NC2=CC(=CC(=C2)C(=O)O)C3=CC=NC=C3)NCC4=CSC=N4,4.522878745280337,O=C(O)c1cc(NC(=O)[C@H](Cc2ccccc2)NCc2cscn2)cc(-c2ccncc2)c1
766,CHEMBL496469,AFXBTOVGCMXHEH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,3386.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC(C2=C(C1)C=C(C=C2)C3=CC(=C(C=C3)O)F)C4=CC=NC=C4.Br,5.4703130462270835,Oc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1F
791,CHEMBL2440638,AGDUASOAFRXTRF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=CC=C1)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CC(=CN=C3)F,6.154901959985743,Cc1cccc(NC(=O)c2cc(Cl)cc(Oc3cncc(F)c3)c2)n1
794,CHEMBL3298906,AGELGZUNOBHRLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)F,4.3979400086720375,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(F)cc3)CC2)cc1
795,CHEMBL391915,AGENZPFZMBQUPS-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,640.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN[C@@H](CC(C)C)C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O,6.1938200260161125,CCN[C@@H](CC(C)C)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
803,CHEMBL25731,AGHKIFOPIORNFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,53810.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CNC1=NC=CC2=C1C3=C(N2C)C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,4.269137007953506,CNc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C
813,CHEMBL563732,AGJNHDXJGSWJRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1N2C=NC=N2)C(=O)NC3CC3C4=CC=CC=C4,5.0,O=C(NC1CC1c1ccccc1)N1CCC(n2cncn2)CC1
818,CHEMBL2207386,AGKMPGSBLMAGAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23141912.0,IC50,=,35970.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH,"Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N(1)-arylsulfonyl indole derivatives as 5-HT(6) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)CC2=C3C=CN(C3=CC=C2)S(=O)(=O)C4=CC=CC=C4Br,4.444059562181489,CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2Br)CC1
822,CHEMBL429420,AGKSAEJJQWDEES-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)CC(=O)NC2=CC(=NC(=N2)C3=CC=CC=N3)N4C(=CC(=N4)C)C)C,5.0,Cc1cc(C)cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)c1
829,CHEMBL2069921,AGMZWJCXRAGFQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1CC2=CC=CC=C2)CC3=NC(=NO3)C4=CC=CC=C4,4.698970004336019,c1ccc(CN2CCN(Cc3nc(-c4ccccc4)no3)CC2)cc1
850,CHEMBL470049,AGQLGMXLTFMOAP-OEHKQELHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,90000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)O)OC(=O)C,4.045757490560675,CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H]1O
851,CHEMBL514198,AGQQFHRGGSZZEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,COc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccc(OC)cc2)cc1
865,CHEMBL238763,AGVLKBKXJWTFQT-IBGZPJMESA-N,SR-1450,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)[C@H](C4=CC=CC=C4)N,6.346787486224656,N[C@H](C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccccc1
870,CHEMBL605410,AGYJPEBXFSGBHP-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OC[C@H](CC5=C(NC6=CC=CC=C65)C#N)N,5.795880017344075,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C#N)[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2n1
874,CHEMBL401418,AGZBTOKWUUPEBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17937987.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and structure-activity relationships of thieno[2,3-b]pyrroles as antagonists of the GnRH receptor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)C2=C(C3=C(N2)SC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)CCN6CCN(CC6)CC(CN7CCNCC7)O)C,5.0,Cc1cc(C)cc(-c2[nH]c3sc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2CCN2CCN(CC(O)CN3CCNCC3)CC2)c1
884,CHEMBL1951344,AHEOXHOZNNFHHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,560.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)NC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C=CNC4=NC=N3,6.251811972993799,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]ccc34)cc2)c1
894,CHEMBL3298322,AHHGHXFTQVZBPO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24835202.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C2C(=C1)C=CN=C2OC3=CC=C(C=C3)F)OC,5.721246399047171,COc1cc2ccnc(Oc3ccc(F)cc3)c2cc1OC
930,CHEMBL450610,AHPTUXAIRHFFGA-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,2.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)OCCOC,8.619788758288394,COCCOC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
931,CHEMBL240391,AHPZPEPKIIZAJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,1670.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)CO)(C)C4=CC(=CC(=C4)F)F,5.777283528852417,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)CO)C(=O)C(C)(c1cc(F)cc(F)c1)O2
932,CHEMBL2419495,AHQASDPCJPXGHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=C(C=C(C=C3)F)F)C,5.853871964321762,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3F)CC2)nc1C
943,CHEMBL3673971,AHSCWWTXGYZDOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320641,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CC(=C(N=C4)OC)F)N=C1,5.301029995663981,COc1ncc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cc1F
944,CHEMBL3673971,AHSCWWTXGYZDOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320685,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CC(=C(N=C4)OC)F)N=C1,5.0,COc1ncc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cc1F
960,CHEMBL3353357,AHXHWEURVLCQAX-MDTIIALHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1)NC(=O)[C@@]23C[C@H]3C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=C(C=C6)CN7CCOCC7,5.522878745280337,Cc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2
961,CHEMBL3353357,AHXHWEURVLCQAX-MDTIIALHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,6200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1)NC(=O)[C@@]23C[C@H]3C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=C(C=C6)CN7CCOCC7,5.2076083105017466,Cc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2
967,CHEMBL258046,AIAKFZWQGGMPFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)OC4CCNCC4)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,5.301029995663981,CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
968,CHEMBL258046,AIAKFZWQGGMPFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)OC4CCNCC4)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,5.301029995663981,CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
969,CHEMBL258046,AIAKFZWQGGMPFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)OC4CCNCC4)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,5.0,CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
971,CHEMBL273208,AIBJZSMLYKTKIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18313294.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C=N1)CNC)OC2=CC=CC=C2OC3=CC=CC=C3,5.522878745280337,CNCc1cnc(C)cc1Oc1ccccc1Oc1ccccc1
972,CHEMBL551964,AIBSVCNXTNBLRF-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19719241.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C3=C(C=C2)OC[C@@H](O3)CN4CCN(CC4)C5=NC6=C(C=C5)C=C(C=C6)C#N,5.0,Cc1ccc2c3c(ccc2n1)OC[C@H](CN1CCN(c2ccc4cc(C#N)ccc4n2)CC1)O3
976,CHEMBL3137483,AICSYLICMPMSRW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C(C4=CC=CC=C4)C(F)(F)F,4.698970004336019,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(C(c3ccccc3)C(F)(F)F)CC2)cc1
990,CHEMBL1090186,AIGMIQVSRPRWAQ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(CC2=C1C=CC(=C2)OC)CCN(C)C)C3=NC=CN=C3OC,5.0,COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccnc1OC
1007,CHEMBL3326587,AILCSHZLWQQZEZ-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4)F)(CF)CF)C=N1,4.698970004336019,Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4cc(F)ccc43)cccc2cn1
1011,CHEMBL3682505,AIOINVRWUCXVAK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,60000.0,NM,291610,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",Metalloenzyme inhibitor compounds,,PATENT,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC(F)(F)F)N3N=CN=N3,4.221848749616356,CC(C)C(c1ccc2cc(OCC(F)(F)F)ccc2c1)n1ncnn1
1012,CHEMBL2448692,AIOKORCUJNJGMS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,700.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1=CC2=C(C=CC(=C2)Br)C=C1OCC(CN3C=CN=C3)O.Cl,6.154901959985743,OC(COc1ccc2cc(Br)ccc2c1)Cn1ccnc1
1055,CHEMBL395942,AJJCOMDYWQVLKY-JTQLQIEISA-N,SR-705,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C(=O)N1CCC(CC1)NC2=CC3=C(C=C2)NN=C3)O,6.0,C[C@H](O)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
1085,CHEMBL2041184,AJOUEHBWWNCZHX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC(=NC=C4)C)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,Cc1nccc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)n1
1094,CHEMBL3403826,AJQNILVHTMISRW-KYLTZZOSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)CC(C)(C)O)C)C)O)C)C(C)(C)O,4.958607314841775,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
1095,CHEMBL3403826,AJQNILVHTMISRW-KYLTZZOSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)CC(C)(C)O)C)C)O)C)C(C)(C)O,4.853871964321762,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
1108,CHEMBL1258754,AJUFRGDVXUPOOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCNC(=O)C4=C3,4.301029995663981,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCNC2=O)CC1
1117,CHEMBL518591,AKBRLFXEFQHICT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC2=C(CC1)C=C3C(=C2)C=CN3S(=O)(=O)C4=CC(=CC=C4)Cl,4.823908740944319,CN1CCc2cc3ccn(S(=O)(=O)c4cccc(Cl)c4)c3cc2CC1
1118,CHEMBL518591,AKBRLFXEFQHICT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,71000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC2=C(CC1)C=C3C(=C2)C=CN3S(=O)(=O)C4=CC(=CC=C4)Cl,4.1487416512809245,CN1CCc2cc3ccn(S(=O)(=O)c4cccc(Cl)c4)c3cc2CC1
1130,CHEMBL2059114,AKIPCTAHXSDOJW-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,19.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(S4)N,7.721246399047171,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N)sc2c1
1131,CHEMBL230308,AKIQDXURYNYZSE-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)N[C@@H](CC4=CC=CC=C4)CO)C5=CC=C(C=C5)F,5.200659450546418,Cc1cc(-c2ccc(F)cc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12
1135,CHEMBL2207503,AKJBLKUZXRMECW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23043539.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 by LC-MS-MS analysis,"Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia.",J. Med. Chem.,PUBLICATION,,CC1=NN(C=C1C2=NC3=NC=C(C(=C3N2)N4CCN(CC4)CC5=CC=C(C=C5)Cl)Cl)C,5.0,Cc1nn(C)cc1-c1nc2ncc(Cl)c(N3CCN(Cc4ccc(Cl)cc4)CC3)c2[nH]1
1151,CHEMBL399045,AKKGFQRBBVGLEB-KRXBUXKQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17869105.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1CN2CCC(CC2)C3=CC=C(C=C3)Cl)C(=O)/C=C/C4=CC(=C(C=C4)Cl)Cl,4.3979400086720375,O=C(/C=C/c1ccc(Cl)c(Cl)c1)N1CCC(CN2CCC(c3ccc(Cl)cc3)CC2)CC1
1156,CHEMBL1642413,AKLPJZCEMGVEQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21134749.0,IC50,=,4770.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Indole-3-piperazinyl derivatives: novel chemical class of 5-HT(6) receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=C(C=C4)F,5.321481620959886,CN1CCN(c2cn(S(=O)(=O)c3ccc(F)cc3)c3ccccc23)CC1
1190,CHEMBL398773,AKVYSQCDHUSFGD-FYYLOGMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCC1(CCN(CC1)C(=O)CC2(CC2)[C@H]3CCC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)CC)O,5.301029995663981,CCCC1(O)CCN(C(=O)CC2([C@H]3CCC[C@@H](CC)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
1192,CHEMBL2380649,AKWMGLFHWVBCBK-YUIFXIQYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1S(=O)(=O)N2CCN(CC2)C3=CN=C(C=C3)N4CCN(C5=CC=CC=C54)C(=O)NC6C7CC8CC6CC(C8)(C7)C(=O)N,4.522878745280337,NC(=O)C12CC3CC(C1)C(NC(=O)N1CCN(c4ccc(N5CCN(S(=O)(=O)C6CC6)CC5)cn4)c4ccccc41)C(C3)C2
1201,CHEMBL1258755,AKYDPJMTCVQONP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCCNC(=O)C4=C3,4.301029995663981,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCCNC2=O)CC1
1227,CHEMBL1078353,ALFVRYXSTFHIKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NCCCC2=CN=CC=C2)C3=CC=CC=C3,5.0,CC1(c2ccccc2)CCCN(C(=O)NCCCc2cccnc2)C1
1240,CHEMBL452298,ALINQGUROWXGAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC(=O)N(C)C(CN1CCOCC1)C2=CC=C(C=C2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,5.6777807052660805,CN(CC(=O)N(C)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1)c1ccc(Cl)c(Cl)c1
1266,CHEMBL2017284,ALRNRROHBGTUFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C5=CC=CC=C5OC(F)(F)F)OC,5.698970004336019,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3OC(F)(F)F)c12
1274,CHEMBL3604137,ALTKPBXHCBSGOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26037322.0,IC50,>,10000.0,NM,Not Active,,,,,,,,,,,,,,Inhibition of human CYP3A4,3-Substituted pyrazoles and 4-substituted triazoles as inhibitors of human 15-lipoxygenase-1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC=C1F)NC(=O)C2=CC=NN2,5.0,O=C(Nc1ccc(F)cn1)c1ccn[nH]1
1277,CHEMBL3699321,ALUBYALCOZFVQB-QCDYIZFSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CN=C(C=C8)N9CCOCC9,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCOCC7)nc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
1285,CHEMBL3403819,ALWXLBHHPZBMRA-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)CCOC)C)C)O)C)C(C)(C)O,5.568636235841013,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
1286,CHEMBL3403819,ALWXLBHHPZBMRA-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)CCOC)C)C)O)C)C(C)(C)O,5.275724130399211,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
1292,CHEMBL3605277,AMAVJINBCBZRCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26183084.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CC2=C1N=C(O2)COC3=CC(=CC=C3)F)C(=O)C4=CC=C(C=C4)F,4.522878745280337,O=C(c1ccc(F)cc1)N1CCc2nc(COc3cccc(F)c3)oc2C1
1307,CHEMBL3331484,AMGZVHXDDMROJU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=CC(=C(C=C2)Cl)Cl)C3CNC3,6.301029995663981,Clc1ccc(CN(C2CC2)C2CNC2)cc1Cl
1313,CHEMBL231610,AMKPHWUXNDGLHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=O)NC5CCCCC5,4.958607314841775,Cc1cc(C(=O)NC2CCCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
1332,CHEMBL2165175,AMPOIPUWOSOMBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23010262.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of phosphoinositide 3-kinases (PI3K) p110ß isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CC(=C1)C2=CC(=O)NC(=N2)NCC3=CC=CC4=CC=CC=C43,6.154901959985743,Cc1cc(-c2cc(=O)[nH]c(NCc3cccc4ccccc34)n2)ccn1
1336,CHEMBL1682898,AMRRJPLOMQHTQO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC1=C(C=CC2=C1C=CC(=C2)C(C3=CN=CN3)(C(C)C)O)C(=O)NC,5.0,CNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1C
1337,CHEMBL403809,AMSKTYLOKZVQRX-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,980.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1(C2=CC=CC=C2)N3C(=NC4=C3N=CC=C4)CNC(=O)[C@@H](CC5=C(C=CC(=C5F)F)F)NC(=O)C6(CC6)C(F)(F)F,6.008773924307505,O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1c(F)ccc(F)c1F)NC(=O)C1(C(F)(F)F)CC1
1356,CHEMBL3409860,AMVUFSYRJVKFEF-YJBOKZPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CO[C@H]1C[C@H](N(C1=O)CC2=CC=C(C=C2)OC(F)(F)F)C3=C(C=CC=C3OC)OC,5.853871964321762,COc1cccc(OC)c1[C@@H]1C[C@H](OC)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
1364,CHEMBL482126,ANBSWCCVJMJABF-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,4.1,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCOCC6,8.387216143280265,Cc1cc(N2CCC(N3CCOCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
1365,CHEMBL482126,ANBSWCCVJMJABF-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCOCC6,5.769551078621726,Cc1cc(N2CCC(N3CCOCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
1369,CHEMBL2386633,ANDWOIMHOOWCLK-IJLUTSLNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1C4CCC(CC4)C#N)C=CN3)O,5.102372908709558,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1C1CCC(C#N)CC1
1370,CHEMBL2386633,ANDWOIMHOOWCLK-IJLUTSLNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1C4CCC(CC4)C#N)C=CN3)O,5.0,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1C1CCC(C#N)CC1
1379,CHEMBL1631540,ANGUXJDGJCHGOG-UHFFFAOYSA-N,GSK163090,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21053897.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using atorvastatin as probe,"Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, Selective, and Orally Active 5-HT1A/B/D Receptor Antagonist.",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=CC(=CC=C4)N5CCNC5=O,4.6777807052660805,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1
1380,CHEMBL1631540,ANGUXJDGJCHGOG-UHFFFAOYSA-N,GSK163090,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21053897.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as probe,"Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, Selective, and Orally Active 5-HT1A/B/D Receptor Antagonist.",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=CC(=CC=C4)N5CCNC5=O,4.6777807052660805,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1
1381,CHEMBL1631540,ANGUXJDGJCHGOG-UHFFFAOYSA-N,GSK163090,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21053897.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as probe,"Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, Selective, and Orally Active 5-HT1A/B/D Receptor Antagonist.",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=CC(=CC=C4)N5CCNC5=O,4.6777807052660805,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1
1382,CHEMBL1631540,ANGUXJDGJCHGOG-UHFFFAOYSA-N,GSK163090,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21053897.0,IC50,=,67000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, Selective, and Orally Active 5-HT1A/B/D Receptor Antagonist.",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=CC(=CC=C4)N5CCNC5=O,4.173925197299173,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1
1397,CHEMBL1813459,ANOHHYWFJGBLHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21658961.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.",Bioorg. Med. Chem.,PUBLICATION,,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)C(C)C.Cl,5.031517051446065,CCCCN1C(=O)C(C(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
1400,CHEMBL1079246,ANRFQNJNXPRQGM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CNC(=O)CCC1(CCCN(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3,5.0,CNC(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
1406,CHEMBL1276654,ANTRYADYILUHOS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801551.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.",Eur. J. Med. Chem.,PUBLICATION,,C1CC2(CCN(CC2)C3=NN=C(C=C3)C4=NN=C(O4)CC5=CN=CC=C5)OC6=C1C(=CC=C6)F,5.795880017344075,Fc1cccc2c1CCC1(CCN(c3ccc(-c4nnc(Cc5cccnc5)o4)nn3)CC1)O2
1420,CHEMBL403313,ANXLTXNOZIKJSV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18308567.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)S(=O)(=O)NC(=O)CCCC1=C(NC2=C1C=C(C=C2)C#N)C3=CC=C(C=C3)F,5.301029995663981,CN(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12
1423,CHEMBL578578,ANYUTTCGGOBCGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=CC=C3N4CCCCC4,5.795880017344075,CC1(CC(=O)NCc2ccccc2N2CCCCC2)CC2(CCCCC2)OO1
1435,CHEMBL2336418,AOBPSENKFBJNAZ-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C2=C1NN=C2)Cl)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.795880017344075,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c(Cl)c2cn[nH]c12
1436,CHEMBL2336418,AOBPSENKFBJNAZ-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C2=C1NN=C2)Cl)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.455931955649724,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c(Cl)c2cn[nH]c12
1446,CHEMBL271581,AOEMSQHYYYHFRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CC1=CC(=CC(=N1)C)C(C)(C)NC(=O)C(C(C)(C)C)Br,4.886056647693163,Cc1cc(C(C)(C)NC(=O)C(Br)C(C)(C)C)cc(C)n1
1461,CHEMBL3601399,AOKBGTDCGVLICS-PGWXNWGFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26181851.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.,J. Med. Chem.,PUBLICATION,,CC(C)OC1=C(C=C2CC(=O)N([C@H](C2=C1)C3=CC=C(C=C3)Cl)C4=CN=C(C=C4)N(C)CC5CCC(CC5)N(C)C)OC,5.301029995663981,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)CC3CCC(N(C)C)CC3)nc1)C(=O)C2
1463,CHEMBL1209538,AOKRQCIWMGZDDW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598534.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,inhibition of CYP3A4,Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=CC(=NN2C(=C1CN)C3=C(C=C(C=C3)Cl)Cl)C4=CC=CC=C4,6.0,Cc1nc2cc(-c3ccccc3)nn2c(-c2ccc(Cl)cc2Cl)c1CN
1480,CHEMBL536754,AOOTYIRLUTVCBQ-PQQSRXGVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN1C(=O)[C@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)[C@@H](C5CCCCC5)O.Cl,4.522878745280337,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
1482,CHEMBL2419501,AOOWVFPXPVQQGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CC(C2)C(=O)NS(=O)(=O)CC3=CC=CC=C3)C,4.301029995663981,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccccc3)C2)nc1C
1488,CHEMBL2381076,AORYYSDWZJZQSQ-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535328.0,IC50,=,64000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=C(C=C1)C2=CC=CC=C2)C(=O)N3CC4(CC4)C[C@H]3CNC5=NC=C(C=C5)C(F)(F)F,4.1938200260161125,Cc1ccc(-c2ccccc2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)n1
1494,CHEMBL3310994,AOTCSTMPIJCZDF-APPDUMDISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,800.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=CN=C2)(C3=C(C=C(C=C3)F)F)O,6.096910013008056,C[C@@H](c1ncncc1F)[C@](O)(Cn1ccnc1)c1ccc(F)cc1F
1495,CHEMBL604087,AOTJVGQNGQYEAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by LCMS/MS assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NC3=CC4=C(CCNC4)C=C3)OC,4.522878745280337,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC
1501,CHEMBL1173087,AOUKQWFJPNRGAH-FGJGXXMFSA-N,"6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20527970.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,COC(CC=C)[C@@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,5.522878745280337,C=CCC(OC)[C@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
1504,CHEMBL2058906,AOVQXARIZDLJRY-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,22.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CC=C4)O)CC(C)C,7.657577319177793,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cccnc3)cc2o1
1516,CHEMBL225412,APBBPNOWHFPBMZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,38000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC(=C3)Cl)Cl,4.42021640338319,O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)cc(Cl)c2)nc1C(F)(F)F
1541,CHEMBL3622924,APIGRKGHKBCGNE-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26384287.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)NC2=NC=CC(=N2)N3C=C(C(=C3)CN4CC[C@H](C4)O)C)C,5.292429823902063,Cc1cc(C)cc(Nc2nccc(-n3cc(C)c(CN4CC[C@@H](O)C4)c3)n2)c1
1542,CHEMBL3664695,APIRJHBAONBUEP-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,21000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C(F)F)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.6777807052660805,C[C@@H](c1ccc(-c2ccc(=O)n(C(F)F)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
1561,CHEMBL2159139,APKMTGCPQZOYKW-FKRNFIPWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NCC)O4)C)(C)O)C)C)C)O)(C)O,5.102372908709558,CCN=C1O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C
1562,CHEMBL2159139,APKMTGCPQZOYKW-FKRNFIPWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NCC)O4)C)(C)O)C)C)C)O)(C)O,5.0,CCN=C1O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C
1568,CHEMBL1222865,APPCPYUGJBDNJO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,4.522878745280337,CN(C)CCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
1569,CHEMBL1682897,APPKRPXUNINZJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C(=C(C=C2)C(=O)NC)Cl)(C3=CN=CN3)O,5.0,CNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1Cl
1576,CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,5.522878745280337,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
1577,CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,5.301029995663981,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
1578,CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,5.096910013008056,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
1579,CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,4.6777807052660805,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
1580,CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,82000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,4.086186147616283,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
1581,CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,4.0,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
1582,CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,5.045757490560675,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
1583,CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,5.045757490560675,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
1586,CHEMBL470048,APRVHMRKRPHQLM-NDUFOHEISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,98300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)OC(=O)C)O,4.007446482167865,CC(=O)O[C@@H]1[C@@H](O)[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@@H]1O
1587,CHEMBL2420674,APSAUQSMWXXDST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,1759.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=C(C3=C(C=CC(=C3)O)C=C2)Cl,5.754734160542538,Oc1ccc2ccc(-c3cccnc3)c(Cl)c2c1
1599,CHEMBL208112,APVPAEUTGJXHOF-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,54.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(=O)OCCN1CCCC2=C1C=C(C=C2)OC[C@H]3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,7.267606240177032,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCOC(=O)C(C)C)CCC3)cc1
1605,CHEMBL3422237,APXCHRRPLFZFMP-IXBGWNDUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=NOC(=C1)[C@H]2C[C@H]3CSC(=N[C@]3(CO2)C4=C(C=C(C=C4)F)F)N,4.522878745280337,Cc1cc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1
1616,CHEMBL1257376,AQACZABFCRPMGE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCN(C(=O)C4=C3)CC5=CC=C(C=C5)F,4.301029995663981,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(Cc3ccc(F)cc3)C2=O)CC1
1636,CHEMBL212084,AQFXVMZZFFFSCG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16759855.0,IC50,=,254.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,"1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=C(C=C(C=C2)CN3C=CN=C3)C4=C1C(=NN4)C5=CSC=C5,6.5951662833800615,c1cn(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)cn1
1648,CHEMBL27,AQHHHDLHHXJYJD-UHFFFAOYSA-N,PROPRANOLOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26565745.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by LC-MS analysis,Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.,J. Med. Chem.,PUBLICATION,,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,5.0,CC(C)NCC(O)COc1cccc2ccccc12
1656,CHEMBL1269597,AQHMBDAHQGYLIU-XNFHFXFQSA-N,SCY-635,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19933795.0,IC50,=,58500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 30 mins,"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.",Antimicrob. Agents Chemother.,PUBLICATION,,CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)(C)O)C)SCCN(C)C)C,4.23284413391782,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](SCCN(C)C)C(=O)N(C)[C@@H](CC(C)(C)O)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
1657,CHEMBL1801238,AQIOMPMNFDEIJO-FICVDOATSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21080647.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2[C@@H](C2NCC3=CC=C(C=C3)Cl)CN1C4=NC=C(C=N4)C(=O)NO,4.301029995663981,O=C(NO)c1cnc(N2C[C@H]3C(NCc4ccc(Cl)cc4)[C@H]3C2)nc1
1659,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,CC1=C(N=CN1)CSCCNC(=NC)NC#N,5.0,CN=C(NC#N)NCCSCc1nc[nH]c1C
1660,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CC1=C(N=CN1)CSCCNC(=NC)NC#N,5.0,CN=C(NC#N)NCCSCc1nc[nH]c1C
1661,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC1=C(N=CN1)CSCCNC(=NC)NC#N,4.823908740944319,CN=C(NC#N)NCCSCc1nc[nH]c1C
1662,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,1000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC1=C(N=CN1)CSCCNC(=NC)NC#N,3.0,CN=C(NC#N)NCCSCc1nc[nH]c1C
1675,CHEMBL595459,AQJWACKPYCXBCF-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C=C(N=CC2=NN1)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OC[C@H](CC5=CNC6=CC=CC=C65)N,5.886056647693163,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cc2c(C)[nH]nc2cn1
1684,CHEMBL3393476,AQQRFOITUMWTQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=CC(=C(C=C6N5)F)F,5.075720713938118,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cc(F)c(F)cc3[nH]2)o1
1697,CHEMBL332643,AQWHKMMTMUZLNF-YSBVTMKBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 with midazolam (4-OH),Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)CCCN1C(=O)C2=CC3=CC=CC=C3N(C2=NC1=O)CCCCOC(=O)C[C@@H]4CC5C6CC[C@@H](C6CCC5[C@@]7(C4=CC(=O)CC7)C)O,6.0,CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O
1698,CHEMBL332643,AQWHKMMTMUZLNF-YSBVTMKBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 with midazolam (1'-OH),Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)CCCN1C(=O)C2=CC3=CC=CC=C3N(C2=NC1=O)CCCCOC(=O)C[C@@H]4CC5C6CC[C@@H](C6CCC5[C@@]7(C4=CC(=O)CC7)C)O,5.958607314841775,CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O
1699,CHEMBL332643,AQWHKMMTMUZLNF-YSBVTMKBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 with testosterone,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)CCCN1C(=O)C2=CC3=CC=CC=C3N(C2=NC1=O)CCCCOC(=O)C[C@@H]4CC5C6CC[C@@H](C6CCC5[C@@]7(C4=CC(=O)CC7)C)O,5.6020599913279625,CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O
1700,CHEMBL332643,AQWHKMMTMUZLNF-YSBVTMKBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,4100.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 with nifedipine,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)CCCN1C(=O)C2=CC3=CC=CC=C3N(C2=NC1=O)CCCCOC(=O)C[C@@H]4CC5C6CC[C@@H](C6CCC5[C@@]7(C4=CC(=O)CC7)C)O,5.3872161432802645,CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O
1703,CHEMBL402071,AQXGGRVGXYPDQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NN1C2=NC(=NC(=C2)NC(=O)CC3=CC=C(C=C3)OC)C4=CC=CC=N4)C,5.7447274948966935,COc1ccc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc1
1708,CHEMBL481233,AQZHZTTUVYQMIN-UHFFFAOYSA-N,"2,4,5-TRIMETHOXYPHENYLACETONE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,28700.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,CC(=O)CC1=CC(=C(C=C1OC)OC)OC,4.542118103266008,COc1cc(OC)c(OC)cc1CC(C)=O
1710,CHEMBL2043169,ARCCMXIHDKFBOJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC(=CC=C6)C(=O)O,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4cccc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
1714,CHEMBL506338,ARERDXBHAZDIGD-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NC)C4=C(C(=CC=C4)OCCOCC(=O)O)F,5.0,CN[C@@H](Cn1c(=O)c(-c2cccc(OCCOCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
1724,CHEMBL479085,ARHIKEBQUQQYQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)C(C2=CC=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,Cc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)cc1
1726,CHEMBL2036958,ARJKMWXLIHZLQZ-UHFFFAOYSA-N,SCH-900271,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CC1(CC1)CCCC2=CC(=O)OC3=C2C(=O)NC(=O)N3,4.301029995663981,CC1(CCCc2cc(=O)oc3[nH]c(=O)[nH]c(=O)c23)CC1
1728,CHEMBL1209625,ARJPLPHVQBNIKZ-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C)C,7.167491087293763,CC(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O
1729,CHEMBL1209625,ARJPLPHVQBNIKZ-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C)C,7.167491087293763,CC(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O
1730,CHEMBL1209626,ARJPLPHVQBNIKZ-FWJOYPJLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C)C,7.167491087293763,CC(C)CC1n2cncc2CN([C@H](C)c2ccc(Cl)cc2)S1(=O)=O
1734,CHEMBL605744,ARKYOPPYXOUDRK-REPLKXPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CN1C[C@H]2CC(C[C@H]2C1)N(CC3=CC(=CC=C3)OC(F)(F)F)C(=O)C4=CN(C=N4)C)O,5.0,Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)C2C[C@@H]3CN(CC(C)(C)O)C[C@@H]3C2)c1
1760,CHEMBL562551,ARYUXFNGXHNNDM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21966889.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)NC(=O)C2=CC=CC=N2)Cl,4.522878745280337,COc1cc(NC(=O)c2ccccn2)ccc1Cl
1765,CHEMBL3400450,ASBKGVWWADMSIU-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NC(=O)OCC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,5.1938200260161125,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCc2ccccc2)C(C)C)ccc1OC
1766,CHEMBL3400450,ASBKGVWWADMSIU-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,14800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NC(=O)OCC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,4.8297382846050425,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCc2ccccc2)C(C)C)ccc1OC
1801,CHEMBL1916399,ASJOLIPQCOYRPT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21852130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C2=C1C=C(C=C2)C3=NOC(=N3)C4=CC(=CC(=C4)C#N)OC(F)(F)F)C(=O)CCC(=O)O,4.301029995663981,N#Cc1cc(OC(F)(F)F)cc(-c2nc(-c3ccc4c(c3)CCN4C(=O)CCC(=O)O)no2)c1
1815,CHEMBL2070161,ASOXHYLKWBYUGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)N2C=C(C=CC2=O)C3=NC4=C(N3)C=C(C=C4)S(=O)(=O)CC(F)(F)F,4.698970004336019,O=c1ccc(-c2nc3ccc(S(=O)(=O)CC(F)(F)F)cc3[nH]2)cn1-c1ccccc1
1823,CHEMBL1208963,ASTXNDZZOAPTNR-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NCCO)C(=O)N,5.431798275933005,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCO)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
1830,CHEMBL2019022,ASVPNBDOVHTUEM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,4010.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=CC=N3,5.396855627379818,COc1ccc2nc(SCc3ccccn3)[nH]c2c1
1844,CHEMBL3702714,ASYDBVRDAOJREX-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10700.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)O,4.97061622231479,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
1846,CHEMBL2437432,ASYPSYLJDLVBFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)C5=NC=CC=N5)CC6=CC(=NC=C6)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ncccn5)c5cc(F)ccc54)CC3)CC2)ccn1
1850,CHEMBL1471,ATALOFNDEOCMKK-OITMNORJSA-N,APREPITANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,46.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,7.337242168318426,C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
1872,CHEMBL504492,ATHBTCOFQCXOFU-DDKZQSMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19447613.0,IC50,>=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@H]2[C@@H]3[C@H]4C5=NC(=CS5)C(=O)N[C@@H](COC(=O)C6=C(CO3)C7=C(COC2=O)C=CC=C7N6O)C8=NC(=CS8)C9=NC(=C(C=C9C1=NC(=CS1)C(=O)N[C@H](C(=O)N/C(=C(\C)/OC)/C1=NC(=CS1)C(=O)N4)[C@@H](C)O)OC)C1=NC(=CS1)C(=O)NCCCN1CCOCC1)(C)O)N(C)C,4.0,CO/C(C)=C1/NC(=O)[C@H]([C@@H](C)O)NC(=O)c2csc(n2)-c2cc(OC)c(-c3nc(C(=O)NCCCN4CCOCC4)cs3)nc2-c2csc(n2)[C@@H]2COC(=O)c3c4c5c(cccc5n3O)COC(=O)[C@@H](O[C@H]3C[C@](C)(O)[C@H](N(C)C)[C@H](C)O3)[C@@H](OC4)[C@H](NC(=O)c3csc1n3)c1nc(cs1)C(=O)N2
1875,CHEMBL1210646,ATIUDCBCVSICHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594839.0,IC50,=,9620.0,NM,,,,,,,,,,,,,,,Inhibition of human CY3A4,Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT(6) receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=C(C=C(C=C1)S(=O)(=O)NC2=CC=CC=C2Br)NC3CCN(CC3)C,5.016824927962187,CCc1ccc(S(=O)(=O)Nc2ccccc2Br)cc1NC1CCN(C)CC1
1879,CHEMBL151646,ATLLIISCQQKAQI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,29300.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CN=CC=C2,4.533132379645891,CCCCOc1ccc(-c2cccnc2)cc1
1884,CHEMBL2409007,ATOKVTDUHKZLMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CCOCC1=C(C=NN1C2=NC=C(C(=N2)N3CCCCC3)C)C(=O)NCC4=CN=CN4C,6.0,CCOCc1c(C(=O)NCc2cncn2C)cnn1-c1ncc(C)c(N2CCCCC2)n1
1888,CHEMBL3702678,ATQBQXJFNKVZEY-YATWDLPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7800.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8CCCC8,5.107905397309519,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
1895,CHEMBL180592,ATRBKKFCGWCOAE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,344.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)[N+](=O)[O-])N4C=CN=C4)N(C)C,6.46344155742847,CC(C(c1ccc2cc(OCc3ccc([N+](=O)[O-])cc3)ccc2c1)n1ccnc1)N(C)C
1897,CHEMBL3699342,ATRYSYOKKNIJSL-MVRBIKRMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2260.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCN(CC)CC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.645891560852599,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(CN(CC)CC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
1900,CHEMBL208158,ATTJXWVUQQZVGI-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,2150.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]([C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N4CCOCC4,5.667561540084395,C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N1CCOCC1
1908,CHEMBL1095678,AUCPKYPLGAVYAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOCCN1C2=CC=CC=C2N=C1C3CCCN(C3)C4CCCCC4,5.301029995663981,CCOCCn1c(C2CCCN(C3CCCCC3)C2)nc2ccccc21
1909,CHEMBL2436210,AUCPUCVXSILLHO-QDMMYLPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)CC5=CN=CC=C5)NC.Cl,5.552841968657781,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)Cc2cccnc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
1913,CHEMBL3114735,AUEWZJYNVLYDFR-PPTMTGTBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(CC[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)C(=O)[C@H](CCN3CCOCC3)NC(=O)N(C)CC4=CSC(=N4)C(C)C,6.568636235841013,CC(C)CN(CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)[C@H](CCN1CCOCC1)NC(=O)N(C)Cc1csc(C(C)C)n1
1917,CHEMBL3358954,AUIFRJWXYUNPPV-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=NC=C2C(=C1)C=C(N2)C[C@](CC(C)(C)C3=C(C=C(C=C3)F)C(=O)N)(C(F)(F)F)O,5.096910013008056,CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1
1918,CHEMBL3358950,AUIFRJWXYUNPPV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=NC=C2C(=C1)C=C(N2)CC(CC(C)(C)C3=C(C=C(C=C3)F)C(=O)N)(C(F)(F)F)O,4.585026652029182,CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1
1921,CHEMBL2436616,AUKNZSATOILHNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2CC3=CC=CC=C3CC4=CC=CC=C42)C(=O)C5(CCN(CC5)CC6=CC(=NC=C6)N)F,4.7447274948966935,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5Cc5ccccc54)CC3)CC2)ccn1
1927,CHEMBL1950743,AUNMHWAGSWQKHU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22290075.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC(=NNC1=O)C2=CC=C(C=C2)OC3CCN(CC3)C4CCC4)C,4.522878745280337,CC1(C)CC(c2ccc(OC3CCN(C4CCC4)CC3)cc2)=NNC1=O
1935,CHEMBL3115190,AUQCZFYQJFJHES-HEWUYBSCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=CN=CS2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,7.096910013008056,O=C(N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)N(Cc1cncs1)C1CC1)Cc1ccccc1)OCc1cncs1
1936,CHEMBL3115170,AUQCZFYQJFJHES-JFPMUIDKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=CN=CS2)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.920818753952375,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)N(Cc1cncs1)C1CC1)Cc1ccccc1)OCc1cncs1
1959,CHEMBL2347337,AUTURIRJHQDRSI-ZEQRLZLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23466233.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)CO)NC(=O)OC,5.161150909262744,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(CO)cc3)cc2)[nH]1)C(C)C
1961,CHEMBL3287188,AUUYAKJPRWOIHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24899257.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 2 to 45 mins by LC-MS/MS analysis,Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=C(C=NC=C1)C2=CC3=C(C=C2)N(CC3)C(=O)C,4.301029995663981,CC(=O)N1CCc2cc(-c3cnccc3C)ccc21
1999,CHEMBL438525,AVESOBXGFYHSSH-AQNXPRMDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1C[C@@H](C[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)CCO)OC,4.522878745280337,CC[C@@H]1C[C@H](OC)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
2000,CHEMBL249085,AVESOBXGFYHSSH-VAMGGRTRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,10100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1C[C@H](C[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)CCO)OC,4.995678626217358,CC[C@@H]1C[C@@H](OC)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
2007,CHEMBL563451,AVFYUSOOXDDQAW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2N4CCC(CC4)N(C)C,5.301029995663981,Cc1ccc(Cn2c(N3CCC(N(C)C)CC3)nc3ccccc32)cc1
2013,CHEMBL2043011,AVIDRKWFHQXSDT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)O,5.0,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1cc(=O)[nH]cn1
2023,CHEMBL3702697,AVNPLQIOVHQFAT-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCCN(C)C,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCN(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
2028,CHEMBL397580,AVPONLNZIPJOOI-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCN,5.173925197299173,CC(C)C[C@H](NC(=O)CCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
2030,CHEMBL1950088,AVRCXDPCPXUSED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC(=NC=C4)F)O)Cl,4.698970004336019,Cc1cc(Cl)cc2c(C(O)c3ccnc(F)c3)c3c(C)[nH]nc3nc12
2031,CHEMBL1950088,AVRCXDPCPXUSED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC(=NC=C4)F)O)Cl,4.698970004336019,Cc1cc(Cl)cc2c(C(O)c3ccnc(F)c3)c3c(C)[nH]nc3nc12
2033,CHEMBL407708,AVSVDPPALUYPPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NC(C)C)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,6.3979400086720375,CC(C)Nc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1
2034,CHEMBL2387507,AVUOMYZMGMHQBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F)Cl,4.522878745280337,O=c1[nH]c2cc(-c3ccccc3Cl)ccc2c2nc(-c3c(F)cccc3Cl)[nH]c12
2039,CHEMBL365985,AVWXVFNJXMOFEK-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,6.522878745280337,N[C@@H](Cn1c(=O)c(-c2ccccc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
2051,CHEMBL1080088,AWDJPCNXSYKBPU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4C=CC=CC4=O)C(=C(N3CC=C)C)C,5.619788758288394,C=CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21
2060,CHEMBL1080293,AWJOAMPQOUEKCN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19891474.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,PUBLICATION,,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CC5CC5(C4)C6=CC=C(C=C6)C(F)(F)F,5.0,Cc1ccc2c(-c3nnc(SCCCN4CC5CC5(c5ccc(C(F)(F)F)cc5)C4)n3C)cccc2n1
2063,CHEMBL3236638,AWJWXXHHLFWIPR-XCXSIRTKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC5=CC=CC=C5,5.769551078621726,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ccccc2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
2064,CHEMBL3422243,AWKVMOUMPQXDPO-NPQNXCPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,C[C@@H]1[C@@H]2C[C@@H](OC[C@@]2(N=C(S1)N)C3=C(C=C(C=C3)F)F)C4=CN(N=C4)C,4.522878745280337,C[C@H]1SC(N)=N[C@@]2(c3ccc(F)cc3F)CO[C@@H](c3cnn(C)c3)C[C@@H]12
2065,CHEMBL195561,AWLCGHPEKZDBDT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC#N)CCO)C3=C(C=CC(=C3)Cl)O,4.886056647693163,N#CCn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21
2066,CHEMBL195561,AWLCGHPEKZDBDT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC#N)CCO)C3=C(C=CC(=C3)Cl)O,4.7447274948966935,N#CCn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21
2083,CHEMBL522964,AWPVHYLYCREWTR-OQHSHRKDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19181519.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(CCN1S(=O)(=O)C2=CC=C(C=C2)C(C)(C(F)(F)F)O)CC3(CC3)C4=CC=NC=C4,6.356547323513812,C[C@@H]1CN(CC2(c3ccncc3)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1
2098,CHEMBL1642258,AWVFHDAVDXQSNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074994.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C(=O)CN1CCC2=CC(=C(C=C2CC1)OC)NC3=NC=C(C(=N3)NC4=C(C=C(C=C4)N5CCOCC5)OC)Cl,5.698970004336019,COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccc(N4CCOCC4)cc3OC)n1)CCN(CC(=O)N(C)C)CC2
2117,CHEMBL3702682,AXCZNYZPBSOAFX-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6960.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)C(=O)N8CCN(CC8)S(=O)(=O)C,5.157390760389438,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
2120,CHEMBL506877,AXGALHYEZXVPRS-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,135000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F,3.869666231504994,COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F
2128,CHEMBL1095819,AXIFLPLKZRNVDP-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC[C@H](C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,5.301029995663981,CN1CCC[C@@H](c2nc3ccccc3n2Cc2ccc(F)cc2)C1
2130,CHEMBL1087089,AXIFLPLKZRNVDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,5.301029995663981,CN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1
2141,CHEMBL271621,AXKQUNLOEFWORV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C(CC1=C(C=C(C=C1)Cl)Cl)C2=CC=NO2,4.920818753952375,CCOC(=O)C(Cc1ccc(Cl)cc1Cl)c1ccno1
2148,CHEMBL1650645,AXMKFPDKHLZNID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21189020.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17ß-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=C(C=C3)O)C4=CN=CC=C4,6.657577319177793,Oc1cccc(-c2ccc3c(-c4cccnc4)c(O)ccc3c2)c1
2153,CHEMBL1682889,AXNQQSNSHKSLDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)NC(=O)C)(C3=CN=CN3)O,6.0,CC(=O)Nc1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
2155,CHEMBL3331502,AXOLLJKPTOLJBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,32700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,C1C(CN1)CN(CC2=C(C(=CC=C2)Cl)Cl)C3=CC=CC=C3.C(=O)(C(F)(F)F)O,4.485452247339714,Clc1cccc(CN(CC2CNC2)c2ccccc2)c1Cl
2156,CHEMBL2419515,AXOSMMGWCJFHKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4,5.0,Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
2157,CHEMBL2419515,AXOSMMGWCJFHKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4,5.0,Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
2161,CHEMBL3125527,AXQMSOFCQLTJGV-ZJTSJXPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1[C@@H]([C@H](C[C@](C1=O)(C)CC(=O)O)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,4.568636235841013,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
2162,CHEMBL100917,AXRLOUATLDLSKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,51000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC1=CC=CC=C1N=CNO,4.292429823902063,CCCCc1ccccc1N=CNO
2176,CHEMBL2440659,AXVLPJHYYFHCHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,22300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CSC(=N1)NC(=O)C2=CC(=CC(=C2)F)OC3=CN=CN=C3,4.651695136951839,Cc1csc(NC(=O)c2cc(F)cc(Oc3cncnc3)c2)n1
2187,CHEMBL2040896,AYBBBAJBBDEEQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)C6=CC=NO6,4.301029995663981,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccno3)cc1)C(=O)N2c1cc(=O)[nH]cn1
2192,CHEMBL1258034,AYDQEBMCUGUQLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20839775.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Exploration of the amine terminus in a novel series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,CN1C(=NN=C1SCCCN2CCC3CC3(CC2)C4=CC=C(C=C4)C(F)(F)F)C5=CN=NC=C5,5.221848749616356,Cn1c(SCCCN2CCC3CC3(c3ccc(C(F)(F)F)cc3)CC2)nnc1-c1ccnnc1
2193,CHEMBL3262028,AYDUTYVLGUMPSM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24758746.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia.",J. Med. Chem.,PUBLICATION,,CC1=C(N2C=CN=C(C2=N1)N3CCOCC3)C4=CN(N=C4)CCOC,5.0,COCCn1cc(-c2c(C)nc3c(N4CCOCC4)nccn23)cn1
2197,CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20800486.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C,5.0,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1
2198,CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C,5.0,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1
2199,CHEMBL2158221,AYFFPEOVSJSGAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCNCC3)NC(=O)C4=NC=C(N4)C#N.C(=O)(C(F)(F)F)O,5.0,N#Cc1cnc(C(=O)Nc2ccc(C3CCNCC3)cc2C2=CCCCC2)[nH]1
2203,CHEMBL1951055,AYHCJXIBRDMYBV-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22297111.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel morpholine ketone analogs as potent histamine H3 receptor inverse agonists with wake activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C(=O)CN3CCOCC3,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCOCC2)cc1
2204,CHEMBL1951055,AYHCJXIBRDMYBV-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450133.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C(=O)CN3CCOCC3,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCOCC2)cc1
2212,CHEMBL3287548,AYKQXOKTTGHBAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900870.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam conversion to 1'-hydroxy midazolam preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis,"Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.",ACS Med. Chem. Lett.,PUBLICATION,,C1CNCC2=C1N(C3=C2C=C(C=C3)F)CCCOC4=CC=C(C=C4)Cl,4.6020599913279625,Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1
2213,CHEMBL3287548,AYKQXOKTTGHBAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900870.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone conversion to 6-hydroxy testosterone preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis,"Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.",ACS Med. Chem. Lett.,PUBLICATION,,C1CNCC2=C1N(C3=C2C=C(C=C3)F)CCCOC4=CC=C(C=C4)Cl,4.301029995663981,Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1
2224,CHEMBL3114740,AYNKEDQCQUBXKC-PXTZSQHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,410.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.3872161432802645,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(C)[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
2228,CHEMBL230260,AYPFLXLPOWWLSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17482464.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(CCCN3CCCOC)C=C2,5.552841968657781,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)CCC2
2234,CHEMBL3318481,AYRNGMFSOUXWOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2C#N)C3=C(C=CC=C3Cl)Cl,5.301029995663981,N#Cc1ccccc1SC1=C(O)CC(c2c(Cl)cccc2Cl)CC1=O
2243,CHEMBL2070159,AYWOBRMICRHNEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)S(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CN(C(=O)C=C3)C4=CC=CC=C4,4.698970004336019,CC(C)(C)S(=O)(=O)c1ccc2nc(-c3ccc(=O)n(-c4ccccc4)c3)[nH]c2c1
2259,CHEMBL221113,AZBGLEQDAYJKBP-NSHDSACASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17315987.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.",J. Med. Chem.,PUBLICATION,,CCC1=CC2=C(C(=C1)C(F)(F)F)C(=O)N3[C@H]2CNCC3,5.060480747381382,CCc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21
2260,CHEMBL2170607,AZBYJNPBRNIJSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CC1C(=O)N2CCC(CC2)C3=C(C=C(C=C3)C(=O)N=C(N)N)C(F)(F)F,4.795880017344075,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)C3CC3)CC2)c(C(F)(F)F)c1
2263,CHEMBL3702724,AZEAMEKURIDBIX-OZLPACJUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2450.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCC2C1CN(C2)C(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.610833915635467,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC6CCN(C)C6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
2268,CHEMBL519132,AZFITEALNSCCOH-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)OC,9.0,COC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
2282,CHEMBL100899,AZLFXTDKWCBSKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC(C)C1=CC=C(C=C1)N=CNO,4.0,CCC(C)c1ccc(N=CNO)cc1
2286,CHEMBL605540,AZPCJFGZZMKYRM-BSUDQKQGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(CN1C[C@H]2CC(C[C@H]2C1)N(CC3=CC(=CC=C3)OC(F)(F)F)C(=O)C4=CN(C=N4)C)F,5.102372908709558,CC(F)CN1C[C@H]2CC(N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1
2287,CHEMBL2010836,AZRVSANIIWCDJQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22061639.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 by HTRF assay,"Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C1CCN(CC1)CC2=CC=C(C=C2)C(F)(F)F)C(=O)CC3=CC=C(C=C3)N4C=NN=N4,4.6020599913279625,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1
2288,CHEMBL3629740,AZSDCDNUQDIYHT-HSQYWUDLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@]2(CCOC2=O)[C@@H]3COC4=C(C=CC(=C4[C@@]3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,4.522878745280337,O=C1OCC[C@]12CCC[C@@]1(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]21
2289,CHEMBL3629740,AZSDCDNUQDIYHT-HSQYWUDLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@]2(CCOC2=O)[C@@H]3COC4=C(C=CC(=C4[C@@]3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,4.522878745280337,O=C1OCC[C@]12CCC[C@@]1(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]21
2295,CHEMBL1078189,AZUMWAWLOFIGCX-NYOKMZSHSA-N,"6',7'-DIHYDROXYBERGAMOTTIN OCTANAL ACETAL",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19689106.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,Minor furanocoumarins and coumarins in grapefruit peel oil as inhibitors of human cytochrome P450 3A4.,J. Nat. Prod.,PUBLICATION,,CCCCCCCC1O[C@@H](C(O1)(C)C)CC/C(=C/COC2=C3C=CC(=O)OC3=CC4=C2C=CO4)/C,6.886056647693163,CCCCCCCC1O[C@H](CC/C(C)=C/COc2c3ccoc3cc3oc(=O)ccc23)C(C)(C)O1
2309,CHEMBL2048062,AZZAPLDRNFVCMT-SYNHAJSKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ß-peptides.,J. Med. Chem.,PUBLICATION,,CC(C)(C)CN1C=C(C=N1)CN[C@H]2CS(=O)(=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,5.173925197299173,CC(C)(C)Cn1cc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)cn1
2321,CHEMBL2069802,BAAOVUUNXIWPLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)S(=O)(=O)CC2=NN=C(O2)C(=O)NCC3=CC=NC=C3,4.698970004336019,O=C(NCc1ccncc1)c1nnc(CS(=O)(=O)c2ccccc2)o1
2329,CHEMBL210322,BABAHNGGVSLMEF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,COC1=CC=CC=C1OC2=CC=CC(=C2)CN3CCC(CC3)NC(=O)CC4=CC=CC=C4,5.0,COc1ccccc1Oc1cccc(CN2CCC(NC(=O)Cc3ccccc3)CC2)c1
2337,CHEMBL2163839,BAEIXDSVHABCNB-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,CN(C)CCN(C)C(=O)[C@H](CC1=CC=C(C=C1)Br)NC(=O)C2(CC2)C3=C(C=C(C=C3)Cl)Cl,5.107905397309519,CN(C)CCN(C)C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1
2338,CHEMBL3702788,BAFJWSOKLYQZFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2570.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCCCN8CCCC8,5.590066876668706,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCCN6CCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
2340,CHEMBL3115253,BAHABGBETCGAQD-WNJJXGMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24462667.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@](C1=CC2=C([C@H](C3=C1C=C(C=C3)Cl)N4CCN(CC4)C(=O)OC(C)(C)C)N=CC=C2)(C5=CN=CN5C)O,6.522878745280337,Cn1cncc1[C@@](C)(O)C1=Cc2cccnc2[C@@H](N2CCN(C(=O)OC(C)(C)C)CC2)c2ccc(Cl)cc21
2355,CHEMBL2331677,BALVINFSPVZXGT-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4=NC=CN4C)C(=N2)N5CCOC[C@@H]5C,5.0,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2nccn2C)C3)cc1
2362,CHEMBL3358938,BAOUXBDVAPNGRU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=CC=C4S(=O)(=O)N,6.301029995663981,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(N)(=O)=O
2371,CHEMBL120185,BARFMAOTOPEJFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177482.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)C2=NC3=C(C=C2)N(C(=N3)C4=CC=C(C=C4)F)C5=NC(=NC=C5)NC6CCCC6,5.698970004336019,CN1CCN(c2ccc3c(n2)nc(-c2ccc(F)cc2)n3-c2ccnc(NC3CCCC3)n2)CC1
2373,CHEMBL3104528,BARKMJDWQGKXIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,800.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC(C)(C)CC(=O)N1CCC(CC1)N(C2=CC=C(C=C2)Cl)C3=CN=CC=C3,6.096910013008056,CC(C)(C)CC(=O)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1
2376,CHEMBL1651534,BATCTBJIJJEPHM-UHFFFAOYSA-N,PF-04457845,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng midazolam substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4,4.522878745280337,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
2377,CHEMBL1651534,BATCTBJIJJEPHM-UHFFFAOYSA-N,PF-04457845,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng testosterone substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4,4.522878745280337,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
2383,CHEMBL3353863,BAUZVWBSZFLVIL-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556092.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=NO1)NC(=O)[C@@H]2CCCN2C3=CC=C(C=C3)Cl,4.301029995663981,CC(C)(C)c1cc(NC(=O)[C@@H]2CCCN2c2ccc(Cl)cc2)no1
2388,CHEMBL595632,BAXFMLZOUPMNQW-ZHACJKMWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19700331.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C2C=C(C=CC2=C1)CCOC3=C(C=CC(=C3)CN4C=CC=N4)/C=C/C(=O)O,4.522878745280337,O=C(O)/C=C/c1ccc(Cn2cccn2)cc1OCCc1ccc2ccccc2c1
2392,CHEMBL3702712,BAZGKZBDGLGUSD-UCFJPLQUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN8CCN(CC8C7)C=O,4.91721462968355,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C=O)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
2395,CHEMBL3137461,BBBIOQXWVKFUKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CN(C)S(=O)(=O)C1=CC=CC=C1N2CCC(CC2)N(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,5.698970004336019,CN(C)S(=O)(=O)c1ccccc1N1CCC(N(c2ccc(C#N)cc2)c2cccnc2)CC1
2407,CHEMBL1585484,BBEBKAGLYIMBCE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1S(=O)(=O)C2=CC3=C(C=C2)N=C(N3)SCC4=CC(=CC=C4)Cl,5.721246399047171,O=S(=O)(c1ccc2nc(SCc3cccc(Cl)c3)[nH]c2c1)N1CCOCC1
2414,CHEMBL3125379,BBFGUZXGQBPQCG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O)C=CC=C2Cl,4.3979400086720375,CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O
2442,CHEMBL235640,BBMVDIOZDPPMNA-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=CC=CC=C1N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CNC,5.638272163982407,CNCC(=O)N[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
2451,CHEMBL1669420,BBPIYFSEHZGVJE-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,2820.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CS4,5.549750891680639,C[C@H](C1=C(CCN(C)Cc2nccs2)Cc2ccccc21)c1cnccn1
2456,CHEMBL3264059,BBQRBXPCOFYEMM-SHTZXODSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24689770.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1).,J. Med. Chem.,PUBLICATION,,C1CC(CCC1N)NC2=NN3C(=NC=C3C4=CN=C(N=C4)NC5=C(C=CC=N5)F)C=C2,4.6020599913279625,NC1CCC(Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1
2466,CHEMBL2017099,BBXHLOWFZRSHFF-GIPWTMENSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNC[C@@H]([C@]1(C2=CC(=C(C=C2)F)F)O)C3=C(C(=NO3)C4=C(C=CC=C4Cl)Cl)Br,4.823908740944319,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2c(Cl)cccc2Cl)c1Br
2471,CHEMBL3605558,BBYGAEPKKAXIBP-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26291341.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method,Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.,J. Med. Chem.,PUBLICATION,,CCN1C2=CC(=NC=C2N=C1[C@@H](C)NS(=O)(=O)C3=CN=C(C=C3)C#N)C4CC4,4.698970004336019,CCn1c([C@@H](C)NS(=O)(=O)c2ccc(C#N)nc2)nc2cnc(C3CC3)cc21
2482,CHEMBL638,BCEHBSKCWLPMDN-MGPLVRAMSA-N,VORICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,13000.0,NM,,inhibition,tissue,binding,,,,,,,,,,,,,,,,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,4.886056647693163,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
2483,CHEMBL638,BCEHBSKCWLPMDN-MGPLVRAMSA-N,VORICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,13000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,4.886056647693163,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
2484,CHEMBL638,BCEHBSKCWLPMDN-MGPLVRAMSA-N,VORICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13000.0,NM,273500,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",Metalloenzyme inhibitor compounds,,PATENT,,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,4.886056647693163,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
2513,CHEMBL1951342,BCHDNCPTPUSOHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,79.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C(=O)C2=CC(=CC=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,7.102372908709558,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(C(=O)N2CCCCC2)c1
2534,CHEMBL1081505,BCTONXHZFGFJIT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC=C2)N(C(=N3)C)C,5.045757490560675,Cc1cccc(C)c1CNc1cccc2c1nc(C)n2C
2535,CHEMBL1081505,BCTONXHZFGFJIT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC=C2)N(C(=N3)C)C,4.886056647693163,Cc1cccc(C)c1CNc1cccc2c1nc(C)n2C
2552,CHEMBL1823410,BDAYYWQLRAMGNO-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21824776.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Amine-constrained pyridazinone histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=CC(=N1)C2=CC=C(C=C2)C(=O)N3CCC[C@H]3CN4CCCC4,4.522878745280337,Cn1nc(-c2ccc(C(=O)N3CCC[C@H]3CN3CCCC3)cc2)ccc1=O
2554,CHEMBL499849,BDBGKADVAYPDNK-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CNCC(=O)O)N,4.443697499232712,N[C@@H](Cn1c(=O)c(-c2ccc(CNCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
2555,CHEMBL499849,BDBGKADVAYPDNK-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CNCC(=O)O)N,4.443697499232712,N[C@@H](Cn1c(=O)c(-c2ccc(CNCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
2570,CHEMBL1951609,BDGAXEZYOOOOBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=NC2=CC=CC=C12)CN3C(=O)C4=C(C(=C(N4CC=C(C)C)N5CCCNCC5)C#N)N(C3=O)C,5.522878745280337,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
2594,CHEMBL310586,BDXLTTUQHGMFEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,<,50.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CN2C3=CC=CC=C3C4=CC(=CC=C4)OC5=C(C=CC(=C5)CN6C=NC=C6CNC1C2=O)C#N,7.301029995663981,N#Cc1ccc2cc1Oc1cccc(c1)-c1ccccc1N1CCC(NCc3cncn3C2)C1=O
2599,CHEMBL1684585,BDYLGPUIUMBDQP-CZTZKLFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24437735.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective ß3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,PUBLICATION,,C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)[C@@H](C4=CC=CC=C4)O,4.0,Nc1nc(CC(=O)Nc2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)cs1
2600,CHEMBL1684585,BDYLGPUIUMBDQP-CZTZKLFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26709102.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,PUBLICATION,,C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)[C@@H](C4=CC=CC=C4)O,4.0,Nc1nc(CC(=O)Nc2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)cs1
2615,CHEMBL449192,BEKQKLIWZQJREN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C)OCC(=O)N2CC(=O)N(C)C(CN3CCOCC3)C4=CC=C(C=C4)C5=CC=C(C=C5)NC(=O)C,5.1938200260161125,CC(=O)Nc1ccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)CN3C(=O)COc4cc(C)c(C)cc43)cc2)cc1
2625,CHEMBL251229,BENXORZPKXUGMY-UHFFFAOYSA-O,STEPHARANINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,COC1=C(C=C2C(=C1)CC[N+]3=C2C=C4C=CC(=C(C4=C3)OC)O)O,5.6020599913279625,COc1cc2c(cc1O)-c1cc3ccc(O)c(OC)c3c[n+]1CC2
2634,CHEMBL1923110,BEPZQODHCZLPEN-MVSFAKPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC=CC=C5CC(=O)O4,5.251811972993799,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC(=O)Cc2ccccc23)C2CC2)cc(OCCOC)c1
2640,CHEMBL283693,BEQXWFPRVYMACF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC(=NC4=C3NC5=C4C=C(C=C5)[N+](=O)[O-])CN6CCOCC6,4.0,O=[N+]([O-])c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)nc(CN4CCOCC4)nc3c2c1
2647,CHEMBL516125,BESWAUVYRXNIKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=NN=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccnn1
2648,CHEMBL2017276,BETHVCQFAJRUPN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4C(=O)C5=CC=CC=N5)C(=O)N)OC,5.508638306165727,COc1cc2c(Nc3ccccc3C(=O)c3ccccn3)c(C(N)=O)cnc2cc1-c1c(C)noc1C
2655,CHEMBL2336416,BEZLXEJGNUZTPC-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C(=C3)Br)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.142667503568732,O=C(N[C@H](Cc1cc(Br)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
2656,CHEMBL2336416,BEZLXEJGNUZTPC-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C(=C3)Br)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.3979400086720375,O=C(N[C@H](Cc1cc(Br)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
2664,CHEMBL565591,BFBTVZNKWXWKNZ-HWKANZROSA-N,DG-041,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19957930.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding.",J. Med. Chem.,PUBLICATION,,CC1=CN(C2=C(C=C(C=C12)F)/C=C/C(=O)NS(=O)(=O)C3=CC(=C(S3)Cl)Cl)CC4=C(C=C(C=C4)Cl)Cl,5.823908740944319,Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(/C=C/C(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12
2665,CHEMBL565591,BFBTVZNKWXWKNZ-HWKANZROSA-N,DG-041,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19957930.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using dibenzylfluorescein as substrate,"Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding.",J. Med. Chem.,PUBLICATION,,CC1=CN(C2=C(C=C(C=C12)F)/C=C/C(=O)NS(=O)(=O)C3=CC(=C(S3)Cl)Cl)CC4=C(C=C(C=C4)Cl)Cl,5.119186407719209,Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(/C=C/C(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12
2675,CHEMBL415274,BFCVOTGOHBEFMZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCN(C)C)CC4=CC=C(C=C4)C5=CC=C(C=C5)Cl,5.096910013008056,CN(C)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
2694,CHEMBL2013045,BFKPZXXQVYWHKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22365751.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)N1CCC(CC1)OC2=CC3=C(C=C2)OC4(CC3)CCN(CC4)C5CCC5,4.522878745280337,CS(=O)(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
2697,CHEMBL3664715,BFMZBCSQICXEMN-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,48000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.318758762624412,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
2700,CHEMBL3137479,BFOXLQWBMPVYPH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CN=C3)C4=CC=C(C=C4)C(F)(F)F,4.795880017344075,FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cncnc3)CC2)cc1
2705,CHEMBL258251,BFPVIFSFUVSFRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,490.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C(N(C1)C(=O)CN(CC#N)C2=CC(=C(C=C2)Cl)Cl)CN3CCOCC3)C4=CC=CC=C4,6.309803919971486,N#CCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1
2732,CHEMBL1668257,BFWQNCCFSCRIGZ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)[C@@H](C(=O)NC2=C(C=C(C=C2)C3=NNN=N3)F)N4C5=CC(=C(C=C5N=C4C6=CC=C(C=C6)Cl)F)F,5.113509274827518,O=C(Nc1ccc(-c2nn[nH]n2)cc1F)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21
2736,CHEMBL438683,BFYGPJBAPDERDU-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCCN,4.823908740944319,CC(C)C[C@H](NCCCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
2759,CHEMBL2419505,BGECQVFGWHCTBJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=C(CN1C(=O)NCC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4)C=NC=C2,5.0,O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)N1Cc2ccncc2C1
2760,CHEMBL2419505,BGECQVFGWHCTBJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=C(CN1C(=O)NCC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4)C=NC=C2,5.0,O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)N1Cc2ccncc2C1
2765,CHEMBL1079258,BGFWYEFBAHLCNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC(=CC=C3)C(F)(F)F,5.0,O=C(O)CCC1(c2cccc(C(F)(F)F)c2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
2780,CHEMBL360541,BGKUWZFWNZFRMO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,128000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1=CC(=CN=C1)C#CCN,3.8927900303521317,NCC#Cc1cccnc1
2781,CHEMBL360541,BGKUWZFWNZFRMO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,365000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1=CC(=CN=C1)C#CCN,3.4377071355435254,NCC#Cc1cccnc1
2794,CHEMBL3394730,BGNOECVQVUFFHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,=,5700.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.2441251443275085,CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1
2795,CHEMBL3394730,BGNOECVQVUFFHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1
2829,CHEMBL1683444,BGUXTVRZPYKBBN-KXBFYZLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21300546.0,IC50,<,0.1,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C[C@@H](CS(=O)(=O)N1CCC(CC1)OCC2=C(C=C(C=C2)Cl)Cl)N(C=O)O)C3=NC=C(C=N3)F,10.0,C[C@@H](C[C@@H](CS(=O)(=O)N1CCC(OCc2ccc(Cl)cc2Cl)CC1)N(O)C=O)c1ncc(F)cn1
2836,CHEMBL3702693,BGZVJJCLWJQDPD-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6820.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCO,5.166215625343521,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
2841,CHEMBL469851,BHCRVKVXJRBQJR-YPDHAKIYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,55800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)OC(=O)C)OC(=O)C)O,4.253365801062421,CC(=O)O[C@H]1[C@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)O[C@@H](C)[C@H](O)[C@H]1OC(C)=O
2842,CHEMBL599482,BHCXDAMJQOPWKM-ACDBMABISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C[C@H]2CC(C[C@H]2C1)N(CC3=CC(=C(C=C3)F)OC4CCCC4)C(=O)C5=CN(C=N5)C,5.0,CN1C[C@H]2CC(N(Cc3ccc(F)c(OC4CCCC4)c3)C(=O)c3cn(C)cn3)C[C@H]2C1
2849,CHEMBL2448723,BHIWKCYRDRDVNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1040.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCS(=O)(=O)N(CC1=CN=CC=C1)C2=CN=CC(=C2)C3=NC4=CC=CC=C4S3,5.982966660701219,CCS(=O)(=O)N(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1
2852,CHEMBL1092812,BHMPPLVSPUZBNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1=CN=C(C=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,COc1ccc(C(C)c2c(CCN(C)C)sc3ccccc23)cn1
2853,CHEMBL2062151,BHMSJQPFCDTTCI-BIIPMVSMSA-N,PF-00422602,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988109.0,IC50,>,900000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4,"Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.",J. Med. Chem.,PUBLICATION,,C1CS(=O)CCC1C2=C(C=C(C=C2)N3C[C@@H](OC3=O)C(=O)N)F,3.0457574905606752,NC(=O)[C@H]1CN(c2ccc(C3CC[S+]([O-])CC3)c(F)c2)C(=O)O1
2873,CHEMBL1088949,BHTGEWHBEIZLOP-VQHVLOKHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C2=CC=CC=C2N1)CCN3CC4=C(C3)C=C(C=C4)/C=C/C(=O)NO,5.0,Cc1[nH]c2ccccc2c1CCN1Cc2ccc(/C=C/C(=O)NO)cc2C1
2895,CHEMBL10188,BIAVGWDGIJKWRM-FQEVSTJZSA-N,TALNETANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H](C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)O,5.3979400086720375,CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1
2896,CHEMBL2436226,BIAWVZMEBADAPM-MJFWUJRASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@H]1[C@@H](C(=O)N(C2=C(N1C(=O)C)C=C(C=C2)C#N)CC3=C(C=CC4=CC=CC=C43)C)NC(=O)[C@H](C)NC.Cl,4.795880017344075,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C
2910,CHEMBL226385,BIFWAJIKBGURHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,51000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC=C3)Cl,4.292429823902063,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
2923,CHEMBL3114731,BIJHYGNWGXBYFX-LDNVYYCDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,340.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(CC3=CC=CC=C3)C(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.468521082957745,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)cs1
2924,CHEMBL1257215,BIJSJQXDPUAQLO-UADZTWIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20839775.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Exploration of the amine terminus in a novel series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3[C@@H]4CC[C@H]3CC(C4)C5=CC=C(C=C5)C(C)(C)C,5.301029995663981,Cc1ncoc1-c1nnc(SCCCN2[C@H]3CC[C@@H]2CC(c2ccc(C(C)(C)C)cc2)C3)n1C
2948,CHEMBL2089032,BIUDJFOTQAVFMN-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22982525.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,CC(C)N1C=NC2=C(N=C(N=C21)NC[C@H](CO)O)NCC3=CC=C(C=C3)C4=CC=CC=N4,5.301029995663981,CC(C)n1cnc2c(NCc3ccc(-c4ccccn4)cc3)nc(NC[C@@H](O)CO)nc21
2962,CHEMBL3112852,BIXKKBQECSTCMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,COC1=CC=CC2=C1CCN2C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,COc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1
2966,CHEMBL1951600,BJBOAPYAMPEKGS-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=NC2=CC=CC=C12)CN3C(=O)C4=C(C(=C(N4CC=C(C)C)N5CCC[C@@H](C5)N)C#N)N(C3=O)C,5.522878745280337,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
2967,CHEMBL392463,BJBXILVBLCBQQY-FTJBHMTQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)F)[C@H]2CN(C[C@@H]2C3=NC(=NO3)C(C)(C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C(=O)C5CCN(CC5)C(=O)C,4.638272163982407,CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)C2)CC1
2968,CHEMBL392464,BJBXILVBLCBQQY-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)F)[C@@H]2CN(C[C@H]2C3=NC(=NO3)C(C)(C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C(=O)C5CCN(CC5)C(=O)C,4.552841968657781,CC(=O)N1CCC(C(=O)N2C[C@@H](c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)[C@H](c3ccc(F)cc3C)C2)CC1
2969,CHEMBL1673059,BJCHGDBASIDUOJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25680029.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C(=O)N)C2=C(C=NC=C2Cl)Cl,5.154901959985743,NC(=O)C1CCN(c2c(Cl)cncc2Cl)CC1
2973,CHEMBL252518,BJDCWCLMFKKGEE-CMDXXVQNSA-N,ARTENIMOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22679214.0,IC50,>,125000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis,,Drug Metab. Dispos.,PUBLICATION,,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@@](O3)(OO4)C)O)C,3.9030899869919438,C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@@]23OO4
2974,CHEMBL252518,BJDCWCLMFKKGEE-CMDXXVQNSA-N,ARTENIMOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22679214.0,IC50,>,125000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis,,Drug Metab. Dispos.,PUBLICATION,,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@@](O3)(OO4)C)O)C,3.9030899869919438,C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@@]23OO4
2999,CHEMBL2158295,BJMQKWRHLJKHOC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)CC4=CC=CC=N4)NC(=O)C5=NC=C(N5)C#N,5.823908740944319,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccccn4)CC3)cc2C2=CCCCC2)[nH]1
3001,CHEMBL3640015,BJMZKSMCWXSRCH-YMJVKMAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2780.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(=O)CCNCCCC(=O)NC1=CC=C(C=C1)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.555955204081924,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)CCCNCCC(C)=O)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
3027,CHEMBL596072,BJSFTYZWWXFKSH-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C=C(C=NC2=NN1)C3=C(N=CC(=C3)OC[C@H](CC4=CNC5=CC=CC=C54)N)C6=COC=C6,6.698970004336019,Cc1[nH]nc2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12
3036,CHEMBL578588,BJXGGWYWXKQKIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)N(C)C,5.318758762624412,CN(C)c1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1
3041,CHEMBL3622879,BKAQDKUFAULKQY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26602277.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(N=C1Cl)C2CC2)NCC3=C(N=C(S3)C)C,4.769551078621726,Cc1nc(C)c(CNc2nc(C3CC3)nc(Cl)c2C)s1
3065,CHEMBL1837038,BKJSIODGIVFGTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21885275.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC(=O)N1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCN(CC4)C5=CC=CC=N5)C1,4.522878745280337,COC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1
3070,CHEMBL480219,BKNPWPRZETXJRA-OYRHEFFESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,46000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)N3C=CN=C3C(=O)N4CCC(CC4)NC5=CC(=CC=C5)F,4.337242168318426,C[C@H]1CN(Cc2ccc(-n3ccnc3C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)C[C@@H](C)N1
3071,CHEMBL480219,BKNPWPRZETXJRA-OYRHEFFESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,58000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)N3C=CN=C3C(=O)N4CCC(CC4)NC5=CC(=CC=C5)F,4.236572006437063,C[C@H]1CN(Cc2ccc(-n3ccnc3C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)C[C@@H](C)N1
3081,CHEMBL1096089,BKRADANXACAJKT-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CC#N,5.853871964321762,Cc1cc(N2CCN(CC#N)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
3087,CHEMBL2170608,BKTAXDHHVZLQOP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,COCC(=O)N1CCC(CC1)C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F,4.522878745280337,COCC(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
3096,CHEMBL218017,BKWXCVZIALOBBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1CNC2=CC=CC=N2)C(=O)OCC3=CC=CC=C3,4.6020599913279625,O=C(OCc1ccccc1)N1CCC(CNc2ccccn2)CC1
3111,CHEMBL1782530,BLBAWGODFTZAEY-PHIMTYICSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21507633.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CCC1N)NC2=C3C(=CC(=C2)Br)C=C(O3)C(=O)O,5.0,NC1CCC(Nc2cc(Br)cc3cc(C(=O)O)oc23)CC1
3112,CHEMBL1782531,BLBAWGODFTZAEY-XYPYZODXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21507633.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CCC1N)NC2=C3C(=CC(=C2)Br)C=C(O3)C(=O)O,5.0,NC1CCC(Nc2cc(Br)cc3cc(C(=O)O)oc23)CC1
3150,CHEMBL319862,BLIJUBJTRKESFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,94000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC1=CC(=C(C=C1)C)N=CNO,4.026872146400302,CCCCc1ccc(C)c(N=CNO)c1
3151,CHEMBL283255,BLIMNWSQDQYNMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3N(C5=CC=CC(=C54)C(=O)N)CC6=CC=NC=C6,6.698970004336019,NC(=O)c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1ccncc1
3163,CHEMBL2397305,BLLVQWSTMVRWIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,710.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)CN(CC2=CC=CC=C2)C(=O)C3=CC=NC=C3)C4=CN=C(C=C4)N,6.1487416512809245,Cc1nc(NC(=O)CN(Cc2ccccc2)C(=O)c2ccncc2)sc1-c1ccc(N)nc1
3166,CHEMBL3291423,BLNAAWXUNQHVNT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)N(C)C)C)C(=O)NCCO)N=C1,4.301029995663981,Cc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(N(C)C)c3C)c2c1
3174,CHEMBL3669004,BLPWIRCAXJRMJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320646,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=NC(=CC=C4)N5CCCC5)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCCC5)n4)nc3)c2c1
3175,CHEMBL3669004,BLPWIRCAXJRMJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320690,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=NC(=CC=C4)N5CCCC5)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCCC5)n4)nc3)c2c1
3197,CHEMBL567597,BLUAFEHZUWYNDE-DKGJTOOQSA-N,ARTEMISININ,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22679214.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis,,Drug Metab. Dispos.,PUBLICATION,,C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@@](O3)(OO4)C)C,4.301029995663981,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4
3198,CHEMBL567597,BLUAFEHZUWYNDE-DKGJTOOQSA-N,ARTEMISININ,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22679214.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis,,Drug Metab. Dispos.,PUBLICATION,,C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@@](O3)(OO4)C)C,4.301029995663981,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4
3205,CHEMBL2018908,BLUDPRGGEJCLGM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,15700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CCCCCCCSC1=NC2=C(N1)C=C(C=C2)OC,4.804100347590766,CCCCCCCSc1nc2ccc(OC)cc2[nH]1
3211,CHEMBL556487,BLVRDPUKIXDEBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC(=NO2)C3=CC=NC=C3)C(=O)NC4CC4C5=CC=CC=C5,5.0,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccncc3)no2)CC1
3212,CHEMBL1911826,BLWAXJUYAKUVSK-ZJSXRUAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)[C@@H]1CCN(C1)C(=O)[C@@H](COCC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,5.142667503568732,CN(C)[C@@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1
3241,CHEMBL2336419,BMBUNRAVRJCKBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC(=CC2=C(NN=C12)C)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.161150909262744,CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2c(C)[nH]nc12
3242,CHEMBL2336419,BMBUNRAVRJCKBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC(=CC2=C(NN=C12)C)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.3979400086720375,CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2c(C)[nH]nc12
3254,CHEMBL359116,BMFUKBQBNCLWGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,7520.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CNC=C2,5.123782159408358,CCCCOc1ccc(-c2cc[nH]c2)cc1
3269,CHEMBL409494,BMMXYTGQGZIMDY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18378449.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C2=CC=C(C=C2)C(=O)NC3=CC=CC=C3N)CCC(=O)NC4=CC=CC=C4F,5.0,Nc1ccccc1NC(=O)c1ccc(C2CCN(CCC(=O)Nc3ccccc3F)CC2)cc1
3281,CHEMBL2436625,BMWUIIPULBWCPO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=C(CN(CCC2)C3CCN(CC3)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F)C=C1,4.522878745280337,COc1ccc2c(c1)CCCN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2
3300,CHEMBL2425606,BNFJJDOJXXRZDV-NAOLWSJMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)CC1=CC(=NO1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F,5.958607314841775,COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(CC(C)(C)C)on3)[C@H]2O)cc(F)c1N)C(F)(F)F
3303,CHEMBL1269895,BNIGHFUMARRMFX-GPJGMNBASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,=,17100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1NC2=C(C=CC=N2)C#N)C(=O)OC3C4CC5CC3CC(C5)(C4)C(=O)N,4.767003889607846,N#Cc1cccnc1N[C@@H]1CCN(C(=O)OC2C3CC4CC2CC(C(N)=O)(C4)C3)C1
3304,CHEMBL1270002,BNIGHFUMARRMFX-VFNAPQHXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,=,18600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@H]1NC2=C(C=CC=N2)C#N)C(=O)OC3C4CC5CC3CC(C5)(C4)C(=O)N,4.730487055782084,N#Cc1cccnc1N[C@H]1CCN(C(=O)OC2C3CC4CC2CC(C(N)=O)(C4)C3)C1
3312,CHEMBL3664677,BNQCJDYJTKIIEZ-CHJDUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,41000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CCN1C(=CC(=CC1=O)C2=CC=C(C=C2)[C@H](C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4)C,4.3872161432802645,CCn1c(C)cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O
3317,CHEMBL2018911,BNQHARADWSRQDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,16400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3CC3,4.785156151952302,COc1ccc2nc(SCC3CC3)[nH]c2c1
3319,CHEMBL3311225,BNRLEARACNMGQQ-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,36000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)Cl,4.443697499232712,O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(Cl)cc2)cn1
3331,CHEMBL2069841,BNVVNCVXADUCNT-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ß-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)OC(F)(F)F,6.0,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(OC(F)(F)F)cc2)CC1)Cc1cc(F)c(F)cc1F
3342,CHEMBL1835487,BOARCKQGDXYXGL-IJLINHMISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21899332.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,P1-Substituted Symmetry-Based Human Immunodeficiency Virus Protease Inhibitors with Potent Antiviral Activity against Drug-Resistant Viruses.,J. Med. Chem.,PUBLICATION,,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C[C@@H]([C@H](CC2=CC=C(C=C2)C3=CC(=CN=C3)F)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,6.853871964321762,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C[C@H](O)[C@H](Cc1ccc(-c2cncc(F)c2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
3364,CHEMBL3237448,BOEVQFOAJBRYBJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,C1CCC(C1)N2C3=C(C=CN=N3)C4=CN=C(N=C42)NC5=NC=C(C=C5)N6CCNCC6,5.0,c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2nn1
3377,CHEMBL3288027,BOLHCUZVJPHIDF-FLSDQSJTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24785301.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CCCC2=CC=C(C=C2)C3=CC(=CC=C3)OC4=C(C=C(C=N4)F)C(=O)NC5CCC(CC5)NC(=O)C6=NN(C(=C6)C)C,6.0,Cc1cc(C(=O)NC2CCC(NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(CCCN5C[C@H](C)N[C@H](C)C5)cc4)c3)CC2)nn1C
3381,CHEMBL3702683,BOPMTQCKAADDSO-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6510.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)C(=O)C2=NC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.186419011431808,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
3382,CHEMBL478649,BOPSUAHGQHFKGG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18614366.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 transfected in Escherichia coli co-expressed with human NADPH reductase,Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)C(=O)NC2CC2)C3=CC=C(C=C3)C(=O)NCC4CC4,5.0,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1
3387,CHEMBL478612,BOSPJTDRCVFWMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(N1C)C=C(C=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,5.769551078621726,Cc1nc2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2n1C
3388,CHEMBL478612,BOSPJTDRCVFWMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(N1C)C=C(C=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,4.585026652029182,Cc1nc2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2n1C
3392,CHEMBL3664676,BOWQJDHKKOERLG-CHJDUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,28000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CCN1C=C(C=C(C1=O)C)C2=CC=C(C=C2)[C@H](C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.552841968657781,CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(C)c1=O
3396,CHEMBL206146,BOXUVZUCCJGJJB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCCN5CCCC5)C,5.468521082957745,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCN5CCCC5)c(C)c34)ccc2[nH]1
3397,CHEMBL2436325,BOYASMFQZGSUQJ-RQBPZYBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CCC3=CC=CC=C3)C(=O)CC(C)C)NC.Cl,5.481486060122113,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(CCc2ccccc2)C1=O
3399,CHEMBL3702681,BPBSAINEGRFZNG-QARUCVQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=O)N8CCOCC8,4.991399828238082,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCOCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
3400,CHEMBL3393473,BPCDCTRGBDOCQS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=C(C=C6)F,4.920818753952375,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3ccc(F)cc3[nH]2)o1
3402,CHEMBL408712,BPDMUPHEAYZMGQ-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1CCN(CC1)C2CC(C2)C3=NC(=C4N3C=CN=C4N)C5=CC6=C(C=C5)C=CC(=N6)C7=CC=CC=C7,5.1249387366083,Nc1nccn2c(C3CC(N4CCCCC4)C3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12
3406,CHEMBL598659,BPFSRDSVMKDEAX-BJWYYQGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C[C@H]2CC(C[C@H]2C1)N(CC3=CC(=CC=C3)OC(F)(F)F)C(=O)C4=CN(C=N4)C,5.0,CN1C[C@H]2CC(N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1
3424,CHEMBL2064412,BPJRFZYPRAUEAA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1COCCN1C2=CC(=O)NC(=N2)CC3=NC4=CC=CC(=C4O3)C5=CC=CC=C5,4.3979400086720375,O=c1cc(N2CCOCC2)nc(Cc2nc3cccc(-c4ccccc4)c3o2)[nH]1
3435,CHEMBL3291427,BPOMAKFXYIVWGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CN=C1OC)CN2C=C(C3=C2C=C(C=N3)OC)C(=O)NCCO,4.301029995663981,COc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(OC)c3C)c2c1
3446,CHEMBL3137441,BPROOBVYFAZDEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2100.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC1=C(C(=NO1)C)C(=O)N2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,5.6777807052660805,Cc1noc(C)c1C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
3463,CHEMBL3669005,BPZSDIOZLNSESC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320652,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=C(N=CC=C4)OC)N=C1,5.301029995663981,COc1ncccc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1
3464,CHEMBL3669005,BPZSDIOZLNSESC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320696,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=C(N=CC=C4)OC)N=C1,5.0,COc1ncccc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1
3472,CHEMBL2179319,BQAVZGJJQFJSMW-UHFFFAOYSA-N,JNJ-42153605,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23072213.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3-Cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): A Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor.",J. Med. Chem.,PUBLICATION,,C1CC1CC2=NN=C3N2C=CC(=C3C(F)(F)F)N4CCC(CC4)C5=CC=CC=C5,4.522878745280337,FC(F)(F)c1c(N2CCC(c3ccccc3)CC2)ccn2c(CC3CC3)nnc12
3496,CHEMBL70,BQJCRHHNABKAKU-KBQPJGBKSA-N,MORPHINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,4.301029995663981,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
3499,CHEMBL1223157,BQJFEWXRGPPWBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC=C(C=C1)C(C2=NN=NN2CC3=CC=CC=C3)N4CCCN(CC4)C5CCC5,4.301029995663981,CS(=O)(=O)c1ccc(C(c2nnnn2Cc2ccccc2)N2CCCN(C3CCC3)CC2)cc1
3506,CHEMBL103313,BQPCBRFOSWMALO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,65000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC1=CC=C(C=C1)N=CNO,4.187086643357144,CCCCc1ccc(N=CNO)cc1
3516,CHEMBL551991,BQUXAJWDRCSKFN-IBGZPJMESA-N,BMS-269223,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19541481.0,IC50,=,18500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC#N,4.732828271596986,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC#N)ccc2o1
3517,CHEMBL551991,BQUXAJWDRCSKFN-IBGZPJMESA-N,BMS-269223,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19541481.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BZR as substrate,Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC#N,4.3979400086720375,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC#N)ccc2o1
3518,CHEMBL551991,BQUXAJWDRCSKFN-IBGZPJMESA-N,BMS-269223,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19541481.0,IC50,>,200000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human TC5 cells,Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC#N,3.6989700043360187,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC#N)ccc2o1
3520,CHEMBL1774931,BQVOMOZXISVWCA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC(=C1C2=NC(=NC3=C2CN(C3)C(=O)NCC(F)(F)F)N)OCCN4C=C(C=N4)F)Cl,5.853871964321762,Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(F)(F)F)C2
3522,CHEMBL2041181,BQVRVXOKDOEPNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CN=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
3526,CHEMBL522877,BQZUAHKGFIUDFA-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,C[C@H]1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC6CC6)C,5.251811972993799,Cc1ccc2c(NC3CC3)noc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1
3559,CHEMBL3608458,BRNXJJBPGRMYLF-LBVMUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26259804.0,IC50,=,38800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2C=C(C=C2C(=O)N(C1)[C@H](CO)C3=CC=CC=C3)C4=NC(=NC=C4)N[C@@H]5C[C@@H]([C@H](C5)F)O,4.411168274405792,O=C1c2cc(-c3ccnc(N[C@@H]4C[C@H](O)[C@@H](F)C4)n3)cn2CCCN1[C@H](CO)c1ccccc1
3560,CHEMBL3608458,BRNXJJBPGRMYLF-LBVMUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26259804.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2C=C(C=C2C(=O)N(C1)[C@H](CO)C3=CC=CC=C3)C4=NC(=NC=C4)N[C@@H]5C[C@@H]([C@H](C5)F)O,4.3979400086720375,O=C1c2cc(-c3ccnc(N[C@@H]4C[C@H](O)[C@@H](F)C4)n3)cn2CCCN1[C@H](CO)c1ccccc1
3564,CHEMBL2409024,BROODMBBHUGCOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC1=CN=C(N=C1C2=CC=CS2)N3C(=C(C=N3)C(=O)NCC4=CC=NC=C4)COC,5.5376020021010435,COCc1c(C(=O)NCc2ccncc2)cnn1-c1ncc(C)c(-c2cccs2)n1
3566,CHEMBL452423,BRQGGNFXDOXIBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CC=NC=C3,4.301029995663981,O=C(CNC(=O)c1ccncc1)NC(c1ccccc1)c1ccc(Cl)cc1
3573,CHEMBL364738,BRRLRVSLZIYEQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,59000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,CC(C)(C1=CC(=C(C=C1)C2=CC=C(C=C2)C3CCCCC3)F)C(=O)O,4.229147988357856,CC(C)(C(=O)O)c1ccc(-c2ccc(C3CCCCC3)cc2)c(F)c1
3577,CHEMBL3646211,BRTHUECZMVKNMQ-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 µL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 µg/mL) were incubated with 5 concentrations of test compound (from 0.1 µM to 10 µM), 1 mM NADPH (Sigma), and 2 µM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,COC1=CC=C(C=C1)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)C[C@@H](CO)O)N,5.0,COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](O)CO)c5)cnc(N)c34)cc2)cc1
3584,CHEMBL1098395,BRXYAENMEBTBTN-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCN(CC1)C2=CC3=C(C(=C2)C)N=C(N3)C4=C(C=CNC4=O)NC[C@H](C5=CC(=CC=C5)Cl)O,5.657577319177793,CCN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
3591,CHEMBL3115186,BSAFIUYYVIIACE-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CN2C=CC=N2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,7.0,CC(C)c1nc(CN(C)C(=O)N[C@@H](Cn2cccn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
3617,CHEMBL400845,BSKMBSPKWWECJR-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=C(C=CC=C1Cl)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,5.275724130399211,CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
3622,CHEMBL528995,BSMNRYCSBFHEMQ-UHFFFAOYSA-N,DOV-216303,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl,5.886056647693163,Clc1ccc(C23CNCC2C3)cc1Cl
3628,CHEMBL3632723,BSOYRWMMIWLZGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=C(C=CC(=C5)C(F)(F)F)F,4.585026652029182,Cn1c(Nc2cc(C(F)(F)F)ccc2F)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
3631,CHEMBL1950091,BSQBUOMKYFGDQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=C(N=C4)C)O)Cl,5.102372908709558,Cc1ncc(C(O)c2c3cc(Cl)cc(C)c3nc3n[nH]c(C)c23)cn1
3632,CHEMBL1950091,BSQBUOMKYFGDQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=C(N=C4)C)O)Cl,4.698970004336019,Cc1ncc(C(O)c2c3cc(Cl)cc(C)c3nc3n[nH]c(C)c23)cn1
3638,CHEMBL1242081,BSRXZCMRRHEYBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC7CC7,5.154901959985743,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC6CC6)ncn4-5)CC3)cccc2n1
3639,CHEMBL1242081,BSRXZCMRRHEYBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC7CC7,5.154901959985743,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC6CC6)ncn4-5)CC3)cccc2n1
3666,CHEMBL249493,BTCOCIJZIJLOOZ-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)N1CCN(CC1)C(=O)CC2(CC2)[C@H]3CCC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,5.823908740944319,CC(C)(CO)N1CCN(C(=O)CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
3667,CHEMBL249493,BTCOCIJZIJLOOZ-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)N1CCN(CC1)C(=O)CC2(CC2)[C@H]3CCC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,5.823908740944319,CC(C)(CO)N1CCN(C(=O)CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
3670,CHEMBL1089865,BTFCCPKDGZFGPR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20218619.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,CC1=C(C=C(C=C1)C(=O)NC2CC2)C3=CC4=C(N(C3=O)C)N(N=C4)C5=C(C=CC=C5F)F,4.6020599913279625,Cc1ccc(C(=O)NC2CC2)cc1-c1cc2cnn(-c3c(F)cccc3F)c2n(C)c1=O
3684,CHEMBL486444,BTGVFQXCQFVKOT-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18539454.0,IC50,=,79000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines as VLA-4 integrin antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC2=C(N1C3=CC=C(C=C3)C[C@@H](C(=O)O)NC4=C(C(=O)C45CCCCC5)Br)N=CC=C2,4.102372908709558,CC(C)c1nc2cccnc2n1-c1ccc(C[C@H](NC2=C(Br)C(=O)C23CCCCC3)C(=O)O)cc1
3693,CHEMBL3264604,BTLRYDPMPQJNBN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CN=CN3)O,5.795880017344075,COc1cc2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2cc1OC
3700,CHEMBL1078337,BTNSKYZYJVZFJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CN=CC=C3,5.0,O=C(O)CCC1(c2cccnc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
3721,CHEMBL286494,BTXNYTINYBABQR-UHFFFAOYSA-N,HYPERICIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20408551.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).,J. Nat. Prod.,PUBLICATION,,CC1=CC(=C2C3=C4C5=C(C(=O)C=C(C5=C2O)O)C6=C7C4=C8C(=C13)C(=CC(=O)C8=C(C7=C(C=C6O)O)O)C)O,5.060480747381382,Cc1cc(O)c2c(O)c3c(O)cc(=O)c4c5c(O)cc(O)c6c(O)c7c(=O)cc(C)c8c1c2c(c34)c(c65)c78
3734,CHEMBL476763,BUDREMAUSZLRFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CC=CC=C3,4.301029995663981,O=C(CNC(=O)c1ccccc1)NC(c1ccccc1)c1ccc(Cl)cc1
3740,CHEMBL3581144,BUGVUVMZGNNHCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=CC(=NC=C3)F,5.823908740944319,COc1cccc(CC(=O)Nc2nc(-c3ccnc(F)c3)cs2)c1
3746,CHEMBL2440625,BUIOHRKCCSCORH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC(=C1)Cl)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CN=C3,5.721246399047171,O=C(Nc1cccc(Cl)n1)c1cc(Cl)cc(Oc2cncnc2)c1
3751,CHEMBL3664710,BUIPWQYAVGFZFQ-CCLHPLFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CC[C@](OC3=O)(CCCO)C4=CC=CC=C4,4.301029995663981,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O
3767,CHEMBL225413,BUMBTDCRGILJJM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C(=CC=C3)Cl)F,4.0,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Cl)c2F)nc1C(F)(F)F
3768,CHEMBL3353340,BUMGKNPRCXMAGM-FVOFJUMPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,C1[C@H]([C@@]12C3=CC=CC=C3NC2=O)C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=NC=C6,6.0,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1
3769,CHEMBL2347414,BUMHWUDGGPIPAG-YLCJPNJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC1(CC(C1)N)NC(=O)C2=CNC3=NC=C(N=C23)C4=NN(C5=C4C=CC(=C5)F)C,4.301029995663981,Cn1nc(-c2cnc3[nH]cc(C(=O)NC4(C)CC(N)C4)c3n2)c2ccc(F)cc21
3770,CHEMBL3702745,BUMKXSPCJBNGGV-LQJZCPKCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCC(=O)O,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCC(=O)O)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
3771,CHEMBL1095364,BUNJVHAEMQLYJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC,5.301029995663981,COc1ccc(Cn2c(C3CCCN(C(C)C)C3)nc3ccccc32)cc1
3776,CHEMBL2058833,BUPRVECGWBHCQV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22524250.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,J. Med. Chem.,PUBLICATION,,CC1(C2=NC(=C(N2CCN1C(=O)CN)NC3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C,5.221848749616356,CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN
3779,CHEMBL3581693,BURHGPHDEVGCEZ-KJGLQBJMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25879485.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",J. Med. Chem.,PUBLICATION,,CC/C(=C(/C1=CC=C(C=C1)/C=C/C(=O)O)\C2=CC3=C(C=C2)NN=C3)/C4=C(C=C(C=C4)F)Cl,4.698970004336019,CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl
3795,CHEMBL3633184,BUYVTPGEWYQFCF-RSPOEFSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26428869.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of dihydroquinazolinone derivatives as potent, selective, and CNS-penetrant M1 and M4 muscarinic acetylcholine receptors agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)N1[C@@H]2CC[C@H]1CC(C2)CN3CC[C@H](C3)N4CC5=CC=CC=C5NC4=O,5.698970004336019,CCOC(=O)N1[C@H]2CC[C@@H]1CC(CN1CC[C@@H](N3Cc4ccccc4NC3=O)C1)C2
3803,CHEMBL267210,BVCMDMYFMGSYTP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17201408.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C2=NC(=C(C(=C2C=C1)C(=O)O)O)C3=CC=C(C=C3)Cl)C,5.154901959985743,Cc1ccc2c(C(=O)O)c(O)c(-c3ccc(Cl)cc3)nc2c1C
3807,CHEMBL3408944,BVEKREGXHABVFX-KQWMEKAXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,5400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)NC(=O)[C@@]23C[C@H]3C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=C(C=C6)CN7CCCCC7,5.267606240177032,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCCCC5)cc4)n[nH]c3c1)C(=O)N2
3808,CHEMBL3408944,BVEKREGXHABVFX-KQWMEKAXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)NC(=O)[C@@]23C[C@H]3C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=C(C=C6)CN7CCCCC7,6.0,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCCCC5)cc4)n[nH]c3c1)C(=O)N2
3816,CHEMBL406388,BVGNPHZIUYGPRQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CN=CC=C5,5.698970004336019,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5cccnc5)cccc4c3)c2cc1OC
3817,CHEMBL3393290,BVGRLIKCJLZVRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1C(=O)NCC2=CC=NC=C2)OC3=CC=C(C=C3)Cl,6.0,O=C(NCc1ccncc1)c1ccc(Oc2ccc(Cl)cc2)cc1
3830,CHEMBL3114730,BVNBEUVSHPWWQG-PPTMTGTBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CCN(CC2=CC=CC=C2)C(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.494850021680094,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
3832,CHEMBL3400459,BVOJUQIDIWBGQI-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NS(=O)(=O)CC2CCOCC2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,5.0,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)CC2CCOCC2)C(C)C)ccc1OC
3844,CHEMBL1092496,BVRYNXDISKCAFZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=C(C=C1)C(C)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,Cc1ccc(C(C)c2c(CCN(C)C)sc3ccccc23)cn1
3851,CHEMBL3394842,BVUZOFDSUCGTDO-IAGOWNOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25577040.0,IC50,=,25400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CC[C@H](CN1C(=O)C2=CC=CC=C2N3N=CC=N3)OC4=C5C=CC=C(C5=NC=C4)F,4.5951662833800615,C[C@@H]1CC[C@@H](Oc2ccnc3c(F)cccc23)CN1C(=O)c1ccccc1-n1nccn1
3859,CHEMBL489480,BVWALIIZZWACOM-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=CC(=C4)C#N,4.443697499232712,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(C#N)c4)CC3)cc2)CCN1
3860,CHEMBL489480,BVWALIIZZWACOM-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,58000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=CC(=C4)C#N,4.236572006437063,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(C#N)c4)CC3)cc2)CCN1
3864,CHEMBL3664651,BVXDMTPIOHLIBK-IGKIAQTJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CC[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CC[C@](OC3=O)(CCO)C4=CC=CC=C4,4.301029995663981,CC[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCO)(c2ccccc2)OC1=O
3868,CHEMBL462622,BWAXVHRXKFQTBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19260711.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.",J. Med. Chem.,PUBLICATION,,C#CC1=C(C=CN=C1N)OC2=C(C=C(C=C2)NC(=O)C3=CC=CN(C3=O)C4=CC=C(C=C4)F)F,6.0,C#Cc1c(Oc2ccc(NC(=O)c3cccn(-c4ccc(F)cc4)c3=O)cc2F)ccnc1N
3871,CHEMBL356066,BWDQBBCUWLSASG-MDZDMXLPSA-N,DACINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)/C=C/C(=O)NO,4.853871964321762,O=C(/C=C/c1ccc(CN(CCO)CCc2c[nH]c3ccccc23)cc1)NO
3896,CHEMBL3422010,BWTVMVHFJRFVFO-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C,4.301029995663981,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1
3897,CHEMBL3422010,BWTVMVHFJRFVFO-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C,4.301029995663981,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1
3908,CHEMBL179399,BWYNAQVMYILNCY-UHFFFAOYSA-O,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,262000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C[N+]1=CNC=C1C2=CN=CC=C2,3.5816987086802543,C[n+]1c[nH]cc1-c1cccnc1
3917,CHEMBL2048057,BXBKECSXPXOHQB-IBZMOEQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ß-peptides.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC(=NC=C1)CN[C@H]2CS(=O)(=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,6.3979400086720375,CC(C)(C)c1ccnc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1
3938,CHEMBL567798,BXHVZWNKTMYVHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,820.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)CN2CCN(CC2)C(=O)C34CC5CC(C3)CC(C5)(C4)C6=CC=C(C=C6)OCC(=O)NC7=CC=CC(=C7)C(=O)OC,6.086186147616283,COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7cccc(OC)c7)CC6)(C5)C3)C4)cc2)c1
3940,CHEMBL2436329,BXIWKBWJRKXQTA-RIAYWLAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)CC(C)C)NC.Cl,5.958607314841775,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
3946,CHEMBL3109945,BXKNUXDLZJPPBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27055065.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach.",J. Med. Chem.,PUBLICATION,,CC(C)(C)OC(=O)N1C(=CC2=CN=C(C=C21)NC3=C(C=C(C=C3)C4=CN=CN4C)Cl)C5=CN(N=C5)C,6.0,Cn1cc(-c2cc3cnc(Nc4ccc(-c5cncn5C)cc4Cl)cc3n2C(=O)OC(C)(C)C)cn1
3959,CHEMBL2165504,BXNGSUWUIWURRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C(C=CC5=C4C=CN5)F)N6CCOCC6,5.823908740944319,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
3972,CHEMBL252615,BXPDPGQJBGTDAC-GDBMZVCRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,11500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N,4.939302159646388,CC[C@@H]1CCC[C@H](C2(CC(N)=O)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
3978,CHEMBL590750,BXRPBINJKFNMDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153655.0,IC50,=,67000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC,Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway.,Bioorg. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1C)N(C(=N2)NCCCO)CC(=O)C3=CC(=C(C(=C3)C(C)(C)C)OC)C(C)(C)C,4.173925197299173,COc1c(C(C)(C)C)cc(C(=O)Cn2c(NCCCO)nc3cc(C)c(C)cc32)cc1C(C)(C)C
4006,CHEMBL3604734,BXZGSIDSJSGAJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,12589.25,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,CC1=CC(=C2C=CC=C(C2=N1)C(=O)N)NCC3=C(C=CC=C3F)C(F)(F)F,4.900000142057633,Cc1cc(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2n1
4012,CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,5000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,5.301029995663981,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
4013,CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,5000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,5.301029995663981,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
4014,CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,6.7447274948966935,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
4015,CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,851.14,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,6.069998998990925,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
4017,CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,100.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,7.0,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
4024,CHEMBL550242,BYFSZZCFOSXKJG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CC2=CC=CC=C2CC1NC(=O)N3CCC(CC3)C4=NC(=NO4)C5=CC=CC=N5,5.0,O=C(NC1CCc2ccccc2C1)N1CCC(c2nc(-c3ccccn3)no2)CC1
4060,CHEMBL2436629,BYPZYWWDUSSBJF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2CC3=CC=CC=C3C2)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,4.522878745280337,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5C4)CC3)CC2)ccn1
4105,CHEMBL179550,BZFNUUDZCGKAST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,750.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)OCC(=O)O)N4C=CN=C4)N(C)C,6.1249387366083,CC(C(c1ccc2cc(OCc3ccc(OCC(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C
4106,CHEMBL223156,BZGALMKCNIYKHV-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17027263.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)NC(=O)[C@]12CC3=C(C2)C=C(C=C3)NC(=O)CN4C5=CC=CC=C5N(C4=O)C6=CC=CC=N6,5.0,CN1C(=O)NC(=O)[C@]12Cc1ccc(NC(=O)Cn3c(=O)n(-c4ccccn4)c4ccccc43)cc1C2
4111,CHEMBL2434978,BZKHTWAGPLWPPO-LJAQVGFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24090135.0,IC50,>,60000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1N2[C@@H](CN(C2=O)C3CCOCC3)C4=CC=CC=C4)CC5=CN=C(C=C5)SC6=CC=C(C=C6)C(=O)O,4.221848749616356,O=C(O)c1ccc(Sc2ccc(CN3CCC(N4C(=O)N(C5CCOCC5)C[C@H]4c4ccccc4)CC3)cn2)cc1
4124,CHEMBL2017286,BZNFHPBYRCLAHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,12900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)CC5=CC=CC=N5)OC,4.889410289700751,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccn3)c12
4125,CHEMBL2017286,BZNFHPBYRCLAHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,12900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)CC5=CC=CC=N5)OC,4.889410289700751,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccn3)c12
4126,CHEMBL2338477,BZNKJBLTXSCEIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC2=C(C=CC(=C2)OC3=C(C=C(C=C3Cl)NS(=O)(=O)C4=C(C=C(C=C4)Cl)Cl)Cl)N=C1,6.0,O=S(=O)(Nc1cc(Cl)c(Oc2ccc3ncccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl
4134,CHEMBL393218,BZQDCQHUEYPQIB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCO)(C)C4=CC(=CC(=C4)F)F,4.522878745280337,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2
4142,CHEMBL257171,BZSFGIPFIXKNRM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C)OCC(=O)N2CC(=O)N3CCCC(C3CN4CCCC4)C5=CC=CC=C5,5.4089353929735005,Cc1cc2c(cc1C)N(CC(=O)N1CCCC(c3ccccc3)C1CN1CCCC1)C(=O)CO2
4143,CHEMBL3640764,BZSFZSCNTDEVRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,64710.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1CC(OC1CN)C2=CN=CC=C2,4.189028600177792,NCC1CCC(c2cccnc2)O1
4148,CHEMBL3087355,BZUSMKVXJJRSBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CC=NC=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,6.221848749616356,O=S(=O)(Nc1ccc(-c2ccncc2)cc1)c1cc(Cl)cc(Cl)c1
4149,CHEMBL3618396,BZVCZJLQADWIEF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26299347.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of a small molecule probe that restores e-cadherin expression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C2=CC(=NO2)C(=O)NCCCCNC(=O)C3=CC=CNC3=O,4.522878745280337,O=C(NCCCCNC(=O)c1ccc[nH]c1=O)c1cc(-c2ccccc2)on1
4164,CHEMBL3601397,BZZYIHQWCXHSMZ-FMSKOOSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26181851.0,IC50,=,11300.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.,J. Med. Chem.,PUBLICATION,,CC(C)OC1=C(C=C2CC(=O)N([C@H](C2=C1)C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)N(C)CC5CCC(CC5)N6CCNC(=O)C6)OC,4.94692155651658,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)CC3CCC(N4CCNC(=O)C4)CC3)cc1)C(=O)C2
4168,CHEMBL3605296,CACDSTLXMIALPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26183084.0,IC50,>=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CC2=C1N=C(O2)COC3=CC=CC=C3)C(=O)C4=C5C=CC=NC5=NN4,4.522878745280337,O=C(c1[nH]nc2ncccc12)N1CCc2nc(COc3ccccc3)oc2C1
4174,CHEMBL3582477,CAFMTLCLARMZDZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26005536.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=CN=CC(=C1)C2=NC3=CC(=C(C=C3N2C4CC4)F)F)O,4.301029995663981,CC(C)(O)c1cncc(-c2nc3cc(F)c(F)cc3n2C2CC2)c1
4175,CHEMBL1077343,CAFSWHHZBLDQKZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCC4=C(N(C=N4)C)Cl)N5CCC(CC5)N6CCN(CC6)C(=O)OC,6.154901959985743,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCCc6ncn(C)c6Cl)cc[nH]c5=O)[nH]c4c3)CC2)CC1
4182,CHEMBL2159132,CAGCEVDTTZJCHN-COMJDZGWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NC(C)C)O4)C)(C)O)C)C)C)O)(C)O,5.107905397309519,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NC(C)C)N3C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
4183,CHEMBL2159132,CAGCEVDTTZJCHN-COMJDZGWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NC(C)C)O4)C)(C)O)C)C)C)O)(C)O,5.0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NC(C)C)N3C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
4189,CHEMBL3218859,CAIAMTHZGVFCNA-XKPGHWPRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,CN1CCN(CC1)CC2=CC(=C(C=C2)C3=NC4=NC=C(C(=C4N3)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl)OC,4.522878745280337,COc1cc(CN2CCN(C)CC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
4190,CHEMBL3218859,CAIAMTHZGVFCNA-XKPGHWPRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,CN1CCN(CC1)CC2=CC(=C(C=C2)C3=NC4=NC=C(C(=C4N3)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl)OC,4.522878745280337,COc1cc(CN2CCN(C)CC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
4191,CHEMBL3216551,CAIIYVGKPOHHBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22318159.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"3,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase (nNOS) inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC(=CC1)C2=CNC3=C2C=C(C=C3)N=C(C4=CC=CO4)N.Cl.Cl,4.0,CN1CC=C(c2c[nH]c3ccc(N=C(N)c4ccco4)cc23)CC1
4194,CHEMBL2441848,CAJWPLGXCPYHLW-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CCN(CC)C(=O)[C@@H](C)N1CC2=NC(=C(C(=C2C1=O)C3=C(C=C(C=C3)Cl)Cl)CN)C,5.017728766960431,CCN(CC)C(=O)[C@@H](C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
4217,CHEMBL2204363,CAVNQHZFZKMWIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)Cl.Cl,5.259637310505756,Cc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1
4218,CHEMBL3125380,CAVORXGEZDVODE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C2=C1C=C(C=C2)F)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O,4.3979400086720375,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21
4221,CHEMBL463246,CAYMSCGTKZIVTN-TYILLQQXSA-N,ALPHA-CONIDENDRIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,COC1=C(C=C2[C@@H]([C@H]3COC(=O)[C@@H]3CC2=C1)C4=CC(=C(C=C4)O)OC)O,6.698970004336019,COc1cc([C@H]2c3cc(O)c(OC)cc3C[C@H]3C(=O)OC[C@H]23)ccc1O
4224,CHEMBL240436,CBDBSQHFOYMVSD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17236765.0,IC50,=,251.19,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of novel glycine sulfonamide antagonists for the EP1 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC=CC=C1N(CC(=O)NCC2=CC=C(C=C2)Cl)S(=O)(=O)C3=CC=C(C=C3)C,6.599997654072044,CCc1ccccc1N(CC(=O)NCc1ccc(Cl)cc1)S(=O)(=O)c1ccc(C)cc1
4225,CHEMBL2425889,CBELSOBXHKFTDF-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,91930.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=C2)C=C(C=C3)Cl)N4CCC[C@H](C4)N,4.036542739883292,CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(Cl)ccc3n2)c1=O
4227,CHEMBL3127507,CBGMGQVEMRTNGL-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@H]3C[C@@H]3C4=CN=CC=C4,6.853871964321762,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1
4228,CHEMBL3127507,CBGMGQVEMRTNGL-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@H]3C[C@@H]3C4=CN=CC=C4,5.823908740944319,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1
4231,CHEMBL3127506,CBGMGQVEMRTNGL-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@@H]3C[C@H]3C4=CN=CC=C4,6.568636235841013,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1
4232,CHEMBL3127506,CBGMGQVEMRTNGL-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@@H]3C[C@H]3C4=CN=CC=C4,5.522878745280337,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1
4250,CHEMBL2436219,CBIBCHQFCAJEHI-WUAPDDLWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@H]1[C@@H](C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=C(C=CC4=CC=CC=C43)C)NC(=O)[C@H](C)NC.Cl,4.494850021680094,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C
4270,CHEMBL3112864,CBPIBWZOJGKQSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,CC1CN(C2=CC=CC=C12)C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,CC1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21
4279,CHEMBL1357034,CBQRSKMWUASQDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27185330.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC2=NC=NC(=C12)N3CCC(CC3)C(=O)NC4=CC=C(C=C4)S(=O)(=O)N)C,4.698970004336019,Cc1sc2ncnc(N3CCC(C(=O)Nc4ccc(S(N)(=O)=O)cc4)CC3)c2c1C
4292,CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12161148.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,6.823908740944319,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
4293,CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852968.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,6.823908740944319,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
4294,CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852969.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,6.823908740944319,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
4295,CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,6.823908740944319,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
4304,CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,400.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,6.3979400086720375,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
4311,CHEMBL194838,CBZPNTGBQQEKFH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,59000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 at 100 uM; activation observed,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,C1CCC(CC1)C2=CC=C(C=C2)C3=C(C=C(C=C3)C4(CC4)C(=O)O)F,4.229147988357856,O=C(O)C1(c2ccc(-c3ccc(C4CCCCC4)cc3)c(F)c2)CC1
4316,CHEMBL1642419,CCAKTJSSELVUBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21134749.0,IC50,=,4610.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Indole-3-piperazinyl derivatives: novel chemical class of 5-HT(6) receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)C2=CN(C3=C2C=C(C=C3)Br)S(=O)(=O)C4=CC=C(C=C4)F,5.336299074610352,CN1CCN(c2cn(S(=O)(=O)c3ccc(F)cc3)c3ccc(Br)cc23)CC1
4317,CHEMBL217716,CCCCPSHFLXQUBH-UHFFFAOYSA-N,ADS-102550,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17107790.0,IC50,=,53000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1OC2=C(O1)C=C(C=C2)CNCCN3C=CC(=N3)C4=CC=C(S4)C(=O)NO,4.275724130399211,O=C(NO)c1ccc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)s1
4318,CHEMBL217716,CCCCPSHFLXQUBH-UHFFFAOYSA-N,ADS-102550,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18247554.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Histone deacetylase inhibitors: from bench to clinic.,J. Med. Chem.,PUBLICATION,,C1OC2=C(O1)C=C(C=C2)CNCCN3C=CC(=N3)C4=CC=C(S4)C(=O)NO,6.292429823902063,O=C(NO)c1ccc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)s1
4319,CHEMBL390529,CCCCRDFOGIQSFC-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC3=C(C=C(C=C3Cl)Cl)C(=O)N2CC4=CC=CC=C4C#N)N,7.096910013008056,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2c(Cl)cc(Cl)cc2c1=O
4323,CHEMBL3673972,CCCJZGXGIRJBEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320642,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=NC=CC(=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)Cl)F,5.301029995663981,Cc1cc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)ccn1
4324,CHEMBL3673972,CCCJZGXGIRJBEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320686,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=NC=CC(=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)Cl)F,5.301029995663981,Cc1cc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)ccn1
4330,CHEMBL2059880,CCCSWRIKNOQGJG-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,84.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CSC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,7.075720713938118,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
4331,CHEMBL2059880,CCCSWRIKNOQGJG-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,870.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 20 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CSC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,6.060480747381382,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
4333,CHEMBL442078,CCGWWGUXCYXFJW-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=C2C=CC=N3)C(=O)C4=CC=CC=C4,4.3979400086720375,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ncccc12
4334,CHEMBL442078,CCGWWGUXCYXFJW-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=C2C=CC=N3)C(=O)C4=CC=CC=C4,4.3979400086720375,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ncccc12
4342,CHEMBL433737,CCLDRSRWGWGQAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=NOC=C2,4.0,CCCCOc1ccc(-c2ccon2)cc1
4349,CHEMBL1801172,CCNVIJIUJHRGEQ-PIIMJCKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21080647.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2[C@@H](C2NS(=O)(=O)C3=CC4=CC=CC=C4C=C3)CN1C5=NC=C(C=N5)C(=O)NO,5.0,O=C(NO)c1cnc(N2C[C@H]3C(NS(=O)(=O)c4ccc5ccccc5c4)[C@H]3C2)nc1
4361,CHEMBL372751,CCTCISPYUXWOGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,84000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,CC1(CCC(CC1)C2=CC=C(C=C2)C3=C(C=C(C=C3)C4(CC4)C(=O)O)F)C,4.075720713938118,CC1(C)CCC(c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC1
4370,CHEMBL2448701,CCXZVZZEXQTCSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CS(=O)(=O)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(N=C3)C4=CC=CC=C4,4.698970004336019,CS(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
4380,CHEMBL271039,CDBUNSHQNIFGRK-WXFUMESZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=CO1)[C@H](C(=O)N2CCOCC2)N3[C@@H](C(=O)N[C@@H](C3=O)C4CC5=CC=CC=C5C4)CC(C)C,4.0,Cc1nc([C@H](C(=O)N2CCOCC2)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1
4385,CHEMBL1671969,CDGHAZKBGHJYNI-PXNMLYILSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,9800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)/C=C\2/C(=O)NC(=O)S2)OC3=C(C=C(C=C3)C(=O)OC)C(F)(F)F,5.008773924307505,COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c(C(F)(F)F)c1
4396,CHEMBL3629745,CDKNJSXTOTWFRF-CKNGDLFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,CP1(=O)OCC[C@]2(CCC[C@@]3([C@H]2COC4=C(C=CC(=C43)F)F)S(=O)(=O)C5=CC=C(C=C5)Cl)CO1,4.698970004336019,CP1(=O)OCC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1
4397,CHEMBL3629745,CDKNJSXTOTWFRF-CKNGDLFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,CP1(=O)OCC[C@]2(CCC[C@@]3([C@H]2COC4=C(C=CC(=C43)F)F)S(=O)(=O)C5=CC=C(C=C5)Cl)CO1,4.698970004336019,CP1(=O)OCC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1
4449,CHEMBL1671981,CEHJREUZXNARDW-JAIQZWGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)/C=C\2/C(=O)NC(=O)S2)OC3=CC=C(C4=CC=CC=C43)C#N,5.346787486224656,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C#N)c2ccccc12
4454,CHEMBL1287844,CEIFOMPAGWECHH-GNAFDRTKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@]1(CCCN(C1)C2=CC3=C(N2CC4=C(C=CC(=C4)F)Cl)C(=O)N(C(=O)N3CCCO)C)N.Cl,5.113509274827518,Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2Cl)n(CCCO)c1=O
4459,CHEMBL1921984,CEJQKSWZQAQWOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)NC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O,5.0,CC(C)NC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
4460,CHEMBL593573,CEKSBBZAKLNEBU-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC1=C(C=C(C(=N1)C2=COC=C2)C3=NC4=C(NN=C4N=C3)C)OC[C@H](CC5=CC=CC=C5)N,5.301029995663981,CCNc1nc(-c2ccoc2)c(-c2cnc3n[nH]c(C)c3n2)cc1OC[C@@H](N)Cc1ccccc1
4461,CHEMBL3699330,CELMLYCAIZGNJJ-ZYBCLOSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCCCOC1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(OCCCC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
4468,CHEMBL2163365,CENBBVPSOFGGNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23006603.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=C2C=C(C(=NC2=NC(=C1C(=O)N)N)C(F)(F)F)Br,4.301029995663981,NC(=O)c1cc2cc(Br)c(C(F)(F)F)nc2nc1N
4474,CHEMBL3116158,CEQKVTUACFLLOZ-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@](C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC(=CS4)C(F)(F)F,4.3979400086720375,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)cs2)c2ccc(Cl)cn2)c1
4475,CHEMBL3116158,CEQKVTUACFLLOZ-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@](C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC(=CS4)C(F)(F)F,4.3979400086720375,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)cs2)c2ccc(Cl)cn2)c1
4482,CHEMBL405895,CETJSTBZOJQTPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18374569.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(=NC2=C(C=C(C(=C2)O)C3=CC=CC=C3F)NC1=O)C4=CC(=CC=C4)N5C=CN=C5,9.0,O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2cc(O)c(-c3ccccc3F)cc2N1
4495,CHEMBL478223,CEVYRUFPINJHBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=C4Cl,5.6020599913279625,O=S(=O)(c1ccccc1Cl)n1ccc2cc3c(cc21)CCNCC3
4496,CHEMBL478223,CEVYRUFPINJHBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=C4Cl,5.494850021680094,O=S(=O)(c1ccccc1Cl)n1ccc2cc3c(cc21)CCNCC3
4501,CHEMBL3645517,CEYMUNJCMDJNBN-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,CC1=CC(=O)N(N=C1C2=CC=C(C=C2)[C@H](C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4)C,4.301029995663981,Cc1cc(=O)n(C)nc1-c1ccc([C@H](C)N2CC[C@](CC(C)(C)O)(c3ccccc3)OC2=O)cc1
4503,CHEMBL3664682,CEZXLGMJECLVEW-SIBVEZHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,47000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CC[C@](OC3=O)(COC)C4=CC=CC=C4,4.327902142064283,COC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccn(C)c(=O)c3)cc2)C(=O)O1
4509,CHEMBL1766178,CFCJVXMNOZCNMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)C(=O)NC)(C3=CN=CN3)O,5.0915149811213505,CNC(=O)c1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)c1
4511,CHEMBL1760005,CFDMYSOWNDTWLE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21414782.0,IC50,>,3162.28,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Phenoxyacetic acids as PPARd partial agonists: synthesis, optimization, and in vivo efficacy.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN(C1=CC=CC(=C1Cl)C2=CC=C(C=C2)OC(F)(F)F)S(=O)(=O)C3=C(C(=C(C=C3)OC(C)C(=O)O)C)C,5.499999678657065,CCCCN(c1cccc(-c2ccc(OC(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C
4515,CHEMBL3137482,CFIZCTGVWKFBQU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC(C)(CN1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)F,4.795880017344075,CC(C)(F)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
4522,CHEMBL151280,CFJNAALMLFXEDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,51100.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CC=NC=C2,4.291579099865287,CCCCOc1ccc(-c2ccncc2)cc1
4543,CHEMBL2407953,CFRHKPBZEFZZII-WNAAXNPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1C(C/C(=N\O)/C2=CC(=NC=C2)C)C3=CC=C(C=C3)CC(=O)O,4.301029995663981,Cc1cc(/C(CC(c2ccc(CC(=O)O)cc2)c2ccccc2C)=N/O)ccn1
4551,CHEMBL3408945,CFVRISSXNGRSCL-PPDHBDSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CN1C2=C(C=C(C=C2)OC)[C@@]3(C1=O)C[C@H]3C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=C(C=C6)CN7CCOCC7,5.221848749616356,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C
4552,CHEMBL3408945,CFVRISSXNGRSCL-PPDHBDSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CN1C2=C(C=C(C=C2)OC)[C@@]3(C1=O)C[C@H]3C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=C(C=C6)CN7CCOCC7,4.698970004336019,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C
4556,CHEMBL2420684,CFXIOEDBHCGEDY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,5046.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC2=C1C=CC(=C2Cl)C3=CC(=CN=C3)O)O,5.297052753818444,Oc1cncc(-c2ccc3ccc(O)cc3c2Cl)c1
4557,CHEMBL499584,CFXKXVRFVROHAJ-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,5.6,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)COC,8.2518119729938,COCC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
4570,CHEMBL393576,CGANDSYNDFLFKG-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCN,5.309803919971486,CC(C)C[C@H](NCCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
4575,CHEMBL3608686,CGCSZFVIPKLGCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC1=NSC(=N1)C2=NN=C3N2CCN(C3(C)C)C(=O)C4=CC=C(C=C4)F,4.0,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3(C)C)n1
4580,CHEMBL447822,CGEKXOQYPSFQKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CC=CC=N4,5.886056647693163,Cc1cccc(C)c1CNc1cc(-c2ccccn2)cn2c(C)c(C)nc12
4581,CHEMBL447822,CGEKXOQYPSFQKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CC=CC=N4,5.7447274948966935,Cc1cccc(C)c1CNc1cc(-c2ccccn2)cn2c(C)c(C)nc12
4598,CHEMBL1209556,CGIWGBIOKQVESP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)C(F)(F)F,7.167491087293763,CC(C)CC1n2cncc2CN(Cc2ccc(C(F)(F)F)cc2)S1(=O)=O
4599,CHEMBL1209556,CGIWGBIOKQVESP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)C(F)(F)F,6.552841968657781,CC(C)CC1n2cncc2CN(Cc2ccc(C(F)(F)F)cc2)S1(=O)=O
4603,CHEMBL1761525,CGKWKTZGGPMTQN-AQZQMVTRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OC[C@H]5C[C@@H]5C(=O)O)C6CC6)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)O)c1
4604,CHEMBL1761525,CGKWKTZGGPMTQN-AQZQMVTRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OC[C@H]5C[C@@H]5C(=O)O)C6CC6)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)O)c1
4607,CHEMBL503624,CGMLBVPTUVDZPK-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)CNCC1=CC=C(C=C1)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,6.455931955649724,CCOC(=O)CNCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1
4608,CHEMBL503624,CGMLBVPTUVDZPK-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)CNCC1=CC=C(C=C1)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,6.455931955649724,CCOC(=O)CNCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1
4609,CHEMBL1761534,CGMNUBKHKAKYOW-AARKOHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC(CC)(CCOC1=CC(=CC(=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)CCCOC)C(=O)O,4.301029995663981,CCC(CC)(CCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1)C(=O)O
4610,CHEMBL1761534,CGMNUBKHKAKYOW-AARKOHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC(CC)(CCOC1=CC(=CC(=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)CCCOC)C(=O)O,4.301029995663981,CCC(CC)(CCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1)C(=O)O
4624,CHEMBL2181635,CGZHPIHDTXQFRE-CXUHLZMHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=NC=C(C=C5)F)C6CCCC6,5.173925197299173,Cn1c(-c2ccc(F)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21
4632,CHEMBL560386,CHCVZZOPCAVWNV-HTAPYJJXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19520574.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1[C@@H](OC2=C(C=CC=C2S1(=O)=O)OC)C3=CC=C(C=C3)OCCCN4CCCC4,5.0,COc1cccc2c1O[C@@H](c1ccc(OCCCN3CCCC3)cc1)[C@H](C)S2(=O)=O
4644,CHEMBL2041172,CHHBYJXILWRZEG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC7=C(C=C6)C=NN7,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc5cn[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
4645,CHEMBL3088175,CHHHEJNQMGBWRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,48000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,J. Med. Chem.,PUBLICATION,,CC1=CSC(=N1)C(C)(C2=NN=C(S2)NC3=NN(C=N3)CC4=C(C=CC=C4F)F)O,4.318758762624412,Cc1csc(C(C)(O)c2nnc(Nc3ncn(Cc4c(F)cccc4F)n3)s2)n1
4649,CHEMBL3215861,CHLPUMOYKYJFFH-PFNYCKIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,=,2730.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)/C=C/C(=O)NO.Cl.Cl,5.5638373529592435,CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC
4650,CHEMBL3215861,CHLPUMOYKYJFFH-PFNYCKIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)/C=C/C(=O)NO.Cl.Cl,4.6020599913279625,CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC
4659,CHEMBL2041187,CHORIEKBRNXNSE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CC=N4)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)O,5.0,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ncccn1
4669,CHEMBL2178714,CHTLTXJCMNCJSN-MBSDFSHPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22989333.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor a Bioactive Conformation.,J. Med. Chem.,PUBLICATION,,CN1C(=O)[C@@H]2CN(C[C@@]2(N=C1N)C3=CC(=CS3)C4=CC=CC(=C4)C#N)C5=NC=C(C=C5)F,5.221848749616356,CN1C(=O)[C@@H]2CN(c3ccc(F)cn3)C[C@]2(c2cc(-c3cccc(C#N)c3)cs2)N=C1N
4672,CHEMBL3291340,CHVFRXVZTYHSFP-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@]12CC[C@@H](C1(C)C)C3=C2N(N(C3=O)C4=CC=CC=C4)CC5=CC=CC=C5,5.113509274827518,CC1(C)[C@@H]2CC[C@@]1(C)c1c2c(=O)n(-c2ccccc2)n1Cc1ccccc1
4676,CHEMBL525049,CHVUDHLIDGFAMH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18479916.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CC#CC1=C(C=CN=C1N)OC2=C(C=C(C=C2)NC(=O)NC(=O)CC3=CC=C(C=C3)F)F,5.568636235841013,CN(C)CC#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N
4677,CHEMBL3260740,CHWARCWCRWGSGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,CN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=CN=C(C=C3)C(F)(F)F)C4=CC=NC=C4)C5=CC=C(C=C5)Cl,5.180456064458132,Cn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O
4698,CHEMBL2441846,CIBRWLRGRGMMMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CCN(CC)C(=O)CN1CC2=NC(=C(C(=C2C1=O)C3=C(C=C(C=C3)Cl)Cl)CN)C,5.180456064458132,CCN(CC)C(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
4699,CHEMBL397584,CICLLDVQTZRNHL-MFMCTBQISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=CC=CC=C1N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCN(C)C,5.161150909262744,CC(C)C[C@H](NC(=O)CCN(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
4715,CHEMBL78742,CIFGPLIJBYKXOG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,CC1C2=CC(=C(C=C2)C#N)OC3=CC=CC(=C3)CN4CCC(C4=O)NCC5=CN=CN15,5.214670164989233,CC1c2ccc(C#N)c(c2)Oc2cccc(c2)CN2CCC(NCc3cncn31)C2=O
4717,CHEMBL2448738,CIFZHDRCJUNMFW-LQKURTRISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C/C(=N\OC)/C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=NC=C(N=C3)C4=CC=CC=C4,5.096910013008056,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)cn2)c1
4721,CHEMBL3634101,CIGZUVLALLRNKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26355532.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition,Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).,Eur. J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C=CC=C2NC(=O)NC3=C(C=C4C=NC=NC4=C3)OCC5=CC(=CC=C5)Cl,5.0,O=C(Nc1cc2ncncc2cc1OCc1cccc(Cl)c1)Nc1cccc2ccccc12
4725,CHEMBL3137477,CIJXDSNTGMSJOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,17000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CCC(C(C)O)N1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3,4.769551078621726,CCC(C(C)O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
4729,CHEMBL2012228,CIPPBSIONMAVDW-NSHDSACASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22401864.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of oxazole-based PDE4 inhibitors with picomolar potency.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=C(N=C(O1)C2=C3C=CC(=NC3=C(C=C2)OC)C(F)(F)F)C(=O)NCC4=C(C=C(C=C4)F)F)N,5.096910013008056,COc1ccc(-c2nc(C(=O)NCc3ccc(F)cc3F)c([C@H](C)N)o2)c2ccc(C(F)(F)F)nc12
4732,CHEMBL3137392,CISLUIONUORHLO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CN=C4,4.698970004336019,O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
4737,CHEMBL315766,CITYKBCBSLSOSB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN(N=C5)C,5.698970004336019,CCN(CC)CCCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
4746,CHEMBL3394724,CIUHVWRNTOWXDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1CCC(CC1)S(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,CC(C)CN1CCC([S+]([O-])c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1
4747,CHEMBL3394724,CIUHVWRNTOWXDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1CCC(CC1)S(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,CC(C)CN1CCC([S+]([O-])c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1
4783,CHEMBL1829777,CJDCHYFYWWTCPZ-CBZJRKILSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCC(=O)N)C4=CC=C(C=C4)F,4.522878745280337,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCC(N)=O)(c2ccc(F)cc2)OC1=O
4796,CHEMBL3672582,CJGMOBVTWWMPMK-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,130.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.886056647693163,CC(C)c1nc(CN(C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
4797,CHEMBL3672582,CJGMOBVTWWMPMK-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,260.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.585026652029182,CC(C)c1nc(CN(C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
4798,CHEMBL3672583,CJGMOBVTWWMPMK-ZAPWPRAASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,110.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.958607314841775,CC(C)c1nc(CN(C)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
4799,CHEMBL3672583,CJGMOBVTWWMPMK-ZAPWPRAASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,250.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.6020599913279625,CC(C)c1nc(CN(C)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
4802,CHEMBL1086657,CJHXBFSJXDUJHP-UHFFFAOYSA-N,MK-6892,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20184326.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.,J. Med. Chem.,PUBLICATION,,CC(C)(CC1=NC(=NO1)C2=NC=C(C=C2)O)C(=O)NC3=C(CCCC3)C(=O)O,4.0,CC(C)(Cc1nc(-c2ccc(O)cn2)no1)C(=O)NC1=C(C(=O)O)CCCC1
4832,CHEMBL2397307,CJQUPESWNTXRJX-MOPGFXCFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,980.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1[C@H](CC[C@H]1C(=O)NC2=NC=C(S2)C3=CC=C(C=C3)N)C4=CC=CC=C4,6.008773924307505,CC(=O)N1[C@H](C(=O)Nc2ncc(-c3ccc(N)cc3)s2)CC[C@@H]1c1ccccc1
4833,CHEMBL1829772,CJSISZXPMQBPSZ-CBZJRKILSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCNC(=O)N)C4=CC=C(C=C4)F,5.301029995663981,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNC(N)=O)(c2ccc(F)cc2)OC1=O
4834,CHEMBL3699319,CJSPFBXNXWDZGH-CRKOEVGVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C4=CN(C5=C(C=CC=C45)CN6C[C@H]7N([C@H](C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCN(C(C)=O)CC7)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
4837,CHEMBL1911829,CJULAJSWQHZFAG-JWQCQUIFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@@H](C2)NC(=O)[C@@H](COCC3=CC=CC=C3)NC(=O)C4=C(N=CC=C4)OC5=C(C=C(C=C5)C(F)(F)F)Cl,4.698970004336019,O=C(N[C@H](COCc1ccccc1)C(=O)N[C@@H]1CN2CCC1CC2)c1cccnc1Oc1ccc(C(F)(F)F)cc1Cl
4838,CHEMBL1911830,CJULAJSWQHZFAG-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@H](C2)NC(=O)[C@@H](COCC3=CC=CC=C3)NC(=O)C4=C(N=CC=C4)OC5=C(C=C(C=C5)C(F)(F)F)Cl,4.698970004336019,O=C(N[C@H](COCc1ccccc1)C(=O)N[C@H]1CN2CCC1CC2)c1cccnc1Oc1ccc(C(F)(F)F)cc1Cl
4841,CHEMBL3087669,CJUSJFAZUSWFLY-KXBFYZLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139584.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 4 hrs,"Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depression.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CCCN1[C@H]2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(ON=C4C)C)C,4.0,Cc1cc(N2CC[C@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1c(C)noc1C
4842,CHEMBL179691,CJUWBZDJMYYRDG-QFIPXVFZSA-N,NBI-42902,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)F)C[C@@H](C3=CC=CC=C3)N)C4=C(C(=CC=C4)OC)F,6.154901959985743,COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F
4854,CHEMBL2057523,CKAAVBBZRMQHBC-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC3CCCCC3)C[C@H]([C@H](CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5)O,7.585026652029182,CCN(C)c1nc2ccc(C(=O)N(CC3CCCCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
4859,CHEMBL256092,CKCKWQLHSQKPAK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18462938.0,IC50,>=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NN1CC2=C(C=CC(=C2)Cl)OCC3=CC=CC=C3)NC(=O)OC(C)C,4.0,Cc1cc(NC(=O)OC(C)C)nn1Cc1cc(Cl)ccc1OCc1ccccc1
4861,CHEMBL178711,CKCZUAVVHJHNJY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,>,400000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CC=C(S2)CNCC3=CC=C(S3)C4=CN=CC=C4,3.3979400086720375,c1cncc(-c2ccc(CNCc3ccc(-c4cccnc4)s3)s2)c1
4864,CHEMBL205092,CKDWXXGKUKOVBA-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CC3=CNC4=C3C=CC=N4)C(=O)N5CC[C@H](C5)O)C(=O)N(C1=O)C,5.173925197299173,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3c[nH]c4ncccc34)sc21
4887,CHEMBL1779003,CKMRXGUDSNAKMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21524576.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Iinhibition of CYP3A4,"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=CC(=C1)F)C2=CN=CC(=C2)CNC3CCCC3,4.698970004336019,COc1cc(F)ccc1-c1cncc(CNC2CCCC2)c1
4899,CHEMBL3338866,CKTWQGHVNRYNCM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26317591.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.,J. Med. Chem.,PUBLICATION,,COC1=C(N=C(C=C1)CNC(=O)C2=C(N=CC(=C2)C3=CC(=CN=C3)Cl)C4=CC=CC=N4)OC,4.552841968657781,COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC
4906,CHEMBL387785,CKVMUGZRWPZHCY-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,CC1=CN(C=N1)CC(=O)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4C[C@@H](OC4=O)CN5C=CN=N5)F,4.698970004336019,Cc1cn(CC(=O)c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)cn1
4916,CHEMBL2441830,CKZFVWOHYQPQSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)C3=CC=CC=C3OC)C4=C(C=C(C=C4)Cl)Cl)CN,6.096910013008056,COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
4917,CHEMBL2441830,CKZFVWOHYQPQSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)C3=CC=CC=C3OC)C4=C(C=C(C=C4)Cl)Cl)CN,5.468521082957745,COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
4919,CHEMBL262321,CLCIJGHLOGXLMK-KBKXWFDOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)[C@H](CC(C)C)NC(=O)[C@@H](C)N,5.5376020021010435,Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@H](CC(C)C)NC(=O)[C@@H](C)N)c1
4929,CHEMBL1774924,CLFXZSRJZJUGCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,C1C2CC1(C2)NC(=O)N3CC4=C(C3)N=C(N=C4C5=C(C=C(C=C5Cl)Cl)OCCN6C=CC=N6)N,5.958607314841775,Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)n1)CN(C(=O)NC13CC(C1)C3)C2
4933,CHEMBL3116155,CLGKMSSPTGEPGJ-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@](C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=C(N4)C=C(C=C5)F,4.494850021680094,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3ccc(F)cc3[nH]2)c2ccc(Cl)cn2)c1
4934,CHEMBL3116155,CLGKMSSPTGEPGJ-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@](C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=C(N4)C=C(C=C5)F,4.3979400086720375,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3ccc(F)cc3[nH]2)c2ccc(Cl)cn2)c1
4942,CHEMBL399973,CLMFOKCFOQCBFM-MDETZSQFSA-N,FIBLEUCINOSIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,C[C@@]12CC=C3C(=O)O[C@H](C[C@]3([C@@H]1[C@H]4C=C[C@@]2(C(=O)O4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)C6=COC=C6,4.0,C[C@@]12C[C@H](c3ccoc3)OC(=O)C1=CC[C@]1(C)[C@H]2[C@H]2C=C[C@]1(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)O2
4944,CHEMBL599060,CLMVMIDTRWHVDW-REPLKXPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)C(=O)N(CC2=CC(=C(C=C2)F)OC3CCCC3)C4C[C@@H]5CNC[C@@H]5C4,5.0,Cn1cnc(C(=O)N(Cc2ccc(F)c(OC3CCCC3)c2)C2C[C@@H]3CNC[C@@H]3C2)c1
4945,CHEMBL1910114,CLNAIMPDNPYUGV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CCOC)C3=C(C=C(C=C3)Cl)Cl)CN,4.657577319177793,COCCN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
4949,CHEMBL3612341,CLPULQHKORXKMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26344593.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)CN3C=NC(=N3)[N+](=O)[O-],4.698970004336019,O=C(Cn1cnc([N+](=O)[O-])n1)Nc1cccc(-c2ccccc2)c1
4951,CHEMBL2448725,CLRJHAXDAVPZGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1=CC=C(C=C1)C2=NC=C(C=N2)C(=O)NC3=CC=CC=C3N4C=CN=C4,5.0,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)nc1
4957,CHEMBL3601398,CLRSLRWKONPSRQ-IIPSPAQQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26181851.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.,J. Med. Chem.,PUBLICATION,,CC(C)OC1=C(C=C2CC(=O)N([C@H](C2=C1)C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)N(C)CC5CCC(CC5)N6CCN(C(=O)C6)C)OC,4.769551078621726,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)CC3CCC(N4CCN(C)C(=O)C4)CC3)cc1)C(=O)C2
4970,CHEMBL1910112,CLVFBWMMCGAYBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)O)C3=C(C=C(C=C3)Cl)Cl)CN,4.3979400086720375,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)O)C2=O
4977,CHEMBL3673947,CLVZDUIYCBVJLA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320625,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3F)c2c1
4978,CHEMBL3673947,CLVZDUIYCBVJLA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320669,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3F)c2c1
5007,CHEMBL3702779,CMJPMPFRFCDLAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2380.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)(C)CNC1=NC=C(C=C1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.623423042943488,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCC(C)(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
5011,CHEMBL1209322,CMLALAZUOVTKKV-HKUYNNGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP1A2,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCCCCC1=NC(=NO1)C2=CC=C(C=C2)CNC(=O)[C@@H]3[C@H](CCN3)O,5.301029995663981,CCCCCCCc1nc(-c2ccc(CNC(=O)[C@H]3NCC[C@@H]3O)cc2)no1
5012,CHEMBL1209322,CMLALAZUOVTKKV-HKUYNNGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCCCCC1=NC(=NO1)C2=CC=C(C=C2)CNC(=O)[C@@H]3[C@H](CCN3)O,5.301029995663981,CCCCCCCc1nc(-c2ccc(CNC(=O)[C@H]3NCC[C@@H]3O)cc2)no1
5013,CHEMBL1829779,CMLGYKTUOFEFSU-XRHLQHRESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCCN)C4=CC=C(C=C4)F,5.698970004336019,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCN)(c2ccc(F)cc2)OC1=O
5014,CHEMBL387125,CMLJYPLKIKPWDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,44000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,CC1=NC(=C(N1CC2=C(C3=C(S2)N(C(=O)N(C3=O)C)CC(C)C)C(=O)N(C)OC)Cl)Cl,4.356547323513813,CON(C)C(=O)c1c(Cn2c(C)nc(Cl)c2Cl)sc2c1c(=O)n(C)c(=O)n2CC(C)C
5016,CHEMBL2041176,CMMVRTXWYOGXHR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C#N,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C#N)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
5027,CHEMBL595944,CMPFTOKTVXYPFY-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OC[C@H](CC5=CNC6=CC=CC=C65)N,5.301029995663981,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2n1
5032,CHEMBL3645516,CMRQSUMZGCSHON-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,31000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,CC1=CC(=NN(C1=O)C)C2=CC=C(C=C2)[C@H](C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.508638306165727,Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)nn(C)c1=O
5033,CHEMBL2151921,CMRWHXYMZPXJTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1C2=CC(=O)NC(=N2)CC(=O)NC3=CC(=CC=C3)Cl,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Cl)c1
5044,CHEMBL2058900,CMTFRXHEOAAMBF-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,23.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@H]([C@H](CC3=CC=C(C=C3)F)NC(=O)OCC4=CN=CS4)O)CC(C)C,7.638272163982407,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccc(F)cc3)NC(=O)OCc3cncs3)cc2o1
5047,CHEMBL397368,CMVZNDZAGPCNJV-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)C(C)(C)N,4.552841968657781,CC(C)C[C@H](NC(=O)C(C)(C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
5061,CHEMBL3702743,CNCXIRXUMVEQSR-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3580.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCOC(=O)CCNC(=O)C1=CN(C2=C(C=CC=C12)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C,5.446116973356125,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCC(=O)OCC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
5067,CHEMBL3350935,CNEBXOWFQASQAR-FTDXYOEWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16033281.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against Cytochrome 450 3A4,"Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)C4)N,4.698970004336019,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(C3)C1)C2
5090,CHEMBL3604733,CNMKNEFBMQWAQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=CC=C1)Cl)CNC2=C3C=CC=C(C3=NC(=C2)C)C(=O)N,5.0,Cc1cc(NCc2c(C)cccc2Cl)c2cccc(C(N)=O)c2n1
5104,CHEMBL1097982,CNSKMPGFRZEZNV-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CC(=O)NCCF,5.619788758288394,Cc1cc(N2CCN(CC(=O)NCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
5123,CHEMBL2397310,COAOLJMLZGYFOT-KLPPZKSPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)C2CCC(CC2)C(F)(F)F)C3=CN=C(C=C3)N,4.522878745280337,Cc1nc(NC(=O)C2CCC(C(F)(F)F)CC2)sc1-c1ccc(N)nc1
5134,CHEMBL2041169,COBUMZLYZWRZDS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CC=NN7,4.301029995663981,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(-c4ccn[nH]4)cc3)cc1)C(=O)N2c1cc(=O)[nH]cn1
5138,CHEMBL246161,COCZJEZLXFFSJJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BFC substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC1CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,4.552841968657781,O=[N+]([O-])c1cnc(NCc2ccccc2Cl)nc1NCC1CCNCC1
5139,CHEMBL246161,COCZJEZLXFFSJJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BQ substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC1CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,4.522878745280337,O=[N+]([O-])c1cnc(NCc2ccccc2Cl)nc1NCC1CCNCC1
5141,CHEMBL3115164,COERSDJIGACFAR-JBKHTMJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N[C@H](CC[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC3=CC=CC=C3)NC(=O)N(CC4=CSC=N4)C5CC5,7.0,CC(C)[C@H](NC(=O)N(Cc1cscn1)C1CC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
5148,CHEMBL226067,COHGAWYVUMIFCS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,82000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1CCC(CC1)CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC=C3)Cl,4.086186147616283,O=C(NCC1CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
5162,CHEMBL3702790,CONPEJUHYPYMIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6950.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC(CC8)O,5.158015195409886,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
5175,CHEMBL1222719,CORLLIXOPXNVDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)OCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,5.221848749616356,CC(C)OCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
5178,CHEMBL3358925,COSBNJYEIDBEST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)C4=CC=CC=C4)(C(F)(F)F)O,5.522878745280337,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(-c3ccccc3)ncc2[nH]1)C(F)(F)F
5184,CHEMBL3104476,COTNVRIGCSTBHG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1N(C2=CC=C(C=C2)C#N)C3=CN=CC=C3)C4=CC=C(C=C4)C(F)(F)F,4.698970004336019,N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1
5185,CHEMBL3104476,COTNVRIGCSTBHG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C#N)C3=CN=CC=C3)C4=CC=C(C=C4)C(F)(F)F,4.698970004336019,N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1
5205,CHEMBL1170367,CPBGMRFHFZVCLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21388809.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of benzothiazole-based adenosine A2B receptor antagonists with improved A2A selectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C1=C2C(=C(C=C1)OC)N=C(S2)NC(=O)C3=CC=NN3C)C(=O)C,4.301029995663981,CCN(C(C)=O)c1ccc(OC)c2nc(NC(=O)c3ccnn3C)sc12
5206,CHEMBL2069588,CPBSLAZOCYUNLG-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22884988.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CC(=C1)C2=CNC(=O)C(=C2)NC(=O)[C@H](CC3=CC=CC=C3)NCC4=CSC=N4,4.522878745280337,Cc1cc(-c2c[nH]c(=O)c(NC(=O)[C@H](Cc3ccccc3)NCc3cscn3)c2)ccn1
5216,CHEMBL1950085,CPFAZCJKWPHSEL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)O)Cl,6.522878745280337,Cc1cc(Cl)cc2c(C(O)c3ccncc3)c3c(C)[nH]nc3nc12
5217,CHEMBL1950085,CPFAZCJKWPHSEL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)O)Cl,6.301029995663981,Cc1cc(Cl)cc2c(C(O)c3ccncc3)c3c(C)[nH]nc3nc12
5223,CHEMBL230626,CPHIGNAWKKTAEQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC12C(=O)NC(=O)N2C3=CC=CC=C3)CC4=CC=C(C=C4)C5=CC=CC(=C5)C#N,5.0,N#Cc1cccc(-c2ccc(CN3CCC4(CC3)C(=O)NC(=O)N4c3ccccc3)cc2)c1
5253,CHEMBL521029,CPUAZCHEZPJRLH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CN=C3)N4CCOCC4)C,4.698970004336019,CC(=O)Nc1cc(-c2cncc(N3CCOCC3)c2)nc(-n2nc(C)cc2C)n1
5260,CHEMBL1241824,CQARAGSWXSYCDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N(C)C,5.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N(C)C)ncn4-5)CC3)cccc2n1
5261,CHEMBL1241824,CQARAGSWXSYCDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N(C)C,5.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N(C)C)ncn4-5)CC3)cccc2n1
5265,CHEMBL270903,CQAZSXLFKOPBIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CC=C(C=C1)CN2C=C(C=N2)C3=CC=NC=C3,4.585026652029182,CS(=O)(=O)c1ccc(Cn2cc(-c3ccncc3)cn2)cc1
5287,CHEMBL2448694,CQJBXYSWHIUOHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCOC(=O)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(N=C3)C4=CC=CC=C4,4.698970004336019,CCOC(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
5288,CHEMBL1923113,CQJOBYOSYKVBFX-HXOBKFHXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=C(C(=CC=C2)Cl)Cl)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F,5.251811972993799,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc(Cl)c1Cl)C1CC1
5294,CHEMBL2441837,CQMFJBQSRKSKOJ-JTQLQIEISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)[C@@H](C)COC)C3=C(C=C(C=C3)Cl)Cl)CN,4.886056647693163,COC[C@H](C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
5297,CHEMBL486162,CQMWNSQCEMHNIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCN(CC4)C)C,4.698970004336019,CC(=O)Nc1cc(-c2cccc(N3CCN(C)CC3)n2)nc(-n2nc(C)cc2C)n1
5320,CHEMBL2448752,CQVOELRYLBGVRX-LQKURTRISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C/C(=N\OC)/C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=NC(=CN=C3)C4=CC=CC=C4,6.0,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cncc(-c3ccccc3)n2)c1
5324,CHEMBL1094457,CQVTWPREUGIHHR-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CC(=O)NC,5.585026652029182,CNC(=O)CN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
5355,CHEMBL2436324,CRHRZPMSHOKHNW-MKSBGGEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)C(=O)CC(C)C)NC.Cl,4.823908740944319,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2ccccc2)C1=O
5357,CHEMBL3702732,CRIDHUXOEBDKJZ-LQJZCPKCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16180.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCO,4.791021482723746,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
5363,CHEMBL515644,CRKSLOZUCXTFQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=CC=CC=C2C(C3=C(O1)C=CC(=C3)F)CNC(=O)CNC(=O)C4=CC=C(C=C4)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2COc2ccc(F)cc21
5365,CHEMBL1951445,CRKUAQPSVMLAMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CC=C(C=C2)O)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,7.522878745280337,O=C(Nc1ccc(-c2ccc(O)cc2)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
5366,CHEMBL241270,CRKXVRDQRQDSOG-IBGZPJMESA-N,SR-710,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)[C@H](C4=CC(=CC=C4)Cl)O,5.698970004336019,O=C([C@@H](O)c1cccc(Cl)c1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
5367,CHEMBL603893,CRMAUZQHGCAUDQ-ACDBMABISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)C(=O)N(CC2=CC(=C(C=C2)OC)OC3CCCC3)C4C[C@@H]5CNC[C@@H]5C4,5.0,COc1ccc(CN(C(=O)c2cn(C)cn2)C2C[C@@H]3CNC[C@@H]3C2)cc1OC1CCCC1
5376,CHEMBL412083,CRPSLFMUGWFWGH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18378449.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC(=O)C1=CC=C(C=C1)CN2CCC(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N,5.0,CCNC(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1
5378,CHEMBL3622437,CRQOWDFBJSYIHC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288685.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=NN=C2N1C3=C(CC2)C=C(C=C3)C4=CC(=CN=C4)C(=O)OC,4.301029995663981,COC(=O)c1cncc(-c2ccc3c(c2)CCc2nnc(C)n2-3)c1
5397,CHEMBL3264601,CRZKGBDGHDTLNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CN=CC=C3)O,5.026872146400302,COc1cc2ccc(C(O)(c3cccnc3)C(C)C)cc2cc1OC
5410,CHEMBL3121798,CSGBHDHHPUNOGD-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1F)C(=C(N2C3=C(C=CC=N3)F)C4=NC=C(C=C4)S(=O)(=O)N[C@@H](C)C(F)(F)F)C#N,5.0,Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccc1F
5412,CHEMBL2436617,CSHNEQFLMBVIPC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2C3=CC=CC=C3SC4=CC=CC=C42)C(=O)C5(CCN(CC5)CC6=CC(=NC=C6)N)F,4.522878745280337,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4c5ccccc5Sc5ccccc54)CC3)CC2)ccn1
5414,CHEMBL1242623,CSKHOLSVNNTGRJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCCCC7,5.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCCC6)ncn4-5)CC3)cccc2n1
5415,CHEMBL1242623,CSKHOLSVNNTGRJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCCCC7,5.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCCC6)ncn4-5)CC3)cccc2n1
5421,CHEMBL192530,CSOUXLJIXTUXNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16107158.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-4-(trifluoromethyl)coumarin (BFC) as fluorogenic substrate,Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.,J. Med. Chem.,PUBLICATION,,CCN1C2=C(C=CC=N2)N(C(=O)C3=C1N=CC(=C3)CCOC4=C(C=C(C=C4)C(=O)O)C)C,4.619788758288394,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2cccnc21
5422,CHEMBL192530,CSOUXLJIXTUXNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16107158.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-quinoline (BQ) as fluorogenic substrate,Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.,J. Med. Chem.,PUBLICATION,,CCN1C2=C(C=CC=N2)N(C(=O)C3=C1N=CC(=C3)CCOC4=C(C=C(C=C4)C(=O)O)C)C,4.522878745280337,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2cccnc21
5441,CHEMBL1078123,CSWTXNVAULACPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC(CC1=CC=C(C=C1)OCC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC(CC4=CC=C(C=C4)OCC5=CC=CC=C5)NC(=O)OCC6=NC=CS6,6.522878745280337,CCN(CC(Cc1ccc(OCc2ccccc2)cc1)NC(=O)OCc1cncs1)CC(Cc1ccc(OCc2ccccc2)cc1)NC(=O)OCc1nccs1
5458,CHEMBL1939560,CTEITUDGLRIHMG-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22130135.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and specific CXCR3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F,5.0,C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(Cl)cc1)N(CC1CCS(=O)(=O)CC1)C(=O)Cc1ccc(C(F)(F)F)c(F)c1
5464,CHEMBL3358939,CTEXWUFIJCMWCX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=CC(=C4)C(=O)N,5.698970004336019,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(C(N)=O)c1
5466,CHEMBL36020,CTFXGZSHNLIYDI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177477.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P3A4,An aminomethylpyrimidine DPP-IV inhibitor with improved properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C2=NC(=C(C(=N2)N)CN)C3=C(C=C(C=C3)Cl)Cl,5.0,NCc1c(N)nc(-c2ccccc2)nc1-c1ccc(Cl)cc1Cl
5468,CHEMBL2436621,CTGSDVZVJSPCBE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NN=C2N1C3=C(C=CS3)C(=O)N(C2)C4CCN(CC4)C(=O)C5(CCN(CC5)CC6=CC(=NC=C6)N)F,4.522878745280337,Cc1nnc2n1-c1sccc1C(=O)N(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2
5474,CHEMBL2177587,CTJRRDKOXVXXEW-HNAOKYFASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061376.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,PUBLICATION,,CN1C[C@@H]([C@H](C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=C(C=C3)/C=C/C(=O)NC4=CC=CC=C4N,4.853871964321762,CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1
5475,CHEMBL2177588,CTJRRDKOXVXXEW-RNMWKOHKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061376.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,PUBLICATION,,CN1C[C@H]([C@@H](C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=C(C=C3)/C=C/C(=O)NC4=CC=CC=C4N,4.6777807052660805,CN1C[C@@H](C(=O)Nc2ccc(Cl)cc2)[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)C1
5487,CHEMBL256970,CTPBZYGSXVZQMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18417343.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C=N1)CN(C)C)OC2=C(C=C(C=C2)Cl)C,5.0,Cc1cc(Oc2ccc(Cl)cc2C)c(CN(C)C)cn1
5502,CHEMBL1909992,CTVCNKIVQXSUSH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2CC3=C(C(=C(N=C3C2=O)C)CN)C4=C(C=C(C=C4)Cl)Cl,6.568636235841013,Cc1ccc(N2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)cc1
5508,CHEMBL501260,CTXCWPVELDJQRF-GWCFXTLKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,CC1=C2[C@@H](CC3=C(C(=O)O[C@H]3C1)C)C(=CC2=O)C,5.055517327849831,CC1=CC(=O)C2=C(C)C[C@@H]3OC(=O)C(C)=C3C[C@@H]12
5509,CHEMBL2018924,CTYYDYWKCWWQAM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,2810.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=NC4=CC=CC=C4C=C3,5.55129368009492,COc1ccc2nc(SCc3ccc4ccccc4n3)[nH]c2c1
5513,CHEMBL3127522,CTZSMGLKBKOIGG-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1[C@H]([C@@H]1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=C(C=C4)N,5.698970004336019,Nc1ccc([C@@H]2C[C@H]2C(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1
5514,CHEMBL3127522,CTZSMGLKBKOIGG-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1[C@H]([C@@H]1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=C(C=C4)N,5.455931955649724,Nc1ccc([C@@H]2C[C@H]2C(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1
5538,CHEMBL389809,CUENABWMXANJQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,6200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)C5=CN=CC(=C5)C#N)N(C2=O)CC6=CC=CC=C6F,5.2076083105017466,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cncc(C#N)c5)cc4)CC3)C2=O)c1
5549,CHEMBL2207388,CULSPSVPJXBZMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23141912.0,IC50,=,30500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH,"Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N(1)-arylsulfonyl indole derivatives as 5-HT(6) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)CC2=C3C=CN(C3=CC=C2)S(=O)(=O)C4=CC=CC=C4,4.515700160653214,CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1
5550,CHEMBL1222864,CULSXUUODLMOSV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CCN5CCOCC5)CC6=CC=NC=C6,4.522878745280337,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCOCC3)c3ccccc32)CC1
5551,CHEMBL1935111,CUMDJLVCVBQTKA-YSSOQSIOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22142542.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"4,5-dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)CC3C,4.522878745280337,CC1CC(=O)NN=C1c1ccc(OCCCN2CCC[C@H]2C)cc1
5582,CHEMBL1269673,CUTKYKYSCGXEOF-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCNC)Cl)C5CC5)Cl,4.853871964321762,CNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
5583,CHEMBL1269673,CUTKYKYSCGXEOF-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCNC)Cl)C5CC5)Cl,4.795880017344075,CNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
5594,CHEMBL2420688,CUWBTTOKHGCTNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,1739.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C=NC=C2C3=C(C4=C(C=CC(=C4)O)C=C3)Cl,5.759700417997288,Oc1ccc2ccc(-c3cncc4ccccc34)c(Cl)c2c1
5595,CHEMBL1916700,CUWBXEPNHLJYKS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958540.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of a biphenylacetic acid series of prostaglandin D(2) receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=CC(=C2)CC(=O)O)OC)C(=O)OCC3=CC=CC=C3,4.7447274948966935,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccccc1
5600,CHEMBL1909647,CVARTXOKUSBAQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CNC(=O)C2=N1)C3=C(C=C(C=C3)Cl)Cl)CN,4.3979400086720375,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CNC2=O
5608,CHEMBL2377662,CVDJQEZVCYECCM-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23584544.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,PUBLICATION,,COC(=S)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCNN(CC3)C(=O)CO)F,4.698970004336019,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1
5610,CHEMBL403441,CVFBVSUFNWOPLD-LJQANCHMSA-N,PF-526014,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20471260.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC1=CC=CC=C1C[C@H](C2=CC=CC=C2)N3CCNCC3,4.522878745280337,CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1
5611,CHEMBL1097078,CVFXBFRIDRAJBH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,923.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC=C(C=C5)Cl)C)OC,6.034798298974088,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccc(Cl)cc1)cc(=O)n2C)c1cncn1C
5613,CHEMBL3628115,CVGSBYQJDYXQRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26426481.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,PUBLICATION,,CC1=C(OC=C1)C(=O)NC2=CC(=C(C=C2)N3C(=O)C4=C(C3=O)C=NC=C4)Cl,4.522878745280337,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccncc3C2=O)c(Cl)c1
5615,CHEMBL2041183,CVJHUBCBROARAB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=NC(=C4)C(F)(F)F)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(C(F)(F)F)ncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1
5616,CHEMBL3335556,CVKXGRRJHJHUFY-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221667.0,IC50,=,15600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by electrospray ionization,,ACS Med. Chem. Lett.,PUBLICATION,,C1CO[C@@H](CN1CC2=CC=C(C=C2)Cl)CCC3=CC=CC=C3,4.806875401645538,Clc1ccc(CN2CCO[C@H](CCc3ccccc3)C2)cc1
5619,CHEMBL3358929,CVNFMOXXWTZVDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)N4CCOCC4)(C(F)(F)F)O,8.0,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F
5640,CHEMBL550818,CVUXESFCUHCXHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,5.301029995663981,CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
5641,CHEMBL550818,CVUXESFCUHCXHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,5.301029995663981,CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
5652,CHEMBL577694,CVYPJFLZLTYYGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=CC=C3)Cl,5.309803919971486,CC1(CC(=O)NCc2cccc(Cl)c2)CC2(CCCCC2)OO1
5657,CHEMBL3617986,CVZOIBZVGKOLJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26365710.0,IC50,=,4920.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay,"Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC1=NN(C(=C1C(=O)NC(CN2C=CN=C2)C(=O)OC(C)C)Cl)C3=CC=CC=C3,5.308034897232639,Cc1nn(-c2ccccc2)c(Cl)c1C(=O)NC(Cn1ccnc1)C(=O)OC(C)C
5662,CHEMBL3706615,CWAPFPHVCGEYRK-YKTJUOTHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852969.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=NC=C(O1)C2=CC(=CN=C2)OC)N3CCN([C@@H](C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,7.3979400086720375,COc1cncc(-c2cnc(C(C)(C)N3CCN(C[C@@H](O)C[C@@H](Cc4ccccc4)C(=O)N[C@H]4c5ccccc5OC[C@H]4O)[C@H](C(=O)NCC(F)(F)F)C3)o2)c1
5669,CHEMBL150146,CWDVFUCLYPBQNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=NC=CN=C2,4.0,CCCCOc1ccc(-c2cnccn2)cc1
5670,CHEMBL1835782,CWDYYODRDVPEOW-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NN(C(=O)C4=C3CCC4)C,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(-c2nn(C)c(=O)c3c2CCC3)cc1
5675,CHEMBL3581150,CWFBWCJRVBRKPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,CS(=O)(=O)NC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)N,4.823908740944319,CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(N)c3)cs2)c1
5676,CHEMBL1940296,CWFNNQMBLVACQD-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153941.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CNC(=O)C1=CC=C(C=C1)OC2=CC=C(C=C2)C#C[C@@]3(CN4CCC3CC4)O,5.0,CNC(=O)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1
5696,CHEMBL1921980,CWOCSWWXAHRGJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,CC(C1=CC2=C(C=C1)C=C(C=C2)C(=O)NC)(C3=CN=CN3C)O,5.161150909262744,CNC(=O)c1ccc2cc(C(C)(O)c3cncn3C)ccc2c1
5697,CHEMBL178780,CWPOROUIZKNJHY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,75100.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)CN2C=C(N=C2)C3=CN=CC=C3,4.124360062995832,c1ccc(Cn2cnc(-c3cccnc3)c2)cc1
5703,CHEMBL400262,CWRBPYURGIMZCJ-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1(C2=CC=CC=C2)N3C(=NC4=C3N=CC=C4)CNC(=O)[C@@H](CC5=CC=CC=C5C(F)(F)F)NC(=O)C6=CC=CC=C6OC(F)(F)F,5.7447274948966935,O=C(N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1)c1ccccc1OC(F)(F)F
5705,CHEMBL2448698,CWSHQIYLOHFEFL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,20000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCN(CC)S(=O)(=O)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(N=C3)C4=CC=CC=C4,4.698970004336019,CCN(CC)S(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
5712,CHEMBL253655,CWWHQEWKNCFPES-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NOC(=N4)CN5CCOCC5,5.585026652029182,CC[C@@H]1CCC[C@H](C2(Cc3noc(CN4CCOCC4)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
5716,CHEMBL2436227,CWXNEODDUDWHDU-WKRVVKTRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@@H]1C(=O)N(C2=CC=CC=C2OC13CCOCC3)CC4=C(N(C5=CC=CC=C54)C6=CC=CC=C6C#N)C#N)NC,5.7447274948966935,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C#N)n(-c3ccccc3C#N)c3ccccc23)c2ccccc2OC12CCOCC2
5723,CHEMBL390776,CWYRIAXMURYWCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,630.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC2=C1N=C(N(C2=O)CC3=CC=CC=C3C#N)N4CCCC(C4)N,6.200659450546418,COc1cccc2c(=O)n(Cc3ccccc3C#N)c(N3CCCC(N)C3)nc12
5726,CHEMBL2448734,CWZYIVSBZLEQJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,470.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CC(=O)N(CC1=CN=CC=C1)C2=C(C=C(C=C2)C3=CC=C(C=C3)F)F,6.327902142064283,CC(=O)N(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F
5729,CHEMBL1782308,CXBHAEGCPVKQMW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19447034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of selective PDE4B inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=C(N=C(N=C1NC2=C(C=C(C=C2)CC(=O)O)F)C3=CC=C(S3)F)C,5.0,CCc1c(C)nc(-c2ccc(F)s2)nc1Nc1ccc(CC(=O)O)cc1F
5731,CHEMBL2018912,CXDABZKLWORATA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,6230.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3CCCCC3,5.205511953340831,COc1ccc2nc(SCC3CCCCC3)[nH]c2c1
5732,CHEMBL3581139,CXDDGXVAUWXVAV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC1=NC=CC(=C1)C2=CSC(=N2)NC(=O)CC3=CC(=CC=C3)OC,5.130768280269024,COc1cccc(CC(=O)Nc2nc(-c3ccnc(C)c3)cs2)c1
5733,CHEMBL1276948,CXDSZAINFKAKPN-AKRCKQFNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,C1C[C@@]2(CC1N3CC(C3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,5.0,O=C(O)C1CN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1
5736,CHEMBL3702751,CXGXIWKKJJULSE-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2540.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)CCCNC(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.595166283380062,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
5737,CHEMBL2016935,CXHZPUIYOWOMEL-VLIAUNLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNC[C@@H]([C@]1(C2=CC(=C(C=C2)F)F)O)C3=CC(=NO3)C4=C(C=C(C=C4)F)Br,5.522878745280337,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2ccc(F)cc2Br)no1
5740,CHEMBL3409853,CXIIMWBTYWXFSS-GJZGRUSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)OC)[C@@H]2C[C@@H](C(=O)N2CC3=CC=C(C=C3)OC(F)(F)F)Cl,5.180456064458132,COc1cccc(OC)c1[C@@H]1C[C@H](Cl)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
5741,CHEMBL1078657,CXIKGNQQHDCIPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCCCC(=O)O)C3=CC=CC=C3,5.0,O=C(O)CCCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
5742,CHEMBL1208892,CXJOVIBONXRCNI-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=NC(=NC=C5)N)C(=O)N,5.167491087293763,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
5743,CHEMBL1208892,CXJOVIBONXRCNI-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=NC(=NC=C5)N)C(=O)N,4.0,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
5771,CHEMBL3645515,CXOMREQXULTUTB-PPHZAIPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15600.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=NN(C(=O)C=C2)CC(F)(F)F)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.806875401645538,C[C@@H](c1ccc(-c2ccc(=O)n(CC(F)(F)F)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
5774,CHEMBL522730,CXPNFWFXVCDMOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,>,6947.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1C=C(C2=C1C=C(C=C2)C3=CC=C(C=C3)F)C4=CN=CC=C4.Cl,5.158202701125645,Fc1ccc(-c2ccc3c(c2)CC=C3c2cccnc2)cc1
5785,CHEMBL2013012,CXQZLLASRGZUFU-RZDIXWSQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22361135.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Indolyl and dihydroindolyl N-glycinamides as potent and in vivo active NPY5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)S(=O)(=O)NCC1CCC(CC1)NC(=O)CN2CCC3=C2C=CC(=C3)Cl,6.154901959985743,CC(C)S(=O)(=O)NCC1CCC(NC(=O)CN2CCc3cc(Cl)ccc32)CC1
5798,CHEMBL3358924,CXXWEXDTTVWKSJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C(=N1)C)NC(=C2)CC(CC(C)(C)C3=C(C=CC(=C3)F)OC)(C(F)(F)F)O,6.698970004336019,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C)nc(C)c2[nH]1)C(F)(F)F
5799,CHEMBL207100,CXYAINZZOIQMET-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,<,70.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CC3=CN=CC4=CC=CC=C43)C(=O)N5CC[C@H](C5)O)C(=O)N(C1=O)C,7.154901959985743,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3cncc4ccccc34)sc21
5808,CHEMBL2441951,CXZGZTKUARYIDS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)NC)C3=C(C=C(C=C3)Cl)Cl)CN,4.3979400086720375,CNC(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
5812,CHEMBL3341983,CYBITNCPJFQMIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26985315.0,IC50,=,77.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC/MS/MS analysis,Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.,ACS Med. Chem. Lett.,PUBLICATION,,C1=CC2=C(C=C1C3=C(C=CC(=C3)Cl)OC4=CC(=C(C=C4F)S(=O)(=O)NC5=NC=NS5)F)C(=NO2)N,7.113509274827518,Nc1noc2ccc(-c3cc(Cl)ccc3Oc3cc(F)c(S(=O)(=O)Nc4ncns4)cc3F)cc12
5814,CHEMBL3298909,CYCDARWXZPYIBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,CCC1=C(N2C=CC(=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)OC(F)(F)F,4.0,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1
5815,CHEMBL374350,CYCGGKILBWERDJ-UHFFFAOYSA-N,CID 2858522,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153655.0,IC50,=,85000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC,Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway.,Bioorg. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1C)N(C(=N2)NCCCO)CC(=O)C3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C,4.070581074285707,Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C
5816,CHEMBL374350,CYCGGKILBWERDJ-UHFFFAOYSA-N,CID 2858522,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20481485.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1C)N(C(=N2)NCCCO)CC(=O)C3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C,5.522878745280337,Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C
5817,CHEMBL486131,CYCJQENBXNRINR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)CN3CCOCC3)C4=CC(=CN=C4)OC)C,4.698970004336019,COc1cncc(-c2cc(NC(=O)CN3CCOCC3)nc(-n3nc(C)cc3C)n2)c1
5827,CHEMBL473921,CYEIOVYZTVJICS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)NC5=CC=C(C=C5)F,4.0,C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
5828,CHEMBL473921,CYEIOVYZTVJICS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)NC5=CC=C(C=C5)F,4.0,C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
5829,CHEMBL473921,CYEIOVYZTVJICS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 25 to 30 mins by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)NC5=CC=C(C=C5)F,5.853871964321762,C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
5830,CHEMBL473921,CYEIOVYZTVJICS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 0 to 5 mins by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)NC5=CC=C(C=C5)F,4.698970004336019,C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
5831,CHEMBL3640259,CYEJSPJMRTVXJN-ORAYPTAESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC(=N1)N2C[C@H]3C(=O)N(C(=N[C@]3(C2)C4=CC=CC=C4)N)C)OC)F,4.522878745280337,COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(C)c1F
5842,CHEMBL2022997,CYKPIMPUPKXTNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22248262.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,CC1=CC(=CC=C1)C(CCCN)(C2=CC=CC=C2)C3=CC=CC=C3,5.259637310505756,Cc1cccc(C(CCCN)(c2ccccc2)c2ccccc2)c1
5850,CHEMBL2017110,CYMWJUNBUBLPTM-CLOONOSVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)[C@H]3CNCC[C@@]3(C4=CC(=C(C=C4)F)F)OC)Br,4.552841968657781,CO[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1noc(-c2ccccc2CCNC(C)=O)c1Br
5861,CHEMBL2393183,CYPHXCMPISHSDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23668988.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)NCC3=CN=C(C=C3)N,5.0,Nc1ccc(CNC(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1
5863,CHEMBL2086759,CYPOOUITBHWAKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC(=CC=C4)F)C5=NC=CN5,4.638272163982407,CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2ncc[nH]2)C(=O)N3)CC1
5882,CHEMBL3403984,CZAMPUPYSSGHRM-WNCULLNHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25754490.0,IC50,<=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate,"trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: Prime site exploration using an oxygen linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1OCC2=CC(=CC=C2)OC)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,6.698970004336019,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OCc2cccc(OC)c2)C(C)C)ccc1OC
5883,CHEMBL517503,CZBRRHLYIHWSOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,9700.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CSC=C4,5.013228265733755,O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3
5884,CHEMBL517503,CZBRRHLYIHWSOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CSC=C4,4.657577319177793,O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3
5891,CHEMBL254316,CZFFBEXEKNGXKS-UHFFFAOYSA-N,RALTEGRAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763751.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.",J. Med. Chem.,PUBLICATION,,CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F,4.301029995663981,Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1
5892,CHEMBL2407749,CZFUYZPXZGGWKC-SRQUHQSVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829549.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents.,J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C(=C(N2)O)/C=C/3\C=CC4=C(N=NC4=C3)/C=C/C5=CC=NC=C5,5.568636235841013,Oc1[nH]c2ccccc2c1/C=c1\ccc2c(c1)N=NC=2/C=C/c1ccncc1
5893,CHEMBL2407749,CZFUYZPXZGGWKC-SRQUHQSVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C(=C(N2)O)/C=C/3\C=CC4=C(N=NC4=C3)/C=C/C5=CC=NC=C5,6.0,Oc1[nH]c2ccccc2c1/C=c1\ccc2c(c1)N=NC=2/C=C/c1ccncc1
5896,CHEMBL496287,CZHBHMYFEKBMAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,1697.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC2=C(C1C3=CN=CC=C3)C=CC(=C2)C4=CC=C(C=C4)F.Cl,5.770318157682325,Fc1ccc(-c2ccc3c(c2)CCC3c2cccnc2)cc1
5920,CHEMBL10441,CZOIKFCTLASDKV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,5.0,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCCC2
5935,CHEMBL1078121,CZQXPDBVKLWLQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,135.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC(COCC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(COCC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,6.8696662315049934,CCN(CC(COCc1ccccc1)NC(=O)OCc1cncs1)CC(COCc1ccccc1)NC(=O)OCc1nccs1
5937,CHEMBL1643735,CZSPPTVCJPFLSX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21195616.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)NC(=O)CN1C2=C(C=C(C=C2)C(C)(C)C(=O)NC(C)(C)C)C=C1C3=CC=C(C=C3)OC(F)(F)F,5.0,CC(C)(C)NC(=O)Cn1c(-c2ccc(OC(F)(F)F)cc2)cc2cc(C(C)(C)C(=O)NC(C)(C)C)ccc21
5938,CHEMBL2018906,CZSQXDMMIUJHSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CCSC1=NC2=C(N1)C=C(C=C2)OC,4.301029995663981,CCSc1nc2ccc(OC)cc2[nH]1
5939,CHEMBL3672580,CZSVRXPBPZIVEN-PYPNIHNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@H](CC[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N6CCOCC6,7.0,CC(C)c1nc(CN(C)C(=O)N2C[C@H](N3CCOCC3)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
5940,CHEMBL3672580,CZSVRXPBPZIVEN-PYPNIHNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,150.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@H](CC[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N6CCOCC6,6.823908740944319,CC(C)c1nc(CN(C)C(=O)N2C[C@H](N3CCOCC3)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
5941,CHEMBL3672579,CZSVRXPBPZIVEN-WSQFZFBESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,120.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N6CCOCC6,6.920818753952375,CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N3CCOCC3)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
5942,CHEMBL3672579,CZSVRXPBPZIVEN-WSQFZFBESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,350.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N6CCOCC6,6.455931955649724,CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N3CCOCC3)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
5951,CHEMBL1770373,CZWQBSKNHUVZLI-UHFFFAOYSA-N,PF-3246799,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21195614.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrimido[4,5-d]azepines as potent and selective 5-HT(2C) receptor agonists: Design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=NC(=NC=C21)CC3=CC=CC=C3,4.522878745280337,c1ccc(Cc2ncc3c(n2)CCNCC3)cc1
5953,CHEMBL1092600,CZXWYWSRENNIBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)CC3=NC=CN=C3,5.0,Cc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1
5962,CHEMBL2043326,DACGAATZKIWONI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC(=C(C=C6)C(=O)O)C,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(C)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
5963,CHEMBL1950082,DACGLYAGZQBCCE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C)(C4=CC=NC=C4)O)OC,5.1487416512809245,COc1cc(C)c2nc3n[nH]c(C)c3c(C(C)(O)c3ccncc3)c2c1
5964,CHEMBL1950082,DACGLYAGZQBCCE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,14200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C)(C4=CC=NC=C4)O)OC,4.847711655616943,COc1cc(C)c2nc3n[nH]c(C)c3c(C(C)(O)c3ccncc3)c2c1
5965,CHEMBL3408947,DADASRPKWOGKCU-FVTQAUBDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O,5.508638306165727,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2
5966,CHEMBL3408947,DADASRPKWOGKCU-FVTQAUBDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O,5.337242168318426,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2
5976,CHEMBL1079244,DAHUROVPPIYTLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC3=NNNN3)C4=CC=CC=C4,5.0,O=C(Nc1ccc(Cl)cc1)N1CCCC(CCC2=NNNN2)(c2ccccc2)C1
5980,CHEMBL2064347,DAIOZRXKBOQYHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,CN1C2=CC=CC(=C2N=C1CC3=NC(=CC(=O)N3)N4CCOCC4)C5=CC=CC=C5,4.3979400086720375,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2c(-c3ccccc3)cccc21
5986,CHEMBL3112861,DALZLCXHMHOFAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,CN1C(=O)C=C(N=C1CC(=O)N2CCC3=CC=CC=C32)N4CCOCC4,4.3979400086720375,Cn1c(CC(=O)N2CCc3ccccc32)nc(N2CCOCC2)cc1=O
6072,CHEMBL552211,DBIFFPLSGSBZGY-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C1)C3=C(N2CC(=O)O)N=CC=C3)S(=O)(=O)C4=CC=C(C=C4)F,4.522878745280337,CN([C@@H]1CCc2c(c3cccnc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1
6087,CHEMBL1078442,DBMJZOMNXBSRED-OQLLNIDSSA-N,BERGAMOTTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19689106.0,IC50,=,2420.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,Minor furanocoumarins and coumarins in grapefruit peel oil as inhibitors of human cytochrome P450 3A4.,J. Nat. Prod.,PUBLICATION,,CC(=CCC/C(=C/COC1=C2C=CC(=O)OC2=CC3=C1C=CO3)/C)C,5.616184634019569,CC(C)=CCC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12
6094,CHEMBL2057791,DBMXSZMLQSZJTB-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)C2=NC3=C(O2)C=C(C=C3)C(=O)N(CC4CCC(CC4)(F)F)C[C@H]([C@H](CC5=CC=CC=C5)NC(=O)OCC6=CN=CS6)O,7.522878745280337,O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CC1CCC(F)(F)CC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1
6101,CHEMBL238103,DBPMWRYLTBNCCE-UHFFFAOYSA-N,BMS-488043,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,COC1=CN=C(C2=C1C(=CN2)C(=O)C(=O)N3CCN(CC3)C(=O)C4=CC=CC=C4)OC,4.3979400086720375,COc1ncc(OC)c2c(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c[nH]c12
6102,CHEMBL238103,DBPMWRYLTBNCCE-UHFFFAOYSA-N,BMS-488043,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,COC1=CN=C(C2=C1C(=CN2)C(=O)C(=O)N3CCN(CC3)C(=O)C4=CC=CC=C4)OC,4.3979400086720375,COc1ncc(OC)c2c(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c[nH]c12
6133,CHEMBL522295,DBWKEBCQXCVXLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18752960.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.,Bioorg. Med. Chem.,PUBLICATION,,C1CC2CC(CC1N2CC3=CC4=C(C=C3)C=C(C=C4)F)NC(=O)C5=CC=CC=C5C6=CC=CC=C6,4.698970004336019,O=C(NC1CC2CCC(C1)N2Cc1ccc2cc(F)ccc2c1)c1ccccc1-c1ccccc1
6146,CHEMBL320105,DCDHWTNKKCKJLQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,76900.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCCCOC1=NC=C(C=C1)N2C=CN=C2,4.114073660198569,CCCCCCOc1ccc(-n2ccnc2)cn1
6157,CHEMBL3629736,DCLAUMXJFMZEKA-UWJYYQICSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@@]2([C@@H](COC3=C(C=CC(=C32)F)F)C(C1)(CO)CO)S(=O)(=O)C4=CC=C(C=C4)Cl,4.958607314841775,O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCCC(CO)(CO)[C@@H]1COc1c(F)ccc(F)c12
6158,CHEMBL3629736,DCLAUMXJFMZEKA-UWJYYQICSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,11500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@@]2([C@@H](COC3=C(C=CC(=C32)F)F)C(C1)(CO)CO)S(=O)(=O)C4=CC=C(C=C4)Cl,4.939302159646388,O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCCC(CO)(CO)[C@@H]1COc1c(F)ccc(F)c12
6163,CHEMBL271580,DCMHHJQTRGXPBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,230.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1Cl)Cl)CN2C=C(C=N2)C3=CC=NC=C3,6.638272163982407,Clc1ccc(Cn2cc(-c3ccncc3)cn2)c(Cl)c1
6182,CHEMBL3545241,DCRWIATZWHLIPN-UHFFFAOYSA-N,AC-430,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,10900.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CC1=CC(=NN1)NC2=NC(=NC3=CC=CC=C32)C(C4=CC=C(C=C4)F)O,4.962573502059376,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
6190,CHEMBL1729,DCSUBABJRXZOMT-UHFFFAOYSA-N,CISAPRIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,300.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,6.522878745280337,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC
6212,CHEMBL58832,DCXYFEDJOCDNAF-REOHCLBHSA-N,ASPARAGINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C([C@@H](C(=O)O)N)C(=O)N,5.0,NC(=O)C[C@H](N)C(=O)O
6213,CHEMBL58832,DCXYFEDJOCDNAF-REOHCLBHSA-N,ASPARAGINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C([C@@H](C(=O)O)N)C(=O)N,5.0,NC(=O)C[C@H](N)C(=O)O
6214,CHEMBL3628112,DCYOTMCWHBEKAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26426481.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,PUBLICATION,,CC1=C(OC=C1)C(=O)NC2=CC(=C(C=C2)N3C(=O)C4=C(C3=O)C=C(C=C4)Cl)Cl,4.522878745280337,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(Cl)cc3C2=O)c(Cl)c1
6219,CHEMBL3234871,DDAWTSCZLAACFR-GVUKDKGQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,C1CN([C@@H]1C(=O)NCCC2=CC=C(C=C2)C#N)C3=NC(=NC(=C3)C4=CC=C(C=C4)C5CCC(CC5)C(=O)O)C(F)(F)F,4.6020599913279625,N#Cc1ccc(CCNC(=O)[C@@H]2CCN2c2cc(-c3ccc(C4CCC(C(=O)O)CC4)cc3)nc(C(F)(F)F)n2)cc1
6220,CHEMBL150278,DDBBWDREHWCNNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=NNN=N2,4.0,CCCCOc1ccc(-c2nn[nH]n2)cc1
6229,CHEMBL3310992,DDDMLZABRFSWRF-MGPLVRAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,8000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=CN=N2)(C3=C(C=C(C=C3)F)F)O,5.096910013008056,C[C@@H](c1ncncc1F)[C@](O)(Cn1ccnn1)c1ccc(F)cc1F
6234,CHEMBL476323,DDDZBLNULGDPGA-UHFFFAOYSA-N,MK-0249,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18598020.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.",J. Med. Chem.,PUBLICATION,,CC1=NC2=CC=CC(=C2C(=O)N1C3=CC=C(C=C3)OCCCN4CCCC4)C(F)(F)F,4.568636235841013,Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1
6240,CHEMBL493001,DDGVRFAFSCAHHH-KQQUZDAGSA-N,GO-Y026,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,13200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,COC1=CC(=CC(=C1O)OC)/C=C/C(=O)/C=C/C2=CC(=C(C(=C2)OC)O)OC,4.87942606879415,COc1cc(/C=C/C(=O)/C=C/c2cc(OC)c(O)c(OC)c2)cc(OC)c1O
6241,CHEMBL493001,DDGVRFAFSCAHHH-KQQUZDAGSA-N,GO-Y026,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,76032627.69,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,COC1=CC(=CC(=C1O)OC)/C=C/C(=O)/C=C/C2=CC(=C(C(=C2)OC)O)OC,1.1190000000229516,COc1cc(/C=C/C(=O)/C=C/c2cc(OC)c(O)c(OC)c2)cc(OC)c1O
6246,CHEMBL558467,DDHSIUUOIYFUOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,5.301029995663981,CN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
6251,CHEMBL3092468,DDKHTWASHUKHLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,=,28600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=NC3=NNC(=C3N=C2)N)NS(=O)(=O)C4=C(C=CC(=C4)Cl)F,4.543633966870957,Nc1[nH]nc2nc(-c3ccc(NS(=O)(=O)c4cc(Cl)ccc4F)cc3)cnc12
6252,CHEMBL3092468,DDKHTWASHUKHLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=NC3=NNC(=C3N=C2)N)NS(=O)(=O)C4=C(C=CC(=C4)Cl)F,4.522878745280337,Nc1[nH]nc2nc(-c3ccc(NS(=O)(=O)c4cc(Cl)ccc4F)cc3)cnc12
6254,CHEMBL429850,DDKRPWSDORFUBF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18329269.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(O1)C2=NC(=CC(=N2)N3C(=CC(=N3)C)C)NC(=O)COC4=C(C=C(C=C4)OC)CN(C)C,5.795880017344075,COc1ccc(OCC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)c(CN(C)C)c1
6259,CHEMBL655,DDLIGBOFAVUZHB-UHFFFAOYSA-N,MIDAZOLAM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,5.0915149811213505,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
6260,CHEMBL655,DDLIGBOFAVUZHB-UHFFFAOYSA-N,MIDAZOLAM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256005.0,IC50,>,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,4.481486060122112,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
6293,CHEMBL1766187,DDQPLMGLQXMKLK-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)[C@](C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,5.0,CC(=O)Nc1cccc(-c2ccc([C@](O)(c3cnc[nH]3)C(C)C)cc2)c1
6294,CHEMBL1766188,DDQPLMGLQXMKLK-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)[C@@](C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,5.173925197299173,CC(=O)Nc1cccc(-c2ccc([C@@](O)(c3cnc[nH]3)C(C)C)cc2)c1
6295,CHEMBL1766176,DDQPLMGLQXMKLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,5.1487416512809245,CC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)c1
6315,CHEMBL273503,DDUPDZLICFQTTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CN(C(=NC1=O)SCC2=CC=C(C=C2)F)CC(=O)N(CCN(CC)CC)CC3=CC=C(C=C3)C4=CC=C(C=C4)Cl,5.154901959985743,CCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(Cl)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O
6318,CHEMBL255858,DDVVRHNNOPQPGB-UHFFFAOYSA-N,GT-1282,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18267361.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=[N+](C=C1)[O-])C)C(=O)N2CCC(CC2)(C)N3CCC(CC3)N(C4=CC=CC=C4)C5=CN=CC=C5,5.275724130399211,Cc1cc[n+]([O-])c(C)c1C(=O)N1CCC(C)(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CC1
6320,CHEMBL242011,DDWGQGZPYDSYEL-LSDHHAIUSA-N,HINOKININ,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,C1[C@@H]([C@H](C(=O)O1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,5.096910013008056,O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2
6327,CHEMBL3664643,DDWYZIPKUZUFSJ-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,25000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)NC=C2)N3CC[C@](OC3=O)(CC(C)(C)C#N)C4=CC=CC=C4,4.6020599913279625,C[C@@H](c1ccc(-c2cc[nH]c(=O)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O
6337,CHEMBL3137462,DEAFEEMWPWVLTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CN(C)S(=O)(=O)C1=CC=CC(=C1)N2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,5.154901959985743,CN(C)S(=O)(=O)c1cccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)c1
6364,CHEMBL2347415,DEIUHXGBXURZNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=C(C=C4)OC(F)F)CCCN(C)C,4.301029995663981,CN(C)CCCn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2cc(OC(F)F)ccc21
6371,CHEMBL526327,DEOLAXKUWDBBIS-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4F)F,4.481486060122112,COc1cccc(-c2cn(Cc3c(F)cccc3F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F
6379,CHEMBL2331688,DEQRJEPSLGPYFN-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4=NC=C(C=N4)F)C(=N2)N5CCOC[C@@H]5C,5.853871964321762,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ncc(F)cn2)C3)cc1
6395,CHEMBL1760338,DEYOMMQLWMIBRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC=C1N2CCN(CC2)C(=O)C3=CC(=NN3)C4=CC=C(C=C4)Cl,5.096910013008056,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n[nH]2)CC1
6412,CHEMBL2436982,DFBYFJSXUCUKLA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,COC1=CC(=CC(=C1OC)OC)C2=CC3=C(NC=C3C4=CN=C(C=C4)N)N=C2,4.522878745280337,COc1cc(-c2cnc3[nH]cc(-c4ccc(N)nc4)c3c2)cc(OC)c1OC
6420,CHEMBL1951346,DFFVLCZIIWJVNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CNC2=NC=NC(=C12)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(=O)NC(C)C,4.657577319177793,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12
6430,CHEMBL2408045,DFJSJLGUIXFDJP-UHFFFAOYSA-N,SAPITINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CNC(=O)CN1CCC(CC1)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC,5.0,CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1
6436,CHEMBL1671877,DFLJUOUAVYDDBB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1CCCC2=CC(=O)OC3=C2C(=O)NC(=N3)C(F)F,4.301029995663981,O=c1cc(CCCC2CC2)c2c(=O)[nH]c(C(F)F)nc2o1
6457,CHEMBL1922660,DFQGDHBGRSTTHX-UHFFFAOYSA-N,FIBOFLAPON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22059882.0,IC50,>,50.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,PUBLICATION,,CCOC1=NC=C(C=C1)C2=CC=C(C=C2)CN3C4=C(C=C(C=C4)OCC5=NC=C(C=C5)C)C(=C3CC(C)(C)C(=O)O)SC(C)(C)C,7.301029995663981,CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1
6460,CHEMBL1215665,DFRORZVGCQQRJH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,2450.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC=C(C=C3)N,5.610833915635467,Nc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1
6475,CHEMBL526466,DFXJFEAHWLUMQK-DHIUTWEWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CC2=C3[C@@H]1N4CC[C@H](C4=O)NCC5=CN=CN5CC6=CC(=C(C=C6)C#N)OC(=C3)C=C2,5.180456064458132,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O
6476,CHEMBL526466,DFXJFEAHWLUMQK-DHIUTWEWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,10400.0,NM,,,,,,,,,,,,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CC2=C3[C@@H]1N4CC[C@H](C4=O)NCC5=CN=CN5CC6=CC(=C(C=C6)C#N)OC(=C3)C=C2,4.982966660701219,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O
6477,CHEMBL526656,DFXJFEAHWLUMQK-PKTZIBPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CC2=C3[C@H]1N4CC[C@H](C4=O)NCC5=CN=CN5CC6=CC(=C(C=C6)C#N)OC(=C3)C=C2,5.552841968657781,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O
6478,CHEMBL526656,DFXJFEAHWLUMQK-PKTZIBPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,14800.0,NM,,,,,,,,,,,,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CC2=C3[C@H]1N4CC[C@H](C4=O)NCC5=CN=CN5CC6=CC(=C(C=C6)C#N)OC(=C3)C=C2,4.8297382846050425,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O
6479,CHEMBL1078452,DFXLYUBDPQCNSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NCCC2=CC3=NC=CN=C3C=C2)C4=CC=CC=C4,5.0,CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc3nccnc3c2)C1
6482,CHEMBL2170637,DFXNQXMRQVGHED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=CC=N3,4.522878745280337,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccccn3)CC2)c(C(F)(F)F)c1
6483,CHEMBL1909986,DFYJCRFQTFRQQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,730.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=CN(C=C2C(=C1CN)C3=C(C=C(C=C3)Cl)Cl)CC4=CC=CC=C4,6.136677139879544,Cc1nc2cn(Cc3ccccc3)cc2c(-c2ccc(Cl)cc2Cl)c1CN
6484,CHEMBL1909986,DFYJCRFQTFRQQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=CN(C=C2C(=C1CN)C3=C(C=C(C=C3)Cl)Cl)CC4=CC=CC=C4,5.958607314841775,Cc1nc2cn(Cc3ccccc3)cc2c(-c2ccc(Cl)cc2Cl)c1CN
6490,CHEMBL557527,DGCSBHYGDCRAOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,>,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)C5=CN=C(C=C5)OC)CC(C)(C)C(=O)O,7.301029995663981,COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)cn1
6496,CHEMBL253641,DGEILIRHSDUTDK-XTEPFMGCSA-N,GSK188909,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC1=CC(=C(C(=C1)N2CCCCS2(=O)=O)F)C(=O)N[C@@H](CC3=CC=CC=C3)[C@@H](CNCC4=CC(=CC=C4)C(F)(F)F)O,6.3979400086720375,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCCS2(=O)=O)c1
6497,CHEMBL253641,DGEILIRHSDUTDK-XTEPFMGCSA-N,GSK188909,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC1=CC(=C(C(=C1)N2CCCCS2(=O)=O)F)C(=O)N[C@@H](CC3=CC=CC=C3)[C@@H](CNCC4=CC(=CC=C4)C(F)(F)F)O,5.795880017344075,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCCS2(=O)=O)c1
6498,CHEMBL207881,DGENZVKCTGIDRZ-UHFFFAOYSA-N,GW9508,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17240142.0,IC50,>,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)OC2=CC=CC(=C2)CNC3=CC=C(C=C3)CCC(=O)O,4.481486060122112,O=C(O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1
6505,CHEMBL3145341,DGGLFHJMXJUSDG-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861813.0,IC50,=,38.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel ß-amino acid derivatives as inhibitors of cathepsin A.,J. Med. Chem.,PUBLICATION,,CC1=CC=CC=C1[C@H](CC(=O)O)NC(=O)C2=CC(=O)N(N2)C3=CC=CC=C3F,7.42021640338319,Cc1ccccc1[C@H](CC(=O)O)NC(=O)c1cc(=O)n(-c2ccccc2F)[nH]1
6535,CHEMBL206145,DGPAWMWBQNMPFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCC5CCN(CC5)C)C,6.154901959985743,Cc1cc2c(F)c(Oc3ncnn4cc(OCCC5CCN(C)CC5)c(C)c34)ccc2[nH]1
6536,CHEMBL2170062,DGPGXHRHNRYVDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22784008.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Synthesis and biological evaluation of the 1-arylpyrazole class of s(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=CC3=CC=CC=C3C=C2)OCCN4CCOCC4,5.0,Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1
6537,CHEMBL2170062,DGPGXHRHNRYVDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22784008.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Synthesis and biological evaluation of the 1-arylpyrazole class of s(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=CC3=CC=CC=C3C=C2)OCCN4CCOCC4,5.0,Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1
6549,CHEMBL2441953,DGSUAHCROANBGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CCCN(C)C(=O)CN1CC2=NC(=C(C(=C2C1=O)C3=C(C=C(C=C3)Cl)Cl)CN)C,5.259637310505756,CCCN(C)C(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
6552,CHEMBL1615152,DGVNGMXASUNRAO-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)[C@@H](C(=O)NC2=C(C=C(C=C2)C(=O)O)F)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,4.4089353929735005,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(F)c1
6574,CHEMBL1236391,DHDKYDLNUPJXFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21033679.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Electron density guided fragment-based lead discovery of ketohexokinase inhibitors.,J. Med. Chem.,PUBLICATION,,CSC1=NN(C2=C1C=CC(=C2)NC(=O)C3CCNCC3)C4=CC=CC=C4,5.0,CSc1nn(-c2ccccc2)c2cc(NC(=O)C3CCNCC3)ccc12
6590,CHEMBL2018481,DHHGEOKAXUKQCM-ZBLYBZFDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,=,7146.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,C1[C@H](CN([C@@H]1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CC4=CN=CN4)CC5=CC=CC=C5,5.145936988133579,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccccc2)CN1C(=O)Cc1cnc[nH]1
6608,CHEMBL3422018,DHRKQJQSMYHSPN-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=NC(=NS5)C,4.096910013008056,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1
6609,CHEMBL3422018,DHRKQJQSMYHSPN-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,=,79000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=NC(=NS5)C,4.102372908709558,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1
6632,CHEMBL564975,DIBROLGRIJOMRQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1N2C=CN=N2)C(=O)NC3CC3C4=CC=CC=C4,5.0,O=C(NC1CC1c1ccccc1)N1CCC(n2ccnn2)CC1
6636,CHEMBL1271600,DIGDIWHKKJZMKG-NZSAHSFTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,13.6,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H]1COC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CC[C@H](C4)O,7.866461091629782,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC[C@@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
6637,CHEMBL1271651,DIGDIWHKKJZMKG-YTQUADARSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H]1COC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CC[C@@H](C4)O,7.522878745280337,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC[C@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
6642,CHEMBL208787,DIHNBIJLWDSARE-ZRJLEYOISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16821776.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4 transfected in human microsome using DEF fluorogenic substrate,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,CC(C)C[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=CC3=C(C=C2)OC=C3)C(=O)NC(C)C)C4CC5=CC=CC=C5C4,5.6020599913279625,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc2occc2c1
6643,CHEMBL208787,DIHNBIJLWDSARE-ZRJLEYOISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16821776.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4 transfected in human microsome using PPR fluorogenic substrate,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,CC(C)C[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=CC3=C(C=C2)OC=C3)C(=O)NC(C)C)C4CC5=CC=CC=C5C4,5.366531544420414,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc2occc2c1
6661,CHEMBL2448741,DIMLXAZFUWCAKB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,612.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CS(=O)(=O)N(CC1=CN=CC=C1)C2=C(C=C(C=C2)C3=CC=C(C=C3)F)F,6.213248577854439,CS(=O)(=O)N(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F
6663,CHEMBL2440637,DIPLMIIVEFADBF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC=C1F)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CC(=CN=C3)F,5.886056647693163,O=C(Nc1ccc(F)cn1)c1cc(Cl)cc(Oc2cncc(F)c2)c1
6671,CHEMBL179398,DIQWXENHCURRML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,23900.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CC=C(S2)C=O,4.621602099051862,O=Cc1ccc(-c2cccnc2)s1
6672,CHEMBL179398,DIQWXENHCURRML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23930.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1=CC(=CN=C1)C2=CC=C(S2)C=O,4.621057301386562,O=Cc1ccc(-c2cccnc2)s1
6681,CHEMBL3667554,DIUDVHGBTFDFCN-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26317591.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.,J. Med. Chem.,PUBLICATION,,COC1=CC=C(C=C1)S(=O)(=O)N2CCC[C@H]2C(=O)NC3=CC(=CC=C3)SC,5.096910013008056,COc1ccc(S(=O)(=O)N2CCC[C@H]2C(=O)Nc2cccc(SC)c2)cc1
6683,CHEMBL358214,DIVNKPFJAVQFJM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,50900.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)N2C=CN=C2C,4.293282217663242,CCCCOc1ccc(-n2ccnc2C)cc1
6685,CHEMBL325829,DIVWCYHNQIMLLP-NKBKYVEPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC3=CC=CC=C3O2)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=NC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,5.657577319177793,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2cc3ccccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1ccncc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
6697,CHEMBL551517,DIYUAKHOKKCOEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC(=NO2)C3=NC=CC=N3)C(=O)NC4CC4C5=CC=CC=C5,5.0,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ncccn3)no2)CC1
6699,CHEMBL399831,DIYWRNLYKJKHAM-MDOVXXIYSA-N,(-)-CUBEBIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,C1[C@@H]([C@H]([C@H](O1)O)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,5.040958607678906,O[C@H]1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2
6719,CHEMBL1093058,DJILKXZJMQURGL-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)N3C=CC=N3,5.0,C[C@H](c1c(CCN(C)C)sc2ccccc12)n1cccn1
6721,CHEMBL498434,DJKTUOFJPXSXPC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,9200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)COC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,5.036212172654444,Cc1cccc(C)c1COc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
6722,CHEMBL498434,DJKTUOFJPXSXPC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)COC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,4.6777807052660805,Cc1cccc(C)c1COc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
6724,CHEMBL2018486,DJLRGOWWXNREJY-FNZWTVRRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,C1[C@@H](CN([C@@H]1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CN4C=NC=N4)CC5=CC=C(C=C5)F,4.698970004336019,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@H](Cc2ccc(F)cc2)CN1C(=O)Cn1cncn1
6725,CHEMBL2018485,DJLRGOWWXNREJY-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,=,12605.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,C1[C@H](CN([C@@H]1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CN4C=NC=N4)CC5=CC=C(C=C5)F,4.899457149987535,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1cncn1
6731,CHEMBL517440,DJNOSUSXPUIIRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=CC=CC=C3Cl,5.698970004336019,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl
6732,CHEMBL517440,DJNOSUSXPUIIRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=CC=CC=C3Cl,5.3979400086720375,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl
6748,CHEMBL240070,DJWUDIFTUQYCIR-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)CCO,6.3979400086720375,CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(CCO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
6749,CHEMBL2158222,DJXBOGHWDLVTJM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C4=CC=CC=N4)NC(=O)C5=NC=C(N5)C#N,5.769551078621726,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(c4ccccn4)CC3)cc2C2=CCCCC2)[nH]1
6750,CHEMBL387611,DJXOQVPIGHGJIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C5=NCCN5C,4.455931955649724,Cc1cc(C2=NCCN2C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
6751,CHEMBL2107826,DJXRIQMCROIRCZ-XOEOCAAJSA-N,VIBEGRON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26709102.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,PUBLICATION,,C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)[C@@H](C5=CC=CC=C5)O,4.0,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21
6786,CHEMBL271240,DKIUFVFEAUCDLY-BDYUSTAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,830.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=CC(=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)OC)C(=O)O,6.080921907623926,COc1ccc(N2C(=O)[C@@H](Cc3cccc(OCCc4nc(-c5ccccc5)oc4C)c3)[C@H]2C(=O)O)cc1
6787,CHEMBL271240,DKIUFVFEAUCDLY-BDYUSTAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=CC(=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)OC)C(=O)O,4.301029995663981,COc1ccc(N2C(=O)[C@@H](Cc3cccc(OCCc4nc(-c5ccccc5)oc4C)c3)[C@H]2C(=O)O)cc1
6794,CHEMBL3115185,DKJJHJFCGCQNOZ-MCQSSSDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CC2=CN(C=N2)C)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.958607314841775,CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2cn(C)cn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
6805,CHEMBL2029988,DKNUPRMJNUQNHR-UHFFFAOYSA-N,CEP-32496,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22168626.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.",J. Med. Chem.,PUBLICATION,,CC(C)(C1=CC(=NO1)NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F,5.0,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
6821,CHEMBL3353348,DKVKUPRCFKTRIY-IRIFPNPLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC=C(C=C1)/C=C/C2=NNC3=C2C=CC(=C3)[C@@H]4C[C@]45C6=C(C=CC(=C6)OC)NC5=O,6.0,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN(C)C)cc4)n[nH]c3c1)C(=O)N2
6822,CHEMBL3353348,DKVKUPRCFKTRIY-IRIFPNPLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC=C(C=C1)/C=C/C2=NNC3=C2C=CC(=C3)[C@@H]4C[C@]45C6=C(C=CC(=C6)OC)NC5=O,5.1249387366083,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN(C)C)cc4)n[nH]c3c1)C(=O)N2
6855,CHEMBL2380640,DLDBIFVUGIHIRD-KISMBWHLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)C2=CN=C(N=C2)N3CCN(C4=CC=CC=C43)C(=O)NC5C6CC7CC5CC(C7)(C6)OC(=O)N,5.0,COc1ccc(-c2cnc(N3CCN(C(=O)NC4C5CC6CC4CC(OC(N)=O)(C6)C5)c4ccccc43)nc2)cc1
6856,CHEMBL2152165,DLEGYAJVPJEXJD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(C1)NC(=O)N[C@](CC2=CC=CC=C2)(C3=NC=C(C=C3)Cl)C4=CC(=CC(=C4)F)OC(C(F)F)(F)F,5.443697499232713,O=C(NC1CCCC1)N[C@@](Cc1ccccc1)(c1cc(F)cc(OC(F)(F)C(F)F)c1)c1ccc(Cl)cn1
6857,CHEMBL2152165,DLEGYAJVPJEXJD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(C1)NC(=O)N[C@](CC2=CC=CC=C2)(C3=NC=C(C=C3)Cl)C4=CC(=CC(=C4)F)OC(C(F)F)(F)F,5.055517327849831,O=C(NC1CCCC1)N[C@@](Cc1ccccc1)(c1cc(F)cc(OC(F)(F)C(F)F)c1)c1ccc(Cl)cn1
6860,CHEMBL222424,DLFIQCGXPLUMEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17352462.0,IC50,=,91900.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect cells,"Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).",J. Med. Chem.,PUBLICATION,,C1CN(CCC1N2CC(NC2=O)(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)CC5=CC=CC=C5,4.036684488613889,O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2ccccc2)CC1
6871,CHEMBL445120,DLGSCKSKWYCGOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)CC2=CC=C(C=C2)N=CNO,4.0,ONC=Nc1ccc(Cc2ccccc2)cc1
6872,CHEMBL3702792,DLHZRUXHGKNJGU-DWQLLFNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2730.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCNCC8,5.5638373529592435,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCNCC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
6875,CHEMBL3264608,DLIXONPOBWMUIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OC(F)F)(C3=NNN=C3)O,4.853871964321762,CC(C)C(O)(c1ccc2cc(OC(F)F)ccc2c1)c1cn[nH]n1
6877,CHEMBL3702741,DLKIIRFCOFZXQS-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2890.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(CCNCCO)CCO,5.539102157243452,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(CCO)CCNCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
6886,CHEMBL2159140,DLRVDRDTIAJMFM-YSXJMYCUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NCC)O4)C)(C)O)C)C)O)(C)O,6.301029995663981,CCN=C1O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C
6887,CHEMBL2159140,DLRVDRDTIAJMFM-YSXJMYCUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,5700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NCC)O4)C)(C)O)C)C)O)(C)O,5.2441251443275085,CCN=C1O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C
6903,CHEMBL3639635,DLWOOKUVKDJBLM-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,14000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)C#N)C4=CC=CC=C4,4.853871964321762,C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O
6907,CHEMBL2312555,DLYCRJBHFXFNNZ-HPBYZVIZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23253441.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(C=N1)C2=C(C=C(C=C2)/C=C/3\CCCN4C3=NOCC[C@@H]4C5=CC(=C(C(=C5)F)F)F)OC,4.522878745280337,COc1cc(/C=C2\CCCN3C2=NOCC[C@@H]3c2cc(F)c(F)c(F)c2)ccc1-n1cnc(C)c1
6920,CHEMBL1650654,DMEBSJDKEXDYPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21189020.0,IC50,=,1070.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17ß-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)N)C2=C(C=CC3=C2C=CC(=C3)C4=CC(=CC=C4)O)O,5.97061622231479,Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1
6935,CHEMBL368448,DMLUZARQJJUBAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,640.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C(=O)O)N4C=CN=C4)N(C)C,6.1938200260161125,CC(C(c1ccc2cc(OCc3ccc(C(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C
6936,CHEMBL368448,DMLUZARQJJUBAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,1180.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C(=O)O)N4C=CN=C4)N(C)C,5.928117992693875,CC(C(c1ccc2cc(OCc3ccc(C(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C
6937,CHEMBL30052,DMLYJUNKHVPUCR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C(=CC=C2)[N+](=O)[O-])C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,4.0,Cn1c2cccc([N+](=O)[O-])c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
6938,CHEMBL3702761,DMNKTIQUDQHBLV-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2390.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NN7CCN(CC7)C8CCCC8,5.621602099051862,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCN(C6CCCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
6947,CHEMBL2087167,DMQYDVBIPXAAJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC(=CC=C4)F)C5=NC=C(N5)C,4.6020599913279625,CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2ncc(C)[nH]2)C(=O)N3)CC1
6949,CHEMBL3137445,DMRRQBPJVXEDNC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=CC=C4,4.958607314841775,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccccc3)CC2)cc1
6950,CHEMBL3137445,DMRRQBPJVXEDNC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=CC=C4,4.698970004336019,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccccc3)CC2)cc1
6953,CHEMBL559506,DMSVLPBDBXCIAW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19552431.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assay,Novel small molecule bradykinin B2 receptor antagonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC=C1)CNC(=O)C(C)C)COC2=CC=CC3=C(C=C(N=C32)C)C4=CC=NN4C,5.508638306165727,Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3CNC(=O)C(C)C)c2n1
7001,CHEMBL1258078,DNJOROZLUNUHBO-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CNC(=O)C2=CC3=CC(=C(C=C3N12)Br)OC4CCN(CC4)C(C)C,4.301029995663981,CC(C)N1CCC(Oc2cc3cc4n(c3cc2Br)[C@@H](C)CNC4=O)CC1
7004,CHEMBL1276946,DNKYHHFCPXKFIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942471.0,IC50,=,20900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.",J. Med. Chem.,PUBLICATION,,CC1=C2C(=CC(=O)N1CC3=CC=CC=N3)NN(C2=O)C4=CC=CC=C4Cl,4.679853713888946,Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccccn1
7007,CHEMBL512126,DNLNFXITFOQXRI-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=C(C=C4)OC)Cl)O)C5CCN(CC5)CCOC,5.113509274827518,COCCN1CCC(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5ccc(OC)c(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
7025,CHEMBL1933349,DNTVJEMGHBIUMW-IBGZPJMESA-N,MK-0893,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22708876.0,IC50,=,60000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in liver microsomes assessed as testosterone 6beta-hydroxylation after 48 hrs,"Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C(=O)NCCC(=O)O)N2C(=CC(=N2)C3=CC(=CC(=C3)Cl)Cl)C4=CC5=C(C=C4)C=C(C=C5)OC,4.221848749616356,COc1ccc2cc(-c3cc(-c4cc(Cl)cc(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1
7044,CHEMBL3403825,DOAHUBOSPSWMOM-CTYWIBQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)CCOC)C)C)O)C)C(C)(C)O,5.107905397309519,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
7045,CHEMBL3403825,DOAHUBOSPSWMOM-CTYWIBQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)CCOC)C)C)O)C)C(C)(C)O,4.657577319177793,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
7089,CHEMBL1210648,DOQWXXFLJCNROA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594839.0,IC50,=,8440.0,NM,,,,,,,,,,,,,,,Inhibition of human CY3A4,Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT(6) receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC(CC1)NC2=C(C=CC(=C2)S(=O)(=O)NC3=C(C(=CC(=C3)Cl)Cl)OC)OC,5.073657553374344,COc1ccc(S(=O)(=O)Nc2cc(Cl)cc(Cl)c2OC)cc1NC1CCN(C)CC1
7090,CHEMBL398772,DORVKDBVLHMAPQ-FYYLOGMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCN(CC4)C(C)(C)CO,5.327902142064283,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
7091,CHEMBL3114716,DOSBKYYTXRWRCG-PXTZSQHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,710.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)N(C)C(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.1487416512809245,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)N(C)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
7092,CHEMBL3104374,DOTQGOWEPGZREI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,4.698970004336019,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1
7093,CHEMBL3104374,DOTQGOWEPGZREI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,4.698970004336019,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1
7097,CHEMBL1642412,DOUUUDLTKJRZKD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21134749.0,IC50,=,5540.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Indole-3-piperazinyl derivatives: novel chemical class of 5-HT(6) receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=CC=CC=C32)N4CCN(CC4)C,5.2564902352715706,CC(C)c1ccc(S(=O)(=O)n2cc(N3CCN(C)CC3)c3ccccc32)cc1
7107,CHEMBL508435,DOYPVXXUUVHXLK-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,48.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C(=O)OCC2=CC=C(C=C2)C3=CN(C(=O)N(C3=O)C[C@@H](C4=CC=CC=C4)N)CC5=C(C=CC=C5F)C(F)(F)F,7.318758762624412,N[C@@H](Cn1c(=O)c(-c2ccc(COC(=O)C3CC3)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
7109,CHEMBL2064352,DPBSWFWWWKYRFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1COCCN1C2=CC(=O)NC(=N2)CC3=NC4=C(O3)C=CC(=C4)F,4.3979400086720375,O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3o2)[nH]1
7125,CHEMBL3104472,DPJQHVMKIJQTCX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=C(C=C4)Cl,4.698970004336019,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(Cl)cc3)CC2)cc1
7127,CHEMBL3104472,DPJQHVMKIJQTCX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=C(C=C4)Cl,4.698970004336019,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(Cl)cc3)CC2)cc1
7130,CHEMBL2436334,DPMXDKUIEMIVNP-YMZODZAASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)C(=O)N2C[C@@H](C(=O)N(C3=CC=CC=C32)CC4=C(C=CC5=C4C=CC(=C5)Br)OC)NC(=O)[C@H](C)NC.Cl,5.853871964321762,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
7132,CHEMBL212521,DPOJEFZKFIWUGN-ROUUACIJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16647256.0,IC50,=,3604.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)C#N)N,5.443215217692974,CC[C@H](N)C(=O)N[C@H](C#N)Cc1ccc(-c2ccccc2)cc1
7133,CHEMBL2048855,DPONSKCACOZTGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727639.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CSC(=N1)N(C2CC2)C(=O)CSC3=NN=C(C=C3)C4=CC=CC=C4,4.522878745280337,Cc1csc(N(C(=O)CSc2ccc(-c3ccccc3)nn2)C2CC2)n1
7134,CHEMBL1777979,DPOWGCZOKVGFCN-CLJLJLNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]3CCCC4=C3C=CC(=C4)CNCC(C)(C)C,5.657577319177793,Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNCC(C)(C)C)ccc32)cc1
7135,CHEMBL1777979,DPOWGCZOKVGFCN-CLJLJLNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]3CCCC4=C3C=CC(=C4)CNCC(C)(C)C,4.522878745280337,Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNCC(C)(C)C)ccc32)cc1
7141,CHEMBL568138,DPSHYRRSRHVRRE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=CC(=C5)F)F,4.5376020021010435,COc1cnc2c(NCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1
7142,CHEMBL568138,DPSHYRRSRHVRRE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=CC(=C5)F)F,4.301029995663981,COc1cnc2c(NCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1
7149,CHEMBL377928,DPUNFIBGNOBPIM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1C2=NC(=C(O2)N)C(=O)N)C(F)(F)F,4.522878745280337,NC(=O)c1nc(-c2ccc(C(F)(F)F)cc2)oc1N
7151,CHEMBL1928095,DPVYRXNZNFJFRP-STBIYBPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22100140.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.,Eur. J. Med. Chem.,PUBLICATION,,CC1=C(SC(=C1C#N)/N=C/C2=CC=C(C=C2)C3=CC=CC=C3)C4=CC(=C(C=C4)OC)OC,4.0,COc1ccc(-c2sc(/N=C/c3ccc(-c4ccccc4)cc3)c(C#N)c2C)cc1OC
7166,CHEMBL1951452,DPZQITNCJMQOKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1CNC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4)Br,6.568636235841013,O=C(NCc1ccc(Br)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
7167,CHEMBL1794073,DQBBVXOEACBXDP-UHFFFAOYSA-N,GW770220A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=NN(C2=C1C=CC(=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N)C.Cl,5.769551078621726,Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12
7168,CHEMBL1794073,DQBBVXOEACBXDP-UHFFFAOYSA-N,GW770220A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=NN(C2=C1C=CC(=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N)C.Cl,4.886056647693163,Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12
7169,CHEMBL255394,DQBDGBGYLBNZBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)N(C)C)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,6.096910013008056,CC(C)c1c(-c2nnc(N(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
7170,CHEMBL27102,DQBOLYOAFHZWDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998323.0,IC50,=,2440.0,NM,,,,,,,,,,,,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.,J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1OC)CNC(=O)C2=C3CCCCN3C4=C2N=CN=C4N5CCN(CC5)CCC6=CC(=C(C=C6)F)F,5.61261017366127,COc1cccc(CNC(=O)c2c3n(c4c(N5CCN(CCc6ccc(F)c(F)c6)CC5)ncnc24)CCCC3)c1OC
7176,CHEMBL567908,DQDNVYJAOVRUOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NSC(=C1)C2=NN3C(=NN=C3COC4=C5C=CC(=CC5=NC=C4)OC)C=C2,5.318758762624412,COc1ccc2c(OCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
7177,CHEMBL567908,DQDNVYJAOVRUOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NSC(=C1)C2=NN3C(=NN=C3COC4=C5C=CC(=CC5=NC=C4)OC)C=C2,4.769551078621726,COc1ccc2c(OCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
7183,CHEMBL563664,DQHOYVVIVFHEBF-LSJNQWAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C1)C3C=CC=CC3N2CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.522878745280337,CN([C@@H]1CCC2=C(C1)C1C=CC=CC1N2CC(=O)O)S(=O)(=O)c1ccc(F)cc1
7217,CHEMBL27007,DQRJVPCIGZXELF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CC1=NC=CC2=C1C3=C(N2C)C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,4.0,Cc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C
7218,CHEMBL3353356,DQTLTCIEAKFGBZ-DNGGJULVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,C1COCCN1CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)F)NC6=O,6.0,O=C1Nc2ccc(F)cc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
7220,CHEMBL1951326,DQTWQNOOTFOMSH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,5.920818753952375,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
7225,CHEMBL1683074,DQWSENNLMPJNRJ-WHLIWEHUSA-N,PF-903,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21295478.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@]1(CC[C@H](C1)N[C@H]2CCOC[C@H]2OC)C(=O)N3CCN(CC3)C4=NC=CC(=C4)C(F)(F)F,4.6020599913279625,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)(C(C)C)C1
7227,CHEMBL3393474,DQXCRLJTGIDAES-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=CC=C6F,5.346787486224656,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)cccc3[nH]2)o1
7228,CHEMBL502182,DQYGXRQUFSRDCH-UQIIZPHYSA-M,ELAGOLIX SODIUM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,56000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],4.251811972993799,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)[O-])c3ccccc3)c2=O)c1F
7229,CHEMBL3417531,DQZAEYUQSKTFAR-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25671290.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,PUBLICATION,,C[C@@](C1CC1)(C2=CC=C(C=C2)C3=CN=C(N=C3)N)C4=NOC(=N4)C5=CN(N=C5)CC(C)(C)O,4.522878745280337,CC(C)(O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1
7247,CHEMBL2207100,DRHNPWMFAGWFPG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23079519.0,IC50,=,5011.87,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,In vivo activity of an azole series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CN(N=N1)CC2=CC(=C(C=C2NS(=O)(=O)C3=CC=C(S3)Cl)Cl)Cl,5.300000202445418,O=S(=O)(Nc1cc(Cl)c(Cl)cc1Cn1ccnn1)c1ccc(Cl)s1
7272,CHEMBL505919,DRQNCWQLZYUQOI-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,3.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)OC,8.455931955649724,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
7273,CHEMBL505919,DRQNCWQLZYUQOI-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)OC,5.455931955649724,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
7284,CHEMBL3702738,DRVYXXNUQCITHS-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7870.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCN(C)C,5.104025267640935,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
7286,CHEMBL478834,DRWJMJVERMOJBX-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621528.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,5.522878745280337,CCOC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
7323,CHEMBL3318978,DSIKPABWAOKGSR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25050169.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A3,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1C2=CC=CN3C2=NN=C3C4(CC4)C5=CC=C(C=C5)Cl,4.698970004336019,Clc1ccc(C2(c3nnc4c(C5CC5)cccn34)CC2)cc1
7325,CHEMBL2387592,DSKHNDVPASXXTC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=C(C=C4)Cl)Cl,4.522878745280337,O=c1[nH]c2ccc(Cl)cc2c2nc(-c3ccccc3Cl)[nH]c12
7330,CHEMBL489297,DSMHXHKJIOOKIY-WCRBZPEASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C(C)C(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,5.060480747381382,CC(C(=O)N1CCC(Nc2ccc(F)cc2)CC1)c1ccc(CN2C[C@H](C)N[C@H](C)C2)cc1
7342,CHEMBL2181634,DSQHZRQDKSGPJS-CXUHLZMHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,10900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=NC=C(C=C5)Cl)C6CCCC6,4.962573502059376,Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21
7349,CHEMBL1927147,DSRNDKNGQPKUQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22041175.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by mass spectrophotometry,"Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1CN(CC2=C3C(=CC(=O)N2C1)NN(C3=O)C4=CC=CC=C4Cl)CC5=CC=CC=C5.Cl,4.6020599913279625,O=c1c2c3n(c(=O)cc2[nH]n1-c1ccccc1Cl)CCCN(Cc1ccccc1)C3
7353,CHEMBL1215620,DSSRNDXICGBGMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20672820.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C(C(=C(N1)CN2C=CC=N2)C(=O)OC)C3=C(C=C(C=C3)F)Cl)C#N,5.958607314841775,COC(=O)C1=C(Cn2cccn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl
7378,CHEMBL493937,DTBFDAJNODVUMF-VOTSOKGWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19256503.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins using 7-benzyloxy 4-trifluoromethylcoumarin as substrate,Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.,J. Med. Chem.,PUBLICATION,,CN1CCCN(CC1)C2=NC(=CN=C2)C3=CC=CC(=C3)/C=C/C(=O)O,4.522878745280337,CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1
7379,CHEMBL493937,DTBFDAJNODVUMF-VOTSOKGWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19256503.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins using 7-benzyloxyquinoline as substrate,Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.,J. Med. Chem.,PUBLICATION,,CN1CCCN(CC1)C2=NC(=CN=C2)C3=CC=CC(=C3)/C=C/C(=O)O,4.522878745280337,CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1
7403,CHEMBL1819089,DTNUQCRCHKWJCE-PKLMIRHRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21865048.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.",Bioorg. Med. Chem.,PUBLICATION,,CN1C2=C(C(=O)N(C1=O)C)N(C(=C2)N3CCC[C@H](C3)N)CC4=C(C=CC(=C4)F)C#N.Cl,5.795880017344075,Cn1c(=O)c2c(cc(N3CCC[C@@H](N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O
7411,CHEMBL2338343,DTQWCHXPSGNTKM-BWAGFHJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23560650.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective s1 receptor ligands.",J. Med. Chem.,PUBLICATION,,CC(C)CCOC1=CC2=C(C=C1)N[C@@H]([C@H]3[C@@H]2OCCC3)C4CCOCC4,5.301029995663981,CC(C)CCOc1ccc2c(c1)[C@H]1OCCC[C@H]1[C@@H](C1CCOCC1)N2
7421,CHEMBL1671972,DTWGKFUSEYNFHI-DHDCSXOGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)/C=C\2/C(=O)NC(=O)S2)OC3=CC=CC=C3C(F)(F)F,5.721246399047171,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccccc1C(F)(F)F
7452,CHEMBL3422091,DUKJABPGWUISRC-BOSRLCDASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1C[C@H]2CC(C[C@H]1N2C3=CC=C(C=C3)C4=NNC5=C4C=C(C=C5)C(=O)N[C@@H](C6CC6)C7=CC=CC=N7)O,5.769551078621726,O=C(N[C@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1
7453,CHEMBL3422091,DUKJABPGWUISRC-BOSRLCDASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1C[C@H]2CC(C[C@H]1N2C3=CC=C(C=C3)C4=NNC5=C4C=C(C=C5)C(=O)N[C@@H](C6CC6)C7=CC=CC=N7)O,5.6777807052660805,O=C(N[C@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1
7454,CHEMBL3422092,DUKJABPGWUISRC-SBZVUBOMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1C[C@H]2CC(C[C@H]1N2C3=CC=C(C=C3)C4=NNC5=C4C=C(C=C5)C(=O)N[C@H](C6CC6)C7=CC=CC=N7)O,5.886056647693163,O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1
7455,CHEMBL3422092,DUKJABPGWUISRC-SBZVUBOMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1C[C@H]2CC(C[C@H]1N2C3=CC=C(C=C3)C4=NNC5=C4C=C(C=C5)C(=O)N[C@H](C6CC6)C7=CC=CC=N7)O,5.853871964321762,O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1
7484,CHEMBL1683577,DUTKICDSXNUMBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21324691.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=CN1CC2=CC(=CC=C2)C(F)(F)F)C(=O)NC3=NN(C=C3)C,4.522878745280337,Cc1c(C(=O)Nc2ccn(C)n2)ncn1Cc1cccc(C(F)(F)F)c1
7487,CHEMBL393204,DUUPSEFOQYYDEP-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=CC=CC=C1N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCNC,5.318758762624412,CNCCN[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
7494,CHEMBL2441845,DUYPYSBUOWVEJT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CCC(=O)O)C3=C(C=C(C=C3)Cl)Cl)CN,4.3979400086720375,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CCC(=O)O)C2
7497,CHEMBL2448697,DVAJHBMDTLCJMY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,250.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCOC(CN1C=CN=C1)COC2=CC3=C(C=C2)C=C(C=C3)Br.C(=O)O,6.6020599913279625,CCOC(COc1ccc2cc(Br)ccc2c1)Cn1ccnc1
7524,CHEMBL499705,DVGGLGXQSFURLP-PYFXTMFGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15568772.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa.",J. Nat. Prod.,PUBLICATION,,C1=CC(=CC=C1/C=C\C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)O)O)O)O,6.154901959985743,O=C(/C=C\c1ccc(O)cc1)OC[C@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H](O)[C@@H]1O
7525,CHEMBL266564,DVGGLGXQSFURLP-VWMSDXGPSA-N,TILIROSIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15568772.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa.",J. Nat. Prod.,PUBLICATION,,C1=CC(=CC=C1/C=C/C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)O)O)O)O,6.154901959985743,O=C(/C=C/c1ccc(O)cc1)OC[C@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H](O)[C@@H]1O
7533,CHEMBL3632722,DVJYMPYLFMEZMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=CC(=C5)C(F)(F)F,4.3979400086720375,Cn1c(Nc2cccc(C(F)(F)F)c2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
7545,CHEMBL468092,DVPZNDPOWUEVAP-UKSTWOGXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19289530.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,PUBLICATION,,CN(C/C=C\CN)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)N)O)O,5.301029995663981,CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)nc(Cl)nc32)[C@H](O)[C@@H]1O
7553,CHEMBL3359270,DVWXXJHSHNVODR-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25423411.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM).",J. Med. Chem.,PUBLICATION,,CCN1CCC[C@H]1CNC(=O)C2=CN(C(=O)C3=C2C4=CC=CC=C4N3C)C5CCCC5,5.494850021680094,CCN1CCC[C@H]1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C
7560,CHEMBL499582,DWAGGUQJLSNEEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C)N(C(=O)C=N2)CC(=O)N(C)C(CN3CCOCC3)C4=CC=C(C=C4)C5=CC(=CC=C5)C(=O)NC,5.045757490560675,CNC(=O)c1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)Cn3c(=O)cnc4cc(C)c(C)cc43)cc2)c1
7561,CHEMBL151037,DWBVBONATVNRGC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,93800.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CC=NN2C,4.027797161620936,CCCCOc1ccc(-c2ccnn2C)cc1
7562,CHEMBL3664679,DWCHGEBWHYTIPU-JRPXNJEYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C3CC3)N4CC[C@](OC4=O)(CC(C)(C)O)C5=CC=CC=C5,4.638272163982407,C[C@@H](c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
7568,CHEMBL3699336,DWHDFUVHGLXNKO-YATWDLPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2510.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)NC(=O)C2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.600326278518962,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NN6CCN(C)CC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
7569,CHEMBL260636,DWHFXDLHZUPSDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18374569.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(=NC2=C(C=C(C=C2)C3=CC=CC=C3F)NC1=O)C4=CC(=CC=C4)N5C=CN=C5,9.0,O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2ccc(-c3ccccc3F)cc2N1
7574,CHEMBL1242533,DWJGZXZILMOEGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCCC7,5.221848749616356,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCC6)ncn4-5)CC3)cccc2n1
7575,CHEMBL1242533,DWJGZXZILMOEGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCCC7,5.221848749616356,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCC6)ncn4-5)CC3)cccc2n1
7581,CHEMBL3622898,DWLPNEAIQATTGD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26602277.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(N=C1Cl)OCCCC2=NC3=CC=CC=C3C=C2)NCC4=C(N=C(S4)C)C,6.045757490560675,Cc1nc(C)c(CNc2nc(OCCCc3ccc4ccccc4n3)nc(Cl)c2C)s1
7583,CHEMBL517933,DWMFXLXZBXBWJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,76000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C(=C1)F)C(=O)N(CCO)CC(CNC(=O)C2=C(N(N=C2)C3=CC=C(C=C3)F)N)(C(F)(F)F)O)F,4.119186407719209,Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1
7584,CHEMBL205447,DWMQJCAMZAGHHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,COC1=CC=CC=C1OC2=CC=CC(=C2)CN3CCC(CC3)NC(=O)C4(CCNCC4)C5=CC=CC=C5,5.0,COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccccc4)CCNCC3)CC2)c1
7585,CHEMBL2035053,DWMYQJBUFRLTQG-GORDUTHDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22339472.0,IC50,=,970.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.",J. Med. Chem.,PUBLICATION,,CC1=CN=C2NC3=CC(=C(C=C3)OCCN4CCCC4)COC/C=C/CCOC5=NC=CC(=C5)C1=N2,6.013228265733755,Cc1cnc2nc1-c1ccnc(c1)OCC/C=C/COCc1cc(ccc1OCCN1CCCC1)N2
7598,CHEMBL270271,DWRKFAJEBUWTQM-UHFFFAOYSA-N,ETACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CCC1COC(O1)(CN2C=NC=N2)C3=C(C=C(C=C3)Cl)Cl,6.6777807052660805,CCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1
7621,CHEMBL3664661,DWXBSPQGQLKLDE-SVEHJYQDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CC[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,CC[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
7634,CHEMBL497031,DXBRVISEKVIIAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N(C(=C3)C(=O)N4CCC(CC4)(F)F)C(C)C,4.301029995663981,CC(C)N1CCC(Oc2ccc3c(c2)cc(C(=O)N2CCC(F)(F)CC2)n3C(C)C)CC1
7636,CHEMBL3702778,DXCUGDBVIFFNKH-RAGPDMHTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2550.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCC(CO)O,5.5934598195660445,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCC(O)CO)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
7649,CHEMBL3673952,DXDZIZAESKHCEH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320621,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(C=C3)NCC4=CN=C(C=C4)C(F)(F)F)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3)c2c1
7650,CHEMBL3673952,DXDZIZAESKHCEH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320665,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(C=C3)NCC4=CN=C(C=C4)C(F)(F)F)N=C1,5.0,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3)c2c1
7679,CHEMBL3421983,DXQQRCJKVWAXDC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C1CN2C(=NN=C2C3=CC=CC=N3)CN1C(=O)C4=CC=C(C=C4)F,4.0,O=C(c1ccc(F)cc1)N1CCn2c(nnc2-c2ccccn2)C1
7680,CHEMBL3216313,DXRIKERZCUUBEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21699209.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,PUBLICATION,,CN(C)CCN1CCCC2=C1C=CC(=C2)N=C(C3=CC=CS3)N.Cl.Cl,4.0,CN(C)CCN1CCCc2cc(N=C(N)c3cccs3)ccc21
7685,CHEMBL2347183,DXYIYKUZINROPB-POYCELQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23586711.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.,J. Med. Chem.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CC=C3)CC4=CC=CC=C4,6.886056647693163,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cccnc2)Cc2ccccc2)C(C)C)cs1
7719,CHEMBL178878,DYEAIDZAOQKZJM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,400000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1=CC(=CN=C1)C2=NC=CC=N2,3.3979400086720375,c1cnc(-c2cccnc2)nc1
7727,CHEMBL3673936,DYGYHFMGUUCRQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320647,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)Cl)F)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1
7728,CHEMBL3673936,DYGYHFMGUUCRQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320691,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)Cl)F)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1
7734,CHEMBL3315062,DYJSODVHTVCXIA-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24980053.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)([C@H]1C2=C(C(=CC=C2)F)OC3=C1C=CC(=N3)C4=CC=C(C=C4)C(=O)N5CCOCC5)C(=O)NC6=NN=CS6,6.522878745280337,CC(C)(C(=O)Nc1nncs1)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21
7735,CHEMBL2420425,DYJWAINZWLNTNQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23855836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)CC(=O)NC2=C3C4=CC=CC=C4SC3=C(C=C2)C5=CC=CC6=C5OC(=CC6=O)N7CCOCC7,5.0,CN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1
7745,CHEMBL2041177,DYPIWIAOPDZEOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)N,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(N)=O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
7749,CHEMBL485972,DYRFUYFXUGUOIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N(C)CCOC)C,5.6020599913279625,COCCN(C)c1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)n1
7751,CHEMBL207028,DYRYDYQWWQHRQE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=CC(=C(S2)C(=O)N)N,5.455931955649724,NC(=O)c1sc(-c2ccccc2)cc1N
7752,CHEMBL495492,DYSGCGRDHIJLBK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,CC1=C(C2=C(C=C1)C(=NO2)NC3CC3)C4=CC5=CN=NC(=C5C=C4)NC(C)C,5.251811972993799,Cc1ccc2c(NC3CC3)noc2c1-c1ccc2c(NC(C)C)nncc2c1
7756,CHEMBL2440639,DYWOKTOZNTWQJV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC=C1F)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CC(=C3)C#N,5.769551078621726,N#Cc1cncc(Oc2cc(Cl)cc(C(=O)Nc3ccc(F)cn3)c2)c1
7762,CHEMBL3706620,DYYJWDSYFDXNOW-FLOLVYIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852968.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=CC=C(O1)C2=CC=NC=C2)N3CCN([C@@H](C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,8.0,CC(C)(c1ccc(-c2ccncc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1
7772,CHEMBL3682506,DZBCCEIMLOAXBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,200000.0,NM,291611,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",Metalloenzyme inhibitor compounds,,PATENT,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)N3N=CN=N3,3.6989700043360187,COc1cc2ccc(C(C(C)C)n3ncnn3)cc2cc1OC
7773,CHEMBL447085,DZCNPAGZPPBTBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2(CCN(CC2)C(=O)CCC3=CC=CC=C3)OC4=C1C=C(C=C4)F,5.0,O=C(CCc1ccccc1)N1CCC2(CCc3cc(F)ccc3O2)CC1
7777,CHEMBL383077,DZEADOQXGYJGID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCCS(=O)(=O)C)C,4.769551078621726,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCS(C)(=O)=O)c(C)c34)ccc2[nH]1
7783,CHEMBL3394741,DZFCBWGZQNGTQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCN1C=C(C=N1)S(=O)(=O)C2=CN=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1
7784,CHEMBL3394741,DZFCBWGZQNGTQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCN1C=C(C=N1)S(=O)(=O)C2=CN=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1
7791,CHEMBL571581,DZIUPOCVDSYPSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19703774.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC2=C1C=CN2)NC3=C(C=NC=C3C#N)C4=CC5=C(O4)C=CC(=C5)CN6CCN(CC6)C,5.0,Cc1c(Nc2c(C#N)cncc2-c2cc3cc(CN4CCN(C)CC4)ccc3o2)ccc2[nH]ccc12
7792,CHEMBL3218645,DZKYPGWZOFNJJM-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,680.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,MedChemComm,PUBLICATION,,CC1=CC=CC=C1C2=NC3=C(C=C(C=C3)C4=CC=C(C=C4)Cl)C(=O)N2C[C@H]5CCCN(C5)C(C)C,6.167491087293763,Cc1ccccc1-c1nc2ccc(-c3ccc(Cl)cc3)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1
7795,CHEMBL346178,DZOJBGLFWINFBF-UMSFTDKQSA-N,OSANETANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N(C)C1(CCN(CC1)CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5,6.0,CC(=O)N(C)C1(c2ccccc2)CCN(CCC[C@]2(c3ccc(Cl)c(Cl)c3)CCCN(C(=O)c3ccccc3)C2)CC1
7796,CHEMBL1289515,DZPCZIBGZIYEKK-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20961756.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@H]1O)CCN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5)C=N2,5.113509274827518,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CC[C@H](O)C2)c1
7815,CHEMBL2036273,DZWCPJPFRNJGMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22420844.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,CNC1CCCC(C1)C2=CNC3=C2C=C(C=C3)N=C(C4=CC=CS4)N.Cl,4.0,CNC1CCCC(c2c[nH]c3ccc(N=C(N)c4cccs4)cc23)C1
7826,CHEMBL3578244,FAALBEAEXAFDGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27117261.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 (unknown origin),Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel non-basic 1-(2H-indazole-5-yl)pyridin-2(1H)-one derivatives and mitigation of mutagenicity in Ames test.,Bioorg. Med. Chem.,PUBLICATION,,CC1=C2C=C(C=CC2=NN1C3CC3)N4C=CC(=CC4=O)OCC5=CSC(=C5)C(F)(F)F,5.0,Cc1c2cc(-n3ccc(OCc4csc(C(F)(F)F)c4)cc3=O)ccc2nn1C1CC1
7834,CHEMBL3326569,FADLVMRJQZQOBL-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1(C[C@H](C2=C(O1)C=CC(=C2)F)NC(=O)NC3=CC=CC4=C3C=CN=C4)C,6.0,CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2cc(F)ccc2O1
7857,CHEMBL3330442,FAHBXTXHOUMNTM-ZFWWWQNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25179681.0,IC50,=,85120.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.",J. Med. Chem.,PUBLICATION,,C1COCC(=O)N1C2=CC3=C(C=C2)N4[C@@H](CO3)[C@@H](OC4=O)CNC(=O)C5=CC=C(S5)Cl,4.069968385049027,O=C(NC[C@@H]1OC(=O)N2c3ccc(N4CCOCC4=O)cc3OC[C@@H]12)c1ccc(Cl)s1
7868,CHEMBL2043172,FAJZUSKJMKJEFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC(=C(C=C6)C(=O)O)Cl,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(Cl)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
7872,CHEMBL1923120,FAMHFRDBTJMOTD-KCWPFWIISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=CC=CC3=CC=CC=C32)C(=O)[C@H]4CNCC[C@]45C6=CC(=C(C=C6CO5)F)F,5.221848749616356,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc2ccccc12)C1CC1
7900,CHEMBL560993,FATGTHLOZSXOBC-UHFFFAOYSA-N,OC000459,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)CC3=NC4=CC=CC=C4C=C3,4.522878745280337,Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O
7902,CHEMBL2177300,FAWSUKOIROHXAP-NPMXOYFQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25249180.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using diethoxyfluorescein as substrate after 10 mins by fluorescence assay,"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.",J. Med. Chem.,PUBLICATION,,C[C@H]1C[C@H](C2=C(N1C(=O)C)C=CC(=C2)C3=CC=C(C=C3)C(=O)O)NC4=CC=C(C=C4)Cl,4.6777807052660805,CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2[C@H](Nc2ccc(Cl)cc2)C[C@@H]1C
7903,CHEMBL2177300,FAWSUKOIROHXAP-NPMXOYFQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25249180.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using 7-benzloxyquinolone as substrate after 10 mins by fluorescence assay,"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.",J. Med. Chem.,PUBLICATION,,C[C@H]1C[C@H](C2=C(N1C(=O)C)C=CC(=C2)C3=CC=C(C=C3)C(=O)O)NC4=CC=C(C=C4)Cl,4.494850021680094,CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2[C@H](Nc2ccc(Cl)cc2)C[C@@H]1C
7922,CHEMBL2017103,FAYUIOXPYLILNE-ODXCJYRJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNC[C@@H]([C@]1(C2=CC(=C(C=C2)F)F)O)C3=NOC(=C3)C4=C(C=CC=C4Cl)Cl,4.769551078621726,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2c(Cl)cccc2Cl)on1
7944,CHEMBL381568,FBIQASFAEYMVBJ-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,3790.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3[C@H](CNCC3=O)COC4=CC5=C(CCCN5CCN6CCOC6=O)C=C4,5.421360790031928,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN2CCOC2=O)CCC3)cc1
7948,CHEMBL460542,FBLFUQVNJABTNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19208473.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microplate-based direct fluorometric assay,"Discovery of novel non-peptidic beta-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CCC1C2=CC=CC=C2OC3=CC=CC=C13)CCC(=O)N4CCN(CC4)C5=CC(=C(C=C5)F)F,5.0,CN(CCC(=O)N1CCN(c2ccc(F)c(F)c2)CC1)CCC1c2ccccc2Oc2ccccc21
7953,CHEMBL2064418,FBMOTDKLUMGRFX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1COCCN1C2=CC(=O)NC(=N2)CC3=NC4=CC=CC=C4O3,4.3979400086720375,O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3o2)[nH]1
7966,CHEMBL2018921,FBPRLONMUCVTOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,4910.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=C(C=C3)I,5.308918507877031,COc1ccc2nc(SCc3ccc(I)cc3)[nH]c2c1
7975,CHEMBL3115168,FBSUYYBKHUUTKC-JBKHTMJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C2CC2)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.958607314841775,CC(C)c1nc(CN(C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C2CC2)cs1
8002,CHEMBL3673946,FBZGWPOPVWFXLR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320624,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=NC=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)OC)F,5.301029995663981,COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(OC)nc4)nc3F)c2c1
8003,CHEMBL3673946,FBZGWPOPVWFXLR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320668,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=NC=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)OC)F,5.0,COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(OC)nc4)nc3F)c2c1
8009,CHEMBL1835787,FCAOLWOHALEOJU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C2=C(CCCC2)C(=N1)C3=CC=C(C=C3)OCCCN4CCCCC4,4.522878745280337,Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2c(c1=O)CCCC2
8012,CHEMBL3699343,FCBOHKLIJSVJMO-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CNC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(NC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
8033,CHEMBL2440624,FCGGFIQFAJSREN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC(=C1)F)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CN=C3,7.0,O=C(Nc1cccc(F)n1)c1cc(Cl)cc(Oc2cncnc2)c1
8034,CHEMBL488642,FCGNBJORLIKCKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC(=O)N(C)C(CN1CCCC1)C2=CC=C(C=C2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,5.309803919971486,CN(CC(=O)N(C)C(CN1CCCC1)c1ccc(-c2ccccc2)cc1)c1ccc(Cl)c(Cl)c1
8040,CHEMBL3137473,FCJZZWNHWMKTJN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=C(C=C(C=C4)C(F)(F)F)C#N,4.698970004336019,N#Cc1cc(C(F)(F)F)ccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
8041,CHEMBL3623278,FCKWCFASCOSSIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26313252.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1CN3CCOCC3)C(=NC=N2)NC4=C(C(=CC=C4)Cl)F,5.0,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCOCC1
8072,CHEMBL3261331,FDBYIYFVSAHJLY-UHFFFAOYSA-N,MGL-3196,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24712661.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor ß Agonist in Clinical Trials for the Treatment of Dyslipidemia.",J. Med. Chem.,PUBLICATION,,CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl,4.301029995663981,CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O
8085,CHEMBL1766180,FDFWKYDHOYTJRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)NC)(C3=CN=CN3)O,5.259637310505756,CNC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)c1
8088,CHEMBL469916,FDHFWHRGVDRJIK-IRXDYDNUSA-N,(-)-DIHYDROCLUSIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,COC1=CC(=CC(=C1OC)OC)C[C@@H](CO)[C@@H](CC2=CC3=C(C=C2)OCO3)CO,6.096910013008056,COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc3c(c2)OCO3)cc(OC)c1OC
8092,CHEMBL2425158,FDJZQQFTZNUNEI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CC=NC=C4,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccncc3)cc2)cc1
8093,CHEMBL1643883,FDKJLUOOFWBTDY-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21146988.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C2=CC=CC3=C2C(=N1)CN(C3=O)[C@H]4CN5CCC4CC5,5.0,Cn1nc2c3c(cccc31)C(=O)N([C@H]1CN3CCC1CC3)C2
8102,CHEMBL455769,FDMBTLJSOVSBHD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)NCCCC(=O)OC)CC4=C(C=CC=C4F)C(F)(F)F,6.292429823902063,COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2cccc(OC)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
8103,CHEMBL455769,FDMBTLJSOVSBHD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)NCCCC(=O)OC)CC4=C(C=CC=C4F)C(F)(F)F,6.292429823902063,COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2cccc(OC)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
8107,CHEMBL3216112,FDNWQXLEXJHDHG-JPKZNVRTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21699209.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,PUBLICATION,,CN1CCC[C@@H]1CCN2CCCC3=C2C=CC(=C3)N=C(C4=CC=CS4)N.Cl.Cl,4.0,CN1CCC[C@@H]1CCN1CCCc2cc(N=C(N)c3cccs3)ccc21
8108,CHEMBL3142403,FDNWQXLEXJHDHG-NTEVMMBTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21699209.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,PUBLICATION,,CN1CCC[C@H]1CCN2CCCC3=C2C=CC(=C3)N=C(C4=CC=CS4)N.Cl.Cl,4.0,CN1CCC[C@H]1CCN1CCCc2cc(N=C(N)c3cccs3)ccc21
8115,CHEMBL252838,FDQCFYCBHPKCAN-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1(C2=CC=CC=C2)N3C(=NC4=C3N=CC=C4)CNC(=O)[C@@H](CC5=CC=CC=C5Cl)NC(=O)C6(CC6)C(F)(F)F,4.698970004336019,O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1ccccc1Cl)NC(=O)C1(C(F)(F)F)CC1
8123,CHEMBL1830397,FDURBWFXDKGGLQ-PKNBQFBNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,=,2280.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=NC2=C(N1CC(C)(C)CN(C)C)C=CC(=C2)/C=C/C(=O)NO,5.642065152999546,CN(C)CC(C)(C)Cn1c(CC(C)(C)C)nc2cc(/C=C/C(=O)NO)ccc21
8124,CHEMBL1830397,FDURBWFXDKGGLQ-PKNBQFBNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=NC2=C(N1CC(C)(C)CN(C)C)C=CC(=C2)/C=C/C(=O)NO,4.6020599913279625,CN(C)CC(C)(C)Cn1c(CC(C)(C)C)nc2cc(/C=C/C(=O)NO)ccc21
8125,CHEMBL1782306,FDVSPBLZPJMXFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19447034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of selective PDE4B inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=C(N=C(N=C1NC2=CC=C(C=C2)CC(=O)O)C3=CC=C(S3)Cl)C,5.0,CCc1c(C)nc(-c2ccc(Cl)s2)nc1Nc1ccc(CC(=O)O)cc1
8126,CHEMBL3664659,FDWSADYIJUUILD-YZNIXAGQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,48000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CC[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)CC)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.318758762624412,CC[C@@H](c1ccc(-c2ccc(=O)n(CC)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
8128,CHEMBL3401115,FDZATKOLZHJUHC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3ß inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1CN(CCO1)C2=NC(=CC(=O)N2C)C3=C(C=NC=C3)F,4.301029995663981,CC(C)C1CN(c2nc(-c3ccncc3F)cc(=O)n2C)CCO1
8148,CHEMBL1915564,FECLNDAIKILJAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21924610.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aminothiazoles as ¿-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C(C=C1)Br)C2=CSC(=N2)NC3=CC(=C(C=C3)N4C=CN=C4)OC,6.698970004336019,COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3ccnc3)c(OC)c2)n1
8151,CHEMBL2165511,FEDDPOSFMNPAII-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=NC=CC5=C4C=CN5)N6CCOCC6,5.0,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4nccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
8154,CHEMBL1951444,FEDMEJWMCJAMHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C#N)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,7.958607314841775,N#Cc1ccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5nc[nH]c45)cc3)cc2)cc1
8178,CHEMBL46,FELGMEQIXOGIFQ-UHFFFAOYSA-N,ONDANSETRON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,4.958607314841775,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
8187,CHEMBL1796296,FEOIBPWKGPFSTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21669521.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selective non zinc binding inhibitors of MMP13.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1C(C2)(C#CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)NCC5=CC=NC=C5)O,5.0,O=C(NCc1ccncc1)c1ccc(Oc2ccc(C#CC3(O)CN4CCC3CC4)cc2)cc1
8189,CHEMBL541214,FEPAAIQAIYOLJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17705360.0,IC50,>,500000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1NC2=CC=CC(=C2)C3=C(C(=C(S3)C(=O)O)OCC(=O)O)Br)S(=O)(=O)CC4=CC=CC=C4,3.3010299956639813,O=C(O)COc1c(C(=O)O)sc(-c2cccc(NC3CCN(S(=O)(=O)Cc4ccccc4)CC3)c2)c1Br
8203,CHEMBL502381,FEUFUIYJXCOHJM-UIUQJESISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19441819.0,IC50,<,400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.",J. Med. Chem.,PUBLICATION,,CCOC(=O)[C@H](CC1=CC=C(C=C1)NC(=O)C2=C(C=NC=C2Cl)Cl)NC(=O)[C@@H]3C[C@H](CN3S(=O)(=O)C4=CC(=CC(=C4)Cl)Cl)NC5CCC5,6.3979400086720375,CCOC(=O)[C@H](Cc1ccc(NC(=O)c2c(Cl)cncc2Cl)cc1)NC(=O)[C@@H]1C[C@@H](NC2CCC2)CN1S(=O)(=O)c1cc(Cl)cc(Cl)c1
8209,CHEMBL1951448,FEXVVARRVIVWEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C2C(=C1)C=CC=C2C3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)C5=C6C(=NC=C5)N=CN6,5.769551078621726,O=C(Nc1ccc(-c2cccc3ccccc23)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
8213,CHEMBL1813314,FEYNATNTSNGKKO-DOMZBBRYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,CN1C[C@H]2CCCC[C@]2(C1)C3=CC(=C(C=C3)Cl)Cl,5.187086643357144,CN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1
8214,CHEMBL1813315,FEYNATNTSNGKKO-SWLSCSKDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,5280.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,CN1C[C@@H]2CCCC[C@@]2(C1)C3=CC(=C(C=C3)Cl)Cl,5.277366077466188,CN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1
8221,CHEMBL1241546,FFCUBEJNESQWBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C(=C(N=N6)C)CO5,5.301029995663981,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C)nnn4-5)CC3)cccc2n1
8222,CHEMBL1241546,FFCUBEJNESQWBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C(=C(N=N6)C)CO5,5.301029995663981,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C)nnn4-5)CC3)cccc2n1
8231,CHEMBL2036215,FFFIIHASYUWNJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,CCCCC(=O)N(CC1=CC=C(C=C1)OC(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)Cl,5.0,CCCCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(Cl)cc(-c2nn[nH]n2)c1
8238,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,5.0,NC(=O)N1c2ccccc2C=Cc2ccccc21
8239,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,5.0,NC(=O)N1c2ccccc2C=Cc2ccccc21
8280,CHEMBL1911827,FFOYIXXRNGMCDQ-NFBKMPQASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN[C@@H]1CCN(C1)C(=O)[C@@H](COCC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,4.920818753952375,CN[C@@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1
8281,CHEMBL1911828,FFOYIXXRNGMCDQ-NZQKXSOJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN[C@H]1CCN(C1)C(=O)[C@@H](COCC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,5.045757490560675,CN[C@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1
8282,CHEMBL427267,FFQLXAQWHRYUNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17188869.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Thienopyridine urea inhibitors of KDR kinase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN=CC=C5)N,6.6020599913279625,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cccnc5)cnc(N)c34)cc2)c1
8306,CHEMBL458224,FGADYIBOWLXZLA-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19140664.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy.,J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)N3CCC[C@@H]3COC)NC(=O)C)C,4.301029995663981,COC[C@H]1CCCN1c1cc(NC(C)=O)nc(-n2nc(C)cc2C)n1
8331,CHEMBL1080472,FGLOYVLTOMTFMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4C=CC=CC4=O)C(=C(N3)C)C,5.522878745280337,Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)[nH]c12
8332,CHEMBL1080472,FGLOYVLTOMTFMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,90000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4C=CC=CC4=O)C(=C(N3)C)C,4.045757490560675,Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)[nH]c12
8335,CHEMBL2324491,FGMUHFCARDYHEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23380375.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCS(=O)(=O)N1CCN(CC1)C2(CCC(CC2)(F)F)CNC(=O)C3=C(C=CC=C3F)F,5.0,CCCS(=O)(=O)N1CCN(C2(CNC(=O)c3c(F)cccc3F)CCC(F)(F)CC2)CC1
8373,CHEMBL252209,FGXUMNZSIFNZHG-AOHZBQACSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCN5CCCC[C@H]5C4,5.376750709602099,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCN4CCCC[C@H]4C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
8388,CHEMBL181309,FHATZVOKYMKNGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,160.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)OC)N4C=CN=C4)N(C)C,6.795880017344075,COC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1
8389,CHEMBL181309,FHATZVOKYMKNGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)OC)N4C=CN=C4)N(C)C,6.6777807052660805,COC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1
8410,CHEMBL26369,FHHKQICOQJWLCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,9250.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CC1=C2C(=CC=C1)NC3=C2N=CN=C3N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,5.0338582672609675,Cc1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12
8430,CHEMBL3188567,FHLVOZBERTUZSC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,=,28200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=C(C=CC(=C2)C(=O)NC(C)CC3=CC=CC=N3)OC,4.549750891680639,COc1ccc(C(=O)NC(C)Cc2ccccn2)cc1OC1CCN(C(C)C)CC1
8439,CHEMBL3409869,FHPANOIZEGWXAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)OC)C2CCC(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54,5.161150909262744,COc1cccc(OC)c1C1CCC(=O)N1Cc1ccc2oc3ccccc3c2c1
8443,CHEMBL3673944,FHPWLAWTGBVVFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320622,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=CN=C4)F)F)N=C1,5.301029995663981,COc1cnc2[nH]cc(Cc3ccc(NCc4cncc(F)c4)nc3F)c2c1
8444,CHEMBL3673944,FHPWLAWTGBVVFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320666,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=CN=C4)F)F)N=C1,5.301029995663981,COc1cnc2[nH]cc(Cc3ccc(NCc4cncc(F)c4)nc3F)c2c1
8458,CHEMBL1092766,FHUODQKGUFFZJE-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(N=CC=C1)Cl)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,C[C@H](c1cccnc1Cl)c1c(CCN(C)C)sc2ccccc12
8469,CHEMBL204476,FHYIMZUERWPLHA-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CC3=C4C=CC=NC4=CC=C3)C(=O)N5CC[C@H](C5)O)C(=O)N(C1=O)C,4.698970004336019,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3cccc4ncccc34)sc21
8476,CHEMBL3409872,FIAZRNWKETVBOU-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)OC)[C@@H]2C[C@H](C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)O,4.7447274948966935,COc1cccc(OC)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1
8484,CHEMBL113275,FIFQJYUSSPRJIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,4460.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCCCCCOC1=CC=C(C=C1)N2C=CN=C2,5.350665141287858,CN(C)CCCCCCOc1ccc(-n2ccnc2)cc1
8487,CHEMBL261146,FIGFBANSNZERLU-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1CCN(C1)C2CC(C2)C3=NC(=C4N3C=CN=C4N)C5=CC6=C(C=C5)C=CC(=N6)C7=CC=CC=C7,4.769551078621726,Nc1nccn2c(C3CC(N4CCCC4)C3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12
8501,CHEMBL2436216,FIIIMJJTBBJHIV-FXXKCHFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@H]1[C@@H](C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)NC(=O)[C@H](C)NC.Cl,5.318758762624412,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3cc(Br)ccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C
8516,CHEMBL386369,FIMRNLAKAARHPD-IRXDYDNUSA-N,ABT-279,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17034148.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.",J. Med. Chem.,PUBLICATION,,CC1(CCN(CC1)C2=NC=CC(=C2)C(=O)O)NCC(=O)N3[C@H](CC[C@H]3C#N)C#C,4.522878745280337,C#C[C@H]1CC[C@@H](C#N)N1C(=O)CNC1(C)CCN(c2cc(C(=O)O)ccn2)CC1
8520,CHEMBL1614766,FIMYFEGKMOCQKT-UHFFFAOYSA-N,RO-4987655,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316218.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(=O)N(OC1)CC2=CC(=C(C(=C2F)F)NC3=C(C=C(C=C3)I)F)C(=O)NOCCO,4.0,O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F
8523,CHEMBL330425,FINMPMBYTTVLPJ-QPPBQGQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15139756.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NC(=N1)O[C@H](C(=O)O)[C@@]2(C3=CC=CC=C3N(C(=O)CN2)C)C4=CC=CC=C4)C,4.301029995663981,Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(C)c3ccccc32)n1
8530,CHEMBL387620,FIPRYNJHSXMAOS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1CCC(CC1)(CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC=C3)Cl)O,5.0,O=C(NCC1(O)CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
8531,CHEMBL1201131,FIPWRIJSWJWJAI-UHFFFAOYSA-N,PIPERONYL BUTOXIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,3000.0,NM,,,,binding,,,,,,,,,,,,,,,,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,5.522878745280337,CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2
8532,CHEMBL1201131,FIPWRIJSWJWJAI-UHFFFAOYSA-N,PIPERONYL BUTOXIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,3000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,5.522878745280337,CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2
8548,CHEMBL2425617,FIUDDEQHPBHZBI-CPTQHNDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,[2H]C([2H])(C1=CC(=CC=C1)C(C)(C)C)N[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F,7.0,[H]C([H])(N[C@H]1C[S@+]([O-])C[C@@H](Cc2cc(F)c(N)c(O[C@H](COC)C(F)(F)F)c2)[C@@H]1O)c1cccc(C(C)(C)C)c1
8549,CHEMBL2425612,FIUDDEQHPBHZBI-XPLIUGCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC=CC(=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F,6.698970004336019,COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F
8553,CHEMBL2419487,FIXSKMNOWATHBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CC(C2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)C)C,4.698970004336019,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(C)cc3)C2)nc1C
8560,CHEMBL2435856,FJAGYOZYOQUDEQ-HKBQPEDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24090135.0,IC50,>,73000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,PUBLICATION,,CCC1=C(C=CC(=N1)OC2=CC=C(C=C2)C(=O)O)CN3CCC(CC3)N4[C@@H](CN(C4=O)C5CCOCC5)C6=CC=CC=C6,4.136677139879544,CCc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1
8561,CHEMBL2425149,FJBJLLWDMQHEBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=NC(=C4Cl)Cl,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(Cl)c3Cl)cc2)cc1
8566,CHEMBL3260567,FJCDSQATIJKQKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24786585.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins prior to substrate addition measured after 10 mins by LC/MS/MS analysis,"Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-ß Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent.",J. Med. Chem.,PUBLICATION,,CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4,5.0,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1
8574,CHEMBL430051,FJFLEPJNZGVFDM-OYRHEFFESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CN(C)C1CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6,4.721246399047171,CN(C)C1CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1
8580,CHEMBL3417504,FJHKZEVPGYADEG-NVPAJSRCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25827402.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C4C3C4,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)C3CC23)cc1
8581,CHEMBL3417585,FJHKZEVPGYADEG-XOKHGSTOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25827402.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)[C@H]4[C@@H]3C4,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@@H]3C[C@H]23)cc1
8582,CHEMBL3417586,FJHKZEVPGYADEG-XYPHTWIQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25827402.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)[C@@H]4[C@H]3C4,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@H]3C[C@@H]23)cc1
8583,CHEMBL219128,FJHLLCXNGZGREC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16908150.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCN(CC1)C(=O)N2CCC(CC2)C(C)(C)C,4.6020599913279625,CC(C)N1CCN(C(=O)N2CCC(C(C)(C)C)CC2)CC1
8593,CHEMBL1682887,FJJLMFGGWNDUMR-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)[C@](C1=CC2=C(C=C1)C=C(C=C2)OC)(C3=CN=CN3)O,6.0,COc1ccc2cc([C@](O)(c3cnc[nH]3)C(C)C)ccc2c1
8594,CHEMBL1766193,FJJLMFGGWNDUMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OC)(C3=CN=CN3)O,6.0,COc1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
8595,CHEMBL1271880,FJKZYQSIFVSZGU-HNYUPJOQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,2.3,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C[C@@H]2COC[C@@H](N2S(=O)(=O)C3=CC=C(C=C3)Cl)C4(CC4)OC(=O)N5CC6CCC(C5)N6CCO,8.638272163982407,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO
8596,CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,3000.0,NM,,,,binding,,,,,,,,,,,,,,,,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,5.522878745280337,CC(C)(C(=O)c1cccnc1)c1cccnc1
8597,CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,3000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,5.522878745280337,CC(C)(C(=O)c1cccnc1)c1cccnc1
8598,CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,4931.74,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,5.306999827360513,CC(C)(C(=O)c1cccnc1)c1cccnc1
8600,CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,800.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,6.096910013008056,CC(C)(C(=O)c1cccnc1)c1cccnc1
8634,CHEMBL3394719,FJWQSGSAPLRSAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1CCC(CC1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,CC(C)CN1CCC(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1
8635,CHEMBL3394719,FJWQSGSAPLRSAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1CCC(CC1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,CC(C)CN1CCC(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1
8643,CHEMBL3408941,FJXHOUJMCHOYIO-QCPDJZBESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C1CN(CCN1)C2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7NC6=O,5.552841968657781,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(N4CCNCC4)cc3)n[nH]c2c1
8650,CHEMBL2425892,FJXWXOWWURDLGA-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,42190.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=C2)C=C(C=C3)OC)N4CCC[C@H](C4)N,4.374790474618119,CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(OC)ccc3n2)c1=O
8651,CHEMBL1209049,FJZCUFZZQCWLDG-BTTYYORXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20630754.0,IC50,>=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(=O)N1C[C@@H]2[C@H](C1)C2CNC3=NC(=CS3)C4=CC=CC=N4,5.154901959985743,CC(C)C(=O)N1C[C@H]2C(CNc3nc(-c4ccccn4)cs3)[C@H]2C1
8673,CHEMBL3134098,FKMUEAUWXYPTIX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,MedChemComm,PUBLICATION,,CCC1(C(=O)NC2=C(C=C(C=C2Cl)S(=O)(=O)NC3=C(C=C(C=C3)F)F)C(=O)N1)C,4.522878745280337,CCC1(C)NC(=O)c2cc(S(=O)(=O)Nc3ccc(F)cc3F)cc(Cl)c2NC1=O
8677,CHEMBL585293,FKNPFDGOZHGKTD-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NN=C2N1N=C(C=C2)C3=CC=CC=C3)OC4=C5C=CC(=CC5=NC=C4)OC,5.4089353929735005,COc1ccc2c(O[C@@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
8678,CHEMBL585293,FKNPFDGOZHGKTD-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NN=C2N1N=C(C=C2)C3=CC=CC=C3)OC4=C5C=CC(=CC5=NC=C4)OC,4.853871964321762,COc1ccc2c(O[C@@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
8680,CHEMBL566253,FKNPFDGOZHGKTD-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=NN=C2N1N=C(C=C2)C3=CC=CC=C3)OC4=C5C=CC(=CC5=NC=C4)OC,5.050609993355088,COc1ccc2c(O[C@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
8681,CHEMBL566253,FKNPFDGOZHGKTD-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=NN=C2N1N=C(C=C2)C3=CC=CC=C3)OC4=C5C=CC(=CC5=NC=C4)OC,4.7447274948966935,COc1ccc2c(O[C@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
8691,CHEMBL2023898,FKRSSPOQAMALKA-CUPIEXAXSA-N,DACLATASVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22704887.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of novel potent HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC,5.142667503568732,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C
8693,CHEMBL2023898,FKRSSPOQAMALKA-CUPIEXAXSA-N,DACLATASVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23466233.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC,5.142667503568732,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C
8695,CHEMBL2023898,FKRSSPOQAMALKA-CUPIEXAXSA-N,DACLATASVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25148100.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of human liver CYP3A4,Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).,J. Med. Chem.,PUBLICATION,,CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC,5.142667503568732,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C
8705,CHEMBL1910107,FKVLYYNFSQERBB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=C(C=C3)F)C4=C(C=C(C=C4)Cl)Cl)CN,5.853871964321762,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(F)cc1)C2=O
8708,CHEMBL485765,FKWNFEDFTOOVQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCCC4)C,4.698970004336019,CC(=O)Nc1cc(-c2cccc(N3CCCC3)n2)nc(-n2nc(C)cc2C)n1
8724,CHEMBL2181638,FLBBIJRWUURIRG-SFQUDFHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=NC(=CC=C5)N)C6CCCC6,5.154901959985743,Cn1c(-c2cccc(N)n2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21
8733,CHEMBL523516,FLEVSYIGMCAFBK-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,C[C@H]1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC(C)C)Cl,5.346787486224656,CC(C)Nc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(Cl)ccc12
8749,CHEMBL2417553,FLLIVPRKOUZFTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23869452.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy trifluoromethylcoumarin as substrate,Cushing's Syndrome: Development of Highly Potent and Selective CYP11B1 Inhibitors of the (Pyridylmethyl)pyridine Type.,J. Med. Chem.,PUBLICATION,,CC1=CC(=CN=C1)CC2=CN=C(C=C2)C3=CC=CC=C3,5.958607314841775,Cc1cncc(Cc2ccc(-c3ccccc3)nc2)c1
8757,CHEMBL407034,FLMOTUCGPJDWCT-KQQUZDAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,40300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,CC1=CC(=CC(=C1O)C)/C=C/C(=O)/C=C/C2=CC(=C(C(=C2)C)O)C,4.394694953858891,Cc1cc(/C=C/C(=O)/C=C/c2cc(C)c(O)c(C)c2)cc(C)c1O
8758,CHEMBL407034,FLMOTUCGPJDWCT-KQQUZDAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,40271703.43,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,CC1=CC(=CC(=C1O)C)/C=C/C(=O)/C=C/C2=CC(=C(C(=C2)C)O)C,1.3950000000274554,Cc1cc(/C=C/C(=O)/C=C/c2cc(C)c(O)c(C)c2)cc(C)c1O
8760,CHEMBL3237445,FLNHSHVOGZEONH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,CC1=NC=CC2=C1N(C3=NC(=NC=C23)NC4=NC=C(C=C4)N5CCNCC5)C6CCCC6,5.0,Cc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12
8766,CHEMBL447955,FLNYCRJBCNNHRH-OIYLJQICSA-N,SERLOPITANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19354254.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.",J. Med. Chem.,PUBLICATION,,C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5,4.4089353929735005,C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
8768,CHEMBL3645513,FLPLVVYBPARPKW-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,32700.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,CCN1C(=O)C=CC(=N1)C2=CC=C(C=C2)[C@H](C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.485452247339714,CCn1nc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O
8769,CHEMBL2064343,FLQGKGPZQLXFCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1CCC(CC1)N2C3=CC=CC=C3N=C2CC4=NC(=CC(=O)N4)N5CCOCC5,4.3979400086720375,O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2C2CCCCC2)[nH]1
8778,CHEMBL1214450,FLTNOXKYIPZZCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)C2=CC3=C(CC(C3)NS(=O)(=O)C(C)C)C=C2,5.0,Cc1cccnc1-c1ccc2c(c1)CC(NS(=O)(=O)C(C)C)C2
8779,CHEMBL496942,FLTYDFYSVZBKOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=C(C=C2)C#CCC3=CC=CC=C3)C(=O)N(C1=O)CC4=CC=C(C=C4)C(=O)O,5.6020599913279625,Cn1c(=O)n(Cc2ccc(C(=O)O)cc2)c(=O)c2cc(C#CCc3ccccc3)ccc21
8780,CHEMBL496942,FLTYDFYSVZBKOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=C(C=C2)C#CCC3=CC=CC=C3)C(=O)N(C1=O)CC4=CC=C(C=C4)C(=O)O,5.6020599913279625,Cn1c(=O)n(Cc2ccc(C(=O)O)cc2)c(=O)c2cc(C#CCc3ccccc3)ccc21
8789,CHEMBL231430,FLVVAVLMHCUYGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17084080.0,IC50,=,58000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Studies towards the identification of a new generation of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC2=C(CC1)C=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)C4=CC=C(C=C4)Cl,4.236572006437063,CN1CCc2ccc(NS(=O)(=O)c3ccc(-c4ccc(Cl)cc4)cc3)cc2CC1
8798,CHEMBL237365,FLYJFSWZKPJYBP-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,650.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N(C)CCN,6.187086643357144,CC(C)C[C@@H](c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1)N(C)CCN
8800,CHEMBL266738,FLYSTSPNPXBSFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)C5=CC=NC=C5)N(C2=O)CC6=CC=CC=C6F,6.522878745280337,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5ccncc5)cc4)CC3)C2=O)c1
8801,CHEMBL550337,FLZIWHXEHDCVMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CCOC)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,5.301029995663981,COCCN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
8805,CHEMBL218067,FMAJVYNCYIOPMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1CNC2=CN=CC=C2)C(=O)OCC3=CC=CC=C3,5.040958607678906,O=C(OCc1ccccc1)N1CCC(CNc2cccnc2)CC1
8819,CHEMBL2036211,FMGHQGPKEYNZBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,CCCCC(=O)N(CC1=CC=C(C=C1)C(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)F,5.0,CCCCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cc(F)cc(-c2nn[nH]n2)c1
8835,CHEMBL3115074,FMJSLPJYTAKVLJ-CQVJSGDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26091726.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of a potent and selective EP4 receptor antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C(=O)O)NC(=O)[C@H]2CCCCN2CCOC3=CC=CC=C3.Cl,5.0,C[C@H](NC(=O)[C@H]1CCCCN1CCOc1ccccc1)c1ccc(C(=O)O)cc1
8839,CHEMBL2165513,FMMAYYQMOFCNPH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=CNC5=NC=C4)N6CCOCC6,7.0,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4ccnc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
8844,CHEMBL2017113,FMQCDKUHURZNPN-AQDMSIBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](COC)COCC1=CC=C(C=C1)[C@]2(CCNC[C@@H]2C3=NOC(=C3Br)C4=CC=CC=C4CCNC(=O)C)O,4.5376020021010435,COC[C@H](C)COCc1ccc([C@@]2(O)CCNC[C@@H]2c2noc(-c3ccccc3CCNC(C)=O)c2Br)cc1
8851,CHEMBL2069799,FMQXAKIGOZZDAL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,=,14200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,C1CC1N2C(=NN=C2SCC3=NOC(=N3)C4=CC(=NC=C4)Cl)C5=CC=NC=C5,4.847711655616943,Clc1cc(-c2nc(CSc3nnc(-c4ccncc4)n3C3CC3)no2)ccn1
8853,CHEMBL3330260,FMRUHQLKCRUMNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=CC=C1)CC)NC(=O)NC2=CC3=C(C=C2)NN=C3C4=CC(=CC=C4)S(=O)(=O)N,6.0,CCc1cccc(CC)c1NC(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1
8854,CHEMBL3330260,FMRUHQLKCRUMNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=CC=C1)CC)NC(=O)NC2=CC3=C(C=C2)NN=C3C4=CC(=CC=C4)S(=O)(=O)N,5.0,CCc1cccc(CC)c1NC(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1
8863,CHEMBL2059798,FMTJCQSCGILGKH-JGCGQSQUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC=CC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,7.522878745280337,O=C(N[C@H](Cc1cccc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
8864,CHEMBL1087637,FMTLMIDADBADOY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3=C(CNCC3)C(=O)N(CC4=C(C(=CC=C4)Cl)Cl)C5CC5)Cl,6.096910013008056,Cc1cc(Cl)c(OCCOc2ccc(C3=C(C(=O)N(Cc4cccc(Cl)c4Cl)C4CC4)CNCC3)cc2)c(Cl)c1
8865,CHEMBL3298273,FMUAFDSEYCJYKD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914612.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).,J. Med. Chem.,PUBLICATION,,C1CNC(=O)C2=C1N=C(C=C2)OCC3=CC(=CC=C3)F,4.522878745280337,O=C1NCCc2nc(OCc3cccc(F)c3)ccc21
8869,CHEMBL2437199,FMXIIIZGXBOJGX-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044938.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Synthesis and in vitro/in vivo antibacterial activity of oxazolidinones having thiocarbamate at C-5 on the A-ring and an amide- or urea-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane as the C-ring.",Eur. J. Med. Chem.,PUBLICATION,,CNC(=O)N1CCN(CCN1)C2=C(C=C(C=C2)N3C[C@@H](OC3=O)CNC(=S)OC)F,4.698970004336019,CNC(=O)N1CCN(c2ccc(N3C[C@H](CNC(=S)OC)OC3=O)cc2F)CCN1
8870,CHEMBL382144,FMXZUNZJIFSWPW-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3[C@H](CNCC3=O)COC4=CC5=C(CCCN5CCC(=O)O)C=C4,5.0,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCC(=O)O)CCC3)cc1
8883,CHEMBL2181789,FNEMLYLQYCOWSI-LICLKQGHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)NC1=CC=C(C=C1)/C=C/C(=O)O)NC(=O)C2=CC3=C(C=C2)C(=C(N3C)C4=NC=C(C=C4)Cl)C5CCCC5,5.026872146400302,Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21
8899,CHEMBL3104478,FNJIMNLSIQAWTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CC=C(C=C1)N2CCC(CC2)N(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,4.920818753952375,CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1
8900,CHEMBL3104478,FNJIMNLSIQAWTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CS(=O)(=O)C1=CC=C(C=C1)N2CCC(CC2)N(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,4.920818753952375,CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1
8908,CHEMBL3640290,FNMJFZYRSQTKIH-HXPMCKFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC(=N1)N2C[C@H]3C(=O)N(C(=N[C@]3(C2)C4=C(C=C(C=C4)F)F)N)C)OC)F,4.522878745280337,COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3F)C2)nc(C)c1F
8911,CHEMBL2206994,FNNLUWFZABEVSW-QHGBNFBXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)C)C)C)O)C)C(C)(C)O,5.4089353929735005,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
8912,CHEMBL2206994,FNNLUWFZABEVSW-QHGBNFBXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)C)C)C)O)C)C(C)(C)O,4.920818753952375,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
8927,CHEMBL3689756,FNQBQSDVRFAVIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23000.0,NM,233065,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4. ",Metalloenzyme inhibitor compounds,,PATENT,,CC(C)C(C1=CC2=CC(=C(C=C2C=N1)OC)OC)(C3=NNN=C3)O,4.638272163982407,COc1cc2cnc(C(O)(c3cn[nH]n3)C(C)C)cc2cc1OC
8937,CHEMBL1077941,FNQUUONWSOHCPS-JHOUSYSJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,70.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@@H](CN(CC2=CC3=CC=CC=C3N=C2)C[C@@H](CC4=CC=CC=C4)NC(=O)OCC5=NC=CS5)NC(=O)OCC6=CN=CS6,7.154901959985743,O=C(N[C@@H](Cc1ccccc1)CN(Cc1cnc2ccccc2c1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
8953,CHEMBL87071,FNUFKVJAONMVTK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCN)CC4=CC=C(C=C4)C5=CC=C(C=C5)Cl,4.823908740944319,Cn1cc(Cc2cn(CC(=O)N(CCN)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
8956,CHEMBL1224590,FNXJLFFFNIDKMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709552.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=CN=C(N3)C(=O)N)C(F)(F)F,4.3979400086720375,NC(=O)c1ncc(-c2cccc(-c3ccccc3C(F)(F)F)c2)[nH]1
8995,CHEMBL3627895,FOHVKOZKLHOUOO-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25978966.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NN(C=N1)C2=CC(=C(C(=C2)Cl)C(=O)NC[C@@H](C3=CC(=CC=C3)F)C4=NC5=C(N4)C=C(C=C5)Cl)Cl,4.301029995663981,Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4ccc(Cl)cc4[nH]3)c(Cl)c2)n1
8996,CHEMBL227899,FOIIYTALCBINLZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,75000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1CC(C1)CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC=C3)Cl,4.1249387366083,O=C(NCC1CCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
8998,CHEMBL555347,FOJGGWIJRFOXIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC(=NO2)C3=CC=CC=N3)C(=O)NC4=CC=C(C=C4)C(F)(F)F,5.0,O=C(Nc1ccc(C(F)(F)F)cc1)N1CCC(c2nc(-c3ccccn3)no2)CC1
9003,CHEMBL3422006,FONDHAXAYFJYSI-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,67000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=CSC(=N4)C5=CC=CC=C5,4.173925197299173,C[C@@H]1c2nnc(-c3csc(-c4ccccc4)n3)n2CCN1C(=O)c1ccc(F)cc1
9011,CHEMBL282156,FOTDWYFVTJDSLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,6620.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3NC5=C4C(=CC=C5)[N+](=O)[O-],5.1791420105603,O=[N+]([O-])c1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12
9012,CHEMBL219861,FOUGTHXAKKBTGL-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,46000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CC3=CC=NC4=CC=CC=C34)C(=O)N5C[C@@H](CO5)O)C(=O)N(C1=O)C,4.337242168318426,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3ccnc4ccccc34)sc21
9019,CHEMBL1269176,FOWDOWQYRZXQDP-UHFFFAOYSA-N,ADAMANTAN-2-OL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2CC3CC1CC(C2)C3O,4.522878745280337,OC1C2CC3CC(C2)CC1C3
9023,CHEMBL1947144,FOYKYLQAKICGEN-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22070604.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor ¿ (PPAR¿) modulators.,J. Med. Chem.,PUBLICATION,,C[C@]1(C(=O)NC(=O)O1)C2=CC=CC(=C2)CN3C4=CC=CC=C4N(C3=O)C5=NOC6=C5C=CC(=C6)OC,4.657577319177793,COc1ccc2c(-n3c(=O)n(Cc4cccc([C@@]5(C)OC(=O)NC5=O)c4)c4ccccc43)noc2c1
9027,CHEMBL2064413,FPAPMCJELAEURQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,=,19000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1COCCN1C2=CC(=O)NC(=N2)CC3=NC4=C(C=CC=C4O3)C5=CC=CS5,4.721246399047171,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4cccs4)cccc3o2)[nH]1
9033,CHEMBL410420,FPDOTOGFAZHEPN-UEVCKROQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=CC=C(S2)Br)C(=O)NC(C)C)C3CC4=CC=CC=C4C3,6.0,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(Br)s1
9040,CHEMBL2064419,FPFCFOIMTFHSNY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1C2=CC(=O)NC(=N2)CC(=O)NC3=CC=CC=C3,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1
9044,CHEMBL3264607,FPFLLZAGPFEDBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,102000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C3=CN=CO3)(C4=NNN=C4)O,3.9913998282380825,CC(C)C(O)(c1ccc2cc(-c3cnco3)ccc2c1)c1cn[nH]n1
9058,CHEMBL495118,FPNJQEAHFJNZFI-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,C[C@H]1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC)Cl,5.221848749616356,CNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(Cl)ccc12
9071,CHEMBL1808640,FPQYARBHMSUIMN-YCRREMRBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)S(=O)(=O)N2CC3=C(C2)C=C(C=C3)/C=C/C(=O)NO,4.301029995663981,COc1ccc(S(=O)(=O)N2Cc3ccc(/C=C/C(=O)NO)cc3C2)cc1
9083,CHEMBL2387596,FPXKRKAWESOZII-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CCCCC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,4.522878745280337,CCCCc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
9085,CHEMBL1209627,FPYFDKXCMNWPRU-HKALDPMFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C)(C)O,7.167491087293763,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC(C)(C)O)S1(=O)=O
9086,CHEMBL1209627,FPYFDKXCMNWPRU-HKALDPMFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C)(C)O,7.167491087293763,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC(C)(C)O)S1(=O)=O
9092,CHEMBL3603923,FQAXDSVNYVVQSE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26225459.0,IC50,>,15848.93,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).,J. Med. Chem.,PUBLICATION,,C1=CC(=NC=C1F)C2=CC(=NC=N2)C3=CC(=CC(=C3)C#N)Cl,4.800000052738446,N#Cc1cc(Cl)cc(-c2cc(-c3ccc(F)cn3)ncn2)c1
9098,CHEMBL361153,FQCXYANVLWAPNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,56900.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CSC=C2,4.244887733604929,c1cncc(-c2ccsc2)c1
9100,CHEMBL361153,FQCXYANVLWAPNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,55910.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1=CC(=CN=C1)C2=CSC=C2,4.252510507741327,c1cncc(-c2ccsc2)c1
9117,CHEMBL2041165,FQMDPZWWVSRDFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=COC(=C6)C(=O)O,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4coc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
9119,CHEMBL213390,FQMMZAXRATYRCZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16806913.0,IC50,>,18000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C2=NC=C(C=C2)C(=O)NC3=CC4=C(C=CC=N4)C=C3,4.7447274948966935,O=C(Nc1ccc2cccnc2c1)c1ccc(-c2ccccc2)nc1
9143,CHEMBL258648,FQUOGEWRQYVMRQ-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1COCCN1C2CC(C2)C3=NC(=C4N3C=CN=C4N)C5=CC6=C(C=C5)C=CC(=N6)C7=CC=CC=C7,4.920818753952375,Nc1nccn2c(C3CC(N4CCOCC4)C3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12
9148,CHEMBL2407899,FQWPBCFJZAKNEQ-CBVNATGFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829549.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents.,J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=NC=C(C=C2)/C=C/C3=C4C=C/C(=C\C5=C(NC6=CC=CC=C65)O)/C=C4N=N3,6.096910013008056,CN1CCN(c2ccc(/C=C/C3=c4cc/c(=C\c5c(O)[nH]c6ccccc56)cc4N=N3)cn2)CC1
9175,CHEMBL399656,FRCSXRRNAXDKOX-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,>,89000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC1=CC(=CC(=C1)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](CNCC3=CN(N=C3)CC)O)N4CCCCS4(=O)=O,4.050609993355088,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cnn(CC)c2)cc(N2CCCCS2(=O)=O)c1
9176,CHEMBL399656,FRCSXRRNAXDKOX-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,>,89000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC1=CC(=CC(=C1)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](CNCC3=CN(N=C3)CC)O)N4CCCCS4(=O)=O,4.050609993355088,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cnn(CC)c2)cc(N2CCCCS2(=O)=O)c1
9177,CHEMBL1766174,FRDLFNZPCFFPFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=C(C=C1)C2=CC=C(C=C2)F)(C3=CN=CN3)O,5.275724130399211,CC(C)C(O)(c1ccc(-c2ccc(F)cc2)cc1)c1cnc[nH]1
9187,CHEMBL427860,FRHBHVROLQSPMW-BTYSJIOQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,9200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@H](C)CC3=CC=C(C=C3)Cl)[C@H](C(C)C)NC(=O)CCN(C)C,5.036212172654444,Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1
9188,CHEMBL3115176,FRHKZTWSEIPHQR-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCO)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.853871964321762,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
9191,CHEMBL510285,FRLGCDYZXBVROR-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)OC)C4=C(C(=CC=C4)OC)F,6.356547323513812,COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2cccc(OC)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
9193,CHEMBL2164048,FROGGFONBYACJB-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22793372.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.",J. Med. Chem.,PUBLICATION,,CC[C@@H](C1=CC=CC=C1)C(=O)NC2=CC=CC=C2N3CCCC3,5.4089353929735005,CC[C@H](C(=O)Nc1ccccc1N1CCCC1)c1ccccc1
9200,CHEMBL2030386,FRRLLRQAGKSVMU-SECBINFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22542012.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of PIM kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1O)CC2=NC3=C(C(=O)N2)OC4=C3C=C(C=C4)Br,4.698970004336019,O=c1[nH]c(CN2CC[C@@H](O)C2)nc2c1oc1ccc(Br)cc12
9203,CHEMBL1288289,FRTRJCUGYXZWQF-GJFSDDNBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,13400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@]1(CCCN(C1)C2=CC3=C(N2CC4=C(C=CC(=C4)F)Cl)C(=O)N(C(=O)N3CC(=O)N(C)C)C)N.Cl,4.872895201635193,CN(C)C(=O)Cn1c(=O)n(C)c(=O)c2c1cc(N1CCC[C@@](C)(N)C1)n2Cc1cc(F)ccc1Cl
9215,CHEMBL1650658,FRZBNIHVXARHST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1070.0,NM,221147,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. Inhibition assay using P450 CYP enzymes.,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,PATENT,,CS(=O)(=O)NC1=CC=CC(=C1)C2=C(C=CC3=C2C=CC(=C3)C4=CC(=CC=C4)O)O,5.97061622231479,CS(=O)(=O)Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1
9216,CHEMBL3137389,FRZSLHWYVJOSPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CN=C4,4.698970004336019,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cncnc3)CC2)cc1
9236,CHEMBL252632,FSDIGHDJKRVNHH-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,980.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1C(F)(F)F)C(=O)NCC2=NC3=C(N2CC(C(F)(F)F)(F)F)N=CC=C3,6.008773924307505,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1CC(F)(F)C(F)(F)F
9297,CHEMBL2425153,FSWRFMXJBKPOTE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CN=CO4,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cnco3)cc2)cc1
9304,CHEMBL413828,FSYHSNLAYZLREB-CXGRPWHSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CN(C)CC1CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6,4.823908740944319,CN(C)CC1CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1
9305,CHEMBL411062,FSYHSNLAYZLREB-LBZQVFOQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CN(C)CC1CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6,4.823908740944319,CN(C)CC1CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1
9306,CHEMBL3702673,FSYNBGHPEGKIGK-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)C8=CN=C(C=C8)N,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N)nc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
9307,CHEMBL480210,FSYXVLMRBONNFA-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)C(=O)C5=CC=C(C=C5)F,5.443697499232713,C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(C(=O)c4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
9308,CHEMBL480210,FSYXVLMRBONNFA-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)C(=O)C5=CC=C(C=C5)F,5.318758762624412,C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(C(=O)c4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
9335,CHEMBL2163825,FTCUCNANDOCSHQ-PRCIMEDXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,430.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,C1C[C@H]2CC(C[C@@H]1N2C(=O)[C@H](CC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4(CC4)C5=C(C=C(C=C5)Cl)Cl)N,6.366531544420414,NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1
9355,CHEMBL2057516,FTKKBBITVQQSEP-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N(C)CCN(C)C,6.7447274948966935,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)CCN(C)C)oc2c1
9357,CHEMBL510298,FTKTXHIRMKWXBE-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,1.7,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)C7CC7,8.769551078621726,Cc1cc(N2CCC(N3CCN(C(=O)C4CC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
9364,CHEMBL2387504,FTNFWJGKFMEIIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CC1=CC=CC=C1C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F,4.522878745280337,Cc1ccccc1-c1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3c(F)cccc3Cl)nc12
9377,CHEMBL1818452,FTQFUQZSKDXZNW-ZYMOGRSISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550808.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC1=CC=NN1CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,5.0,Cc1ccnn1CC12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
9379,CHEMBL498251,FTQWKXRWLDQPEE-OALUTQOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)N[C@@H]3[C@H](CC4=CC=CC=C34)O)N5C=NC=N5)C,5.508638306165727,Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3cncn3)cn2c1C
9380,CHEMBL498251,FTQWKXRWLDQPEE-OALUTQOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)N[C@@H]3[C@H](CC4=CC=CC=C34)O)N5C=NC=N5)C,4.823908740944319,Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3cncn3)cn2c1C
9409,CHEMBL3104537,FUCHTSBIUIZRIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=CC=C4C#N,5.2839966563652006,N#Cc1ccccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
9410,CHEMBL3104537,FUCHTSBIUIZRIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5200.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=CC=C4C#N,5.2839966563652006,N#Cc1ccccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
9411,CHEMBL1823817,FUCKCIVGBCBZNP-MRXNPFEDSA-N,CE-224535,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21565499.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC[C@@H](CN1C(=O)C=NN(C1=O)C2=CC(=C(C=C2)Cl)C(=O)NCC3(CCCCCC3)O)O,4.522878745280337,COC[C@H](O)Cn1c(=O)cnn(-c2ccc(Cl)c(C(=O)NCC3(O)CCCCCC3)c2)c1=O
9413,CHEMBL2181899,FUDKQBKYDLVSHY-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)C[C@@H]2NC[C@H]([C@H](CC4=CC=C(C=C4)C#C)NC(=O)COC)O,7.0,C#Cc1ccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)cc1
9414,CHEMBL1242717,FUDKWFQKXWHRLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCOCC7,5.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCOCC6)ncn4-5)CC3)cccc2n1
9415,CHEMBL1242717,FUDKWFQKXWHRLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCOCC7,5.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCOCC6)ncn4-5)CC3)cccc2n1
9420,CHEMBL410659,FUGZYLOFWXVFQU-OKDJAKQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1CN(C1)CC2CC(C2)C3=NC(=C4N3C=CN=C4N)C5=CC6=C(C=C5)C=CC(=N6)C7=CC=CC=C7,4.698970004336019,Nc1nccn2c(C3CC(CN4CCC4)C3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12
9421,CHEMBL260298,FUGZYLOFWXVFQU-UILWBTOOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1CN(C1)CC2CC(C2)C3=NC(=C4N3C=CN=C4N)C5=CC6=C(C=C5)C=CC(=N6)C7=CC=CC=C7,4.769551078621726,Nc1nccn2c(C3CC(CN4CCC4)C3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12
9427,CHEMBL596290,FULBTJANHDAKTA-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)N=CC(=N2)C3=C(N=CC(=C3)OC[C@H](CC4=CNC5=CC=CC=C54)N)C6=COC=C6,6.3979400086720375,Cc1[nH]nc2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12
9429,CHEMBL1803004,FUNHEVBLXUQXLG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21608528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.",J. Med. Chem.,PUBLICATION,,CS(=O)(=O)NC1=CC2=C(C=C1)C=CC3=C(C2=O)C=C(C=N3)C4=CC=CC=C4,4.301029995663981,CS(=O)(=O)Nc1ccc2ccc3ncc(-c4ccccc4)cc3c(=O)c2c1
9442,CHEMBL1076449,FUPYLBRXZJOVDD-SKCUWOTOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19853442.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New classes of potent and bioavailable human renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@@H]2C(=C(C[C@@H]1N2)C3=CC=C(C=C3)CCCOC4=C(C=CC(=C4Cl)F)F)C(=O)N(CC5=C(C(=CC=C5)Cl)Cl)C6CC6,5.721246399047171,O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)C[C@H]2CC[C@H]1N2)N(Cc1cccc(Cl)c1Cl)C1CC1
9449,CHEMBL2387606,FUSNGHKYBLQGJW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CC=NC=C5)Cl,4.522878745280337,O=c1[nH]c2cc(-c3ccncc3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
9457,CHEMBL3702826,FUTQMNXPKCMVCI-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6410.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(N=C7)N(C)C,5.193141970481182,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cnc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
9461,CHEMBL477563,FUUMHDABRAONFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(N1C)C=CC(=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,4.568636235841013,Cc1nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc2n1C
9462,CHEMBL477563,FUUMHDABRAONFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,45000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(N1C)C=CC(=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,4.346787486224656,Cc1nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc2n1C
9467,CHEMBL2018913,FUVYXGUCJOVMNB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,5490.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCCCO,5.260427655549908,COc1ccc2nc(SCCCO)[nH]c2c1
9471,CHEMBL238762,FUWYDCSEHWKYSH-JTQLQIEISA-N,SR-1448,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C(=O)N1CCC(CC1)NC2=CC3=C(C=C2)NN=C3)N,5.0,C[C@H](N)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
9490,CHEMBL214021,FVFURMJFTAJXRH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17234405.0,IC50,=,23500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC(=O)C2=CC(=O)C3=C(O2)C=C(C=C3)F)CC4=CC5=C(C=C4)OCO5,4.628932137728264,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(F)cc2o1
9491,CHEMBL3137463,FVGJATLYSKGWEO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CN(C)S(=O)(=O)C1=CC=CC(=C1)N2CCC(CC2)N(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,5.221848749616356,CN(C)S(=O)(=O)c1cccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)c1
9493,CHEMBL2013195,FVHKIGHCUWTXCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22366657.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)CC2=C(C=CC3=C2N=C(N3)C4=CC=CC=C4)O,4.522878745280337,Oc1ccc2[nH]c(-c3ccccc3)nc2c1CN1CCCCC1
9496,CHEMBL254705,FVHUZYZMUXKNEP-QWFCFKBJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,11900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CC[C@H](C4)O,4.924453038607469,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC[C@@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
9497,CHEMBL2448735,FVHYOKKAMSUARF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1500.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CS(=O)(=O)N(CC1=CN=CN1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4S3,5.823908740944319,CS(=O)(=O)N(Cc1cnc[nH]1)c1ccc(-c2nc3ccccc3s2)cc1
9500,CHEMBL219483,FVIJIRCHSMDMJH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CN3C4=CC=CC=C4N=C3NC)C(=O)N5CCC5)C(=O)N(C1=O)C,6.0,CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CCC1)c(=O)n(C)c(=O)n2CC(C)C
9508,CHEMBL517828,FVKXOARNHRLXBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=C4,4.920818753952375,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
9509,CHEMBL517828,FVKXOARNHRLXBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=C4,4.698970004336019,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
9512,CHEMBL2059122,FVLSAYPPCYXSQP-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CCN(C[C@H]([C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)O)C(=O)C4=CC5=C(C=C4)N=C(O5)N6CCCC6,6.886056647693163,O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CCN1CCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1
9515,CHEMBL249494,FVMSLFYQMWOIFN-OEMFJLHTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)N1CCN(CC1)C(=O)CC2(CC2)[C@H]3C[C@H](C[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5)O,4.958607314841775,CC(C)(CO)N1CCN(C(=O)CC2([C@H]3C[C@@H](O)C[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
9520,CHEMBL3398252,FVQZBYCHVJMDDI-QHDYCIAZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25677656.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled mixed-gender human liver microsomes using testosterone substrate in presence of NADPH pre-incubated for 3 mins by HPLC-UV detection method,A novel molecule with notable activity against multi-drug resistant tuberculosis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC=C(C=C2)N3C=CC=C3)C(=O)C(=O)/C=C(/C4=CC(=CN(C4=O)CC5=CC=CC=C5F)CC6=CC(=CC(=C6)F)F)\O,4.301029995663981,O=C(/C=C(\O)c1cc(Cc2cc(F)cc(F)c2)cn(Cc2ccccc2F)c1=O)C(=O)N1CCN(c2ccc(-n3cccc3)cc2)CC1
9521,CHEMBL3398252,FVQZBYCHVJMDDI-QHDYCIAZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25677656.0,IC50,>,85000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled mixed-gender human liver microsomes using triazolam substrate in presence of NADPH pre-incubated for 3 mins by HPLC-UV detection method,A novel molecule with notable activity against multi-drug resistant tuberculosis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC=C(C=C2)N3C=CC=C3)C(=O)C(=O)/C=C(/C4=CC(=CN(C4=O)CC5=CC=CC=C5F)CC6=CC(=CC(=C6)F)F)\O,4.070581074285707,O=C(/C=C(\O)c1cc(Cc2cc(F)cc(F)c2)cn(Cc2ccccc2F)c1=O)C(=O)N1CCN(c2ccc(-n3cccc3)cc2)CC1
9542,CHEMBL1829769,FVYWUKYMYNOWNN-QMTYFTJSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CC(=O)N)C4=CC=C(C=C4)F,4.522878745280337,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CC(N)=O)(c2ccc(F)cc2)OC1=O
9556,CHEMBL3187348,FWNNFDXOWQESMM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=CS1)CNC(=O)C2=CC(=C(C=C2)OC)OC3CCN(CC3)C(C)C,4.522878745280337,COc1ccc(C(=O)NCc2csc(C)n2)cc1OC1CCN(C(C)C)CC1
9570,CHEMBL509075,FWSQRSDDLDNXGE-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4F)C(F)(F)F,4.443697499232712,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F
9571,CHEMBL509075,FWSQRSDDLDNXGE-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,39810.72,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4F)C(F)(F)F,4.399999967876858,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F
9572,CHEMBL509075,FWSQRSDDLDNXGE-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4F)C(F)(F)F,4.443697499232712,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F
9573,CHEMBL509075,FWSQRSDDLDNXGE-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4F)C(F)(F)F,4.443697499232712,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F
9596,CHEMBL271941,FXFJPJRHXSPGDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCO)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,5.2839966563652006,CC(C)c1c(-c2nnc(NCCO)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
9597,CHEMBL252614,FXFOLNQQHHEMOR-UIIQDGRDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@H](N([C@H](C1)C2(CC2)CC(=O)N3CC4CCC(C3)N4CCO)S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,6.0,O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO
9600,CHEMBL2017268,FXGZSKNYBROIMW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=CC3=NC=C(C(=C3C=C2)NC4=CC=CC=C4C(C)(C)C)C(=O)N,5.698970004336019,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2c1
9604,CHEMBL1923107,FXKQOXVNWKMPRT-OFSOJUDTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC=CC=C5C(=O)O4,5.142667503568732,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC(=O)c2ccccc23)C2CC2)cc(OCCOC)c1
9622,CHEMBL1910121,FXPZWVGNKACNOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCN(CC3)S(=O)(=O)C)C4=C(C=C(C=C4)Cl)Cl)CN,4.769551078621726,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCN(S(C)(=O)=O)CC1)C2=O
9628,CHEMBL3114721,FXUQDXOBSPOBSH-ABANCFTRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H]3[C@H](OC(O3)(C)C)[C@H](CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5,6.508638306165727,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H]2OC(C)(C)O[C@@H]2[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
9644,CHEMBL1222718,FYAWQQTZMXAAFH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,13500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,4.869666231504994,CCOCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
9645,CHEMBL1272098,FYBUXXZDXWUPPE-ZQJMJJNQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@H]1CN([C@@H](CN1C(=O)OC2(CC2)[C@H]3COC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)CC5CC5)C)C(=O)C,7.522878745280337,CC[C@H]1CN(C(C)=O)[C@H](C)CN1C(=O)OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1
9668,CHEMBL2036643,FYNKTKAUIWKPFC-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450133.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C(=O)CN3CCC(CC3)(F)F,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCC(F)(F)CC2)cc1
9671,CHEMBL3702776,FYOUXYBMHVIQDP-JSXFGMRASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6750.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N(C)C,5.170696227168975,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
9698,CHEMBL1818455,FYXXTOJUMHTXEW-QRWMCTBCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550808.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC1=CC(=NN1CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl)C,5.096910013008056,Cc1cc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
9699,CHEMBL3702695,FYYNKEATFHKTBH-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCCO,4.94692155651658,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
9700,CHEMBL3702737,FYYWCVHKYFUZEZ-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2010.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCCOC,5.696803942579511,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCCOC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
9701,CHEMBL2437420,FYZINNJJPXURBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC(=NC=C5)N,4.522878745280337,COCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccnc(N)c4)CC3)CC2)c2ccccc21
9710,CHEMBL2064417,FZBMKSZVGOJNQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1COCCN1C2=CC(=O)NC(=N2)CC3=NC4=C(O3)C=CC(=C4C5=CC=CC=C5)F,4.3979400086720375,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)c(F)ccc3o2)[nH]1
9722,CHEMBL2419485,FZGNWTQJSVKAPD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CC(C2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)Cl)C,5.481486060122113,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(Cl)cc3)C2)nc1C
9725,CHEMBL1079896,FZIDUWWIFBUCIN-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@@H](CNC[C@@H](CC2=CC=CC=C2)NC(=O)OCC3=NC=CS3)NC(=O)OCC4=CN=CS4,7.045757490560675,O=C(N[C@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
9726,CHEMBL1079897,FZIDUWWIFBUCIN-DNQXCXABSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,99.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@H](CNC[C@@H](CC2=CC=CC=C2)NC(=O)OCC3=NC=CS3)NC(=O)OCC4=CN=CS4,7.00436480540245,O=C(N[C@@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
9727,CHEMBL1079722,FZIDUWWIFBUCIN-ZEQRLZLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,148.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@@H](CNC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=NC=CS3)NC(=O)OCC4=CN=CS4,6.8297382846050425,O=C(N[C@H](CNC[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
9742,CHEMBL3091529,FZPYWVVOFIWWAQ-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3ß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1N2CCO[C@H](C2)C3=CC=C(C=C3)F)C4=CC=NC=C4,4.301029995663981,Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O
9744,CHEMBL3091547,FZPYWVVOFIWWAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3ß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1N2CCOC(C2)C3=CC=C(C=C3)F)C4=CC=NC=C4,4.301029995663981,Cn1c(N2CCOC(c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O
9751,CHEMBL519149,FZSIIVFTLMHKAP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2=CC=CC=C2CCC1NC(=O)N3CCC4(CC3)CC(=O)C5=CC=CC=C5O4,5.0,O=C1CC2(CCN(C(=O)NC3CCc4ccccc4CC3)CC2)Oc2ccccc21
9759,CHEMBL1086579,FZTUPODAEPTYNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20565112.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 from human liver microsome by LC-MS/MS analysis,"Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NO1)CN2CCN(CC2)C3=C4C(=NC=C3Br)N=C(N4)N5CCN(CC5)C,5.0,Cc1cc(CN2CCN(c3c(Br)cnc4nc(N5CCN(C)CC5)[nH]c34)CC2)no1
9771,CHEMBL1078190,GAAPAEWIPWJVMW-AYBMPSMDSA-N,"6',7'-DIHYDROXYBERGAMOTTIN DECANAL ACETAL",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19689106.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,Minor furanocoumarins and coumarins in grapefruit peel oil as inhibitors of human cytochrome P450 3A4.,J. Nat. Prod.,PUBLICATION,,CCCCCCCCCC1O[C@@H](C(O1)(C)C)CC/C(=C/COC2=C3C=CC(=O)OC3=CC4=C2C=CO4)/C,6.568636235841013,CCCCCCCCCC1O[C@H](CC/C(C)=C/COc2c3ccoc3cc3oc(=O)ccc23)C(C)(C)O1
9772,CHEMBL3702691,GAARYPFMGZTUSF-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8040.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCN1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.094743951251549,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
9777,CHEMBL2440663,GAENEKJGLXICIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,6200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC=C1F)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CN=C3,5.2076083105017466,O=C(Nc1ccc(F)cn1)c1cc(Cl)cc(Oc2cncnc2)c1
9780,CHEMBL3604174,GAGGCNZJYKWGJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26037322.0,IC50,=,58100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,3-Substituted pyrazoles and 4-substituted triazoles as inhibitors of human 15-lipoxygenase-1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1Cl)Cl)NC(=O)C2=NNN=C2,4.235823867609669,O=C(Nc1ccc(Cl)cc1Cl)c1cn[nH]n1
9785,CHEMBL1208962,GALNGZPXDPAWDR-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NCCS(=O)(=O)C)C(=O)N,5.455931955649724,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCS(C)(=O)=O)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
9793,CHEMBL3605557,GAPKQSFTRWQZTL-SNVBAGLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26291341.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method,Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.,J. Med. Chem.,PUBLICATION,,CCN1C2=CC(=NC=C2N=C1[C@@H](C)NS(=O)(=O)C3=CN=C(C=C3)C#N)C(F)(F)F,4.698970004336019,CCn1c([C@@H](C)NS(=O)(=O)c2ccc(C#N)nc2)nc2cnc(C(F)(F)F)cc21
9801,CHEMBL3633320,GARYHNNCUAMEQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26363868.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human Liver microsomes after 5 mins by LC-MS/MS method,3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.,Eur. J. Med. Chem.,PUBLICATION,,C1CN(CCN1CC2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=NC(=N3)[N+](=O)[O-],4.698970004336019,O=C(Cn1cnc([N+](=O)[O-])n1)N1CCN(Cc2ccc(C(F)(F)F)cc2)CC1
9802,CHEMBL1270834,GASOVDDSXLJYME-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ß-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCC#CC1=C(C=CC(=C1)[C@@]2(C(=O)N(C(=N2)N)C)C3=CC(=C(C=C3)OC(F)F)C)F,5.468521082957745,CCCC#Cc1cc([C@@]2(c3ccc(OC(F)F)c(C)c3)N=C(N)N(C)C2=O)ccc1F
9812,CHEMBL1271608,GAWPXOIHRKJZND-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20934334.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(=O)NC2=NC=C(C=C2)N3C(=CC(=N3)C4=CN=CC=C4)C(F)(F)F,7.522878745280337,O=C(Nc1ccc(-n2nc(-c3cccnc3)cc2C(F)(F)F)cn1)c1ccccc1
9814,CHEMBL3350936,GAWUJFVQGSLSSZ-SZRCHTAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 3 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)(CC(C5)(C4)O)O)N,3.6989700043360187,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2
9815,CHEMBL3350936,GAWUJFVQGSLSSZ-SZRCHTAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)(CC(C5)(C4)O)O)N,3.6989700043360187,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2
9816,CHEMBL3350936,GAWUJFVQGSLSSZ-SZRCHTAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)(CC(C5)(C4)O)O)N,3.6989700043360187,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2
9817,CHEMBL3350936,GAWUJFVQGSLSSZ-SZRCHTAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)(CC(C5)(C4)O)O)N,3.6989700043360187,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2
9818,CHEMBL3288451,GAWXPLJRMGISPF-AAYBCKPTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)[C@@]3(CCCN([C@@H]3CCO)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,6.045757490560675,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CCO)CC1
9819,CHEMBL3288451,GAWXPLJRMGISPF-AAYBCKPTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,13300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)[C@@]3(CCCN([C@@H]3CCO)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,4.876148359032914,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CCO)CC1
9828,CHEMBL553025,GBABOYUKABKIAF-IELIFDKJSA-N,VINORELBINE BASE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,6.0,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
9840,CHEMBL2151497,GBGNPCMUCLQITD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22975301.0,IC50,=,25000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azetidinyl oxadiazoles as potent mGluR5 positive allosteric modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CCC1C(=O)N2CC(C2)C3=NC(=NO3)C4=CC(=CC=C4)Cl)(F)F,1.6020599913279623,O=C(C1CCC(F)(F)CC1)N1CC(c2nc(-c3cccc(Cl)c3)no2)C1
9841,CHEMBL321814,GBGNQOSPNHQALW-CEWIDEQNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC3=C(O2)C(=CC=C3)Cl)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CN=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,6.301029995663981,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2cc3cccc(Cl)c3o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
9846,CHEMBL2070142,GBMMBKZVOXBMPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=CC=C3)C(F)(F)F,4.698970004336019,CCCS(=O)(=O)c1ccc2nc(-c3cccc(C(F)(F)F)c3)[nH]c2c1
9857,CHEMBL2407900,GBUDRABUNBYJKG-WWAWLHJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829549.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents.,J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=NC=C(C=C2)/C=C/C3=C4C=C/C(=C\C5=C(NC6=C5C=C(C=C6)OC)O)/C=C4N=N3,5.0,COc1ccc2[nH]c(O)c(/C=c3\ccc4c(c3)N=NC=4/C=C/c3ccc(N4CCN(C)CC4)nc3)c2c1
9858,CHEMBL2407900,GBUDRABUNBYJKG-WWAWLHJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=NC=C(C=C2)/C=C/C3=C4C=C/C(=C\C5=C(NC6=C5C=C(C=C6)OC)O)/C=C4N=N3,6.0,COc1ccc2[nH]c(O)c(/C=c3\ccc4c(c3)N=NC=4/C=C/c3ccc(N4CCN(C)CC4)nc3)c2c1
9863,CHEMBL2419518,GBWFXYVAVDSWDW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4,5.0,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
9864,CHEMBL2419518,GBWFXYVAVDSWDW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4,5.0,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
9874,CHEMBL240355,GBXSOZDYCSBLQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C,4.522878745280337,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(C)O2
9876,CHEMBL481745,GBZPNPQJVWRRPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19119007.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel imidazole-based histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCC(CC1)COC2=NC=C(N2C)C(=O)C3=CC=C(C=C3)Cl,5.0,CC(C)N1CCC(COc2ncc(C(=O)c3ccc(Cl)cc3)n2C)CC1
9881,CHEMBL3394729,GCBARIQAGXVYET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1
9882,CHEMBL3394729,GCBARIQAGXVYET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1
9886,CHEMBL572184,GCBIADPPDPBDLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=CC=C3)Br,5.301029995663981,CC1(CC(=O)NCc2cccc(Br)c2)CC2(CCCCC2)OO1
9896,CHEMBL2170605,GCFQTXXNPYVOLQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C(=O)N1CCC(CC1)C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F,4.886056647693163,CC(C)(C)C(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
9900,CHEMBL10440,GCGPDMHRIZLRII-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)C,4.886056647693163,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(C)c(=O)nc1SCc1ccc(F)cc1
9915,CHEMBL1951331,GCLFXARMPHAWHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,7.585026652029182,O=C(Nc1ccc(-c2ccccc2)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
9917,CHEMBL150799,GCLVZVSTRWZGFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=CC=C1C2=CC=NO2,4.0,CCCCOc1ccccc1-c1ccno1
9919,CHEMBL3127500,GCNBJSNHYPKHIT-LEWJYISDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CC(=CC=C1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@@H]3C[C@H]3C4=CN=CC=C4,6.7447274948966935,CS(=O)(=O)c1cccc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)c1
9920,CHEMBL3127500,GCNBJSNHYPKHIT-LEWJYISDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,890.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CC(=CC=C1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@@H]3C[C@H]3C4=CN=CC=C4,6.050609993355088,CS(=O)(=O)c1cccc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)c1
9926,CHEMBL2024248,GCNDDOJRCKHYLZ-ZXMXYHOLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CNC[C@H](C[C@H]1CCCOC1)NC(=O)N2CCC[C@H](C2)[C@H](C3=CC(=CC=C3)Cl)OCCNC(=O)OC,4.552841968657781,CNC[C@H](C[C@H]1CCCOC1)NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1
9927,CHEMBL1911824,GCNGNRXFHCZYCX-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC1)COC[C@H](C(=O)N2CCN(CC2)C)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,4.698970004336019,CN1CCN(C(=O)[C@@H](COCC2(C)CC2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
9934,CHEMBL262968,GCRYIIOKZWQWIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,417.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CN=C1)CCCOC2=CC=C(C=C2)N3C=CN=C3,6.379863945026242,c1cncc(CCCOc2ccc(-n3ccnc3)cc2)c1
9949,CHEMBL218410,GDAGKQMCMNZJDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16908150.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCN(CC1)C(=O)N2CCC(CC2)C(=O)OC(C)(C)C,4.6020599913279625,CC(C)N1CCN(C(=O)N2CCC(C(=O)OC(C)(C)C)CC2)CC1
9950,CHEMBL329477,GDAGOGOXJLUVGB-OFSOJUDTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15139756.0,IC50,=,41000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NC(=N1)O[C@H](C(=O)O)[C@@]2(C3=CC=CC=C3N(C(=O)CN2)CC4=C(C=C(C=C4F)F)F)C5=CC=CC=C5)C,4.3872161432802645,Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1
9956,CHEMBL1915565,GDEPVUVIBMMPRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21924610.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aminothiazoles as ¿-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(C=N1)C2=CC=C(C=C2)NC3=NC(=CS3)C4=C(C=CC(=C4)Br)OC,5.920818753952375,COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3cnc(C)c3)cc2)n1
9957,CHEMBL3645519,GDEYVKYYDNYXSM-WRONEBCDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15700.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=NN(C(=O)C=C2)C3CC3)N4CC[C@](OC4=O)(CC(C)(C)O)C5=CC=CC=C5,4.804100347590766,C[C@@H](c1ccc(-c2ccc(=O)n(C3CC3)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
9963,CHEMBL3702768,GDHZDZNRIQPUBT-ZYBCLOSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9650.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)C2=CC=C(C=C2)C(=O)N3CCC(CC3)NC(=O)C4=CN(C5=C(C=CC=C45)CN6C[C@H]7N([C@H](C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,5.015472686656207,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)c6ccc(N7CCN(C)CC7)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
9966,CHEMBL1209617,GDJANRNMFHNVOW-DCPHZVHLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP1A2,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCC3)NC(=O)[C@@H]4[C@H](CCN4)O,5.301029995663981,C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCC3)n2)cc1
9967,CHEMBL1209617,GDJANRNMFHNVOW-DCPHZVHLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCC3)NC(=O)[C@@H]4[C@H](CCN4)O,5.301029995663981,C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCC3)n2)cc1
9971,CHEMBL578928,GDKCAAWSNQLXNX-UHFFFAOYSA-N,GNF-PF-2094,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19914064.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NC(=N1)NCC2=CC=CC=C2)NC3CCCCC3,5.301029995663981,Cc1cc(NC2CCCCC2)nc(NCc2ccccc2)n1
9972,CHEMBL3235253,GDLACGKFMPNRBW-MSOLQXFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24630562.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CC[C@H](CN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C#CC4=NC=C(C=C4)F,4.301029995663981,Cc1ccc(-n2nccn2)c(C(=O)N2C[C@H](C#Cc3ccc(F)cn3)CC[C@H]2C)c1
9989,CHEMBL518287,GDLSKBDRIIJEHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC(=CC=C2)Cl)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccc(Cl)c1
10008,CHEMBL1230065,GDTQLZHHDRRBEB-UHFFFAOYSA-N,BMS-582949,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20804198.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38a MAP kinase inhibitor for the treatment of inflammatory diseases.",J. Med. Chem.,PUBLICATION,,CCCNC(=O)C1=CN2C(=C1C)C(=NC=N2)NC3=C(C=CC(=C3)C(=O)NC4CC4)C,4.7447274948966935,CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C
10009,CHEMBL1091774,GDVOQNXWYQVYJH-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN4CCCC4,5.0,C[C@@H](c1ccccn1)c1c(CCN2CCCC2)sc2ccccc12
10017,CHEMBL1269692,GEBGDXKEDPYHHN-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)CC(F)(F)F)Cl)C5CC5)Cl,5.3979400086720375,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
10018,CHEMBL1269692,GEBGDXKEDPYHHN-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)CC(F)(F)F)Cl)C5CC5)Cl,5.102372908709558,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
10027,CHEMBL3236639,GEDLWRDUBQVNGB-JCUDBWTNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC5=NC=CC(=C5)C(=O)O,4.568636235841013,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2cc(C(=O)O)ccn2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
10057,CHEMBL1708,GELRVIPPMNMYGS-RVXRQPKJSA-N,PAROXETINE HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,24100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4.Cl,4.617982957425132,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
10070,CHEMBL1672632,GEPUTKWSUKGITG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1C(=O)NC2=CN=C(C(=N2)C3=NC=CO3)C4=C(C=NC=C4)F,4.6020599913279625,O=C(Nc1cnc(-c2ccncc2F)c(-c2ncco2)n1)C1CC1
10072,CHEMBL396186,GEQDEWSMDBTYED-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCCN,4.823908740944319,CC(C)C[C@H](NC(=O)CCCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
10081,CHEMBL3330652,GERXWWPNRKXYSR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1I)F)NC2=C(C=CN3C2=CN=C3)C(=O)NOCCO,5.0,O=C(NOCCO)c1ccn2cncc2c1Nc1ccc(I)cc1F
10082,CHEMBL3330652,GERXWWPNRKXYSR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1I)F)NC2=C(C=CN3C2=CN=C3)C(=O)NOCCO,5.0,O=C(NOCCO)c1ccn2cncc2c1Nc1ccc(I)cc1F
10084,CHEMBL1092377,GETROLYXSDDSDH-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)F,5.0,C[C@@H](c1ncccc1F)c1c(CCN(C)C)sc2ccccc12
10086,CHEMBL1269675,GETZVQZESTVPJG-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNCC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,4.853871964321762,CCNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
10087,CHEMBL1269675,GETZVQZESTVPJG-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNCC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,4.769551078621726,CCNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
10099,CHEMBL520828,GEWPHZNCWUIEEN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,CC1=C(C(N=C(N1)C2=CC=C(C=C2)OC)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=CC5=C(C=C4)NN=C5,5.568636235841013,COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cc1
10106,CHEMBL2152252,GEYLKEHPEKRUTC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22548342.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using midazolam as substrate after 15 mins by LC/MS/MS analysis,Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase ¿ Inhibitors.,J. Med. Chem.,PUBLICATION,,CNC(=O)C1=NC(=CN=C1N)C2=CC(=C(C=C2)Cl)S(=O)(=O)NC3=C(C(=CC=C3)F)F,4.698970004336019,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N
10107,CHEMBL2152252,GEYLKEHPEKRUTC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22548342.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 15 mins by LC/MS/MS analysis,Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase ¿ Inhibitors.,J. Med. Chem.,PUBLICATION,,CNC(=O)C1=NC(=CN=C1N)C2=CC(=C(C=C2)Cl)S(=O)(=O)NC3=C(C(=CC=C3)F)F,4.698970004336019,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N
10131,CHEMBL226345,GFFGJBXGBJISGV-UHFFFAOYSA-N,ADENINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=NC2=NC=NC(=C2N1)N,5.0,Nc1ncnc2nc[nH]c12
10132,CHEMBL226345,GFFGJBXGBJISGV-UHFFFAOYSA-N,ADENINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=NC2=NC=NC(=C2N1)N,5.0,Nc1ncnc2nc[nH]c12
10133,CHEMBL569185,GFFIHDXPUGXVGG-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19888755.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.,J. Med. Chem.,PUBLICATION,,COC1=CC=C(C=C1)CCN2[C@@H](CN(C2=O)NS(=O)(=O)C)C3=CC=C(C=C3)OC,4.431798275933005,COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)C[C@H]2c2ccc(OC)cc2)cc1
10138,CHEMBL252240,GFFRRUFVZMBJGA-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,810.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=C(C(=CC=C1)F)C(F)(F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,6.0915149811213505,CC(C)(C)OC(=O)N[C@H](Cc1cccc(F)c1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
10143,CHEMBL525001,GFGBAMIIMZDJCH-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C3=C(C2=N1)N[C@@H](CC3)C4=CC=CC=C4)N5C=CC=CC5=O)C,5.113509274827518,Cc1nc2c3c(c(-n4ccccc4=O)cn2c1C)CC[C@@H](c1ccccc1)N3
10145,CHEMBL1607077,GFGKJXGFRNRWOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC=NC=C3,6.0,O=C(NCc1ccncc1)c1ccc(Oc2ccccc2)cc1
10147,CHEMBL1172882,GFIBJCSJSOCGMM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,538.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)O)C2=CC=C(C=C2)CC3=CC=NC=C3,6.269217724333611,Oc1cccc(-c2ccc(Cc3ccncc3)cc2)c1
10148,CHEMBL1172882,GFIBJCSJSOCGMM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,538.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)O)C2=CC=C(C=C2)CC3=CC=NC=C3,6.269217724333611,Oc1cccc(-c2ccc(Cc3ccncc3)cc2)c1
10149,CHEMBL3113764,GFIGTNGISUKHQE-BBRMVZONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1C[C@H](N(C1=O)CC2=CC=C(C=C2)OC(F)(F)F)C3=C(C=CC=C3OC)OC,5.060480747381382,COc1cccc(OC)c1[C@@H]1C[C@H](C)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
10153,CHEMBL2407949,GFIMEKUFCRTWGH-DARPEHSRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1C(C/C(=N\O)/C2=CC=NC=C2)C3=CC=C(C=C3)Br,6.698970004336019,Cc1ccccc1C(C/C(=N\O)c1ccncc1)c1ccc(Br)cc1
10160,CHEMBL394438,GFJJIBKQWYQEJL-UHFFFAOYSA-N,SR-1351,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,530.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Cl)N,6.275724130399211,NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Cl)cc1
10163,CHEMBL1951336,GFKDVMSTTKOYOX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)NC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,7.045757490560675,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
10164,CHEMBL3628942,GFKPWKCDJBRXQK-OHMHCFLMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,314.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC(C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=C(N=N2)[C@](C)(C(C)C)NCC3=NC4=CC=NN4C=C3,6.503070351926785,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccn3nccc3n2)C(C)C)nn1
10170,CHEMBL1451,GFNANZIMVAIWHM-OBYCQNJPSA-N,TRIAMCINOLONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,49100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O,4.308918507877031,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
10182,CHEMBL3291124,GFQOLQIWVXUSEO-HMQJICCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,216.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)CO)C,6.665546248849069,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
10183,CHEMBL3291124,GFQOLQIWVXUSEO-HMQJICCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,242.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)CO)C,6.616184634019569,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
10196,CHEMBL231334,GGAQZJOAVWSKSS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17084080.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Studies towards the identification of a new generation of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC1=CC=C(C=C1)S(=O)(=O)NC2=CC3=C(CCN(CC3)C)C=C2,4.920818753952375,CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(C)CC3)cc1
10214,CHEMBL2151935,GGNJJMKBSUZZTH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1CC(=O)NC2=CC(=C(C=C2)F)Cl)N3CCOCC3,4.3979400086720375,Cn1c(CC(=O)Nc2ccc(F)c(Cl)c2)nc(N2CCOCC2)cc1=O
10220,CHEMBL114555,GGPFRXPJXXCZQB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)N1CCN(CC1)CCOC2=CC=C(C=C2)N3C=CN=C3,4.0,CCOC(=O)N1CCN(CCOc2ccc(-n3ccnc3)cc2)CC1
10226,CHEMBL396433,GGRHVKPDRUOVCO-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCC(=O)O,4.301029995663981,CC(C)C[C@H](NCC(=O)O)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
10270,CHEMBL3104536,GHDKWWRARPMTNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,30200.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=C(C=C4)C(F)(F)F,4.519993057042849,FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
10272,CHEMBL3104536,GHDKWWRARPMTNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=C(C=C4)C(F)(F)F,4.0,FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
10280,CHEMBL1209693,GHGFTZSRECGLSO-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C)(C)OC,7.167491087293763,COC(C)(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O
10281,CHEMBL1209693,GHGFTZSRECGLSO-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,530.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C)(C)OC,6.275724130399211,COC(C)(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O
10282,CHEMBL1271601,GHHUJPFVTHAWJJ-LEWJYISDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,13.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H]1COC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCC(CC4)CO,7.860120913598763,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CCC(CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
10283,CHEMBL1951431,GHICRWADWFXKES-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=CCN1C2=C(C(=C1N3CCC[C@@H](C3)N)C#N)N=CN(C2=O)CC4=CC=NC5=CC=CC=C45)C,5.522878745280337,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2ncn(Cc3ccnc4ccccc34)c(=O)c21
10294,CHEMBL271622,GHLQJCUCOQSQFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,COC1=CC=C(C=C1)C2=NOC(=C2)CNS(=O)(=O)C3=CC=CC=C3,4.481486060122112,COc1ccc(-c2cc(CNS(=O)(=O)c3ccccc3)on2)cc1
10296,CHEMBL229861,GHMFVPOVQMEIHB-CORIIIEPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17552509.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.,J. Med. Chem.,PUBLICATION,,CC[C@H]1[C@@H]2[C@H](CCN2C(=O)N1C3=C(C(=C(C=C3)C#N)Cl)C)O,4.3979400086720375,CC[C@H]1[C@@H]2[C@@H](O)CCN2C(=O)N1c1ccc(C#N)c(Cl)c1C
10300,CHEMBL1774932,GHMZDEVGWDRXIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,CC(CNC(=O)N1CC2=C(C1)N=C(N=C2C3=C(C=C(C=C3Cl)Cl)OCCN4C=C(C=N4)F)N)(F)F,6.221848749616356,CC(F)(F)CNC(=O)N1Cc2nc(N)nc(-c3c(Cl)cc(Cl)cc3OCCn3cc(F)cn3)c2C1
10301,CHEMBL1171991,GHOBTHCFQZXIBK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,1770.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,CC(=C(C1=CC=C(C=C1)C2=CC(=C(C=C2)N)N)C3=CC=NC=C3)C,5.752026733638194,CC(C)=C(c1ccncc1)c1ccc(-c2ccc(N)c(N)c2)cc1
10320,CHEMBL497011,GHVIMBCFLRTFHI-UHFFFAOYSA-N,LINAPRAZAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO,5.075720713938118,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12
10321,CHEMBL497011,GHVIMBCFLRTFHI-UHFFFAOYSA-N,LINAPRAZAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO,4.853871964321762,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12
10322,CHEMBL497011,GHVIMBCFLRTFHI-UHFFFAOYSA-N,LINAPRAZAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO,5.045757490560675,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12
10323,CHEMBL497011,GHVIMBCFLRTFHI-UHFFFAOYSA-N,LINAPRAZAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO,4.920818753952375,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12
10326,CHEMBL1079362,GHVKHDJQMCSVLZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NC2=CC=NC=C2)C3=CC=CC=C3,5.0,CC1(c2ccccc2)CCCN(C(=O)Nc2ccncc2)C1
10327,CHEMBL3353359,GHVNNCGXWGZXJH-DAGBDIRBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7NC6=O,5.0,CN1CCN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1
10344,CHEMBL559060,GHZHZIJXYOTTAA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NCC2CCOCC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,5.301029995663981,Fc1ccc(Cn2c(N3CCC(NCC4CCOCC4)CC3)nc3ccccc32)cc1
10349,CHEMBL1208801,GIBBMQIFJKTBNZ-WHUIICBVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC4CC4,7.167491087293763,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2CC2)S1(=O)=O
10350,CHEMBL1208801,GIBBMQIFJKTBNZ-WHUIICBVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC4CC4,6.7447274948966935,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2CC2)S1(=O)=O
10352,CHEMBL1682895,GICBPQGKGLLFIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCCNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C(C3=CN=CN3)(C(C)C)O,5.468521082957745,CCCNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
10359,CHEMBL558468,GIEBQTVDYXTBCS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC,5.301029995663981,COc1ccc(Cn2c(N3CCC(N(C)C)CC3)nc3ccccc32)cc1
10368,CHEMBL245412,GIHNTRQPEMKFKO-SKTNYSRSSA-N,ZERUMBONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,21800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C/C/1=C\CC(/C=C/C(=O)/C(=C/CC1)/C)(C)C,4.661543506395395,C/C1=C\CC(C)(C)/C=C/C(=O)/C(C)=C/CC1
10379,CHEMBL242711,GIJHDGJRTUSBJR-UHFFFAOYSA-N,BERGAPTOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17400460.0,IC50,=,24920.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC(=O)OC2=CC3=C(C=CO3)C(=C21)O,4.603451962012868,O=c1ccc2c(O)c3ccoc3cc2o1
10409,CHEMBL2338482,GIORSITYZQXFRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,360.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,CC(=O)C1=CC(=CN=C1)OC2=C(C=C(C=C2Cl)NS(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)Cl,6.443697499232713,CC(=O)c1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1
10410,CHEMBL3702742,GIPAHZVDJUDHQA-NRMCGMLCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10890.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,C[C@H](C(=O)OC)NC(=O)C1=CN(C2=C(C=CC=C12)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C,4.962972120244225,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N[C@H](C)C(=O)OC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
10420,CHEMBL14563,GIUZEIJUFOPTMR-UHFFFAOYSA-N,SB-242084,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9357513.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human Cytochrome P450 3A at 1 uM,6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.,J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1Cl)N(CC2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C,4.0,Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2
10421,CHEMBL14563,GIUZEIJUFOPTMR-UHFFFAOYSA-N,SB-242084,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,10737744.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human cytochrome P450 3A4,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1Cl)N(CC2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C,4.0,Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2
10423,CHEMBL1649656,GIVZDASVXCBGBL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,C1CCN(C1)C(=O)C2=CC=C(C=C2)N3C4=C(COCC4)C(=N3)C(F)(F)F,5.0,O=C(c1ccc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1)N1CCCC1
10448,CHEMBL3422099,GJGMLBSXNZXSBX-NDIVSWGXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1C[C@H]2CC(C[C@H]1N2C3=CC=C(C=C3)C4=NNC5=C4C=C(C=C5)C(=O)N[C@H](CC6CC6)C7=CC=CC=N7)O,5.886056647693163,O=C(N[C@H](CC1CC1)c1ccccn1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1
10454,CHEMBL2178249,GJJWKAPPVNNWLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)Cl)C2=C(C=CN=C2)NC(=O)C3=C4N=CC=CN4N=C3,6.698970004336019,O=C(Nc1ccncc1-c1cccc(Cl)c1)c1cnn2cccnc12
10482,CHEMBL100379,GJTBBHPPJLHWKQ-ULYATVDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC(=C(C=C1)F)N2CCOCC2)NC(=O)/C=C/C3=CC=C(C=C3)F,4.7447274948966935,C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1
10483,CHEMBL100379,GJTBBHPPJLHWKQ-ULYATVDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC(=C(C=C1)F)N2CCOCC2)NC(=O)/C=C/C3=CC=C(C=C3)F,4.721246399047171,C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1
10484,CHEMBL100379,GJTBBHPPJLHWKQ-ULYATVDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC(=C(C=C1)F)N2CCOCC2)NC(=O)/C=C/C3=CC=C(C=C3)F,4.721246399047171,C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1
10485,CHEMBL100379,GJTBBHPPJLHWKQ-ULYATVDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC(=C(C=C1)F)N2CCOCC2)NC(=O)/C=C/C3=CC=C(C=C3)F,4.6777807052660805,C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1
10492,CHEMBL3628943,GJWDUYBKAOXWIS-JKDDQTOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,263.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC(C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=C(N=N2)[C@](C)(C3CCCC3)NCC4=NC5=CC=NN5C=C4,6.580044251510242,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccn3nccc3n2)C2CCCC2)nn1
10494,CHEMBL3358927,GJXAQWRUPWTIBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)N(C)C)(C(F)(F)F)O,6.221848749616356,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N(C)C)ncc2[nH]1)C(F)(F)F
10511,CHEMBL2103830,GKDRMWXFWHEQQT-UHFFFAOYSA-N,FOSTAMATINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C,4.301029995663981,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC
10512,CHEMBL1835784,GKEPUTPZCYQUOQ-PBPGXSGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NN(C(=O)C4C3CCC4)C,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(C2=NN(C)C(=O)C3CCCC23)cc1
10517,CHEMBL2431365,GKIDVBFFLSYPRO-RMKNXTFCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC(=CC(=C1OC)/C=C/C2=CC=C(C=C2)NS(=O)(=O)C)C3=CC(=CNC3=O)F,4.301029995663981,COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2cc(F)c[nH]c2=O)cc1C(C)(C)C
10518,CHEMBL2431365,GKIDVBFFLSYPRO-RMKNXTFCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC(=CC(=C1OC)/C=C/C2=CC=C(C=C2)NS(=O)(=O)C)C3=CC(=CNC3=O)F,4.301029995663981,COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2cc(F)c[nH]c2=O)cc1C(C)(C)C
10534,CHEMBL3673976,GKKXSXHWFUUCKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320655,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CN1C=C(C=C(C1=O)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl)F,5.301029995663981,Cn1cc(F)cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1=O
10535,CHEMBL3673976,GKKXSXHWFUUCKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320699,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CN1C=C(C=C(C1=O)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl)F,5.0,Cn1cc(F)cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1=O
10542,CHEMBL3673960,GKLDYZQMDUADGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320673,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)OC)F)N=C1,5.301029995663981,COc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4OC)nc3F)c2c1
10543,CHEMBL3673960,GKLDYZQMDUADGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320629,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)OC)F)N=C1,5.0,COc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4OC)nc3F)c2c1
10562,CHEMBL1738841,GKQIKYWYJQQLLD-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21441024.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1C(=O)N(C(=O)N1CC2=CC=NC3=CC=CC=C23)C4=CC=C(C=C4)S(=O)(=O)C(F)(F)F,4.823908740944319,C[C@H]1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccnc2ccccc12
10563,CHEMBL460291,GKQPCPXONLDCMU-CCEZHUSRSA-N,LACIDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,900.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C,6.045757490560675,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C
10565,CHEMBL179589,GKRQVVOAAXTIGR-UHFFFAOYSA-N,"5-METHYL-[2,3']BIPYRIDINYL",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,84230.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,CC1=CN=C(C=C1)C2=CN=CC=C2,4.074533199308462,Cc1ccc(-c2cccnc2)nc1
10583,CHEMBL2419486,GKUTXOAQZPNFCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CC(C2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)F)C,4.698970004336019,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3)C2)nc1C
10588,CHEMBL2334760,GKVOTXQBCIYYJV-INIZCTEOSA-N,6-AZA-THQ,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CN(CC3)C4COC4)C(=N2)N5CCOC[C@@H]5C,5.6020599913279625,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CN(C2COC2)CC3)cc1
10601,CHEMBL538357,GLCGPUDWOPXBAY-HLRBRJAUSA-M,CALIFORNIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16562853.0,IC50,>,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,C[N+]1([C@H]2CC3=CC4=C(COC4)C=C3[C@@H]1CC5=CC6=C(C=C25)OCO6)C.[Cl-],4.096910013008056,C[N+]1(C)[C@H]2Cc3cc4c(cc3[C@@H]1Cc1cc3c(cc12)COC3)OCO4
10604,CHEMBL3702709,GLDNZQYGNSOWKA-HWHSMDOUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(=O)N1CCN2CCN(CC2C1)C(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,4.823908740944319,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C(C)=O)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
10611,CHEMBL1649675,GLEVYNXKNNNUSS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,<=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,CC(=O)CC1=CC=C(C=C1)N2C3=C(CCCC3)C(=N2)C(F)(F)F,6.0,CC(=O)Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1
10618,CHEMBL256072,GLISBSFAODYFPL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCC4=C(N(C=N4)C)Cl)N5CCOCC5,5.721246399047171,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCCc4ncn(C)c4Cl)cc[nH]c3=O)nc12
10640,CHEMBL2347405,GLPNWSBFGKTKTK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NNC4=C3C=C(C=C4)OC(F)F,4.721246399047171,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3n[nH]c4ccc(OC(F)F)cc34)nc12
10643,CHEMBL257517,GLSSNBLKKWINSD-JDXGNMNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=C(C=C2)OC)CCOC3=CC=CC(=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,4.920818753952375,COc1ccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)cc1
10647,CHEMBL27415,GLTOTRUXBZKBKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,9440.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)Cl,5.025028005701931,Cn1c2ccnc(Cl)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
10648,CHEMBL397666,GLTRPHMPCVLOJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC4=CC=CC=N4)N5C=CN=C5,7.096910013008056,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCc4ccccn4)cc[nH]c3=O)nc12
10653,CHEMBL3263996,GLVLHQQZXXQWEI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)OC2=C1C=CC(=C2)OC(=O)N(C)C)CC3=CC(=NC=C3)NS(=O)(=O)NC,4.0,CNS(=O)(=O)Nc1cc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)ccn1
10654,CHEMBL3263996,GLVLHQQZXXQWEI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)OC2=C1C=CC(=C2)OC(=O)N(C)C)CC3=CC(=NC=C3)NS(=O)(=O)NC,4.0,CNS(=O)(=O)Nc1cc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)ccn1
10666,CHEMBL1761520,GLYFGYIXZOBFGF-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCN(C)C)C5CC5)Cl,5.853871964321762,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCN(C)C)c1
10667,CHEMBL1761520,GLYFGYIXZOBFGF-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,22700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCN(C)C)C5CC5)Cl,4.6439741428068775,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCN(C)C)c1
10679,CHEMBL267690,GMAUZWFHZJGCSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)C5=CC(=CN=C5)OC)N(C2=O)CC6=CC=CC=C6F,5.698970004336019,COc1cncc(-c2ccc(CN3CCC4(CC3)C(=O)N(c3cccc(OC)c3)C(=O)N4Cc3ccccc3F)cc2)c1
10680,CHEMBL281496,GMAXIWRMMJVMOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,33690.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C3=C(C=CN=C31)C(=O)N)N=C(N=C2N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)CN6CCOCC6,4.47249898901888,Cn1c2nccc(C(N)=O)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
10684,CHEMBL324777,GMBQUUCZMIXCEQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177477.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome cytochrome P450 3A4,An aminomethylpyrimidine DPP-IV inhibitor with improved properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CCOC)C1=NC(=C(C(=N1)N)CN)C2=C(C=C(C=C2)Cl)Cl,4.522878745280337,COCCN(C)c1nc(N)c(CN)c(-c2ccc(Cl)cc2Cl)n1
10691,CHEMBL251800,GMGMXDBCSMRQME-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CC2=NC(=NO2)CC3(CC3)[C@H]4CCC[C@H](N4S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,5.920818753952375,O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2noc(CN3CCCC3)n2)CC1
10698,CHEMBL2177737,GMIREKPIMOCOBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)NC2=C3C(=NC(=N2)C4=CC(=CC=C4)C(=O)NC5=CC=C(C=C5)C(=O)O)SC=N3)OC,4.301029995663981,COc1ccc(Nc2nc(-c3cccc(C(=O)Nc4ccc(C(=O)O)cc4)c3)nc3scnc23)cc1OC
10707,CHEMBL471067,GMLDZDDTZKXJLU-JKSUJKDBSA-N,(-)-DEOXYPODORHIZONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,COC1=CC(=CC(=C1OC)OC)C[C@@H]2[C@H](COC2=O)CC3=CC4=C(C=C3)OCO4,6.0,COc1cc(C[C@H]2C(=O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC
10712,CHEMBL2017111,GMLLRQVRERMQBQ-CJAUYULYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)[C@H]3CNCC[C@@]3(C4=CC(=C(C=C4)F)F)C(=O)N)Br,4.443697499232712,CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(C(N)=O)c2ccc(F)c(F)c2)c1Br
10724,CHEMBL1078354,GMTQAOXNCHJFPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NCCC2=CC3=C(C=C2)N=CN3)C4=CC=CC=C4,5.0,CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc3nc[nH]c3c2)C1
10733,CHEMBL179825,GMYMOUHNOWZKMI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)CC(=O)OC)N4C=CN=C4)N(C)C,8.397940008672037,COC(=O)Cc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1
10752,CHEMBL380866,GNLDZONRYOENMG-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,42.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3[C@H](CNCC3=O)COC4=CC5=C(CCCN5CCN6CCCC6=O)C=C4,7.376750709602099,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN2CCCC2=O)CCC3)cc1
10756,CHEMBL360148,GNOBXZHCXJWOKL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,481.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)N)N4C=CN=C4)N(C)C,6.317854923626168,CC(C(c1ccc2cc(OCc3cccc(C(N)=O)c3)ccc2c1)n1ccnc1)N(C)C
10761,CHEMBL3393475,GNSDDKAAHUFOKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=C(C=C6F)F,6.0,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)cc(F)cc3[nH]2)o1
10770,CHEMBL501315,GNURRCJPQXKFTN-HNRBIFIRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(CCC4=CC(=CC=C4)OC)C(=O)NC5CCCCC5,6.698970004336019,COc1cccc(CCN(Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)C(=O)NC2CCCCC2)c1
10771,CHEMBL501315,GNURRCJPQXKFTN-HNRBIFIRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(CCC4=CC(=CC=C4)OC)C(=O)NC5CCCCC5,6.3979400086720375,COc1cccc(CCN(Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)C(=O)NC2CCCCC2)c1
10787,CHEMBL567904,GNYXHJVKEWBHAI-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=CC=C5,6.522878745280337,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3cccnc3)ccc2o1
10788,CHEMBL2436976,GNZKXRXWADXJOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,COC1=CC(=CC(=C1OC)OC)C2=CC3=C(NC=C3C4=CN=C(N=C4)N)N=C2,4.522878745280337,COc1cc(-c2cnc3[nH]cc(-c4cnc(N)nc4)c3c2)cc(OC)c1OC
10802,CHEMBL498652,GOEOPYMHOCPWHT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,8757.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC2=C(C=CC(=C2)C3=CC=C(C=C3)F)C(C1)(C4=CC=NC=C4)O,5.057644650292323,OC1(c2ccncc2)CCCc2cc(-c3ccc(F)cc3)ccc21
10811,CHEMBL3331503,GOHLFHFVKPDRNY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)N(CC1CNC1)CC2=CC(=C(C=C2)Cl)Cl.Cl,5.958607314841775,CC(C)N(Cc1ccc(Cl)c(Cl)c1)CC1CNC1
10812,CHEMBL1836215,GOJFPSNMWCYOTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21838322.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using vivid green as substrate,Discovery of a Brain-Penetrant S1P(3)-Sparing Direct Agonist of the S1P(1) and S1P(5) Receptors Efficacious at Low Oral Dose.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC2=C1CCN(C2)C(CO)CO)C3=NOC(=N3)C4=CC(=C(C=C4)OC(C)C)C#N,5.075720713938118,Cc1c(-c2noc(-c3ccc(OC(C)C)c(C#N)c3)n2)ccc2c1CCN(C(CO)CO)C2
10813,CHEMBL1836215,GOJFPSNMWCYOTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21838322.0,IC50,=,15300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using vivid red as substrate,Discovery of a Brain-Penetrant S1P(3)-Sparing Direct Agonist of the S1P(1) and S1P(5) Receptors Efficacious at Low Oral Dose.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC2=C1CCN(C2)C(CO)CO)C3=NOC(=N3)C4=CC(=C(C=C4)OC(C)C)C#N,4.815308569182402,Cc1c(-c2noc(-c3ccc(OC(C)C)c(C#N)c3)n2)ccc2c1CCN(C(CO)CO)C2
10818,CHEMBL2023123,GOOZHZPTJHCQEV-VGCGRUFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CNC[C@H]([C@H](C1CCCCC1)O)NC(=O)N2CCC[C@H](C2)[C@H](C3=CC(=CC=C3)Cl)OCCNC(=O)OC,5.1487416512809245,CNC[C@@H](NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1)[C@@H](O)C1CCCCC1
10819,CHEMBL3581121,GOPDRFODUBCWMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,750.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=CC=NC=C3,6.1249387366083,COc1cccc(CC(=O)Nc2nc(-c3ccncc3)cs2)c1
10826,CHEMBL218573,GOSZMIDOMHVHDD-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CC3=CC=CC=C3C(F)(F)F)C(=O)N4C[C@@H](CO4)O)C(=O)N(C1=O)C,5.080921907623926,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3ccccc3C(F)(F)F)sc21
10844,CHEMBL402319,GOZLZTGPYFRJDJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCN)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,4.3979400086720375,CC(C)c1c(-c2nnc(NCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
10854,CHEMBL475684,GPBATYISDDVOGP-KQWNVCNZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19321349.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,PUBLICATION,,CC1=NN(C=C1)C2=CC(=C(C=C2)C(=O)N3CCC(/C(=C\C(=O)NCC4=NN=CC=C4)/C5=CC=CC=C53)(F)F)Cl,5.102372908709558,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCc4cccnn4)c4ccccc43)c(Cl)c2)n1
10894,CHEMBL2391518,GPOINCDNNRDNCO-SFQUDFHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23324405.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2=CC=CC=C2N(C1)C(=O)/C(=C/C3=CN(C4=CC=CC=C43)CC(=O)O)/C#N,5.0,N#C/C(=C\c1cn(CC(=O)O)c2ccccc12)C(=O)N1CCCc2ccccc21
10912,CHEMBL1276947,GPWMNUXSJDSCAV-NZICPMOKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,C1C[C@@]2(CC1N3C[C@@H]4C[C@@]4(C3)C(=O)O)CC5=CC=CC=C5CC6=CC=CC=C26,5.0,O=C(O)[C@]12C[C@H]1CN(C1CC[C@]3(Cc4ccccc4Cc4ccccc43)C1)C2
10917,CHEMBL511410,GPXKVULNYYNGDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19364658.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)O)C(C(=O)N)NC2=C(C(=O)C2=O)NC3=CC=NC=C3,5.0,NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1cccc(O)c1
10923,CHEMBL371409,GQCGJUPPZILNPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC(=O)N)CCO)C3=C(C=CC(=C3)Cl)O,4.585026652029182,NC(=O)Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21
10924,CHEMBL371409,GQCGJUPPZILNPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC(=O)N)CCO)C3=C(C=CC(=C3)Cl)O,4.301029995663981,NC(=O)Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21
10926,CHEMBL3353881,GQCPYMUOLFAADB-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556092.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=NOC(=C1)NC(=O)[C@@H]2CCC(=O)N2C3=CC=C(C=C3)C(F)(F)F,4.301029995663981,CC(C)(C)c1cc(NC(=O)[C@@H]2CCC(=O)N2c2ccc(C(F)(F)F)cc2)on1
10938,CHEMBL2441844,GQGRTDFKONOVAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)O)C3=C(C=C(C=C3)Cl)Cl)CN,4.3979400086720375,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)O)C2
10945,CHEMBL2170636,GQLSQBMTTDVNKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CN=CC=C3,4.522878745280337,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3cccnc3)CC2)c(C(F)(F)F)c1
10950,CHEMBL1171008,GQLXQNMFKWOOSD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20627722.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)C(=O)O)OC2=C(C=C(C=N2)Cl)NS(=O)(=O)C3=CC(=C(C=C3)Cl)Cl,4.0,O=C(O)c1ccccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1
10954,CHEMBL552196,GQPZWGHDZGLONB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,CC1=C(ONC1=O)C2CCN(CC2)C(=O)NC3CC3C4=CC=CC=C4,5.0,Cc1c(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)o[nH]c1=O
10957,CHEMBL1076192,GQQOBKGSKQCRQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2C=C(N3C)C,5.508638306165727,Cc1cccc(C)c1CNc1nccc2c1cc(C)n2C
10958,CHEMBL1076192,GQQOBKGSKQCRQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2C=C(N3C)C,5.366531544420414,Cc1cccc(C)c1CNc1nccc2c1cc(C)n2C
10966,CHEMBL1951327,GQSDFZXXEZBDPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,5.823908740944319,Cc1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
10973,CHEMBL509347,GQUNRVHHNJVPMJ-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NC)C4=C(C(=CC=C4)OCCCOCC(=O)O)F,4.657577319177793,CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCOCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
10977,CHEMBL1778506,GQXDJHYRFLVFCI-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21515053.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)C(=O)CC4=CC=C(C=C4)F,4.301029995663981,CN(C(=O)Cc1ccc(F)cc1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1
10981,CHEMBL3116154,GQXQRBDIIIITDT-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@](C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=C(N4)C=C(C=C5F)F,4.721246399047171,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3c(F)cc(F)cc3[nH]2)c2ccc(Cl)cn2)c1
10982,CHEMBL3116154,GQXQRBDIIIITDT-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@](C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=C(N4)C=C(C=C5F)F,4.619788758288394,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3c(F)cc(F)cc3[nH]2)c2ccc(Cl)cn2)c1
10989,CHEMBL528996,GRCPGLCEGKJUFI-ULJHMMPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19321349.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,PUBLICATION,,CC1=NN(C=C1)C2=CC(=C(C=C2)C(=O)N3CCC(/C(=C\C(=O)NCC4=CC=CC=N4)/C5=CC=CC=C53)(F)F)Cl,4.958607314841775,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCc4ccccn4)c4ccccc43)c(Cl)c2)n1
10994,CHEMBL237847,GRFNBEZIAWKNCO-UHFFFAOYSA-N,SR-1C8,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,767361.49,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)O,3.1149999996388162,Oc1cccnc1
10997,CHEMBL3112778,GRGMVSNJGMXWAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24486134.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) compound preincubated with substrate,Substituted piperidines as HDM2 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,6.522878745280337,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1
10998,CHEMBL3112778,GRGMVSNJGMXWAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24486134.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) compound co-incubated with substrate,Substituted piperidines as HDM2 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,5.309803919971486,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1
10999,CHEMBL3288447,GRGMVSNJGMXWAY-YNMZEGNTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)[C@@]3(CCCN(C3)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,6.522878745280337,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1
11000,CHEMBL3288447,GRGMVSNJGMXWAY-YNMZEGNTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)[C@@]3(CCCN(C3)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,5.309803919971486,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1
11003,CHEMBL1951320,GRHDAFPDCKOVQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=C3C(=NC=C2)N=CN3)NC(=O)NC4=CC=C(C=C4)Cl,6.508638306165727,O=C(Nc1ccc(Cl)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
11019,CHEMBL364914,GRKSCYLPVRPFEA-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,380.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)N)CC4=C(C=CC=C4S(=O)(=O)C)F,6.42021640338319,COc1cccc(-c2cn(Cc3c(F)cccc3S(C)(=O)=O)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F
11020,CHEMBL2178247,GRKVHVFMHBOEFZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=NN(C(=C1)NC(=O)C2=C3N=C(C=CN3N=C2)NC)C4=CC(=CC=C4)Cl,5.0,CNc1ccn2ncc(C(=O)Nc3cc(C)nn3-c3cccc(Cl)c3)c2n1
11028,CHEMBL539650,GRQYMCJQVKMJAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,=,1.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)C5=NC=CS5)CC(C)(C)C(=O)O,8.853871964321762,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3nccs3)cc2)c2ccc(OCc3ccccn3)cc12
11059,CHEMBL1077940,GSCQTFZOCSWXSI-SVBPBHIXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,66.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@@H](CN(CC2=CN=CN2)C[C@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,7.180456064458132,O=C(N[C@@H](Cc1ccccc1)CN(Cc1cnc[nH]1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
11079,CHEMBL521982,GSGDLBUOSWGZER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26426481.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)C(=O)NC4=NC(=CO4)C(F)(F)F,4.522878745280337,O=C(Nc1nc(C(F)(F)F)co1)C1c2ccccc2Oc2ccccc21
11080,CHEMBL521982,GSGDLBUOSWGZER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27013388.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Re-exploration of the mGlu1 PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)C(=O)NC4=NC(=CO4)C(F)(F)F,4.522878745280337,O=C(Nc1nc(C(F)(F)F)co1)C1c2ccccc2Oc2ccccc21
11092,CHEMBL497418,GSIKNNVDKLEWNH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)NCC3=CC=CC=C3)N4C=CC=CC4=O)C,4.721246399047171,Cc1nc2c(NCc3ccccc3)cc(-n3ccccc3=O)cn2c1C
11093,CHEMBL497418,GSIKNNVDKLEWNH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)NCC3=CC=CC=C3)N4C=CC=CC4=O)C,4.619788758288394,Cc1nc2c(NCc3ccccc3)cc(-n3ccccc3=O)cn2c1C
11094,CHEMBL1078207,GSIRAOVJCFHRIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC2=C1C=CC(=C2)NS(=O)(=O)C3=CC=C(C=C3)C4=CC=CC=C4)CC5=CC=NN5,7.0,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1ccn[nH]1)CC2)c1ccc(-c2ccccc2)cc1
11095,CHEMBL1078207,GSIRAOVJCFHRIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC2=C1C=CC(=C2)NS(=O)(=O)C3=CC=C(C=C3)C4=CC=CC=C4)CC5=CC=NN5,7.0,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1ccn[nH]1)CC2)c1ccc(-c2ccccc2)cc1
11096,CHEMBL2415098,GSJRIJNVASEMGE-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23890837.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design and synthesis of bicyclic heterocycles as potent ¿-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(C=N1)C2=C(C=C(C=C2)C3=NN4CCO[C@H](C4=N3)C5=CC=CC=C5C(F)(F)F)OC,5.958607314841775,COc1cc(-c2nc3n(n2)CCO[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1
11102,CHEMBL2043170,GSKYNYTYBPKISP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=CC=C6C(=O)O,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccccc4C(=O)O)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
11148,CHEMBL3114792,GTCKEOBLPDFXJN-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24461352.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCS(=O)(=O)N1CCC(CC1)(C2=CC=CC=C2)[C@H](C)NC(=O)C3=C(C=C(C=C3)Cl)Cl,5.0,CCCS(=O)(=O)N1CCC(c2ccccc2)([C@H](C)NC(=O)c2ccc(Cl)cc2Cl)CC1
11166,CHEMBL2070163,GTLZLQHDDDIYEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CN(C3=O)C4=CC=CC=C4.Cl,4.698970004336019,CCCS(=O)(=O)c1ccc2nc(-c3cccn(-c4ccccc4)c3=O)[nH]c2c1
11167,CHEMBL3702752,GTMVVLWZHLESSJ-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5040.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)C(=O)CN(C)C(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.297569463554475,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CC(=O)N5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
11171,CHEMBL3702677,GTOJANLBFNSIOW-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9480.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8=CC=C(C=C8)OC,5.023191662661934,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccc(OC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
11174,CHEMBL3672581,GTQUHFLNJSGNRA-UWEBUPBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)NC(=O)C,7.0,CC(=O)N[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1
11175,CHEMBL3672581,GTQUHFLNJSGNRA-UWEBUPBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,370.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)NC(=O)C,6.431798275933005,CC(=O)N[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1
11176,CHEMBL2381946,GTRSBOPVOQICBF-SPEDKVCISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23701517.0,IC50,=,5400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.",J. Med. Chem.,PUBLICATION,,CC1([C@@H](N(C(=O)O1)C2CCC(CC2)N3C4=C(C(=C(C=C4)C#N)F)NC3=O)C5=CC=CC=C5)C,5.267606240177032,CC1(C)OC(=O)N(C2CCC(n3c(=O)[nH]c4c(F)c(C#N)ccc43)CC2)[C@H]1c1ccccc1
11177,CHEMBL2158301,GTTVVDKDTQATHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4)N,5.0,CC(C)(N)C(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1
11178,CHEMBL2059878,GTTXVOAFXQHQKC-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=NNN=C4C=C3)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.638272163982407,O=C(N[C@H](Cc1ccc2n[nH]nc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
11191,CHEMBL2448695,GTWXTKFMPIUMBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,19000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCN(C1=CC=CC=C1)S(=O)(=O)C2=CC(=C(C=C2)NC(=O)CN(C)C3CCN(CC3)C)Cl.Cl,4.721246399047171,CCN(c1ccccc1)S(=O)(=O)c1ccc(NC(=O)CN(C)C2CCN(C)CC2)c(Cl)c1
11195,CHEMBL230761,GTXFFNURYUQKEA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17715908.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.,J. Med. Chem.,PUBLICATION,,CN1C=C(N=C1)CNC2=CC3=C(C(=CN=C3C(=C2)Br)C#N)NC4=CC(=C(C=C4)F)Cl,4.823908740944319,Cn1cnc(CNc2cc(Br)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)c1
11204,CHEMBL565843,GTZBFNQZVAGCGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,4.795880017344075,COc1cnc2c(NCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
11205,CHEMBL565843,GTZBFNQZVAGCGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,4.301029995663981,COc1cnc2c(NCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
11209,CHEMBL1908842,GUBJNPWVIUFSTR-UHFFFAOYSA-N,JNJ-28312141,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,CN(C)CC(=O)N1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4,5.318758762624412,CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1
11213,CHEMBL1257850,GUBYCKMGWYDLAE-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CN2C3=C(C=C(C=C3)OC4CCN(CC4)C(C)C)C=C2C(=O)N1,4.301029995663981,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@H](C)NC2=O)CC1
11214,CHEMBL1257729,GUBYCKMGWYDLAE-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN2C3=C(C=C(C=C3)OC4CCN(CC4)C(C)C)C=C2C(=O)N1,4.301029995663981,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@@H](C)NC2=O)CC1
11215,CHEMBL1209555,GUDPVWCEUPKJOV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)OC(F)(F)F,7.167491087293763,CC(C)CC1n2cncc2CN(Cc2ccc(OC(F)(F)F)cc2)S1(=O)=O
11216,CHEMBL1209555,GUDPVWCEUPKJOV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,490.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)OC(F)(F)F,6.309803919971486,CC(C)CC1n2cncc2CN(Cc2ccc(OC(F)(F)F)cc2)S1(=O)=O
11217,CHEMBL3634013,GUDQJFKBBOAOIC-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26522950.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)OC)NC(=O)COC2=NC3=C(C(=C2)C(F)(F)F)C(=NN3C)C4=CC=CC=C4,5.096910013008056,COc1ccc([C@H](C)NC(=O)COc2cc(C(F)(F)F)c3c(-c4ccccc4)nn(C)c3n2)cc1
11233,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,6.494850021680094,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
11238,CHEMBL2448714,GUGQLGOBTCENLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,250.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCS(=O)(=O)N(CC1=CN=CC=C1)C2=CC=CC(=C2)C3=NC4=CC=CC=C4S3,6.6020599913279625,CCS(=O)(=O)N(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1
11262,CHEMBL1091782,GUNAZEDORZMWRN-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CSC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,C[C@@H](c1cscn1)c1c(CCN(C)C)sc2ccccc12
11271,CHEMBL3394734,GUOKRDAMSCOAIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC=C1S(=O)(=O)C2=CC(=CC(=C2)F)F)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1
11272,CHEMBL3394734,GUOKRDAMSCOAIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC=C1S(=O)(=O)C2=CC(=CC(=C2)F)F)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1
11289,CHEMBL1834657,GUQNHCGYHLSITB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl.OP(=O)(O)O,5.0,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
11290,CHEMBL1834657,GUQNHCGYHLSITB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl.OP(=O)(O)O,5.0,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
11291,CHEMBL3627896,GUQYDHZACNNLCK-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25978966.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)[C@@H](CNC(=O)C3=C(C=C(C=C3Cl)N4C=NC(=N4)C)Cl)C5=CC(=CC=C5)F)Cl,4.301029995663981,Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4c(C)cc(Cl)cc4[nH]3)c(Cl)c2)n1
11294,CHEMBL1093937,GURZVIGBGHQFAY-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20206513.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCCC2=CC=C(C=C2)C[C@H](CN)C(=O)N(CC3=CC(=CC(=C3)CCCOC)OCCOC)C4CC4)Cl,5.886056647693163,COCCCc1cc(CN(C(=O)[C@@H](CN)Cc2ccc(CCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1
11296,CHEMBL2059124,GUUNMYDKORYEGX-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)NCCN(C)C,6.698970004336019,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCN(C)C)oc2c1
11317,CHEMBL2203434,GVFQHBBRWBJGNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)OC2=CN=C(C=C2)C(=O)NC3=CC=C(C=C3)NC(=O)NC4=NOC(=C4)C(C)(C)C,4.3979400086720375,CCN1CCC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1
11318,CHEMBL2070948,GVFZKOCFOOBUQV-IAGOWNOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22858142.0,IC50,=,3981.07,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C#N)C1=CN=C(S1)N2CCN(CC2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NC4(CC4)C#N,5.40000018605658,CC(C)(C#N)c1cnc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)s1
11319,CHEMBL3310484,GVIKXRIOBFGDFP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,710.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3F,6.1487416512809245,Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl
11328,CHEMBL207486,GVLPJHAOLSTQRA-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]([C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N(C)C(C)C,6.3979400086720375,CC(C)N(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
11337,CHEMBL2338480,GVPOBQMDDUCYKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,CC1=CC(=CN=C1)OC2=C(C=C(C=C2Cl)NS(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)Cl,9.0,Cc1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1
11339,CHEMBL1761673,GVPWTNYUPQDJAS-QYSAAILDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OC[C@H]5C[C@@H]5C(=O)NS(=O)(=O)C)C6CC6)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)NS(C)(=O)=O)c1
11340,CHEMBL1761673,GVPWTNYUPQDJAS-QYSAAILDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OC[C@H]5C[C@@H]5C(=O)NS(=O)(=O)C)C6CC6)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)NS(C)(=O)=O)c1
11347,CHEMBL1774926,GVSHPPIHCUEEAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,C1C2=C(CN1C(=O)NCC(F)(F)F)N=C(N=C2C3=C(C=C(C=C3Cl)Cl)OCCN4C=CC=N4)N,5.721246399047171,Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)n1)CN(C(=O)NCC(F)(F)F)C2
11352,CHEMBL3310486,GVURCJXFYIMVMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=C(C=C3)F,6.3979400086720375,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1
11360,CHEMBL1209628,GVZKXJCNQYYFST-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC4(COC4)C,7.167491087293763,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2(C)COC2)S1(=O)=O
11361,CHEMBL1209628,GVZKXJCNQYYFST-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC4(COC4)C,7.167491087293763,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2(C)COC2)S1(=O)=O
11380,CHEMBL605162,GWEYXGKHUJIVFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20064717.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirocyclic ureas: orally bioavailable 11beta-HSD1 inhibitors identified by computer-aided drug design.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC12CC(C3=C2C(=CC=C3)Br)CC(=O)O)C(=O)NC4C5CC6CC(C5)CC4C6,4.823908740944319,O=C(O)CC1CC2(CCN(C(=O)NC3C4CC5CC(C4)CC3C5)CC2)c2c(Br)cccc21
11384,CHEMBL2338484,GWGJULRGKVMITG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1NS(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)C#N)OC3=CC(=CN=C3)Cl,6.221848749616356,N#Cc1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc1cncc(Cl)c1
11385,CHEMBL1649684,GWGLGISJEZMMGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,C1CC(=O)N(C1)CC2=CC=C(C=C2)N3C4=C(CCOC4)C(=N3)C(F)(F)F,5.0,O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2COCC3)cc1
11407,CHEMBL3702699,GWPBPJXIAURZGV-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)S(=O)(=O)C,4.950781977329818,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(S(C)(=O)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
11427,CHEMBL1209685,GWRUOXQHIKZCTE-ZRCAFCQKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCCC3)NC(=O)[C@@H]4[C@H](CCN4)O,5.366531544420414,C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1
11428,CHEMBL1209685,GWRUOXQHIKZCTE-ZRCAFCQKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP1A2,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCCC3)NC(=O)[C@@H]4[C@H](CCN4)O,5.301029995663981,C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1
11429,CHEMBL453067,GWRZMVNMDPUMHU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C(CN1CCCC1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N)C(=O)CN(CCOC)C4=CC(=C(C=C4)Cl)Cl,5.585026652029182,COCCN(CC(=O)N(C)C(CN1CCCC1)c1ccc(-c2ccc(C(N)=O)cc2)cc1)c1ccc(Cl)c(Cl)c1
11436,CHEMBL3121096,GWVIOFUJTJGECV-MSOLQXFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24513042.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): Histamine H3 receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)C4=NNC(=O)[C@@H]5[C@H]4C5,4.522878745280337,O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@@H]2C[C@H]12
11437,CHEMBL3121095,GWVIOFUJTJGECV-ZWKOTPCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24513042.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): Histamine H3 receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)C4=NNC(=O)[C@H]5[C@@H]4C5,4.522878745280337,O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@H]2C[C@@H]12
11439,CHEMBL3318482,GWYLMRVMCFHIIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2C#N)C3=C(C=CC=C3Br)Cl,5.301029995663981,N#Cc1ccccc1SC1=C(O)CC(c2c(Cl)cccc2Br)CC1=O
11441,CHEMBL3105228,GXBAKXRLQAPKEE-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24164599.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,"Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375).",J. Med. Chem.,PUBLICATION,,C1CN([C@]2(N1C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl)C(=O)C5=CC(=C(C=C5)F)F,4.795880017344075,O=C(c1ccc(F)c(F)c1)N1CCN2C(=O)c3ccccc3[C@@]12c1ccc(Cl)cc1
11445,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,5.481486060122113,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
11446,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,10600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,4.97469413473523,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
11458,CHEMBL284676,GXENRQLSQOSEPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)OC,4.0,COc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C
11467,CHEMBL3422073,GXKIHPXGVQZMIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1CC1C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)OC6CCN(CC6)C=O,5.823908740944319,O=CN1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccn5)C5CC5)cc34)cc2)CC1
11471,CHEMBL2011266,GXKRHWPFLHJAKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22148957.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 co-incubated with substrate,Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.,J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1F)N(C(=C2C3=CC=CNC3=O)C(=O)NS(=O)(=O)C4CC4)CC5=C(C=CC(=C5)F)F,4.698970004336019,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc(F)ccc3F)c2cc1F
11472,CHEMBL2011266,GXKRHWPFLHJAKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22148957.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated prior to substrate addition,Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.,J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1F)N(C(=C2C3=CC=CNC3=O)C(=O)NS(=O)(=O)C4CC4)CC5=C(C=CC(=C5)F)F,4.698970004336019,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc(F)ccc3F)c2cc1F
11497,CHEMBL3112857,GXZTVBBVCJUSKC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=CC=CC(=C21)C3=CN=CC=C3)C(=O)CC4=NC(=CC(=O)N4)N5CCOCC5,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3cccnc3)cccc21
11505,CHEMBL3604713,GYCQQTSTDOHQQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,12589.25,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,CC1=CC(=C2C=CC=C(C2=N1)C(=O)N)NCC3=CC=CC=C3C(F)(F)F,4.900000142057633,Cc1cc(NCc2ccccc2C(F)(F)F)c2cccc(C(N)=O)c2n1
11506,CHEMBL1095818,GYCWXDHHROKGSJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CSC(=N1)CN2C3=CC=CC=C3N=C2C4CCCN(C4)C5CCOCC5,5.301029995663981,Cc1csc(Cn2c(C3CCCN(C4CCOCC4)C3)nc3ccccc32)n1
11517,CHEMBL3422015,GYGRAOHPQAELJF-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,43000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=COC(=N5)C(C)C,4.366531544420414,CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)co1
11518,CHEMBL577316,GYHNFQYONGGRTE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,2840.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C2CN(CCC2=C1)C(=O)C34CC5CC(C3)CC(C5)(C4)C6=CC=C(C=C6)OCC(=O)NC7=CC=CC8=C7N=CC=C8)OC,5.546681659952962,COc1cc2c(cc1OC)CN(C(=O)C13CC4CC(C1)CC(c1ccc(OCC(=O)Nc5cccc6cccnc56)cc1)(C4)C3)CC2
11535,CHEMBL404289,GYNUNSOVAWLPHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C(N(C1)C(=O)CN2C3=C(C=CC(=C3)Cl)OC2=O)CN4CCOCC4)C5=CC=CC=C5,5.886056647693163,O=C(Cn1c(=O)oc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1
11536,CHEMBL1823591,GYNUQDKANQWZSX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21803580.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=NC(=NO2)C3=NC4=CC=CC=C4C=C3)C(=O)NC5=CC=CC=C5Cl,4.6020599913279625,O=C(Nc1ccccc1Cl)N1CCN(c2nc(-c3ccc4ccccc4n3)no2)CC1
11538,CHEMBL2062808,GYQHHRDRGBGZKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22594690.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779.",J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CC=C(C=C1)C2=CC=CN3C2=NC(=N3)NC4=CC(=CC=C4)N5CCC(CC5)N6CCOCC6,6.698970004336019,CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCC(N6CCOCC6)CC5)c4)nc23)cc1
11548,CHEMBL3262163,GYVJDAOHVCIKJN-XFULWGLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24814197.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,COC1=CC=C(C=C1)NC(=O)N2CCNC[C@@H]2COC3=CN=CC=C3.Cl,4.0,COc1ccc(NC(=O)N2CCNC[C@@H]2COc2cccnc2)cc1
11549,CHEMBL577103,GYVVGEZWBYIVER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,3790.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C2CN(CCC2=C1)C(=O)C34CC5CC(C3)CC(C5)(C4)C6=CC=C(C=C6)OCC(=O)NC7=CC=CC=C7C(=O)OC)OC,5.421360790031928,COC(=O)c1ccccc1NC(=O)COc1ccc(C23CC4CC(CC(C(=O)N5CCc6cc(OC)c(OC)cc6C5)(C4)C2)C3)cc1
11550,CHEMBL1077938,GYWHTWFXMMRVDZ-KYJUHHDHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,66.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@@H](CN(CC2=CN=CC=C2)C[C@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,7.180456064458132,O=C(N[C@@H](Cc1ccccc1)CN(Cc1cccnc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
11556,CHEMBL2348853,GYZYQCKKUYZJRF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)Cl)C,4.301029995663981,Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2ccc(Cl)cc21
11558,CHEMBL3702811,GZAPAWDCWTYELQ-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4870.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CC(C8)O,5.3124710387853655,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(O)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
11570,CHEMBL566875,GZLYPLRRKZCYLV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,41000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,4.3872161432802645,COc1cnc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
11571,CHEMBL566875,GZLYPLRRKZCYLV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,4.301029995663981,COc1cnc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
11581,CHEMBL2041175,GZOBVYAVRWIDTA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)C6=CC7=C(C=C6)SC=N7,4.301029995663981,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc4scnc4c3)cc1)C(=O)N2c1cc(=O)[nH]cn1
11586,CHEMBL254328,GZOSMCIZMLWJML-VJLLXTKPSA-N,ABIRATERONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,2704.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O,5.567993312730402,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1
11588,CHEMBL254328,GZOSMCIZMLWJML-VJLLXTKPSA-N,ABIRATERONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19211174.0,IC50,=,2704.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,"Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.",Eur. J. Med. Chem.,PUBLICATION,,C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O,5.567993312730402,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1
11589,CHEMBL254328,GZOSMCIZMLWJML-VJLLXTKPSA-N,ABIRATERONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O,5.568636235841013,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1
11590,CHEMBL254328,GZOSMCIZMLWJML-VJLLXTKPSA-N,ABIRATERONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O,5.568636235841013,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1
11625,CHEMBL2407955,GZXVWGBFYAAUGQ-CCFHIKDMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1C(C/C(=N\O)/C2=CC(=NC=C2)C)C3=CC=C(C=C3)C4=CC(=CC=C4)C(=O)O,4.301029995663981,Cc1cc(/C(CC(c2ccc(-c3cccc(C(=O)O)c3)cc2)c2ccccc2C)=N/O)ccn1
11670,CHEMBL3291422,HAXIOICGNCICAB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCC(F)F)N=C1,4.301029995663981,COc1ncnc(Cn2cc(C(=O)NCC(F)F)c3ncc(C)cc32)c1C
11672,CHEMBL237147,HAYIRZKTTMIXAL-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCO,6.318758762624412,CC(C)C[C@H](NCCO)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
11673,CHEMBL1921983,HAYOATKZZXIZAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,C1CC1NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C4(CCN5C4=CN=C5)O,5.0,O=C(NC1CC1)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
11678,CHEMBL9861,HBDKFZNDMVLSHM-UHFFFAOYSA-N,TIMOPRAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,309029.54,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)NC(=N2)S(=O)CC3=CC=CC=N3,3.5100000045692954,[O-][S+](Cc1ccccn1)c1nc2ccccc2[nH]1
11679,CHEMBL1945843,HBDLBTSITBUDIR-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22107017.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H3 receptor antagonists with potent cognition enhancing activity.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=CC(=O)N(N=C3)C4=CC=CC=N4,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(-c2cnn(-c3ccccn3)c(=O)c2)cc1
11700,CHEMBL45816,HBNPJJILLOYFJU-VMPREFPWSA-N,MIBEFRADIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,6.886056647693163,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C
11721,CHEMBL45816,HBNPJJILLOYFJU-VMPREFPWSA-N,MIBEFRADIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22409598.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks.,J. Med. Chem.,PUBLICATION,,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,6.522878745280337,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C
11724,CHEMBL45816,HBNPJJILLOYFJU-VMPREFPWSA-N,MIBEFRADIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,6.327902142064283,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C
11725,CHEMBL45816,HBNPJJILLOYFJU-VMPREFPWSA-N,MIBEFRADIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26231163.0,IC50,=,140000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method,Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,3.853871964321762,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C
11732,CHEMBL450668,HBOINTMVWRSZQS-SSEXGKCCSA-N,BMS-694153,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O,5.107905397309519,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
11733,CHEMBL450668,HBOINTMVWRSZQS-SSEXGKCCSA-N,BMS-694153,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O,4.585026652029182,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
11734,CHEMBL450668,HBOINTMVWRSZQS-SSEXGKCCSA-N,BMS-694153,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes assessed as metabolism of testosterone,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O,4.3979400086720375,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
11735,CHEMBL450668,HBOINTMVWRSZQS-SSEXGKCCSA-N,BMS-694153,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O,5.173925197299173,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
11736,CHEMBL450668,HBOINTMVWRSZQS-SSEXGKCCSA-N,BMS-694153,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O,4.585026652029182,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
11757,CHEMBL2059853,HBRMZOPADQKLOP-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C=C3)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.522878745280337,O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
11759,CHEMBL179477,HBSOMQPAIFVKGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,77540.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1=CC(=CN=C1)N2C=CN=C2,4.110474203328809,c1cncc(-n2ccnc2)c1
11760,CHEMBL179477,HBSOMQPAIFVKGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,109000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1=CC(=CN=C1)N2C=CN=C2,3.962573502059376,c1cncc(-n2ccnc2)c1
11786,CHEMBL1099326,HCBQJHASLYAXLH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,C1=CC(=C(C(=C1)OCCCC(=O)O)CCC(=O)O)CCCCCCOC2=CC(=CC(=C2)C3=CC=NC=C3)C4=CC=NC=C4,5.1249387366083,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccncc3)cc(-c3ccncc3)c2)c1CCC(=O)O
11812,CHEMBL2407897,HCLJFCCORISDCX-NLUXTTPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829549.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents.,J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC=C(C=C1)/C=C/C2=C3C=C/C(=C\C4=C(NC5=CC=CC=C54)O)/C=C3N=N2,5.0,CN(C)Cc1ccc(/C=C/C2=c3cc/c(=C\c4c(O)[nH]c5ccccc45)cc3N=N2)cc1
11813,CHEMBL2407897,HCLJFCCORISDCX-NLUXTTPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,=,940.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC=C(C=C1)/C=C/C2=C3C=C/C(=C\C4=C(NC5=CC=CC=C54)O)/C=C3N=N2,6.026872146400302,CN(C)Cc1ccc(/C=C/C2=c3cc/c(=C\c4c(O)[nH]c5ccccc45)cc3N=N2)cc1
11818,CHEMBL1835918,HCOIQQJHIUTQMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21907579.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NN=C(C=C1)N2CC(C2)COC3=CC=C(C=C3)C4=NOC(=N4)C,5.0,Cc1ccc(N2CC(COc3ccc(-c4noc(C)n4)cc3)C2)nn1
11819,CHEMBL1835918,HCOIQQJHIUTQMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21907579.0,IC50,>,50118.72,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NN=C(C=C1)N2CC(C2)COC3=CC=C(C=C3)C4=NOC(=N4)C,4.300000029139089,Cc1ccc(N2CC(COc3ccc(-c4noc(C)n4)cc3)C2)nn1
11828,CHEMBL3341815,HCVDCGIODJNTBK-XXBGQOOISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25148100.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver CYP3A4,Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).,J. Med. Chem.,PUBLICATION,,CC(C)[C@@H](C(=O)N1CCC[C@@H]1C2=NC=C(N2)C#CC#CC3=CC=C(C=C3)C4=CN=C(N4)[C@H]5CCCN5C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC.Cl,5.0,COC(=O)N[C@H](C(=O)N1CCC[C@@H]1c1ncc(C#CC#Cc2ccc(-c3cnc([C@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]3)cc2)[nH]1)C(C)C
11866,CHEMBL1951323,HDAZCZMFLGRFRE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,710.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC(=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,6.1487416512809245,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(F)c1
11867,CHEMBL2425155,HDCHOQUOIZCTAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=NN=CN4C,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nncn3C)cc2)cc1
11913,CHEMBL2064340,HDOZVDVCQITIFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,CCN1C2=CC=CC=C2N=C1CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,CCn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21
11935,CHEMBL3125381,HDZUKCNSPUYSLP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O)C=CC(=C2)F,4.3979400086720375,CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O
11937,CHEMBL2069800,HEACMNRMWPGIPI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,C1CC1N2C(=NN=C2SCC3=NN=C(O3)C4=CC(=NC=C4)Cl)C5=CC=NC=C5,4.698970004336019,Clc1cc(-c2nnc(CSc3nnc(-c4ccncc4)n3C3CC3)o2)ccn1
11939,CHEMBL496102,HEAIZQNMNCHNFD-UHFFFAOYSA-N,AMG-208,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,4100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,5.3872161432802645,COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
11940,CHEMBL496102,HEAIZQNMNCHNFD-UHFFFAOYSA-N,AMG-208,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,4.494850021680094,COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
11944,CHEMBL519300,HEBKCUAEAWNUQL-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,3.9,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N(C)C,8.4089353929735,Cc1cc(N2CCC(N(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
11945,CHEMBL1784356,HECFJRXDSZZJLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC(CC1)(CS(=O)(=O)N2CCN(CC2)C3=CC=C(C=C3)F)N(C=O)O,5.0,CN1CCC(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)(N(O)C=O)CC1
11946,CHEMBL2387604,HEDJFFINYDHRNV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CC=CO5)Cl,4.522878745280337,O=c1[nH]c2cc(-c3ccco3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
11960,CHEMBL372416,HEFYJBZEIVFECQ-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,455.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3[C@H](CNCC3=O)COC4=CC5=C(CCCN5CCCO)C=C4,6.341988603342887,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCCO)CCC3)cc1
11965,CHEMBL1241547,HEHHNIMMUJHLIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,<,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=C(N=C6CO5)C,5.3979400086720375,Cc1cn2c(n1)COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
11966,CHEMBL205457,HEILLZBUQBOKMO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,COC1=CC=CC=C1OC2=CC=CC(=C2)CN3CCC(CC3)NC(=O)C4(CCCCC4)C5=CC=C(C=C5)Cl,5.0,COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccc(Cl)cc4)CCCCC3)CC2)c1
11972,CHEMBL1796063,HELJPBHTIIYJPZ-RPWUZVMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21621998.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1Br)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC(=O)N(C=C4)C)CCCOC,5.187086643357144,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C
11973,CHEMBL1796063,HELJPBHTIIYJPZ-RPWUZVMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21621998.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone preincubated for 30 mins,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1Br)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC(=O)N(C=C4)C)CCCOC,4.795880017344075,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C
11974,CHEMBL1796063,HELJPBHTIIYJPZ-RPWUZVMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21621998.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1Br)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC(=O)N(C=C4)C)CCCOC,4.698970004336019,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C
11986,CHEMBL1951345,HENQQNHTKQZKIP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)NC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C=CN(C4=NC=N3)C,5.5376020021010435,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4c3ccn4C)cc2)c1
11991,CHEMBL2425145,HEQHRPBZBOEOFA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=C(N=C4)C,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(C)c3)cc2)cc1
11992,CHEMBL3627897,HERLNGSHQVSJKT-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25978966.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(N1)C=C(C=C2)[C@@H](CNC(=O)C3=C(C=C(C=C3Cl)N4C=NC(=N4)C)Cl)C5=CC(=CC=C5)F,4.301029995663981,Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3ccc4nc(C)[nH]c4c3)c(Cl)c2)n1
12000,CHEMBL2171398,HEVPKOFLFHIHOI-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861813.0,IC50,=,15.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel ß-amino acid derivatives as inhibitors of cathepsin A.,J. Med. Chem.,PUBLICATION,,CC1=CC=CC=C1[C@H](CC(=O)O)NC(=O)C2=NN(C(=C2)OCC3CC3)C4=CC=CC=C4F,7.823908740944319,Cc1ccccc1[C@H](CC(=O)O)NC(=O)c1cc(OCC2CC2)n(-c2ccccc2F)n1
12003,CHEMBL2441832,HEZZWSOOCHPSTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CC3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,6.045757490560675,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ccccc1)C2
12008,CHEMBL252210,HFBWMSOJXRBXJD-IFMALSPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCC5(CCN5)CC4,5.251811972993799,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC4(CCN4)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
12013,CHEMBL3234579,HFCRZUQHFUTZFW-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CCN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CC[C@H]3C(=O)NCCC4=CN=C(C=C4)C#N,5.107905397309519,CCN1CCN(c2cc(N3CC[C@H]3C(=O)NCCc3ccc(C#N)nc3)nc(C(F)(F)F)n2)CC1
12015,CHEMBL3137443,HFDMMKOMGWVDMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4400.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C(=O)C4=CC=C(C=C4)F,5.356547323513812,O=C(c1ccc(F)cc1)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
12020,CHEMBL2397311,HFFDHCIWKMSYST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)C2(CCCCC2)C)C3=CN=C(C=C3)N,4.769551078621726,Cc1nc(NC(=O)C2(C)CCCCC2)sc1-c1ccc(N)nc1
12039,CHEMBL1683000,HFJIPLBZCAJCMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21295471.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"A new structural alert for benzimidazoles: 2,6-dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1C2=NC3=C(N2)C=C(C=C3)C(=O)NC4=NC5=CC=CC=C5C=C4,4.301029995663981,Cc1ccccc1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1
12040,CHEMBL1683000,HFJIPLBZCAJCMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21295471.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome measured after 30 mins preincubation in presence of NADPH,"A new structural alert for benzimidazoles: 2,6-dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1C2=NC3=C(N2)C=C(C=C3)C(=O)NC4=NC5=CC=CC=C5C=C4,4.301029995663981,Cc1ccccc1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1
12048,CHEMBL402520,HFKOPAUXFQJXCN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,730.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C(N(C1)C(=O)CN2C(=O)COC3=CC(=C(C=C32)Cl)Cl)CN4CCOCC4)C5=CC=CC=C5,6.136677139879544,O=C1COc2cc(Cl)c(Cl)cc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1
12053,CHEMBL1091791,HFLPUFFCCFMOMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NC=C1)C(C)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,Cc1ccnc(C(C)c2c(CCN(C)C)sc3ccccc23)c1
12054,CHEMBL2441346,HFOKVVVCWLIUBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,20500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,CC1=CC(=NN1CC(=O)N2CCC3=C2C=CC(=C3F)C4=CN(C5=NC=NC(=C45)N)C)C,4.688246138944246,Cc1cc(C)n(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1
12055,CHEMBL2441346,HFOKVVVCWLIUBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,CC1=CC(=NN1CC(=O)N2CCC3=C2C=CC(=C3F)C4=CN(C5=NC=NC(=C45)N)C)C,4.6020599913279625,Cc1cc(C)n(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1
12059,CHEMBL2057789,HFPGPGDSWIYRPR-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,97.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)(C)O,7.013228265733755,CCNc1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)O)cc2o1
12064,CHEMBL1290746,HFTDLOVSQHYBFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21035336.0,IC50,>,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-amino-pyrazoles as potent and selective p38a inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)C(=O)NC2=NOC=C2)NC(=O)C3=C(N(N=C3)C4=CC=CC=C4F)N,4.886056647693163,Cc1ccc(C(=O)Nc2ccon2)cc1NC(=O)c1cnn(-c2ccccc2F)c1N
12066,CHEMBL1222650,HFUSFQGTWBGKDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,5.823908740944319,CC(C)Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
12082,CHEMBL3702799,HGEWYKGKUXXAQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)(C)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.377785977033705,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)(C)C)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
12086,CHEMBL500157,HGHDKUIVPHCCKQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18479916.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1CC(=O)NC(=O)NC2=CC(=C(C=C2)OC3=C(C(=NC=C3)N)C#CCO)F)F,6.154901959985743,Nc1nccc(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)c1C#CCO
12087,CHEMBL1951599,HGHVKBWSAOTJGC-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=CCN1C2=C(C(=C1N3CCC[C@@H](C3)N)C#N)N(C(=O)N(C2=O)CC4=NC=CC5=CC=CC=C54)C)C,5.522878745280337,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C
12088,CHEMBL1669421,HGLDEVLFUAEPJC-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,4840.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CO4,5.315154638355588,C[C@H](C1=C(CCN(C)Cc2ncco2)Cc2ccccc21)c1cnccn1
12089,CHEMBL1243305,HGLGWLWXYRAXPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20690643.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,C1CNCCC1C(CSC2=CC=C(C=C2)C(F)(F)F)C3=CN=CN3,4.769551078621726,FC(F)(F)c1ccc(SCC(c2cnc[nH]2)C2CCNCC2)cc1
12101,CHEMBL1172346,HGOSXKUMUKYUKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20570147.0,IC50,=,87.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3=CC=NC=C3)NC(=O)C4=NC=C(N4)C#N,7.060480747381382,N#Cc1cnc(C(=O)Nc2ccc(-c3ccncc3)cc2C2=CCCCC2)[nH]1
12109,CHEMBL1210434,HGSCTPUCDDAAQZ-OIDHKYIRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20579874.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)N(C1=CC=CC=C1)C2=CC(=CC(=C2)C(=O)N[C@@H](CC3=CC=CC=C3)[C@@H](CNCC4=CC(=CC=C4)C(F)(F)F)O)C5CCCC5,6.522878745280337,CS(=O)(=O)N(c1ccccc1)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)cc(C2CCCC2)c1
12110,CHEMBL1210434,HGSCTPUCDDAAQZ-OIDHKYIRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20579874.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)N(C1=CC=CC=C1)C2=CC(=CC(=C2)C(=O)N[C@@H](CC3=CC=CC=C3)[C@@H](CNCC4=CC(=CC=C4)C(F)(F)F)O)C5CCCC5,6.221848749616356,CS(=O)(=O)N(c1ccccc1)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)cc(C2CCCC2)c1
12117,CHEMBL1668259,HGULPEXUXHAGBL-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,49000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)[C@@H](C(=O)NC2=C(C=C(C=C2)C(=O)O)C(F)(F)F)N3C4=CC=CC=C4N=C3C5=CC=C(C=C5)Cl,4.309803919971486,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3ccccc32)c(C(F)(F)F)c1
12118,CHEMBL2151616,HGULSDBPQFERGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22975301.0,IC50,=,25000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azetidinyl oxadiazoles as potent mGluR5 positive allosteric modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1CCCCC1C(=O)N2CC(C2)C3=NC(=NO3)C4=CC(=CC=C4)F,1.6020599913279623,CC1CCCCC1C(=O)N1CC(c2nc(-c3cccc(F)c3)no2)C1
12130,CHEMBL3331504,HGXZDFUNUJFDRQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,810.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)N(CC2=CC=C(C=C2)Cl)C3CNC3,6.0915149811213505,Clc1ccc(CN(C2CCCCC2)C2CNC2)cc1
12133,CHEMBL2448744,HGZPMOZVQYACMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13040.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1=CC=C2C(=C1)N=C(S2)C3=CC=C(C=C3)N(CC4=CN=CC=C4)C(=O)CN,4.884722408604099,NCC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1
12156,CHEMBL3093462,HHJSGMINRSKVLO-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24215891.0,IC50,=,940.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H](CN1C=C(C2=CC=CC=C21)C)NS(=O)(=O)C3=C(C=C(C=C3Cl)Cl)N,6.026872146400302,CC[C@@H](Cn1cc(C)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl
12162,CHEMBL3353992,HHLPOWRWLBEWKR-PZGXJGMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25249180.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using diethoxyfluorescein as substrate after 10 mins by fluorescence assay,"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.",J. Med. Chem.,PUBLICATION,,C[C@H]1C[C@H](C2=C(N1C(=O)C)C=CC(=C2)C3=CC=C(C=C3)CN4CCCCC4)NC5=CC=CC=C5,5.698970004336019,CC(=O)N1c2ccc(-c3ccc(CN4CCCCC4)cc3)cc2[C@H](Nc2ccccc2)C[C@@H]1C
12163,CHEMBL3353992,HHLPOWRWLBEWKR-PZGXJGMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25249180.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using 7-benzloxyquinolone as substrate after 10 mins by fluorescence assay,"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.",J. Med. Chem.,PUBLICATION,,C[C@H]1C[C@H](C2=C(N1C(=O)C)C=CC(=C2)C3=CC=C(C=C3)CN4CCCCC4)NC5=CC=CC=C5,5.0,CC(=O)N1c2ccc(-c3ccc(CN4CCCCC4)cc3)cc2[C@H](Nc2ccccc2)C[C@@H]1C
12165,CHEMBL3287739,HHMPSPSPFJQPAI-MKPDMIMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24785301.0,IC50,=,501.19,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD.,J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C)C(=O)NC2CCC(CC2)NC(=O)C3=C(N=CC(=C3)F)OC4=CC=CC(=C4)C5=C(C=C(C=C5)O)CN6CCOCC6,6.299997602857746,Cc1cc(C(=O)NC2CCC(NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(O)cc4CN4CCOCC4)c3)CC2)nn1C
12168,CHEMBL200267,HHRJZEIOBZQYGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16297617.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1CC2=CN=CN2)CCCOC3=CC=CC=C3,4.698970004336019,c1ccc(OCCCN2CCC(Cc3cnc[nH]3)CC2)cc1
12171,CHEMBL3628113,HHRZBUWNLICHOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26426481.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,PUBLICATION,,CC1=C(OC=C1)C(=O)NC2=CC(=C(C=C2)N3C(=O)C4=C(C3=O)C(=CC=C4)F)Cl,4.522878745280337,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(F)c3C2=O)c(Cl)c1
12177,CHEMBL2204357,HHVBUSGGPUQAOP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=CC=C1)SC2=CC=CC=C2N3CCNCC3)C.Cl,5.060480747381382,Cc1cccc(Sc2ccccc2N2CCNCC2)c1C
12180,CHEMBL2048293,HHVPFOZVFPAJBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22633692.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Fused tricyclic indoles as S1P(1) agonists with robust efficacy in animal models of autoimmune disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2C3=C(C=C(C=C3)C4=NOC(=N4)C5=CC(=CC(=C5)C#N)OC(F)(F)F)C=C2C1CC(=O)O,4.522878745280337,N#Cc1cc(OC(F)(F)F)cc(-c2nc(-c3ccc4c(c3)cc3n4CCC3CC(=O)O)no2)c1
12187,CHEMBL397667,HHYOQRDAWFAMAJ-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)N[C@@H](CC4=CC=CC=C4)CO)Br,5.508638306165727,Cc1cc(Br)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12
12188,CHEMBL404622,HHYSIKMUKJWYNN-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=C(C=CC(=C1)F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,4.698970004336019,CC(C)(C)OC(=O)N[C@H](Cc1cc(F)ccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
12203,CHEMBL3581140,HIGGJLMBFDDVKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=CC(=NC=C3)N,4.585026652029182,COc1cccc(CC(=O)Nc2nc(-c3ccnc(N)c3)cs2)c1
12209,CHEMBL3393477,HIJNIPAQZUMXON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=CC(=C6F)F,4.468521082957745,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)c(F)ccc3[nH]2)o1
12224,CHEMBL1671918,HIPNUROOFUMNSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,CCCC(=O)NC1=CC=C(C=C1)C(=O)NC2=NC=CS2,4.3979400086720375,CCCC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
12225,CHEMBL1078264,HIQKQNMARNQIET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NCC2=CC=C(C=C2)C3=CC4=C(C=C3)NC=C4)C5=CC=CC=C5,5.0,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccc4[nH]ccc4c3)cc2)C1
12226,CHEMBL403268,HIQWWDCRULXYDF-SWROZOJRSA-N,GRL-8234,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18180160.0,IC50,=,696.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1)NC(=O)C2=CC(=CC(=C2)N(C)S(=O)(=O)C)C(=O)N[C@@H](CC3=CC=CC=C3)[C@@H](CNCC4=CC(=CC=C4)OC)O,6.157390760389438,COc1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)c2cc(C(=O)N[C@H](C)c3ccccc3)cc(N(C)S(C)(=O)=O)c2)c1
12227,CHEMBL1079481,HIRZFMOIKMLUHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC=C(C=C5)C(F)(F)F,5.0,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(C(F)(F)F)cc3)C2)n1C
12234,CHEMBL3234858,HIVDHOVSADNOOW-KWMCUTETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24630411.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1)N2C(=O)[C@@](OC2=O)(CC3=CC=CC=C3)C4=NN=C(O4)C5=CC(=CC(=C5)OC)OC,4.301029995663981,COc1cc(OC)cc(-c2nnc([C@@]3(Cc4ccccc4)OC(=O)N([C@H](C)c4ccccc4)C3=O)o2)c1
12239,CHEMBL2325503,HIWVLHPKZNBSBE-OUKQBFOZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473363.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Structural Basis and SAR for G007-LK, a Lead Stage 1,2,4-Triazole Based Specific Tankyrase 1/2 Inhibitor.",J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CN=C(C=C1)C2=NN=C(N2C3=CC=CC=C3Cl)/C=C/C4=NN=C(O4)C5=CC=C(C=C5)C#N,4.6020599913279625,CS(=O)(=O)c1ccc(-c2nnc(/C=C/c3nnc(-c4ccc(C#N)cc4)o3)n2-c2ccccc2Cl)nc1
12240,CHEMBL1672621,HIXMVSBRCJHLQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CN=CC=C3)C4=CC=NC=C4,5.301029995663981,O=C(Nc1cnc(-c2ccncc2)c(-c2cccnc2)n1)C1CC1
12244,CHEMBL2386629,HIXYDBSLZYKHEU-IJLUTSLNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1C4CCC(CC4)NCC(F)(F)F)C=CN3)O,5.0,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1C1CCC(NCC(F)(F)F)CC1
12245,CHEMBL2386629,HIXYDBSLZYKHEU-IJLUTSLNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1C4CCC(CC4)NCC(F)(F)F)C=CN3)O,5.0,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1C1CCC(NCC(F)(F)F)CC1
12250,CHEMBL3137468,HIYFVUVAYQAIHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1900.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)Cl)C3=CN=CC=C3)C(=O)C4=CC=CC=C4,5.721246399047171,O=C(c1ccccc1)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1
12257,CHEMBL3407774,HJBSZHIETZPEQW-NQWXTVAOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25422861.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,In vivo phenotypic screening for treating chronic neuropathic pain: modification of c2-arylethynyl group of conformationally constrained a3 adenosine receptor agonists.,J. Med. Chem.,PUBLICATION,,CNC1=C2C(=NC(=N1)C#CC3=NC=CN=C3)N(C=N2)[C@@H]4[C@H]5C[C@]5([C@H]([C@H]4O)O)C(=O)NC,5.0,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4cnccn4)nc31)[C@H](O)[C@@H]2O
12258,CHEMBL3114880,HJDCUVZLLHFFAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412066.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)OC(=O)N1CCC(CC1)N2C3=C(C=N2)C(=NC=N3)OC4=CC=C(C=C4)S(=O)(=O)C,5.221848749616356,CC(C)OC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1
12260,CHEMBL2111784,HJEPFPDXSFKWQH-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177482.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=CC=C1)NC2=NC=CC(=C2)C3=C(N=C(S3)C4CCN(CC4)C)C5=CC=C(C=C5)F,5.698970004336019,C[C@H](Nc1cc(-c2sc(C3CCN(C)CC3)nc2-c2ccc(F)cc2)ccn1)c1ccccc1
12281,CHEMBL271579,HJJVPARKXDDIQD-UHFFFAOYSA-N,BROMUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,C1C(COC1(CN2C=NC=N2)C3=C(C=C(C=C3)Cl)Cl)Br,6.886056647693163,Clc1ccc(C2(Cn3cncn3)CC(Br)CO2)c(Cl)c1
12284,CHEMBL2047188,HJKMXSQUWHPDOS-KRCBVYEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22704887.0,IC50,=,13800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of novel potent HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC(=C(N2)Cl)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=C(NC(=N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)Cl)NC(=O)OC,4.860120913598763,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc(-c3ccc(-c4nc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c4Cl)cc3)cc2)c(Cl)[nH]1)C(C)C
12292,CHEMBL1669408,HJNGVQMITVXZEN-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCF,5.0,C[C@H](C1=C(CCN(C)CCF)Cc2ccccc21)c1cnccn1
12311,CHEMBL2043144,HJQQACDTLSCNQF-FBHDLOMBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 3 mins prior to NAPDH-addition measured after 30 mins by RP-HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)CN2C=C(C=C(C2=O)/C(=C/C(=O)C(=O)O)/O)CC3=C(C=C(C=C3)F)F)F,3.6989700043360187,O=C(O)C(=O)/C=C(\O)c1cc(Cc2ccc(F)cc2F)cn(Cc2ccccc2F)c1=O
12312,CHEMBL2043144,HJQQACDTLSCNQF-FBHDLOMBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using triazolam as substrate incubated for 3 mins prior to NAPDH-addition measured after 30 mins by RP-HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)CN2C=C(C=C(C2=O)/C(=C/C(=O)C(=O)O)/O)CC3=C(C=C(C=C3)F)F)F,3.6989700043360187,O=C(O)C(=O)/C=C(\O)c1cc(Cc2ccc(F)cc2F)cn(Cc2ccccc2F)c1=O
12313,CHEMBL3628116,HJQXPBKPTGWZCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26426481.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,PUBLICATION,,C1=CC2=C(C(=C1)Cl)C(=O)N(C2=O)C3=C(C=C(C=C3)NC(=O)C4=C(C=CC=N4)Cl)Cl,4.522878745280337,O=C(Nc1ccc(N2C(=O)c3cccc(Cl)c3C2=O)c(Cl)c1)c1ncccc1Cl
12342,CHEMBL1094525,HJXPDUZXVIVZJB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)N2CCCC(C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,5.301029995663981,Fc1ccc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)cc1
12355,CHEMBL473326,HKDAECHYHSQLRG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,C1CC2=C(C1)N=C(NC2=O)SCC3=CC=C(C=C3)Cl,4.698970004336019,O=c1[nH]c(SCc2ccc(Cl)cc2)nc2c1CCC2
12356,CHEMBL473326,HKDAECHYHSQLRG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,C1CC2=C(C1)N=C(NC2=O)SCC3=CC=C(C=C3)Cl,4.698970004336019,O=c1[nH]c(SCc2ccc(Cl)cc2)nc2c1CCC2
12357,CHEMBL398430,HKDPOFYBYXNETQ-NOZRDPDXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)OC[C@H]3CCC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,5.920818753952375,O=C(OC[C@H]1CCC[C@@H](C2CC2)N1S(=O)(=O)c1ccc(Cl)cc1)N1CCC(N2CCCCC2)CC1
12366,CHEMBL490609,HKIDSMNVQATMCD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C2=CC=CC=C2C(C3=CC=CC=C3C1=O)CNC(=O)CNC(=O)C4=CC=C(C=C4)F,4.301029995663981,CN1C(=O)c2ccccc2C(CNC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc21
12370,CHEMBL3311223,HKIZMJLDZKXRKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,16000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C#N)C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F,4.795880017344075,N#Cc1ccc(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cc1
12371,CHEMBL3311223,HKIZMJLDZKXRKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16000.0,NM,253314,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",Metalloenzyme inhibitor compounds,,PATENT,,C1=CC(=CC=C1C#N)C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F,4.795880017344075,N#Cc1ccc(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cc1
12372,CHEMBL178873,HKJCSUNJDASSCM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(=O)O)N3C=CN=C3)N(C)C,5.657577319177793,CC(C(c1ccc2cc(OCC(=O)O)ccc2c1)n1ccnc1)N(C)C
12375,CHEMBL2058901,HKJYWDQSNKARFG-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,42.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N,7.376750709602099,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N)oc2c1
12377,CHEMBL557052,HKMFVKRDAUAEAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,>,10.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)C5=NC=CC=N5)CC(C)(C)C(=O)O,8.0,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3ncccn3)cc2)c2ccc(OCc3ccccn3)cc12
12378,CHEMBL3236361,HKMNSIXDWLMKFA-JVUUKAHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)C(=O)O,4.568636235841013,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)C(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
12381,CHEMBL3581138,HKOLLRSMOQGSSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=NC=NC=C3,5.698970004336019,COc1cccc(CC(=O)Nc2cc(-c3ccncn3)cs2)c1
12382,CHEMBL456807,HKOOXMFOFWEVGF-UHFFFAOYSA-N,PHENYLHYDRAZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,900.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C1=CC=C(C=C1)NN,6.045757490560675,NNc1ccccc1
12395,CHEMBL3394721,HKRNGLFQUVCSOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4)C5CCOCC5,5.0,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2ccncc2o1
12396,CHEMBL3394721,HKRNGLFQUVCSOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4)C5CCOCC5,5.0,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2ccncc2o1
12414,CHEMBL2207044,HLADQIZFAZEQAS-PUSSPCMTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CCOC)C)C)O)C)C(C)(C)O,5.958607314841775,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CCOC)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
12423,CHEMBL375955,HLCPJLIYGNWTAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)Cl)NC2=NC=C(C(=N2)C(F)(F)F)C(=O)NCC3=CC=NC=C3,7.0,O=C(NCc1ccncc1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
12440,CHEMBL2159130,HLHNWIOLRRCKAX-RYJGLGLWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,1330.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](NC(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NCCCSC)O4)C)(C)OC)C)C)O)(C)O,5.876148359032914,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NCCCSC)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O
12441,CHEMBL2159130,HLHNWIOLRRCKAX-RYJGLGLWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](NC(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NCCCSC)O4)C)(C)OC)C)C)O)(C)O,5.0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NCCCSC)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O
12450,CHEMBL465956,HLKTZTOQJFCERL-IKJXHCRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19181519.0,IC50,=,65000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(CCN1S(=O)(=O)C2=CC=C(C=C2)C(C)(C(F)(F)F)O)CC3(CCC3)C(=O)N,4.187086643357144,C[C@@H]1CN(CC2(C(N)=O)CCC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1
12461,CHEMBL258502,HLMBXBGDBBCYII-UHFFFAOYSA-N,SK&F-96365,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,45.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,COC1=CC=C(C=C1)CCCOC(CN2C=CN=C2)C3=CC=C(C=C3)OC,7.346787486224656,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1
12463,CHEMBL2181313,HLNMMXYNDBSAPI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21604762.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.",J. Med. Chem.,PUBLICATION,,COC1=C2COCC=CCOCC3=C(C=CC(=C3)NC4=NC=CC(=N4)C(=C2)C=C1)OCCN5CCCC5,5.0,COc1ccc2cc1COCC=CCOCc1cc(ccc1OCCN1CCCC1)Nc1nccc-2n1
12468,CHEMBL3673966,HLNUKOUNRKYWML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320636,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(C=CN=C4)C(F)(F)F)F)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3F)c2c1
12469,CHEMBL3673966,HLNUKOUNRKYWML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320680,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(C=CN=C4)C(F)(F)F)F)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3F)c2c1
12482,CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,61000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,4.214670164989233,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
12483,CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,88000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,4.055517327849832,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
12484,CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,4.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
12485,CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,4.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
12486,CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,5.045757490560675,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
12487,CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,5.045757490560675,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
12491,CHEMBL563949,HLSYGDSWXJGENX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19592244.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C2=C(N1S(=O)(=O)C3=CC(=C(C=C3)F)F)N=CC=C2)CC(=O)O,5.0,Cc1c(CC(=O)O)c2cccnc2n1S(=O)(=O)c1ccc(F)c(F)c1
12499,CHEMBL1641808,HLWCJDUVRWNSEA-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21185722.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azaindoles as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=C(N2C1)N=CC=C3)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.301029995663981,CN([C@@H]1CCc2c(CC(=O)O)c3cccnc3n2C1)S(=O)(=O)c1ccc(F)cc1
12501,CHEMBL494916,HLWJGXQCGMRQQG-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,C[C@H]1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5N)C,4.920818753952375,Cc1ccc2c(N)noc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1
12502,CHEMBL3400449,HLXHCRZAVCFDIS-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NC(=O)OCC2CCCCC2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,5.494850021680094,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCC2CCCCC2)C(C)C)ccc1OC
12503,CHEMBL3400449,HLXHCRZAVCFDIS-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NC(=O)OCC2CCCCC2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,5.468521082957745,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCC2CCCCC2)C(C)C)ccc1OC
12512,CHEMBL471757,HLZVKJIKNRQXFG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19231183.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)CNC1=C(C(=NC(=N1)C#N)N2CCOCC2)N,5.0,CC(C)(C)CNc1nc(C#N)nc(N2CCOCC2)c1N
12525,CHEMBL1078122,HMEXQGCRIYZAFX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,91.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC(CC1=CC=C(C=C1)O)NC(=O)OCC2=CN=CS2)CC(CC3=CC=C(C=C3)O)NC(=O)OCC4=NC=CS4,7.040958607678906,CCN(CC(Cc1ccc(O)cc1)NC(=O)OCc1cncs1)CC(Cc1ccc(O)cc1)NC(=O)OCc1nccs1
12534,CHEMBL384536,HMICMRQBKBXVSC-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CC3=CNC4=C3C=CC=N4)C(=O)N5C[C@@H](CO5)O)C(=O)N(C1=O)C,4.823908740944319,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3c[nH]c4ncccc34)sc21
12540,CHEMBL1648,HMJIYCCIJYRONP-UHFFFAOYSA-N,ISRADIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC,4.522878745280337,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12
12547,CHEMBL3125537,HMKAZNCSHAJLSA-HIJQLYNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)O,4.568636235841013,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
12550,CHEMBL3125537,HMKAZNCSHAJLSA-HIJQLYNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,0.0962,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Homogenous Time-Resolved Fluorescence Assay (HTRF). The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",Benzoic acid derivative MDM2 inhibitor for the treatment of cancer,,PATENT,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)O,10.016824927962187,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
12574,CHEMBL3702735,HMTKWBHPXLSHBK-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16360.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCOCCO,4.786216700664696,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCOCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
12576,CHEMBL576457,HMUIATLYRCNFSD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)C(C)(C)C,5.301029995663981,CC1(CC(=O)NCc2ccc(C(C)(C)C)cc2)CC2(CCCCC2)OO1
12581,CHEMBL3699323,HMVQIFYVRUUARJ-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15970.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC=CC(=C8)C(=O)N,4.7966950838615166,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(C(N)=O)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
12602,CHEMBL17962,HNDVDQJCIGZPNO-YFKPBYRVSA-N,HISTIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=C(NC=N1)C[C@@H](C(=O)O)N,5.0,N[C@@H](Cc1cnc[nH]1)C(=O)O
12603,CHEMBL17962,HNDVDQJCIGZPNO-YFKPBYRVSA-N,HISTIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=C(NC=N1)C[C@@H](C(=O)O)N,5.0,N[C@@H](Cc1cnc[nH]1)C(=O)O
12650,CHEMBL3702765,HNTUEHPJUVJGOY-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5120.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(=O)N1CCC(CC1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.29073003902417,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(C)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
12656,CHEMBL509440,HOAMIPKTWNMGQI-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCC(=O)O)C4=C(C(=CC=C4)OC)F,4.443697499232712,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCC(=O)O)c3ccccc3)c2=O)c1F
12659,CHEMBL239074,HOBWYNFQYPRIDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,590.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C4=CC=C(C=C4)Cl,6.229147988357856,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1ccc(Cl)cc1)O2
12660,CHEMBL3114724,HOCVGRINDQNQSX-XIFFEERXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,240.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N(CCCCN(CC2=CC=CC=C2)C(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.619788758288394,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(CCCCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
12679,CHEMBL3664696,HOIIUDAZGJZKGR-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,29000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C(F)F)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.5376020021010435,C[C@@H](c1ccc(-c2ccn(C(F)F)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
12704,CHEMBL3344121,HOUNMJYTCWEHQD-WGQHWTFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25300820.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using AMMC by fluorescence assay,"Chemical synthesis, cytotoxicity, selectivity and bioavailability of 5a-androstane-3a,17ß-diol derivatives.",Bioorg. Med. Chem.,PUBLICATION,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCN(CC5)C(=O)[C@@H]6CCCN6C(=O)C7=NC8=CC=CC=C8C=C7)C,5.42021640338319,C#C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@@H](N5CCN(C(=O)[C@@H]6CCCN6C(=O)c6ccc7ccccc7n6)CC5)C[C@]4(C)[C@H]3CC[C@@]21C
12707,CHEMBL1092813,HOUUGSUKNBXWNT-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC=N1)[C@@H](C)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,Cc1ncccc1[C@@H](C)c1c(CCN(C)C)sc2ccccc12
12717,CHEMBL486757,HOWZJLASEFUNIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18823779.0,IC50,>,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC1=CC2=C(C=C1)N(C(=N2)NC(=O)C3=CC=C(C=C3)C#N)CCCOC)C4CCCCC4,4.853871964321762,COCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(CN(C)C3CCCCC3)ccc21
12718,CHEMBL256721,HOXGYLKYFIXRJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C)N(C(=O)C=N2)CC(=O)N3CCCC(C3CN4CCOCC4)C5=CC=CC=C5,5.568636235841013,Cc1cc2ncc(=O)n(CC(=O)N3CCCC(c4ccccc4)C3CN3CCOCC3)c2cc1C
12719,CHEMBL1669413,HOXVEGPFZJNLIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,5.0,c1ccc2c(c1)CC(CCN1CCCC1)=C2Cc1cnccn1
12726,CHEMBL2425952,HPCPCLJRBNRLLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23905680.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using Vivid BOMR as substrate,Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.,J. Med. Chem.,PUBLICATION,,CCC1=NC2=C(C=CC=C2C(=O)N1CCC3=CC=CC=C3)CC4=CC=C(C=C4)C(=O)NO,7.0,CCc1nc2c(Cc3ccc(C(=O)NO)cc3)cccc2c(=O)n1CCc1ccccc1
12727,CHEMBL3114739,HPCUDPZRFYSGPP-AEHIRBQFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,460.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)NC(CC3=CC=CC=C3)CN(CC4=CC=CC=C4)C(=O)OCC5=CN=CS5,6.337242168318426,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)NC(Cc2ccccc2)CN(Cc2ccccc2)C(=O)OCc2cncs2)cs1
12728,CHEMBL3114739,HPCUDPZRFYSGPP-AEHIRBQFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)NC(CC3=CC=CC=C3)CN(CC4=CC=CC=C4)C(=O)OCC5=CN=CS5,6.301029995663981,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)NC(Cc2ccccc2)CN(Cc2ccccc2)C(=O)OCc2cncs2)cs1
12732,CHEMBL1210552,HPGPGSLIDVUPKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC=C(C=C5)S(F)(F)(F)(F)F,5.0,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C
12733,CHEMBL1210552,HPGPGSLIDVUPKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC=C(C=C5)S(F)(F)(F)(F)F,5.0,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C
12744,CHEMBL2441840,HPJPGGHVDQQGCO-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)C[C@@H]3CCCN3)C4=C(C=C(C=C4)Cl)Cl)CN,4.3979400086720375,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCN1)C2
12751,CHEMBL1923122,HPNCTFIRUULSCT-NEEKEDPPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC=CC2=C1C(=CC=C2)CN(C3CC3)C(=O)[C@H]4CNCC[C@]45C6=CC(=C(C=C6CO5)F)F,4.823908740944319,COCCCc1cccc2cccc(CN(C(=O)[C@H]3CNCC[C@@]34OCc3cc(F)c(F)cc34)C3CC3)c12
12772,CHEMBL1092651,HPVUAGMZZRSSHI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NC=CN=C3OC,5.0,COc1nccnc1CC1=C(CCN(C)C)Cc2cc(F)ccc21
12773,CHEMBL228133,HPWBHQIUIBFTQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17451235.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.,J. Med. Chem.,PUBLICATION,,C1CNCCC1(C2=CC=C(C=C2)C3=C4C(=NC=N3)N=CN4)C5=CC=C(C=C5)Cl,5.0,Clc1ccc(C2(c3ccc(-c4ncnc5nc[nH]c45)cc3)CCNCC2)cc1
12782,CHEMBL3672586,HQAFPESZZWFRFI-XDUPDYOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,170.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)NC,6.769551078621726,CN[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1
12783,CHEMBL3672586,HQAFPESZZWFRFI-XDUPDYOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,360.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)NC,6.443697499232713,CN[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1
12793,CHEMBL3408951,HQCQFKQGMPBYGP-HQXRPOMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)/C=C/C2=NNC3=C2C=CC(=C3)[C@@H]4C[C@]45C6=C(C=CC(=C6)OC)N(C5=O)C)N7CCOCC7,6.346787486224656,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc([C@H](C)N5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C
12794,CHEMBL3408951,HQCQFKQGMPBYGP-HQXRPOMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)/C=C/C2=NNC3=C2C=CC(=C3)[C@@H]4C[C@]45C6=C(C=CC(=C6)OC)N(C5=O)C)N7CCOCC7,4.958607314841775,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc([C@H](C)N5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C
12799,CHEMBL3608740,HQFWWFCJWZXHFM-SNVBAGLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=CC=C3)C4=NC(=NS4)C,4.508638306165727,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccccc2)[C@@H]3C)n1
12823,CHEMBL477387,HQMMZOJQYXBMCZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=N4,4.4089353929735005,O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3
12824,CHEMBL477387,HQMMZOJQYXBMCZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,77000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=N4,4.113509274827518,O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3
12830,CHEMBL1867804,HQPRJYQZDYZZOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22260203.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,PUBLICATION,,CC1=NN=C(N1C2=CC=C(C=C2)OC)SCC3=NC(=NO3)C4=CC(=C(C=C4)OC)OC,5.275724130399211,COc1ccc(-n2c(C)nnc2SCc2nc(-c3ccc(OC)c(OC)c3)no2)cc1
12848,CHEMBL2010883,HQXPCHZUQMTZKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22366657.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CC2=C(C=CC3=C2N=C(N3)C4=CC=CC=C4)F,4.522878745280337,Fc1ccc2[nH]c(-c3ccccc3)nc2c1CN1CCCC1
12868,CHEMBL552061,HRCSHGYOQCEMTF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC(=NO2)C3=NC=CC4=CC=CC=C43)C(=O)NC5CC5C6=CC=CC=C6,5.0,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3nccc4ccccc34)no2)CC1
12884,CHEMBL2425605,HRIOTEGBWIQIPA-ZZSUWZICSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)CN1C=C(C=N1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F,5.443697499232713,COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cnn(CC(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F
12892,CHEMBL272980,HRNLUBSXIHFDHP-UHFFFAOYSA-N,MOCETINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,=,570.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4,6.2441251443275085,Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1
12905,CHEMBL2387501,HRSOWEMVVPAURP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)C(F)(F)F,5.1249387366083,O=c1[nH]c2cc(-c3ccccc3)ccc2c2nc(-c3c(Cl)cccc3C(F)(F)F)[nH]c12
12907,CHEMBL178534,HRTKQHILWNVFIX-KPKJPENVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CC=C(S2)/C=N/O,4.886056647693163,O/N=C/c1ccc(-c2cccnc2)s1
12910,CHEMBL2018916,HRUYBRGMRSNLNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,8860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)CSC2=NC3=C(N2)C=C(C=C3)OC,5.052566278112949,COc1ccc2nc(SCc3ccc(C)cc3)[nH]c2c1
12913,CHEMBL562926,HRXSTBZYYQOBSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CC2=CC=CC=C2CCC1NC(=O)N3CCC(CC3)C4=NC(=NO4)C5=CC=CC=N5,5.0,O=C(NC1CCc2ccccc2CC1)N1CCC(c2nc(-c3ccccn3)no2)CC1
12916,CHEMBL257415,HRYXMTQIDOBCMH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C)N(C(=O)C=N2)CC(=O)N3CCCC(C3CN4CCCC4)C5=CC=CC=C5,5.167491087293763,Cc1cc2ncc(=O)n(CC(=O)N3CCCC(c4ccccc4)C3CN3CCCC3)c2cc1C
12922,CHEMBL477611,HSCPAFQDYZFJML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=C2C=CC(=CC2=NN1)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,5.119186407719209,Cc1[nH]nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12
12923,CHEMBL477611,HSCPAFQDYZFJML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=C2C=CC(=CC2=NN1)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,4.795880017344075,Cc1[nH]nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12
12943,CHEMBL236731,HSIYJWUPHNPTOY-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N,6.769551078621726,CC(C)C[C@H](N)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
12957,CHEMBL2059794,HSLRVLOIHHUQLE-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC(=C(C(=C3)Br)O)Br)NC(=O)N4CCC(CC4)N5C6=CC=CC=C6NC5=O,5.619788758288394,O=C(N[C@H](Cc1cc(Br)c(O)c(Br)c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
12978,CHEMBL1412368,HSNSQMGDNFKEES-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21375347.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis.",J. Med. Chem.,PUBLICATION,,C1C(=O)N(C(=O)N(C1=O)CCC2=CC=CC=C2)CCC3=CC=CC=C3,4.301029995663981,O=C1CC(=O)N(CCc2ccccc2)C(=O)N1CCc1ccccc1
12985,CHEMBL2436321,HSRCYVWMJRQEPM-OGZMHEHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=CC=CC4=CC=CC=C43)C(=O)CC(C)C)NC.Cl,5.7447274948966935,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2cccc3ccccc23)C1=O
13012,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,217270.12,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,3.66299999577514,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13018,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,7.0,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13019,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,7.0,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13020,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,5.0915149811213505,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13021,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,5.017728766960431,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13022,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,4.920818753952375,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13023,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,4.721246399047171,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13024,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,4.443697499232712,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13025,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,4.207608310501746,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13026,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,80000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,4.096910013008056,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13027,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,4.0,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13028,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,110000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,3.958607314841775,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13029,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,110000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,3.958607314841775,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13030,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,146000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,3.835647144215563,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13031,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,190000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,3.721246399047171,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13032,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,220000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,3.657577319177794,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13033,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,220000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,3.657577319177794,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13049,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1836.6,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,5.735985420019022,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
13059,CHEMBL193816,HSXYVWHEMSHBBB-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,35.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCN1C(=O)CCC2=C1C=C(C=C2)OC[C@H]3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,7.455931955649724,COCCCN1C(=O)CCc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21
13080,CHEMBL3115061,HTGQYRRHOSKREA-NLWFPOLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 10 to 30 mins,,ACS Med. Chem. Lett.,PUBLICATION,,C1/C=C/COC2=CC(=C(C=C2)Cl)C(=O)N[C@@H](CC3=CN1C=N3)C(=O)O.Cl,4.522878745280337,O=C1N[C@H](C(=O)O)Cc2cn(cn2)C/C=C/COc2ccc(Cl)c1c2
13081,CHEMBL501329,HTGWEIMTGKBAKN-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,69000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCC(=O)O)C4=C(C(=CC=C4)OC)F,4.161150909262744,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCC(=O)O)c3ccccc3)c2=O)c1F
13100,CHEMBL2159210,HTMCBXLLCSRXLQ-GHMZBOCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22698084.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 using midazolam as substrate,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,CC1=NC2=CN=C3C(=C2N1[C@@H]4CCC[C@H](C4)O)C=CN3,5.0,Cc1nc2cnc3[nH]ccc3c2n1[C@@H]1CCC[C@@H](O)C1
13101,CHEMBL2159210,HTMCBXLLCSRXLQ-GHMZBOCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22698084.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 using testosterone as substrate,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,CC1=NC2=CN=C3C(=C2N1[C@@H]4CCC[C@H](C4)O)C=CN3,5.0,Cc1nc2cnc3[nH]ccc3c2n1[C@@H]1CCC[C@@H](O)C1
13109,CHEMBL1016,HTQMVQVXFRQIKW-UHFFFAOYSA-N,CANDESARTAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,5.045757490560675,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
13114,CHEMBL1939222,HTSQRRQNKJNSLH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22191331.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.,J. Med. Chem.,PUBLICATION,,C1=C(C=C(C=C1Cl)Cl)OCC2=CC(=O)NN2,4.301029995663981,O=c1cc(COc2cc(Cl)cc(Cl)c2)[nH][nH]1
13115,CHEMBL1939222,HTSQRRQNKJNSLH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22191331.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.,J. Med. Chem.,PUBLICATION,,C1=C(C=C(C=C1Cl)Cl)OCC2=CC(=O)NN2,4.301029995663981,O=c1cc(COc2cc(Cl)cc(Cl)c2)[nH][nH]1
13117,CHEMBL1092238,HTXMSBSZASVVFP-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by P450-Glo method,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=CC=CC=C4Cl,5.0,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3Cl)CC2)C1
13118,CHEMBL3291424,HTYQZSAJLSHXHT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC(F)F)C)C(=O)NCCO)N=C1,4.301029995663981,Cc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(OC(F)F)c3C)c2c1
13130,CHEMBL555260,HUDSSSKDWYXKGP-UHFFFAOYSA-N,2-ANILINOPYRIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,430526.61,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)NC2=CC=CC=N2,3.366000000496014,c1ccc(Nc2ccccn2)cc1
13131,CHEMBL1223237,HUDWMNWXZIMODJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)N2CCCN(CC2)C(C3=CC4=C(C=C3)OC=C4)C5=NN=NN5CC6=CC=CC=C6,5.619788758288394,c1ccc(Cn2nnnc2C(c2ccc3occc3c2)N2CCCN(C3CCC3)CC2)cc1
13134,CHEMBL476312,HUGQKIWTNMQGCP-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621528.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,5.522878745280337,CS(=O)(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
13153,CHEMBL2017112,HUNKRAKTFQRWLG-HAPXSTRYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)[C@H]3CNCC[C@@]3(C4=CC(=C(C=C4)F)F)OCC(CO)O)Br,4.301029995663981,CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(OCC(O)CO)c2ccc(F)c(F)c2)c1Br
13163,CHEMBL1672630,HUPNMGIBODMDOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CC=NC=C3)C4=C(C=NC=C4)F,6.0,O=C(Nc1cnc(-c2ccncc2F)c(-c2ccncc2)n1)C1CC1
13164,CHEMBL1669427,HUPZZDHJGMFMTN-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4CCOCC4,5.0,C[C@H](C1=C(CCN(C)CC2CCOCC2)Cc2ccccc21)c1cnccn1
13178,CHEMBL3702825,HUUMXLZSQBAKBN-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2090.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC8=CC=CC=C8N=C7,5.679853713888946,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cnc6ccccc6c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
13183,CHEMBL489479,HUZVCBYMIXTYBP-OYRHEFFESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C(C)(C)C(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,5.327902142064283,C[C@H]1CN(Cc2ccc(C(C)(C)C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
13197,CHEMBL3422242,HVEVDFRWOQHAPJ-CKMNQQOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,C[C@@H]1[C@@H]2C[C@@H](OC[C@@]2(N=C(S1)N)C3=C(C=C(C=C3)F)F)C4=CC(=NO4)C,4.522878745280337,Cc1cc([C@H]2C[C@H]3[C@@H](C)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1
13203,CHEMBL3706711,HVJDCVDGPGBRLJ-KFIZHRIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)COC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](CN3CCN(C[C@H]3C(=O)NC(C)(C)C)CC4=CC=CC5=C4COC5)O,4.920818753952375,CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cccc4c3COC4)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1
13216,CHEMBL1939559,HVQPVIBEPUHUPH-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22130135.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and specific CXCR3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F,5.0,C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(Cl)cc1)N(CC1CCS(=O)(=O)CC1)C(=O)Cc1ccc(F)c(C(F)(F)F)c1
13220,CHEMBL1923132,HVSAPLYLNVBLPG-MYVCOICNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=C(C(=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F)Cl)CCC(=O)N6CCOCC6,5.552841968657781,COCCCc1cc(CCC(=O)N2CCOCC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1
13231,CHEMBL1682888,HVVULDASPWETLY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)C)(C3=CN=CN3)O,5.853871964321762,CC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
13241,CHEMBL221401,HWCBLDPYKRZMKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17352462.0,IC50,>,100000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect cells,"Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).",J. Med. Chem.,PUBLICATION,,C1CN(CCC1N2CC(NC2=O)(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)CC5=CC(=CC=C5)F,4.0,O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2cccc(F)c2)CC1
13274,CHEMBL105592,HWLBLFBLGGVDBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497764.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in liver microsomes,"Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)C(=O)C2=CN(C=C2C3=CC=CC4=CC=CC=C43)CC5=CN=CN5CC6=CC7=C(C=C6)OCO7,6.853871964321762,CN1CCN(C(=O)c2cn(Cc3cncn3Cc3ccc4c(c3)OCO4)cc2-c2cccc3ccccc23)CC1
13279,CHEMBL3629741,HWLVLRSTFUBCSW-CVDCTZTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@@]2([C@@H](COC3=C(C=CC(=C32)F)F)C4(C1)CCS(=O)(=O)CC4)S(=O)(=O)C5=CC=C(C=C5)Cl,4.698970004336019,O=S1(=O)CCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CC1
13280,CHEMBL3629741,HWLVLRSTFUBCSW-CVDCTZTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@@]2([C@@H](COC3=C(C=CC(=C32)F)F)C4(C1)CCS(=O)(=O)CC4)S(=O)(=O)C5=CC=C(C=C5)Cl,4.698970004336019,O=S1(=O)CCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CC1
13283,CHEMBL404451,HWOKKMFQJSXDKU-XRKRLSELSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@@H]4[C@@H](N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,4.3979400086720375,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)cc1
13284,CHEMBL404451,HWOKKMFQJSXDKU-XRKRLSELSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@@H]4[C@@H](N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,4.3979400086720375,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)cc1
13285,CHEMBL256468,HWOKKMFQJSXDKU-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,4.552841968657781,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)cc1
13286,CHEMBL256468,HWOKKMFQJSXDKU-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,4.3979400086720375,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)cc1
13297,CHEMBL3087349,HWRMSAWZMPETAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=NN=CO2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,4.568636235841013,O=S(=O)(Nc1ccc(-c2nnco2)cc1)c1cc(Cl)cc(Cl)c1
13298,CHEMBL2380644,HWRSTJLFROXQGG-TUWUEMEQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)N3CCN(C4=CC=CC=C43)C(=O)NC5C6CC7CC5CC(C7)(C6)C(=O)N,5.0,CS(=O)(=O)N1CCN(c2ccc(N3CCN(C(=O)NC4C5CC6CC4CC(C(N)=O)(C6)C5)c4ccccc43)cc2)CC1
13314,CHEMBL2181330,HWXVIOGONBBTBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21604762.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.",J. Med. Chem.,PUBLICATION,,C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,5.301029995663981,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC1
13316,CHEMBL254918,HWYCIQPXYXDOBI-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,820.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1C(F)(F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,6.086186147616283,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
13320,CHEMBL286272,HXAMYHYXTZMWQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998323.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CCNC(=O)C1=C2CCCCN2C3=C1N=CN=C3N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,4.0,CCNC(=O)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2
13327,CHEMBL2035183,HXETYVYQZULBML-ONEGZZNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22339472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.",J. Med. Chem.,PUBLICATION,,C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC=C(S4)C5=NC(=NC=C5)NC(=C3)C=C2,5.0,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(s2)COC/1
13344,CHEMBL1483,HXHWSAZORRCQMX-UHFFFAOYSA-N,ALBENDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,4.522878745280337,CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
13352,CHEMBL1209623,HXLCTJVFRQYWNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=CS3,7.167491087293763,CC(C)CC1n2cncc2CN(Cc2cccs2)S1(=O)=O
13353,CHEMBL1209623,HXLCTJVFRQYWNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,1160.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=CS3,5.935542010773082,CC(C)CC1n2cncc2CN(Cc2cccs2)S1(=O)=O
13362,CHEMBL2420677,HXMFOYHQXLDGBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,1009.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,COC1=C(C2=C(C=CC(=C2Cl)C3=CN=CC=C3)C=C1)F,5.996108833763089,COc1ccc2ccc(-c3cccnc3)c(Cl)c2c1F
13364,CHEMBL2022495,HXNBYYPGRZHDKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22503248.0,IC50,=,48000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Identification of a series of 1,3,4-oxadiazol-2-amines as potent alpha-7 agonists with efficacy in the novel object recognition model of cognition.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=CC(=C1)NC(=O)C2=CC=CC=C2F)C3=NN=C(O3)NCCCN4CCCCC4,4.318758762624412,COc1cc(NC(=O)c2ccccc2F)ccc1-c1nnc(NCCCN2CCCCC2)o1
13365,CHEMBL2022495,HXNBYYPGRZHDKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22503248.0,IC50,=,76000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Identification of a series of 1,3,4-oxadiazol-2-amines as potent alpha-7 agonists with efficacy in the novel object recognition model of cognition.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=CC(=C1)NC(=O)C2=CC=CC=C2F)C3=NN=C(O3)NCCCN4CCCCC4,4.119186407719209,COc1cc(NC(=O)c2ccccc2F)ccc1-c1nnc(NCCCN2CCCCC2)o1
13366,CHEMBL3358006,HXNOCBIFNWVJLT-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25286150.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by high throughput fluorescence assay,Circumventing Seizure Activity in a Series of G Protein Coupled Receptor 119 (GPR119) Agonists.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C2=NC=C(C=N2)OCC3=C(C=C(C=C3)CS(=O)(=O)C)F)C4=NC(=NO4)C(F)(F)F,5.0,C[C@@H]1CN(c2nc(C(F)(F)F)no2)CCN1c1ncc(OCc2ccc(CS(C)(=O)=O)cc2F)cn1
13378,CHEMBL1258308,HXPHDFPROQRYEG-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC3=C(C=C2)N4CCNC(=O)C4=C3,4.301029995663981,C[C@@H]1CCCN1CCCOc1ccc2c(c1)cc1n2CCNC1=O
13379,CHEMBL2041173,HXQJWMVKPWEYDZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC7=C(C=C6)NN=C7,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc5[nH]ncc5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
13384,CHEMBL205710,HXSAWRBPCYILHG-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](COC)O)C,6.0,COC[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C
13396,CHEMBL1770317,HXVAXOYPIPUCRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50118.72,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)C1(C(=O)NC(=O)O1)C2=CC=C(NC2=O)C3=CC4=CC=CC=C4C=C3,4.300000029139089,CC(C)C1(c2ccc(-c3ccc4ccccc4c3)[nH]c2=O)OC(=O)NC1=O
13398,CHEMBL402303,HXWCQEQIPYCSAM-QPPBQGQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18420409.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,2-Aminomethyl piperidines as novel urotensin-II receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC(=O)N1CCC[C@@H]([C@@H]1CN2CCCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,5.853871964321762,CN(CC(=O)N1CCC[C@H](c2ccccc2)[C@@H]1CN1CCCC1)c1ccc(Cl)c(Cl)c1
13399,CHEMBL254356,HXWCQEQIPYCSAM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC(=O)N1CCCC(C1CN2CCCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,5.853871964321762,CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1
13400,CHEMBL254356,HXWCQEQIPYCSAM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC(=O)N1CCCC(C1CN2CCCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,5.853871964321762,CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1
13405,CHEMBL474934,HXXABQAEGBRHAX-BGYRXZFFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,41000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,4.3872161432802645,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
13406,CHEMBL474934,HXXABQAEGBRHAX-BGYRXZFFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,59000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,4.229147988357856,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
13411,CHEMBL3408523,HXZWMRQMVOIXHQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,CC1=CSC(C2=NOC(=O)N12)(C3=CC=C(C=C3)Br)OCC(F)(F)F,4.698970004336019,CC1=CSC(OCC(F)(F)F)(c2ccc(Br)cc2)c2noc(=O)n21
13412,CHEMBL3408523,HXZWMRQMVOIXHQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,CC1=CSC(C2=NOC(=O)N12)(C3=CC=C(C=C3)Br)OCC(F)(F)F,4.698970004336019,CC1=CSC(OCC(F)(F)F)(c2ccc(Br)cc2)c2noc(=O)n21
13426,CHEMBL192172,HYFHKEYEUYHQDQ-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)F)C4=CC=CC=C4Cl)N,6.356547323513812,N[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2F)c1=O)c1ccccc1
13431,CHEMBL3358953,HYFZBJIDQLQGIG-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=NC=C2C(=C1)C=C(N2)C[C@](CC(C)(C)C3=CC=CC=C3C(=O)N)(C(F)(F)F)O,4.468521082957745,CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1
13432,CHEMBL3358949,HYFZBJIDQLQGIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=NC=C2C(=C1)C=C(N2)CC(CC(C)(C)C3=CC=CC=C3C(=O)N)(C(F)(F)F)O,4.853871964321762,CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1
13436,CHEMBL3629744,HYGZSKLILPYKMS-LZYVTZSCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,CP1(=O)OCC2(CCC[C@@]3([C@H]2COC4=C(C=CC(=C43)F)F)S(=O)(=O)C5=CC=C(C=C5)Cl)CO1,4.698970004336019,CP1(=O)OCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1
13437,CHEMBL3629744,HYGZSKLILPYKMS-LZYVTZSCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,CP1(=O)OCC2(CCC[C@@]3([C@H]2COC4=C(C=CC(=C43)F)F)S(=O)(=O)C5=CC=C(C=C5)Cl)CO1,4.698970004336019,CP1(=O)OCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1
13441,CHEMBL271326,HYHBTUQUIVVEHT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CCOC1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N3C=NN=N3,4.468521082957745,CCOc1ccc(NC(=O)c2ccc(-n3cnnn3)cc2)cc1
13445,CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,5.0,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
13446,CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,46989.41,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,4.3280000079532766,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
13447,CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256005.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,4.958607314841775,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
13450,CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,5620.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,5.250263684430939,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
13466,CHEMBL1950086,HYMHPKUKPVAHSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CC=C4)O)Cl,5.958607314841775,Cc1cc(Cl)cc2c(C(O)c3cccnc3)c3c(C)[nH]nc3nc12
13467,CHEMBL1950086,HYMHPKUKPVAHSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CC=C4)O)Cl,5.6777807052660805,Cc1cc(Cl)cc2c(C(O)c3cccnc3)c3c(C)[nH]nc3nc12
13468,CHEMBL3115177,HYMRCMPXDULDOD-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.6777807052660805,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
13470,CHEMBL3623127,HYNANJUKEMCYEQ-GVYRHCHYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288692.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)N[C@@H]1C[C@]2([C@@H]3[C@H]([C@]1(O2)C)C(=O)N(C3=O)C4=CC(=C(C=C4)C#N)C(F)(F)F)C,4.3979400086720375,CCS(=O)(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12
13476,CHEMBL3408943,HYQVDRMLTQMPMN-ABKNGVQNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C1CN(C[C@@H]1F)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7NC6=O,5.0,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CC[C@@H](F)C4)cc3)n[nH]c2c1
13477,CHEMBL3408943,HYQVDRMLTQMPMN-ABKNGVQNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C1CN(C[C@@H]1F)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7NC6=O,6.0,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CC[C@@H](F)C4)cc3)n[nH]c2c1
13478,CHEMBL3319533,HYRZJDXFIXBPRU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25001129.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket.,J. Med. Chem.,PUBLICATION,,CN1C=C(C=N1)C2=C(N=CC(=C2)C(C(F)(F)F)(C(F)(F)F)O)N3CCN(CC3)S(=O)(=O)C4=CN=C(C=C4)N,4.568636235841013,Cn1cc(-c2cc(C(O)(C(F)(F)F)C(F)(F)F)cnc2N2CCN(S(=O)(=O)c3ccc(N)nc3)CC2)cn1
13489,CHEMBL2437427,HYUUZONCAYJTHP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(C1)N2C3=C(C=CC(=C3)F)N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC(=NC=C6)N,4.657577319177793,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(C5CCCC5)c5cc(F)ccc54)CC3)CC2)ccn1
13495,CHEMBL1671916,HYWCKSHSBGMFFR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)NC3=NC=CS3,5.853871964321762,Cc1ccccc1C(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
13520,CHEMBL306226,HYZJCKYKOHLVJF-UHFFFAOYSA-N,BENZIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC=C2C(=C1)NC=N2,5.0,c1ccc2[nH]cnc2c1
13521,CHEMBL306226,HYZJCKYKOHLVJF-UHFFFAOYSA-N,BENZIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CC=C2C(=C1)NC=N2,5.0,c1ccc2[nH]cnc2c1
13523,CHEMBL2338479,HYZYVEZIXMCICK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1Cl)Cl)S(=O)(=O)NC2=CC(=C(C(=C2)Cl)OC3=CN=CC(=C3)C#N)Cl,8.0,N#Cc1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1
13526,CHEMBL3357641,HZBHTRUJNPPRNW-KAZCASEASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25409491.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method,A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles.,J. Med. Chem.,PUBLICATION,,CN(C)C/C=C(/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4)\F,5.0,CN(C)C/C=C(\F)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1
13559,CHEMBL253528,HZUKSEBFKWBMBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18329269.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(O1)C2=NC(=CC(=N2)N3C(=CC(=N3)C)C)NC(=O)COC4=CC(=NC(=C4)C)C,5.958607314841775,Cc1cc(OCC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)cc(C)n1
13585,CHEMBL3112849,IADWZPWKRCWMPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=C1C(=CC=C2)Cl)C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Cl)cccc21
13588,CHEMBL2387224,IAFNAEGXTKTGHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23867602.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Lead identification of novel and selective TYK2 inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,C1CC1C(=O)NC2=NC=CC(=C2)NC(=O)C3=C(C=CC=C3Cl)Cl,5.0,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cccc1Cl
13590,CHEMBL2113263,IAFVOFFJCUHEHP-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17274610.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CCCC1=C(C=CC(=C1)C2=NC3=C(S2)CCCC3)OCCCOC4=CC5=C(C=C4)[C@@H](CC5)CC(=O)O,5.0,CCCc1cc(-c2nc3c(s2)CCCC3)ccc1OCCCOc1ccc2c(c1)CC[C@H]2CC(=O)O
13591,CHEMBL571204,IAGNLKFJNSJHHD-GAJHUEQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19632830.0,IC50,>,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]([C@@H](CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(C)(C)C(=O)NC3=NC=C(C=C3)C(F)(F)F,4.455931955649724,C[C@H](NC(C)(C)C(=O)Nc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1
13606,CHEMBL107,IAKHMKGGTNLKSZ-INIZCTEOSA-N,COLCHICINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,4.301029995663981,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
13622,CHEMBL2181898,IANAVLJQRMMYRG-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)C[C@@H]2NC[C@H]([C@H](CC4=CC=C(C=C4)C5=NC=CS5)NC(=O)COC)O,7.522878745280337,COCC(=O)N[C@@H](Cc1ccc(-c2nccs2)cc1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
13632,CHEMBL1950643,IAUVZRBJEZBOFA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22290075.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)C4=NNC(=O)C=C4,4.522878745280337,O=c1ccc(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)n[nH]1
13646,CHEMBL577965,IBABQVTVKGTVDW-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=CC(=C5)C(=O)N,6.3979400086720375,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3cncc(C(N)=O)c3)ccc2o1
13652,CHEMBL579199,IBCNGCWXJWSCOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=CC(=C3)OC)OC,5.769551078621726,COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1
13656,CHEMBL239099,IBEQZETWFPHMMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)C#N.C(=O)O,4.0,N#Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1
13657,CHEMBL239099,IBEQZETWFPHMMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using diethoxyfluorescein substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)C#N.C(=O)O,4.0,N#Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1
13672,CHEMBL1090527,IBILQKIYEWGQDQ-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CS3,5.0,C[C@H](C1=C(CCN(C)C)Cc2cc(F)ccc21)c1nccs1
13678,CHEMBL373039,IBJYNRZEQITOHY-VIHJOENHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16203148.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=NC=C(O1)C2=CC=C(C=C2)Cl)N3CCN([C@@H](C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC5=C(S4)C=CN=C5)C(=O)N[C@@H]6[C@@H](COC7=CC=CC=C67)O)O,6.0,CC(C)(c1ncc(-c2ccc(Cl)cc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2cc3cnccc3s2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1
13690,CHEMBL248231,IBOXMUIHNFMJTF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCN(CC3)CC4=CC5=C(C=C4)OCC(=O)N5CC6=CC=CC=C6,4.920818753952375,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(Cc4ccccc4)C(=O)CO5)CC3)cccc2n1
13694,CHEMBL2181895,IBQBCHBBSWVJOQ-HZFUHODCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC1=CSC(=N1)C2=CC=CC(=C2)C[C@@H]([C@@H](CN[C@H]3CC4(CCC4)OC5=C3C=C(C=N5)CC(C)(C)C)O)NC(=O)COC,7.0,COCC(=O)N[C@@H](Cc1cccc(-c2nc(C)cs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
13703,CHEMBL3664646,IBSYVSTWEQVFDZ-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4F,4.301029995663981,C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O
13708,CHEMBL534942,IBUZSMCHAASZTO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16750363.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CC=CC=C3.Cl,4.522878745280337,Clc1ccccc1CC(c1ccccc1)N1CCNCC1
13723,CHEMBL608151,IBZJKEOJOGAMGJ-COPLHBTASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,CCOC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,5.045757490560675,CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
13728,CHEMBL2207099,ICBWFOBAWJKURO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23079519.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,In vivo activity of an azole series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=NN=N1)CC2=C(C=C(C=N2)Cl)NS(=O)(=O)C3=CC(=C(C=C3)Cl)Cl,5.0,Cn1nnnc1Cc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1
13735,CHEMBL570596,ICDRVGLMFQWTDX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19831396.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC(=C1)C2=CC=C(S2)C3=CC(=CC=C3)O)O,6.301029995663981,Cc1cc(-c2ccc(-c3cccc(O)c3)s2)ccc1O
13736,CHEMBL239497,ICDYHYNUXPDZEQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,460.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(CC)C4=CC(=CC(=C4)F)F,6.337242168318426,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(c1cc(F)cc(F)c1)O2
13747,CHEMBL1222799,ICHWSWUZDRHGDT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,10600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOCCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,4.97469413473523,CCOCCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
13760,CHEMBL1916686,ICMOGANJAUQPKT-LMKMVOKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958540.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of a biphenylacetic acid series of prostaglandin D(2) receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=C(C=CC(=C3)CC(=O)O)OC)C4=CC=CC=C4,4.522878745280337,COc1ccc(CC(=O)O)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2ccccc2)[C@@H]1C
13772,CHEMBL1081874,ICNXLCSJEDSWTK-CLJLJLNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)C[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,6.958607314841775,CCN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1
13773,CHEMBL1081147,ICNXLCSJEDSWTK-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)C[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,6.958607314841775,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1
13774,CHEMBL1080964,ICNXLCSJEDSWTK-UIOOFZCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)C[C@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,6.823908740944319,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1
13788,CHEMBL1173532,ICXJGCSEMJXNQF-ZIAGYGMSSA-N,"1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20527970.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,5.0,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
13793,CHEMBL3633460,ICYNYWFGIDGBRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26509551.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.",J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)Cl)C2=CC(=O)NC(=S)N2CC(=O)N,4.0,COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O
13794,CHEMBL3633460,ICYNYWFGIDGBRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26509551.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes,"Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.",J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)Cl)C2=CC(=O)NC(=S)N2CC(=O)N,4.0,COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O
13799,CHEMBL2042239,IDAMFVNNSWRUTJ-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CN1C(=O)N(C(=O)[C@@]12C3=C(C=CC(=C3)Cl)N(C2=O)CC(=O)O)CC4=C(C=CC(=C4)Cl)F,5.0,CN1C(=O)N(Cc2cc(Cl)ccc2F)C(=O)[C@]12C(=O)N(CC(=O)O)c1ccc(Cl)cc12
13811,CHEMBL3673957,IDCXHTGCSOGOJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320614,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)OC)F)N=C1,5.301029995663981,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2F)cn1
13812,CHEMBL3673957,IDCXHTGCSOGOJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320660,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)OC)F)N=C1,5.301029995663981,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2F)cn1
13835,CHEMBL2380637,IDEUQHDUZMBFNX-KVFJJHLMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)C2=CN=C(N=C2)N3CCN(C4=CC=CC=C43)C(=O)NC5C6CC7CC5CC(C7)(C6)O,5.0,COc1ccc(-c2cnc(N3CCN(C(=O)NC4C5CC6CC4CC(O)(C6)C5)c4ccccc43)nc2)cc1
13848,CHEMBL2331747,IDMZBDJWQBWWLK-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23206863.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Sulfonylpiperidines as novel, antibacterial inhibitors of Gram-positive thymidylate kinase (TMK).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(C(=O)NC1=O)[C@H]2CCCN(C2)S(=O)(=O)C3=CC(=C(C=C3)O)OC4=CC(=CC=C4)Cl,4.698970004336019,Cc1cn([C@H]2CCCN(S(=O)(=O)c3ccc(O)c(Oc4cccc(Cl)c4)c3)C2)c(=O)[nH]c1=O
13849,CHEMBL248677,IDOAKQMETXZJBC-NOZRDPDXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCC(CC3)N4CCCCC4,5.886056647693163,CC(C)[C@@H]1CCC[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
13867,CHEMBL238146,IDSZXCFCCNVXER-UHFFFAOYSA-N,AR-HO47108,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N)C,5.42021640338319,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12
13868,CHEMBL238146,IDSZXCFCCNVXER-UHFFFAOYSA-N,AR-HO47108,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N)C,5.4089353929735005,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12
13869,CHEMBL238146,IDSZXCFCCNVXER-UHFFFAOYSA-N,AR-HO47108,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N)C,5.42021640338319,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12
13870,CHEMBL238146,IDSZXCFCCNVXER-UHFFFAOYSA-N,AR-HO47108,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N)C,5.4089353929735005,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12
13877,CHEMBL1096182,IDUFEEHNNASCMH-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20423086.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1)C(=O)N[C@@H]2CC(OC3=C2C=C(C(=N3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)Cl)(C)C,5.481486060122113,Cc1cc(C(=O)N[C@@H]2CC(C)(C)Oc3nc(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)cc32)n[nH]1
13880,CHEMBL3311228,IDUYJRXRDSPPRC-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,65000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F,4.187086643357144,O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1
13883,CHEMBL1642362,IDVWFRRQOFXIBN-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)[C@@H](C(=O)NC2CCCCC2)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)Cl,5.346787486224656,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(Cl)cc21
13894,CHEMBL3115162,IDZMIOJJLGAUFK-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,7.0,Cc1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
13895,CHEMBL590472,IDZYJTXHWNKKBY-VIKVFOODSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,C1CC(C1)OCC2([C@H]3[C@@H]2CNC3)C4=CC(=C(C=C4)Cl)Cl,5.522878745280337,Clc1ccc(C2(COC3CCC3)[C@H]3CNC[C@H]32)cc1Cl
13896,CHEMBL2448703,IEAFYLRKILUQOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3280.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1=CC2=C(C=CC(=C2)Br)C=C1C(=O)NCCC3=CN=CN3,5.484126156288321,O=C(NCCc1cnc[nH]1)c1ccc2cc(Br)ccc2c1
13898,CHEMBL3702684,IEALSSJEWUOVJF-VYQNARHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,20390.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=O)NCC8=CC=CC=C8,4.69058277422186,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCc6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
13946,CHEMBL3237443,IEPYZPJZYINELK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,C1CCC(C1)N2C3=C(C=CN=C3F)C4=CN=C(N=C42)NC5=NC=C(C=C5)N6CCNCC6,5.0,Fc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12
13948,CHEMBL2018922,IEQJLSGPTIUFRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=C(C=C3)C(=O)O,4.301029995663981,COc1ccc2nc(SCc3ccc(C(=O)O)cc3)[nH]c2c1
13971,CHEMBL3581147,IEYJDPAUIUNGSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)Cl,5.301029995663981,COc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1
13972,CHEMBL1777878,IEYUZLGWSIHESL-WMLDXEAASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC#C[C@H]([C@@H]1C(=O)NC(=O)O1)C2=CC=C(C=C2)OC3=C(C=C(C=C3)C(F)(F)F)OC(F)F,4.301029995663981,CC#C[C@@H](c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1)[C@H]1OC(=O)NC1=O
13985,CHEMBL3127501,IFEXCZMSTXWJSK-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,65.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1[C@H]([C@@H]1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC(=C3)OC(F)(F)F)C4=CN=CC=C4,7.187086643357144,O=C(Nc1ccc(S(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)[C@@H]1C[C@H]1c1cccnc1
13986,CHEMBL3127501,IFEXCZMSTXWJSK-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,890.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1[C@H]([C@@H]1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC(=C3)OC(F)(F)F)C4=CN=CC=C4,6.050609993355088,O=C(Nc1ccc(S(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)[C@@H]1C[C@H]1c1cccnc1
13990,CHEMBL1223235,IFFHPDKLLFCYAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)N2CCCN(CC2)C(C3=CC=C(C=C3)N4C=NC=N4)C5=NN=NN5CC6=CC=CC=C6,4.5376020021010435,c1ccc(Cn2nnnc2C(c2ccc(-n3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1
13995,CHEMBL576094,IFHTTXSATPHTDC-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)NC,4.7447274948966935,CNC(=O)c1ccc(C(=O)NC(=N[C@H]2CCCCN(CC(=O)N3CCCC3)C2=O)Nc2ccc3oc(C)cc3c2)cn1
14006,CHEMBL3401121,IFMJXLLSGLDSMX-JTQLQIEISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3ß inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1COCCN1C2=NC(=CC(=O)N2C)C3=C(C=NC=C3)F,4.301029995663981,C[C@H]1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C
14007,CHEMBL3401118,IFMJXLLSGLDSMX-SNVBAGLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3ß inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1COCCN1C2=NC(=CC(=O)N2C)C3=C(C=NC=C3)F,4.301029995663981,C[C@@H]1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C
14011,CHEMBL3673970,IFMNZLKDCPETDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320640,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4F)OC)F)N=C1,5.301029995663981,COc1cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(F)cn1
14012,CHEMBL3673970,IFMNZLKDCPETDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320684,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4F)OC)F)N=C1,5.301029995663981,COc1cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(F)cn1
14040,CHEMBL1644183,IGCXZPHCSPIQHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21147532.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1CN2C(=CC(=N2)C3=CC(=CC(=C3)Cl)Cl)C4=CC=C(C=C4)OC(F)(F)F)C(=O)NCCC(=O)O,4.4089353929735005,O=C(O)CCNC(=O)c1ccc(Cn2nc(-c3cc(Cl)cc(Cl)c3)cc2-c2ccc(OC(F)(F)F)cc2)cc1
14044,CHEMBL2070162,IGDKFGZQZAKEIU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CN(C=CC3=O)C4=CC=CC=C4,4.698970004336019,CCCS(=O)(=O)c1ccc2nc(-c3cn(-c4ccccc4)ccc3=O)[nH]c2c1
14046,CHEMBL401895,IGEDPAQDLDJKOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18329269.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(O1)C2=NC(=CC(=N2)N3C(=CC(=N3)C)C)NC(=O)COC4=CC=CC(=C4)CN(C)C,5.221848749616356,Cc1cc(C)n(-c2cc(NC(=O)COc3cccc(CN(C)C)c3)nc(-c3ccc(C)o3)n2)n1
14058,CHEMBL3682507,IGKOLFMBNAVTIP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,200000.0,NM,291612,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",Metalloenzyme inhibitor compounds,,PATENT,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OC(F)F)N3N=CN=N3,3.6989700043360187,CC(C)C(c1ccc2cc(OC(F)F)ccc2c1)n1ncnn1
14060,CHEMBL2336417,IGMSWNYDGFNYAI-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C(=C3)Cl)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.769551078621726,O=C(N[C@H](Cc1cc(Cl)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
14061,CHEMBL2336417,IGMSWNYDGFNYAI-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C(=C3)Cl)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.3979400086720375,O=C(N[C@H](Cc1cc(Cl)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
14069,CHEMBL575966,IGRCWJPBLWGNPX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19902954.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N(C)C3=CC=C(C=C3)Cl,5.899998417198648,Cc1onc(-c2ccccc2Cl)c1C(=O)N(C)c1ccc(Cl)cc1
14070,CHEMBL575966,IGRCWJPBLWGNPX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20097073.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of a series of 3-aryl-4-isoxazolecarboxamides as a new class of TGR5 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N(C)C3=CC=C(C=C3)Cl,5.899998417198648,Cc1onc(-c2ccccc2Cl)c1C(=O)N(C)c1ccc(Cl)cc1
14075,CHEMBL210514,IGTBNUVMBDYPQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16722655.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1OC3=CC=C(O3)C(=O)NC4=C(N=C(N=C4OC)NCCCN5CCOCC5)OC)C(CC2)(C)C,4.522878745280337,COc1nc(NCCCN2CCOCC2)nc(OC)c1NC(=O)c1ccc(Oc2cc3c(cc2C)CCC3(C)C)o1
14078,CHEMBL1935441,IGUBZXXWVQQSPY-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2[C@H]4CNCCO4,4.698970004336019,Cc1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1
14079,CHEMBL2069398,IGUGPXBOXUANHO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22832311.0,IC50,>,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,N-Aryl pyrrolidinonyl oxadiazoles as potent mGluR5 positive allosteric modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC=C1)C2=NOC(=N2)C3CC(=O)N(C3)C4=CC=C(C=C4)F,4.958607314841775,Cc1cccc(-c2noc(C3CC(=O)N(c4ccc(F)cc4)C3)n2)c1
14090,CHEMBL3263640,IGXJXMLDIIGDNE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24685542.0,IC50,=,9800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC=C1NC(=O)C2=CC=C(C=C2)C(C)(C)C)C3=NC4=C(C(=N3)NC5=CC=C(C=C5)C(=O)N6CCOCC6)NC=N4,5.008773924307505,Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2[nH]cnc2n1
14091,CHEMBL3263640,IGXJXMLDIIGDNE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24685542.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC=C1NC(=O)C2=CC=C(C=C2)C(C)(C)C)C3=NC4=C(C(=N3)NC5=CC=C(C=C5)C(=O)N6CCOCC6)NC=N4,4.3979400086720375,Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2[nH]cnc2n1
14097,CHEMBL2170629,IHADGKOGTFHZIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=C(C=C3)C#N,4.958607314841775,N#Cc1ccc(C(=O)N2CCC(c3ccc(C(=O)N=C(N)N)cc3C(F)(F)F)CC2)cc1
14098,CHEMBL2386081,IHAXLPDVOWLUOS-UHFFFAOYSA-N,SETIPIPRANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54,4.301029995663981,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc3ccccc13)CC2
14102,CHEMBL2414256,IHDMNALHWVSDJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation and testosterone 6beta-hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(C)N1C(=NN=N1)C(C2=CC=C(C=C2)Cl)NCCNC3=C4C=CC(=CC4=NC=C3)Cl,7.096910013008056,CC(C)(C)n1nnnc1C(NCCNc1ccnc2cc(Cl)ccc12)c1ccc(Cl)cc1
14105,CHEMBL1784351,IHEWXNWFNBGUFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)CCC2CCN(CC2)S(=O)(=O)CC3(CCN(CC3)C)N(C=O)O,5.0,Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCN(C)CC2)CC1
14130,CHEMBL429845,IHOOKNMBJBLZPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)N4CCN(CC4)C)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,6.698970004336019,CC(C)c1c(-c2nnc(N3CCN(C)CC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
14135,CHEMBL1097426,IHQMLJBDDJVMHI-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCO,5.481486060122113,Cc1cc(N2CCN(CCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
14139,CHEMBL3622137,IHSTUTBJVPZZHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288682.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,CCN1C(=CC2=C3C(=C(N=C21)NC4=NC(=C(S4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6,5.522878745280337,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3nc(C)c(C)s3)nc21
14142,CHEMBL3407554,IHUMWHKQAVMWCV-HXZUPTHJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,0.102,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Homogenous Time-Resolved Fluorescence Assay (HTRF). The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",Benzoic acid derivative MDM2 inhibitor for the treatment of cancer,,PATENT,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC(=C(C=C3)Cl)F)C4=CC(=CC=C4)Cl)CC(=O)O,9.991399828238082,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)c(F)c1
14146,CHEMBL3673980,IHUPHYFSKVFFFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320619,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)Cl,5.301029995663981,Clc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3)c2c1
14147,CHEMBL3673980,IHUPHYFSKVFFFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320663,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)Cl,5.0,Clc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3)c2c1
14154,CHEMBL1270738,IHWKYASJAJITBL-MSGZWQTISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20888225.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a vorapaxar analog with increased aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/C4=NC=C(C=C4)C5=CC=CC=N5)[C@H](OC3=O)C,4.522878745280337,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccn2)cn1
14174,CHEMBL2397314,IIFUCWPNUMIYRT-SSDOTTSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)[C@H](C)CC(F)(F)F)C2=CN=C(C=C2)N,4.522878745280337,Cc1nc(NC(=O)[C@H](C)CC(F)(F)F)sc1-c1ccc(N)nc1
14175,CHEMBL2397312,IIFUCWPNUMIYRT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)C(C)CC(F)(F)F)C2=CN=C(C=C2)N,4.522878745280337,Cc1nc(NC(=O)C(C)CC(F)(F)F)sc1-c1ccc(N)nc1
14176,CHEMBL2397315,IIFUCWPNUMIYRT-ZETCQYMHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)[C@@H](C)CC(F)(F)F)C2=CN=C(C=C2)N,4.522878745280337,Cc1nc(NC(=O)[C@@H](C)CC(F)(F)F)sc1-c1ccc(N)nc1
14177,CHEMBL266513,IIFWQQSTZJCTCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=NC=C1)C2=CC=C(C=C2)CN3CCC4(CC3)C(=O)N(C(=O)N4CC5=CC=CC=C5F)C6=CC(=CC=C6)OC,5.769551078621726,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cnccc5OC)cc4)CC3)C2=O)c1
14180,CHEMBL1824235,IIGOTHGDDVVXRO-AFARHQOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21783360.0,IC50,=,48000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)CCCOC2=CC=C(C=C2)C3CCC(CC3)N4CCCC4,4.318758762624412,c1cc(C2CCC(N3CCCC3)CC2)ccc1OCCCN1CCCCC1
14181,CHEMBL1824234,IIGOTHGDDVVXRO-DKXQDJALSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21783360.0,IC50,=,41700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)CCCOC2=CC=C(C=C2)C3CCC(CC3)N4CCCC4,4.379863945026242,c1cc(C2CCC(N3CCCC3)CC2)ccc1OCCCN1CCCCC1
14185,CHEMBL1784345,IIJIMCYNCLMHHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)CCC2CCN(CC2)S(=O)(=O)CC3(CCN(CC3)C(=O)C4CCC4)N(C=O)O,5.0,Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCN(C(=O)C3CCC3)CC2)CC1
14193,CHEMBL1915566,IILXHJHOJNRNFS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21924610.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aminothiazoles as ¿-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(C=N1)C2=C(C=C(C=C2)NC3=NC(=CS3)C4=C(C=CC(=C4)Br)OC)OC,5.657577319177793,COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3cnc(C)c3)c(OC)c2)n1
14206,CHEMBL562822,IIPPFWIHUHXQNA-PKOBYXMFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC(=NO2)C3=CC=CC=N3)C(=O)N[C@@H]4C[C@H]4C5=CC=CC=C5,5.0,O=C(N[C@@H]1C[C@H]1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1
14207,CHEMBL552382,IIPPFWIHUHXQNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC(=NO2)C3=CC=CC=N3)C(=O)NC4CC4C5=CC=CC=C5,5.0,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1
14208,CHEMBL3702733,IIQWUYYKWLTINN-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3680.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(C)CCCO,5.434152181326482,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
14210,CHEMBL3544960,IIRWNGPLJQXWFJ-KRWDZBQOSA-N,AT-13148,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,inhibition,,,,,,,,,,,,,,,,,,C1=CC(=CC=C1C2=CNN=C2)[C@@](CN)(C3=CC=C(C=C3)Cl)O,5.0,NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1
14225,CHEMBL3673934,IITAGIUAJYXYRU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320679,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=C(N=CC(=C4)F)OC)N=C1,5.301029995663981,COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1
14226,CHEMBL3673934,IITAGIUAJYXYRU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320635,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=C(N=CC(=C4)F)OC)N=C1,5.0,COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1
14235,CHEMBL1669414,IIVFRUJVDGTOEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CN1CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4)F,5.0,FC1CN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
14236,CHEMBL3086045,IIXUBHOQXODODU-FZCBKRAZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24157366.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1[C@H]2C[C@H](CC[C@@H]2C(=O)N3CC(C3)(C4=CC=CC=C4)C5=CC=CC=C5)NCC6=CC=C(C=C6)Cl,4.6020599913279625,Cc1ccccc1[C@H]1C[C@@H](NCc2ccc(Cl)cc2)CC[C@@H]1C(=O)N1CC(c2ccccc2)(c2ccccc2)C1
14238,CHEMBL253883,IIZFMAZANLMCRM-CAWMZFRYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1CC1)N2C(=NC3=C2N=CC=C3)CNC(=O)[C@@H](CC4=CC=CC=C4C(F)(F)F)NC(=O)OC(C)(C)C,6.0655015487564325,CC(C1CC1)n1c(CNC(=O)[C@@H](Cc2ccccc2C(F)(F)F)NC(=O)OC(C)(C)C)nc2cccnc21
14247,CHEMBL380360,IJDCSVYTXFLAHR-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3[C@H](CNCC3=O)CSC4=CC5=C(C=C4)OCC(=O)N5CC(=O)O,4.823908740944319,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2CSc2ccc3c(c2)N(CC(=O)O)C(=O)CO3)cc1
14250,CHEMBL203567,IJDQETGUEUJVTB-HNNXBMFYSA-N,RO-3201195,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16509574.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.",J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)OC[C@H](CO)O)C(=O)C2=C(N(N=C2)C3=CC=C(C=C3)F)N,4.6020599913279625,Nc1c(C(=O)c2cccc(OC[C@@H](O)CO)c2)cnn1-c1ccc(F)cc1
14251,CHEMBL1669424,IJFPVAYNHAMKAK-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,4783.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CC=N4,5.320299619128036,C[C@H](C1=C(CCN(C)Cc2ccccn2)Cc2ccccc21)c1cnccn1
14254,CHEMBL496624,IJGCNVPTZVEOMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C4=NC=NN4C)C,5.1249387366083,CCc1cccc(C)c1CNc1cc(-c2ncnn2C)cn2c(C)c(C)nc12
14255,CHEMBL496624,IJGCNVPTZVEOMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C4=NC=NN4C)C,4.886056647693163,CCc1cccc(C)c1CNc1cc(-c2ncnn2C)cn2c(C)c(C)nc12
14280,CHEMBL487372,IJOJVQBWEGAGTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N)C,4.698970004336019,CC(=O)Nc1cc(-c2cccc(N)n2)nc(-n2nc(C)cc2C)n1
14281,CHEMBL557885,IJOLYFZBLJPKPI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,4.823908740944319,COc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
14282,CHEMBL557885,IJOLYFZBLJPKPI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 coincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,4.522878745280337,COc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
14286,CHEMBL255034,IJRBORPEVKCEQD-JMQWOFAPSA-N,MAKISTERONE A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,C[C@H](C[C@H]([C@@](C)([C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)C)O)O)O)C(C)(C)O,4.0,C[C@H](C[C@@H](O)[C@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C)C(C)(C)O
14289,CHEMBL3236948,IJTCACUKYBFEGJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24512187.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of isoquinolinone indole acetic acids as antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.,J. Med. Chem.,PUBLICATION,,CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)C3=CN(C(=O)C4=CC=CC=C43)C(C)C,4.0,Cc1c(-c2cn(C(C)C)c(=O)c3ccccc23)c2cc(F)ccc2n1CC(=O)O
14296,CHEMBL1761843,IKCNXAIMXSHWAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21439819.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11ß-hydroxysteroid-dehydrogenase type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1COC2=CC=CC=C2N1C(=O)N3CCC(CC3)C4=CN=CN4,6.0,CC1COc2ccccc2N1C(=O)N1CCC(c2cnc[nH]2)CC1
14308,CHEMBL226335,IKGXIBQEEMLURG-NVPNHPEKSA-N,RUTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16562853.0,IC50,>,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O,4.096910013008056,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
14311,CHEMBL3137476,IKHACWFDYVNHCT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC(C)(CN1CCC(CC1)N(C2=CC=C(C=C2)C#N)C3=CN=CC=C3)O,4.698970004336019,CC(C)(O)CN1CCC(N(c2ccc(C#N)cc2)c2cccnc2)CC1
14316,CHEMBL381354,IKJHFSQVBUKKHY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,CCC(=O)NC1CCN(CC1)CC2=CC(=CC=C2)OC3=CC=CC=C3,5.0,CCC(=O)NC1CCN(Cc2cccc(Oc3ccccc3)c2)CC1
14317,CHEMBL3401129,IKJQAMMPHAQXBH-HUUCEWRRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,=,445000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3ß inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1N2CCO[C@H]3[C@H]2CCC3)C4=C(C=NC=C4)F,3.3516399890190685,Cn1c(N2CCO[C@@H]3CCC[C@H]32)nc(-c2ccncc2F)cc1=O
14319,CHEMBL579016,IKKXEAGTIWLWTR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=NC=C3,5.301029995663981,CC1(CC(=O)NCc2ccncc2)CC2(CCCCC2)OO1
14320,CHEMBL2436213,IKLDGCFWCBGUCZ-FEINMWSASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5CCOCC5)NC.Cl,5.638272163982407,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)C2CCOCC2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
14333,CHEMBL2036270,IKMZLQWBQYJRNA-KBGJBQQCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22420844.0,IC50,=,23100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,CCNC1CCC(CC1)C2=CNC3=C2C=C(C=C3)N=C(C4=CC=CS4)N.Cl,4.636388020107856,CCNC1CCC(c2c[nH]c3ccc(N=C(N)c4cccs4)cc23)CC1
14338,CHEMBL2381100,IKQMQSFNINGJEH-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535328.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=C(S1)C2=CC=CC=C2)C(=O)N3CC4(CC4)C[C@H]3CNC5=NC=C(C=C5)C(F)(F)F,4.0,Cc1nc(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)c(-c2ccccc2)s1
14346,CHEMBL2386635,IKSRDHMMQOCRHN-JHJVBQTASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1C4CCC(CC4)CC#N)C=CN3)O,5.055517327849831,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1C1CCC(CC#N)CC1
14347,CHEMBL2386635,IKSRDHMMQOCRHN-JHJVBQTASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1C4CCC(CC4)CC#N)C=CN3)O,5.0,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1C1CCC(CC#N)CC1
14353,CHEMBL2441829,IKUISOBQXBKHEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)C3=CC=C(C=C3)OC)C4=C(C=C(C=C4)Cl)Cl)CN,6.045757490560675,COc1ccc(N2Cc3nc(C)c(CN)c(-c4ccc(Cl)cc4Cl)c3C2=O)cc1
14354,CHEMBL3289805,IKURNPPRPBOJIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914738.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,PUBLICATION,,C1=CC(=C(C(=C1)Cl)Cl)C(CN2C3=C(C=CC=N3)N=C2N)O,4.522878745280337,Nc1nc2cccnc2n1CC(O)c1cccc(Cl)c1Cl
14358,CHEMBL1949930,IKXSPLZKOZXPFB-RQBPZYBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22226656.0,IC50,>,5900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP 3A4,"Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT6 receptor antagonist showing activity in rat social recognition test.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)OC1=CC(=CC(=C1)OC)S(=O)(=O)C2=CC3=C(C=C2)[C@@H]4CCNC[C@@H]4O3.Cl,5.229147988357856,COc1cc(OC(C)C)cc(S(=O)(=O)c2ccc3c(c2)O[C@H]2CNCC[C@@H]32)c1
14378,CHEMBL2064348,ILFYEJCKTMDWME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,CN1C(=NC2=CC=CC(=C21)C3=CC=CC=C3)CC4=NC(=CC(=O)N4)N5CCOCC5,4.3979400086720375,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cccc(-c3ccccc3)c21
14379,CHEMBL2437431,ILGIWHFMFHNSOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)C5=CC=CC=N5)CC6=CC(=NC=C6)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ccccn5)c5cc(F)ccc54)CC3)CC2)ccn1
14391,CHEMBL482102,ILKQWXHVEJRPAL-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,2.6,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)NC,8.585026652029182,CNC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
14393,CHEMBL3702816,ILKXQTQAKMXMSJ-ZUCLMTDXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4600.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC9CCCN9C8,5.337242168318426,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCC7CCCN7C6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
14414,CHEMBL3218854,ILSYFQQNAQIMBK-BBNYVJOESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,COC1=C(C=CC(=C1)N2CCOCC2)C3=NC4=NC=C(C(=C4N3)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl,5.275724130399211,COc1cc(N2CCOCC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
14415,CHEMBL3218854,ILSYFQQNAQIMBK-BBNYVJOESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,COC1=C(C=CC(=C1)N2CCOCC2)C3=NC4=NC=C(C(=C4N3)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl,5.267606240177032,COc1cc(N2CCOCC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
14438,CHEMBL2070152,IMBFWYWYCCHQOY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=C3C)C4=CC=CC=C4,5.2839966563652006,CCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)c3C)[nH]c2c1
14441,CHEMBL3234578,IMDHTJNGKGZRCP-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CC[C@@H]3C(=O)NCCC4=CC=C(C=C4)C#N,6.096910013008056,CN1CCN(c2cc(N3CC[C@@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1
14442,CHEMBL3234577,IMDHTJNGKGZRCP-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CC[C@H]3C(=O)NCCC4=CC=C(C=C4)C#N,5.522878745280337,CN1CCN(c2cc(N3CC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1
14450,CHEMBL360999,IMFKJIBLFGZFSW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,262000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,CN1C=C(N=C1)C2=CN=CC=C2,3.5816987086802543,Cn1cnc(-c2cccnc2)c1
14452,CHEMBL360999,IMFKJIBLFGZFSW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,261900.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,CN1C=C(N=C1)C2=CN=CC=C2,3.581864501574768,Cn1cnc(-c2cccnc2)c1
14472,CHEMBL3526984,IMIUKXZVUAUOBR-GFILMBHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21149541.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine substrate by HPLC-MS/MS method,Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.,Drug Metab. Dispos.,PUBLICATION,,CC1=C(C=CC(=C1)F)[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(C(C4)O)C(=O)C,5.251811972993799,CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1O
14473,CHEMBL3526984,IMIUKXZVUAUOBR-GFILMBHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21149541.0,IC50,=,8220.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method,Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.,Drug Metab. Dispos.,PUBLICATION,,CC1=C(C=CC(=C1)F)[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(C(C4)O)C(=O)C,5.0851281824599495,CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1O
14474,CHEMBL1766189,IMIWIUDULMYEKK-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)[C@](C1=CC=C(C=C1)C2=NC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,5.0,CC(=O)Nc1cccc(-c2ccc([C@](O)(c3cnc[nH]3)C(C)C)cc2)n1
14475,CHEMBL1766190,IMIWIUDULMYEKK-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)[C@@](C1=CC=C(C=C1)C2=NC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,5.0,CC(=O)Nc1cccc(-c2ccc([C@@](O)(c3cnc[nH]3)C(C)C)cc2)n1
14476,CHEMBL1766182,IMIWIUDULMYEKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=C(C=C1)C2=NC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,5.0,CC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)n1
14479,CHEMBL112592,IMJROXJEYNKELD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,630.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=NC(=C1)COC2=CC=C(C=C2)N3C=CN=C3,6.200659450546418,c1ccc(COc2ccc(-n3ccnc3)cc2)nc1
14490,CHEMBL3310294,IMOQEWXBWXGJOX-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24939756.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH,Strategies for the modulation of phase II metabolism in a series of PKCe inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1(C#N)C2=CC(=CC(=C2)C3=CC=NC4=NNC(=C34)C(F)(F)F)C[C@@H](CO)O,4.698970004336019,N#CC1(c2cc(C[C@H](O)CO)cc(-c3ccnc4n[nH]c(C(F)(F)F)c34)c2)CC1
14491,CHEMBL3310295,IMOQEWXBWXGJOX-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24939756.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH,Strategies for the modulation of phase II metabolism in a series of PKCe inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1(C#N)C2=CC(=CC(=C2)C3=CC=NC4=NNC(=C34)C(F)(F)F)C[C@H](CO)O,4.698970004336019,N#CC1(c2cc(C[C@@H](O)CO)cc(-c3ccnc4n[nH]c(C(F)(F)F)c34)c2)CC1
14494,CHEMBL514800,IMOZEMNVLZVGJZ-QGZVFWFLSA-N,APREMILAST,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19256507.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.",J. Med. Chem.,PUBLICATION,,CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC,5.0,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
14513,CHEMBL447424,IMUUVHRSPPDBTR-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NC)C4=C(C(=CC=C4)OCCC(C)(C)CC(=O)O)F,5.0,CN[C@@H](Cn1c(=O)c(-c2cccc(OCCC(C)(C)CC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
14523,CHEMBL401250,IMYWIXVEAKDSQK-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@H](C)CC3=CC=C(C=C3)Cl)[C@H](C(C)C)N,5.080921907623926,Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](N)C(C)C)c1
14560,CHEMBL1077929,INGULWRLHYWXJR-NSOVKSMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)C[C@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,6.958607314841775,CC(C)CN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1
14561,CHEMBL1077931,INGULWRLHYWXJR-VSGBNLITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,67.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)C[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,7.173925197299173,CC(C)CN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1
14562,CHEMBL1077930,INGULWRLHYWXJR-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)C[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,7.045757490560675,CC(C)CN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1
14572,CHEMBL2331699,INKYZVZPRLGVGC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25711516.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using midazolam substrate by LC-MS/MS method,"Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.",J. Med. Chem.,PUBLICATION,,CC1=NN=C2N1C3=C(CC2)C=C(C=C3F)C4=CC(=CN=C4)F,4.301029995663981,Cc1nnc2n1-c1c(F)cc(-c3cncc(F)c3)cc1CC2
14575,CHEMBL3645512,INMWFVJXYNMTDV-MYUZEXMDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=NN(C(=O)C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=C(C=C4)F,4.301029995663981,C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O
14576,CHEMBL2206277,INOASWZOZPQAQM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CC1(CC(CC(N1C)(C)C)OC2=CN=C(C=C2)C(=O)NC3=CC=C(C=C3)NC(=O)NC4=NOC(=C4)C(C)(C)C)C,4.3979400086720375,CN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C
14577,CHEMBL3091546,INOJXUNPXDYZIP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3ß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1N2CCOC(C2)C3=CC=CC=C3)C4=CC=NC=C4,4.301029995663981,Cn1c(N2CCOC(c3ccccc3)C2)nc(-c2ccncc2)cc1=O
14579,CHEMBL2425144,INQBVHWEOAKYED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=NC5=C(N=CN=C54)N,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1
14595,CHEMBL27759,INVTYAOGFAGBOE-UHFFFAOYSA-N,ENTINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,=,730.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3,6.136677139879544,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1
14630,CHEMBL3326582,IOEXPPPOEMRUCU-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4F)F)(C)C)C=N1,4.698970004336019,Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4c3ccc(F)c4F)cccc2cn1
14631,CHEMBL1940315,IOEYWFCDGXVEFG-JVHFYALYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153941.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CS(=O)(=O)C1)NC(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)C#C[C@@]4(CN5CCC4CC5)O,5.0,O=C(NC1CCCS(=O)(=O)C1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1
14661,CHEMBL497999,IOSCQMWDOQVSFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18752953.0,IC50,>,29100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC(=C(C=C1)OCC2CC2)C(=O)N3CCN(CC3)C4=C(C=C(C=C4)C#N)F,4.536107011014093,CS(=O)(=O)c1ccc(OCC2CC2)c(C(=O)N2CCN(c3ccc(C#N)cc3F)CC2)c1
14689,CHEMBL3702701,IOZXECSGCQCHGF-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)C2CCN(CC2)C(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N6CCN(C)CC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
14707,CHEMBL1923115,IPEIMNMDXCTULH-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=C(C=CC(=C2)Cl)Cl)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F,5.795880017344075,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cc(Cl)ccc1Cl)C1CC1
14711,CHEMBL228004,IPGJEBMBCSCKBX-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC3=C(C=CC(=C3)Cl)C(=O)N2CC4=CC=CC=C4C#N)N,6.6020599913279625,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cc(Cl)ccc2c1=O
14723,CHEMBL1766179,IPNCNQRVJPVKSD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)S(=O)(=O)NC)(C3=CN=CN3)O,5.481486060122113,CNS(=O)(=O)c1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)c1
14742,CHEMBL2057285,IPVDZHXIOYMFOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22500954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of Novel 1,2,4-Thiadiazole Derivatives as Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)).",J. Med. Chem.,PUBLICATION,,CCC1=C(C=CC=C1C2=NSC(=N2)C3=CC(=C(C=C3)CC(C)C)C#N)CCN4CCC(CC4)C(=O)O,5.0,CCc1c(CCN2CCC(C(=O)O)CC2)cccc1-c1nsc(-c2ccc(CC(C)C)c(C#N)c2)n1
14747,CHEMBL2163826,IPXCMYKDOHLHDR-CRHVVPOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,C1C[C@H]2CC(C[C@@H]1N2C(=O)[C@H](CC3=CC=C(C=C3)Br)NC(=O)C4(CC4)C5=C(C=C(C=C5)Cl)Cl)N,6.221848749616356,NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1
14748,CHEMBL393109,IPXPSGDBCIRUBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,1060.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOCC)(C)C4=CC(=CC(=C4)F)F,5.97469413473523,CCOCCCN1C(=O)C(C)(c2cc(F)cc(F)c2)Oc2ccc(-c3c(N)nc(N)nc3CC)cc21
14755,CHEMBL515252,IQAMTZLKUHMPPE-UHFFFAOYSA-N,"3,8'-BIAPIGENIN",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20408551.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).,J. Nat. Prod.,PUBLICATION,,C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4=C(OC5=CC(=CC(=C5C4=O)O)O)C6=CC=C(C=C6)O)O,7.096910013008056,O=c1c(-c2c(O)cc(O)c3c(=O)cc(-c4ccc(O)cc4)oc23)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12
14757,CHEMBL2087169,IQCIFDSCWKQXJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC=CC=C4F)C5=NC=C(N5)C,4.585026652029182,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ncc(C)[nH]2)c2ccccc2F)C(=O)N3)CC1
14760,CHEMBL386515,IQEPRBDBRZZHBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17428043.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(C1=NC(=C(C(=O)N1)O)C(=O)NCC2=CC=C(C=C2)F)N(C)C,4.698970004336019,CN(C)C(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)[nH]1
14775,CHEMBL2431457,IQGTYRBVWNLIFW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=C(C(=CC(=C1)C2=CC=CNC2=O)NC(=O)C3=CC=C(C=C3)NS(=O)(=O)C)OC,4.301029995663981,COc1c(NC(=O)c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C
14776,CHEMBL2206059,IQHKHGHDPGFXAV-MISXGVKJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23107482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)NCC1=NC2=CN=C3C(=C2N1[C@@H]4C[C@H]5CC[C@@H]4C5)C=CN3,5.0,CS(=O)(=O)NCc1nc2cnc3[nH]ccc3c2n1[C@@H]1C[C@H]2CC[C@@H]1C2
14783,CHEMBL1099330,IQMZIBZJCFEUSM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=CC(=NC(=C2)OCCCCCCC3=C(C(=CC=C3)OCCCC(=O)O)CCC(=O)O)C4=CC=CC=C4,5.1249387366083,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccccc3)cc(-c3ccccc3)n2)c1CCC(=O)O
14787,CHEMBL495992,IQOLDUIYVMZEKG-VWNXMTODSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC12CC(=O)C3=C(O2)C=CC(=C3)C4=CC=NC=C4)C(=O)N[C@H]5C[C@@H]5C6=CC=CC=C6,5.0,O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2ccc(-c3ccncc3)cc21
14805,CHEMBL230042,IQSICYGTAPFFKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C5=NCC(N5)(C)C,4.886056647693163,Cc1cc(C2=NCC(C)(C)N2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
14814,CHEMBL431770,IQVRBWUUXZMOPW-PKNBQFBNSA-N,ISTRADEFYLLINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)/C=C/C3=CC(=C(C=C3)OC)OC)C,4.3979400086720375,CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O
14815,CHEMBL1091775,IQWBKNWLBVZZLG-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN4CCC4,5.0,C[C@@H](c1ccccn1)c1c(CCN2CCC2)sc2ccccc12
14826,CHEMBL2425888,IRBQSRFDQHFUPM-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,79360.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=C2)C=C(C=C3)Br)N4CCC[C@H](C4)N,4.100398340853878,CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(Br)ccc3n2)c1=O
14827,CHEMBL392609,IRCMQFHWDQBWEZ-UHFFFAOYSA-N,SR-1457,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC(=CC=C4)Cl)N,6.769551078621726,NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1
14831,CHEMBL2448739,IRDKASZLBXOERK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CC1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(S3)C4=CC=CC=C4,6.0,Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1
14843,CHEMBL1774933,IRGGXYIIIARJBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC(=C1C2=NC(=NC3=C2CN(C3)C(=O)NCC(C)(F)F)N)OCCN4C=C(C=N4)F)Cl,5.327902142064283,Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(C)(F)F)C2
14844,CHEMBL1774933,IRGGXYIIIARJBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC(=C1C2=NC(=NC3=C2CN(C3)C(=O)NCC(C)(F)F)N)OCCN4C=C(C=N4)F)Cl,4.522878745280337,Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(C)(F)F)C2
14845,CHEMBL1277312,IRGGYSVFJCBILG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,C1CC2(CC1N3CC(C3)C(=O)O)CC4=CC=CC=C4OC5=CC=CC=C25,5.0,O=C(O)C1CN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)C1
14862,CHEMBL3622434,IRIDOYGIOXFPNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288685.0,IC50,=,36510.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC2=NN=C(N2C3=C1C=C(C=C3)C4=CN=CC=C4)C5=CC=CC=C5,4.437588167050272,c1ccc(-c2nnc3n2-c2ccc(-c4cccnc4)cc2CC3)cc1
14873,CHEMBL1922662,IRQIBOAVBGKTBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22059882.0,IC50,=,8.5,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CN=C(C=C1)COC2=CC3=C(C=C2)N(C(=C3SC(C)(C)C)CC(C)(C)C(=O)O)CC4=CC=C(C=C4)C5=NC=C(C=C5)C,8.070581074285707,Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(C)cn3)cc2)nc1
14875,CHEMBL1872483,IRQYACHFLTWGHT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NOC(=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC3CCN(CC3)C(C)C,4.522878745280337,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C(C)C)CC1
14884,CHEMBL2425151,IRSCZNCGMYWXAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CSN=N4,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3csnn3)cc2)cc1
14892,CHEMBL2431462,IRVBXJQSVGDYQB-DHZHZOJOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC(=CC(=C1OC)/C=C/C2=CC=C(C=C2)NS(=O)(=O)C)C3=CC=CNC3=O,5.958607314841775,COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C
14893,CHEMBL2086756,IRVGRHMDHCZIOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=C3C(=C4N=C5C=CC=CC5=N4)C6=CC(=CC=C6)F)O,5.3979400086720375,CCN1CCC(Nc2ccc3[nH]c(O)c(C(=C4N=c5ccccc5=N4)c4cccc(F)c4)c3c2)CC1
14932,CHEMBL3297778,ISIATOZGACZZRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24835202.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1OC2=NC=CC3=C2C=CN3)F,4.698970004336019,Fc1ccc(Oc2nccc3[nH]ccc23)cc1
14935,CHEMBL375166,ISIVOJWVBJIOFM-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NN1)C)CC2=C(C3=C(S2)N(C(=O)N(C3=O)C)CC(C)C)C(=O)N4C[C@@H](CO4)O,4.0,Cc1n[nH]c(C)c1Cc1sc2c(c1C(=O)N1C[C@H](O)CO1)c(=O)n(C)c(=O)n2CC(C)C
14940,CHEMBL3699338,ISLCCZIUPKFGKN-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)C8=CC=C(C=C8)OC,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(OC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
14964,CHEMBL3403816,ITAXZEXGQGVKHD-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)C(C)C)C)C)O)C)C(C)(C)O,4.6020599913279625,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
14965,CHEMBL3403816,ITAXZEXGQGVKHD-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)C(C)C)C)C)O)C)C(C)(C)O,4.431798275933005,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
14977,CHEMBL3422235,ITDPHYUDGLCWQU-VAHXTSCQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,C1[C@H]2CSC(=N[C@]2(CO[C@H]1C3=NC=CO3)C4=C(C=C(C=C4)F)F)N,4.522878745280337,NC1=N[C@@]2(c3ccc(F)cc3F)CO[C@@H](c3ncco3)C[C@H]2CS1
14985,CHEMBL2070150,ITFCVHBIFHOZNC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=C(C=CC(=C3)C4=CC=CC=C4)Cl,5.301029995663981,CCS(=O)(=O)c1ccc2nc(-c3cc(-c4ccccc4)ccc3Cl)[nH]c2c1
15001,CHEMBL2387595,ITJZUXOTSQYHCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CCCC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,4.522878745280337,CCCc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
15005,CHEMBL388012,ITMSPKNBOCNPGW-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,CC1=NC=CN1CC(=O)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4C[C@@H](OC4=O)CN5C=CN=N5)F,4.698970004336019,Cc1nccn1CC(=O)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1
15014,CHEMBL3640255,ITPNKZFHSOFLSJ-APBUJDDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC(=N1)N2C[C@H]3C(=O)N(C(=N[C@]3(C2)C4=CC(=C(C=C4F)F)F)N)C)OC)F,4.698970004336019,COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cc(F)c(F)cc3F)C2)nc(C)c1F
15019,CHEMBL207411,ITQXAONDFWOMPJ-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,448.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]([C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N(C)C4CCCCC4,6.348721986001856,C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C1CCCCC1
15030,CHEMBL1209554,ITUKYMGUUJBALP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=CC=C3,7.0,CC(C)CC1n2cncc2CN(Cc2ccccc2)S1(=O)=O
15031,CHEMBL1209554,ITUKYMGUUJBALP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=CC=C3,5.853871964321762,CC(C)CC1n2cncc2CN(Cc2ccccc2)S1(=O)=O
15034,CHEMBL3087043,ITVVFGALQBNWTP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCC1=NC=CC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,4.568636235841013,CCCc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
15035,CHEMBL3623830,ITXORCJLPUUDIY-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26403853.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,PUBLICATION,,CCC(=O)N[C@@H]1CCCC2=C1C=NC=C2C3=CC=C(C=C3)C#N,4.301029995663981,CCC(=O)N[C@@H]1CCCc2c(-c3ccc(C#N)cc3)cncc21
15036,CHEMBL3623831,ITXORCJLPUUDIY-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26403853.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,PUBLICATION,,CCC(=O)N[C@H]1CCCC2=C1C=NC=C2C3=CC=C(C=C3)C#N,4.698970004336019,CCC(=O)N[C@H]1CCCc2c(-c3ccc(C#N)cc3)cncc21
15037,CHEMBL3623824,ITXORCJLPUUDIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26403853.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,PUBLICATION,,CCC(=O)NC1CCCC2=C1C=NC=C2C3=CC=C(C=C3)C#N,4.301029995663981,CCC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21
15038,CHEMBL151207,ITXWTUUAROJZDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,9170.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)N2C=C(N=C2)C,5.037630664329979,CCCCOc1ccc(-n2cnc(C)c2)cc1
15041,CHEMBL3699333,ITYPOIOJLXUMJH-KWMOVAKFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)(C)OC(=O)NC1CCC(CC1)NC(=O)C2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NC6CCC(NC(=O)OC(C)(C)C)CC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
15050,CHEMBL13,IUBSYMUCCVWXPE-UHFFFAOYSA-N,METOPROLOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,4.301029995663981,COCCc1ccc(OCC(O)CNC(C)C)cc1
15079,CHEMBL3699332,IUKGTWNYPLJBGP-GSVOJQHPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13700.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)OC1=CC=CC(=C1)NC(=O)C2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,4.863279432843593,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OC(C)C)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
15108,CHEMBL1928243,IUQFLLUDDADQCI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22061640.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 4-aminomethylphenylacetic acids as ¿-secretase modulators via a scaffold design approach.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)CC(C1=C(C=C(C=C1)CC(=O)O)C2=CC=C(C=C2)C(F)(F)F)N3CCC(CC3)C(F)(F)F,5.0,CC(C)(C)CC(c1ccc(CC(=O)O)cc1-c1ccc(C(F)(F)F)cc1)N1CCC(C(F)(F)F)CC1
15110,CHEMBL483876,IUTAFCQVIUFADT-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2(CCN(CC2)C(=O)N[C@H]3C[C@@H]3C4=CC=CC=C4)OC5=C1C=C(C=C5)F,5.0,O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3cc(F)ccc3O2)CC1
15112,CHEMBL477145,IUUQWNJIQOXGIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18632268.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NNC1=O)CC2=C(C(=C(C=C2)Cl)OC3=CC(=CC(=C3)C#N)F)F,4.619788758288394,Cc1cc(Cc2ccc(Cl)c(Oc3cc(F)cc(C#N)c3)c2F)n[nH]c1=O
15119,CHEMBL3664681,IUVZNWZLVHMDDR-SIBVEZHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CC[C@](OC3=O)(COC)C4=CC=CC=C4,4.301029995663981,COC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccc(=O)n(C)c3)cc2)C(=O)O1
15160,CHEMBL3353099,IVHDOVLHZVPDCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25454273.0,IC50,=,25400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Anilinotriazoles as potent gamma secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(C=N1)C2=C(N=C(C=C2)C3=NN(C(=N3)NC4=C(C=CC(=C4)C(F)(F)F)F)C)OC,4.5951662833800615,COc1nc(-c2nc(Nc3cc(C(F)(F)F)ccc3F)n(C)n2)ccc1-n1cnc(C)c1
15186,CHEMBL207942,IVTCSKRCJOCTBF-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)[C@H](C)[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCCC3)C(=O)O)N4C=CN=C4,5.638272163982407,CCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1
15187,CHEMBL443060,IVTUNYRYCDBVQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C(=O)COC2=C1C(=C(C=C2)CN3CCN(CC3)CCOC4=CC=CC5=C4C=CC(=N5)C)F,5.045757490560675,CCN1C(=O)COc2ccc(CN3CCN(CCOc4cccc5nc(C)ccc45)CC3)c(F)c21
15188,CHEMBL2348851,IVTZBZBZVFLWIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(CO)NC(=O)C1=CNC2=NC=C(N=C12)C3=CC(=C(C=C3)OC)OC,4.301029995663981,COc1ccc(-c2cnc3[nH]cc(C(=O)NC(C)CO)c3n2)cc1OC
15189,CHEMBL1222938,IVUVZXDTPUJHFC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CC5=CC=CC=C5)CC6=CC=NC=C6,6.3979400086720375,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3)c3ccccc32)CC1
15201,CHEMBL1951350,IVWHDODYYCRXLZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C2=C(N=CN=C2NC1=O)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(=O)NC(C)C,4.585026652029182,CCn1c(=O)[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c21
15202,CHEMBL3137460,IVWIUEUINWDXLX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5300.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC(C)(CN1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)O,5.275724130399211,CC(C)(O)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
15203,CHEMBL3580669,IVWXFGRLNHCKNV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,CS(=O)(=O)NC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)F,4.522878745280337,CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1
15204,CHEMBL468970,IVXGFXACZQBKSB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20850301.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorometric assay,Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1C2=CC(=CC(=C2)NC3=NC=CC(=N3)NC4=C(C=CC5=C4OCO5)Cl)N6CCOCC6,6.045757490560675,Clc1ccc2c(c1Nc1ccnc(Nc3cc(N4CCOCC4)cc(N4CCOCC4)c3)n1)OCO2
15218,CHEMBL2048058,IWBWMEKXFWHGKV-YWMUFLPLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ß-peptides.,J. Med. Chem.,PUBLICATION,,CC(C)(C1=CC=CC(=C1)CN[C@H]2CS(=O)(=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F)O,5.6777807052660805,CC(C)(O)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1
15224,CHEMBL406917,IWCKJSOBOIUYSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)CSC2=NN=C(N2C3=CC=C(C=C3)Br)C4=CC=NC=C4,5.886056647693163,Brc1ccc(-n2c(SCc3ccccc3)nnc2-c2ccncc2)cc1
15229,CHEMBL3288010,IWFKTDGQARWPEC-MAYPULDCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24785301.0,IC50,=,398.11,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC(=CC=C3)OC4=C(C=C(C=N4)F)C(=O)NC5CCC(CC5)NC(=O)C6=NN7C=CC=CC7=C6,6.399996913372259,C[C@H]1CN(Cc2ccc(-c3cccc(Oc4ncc(F)cc4C(=O)NC4CCC(NC(=O)c5cc6ccccn6n5)CC4)c3)cc2)C[C@@H](C)N1
15236,CHEMBL3673953,IWGLCABRVPLEJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320616,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC(=O)NC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC(=C4)F)OC)F)N=C1,5.301029995663981,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(NC(C)=O)cc23)c(F)n1
15242,CHEMBL1762427,IWGWKANZPRNVTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21354795.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin),"1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=NO1)NC(=O)N2CCCN(CC2)C(=O)CN3CCS(=O)(=O)CC3,4.522878745280337,CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)CN3CCS(=O)(=O)CC3)CC2)no1
15257,CHEMBL596515,IWLZOZCKKUEBQR-MDZDMXLPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19700331.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C2C=C(C=CC2=C1)CCOC3=C(C=CC(=C3)CN4C=CN=C4)/C=C/C(=O)O,6.0,O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1OCCc1ccc2ccccc2c1
15259,CHEMBL1209217,IWNSSSZVCTUKAL-KWODUOEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20630754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCC1C(=O)N2C[C@@H]3[C@H](C2)C3CNC4=NC(=CS4)C5=CC=CC=N5,5.0,O=C(C1CCOC1)N1C[C@H]2C(CNc3nc(-c4ccccn4)cs3)[C@H]2C1
15268,CHEMBL1784347,IWRJDNKXMJBFEA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)CCC2CCN(CC2)S(=O)(=O)CC3(CCS(=O)(=O)CC3)N(C=O)O,5.0,Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCS(=O)(=O)CC2)CC1
15276,CHEMBL3358942,IWTKLSNKJDHVML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=CC=CC=C3C(=O)N,4.522878745280337,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1C(N)=O
15294,CHEMBL1650443,IWYJYHUNXVAVAA-OAHLLOKOSA-N,TRELAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21186796.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.,J. Med. Chem.,PUBLICATION,,CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCC[C@H](C3)N,5.0,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O
15295,CHEMBL3604739,IWZDHCYXTXFDQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,3981.07,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,CC1=CC(=C2C=CC=C(C2=N1)C(=O)N)NCC3=C(C=CC(=C3Cl)Cl)F,5.40000018605658,Cc1cc(NCc2c(F)ccc(Cl)c2Cl)c2cccc(C(N)=O)c2n1
15308,CHEMBL3684869,IXDKFUBXESWHSL-JQWIXIFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26985297.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.",ACS Med. Chem. Lett.,PUBLICATION,,CC[C@@H](C[C@H]1COC(=N1)N)C2=CC=CC=C2,4.301029995663981,CC[C@@H](C[C@H]1COC(N)=N1)c1ccccc1
15317,CHEMBL497419,IXGNTQQGMMPWEG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)NCC3=CC=CC=C3OC)N4C=CC=CC4=O)C,5.376750709602099,COc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
15318,CHEMBL497419,IXGNTQQGMMPWEG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)NCC3=CC=CC=C3OC)N4C=CC=CC4=O)C,5.337242168318426,COc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
15329,CHEMBL3326584,IXIWLJNULBBLPQ-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4F)C(F)(F)F)(C)C)C=N1,4.7447274948966935,Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4c3ccc(C(F)(F)F)c4F)cccc2cn1
15334,CHEMBL497171,IXKMSVHWGUFUOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18768319.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"N-alkyl-5H-pyrido[4,3-b]indol-1-amines and derivatives as novel urotensin-II receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCNC1=NC=CC2=C1C3=CC=CC=C3N2,7.0,CCCCNc1nccc2[nH]c3ccccc3c12
15337,CHEMBL486140,IXMNYLMWWGRTJQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CCC(=O)NC1=NC(=NC(=C1)C2=CC(=CN=C2)OC)N3C(=CC(=N3)C)C,4.769551078621726,CCC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1
15355,CHEMBL1077963,IXTGDXLZCDARRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=CC=N3,5.0,O=C(O)CCC1(c2ccccn2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
15366,CHEMBL3087352,IXVQEZZFBBXSMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1NS(=O)(=O)C2=CC(=CC(=C2)Cl)Cl)N3C=CN=C3,7.0,O=S(=O)(Nc1ccc(-n2ccnc2)cc1)c1cc(Cl)cc(Cl)c1
15380,CHEMBL1079119,IXZUPBUEKFXTSD-INMULRNOSA-N,"6',7'-DIHYDROXYBERGAMOTTIN",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19689106.0,IC50,=,1580.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,Minor furanocoumarins and coumarins in grapefruit peel oil as inhibitors of human cytochrome P450 3A4.,J. Nat. Prod.,PUBLICATION,,C/C(=C\COC1=C2C=CC(=O)OC2=CC3=C1C=CO3)/CC[C@H](C(C)(C)O)O,5.801342913045578,C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CC[C@@H](O)C(C)(C)O
15381,CHEMBL1079119,IXZUPBUEKFXTSD-INMULRNOSA-N,"6',7'-DIHYDROXYBERGAMOTTIN",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22342630.0,IC50,=,810.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence assay,"Biotransformations of 6',7'-dihydroxybergamottin and 6',7'-epoxybergamottin by the citrus-pathogenic fungi diminish cytochrome P450 3A4 inhibitory activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C/C(=C\COC1=C2C=CC(=O)OC2=CC3=C1C=CO3)/CC[C@H](C(C)(C)O)O,6.0915149811213505,C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CC[C@@H](O)C(C)(C)O
15398,CHEMBL3422075,IYBGHBZUXSMOKI-FCEYLIBWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,CN1[C@@H]2CC[C@H]1CC(C2)OC3=CC=C(C=C3)C4=NNC5=C4C=C(C=C5)C(=O)NC(C6CC6)C7=CC=CC=C7,5.619788758288394,CN1[C@H]2CC[C@@H]1CC(Oc1ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc1)C2
15408,CHEMBL2047191,IYDMAGVFBIEVMF-KRCBVYEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22704887.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of novel potent HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC(=C(N2)F)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=C(NC(=N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)F)NC(=O)OC,5.508638306165727,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc(-c3ccc(-c4nc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c4F)cc3)cc2)c(F)[nH]1)C(C)C
15455,CHEMBL1214451,IYPRGGZMVDCNQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=NC=C(C=C3)Cl,5.0,CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(Cl)cn3)cc2C1
15466,CHEMBL3234863,IYSJAKSFBLSTEX-ACSYHNTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24630411.0,IC50,>,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1)N2C(=O)[C@@](OC2=O)(CC3=CC=CC=C3)C4=NN=C(O4)C5(CC5)C6=CC=CC=C6,4.721246399047171,C[C@H](c1ccccc1)N1C(=O)O[C@](Cc2ccccc2)(c2nnc(C3(c4ccccc4)CC3)o2)C1=O
15467,CHEMBL1214337,IYSOHQIRVSYPNJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=C(N=CC=C3)F,5.0,CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccnc3F)cc2C1
15469,CHEMBL234412,IYTDSNSLAQHLJL-XIRDDKMYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17418568.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1N)OC)OC,4.301029995663981,CCCC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1N
15475,CHEMBL3261479,IYUQYZMILCFRJI-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@@H](C2)N3CCN4C=CC5=C4C(=CC=C5)C3=O,4.301029995663981,O=C1c2cccc3ccn(c23)CCN1[C@@H]1CN2CCC1CC2
15477,CHEMBL3645518,IYVALPSKVAMDMH-JRPXNJEYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5700.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=NN(C(=O)C=C2)CC3CC3)N4CC[C@](OC4=O)(CC(C)(C)O)C5=CC=CC=C5,5.2441251443275085,C[C@@H](c1ccc(-c2ccc(=O)n(CC3CC3)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
15481,CHEMBL2403888,IYWRCNFZPNEADN-CXODAYGWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24555570.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.",J. Med. Chem.,PUBLICATION,,CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=CC5=C4C=CC(=C5)OC)NC(=O)OC(C)(C)C,5.698970004336019,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1
15509,CHEMBL1288261,IZHYDDUYSBYFJI-VZYDHVRKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,20200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)CN2C(=CC3=C2C(=O)N(C(=O)N3C)C)N4CCC[C@@](C4)(C)N.Cl,4.694648630553377,Cc1ccc(F)cc1Cn1c(N2CCC[C@@](C)(N)C2)cc2c1c(=O)n(C)c(=O)n2C
15517,CHEMBL3699339,IZKQXLOXCDKRSU-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)C8=CC=C(C=C8)N,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
15520,CHEMBL2170638,IZNOPBBLCFPKHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,24500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=C(C=C3)C(=O)N,4.610833915635467,NC(=O)c1ccc(C(=O)N2CCC(c3ccc(C(=O)N=C(N)N)cc3C(F)(F)F)CC2)cc1
15524,CHEMBL541941,IZQNXPIWJTTZEN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19211174.0,IC50,=,91.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome at 1 uM,"Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.",Eur. J. Med. Chem.,PUBLICATION,,CCC(C1=CC=C(C=C1)C2=CC(=C(C=C2)O)Cl)N3C=CN=C3,7.040958607678906,CCC(c1ccc(-c2ccc(O)c(Cl)c2)cc1)n1ccnc1
15527,CHEMBL3137390,IZRBWBHTBCWWHX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CN=C4,4.698970004336019,O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1
15571,CHEMBL497309,JAHLIPBSDIJMHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,2394.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,COC1=CC=C(C=C1)C2=CC3=C(C=C2)C(=CC3)C4=CC=NC=C4.Cl,5.620875853929608,COc1ccc(-c2ccc3c(c2)CC=C3c2ccncc2)cc1
15573,CHEMBL3330409,JAHXQCZCZURPTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=CC=C1C(C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC(=CC=C4)S(=O)(=O)N)N(C)C,6.154901959985743,CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C
15574,CHEMBL3330409,JAHXQCZCZURPTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=CC=C1C(C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC(=CC=C4)S(=O)(=O)N)N(C)C,5.5376020021010435,CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C
15575,CHEMBL1080974,JAJFLSQZGKSQFF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NCC2=CC=C(C=C2)C3=CC=CC=C3C(F)(F)F)C4=CC=CC=C4,5.0,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccccc3C(F)(F)F)cc2)C1
15577,CHEMBL3310485,JAJZURBQJLCEQE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)F,6.292429823902063,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1
15581,CHEMBL3298837,JAKPRCPHHDOYBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,CCC1=C(N2C=CC(=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCN(CC4)C5=CC=C(C=C5)OC(F)(F)F,4.3979400086720375,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)cc1
15603,CHEMBL1671964,JATLXGAUZPZTKI-PXNMLYILSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)/C=C\2/C(=O)NC(=O)S2)OC3=C(C=C(C=C3)C(=O)OC)Cl,5.6020599913279625,COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c(Cl)c1
15621,CHEMBL464909,JAZXUPQDNGHUCB-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)COC4=CC=C(C=C4)F,5.221848749616356,C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccc(F)cc3)cc2)C[C@@H](C)N1
15622,CHEMBL464909,JAZXUPQDNGHUCB-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)COC4=CC=C(C=C4)F,5.136677139879544,C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccc(F)cc3)cc2)C[C@@H](C)N1
15639,CHEMBL2017280,JBGVCJHAJVIUSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4C(=O)N5CCCCC5)C(=O)N)OC,5.7447274948966935,COc1cc2c(Nc3ccccc3C(=O)N3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C
15651,CHEMBL2043240,JBKSEOCGJGAYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22749190.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Wake-promoting agents: search for next generation modafinil: part IV.,Eur. J. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)CS(=O)CC(=O)N)OC2=CC(=C(C=C2)Cl)Cl,4.494850021680094,NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1
15652,CHEMBL2043240,JBKSEOCGJGAYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22749190.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Wake-promoting agents: search for next generation modafinil: part IV.,Eur. J. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)CS(=O)CC(=O)N)OC2=CC(=C(C=C2)Cl)Cl,4.3979400086720375,NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1
15653,CHEMBL1277677,JBMFBKALKQFKHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942471.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.",J. Med. Chem.,PUBLICATION,,CN(CC1=C2C(=CC(=O)N1CC3=CC=NC=C3)NN(C2=O)C4=CC=CC=C4Cl)C5=CC=CC=C5,5.958607314841775,CN(Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccncc1)c1ccccc1
15657,CHEMBL381630,JBMUJPIOBHXTBM-KCMFSSCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16203148.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=NC=C(O1)C2=CC=C(C=C2)Cl)N3CCN([C@@H](C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC5=C(O4)C=NC=C5)C(=O)N[C@@H]6[C@@H](COC7=CC=CC=C67)O)O,6.0,CC(C)(c1ncc(-c2ccc(Cl)cc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2cc3ccncc3o2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1
15661,CHEMBL2181776,JBSNALXXNTWUEC-SFQUDFHCSA-N,BILB 1941,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,9500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=CC=CC=N5)C6CCCC6,5.022276394711152,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21
15662,CHEMBL2181776,JBSNALXXNTWUEC-SFQUDFHCSA-N,BILB 1941,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25393851.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection.",J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=CC=CC=N5)C6CCCC6,4.522878745280337,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21
15671,CHEMBL2440660,JBUDGQFEYJAIBH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CSC(=N1)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CN=C3,5.657577319177793,Cc1csc(NC(=O)c2cc(Cl)cc(Oc3cncnc3)c2)n1
15672,CHEMBL3261483,JBVRKZZSTULWTO-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@@H](C2)N3CCN4C5=C(C=C(C=C5C3=O)Cl)C=N4,4.301029995663981,O=C1c2cc(Cl)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
15680,CHEMBL3330410,JBZRAEUHDPMQSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,C1CCN(C1)C(C2=CSC=C2)C(=O)NC3=CC4=C(C=C3)NN=C4C5=CC(=CC=C5)S(=O)(=O)N,5.3979400086720375,NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1
15681,CHEMBL3330410,JBZRAEUHDPMQSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,C1CCN(C1)C(C2=CSC=C2)C(=O)NC3=CC4=C(C=C3)NN=C4C5=CC(=CC=C5)S(=O)(=O)N,6.0,NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1
15688,CHEMBL3121811,JCBVSCDADXSWFS-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1F)C(=C(N2C3=NC=CC=N3)C4=NC=C(C=C4)S(=O)(=O)N[C@@H](C)C(F)(F)F)C#N,5.0,Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccn1
15690,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,4.522878745280337,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
15704,CHEMBL2420680,JCEKIEMNLATOCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,3581.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC2=C1C=CC(=C2Cl)C3=CC(=CN=C3)F)O,5.445995678988097,Oc1ccc2ccc(-c3cncc(F)c3)c(Cl)c2c1
15712,CHEMBL3260743,JCIBBNGOHWXOKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,3000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=CC=NC=C4)C5=CC=C(C=C5)Cl,5.522878745280337,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
15713,CHEMBL3260743,JCIBBNGOHWXOKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=CC=NC=C4)C5=CC=C(C=C5)Cl,5.040958607678906,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
15714,CHEMBL3545215,JCINBYQJBYJGDM-UHFFFAOYSA-N,BMS-911543,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288683.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6,5.522878745280337,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
15718,CHEMBL1951324,JCJHYMTUOKATGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC(=C1)Cl)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,6.318758762624412,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(Cl)c1
15725,CHEMBL1223001,JCMLBHBSAUYDRL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CC5=CC=C(C=C5)Cl)CC6=CC=NC=C6,6.3979400086720375,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccc(Cl)cc3)c3ccccc32)CC1
15728,CHEMBL3291395,JCNNVJAIWLPOMY-JETXTKBJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1630.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)NC(=O)CN5CCC(CC5)O)C,5.787812395596042,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCC(O)CC3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
15729,CHEMBL3291395,JCNNVJAIWLPOMY-JETXTKBJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1890.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)NC(=O)CN5CCC(CC5)O)C,5.723538195826756,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCC(O)CC3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
15736,CHEMBL1945723,JCOILWGRHHMFON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22196117.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of triazolopyridazinones as potent p38a inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C(=O)C(=CC2=NN=C(N21)C3=C(C=CC=C3Cl)F)C4=C(C=CC(=C4)C(=O)NC5CC5)C,4.568636235841013,CCn1c(=O)c(-c2cc(C(=O)NC3CC3)ccc2C)cc2nnc(-c3c(F)cccc3Cl)n21
15754,CHEMBL2387593,JCWUZABSZGZYPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,4.522878745280337,Cc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
15759,CHEMBL101168,JCXKHYLLVKZPKE-UHFFFAOYSA-N,1-AMINOBENZOTRIAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C2C(=C1)N=NN2N,6.346787486224656,Nn1nnc2ccccc21
15769,CHEMBL3142317,JCYICIRSTHXKMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21923116.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of N-(3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a Selective Inhibitor of Human Neuronal Nitric Oxide Synthase (nNOS) for the Treatment of Pain.",J. Med. Chem.,PUBLICATION,,C1CN2CCC1C(C2)C3=CNC4=C3C=CC(=C4)N=C(C5=CC=CS5)N.Cl.Cl,4.0,NC(=Nc1ccc2c(C3CN4CCC3CC4)c[nH]c2c1)c1cccs1
15770,CHEMBL3142317,JCYICIRSTHXKMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21923116.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BQ as substrate,"Discovery of N-(3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a Selective Inhibitor of Human Neuronal Nitric Oxide Synthase (nNOS) for the Treatment of Pain.",J. Med. Chem.,PUBLICATION,,C1CN2CCC1C(C2)C3=CNC4=C3C=CC(=C4)N=C(C5=CC=CS5)N.Cl.Cl,4.0,NC(=Nc1ccc2c(C3CN4CCC3CC4)c[nH]c2c1)c1cccs1
15795,CHEMBL1951337,JDJSPHQNBFVVDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,6.958607314841775,CN(C)C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
15797,CHEMBL572324,JDKMJELQOXOOJD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19883100.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.,J. Med. Chem.,PUBLICATION,,C1=CC(=NC2=NNC(=C21)COC3=CC(=C(C(=C3)F)Cl)OC4=CC(=CC(=C4)C#N)Cl)N,5.356547323513812,N#Cc1cc(Cl)cc(Oc2cc(OCc3[nH]nc4nc(N)ccc34)cc(F)c2Cl)c1
15819,CHEMBL2441200,JDNUWBKKCJHGHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2D6 (unknown origin) coincubated with substrate,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)OC(=O)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=C(N=C(O3)N4CCCCC4)C(F)(F)F,4.698970004336019,CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1
15820,CHEMBL2441200,JDNUWBKKCJHGHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) coincubated with substrate,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)OC(=O)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=C(N=C(O3)N4CCCCC4)C(F)(F)F,4.698970004336019,CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1
15821,CHEMBL2441200,JDNUWBKKCJHGHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated prior to substrate addition,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)OC(=O)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=C(N=C(O3)N4CCCCC4)C(F)(F)F,4.698970004336019,CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1
15824,CHEMBL3702775,JDQVENXWSYDAIX-HHDOLNPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13030.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)OCCCN(C)C,4.885055584287415,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
15845,CHEMBL2420683,JDZSWHXANGNAGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,6720.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CC(=CN=C3)O,5.172630726946175,COc1ccc2ccc(-c3cncc(O)c3)c(Cl)c2c1
15848,CHEMBL462513,JECPEAXUEYTRPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18855374.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,"Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).",J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)O)C2=CSC(=C2)C3=CC=C(C=C3)O,5.721246399047171,Oc1ccc(-c2cc(-c3cccc(O)c3)cs2)cc1
15850,CHEMBL1807440,JEEFQVVXVXIPDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21705217.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38a MAP kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC(=C2)F)N3CCOCC3)NC4=NC=NN5C4=C(C(=C5)C(=O)C6=CC=CC=C6)C,6.327902142064283,Cc1ccc(NC(=O)c2cc(F)cc(N3CCOCC3)c2)cc1Nc1ncnn2cc(C(=O)c3ccccc3)c(C)c12
15854,CHEMBL1951449,JEFLAXCYXPNMCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CN=C1)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,6.657577319177793,O=C(Nc1ccc(-c2cccnc2)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
15858,CHEMBL1923119,JEGFJOUJUPKNPT-IRPSRAIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1C)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F)CCCOC,5.455931955649724,COCCCc1cc(C)c(C)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1
15860,CHEMBL1222800,JEHMSKUGFGBZMO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,4.522878745280337,CN(C)CCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
15862,CHEMBL3127163,JELFUQAHMVGHOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24508133.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of 2-(1H-indazol-1-yl)-thiazole derivatives as selective EP1 receptor antagonists for treatment of overactive bladder by core structure replacement.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C2=NN(C3=C2C=CC(=C3)C(F)(F)F)C4=NC(=CS4)C(=O)O,5.0,O=C(O)c1csc(-n2nc(-c3ccccc3)c3ccc(C(F)(F)F)cc32)n1
15867,CHEMBL453167,JELUMXNSIYVRCU-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4S(=O)(=O)C)F,4.301029995663981,COc1cccc(-c2cn(Cc3c(F)cccc3S(C)(=O)=O)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F
15879,CHEMBL487553,JENSDTKXNVHSSN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCC(CC4)OC)C,4.698970004336019,COC1CCN(c2cccc(-c3cc(NC(C)=O)nc(-n4nc(C)cc4C)n3)n2)CC1
15882,CHEMBL398126,JEPDINCGXLHLDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17531480.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCCC(CC1)C2=C(C=CC(=C2)Cl)OCC(=O)O,5.0,O=C(O)COc1ccc(Cl)cc1C1CCCCCC1
15884,CHEMBL3104538,JEQFEWYKPONMMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=C(C=C4)C#N,5.3979400086720375,N#Cc1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
15900,CHEMBL2087168,JEUQHZZAJFLFGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC(=CC(=C4)F)F)C5=NC=C(N5)C,5.0,CCN1CCC(Nc2ccc3c(c2)C(=C(c2cc(F)cc(F)c2)c2ncc(C)[nH]2)C(=O)N3)CC1
15925,CHEMBL3673968,JEYWLGNUKVSWDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320639,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4)C)F)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(C)c4)nc3F)c2c1
15926,CHEMBL3673968,JEYWLGNUKVSWDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320683,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4)C)F)N=C1,5.0,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(C)c4)nc3F)c2c1
15931,CHEMBL2018904,JEZZAOQPWKKIKT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,26300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CCCCCSC1=NC2=C(N1)C=C(C=C2)OC,4.580044251510242,CCCCCSc1nc2ccc(OC)cc2[nH]1
15943,CHEMBL2165508,JFGXHJQNIFKDJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=CNC5=C(C=C4F)F)N6CCOCC6,6.221848749616356,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)cc(F)c5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
15945,CHEMBL1829472,JFHYZQNXNHZARY-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21782432.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NN(C(=O)C=C3)C4=NC=CC=N4,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(-c3ncccn3)n2)cc1
15956,CHEMBL1923126,JFLDDEFROOZARM-HXOBKFHXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=C(C(=CC=C2)C(F)(F)F)Cl)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5C(=O)O4)F)F,6.154901959985743,O=C1O[C@@]2(CCNC[C@@H]2C(=O)N(Cc2cccc(C(F)(F)F)c2Cl)C2CC2)c2cc(F)c(F)cc21
15958,CHEMBL405981,JFLFKVDUANRIPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCN4CCCC4)CC5=CC=C(C=C5)C6=CC=C(C=C6)Cl,5.221848749616356,Cn1cc(Cc2cn(CC(=O)N(CCN3CCCC3)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
15970,CHEMBL2048028,JFOZKMSJYSPYLN-QHCPKHFHSA-N,LIFITEGRAST,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl,4.698970004336019,CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1
15996,CHEMBL2331676,JFXLXTLDGUAURJ-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4=NC=NC(=C4)C)C(=N2)N5CCOC[C@@H]5C,5.075720713938118,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2cc(C)ncn2)C3)cc1
16006,CHEMBL1951447,JGCVYORJEGYXGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,48.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,7.318758762624412,COc1cccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5nc[nH]c45)cc3)cc2)c1
16008,CHEMBL1822792,JGEBLDKNWBUGRZ-HXUWFJFHSA-N,MK-2461,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21608528.0,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.",J. Med. Chem.,PUBLICATION,,CN1C=C(C=N1)C2=CC3=C(C=CC4=C(C3=O)C=C(C=C4)NS(=O)(=O)N(C)C[C@@H]5COCCO5)N=C2,5.1487416512809245,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1
16018,CHEMBL1272207,JGLTVCVKQGVHKR-FYYLOGMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC12CCN(CC2)C(=O)OC3(CC3)[C@H]4COC[C@H](N4S(=O)(=O)C5=CC=C(C=C5)Cl)CC6CC6,7.522878745280337,CN1CCC12CCN(C(=O)OC1([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)CC2
16026,CHEMBL252556,JGPMMRGNQUBGND-UHFFFAOYSA-N,IDEBENONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,5.154901959985743,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
16050,CHEMBL1257964,JGXUYJUQTMMZNX-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CNC(=O)C2=CC3=C(N12)C=CC(=C3)OC4CCN(CC4)C(C)C,4.585026652029182,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3[C@@H](C)CNC2=O)CC1
16051,CHEMBL1257851,JGXUYJUQTMMZNX-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CNC(=O)C2=CC3=C(N12)C=CC(=C3)OC4CCN(CC4)C(C)C,4.301029995663981,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3[C@H](C)CNC2=O)CC1
16052,CHEMBL1257607,JGXWDNPDGKMFIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCN(C(=O)C4=C3)CCO,4.301029995663981,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(CCO)C2=O)CC1
16063,CHEMBL487438,JHBJKRQQEIQKHE-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18539454.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines as VLA-4 integrin antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC2(CC1)C(=C(C2=O)Br)N[C@@H](CC3=CC=C(C=C3)N4C5=C(C=CC=N5)N=C4C6(CC6)C(F)(F)F)C(=O)O,5.0,O=C(O)[C@H](Cc1ccc(-n2c(C3(C(F)(F)F)CC3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2
16076,CHEMBL1079958,JHGFMOUZDYZILF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C(=C(C2=CC(=NC(=C21)NCC3=C(C=CC=C3C)C)N4C=CC=CC4=O)C)C,5.5376020021010435,CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21
16079,CHEMBL2409691,JHHVLAYNAWPINK-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810497.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Hydantoin based inhibitors of MMP13-Discovery of AZD6605.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@]1(C(=O)NC(=O)N1)CS(=O)(=O)N2CCC(CC2)OC3=CC=C(C=C3)OCC4=CC=CC=N4,5.0,C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(OCc4ccccn4)cc3)CC2)NC(=O)NC1=O
16080,CHEMBL3087343,JHIBNQJIDVCRSZ-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CC(=C1)C2=CC=C(C=C2)NC(=O)[C@@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,4.568636235841013,Cc1cc(-c2ccc(NC(=O)[C@@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
16081,CHEMBL3087342,JHIBNQJIDVCRSZ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CC(=C1)C2=CC=C(C=C2)NC(=O)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,4.568636235841013,Cc1cc(-c2ccc(NC(=O)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
16085,CHEMBL359657,JHLIGYPHPBLDDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,58700.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CC=C(S2)CN,4.231361898752385,NCc1ccc(-c2cccnc2)s1
16088,CHEMBL103651,JHMFRQRLRFFSIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1N=CNO,4.0,Cc1ccccc1N=CNO
16105,CHEMBL2436225,JHUGQHSVPSEAPO-FXXKCHFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@H]1[C@@H](C(=O)N(C2=C(N1C(=O)C)C=C(C=C2)C#N)CC3=C(C=CC4=CC=CC=C43)OC)NC(=O)[C@H](C)NC.Cl,4.7447274948966935,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C
16111,CHEMBL264241,JHVAMHSQVVQIOT-MFAJLEFUSA-N,ANIDULAFUNGIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19029327.0,IC50,>,17500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.,Antimicrob. Agents Chemother.,PUBLICATION,,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O,4.756961951313706,CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1
16112,CHEMBL2064344,JHVHZYMEYYOABD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1COCCN1C2=CC(=O)NC(=N2)CC3=NC4=CC=CC=C4N3C5=CC=CC=C5,4.3979400086720375,O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2-c2ccccc2)[nH]1
16116,CHEMBL205280,JHXQEUXIBMCBIF-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,2270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN(C)[C@H](C)[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3,5.6439741428068775,CCCCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
16119,CHEMBL549930,JHYBPHVVKVPUAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(CN1C=CN=C1)NC(=O)NC2CCN(CC2)CC3=CN(C=C3)C4=CC=C(C=C4)C(F)(F)F,6.494850021680094,CC(Cn1ccnc1)NC(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1
16122,CHEMBL443098,JHZWEYCWMPNVEC-DIVCQZSQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19217287.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCN1CCN(CC1)C2CCC(CC2)N3C4=NC=NC(=C4C(=N3)C5=CC6=C(C=C5)N=C(N6)CC7=CC=CC=C7OC)N,4.698970004336019,COCCCN1CCN(C2CCC(n3nc(-c4ccc5nc(Cc6ccccc6OC)[nH]c5c4)c4c(N)ncnc43)CC2)CC1
16129,CHEMBL3422245,JIAYOIBUKDISBO-IYPIGGPWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=NOC(=C1)[C@H]2C[C@H]3[C@H](SC(=N[C@]3(CO2)C4=C(C=C(C=C4)F)F)N)CF,4.522878745280337,Cc1cc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1
16132,CHEMBL246160,JIEPFEWJSJUYOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BFC substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CC1CCC(CC1)CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,5.769551078621726,CN(C)CC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1
16133,CHEMBL246160,JIEPFEWJSJUYOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BQ substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CC1CCC(CC1)CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,4.886056647693163,CN(C)CC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1
16139,CHEMBL2170635,JIIGIBJNCCBNQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=NC=C3,4.522878745280337,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccncc3)CC2)c(C(F)(F)F)c1
16151,CHEMBL179669,JIOQSJVEVFADJG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,CC1=C(SC=C1)C2=CN=CC=C2,5.221848749616356,Cc1ccsc1-c1cccnc1
16155,CHEMBL2448709,JIRODWLZHQDZBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,44400.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CN1CCC(CC1)NCC(COC2=CC3=C(C=C2)C=C(C=C3)Br)O,4.35261702988538,CN1CCC(NCC(O)COc2ccc3cc(Br)ccc3c2)CC1
16157,CHEMBL392064,JISHTAQRIKFVMS-IBGZPJMESA-N,SR-709,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)[C@H](C4=CC=CC=C4Cl)O,5.3979400086720375,O=C([C@@H](O)c1ccccc1Cl)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
16170,CHEMBL1078336,JIXUFNPVCLBVDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=NC=C3,5.0,O=C(O)CCC1(c2ccncc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
16175,CHEMBL2059801,JIZRFQIOTHWMPY-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CNC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,4.3979400086720375,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
16185,CHEMBL1221429,JJDRNYKHCUPAGX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CNC(=O)C1=CC=C(C=C1)C(C2=NN=NN2CC3=CC=CC=C3)N4CCCN(CC4)C5CCC5,4.301029995663981,CNC(=O)c1ccc(C(c2nnnn2Cc2ccccc2)N2CCCN(C3CCC3)CC2)cc1
16186,CHEMBL3125385,JJEQHQDCYGPKKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C2=CC=CC=C21)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N,4.3979400086720375,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2ccccc21
16189,CHEMBL3702739,JJGHCLANFUCWPB-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3640.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCN(CC)CCNC(=O)C1=CN(C2=C(C=CC=C12)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C,5.438898616350944,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN(CC)CC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
16191,CHEMBL3680985,JJHAQEOFFYLRAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3800.0,NM,253318,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",Metalloenzyme inhibitor compounds,,PATENT,,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OC(F)(F)F,5.42021640338319,OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OC(F)(F)F)cc2)cn1
16207,CHEMBL1682900,JJPKQUVDOTUNRO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C3=C(C=C2)C(=O)NC3)(C4=CN=CN4)O,5.173925197299173,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1cnc[nH]1
16208,CHEMBL1682900,JJPKQUVDOTUNRO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C3=C(C=C2)C(=O)NC3)(C4=CN=CN4)O,5.130768280269024,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1cnc[nH]1
16209,CHEMBL1682900,JJPKQUVDOTUNRO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C3=C(C=C2)C(=O)NC3)(C4=CN=CN4)O,5.0,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1cnc[nH]1
16216,CHEMBL3331521,JJQZDOKXARNTKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221665.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,CCCCOC1=CN=CC(=C1)C2=NN=C3N2C4=C(C=CC(=C4)CN5CCOCC5)N=C3C,5.0,CCCCOc1cncc(-c2nnc3c(C)nc4ccc(CN5CCOCC5)cc4n23)c1
16223,CHEMBL2397306,JJSJJDRYTQMCBL-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)CN2[C@@H](COC2=O)C(C)C)C3=CC=C(C=C3)N,4.522878745280337,Cc1nc(NC(=O)CN2C(=O)OC[C@H]2C(C)C)sc1-c1ccc(N)cc1
16225,CHEMBL2436223,JJTKZZXKJLOOGG-UZIITKLFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@H]1[C@@H](C(=O)N(C2=C(N1C(=O)CS(=O)(=O)C)C=C(C=C2)C#N)CC3=C(C=CC4=CC=CC=C43)OC)NC(=O)[C@H](C)NC.Cl,4.301029995663981,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)[C@H]1C
16230,CHEMBL2397415,JJVAPHYEOZSKJZ-JGCGQSQUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23632269.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus-infected insect cell microsomes assessed as benzoylresorufin conversion to resorufin metabolites after 45 mins by fluorescence assay,"Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O,4.619788758288394,Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12
16231,CHEMBL2397415,JJVAPHYEOZSKJZ-JGCGQSQUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23632269.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus-infected insect cell microsomes assessed as 7-benzyloxy-4-trifluoromethylcoumarin conversion to 7-hydroxy-4-trifluoromethylcoumarin after 20 mins by fluorescence assay,"Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O,4.3979400086720375,Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12
16237,CHEMBL2030402,JJWLXRKVUJDJKG-VIFPVBQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22560567.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of XL413, a potent and selective CDC7 inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@H](NC1)C2=NC3=C(C(=O)N2)OC4=C3C=C(C=C4)Cl,4.301029995663981,O=c1[nH]c([C@@H]2CCCN2)nc2c1oc1ccc(Cl)cc12
16238,CHEMBL241241,JJWMJWGVQCRRFZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC(F)(F)F)(C)C4=CC(=CC(=C4)F)F,6.568636235841013,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC(F)(F)F)C(=O)C(C)(c1cc(F)cc(F)c1)O2
16243,CHEMBL2425611,JJZNHUUZTYYRMQ-KYJTYKTMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC=CC(=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)OCC(F)(F)F,6.522878745280337,CC(C)(C)c1cccc(CN[C@H]2C[S@+]([O-])C[C@@H](Cc3cc(F)c(N)c(OCC(F)(F)F)c3)[C@@H]2O)c1
16245,CHEMBL2158289,JJZWAMOLUCACLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,CN(CCO)CC(=O)N1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4,5.173925197299173,CN(CCO)CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1
16248,CHEMBL486597,JKCVMTYNARDGET-HOTGVXAUSA-N,DIHYDROCUBEBIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,9500.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,C1OC2=C(O1)C=C(C=C2)C[C@@H](CO)[C@@H](CC3=CC4=C(C=C3)OCO4)CO,5.022276394711152,OC[C@H](Cc1ccc2c(c1)OCO2)[C@H](CO)Cc1ccc2c(c1)OCO2
16252,CHEMBL1173259,JKDQWEZESBYNMI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,730.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,CC(=C(C1=CC=C(C=C1)C2=CC(=CC=C2)O)C3=CC=NC=C3)C,6.136677139879544,CC(C)=C(c1ccncc1)c1ccc(-c2cccc(O)c2)cc1
16261,CHEMBL437341,JKIHWNQARLENJW-GGMFNZDASA-N,ABT-341,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17064063.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.",J. Med. Chem.,PUBLICATION,,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C3=CC[C@@H]([C@H](C3)N)C4=CC(=C(C(=C4)F)F)F.C(=O)(C(F)(F)F)O,4.522878745280337,N[C@H]1CC(C(=O)N2CCn3c(nnc3C(F)(F)F)C2)=CC[C@@H]1c1cc(F)c(F)c(F)c1
16266,CHEMBL480965,JKKIQRNCGVRLBH-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,4.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCCC6,8.346787486224656,Cc1cc(N2CCC(N3CCCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
16280,CHEMBL3627899,JKMOLEWKZMQMRF-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25978966.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=C(C=C1)F)N=C(NC2=O)[C@@H](CNC(=O)C3=C(C=C(C=C3Cl)N4C=NC(=N4)C)Cl)C5=CC(=CC=C5)F,4.301029995663981,Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4c(F)ccc(C)c4c(=O)[nH]3)c(Cl)c2)n1
16298,CHEMBL1784354,JKTGELXOMXEKJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)F)N(C=O)O,5.0,CC(C)(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O
16314,CHEMBL538632,JLCRPHKUMRKGFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,=,4.7,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)C5=CN=CC=C5)CC(C)(C)C(=O)O,8.327902142064282,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3cccnc3)cc2)c2ccc(OCc3ccccn3)cc12
16322,CHEMBL2376562,JLEWSFZFGVKGLO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23545108.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC(=C2)OC3=CC=CC=C3)C(=O)O,4.522878745280337,Cc1ccc(S(=O)(=O)Nc2cc(Oc3ccccc3)ccc2C(=O)O)cc1
16339,CHEMBL1288288,JLKSCYCLWCURKZ-GNAFDRTKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C2=C(C(=O)N(C1=O)C)N(C(=C2)N3CCC[C@@](C3)(C)N)CC4=C(C=CC(=C4)F)C#N.Cl,5.026872146400302,CCn1c(=O)n(C)c(=O)c2c1cc(N1CCC[C@@](C)(N)C1)n2Cc1cc(F)ccc1C#N
16372,CHEMBL219162,JLSTVOPSMZBZSR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16950620.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C2=CC=CC=C2N=C1C3=CC=CC=C3)C(=O)NN(C4=CC=CC=C4)C(=O)OC,4.920818753952375,COC(=O)N(NC(=O)c1c(OC)c(-c2ccccc2)nc2ccccc12)c1ccccc1
16384,CHEMBL3359017,JLVUZSRCFYVLQG-ZSOGYDGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25210858.0,IC50,=,53000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2CN(C[C@@H]2CC1C3=CC=CC=C3C(F)(F)F)C(=O)NC4=C(C=C(C=C4)F)C(=O)O,4.275724130399211,O=C(O)c1cc(F)ccc1NC(=O)N1C[C@H]2CC(c3ccccc3C(F)(F)F)C[C@H]2C1
16388,CHEMBL3325551,JLXFCNWPMMNUMM-RHSMWYFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25176194.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNC[C@@H]([C@H]1C2=CC=C(C=C2)Cl)COC3=CC(=C(C=C3F)S(=O)(=O)NC4=NC=C(C=N4)F)F,5.0,O=S(=O)(Nc1ncc(F)cn1)c1cc(F)c(OC[C@H]2CNCC[C@@H]2c2ccc(Cl)cc2)cc1F
16395,CHEMBL2048063,JMAIWRCWOGUIRQ-VOWSPCBNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ß-peptides.,J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=CC(=NO1)CN[C@H]2CS(=O)(=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,6.3979400086720375,CC(C)(C)Cc1cc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)no1
16397,CHEMBL3415629,JMBODOHYRWZQEW-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25734520.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis,Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.,J. Med. Chem.,PUBLICATION,,C[C@@]1(CCN(C1=O)C2=CC=C(C=C2)Cl)NC3=CC=C(C=C3)C(=O)NO,4.301029995663981,C[C@]1(Nc2ccc(C(=O)NO)cc2)CCN(c2ccc(Cl)cc2)C1=O
16398,CHEMBL526081,JMBWJWVAQBXXJN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,357.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC2=C(C=CC(=C2)C3=CC(=C(C=C3)O)O)C(=C1)C4=CC=NC=C4.Br,6.447331783887807,Oc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1O
16401,CHEMBL1094552,JMEWMZJZKKQIDU-RBSBEOHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,420.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OC[P@@]4(=O)OCC[C@H](O4)C5=CC(=CC=C5)Cl,6.376750709602099,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccc(Cl)c3)O2)c2c(c1C)Cc1scnc1-2
16402,CHEMBL1096871,JMEWMZJZKKQIDU-YRVHBCJASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OC[P@]4(=O)OCC[C@H](O4)C5=CC(=CC=C5)Cl,5.568636235841013,Cc1cc(OC[P@]2(=O)OCC[C@@H](c3cccc(Cl)c3)O2)c2c(c1C)Cc1scnc1-2
16420,CHEMBL12131,JMPFSEBWVLAJKM-UHFFFAOYSA-N,CLOSANTEL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)I)I)O)Cl)C(C#N)C3=CC=C(C=C3)Cl,5.301029995663981,Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O
16425,CHEMBL2425156,JMQOIKOCLOMDPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CN=CC=C4,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cccnc3)cc2)cc1
16436,CHEMBL526841,JMWWMMLEAUJIFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)NCC3=C(C=C(C=C3)F)Cl)N4C=NC=N4)C,5.5376020021010435,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3cncn3)cn2c1C
16437,CHEMBL526841,JMWWMMLEAUJIFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)NCC3=C(C=C(C=C3)F)Cl)N4C=NC=N4)C,5.2839966563652006,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3cncn3)cn2c1C
16440,CHEMBL2386077,JMYRYCOGQOEXOC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC(=CC=C4)Cl,4.301029995663981,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc(Cl)c1)CC2
16452,CHEMBL3393485,JNCWYNONXJVKGY-ZMBIFBSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)[C@@H](C3=C(N2)CN(CC3=O)C(=O)CN)C4=CC=C(O4)SC5=NC6=CC=CC=C6N5.Cl,6.301029995663981,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CN(C(=O)CN)C1)[C@H]2c1ccc(Sc2nc3ccccc3[nH]2)o1
16461,CHEMBL1097425,JNGUPQQSJDYXDB-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)S(=O)(=O)C,6.221848749616356,Cc1cc(N2CCN(S(C)(=O)=O)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
16463,CHEMBL3358933,JNJSRSUVKCYZLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC(=CC=C4)F,7.0,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(F)c1
16464,CHEMBL605209,JNLXUEPMJIMNHM-JMSVASOKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)OC[C@@H]1[C@@H]2[C@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,5.096910013008056,CC(C)OC[C@@H]1[C@H]2CNC[C@]21c1ccc(Cl)c(Cl)c1
16478,CHEMBL3114729,JNRQQUKZSNQOTK-YTTGMZPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N(CCCN(CC2=CC=CC=C2)C(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.522878745280337,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(CCCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
16487,CHEMBL3234574,JNWZPZQICCVLFU-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCCC[C@H]3C(=O)NCCC4=CC=C(C=C4)C#N,6.3979400086720375,CN1CCN(c2cc(N3CCCC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1
16495,CHEMBL2017288,JNYUGWPUYNNZOZ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)[C@H](C)C5=CC=CC=C5)OC,5.823908740944319,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccc3)c12
16496,CHEMBL2017288,JNYUGWPUYNNZOZ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)[C@H](C)C5=CC=CC=C5)OC,5.823908740944319,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccc3)c12
16497,CHEMBL2017287,JNYUGWPUYNNZOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=C5)OC,5.698970004336019,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccc3)c12
16512,CHEMBL389408,JOBKFJOPMWJCEM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=C(C=C3)Cl)Cl,4.6020599913279625,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)c(Cl)c2)nc1C(F)(F)F
16520,CHEMBL3408946,JOCNOQUWDPPPRY-LYWAIKEGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7NC6=O,5.301029995663981,C[C@H]1CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)C[C@@H](C)O1
16521,CHEMBL3408946,JOCNOQUWDPPPRY-LYWAIKEGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7NC6=O,5.292429823902063,C[C@H]1CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)C[C@@H](C)O1
16527,CHEMBL205742,JOFQERPJMGKMMX-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CC3=CC=NC4=CC=CC=C34)C(=O)N5CC[C@H](C5)O)C(=O)N(C1=O)C,4.795880017344075,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccccc34)sc21
16528,CHEMBL205742,JOFQERPJMGKMMX-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CC3=CC=NC4=CC=CC=C34)C(=O)N5CC[C@H](C5)O)C(=O)N(C1=O)C,4.795880017344075,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccccc34)sc21
16543,CHEMBL2387602,JOJCAIVXGLEAHI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C2C=C(C=CC2=C1)C3=CC4=C(C=C3)C5=C(C(=O)N4)NC(=N5)C6=CC=CC=C6Cl,4.522878745280337,O=c1[nH]c2cc(-c3ccc4ccccc4c3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
16547,CHEMBL2448727,JOJLHQJMMXWUOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,775.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCN(CC1=CN=CC=C1)C2=CC(=CC(=C2)C3=NC4=CC=CC=C4S3)F,6.110698297493689,CCN(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1
16548,CHEMBL2204360,JOJYHYRCIYAVHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C.Cl,5.0,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1
16550,CHEMBL3084389,JONDVPWMQDOELC-FVQHAEBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536438.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=CN=C1OC2C[C@H]3CC[C@@H](C2)N3S(=O)(=O)C4CC4)NC5=C(C=C(C=C5)C#N)Cl,4.698970004336019,Cc1c(Nc2ccc(C#N)cc2Cl)ncnc1OC1C[C@@H]2CC[C@H](C1)N2S(=O)(=O)C1CC1
16560,CHEMBL2436332,JOONUKBNTJXHQT-GYUFFBBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC(=CC=C5)F)NC.Cl,5.920818753952375,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cccc(F)c2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
16564,CHEMBL3673967,JOPUUWAQIQBQBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320637,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=C(C=CN=C4)C(F)(F)F,5.301029995663981,FC(F)(F)c1ccncc1CNc1ccc(Cc2c[nH]c3ncc(Cl)cc23)cn1
16565,CHEMBL3673967,JOPUUWAQIQBQBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320681,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=C(C=CN=C4)C(F)(F)F,5.301029995663981,FC(F)(F)c1ccncc1CNc1ccc(Cc2c[nH]c3ncc(Cl)cc23)cn1
16569,CHEMBL205142,JOPYKTLQPXTHOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCCN5CCCCC5)C,6.0,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCN5CCCCC5)c(C)c34)ccc2[nH]1
16570,CHEMBL3091464,JOPYOUMYBIOXDP-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3ß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1N2CCO[C@H](C2)C3=CC(=CC=C3)OC)C4=NC=NC=C4,4.301029995663981,COc1cccc([C@H]2CN(c3nc(-c4ccncn4)cc(=O)n3C)CCO2)c1
16573,CHEMBL1911825,JOTGVMDUCWBJHB-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,5400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C1CN(C1)C(=O)[C@@H](COCC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,5.267606240177032,CN(C)C1CN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1
16580,CHEMBL3114896,JOYCVKLNKIMEJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412066.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N1CCC(CC1)N2C3=NC=NC(=C3C=N2)NC4=C(C=C(C=C4)S(=O)(=O)C)F,5.508638306165727,CC(C)(C)OC(=O)N1CCC(n2ncc3c(Nc4ccc(S(C)(=O)=O)cc4F)ncnc32)CC1
16590,CHEMBL1222485,JPGAOJPEVJFAIQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,9500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4NC3=O)CC5=CC=NC=C5,5.022276394711152,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
16598,CHEMBL2415097,JPJZDOOCHAXOHX-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23890837.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design and synthesis of bicyclic heterocycles as potent ¿-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(C=N1)C2=C(C=C(C=C2)C3=NN4CCC[C@H](C4=N3)C5=CC=CC=C5C(F)(F)F)OC,7.0,COc1cc(-c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1
16606,CHEMBL3702821,JPMVTIGHBDXBLG-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9330.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C#N,5.0301183562535,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C#N)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
16622,CHEMBL324033,JPSLHUGQAVTRKD-SSNHPIBPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)COC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](CN3CCN(C[C@H]3C(=O)NC(C)(C)C)CC4=CN=CC=C4)O,5.638272163982407,CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cccnc3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1
16623,CHEMBL1169660,JPSNCFIAJUMDJJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20627722.0,IC50,=,20417.38,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)C(=O)NCCO)OC2=C(C=C(C=N2)Cl)NS(=O)(=O)C3=CC(=C(C=C3)Cl)Cl,4.6899999882307535,O=C(NCCO)c1ccccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1
16625,CHEMBL1782521,JPSRNNAKSXAWPL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21507633.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC1CNC2=C3C(=CC(=C2)Br)C=C(O3)C(=O)O,5.0,O=C(O)c1cc2cc(Br)cc(NCC3CCNCC3)c2o1
16626,CHEMBL3127494,JPTLLIYJDQIUGS-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1COCCC1N2C=C(C=N2)S(=O)(=O)C3=CC=C(C=C3)NC(=O)[C@@H]4C[C@H]4C5=CN=CC=C5,5.853871964321762,O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)[C@@H]1C[C@H]1c1cccnc1
16627,CHEMBL3127494,JPTLLIYJDQIUGS-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1COCCC1N2C=C(C=N2)S(=O)(=O)C3=CC=C(C=C3)NC(=O)[C@@H]4C[C@H]4C5=CN=CC=C5,5.7447274948966935,O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)[C@@H]1C[C@H]1c1cccnc1
16645,CHEMBL460996,JPXZSYDJAAJFSV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)C5CCN(CC5)CCO,4.638272163982407,Cc1cc(C2CCN(CCO)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12
16651,CHEMBL3120454,JQAPVYUJGNPKDM-OXTACIITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25597006.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1C[C@H](N(C1)C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=C(S3)C4=CC=C(C=C4)C5=CC=C(C=C5)C6=CN=C(N6)[C@@H]7C[C@@H](CN7C(=O)[C@H](C(C)C)NC(=O)OC)C,4.522878745280337,COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5s4)cc3)cc2)[nH]1)C(C)C
16654,CHEMBL2059906,JQBAIBGWHDJVCY-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22732695.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CSC4=CC=CC=C43)NC(=O)N5CCC6(CC5)C7=CC=CC=C7NC(=O)N6,7.0,O=C1Nc2ccccc2C2(CCN(C(=O)N[C@H](Cc3csc4ccccc34)C(=O)N3CCC(N4CCCCC4)CC3)CC2)N1
16655,CHEMBL3403987,JQBSHVXVLBXSPW-FREGXXQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25754490.0,IC50,<=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate,"trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: Prime site exploration using an oxygen linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1OCC2=CC(=CC=C2)N3C=CC=C3)C(=O)C4=CC(=C(C=C4)OC)OCCCOC,6.698970004336019,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OCc2cccc(-n3cccc3)c2)C(C)C)ccc1OC
16668,CHEMBL599480,JQEUMGMNJYJROS-BJWYYQGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C[C@H]2CC(C[C@H]2C1)N(CC3=CC(=C(C=C3)F)C(F)(F)F)C(=O)C4=CN(C=N4)C,5.301029995663981,CCN1C[C@H]2CC(N(Cc3ccc(F)c(C(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1
16689,CHEMBL400846,JQJQHTPYDUTCAK-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=C(C=CC=C1F)C(F)(F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,5.468521082957745,CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
16690,CHEMBL1081703,JQJWBTBQHCLTMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NCC2=CC=C(C=C2)C3=CC=CC=N3)C4=CC=CC=C4,5.0,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccccn3)cc2)C1
16696,CHEMBL476557,JQODSYNHBPRORC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC(=C1)F)C(C2=CC(=CC=C2)F)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NC(c1cccc(F)c1)c1cccc(F)c1
16697,CHEMBL3422086,JQONSQMAQRQLRF-KBSXYSMTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,930.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1CCC(C1)[C@@H](C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6COC7,6.031517051446065,O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
16698,CHEMBL3422087,JQONSQMAQRQLRF-NZAOONQGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,360.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1CCC(C1)[C@H](C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6COC7,6.443697499232713,O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
16708,CHEMBL591578,JQRFWBUMHAMLAJ-VJTSUQJLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CNC[C@H](CC1CCCCC1)NC(=O)N2CCC[C@H](C2)[C@H](C3=CC(=CC=C3)Cl)OCCNC(=O)OC,5.337242168318426,CNC[C@H](CC1CCCCC1)NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1
16709,CHEMBL1951610,JQSFOIUVRSFMQS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=CN5C=CC=CC5=N4)C)C,5.522878745280337,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1cn3ccccc3n1)c(=O)n2C
16770,CHEMBL2415099,JRESZLRLRZIQBU-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23890837.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design and synthesis of bicyclic heterocycles as potent ¿-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(C=N1)C2=C(N=C(C=C2)C3=NN4CCC[C@H](C4=N3)C5=CC=CC=C5C(F)(F)F)OC,5.0,COc1nc(-c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1
16777,CHEMBL520276,JRGXELISXJQLFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=C(C=CC=N3)Cl,5.3979400086720375,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ncccc1Cl
16787,CHEMBL219113,JRLRJUXCVXQXRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1CNC2=NN=CS2)C(=O)OCC3=CC=CC=C3,4.6020599913279625,O=C(OCc1ccccc1)N1CCC(CNc2nncs2)CC1
16807,CHEMBL3702802,JRUHHFVCRKGWKQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3970.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC(CC8)N9CCCC9,5.401209493236885,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
16836,CHEMBL1909989,JSBRNGDYGFBUPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=C(C=C3)OC)C4=C(C=C(C=C4)Cl)Cl)CN,5.6020599913279625,COc1ccc(N2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)cc1
16847,CHEMBL2165505,JSISTYTUHYTCID-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C1CN(C[C@H]2N1CCOC2)CC3=CC4=C(S3)C(=NC(=N4)C5=C(C=CC6=C5C=CN6)F)N7CCOCC7,5.154901959985743,Fc1ccc2[nH]ccc2c1-c1nc(N2CCOCC2)c2sc(CN3CCN4CCOC[C@H]4C3)cc2n1
16862,CHEMBL2420678,JSKZNFLNBMGDAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=C(C3=C(C=C2)C=CC(=C3F)O)Cl,5.0,Oc1ccc2ccc(-c3cccnc3)c(Cl)c2c1F
16864,CHEMBL1829770,JSLCIPMQVPVXCO-MRDQGFSESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCN)C4=CC=C(C=C4)F,5.522878745280337,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCN)(c2ccc(F)cc2)OC1=O
16865,CHEMBL3632720,JSLFPRZIKITLJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC=C(C=C1)NC2=NC3=C(N2C)C=CC(=C3)OC4=CC(=NC=C4)C5=NC=C(N5)C(F)(F)F,4.468521082957745,Cn1c(Nc2ccc(C(C)(C)C)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
16881,CHEMBL3702800,JSTSCVPRCNNUJT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6940.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)C9CC9,5.158640529545145,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C7CC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
16882,CHEMBL1672629,JSTVKVBTXCGTLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CN=CC=C3)C4=C(C=NC=C4F)F,4.6020599913279625,O=C(Nc1cnc(-c2c(F)cncc2F)c(-c2cccnc2)n1)C1CC1
16885,CHEMBL2425150,JSUVAYVYZLLXNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=NC=C4C,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cncc3C)cc2)cc1
16895,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,6.221848749616356,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
16896,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21146988.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,6.221848749616356,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
16897,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,6.221848749616356,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
16906,CHEMBL2181888,JSYZFOJZNAGVKR-OIFRRMEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,160.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)C[C@@H]2NC[C@H]([C@H](CC4=CC(=CC=C4)C5=CC=NC=C5)NC(=O)COC)O,6.795880017344075,COCC(=O)N[C@@H](Cc1cccc(-c2ccncc2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
16921,CHEMBL561132,JTCAGRAKUAAYDY-OAHLLOKOSA-N,MK-7246,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,5.154901959985743,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1
16923,CHEMBL561132,JTCAGRAKUAAYDY-OAHLLOKOSA-N,MK-7246,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106375.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.468521082957745,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1
16924,CHEMBL561132,JTCAGRAKUAAYDY-OAHLLOKOSA-N,MK-7246,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21185722.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azaindoles as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.468521082957745,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1
16925,CHEMBL561132,JTCAGRAKUAAYDY-OAHLLOKOSA-N,MK-7246,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21515053.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.468521082957745,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1
16928,CHEMBL3291337,JTCWAXISFRLVOA-ACJLOTCBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@]12CC[C@@H](C1(C)C)C3=C2N(N(C3=O)C4=CC=CC=C4)C,4.301029995663981,Cn1c2c(c(=O)n1-c1ccccc1)[C@H]1CC[C@]2(C)C1(C)C
16933,CHEMBL272336,JTGDXZKJMAMXST-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=C(C=C2)Cl)CCOC3=CC=CC(=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,5.327902142064283,Cc1oc(-c2ccc(Cl)cc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1
16936,CHEMBL252211,JTHCGPJOCAGQDY-UYAOXDASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCNCC4,6.522878745280337,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCNCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
16947,CHEMBL3358921,JTNNQTQMGYMRGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=C(C3=C(N2)C=NC=C3)C)(C(F)(F)F)O,7.0,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1[nH]c2cnccc2c1C)C(F)(F)F
16948,CHEMBL3358921,JTNNQTQMGYMRGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=C(C3=C(N2)C=NC=C3)C)(C(F)(F)F)O,5.42021640338319,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1[nH]c2cnccc2c1C)C(F)(F)F
16957,CHEMBL2204356,JTQUHGRGBNXQDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,C1CN(CCN1)C2=CC=CC=C2SC3=C(C(=CC=C3)Cl)Cl.Cl,5.214670164989233,Clc1cccc(Sc2ccccc2N2CCNCC2)c1Cl
16992,CHEMBL598336,JUBQGWGPNRKSSH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3=CC=NC=C3)OC,5.3979400086720375,COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC
16993,CHEMBL598336,JUBQGWGPNRKSSH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3=CC=NC=C3)OC,4.6777807052660805,COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC
16994,CHEMBL1649665,JUCJQZNUMLLICR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,C1CCC(C1)NC(=O)CC2=CC=C(C=C2)N3C4=C(CCCC4)C(=N3)C(F)(F)F,6.154901959985743,O=C(Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1)NC1CCCC1
17002,CHEMBL2010880,JUEPWZSXQYFPDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22366657.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)CC2=C3C(=CC=C2)NC(=N3)C4=CC=CC=C4,4.301029995663981,c1ccc(-c2nc3c(CN4CCCCC4)cccc3[nH]2)cc1
17007,CHEMBL266158,JUJWROOIHBZHMG-UHFFFAOYSA-N,PYRIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26371436.0,IC50,=,4000000.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase,Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.,J. Med. Chem.,PUBLICATION,,C1=CC=NC=C1,2.3979400086720375,c1ccncc1
17011,CHEMBL3702692,JUKYJTSFENURII-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2240.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)N1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.649751981665837,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
17012,CHEMBL2387597,JULNGCZCLLQCAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CCCCCC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,4.522878745280337,CCCCCc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
17015,CHEMBL526887,JULWIPZNVYARKY-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)F)C4=CC=CC=C4Cl)NCCCC(=O)O,4.698970004336019,O=C(O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2F)c1=O)c1ccccc1
17055,CHEMBL3234564,JUZFKXCBDWBAPH-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NC(=N1)N2CCC[C@H](C2)C(=O)NCCC3=CC=C(C=C3)C#N)N4CCN(CC4)C,4.6020599913279625,Cc1cc(N2CCN(C)CC2)nc(N2CCC[C@@H](C(=O)NCCc3ccc(C#N)cc3)C2)n1
17056,CHEMBL3640786,JUZUBCBEFKWHQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12980.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1=CC(=CN=C1)C2=CC=C(S2)CN=O,4.88672530753565,O=NCc1ccc(-c2cccnc2)s1
17065,CHEMBL3407558,JVBGVXAXEZXWTE-MCUOQOIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,0.0503,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Homogenous Time-Resolved Fluorescence Assay (HTRF). The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",Benzoic acid derivative MDM2 inhibitor for the treatment of cancer,,PATENT,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)NC5=CC(=C(C=C5)C(=O)O)OC,10.298432014944073,COc1cc(NC(=O)C[C@@]2(C)C[C@H](c3cccc(Cl)c3)[C@@H](c3ccc(Cl)cc3)N([C@H](CS(=O)(=O)C(C)(C)C)C3CC3)C2=O)ccc1C(=O)O
17072,CHEMBL2206278,JVCWPUFNLFSKFS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CCN1C(CC(CC1(C)C)OC2=CN=C(C=C2)C(=O)NC3=CC=C(C=C3)NC(=O)NC4=NOC(=C4)C(C)(C)C)(C)C,4.3979400086720375,CCN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C
17081,CHEMBL3112853,JVFSDXQBBQIWBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=CC=CC(=C21)C(F)(F)F)C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c1cccc2C(F)(F)F
17103,CHEMBL1779012,JVJRXNFULOSTER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21524576.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Iinhibition of CYP3A4,"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=CC(=C1)F)C2=CN=CC(=C2)CNC(=O)C3=NC=CN=C3,4.698970004336019,COc1cc(F)ccc1-c1cncc(CNC(=O)c2cnccn2)c1
17107,CHEMBL2347185,JVLQVDCETUHZMB-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23586711.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.,J. Med. Chem.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CN3)CC4=CC=CC=C4,6.552841968657781,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnc[nH]2)Cc2ccccc2)C(C)C)cs1
17120,CHEMBL2181892,JVNKLECJDZSZDR-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)C[C@@H]2NC[C@H]([C@H](CC4=CC(=CC=C4)C5=NC=CS5)NC(=O)COC)O,7.0,COCC(=O)N[C@@H](Cc1cccc(-c2nccs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
17121,CHEMBL2437417,JVNKPOHWBICHOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CCCC(F)(F)F)CC5=CC(=NC=C5)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCCC(F)(F)F)c5ccccc54)CC3)CC2)ccn1
17123,CHEMBL475927,JVOWBHDCJOSBIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CC=C(C=C3)C#N,4.301029995663981,N#Cc1ccc(C(=O)NCC(=O)NC(c2ccccc2)c2ccc(Cl)cc2)cc1
17126,CHEMBL3335537,JVQBISWUXRKBAJ-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221667.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by electrospray ionization,,ACS Med. Chem. Lett.,PUBLICATION,,C1CO[C@@H](CN1CC2=NC3=CC=CC=C3N2)CCC4=CC=CC=C4,4.522878745280337,c1ccc(CC[C@@H]2CN(Cc3nc4ccccc4[nH]3)CCO2)cc1
17137,CHEMBL2059121,JVUSBRIMSCDKMU-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CCN3CCCC3)C[C@H]([C@H](CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5)O,6.853871964321762,CCN(C)c1nc2ccc(C(=O)N(CCN3CCCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
17138,CHEMBL226386,JVVHLTXQSFRAFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,65000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1CCC(C1)CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC=C3)Cl,4.187086643357144,O=C(NCC1CCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
17145,CHEMBL3289038,JVWTZUKPDMRNDC-XYWHTSSQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24794746.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.",Bioorg. Med. Chem.,PUBLICATION,,C1CC(CCC1N)OC(=O)C2=CC(=CC(=C2)OC3=CC=C(C=C3)C(=N)N)OC4=CC=C(C=C4)C(=N)N,4.522878745280337,N=C(N)c1ccc(Oc2cc(Oc3ccc(C(=N)N)cc3)cc(C(=O)OC3CCC(N)CC3)c2)cc1
17157,CHEMBL1684057,JWGAGXNBADXJOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21310612.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)NC.Cl,4.6020599913279625,CNC(C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
17166,CHEMBL2059877,JWHJIIANXOMUPH-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C=C3)NC(=O)C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.958607314841775,O=C1Cc2cc(C[C@@H](NC(=O)N3CCC(N4Cc5ccccc5NC4=O)CC3)C(=O)N3CCC(N4CCCCC4)CC3)ccc2N1
17171,CHEMBL2163824,JWJDSNJWYOUETR-IRZJEQJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,420.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,C1CC(CC(C1)NC(=O)[C@H](CC2=C(C=C(C=C2)Cl)Cl)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl)N,6.376750709602099,NC1CCCC(NC(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)C1
17175,CHEMBL1270432,JWLSQAAJQTZDQT-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,4100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ß-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)[C@]2(C(=O)N(C(=N2)N)C)C3=CC(=C(C=C3)F)C#CC4CC4)OC(F)F,5.3872161432802645,Cc1cc([C@]2(c3ccc(F)c(C#CC4CC4)c3)N=C(N)N(C)C2=O)ccc1OC(F)F
17194,CHEMBL1951334,JWSOACJPVMVQGH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,98.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CNC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,7.008773924307505,CNC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
17209,CHEMBL455683,JWWBRTLPEUWQCU-OQECSOMKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18990568.0,IC50,=,20600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using dibenzylfluorescein as substrate,Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C2=CNC3=C2C=CC=N3)[C@H](CO)C4CCN(CC4)C(=O)/C=C/C5=CC(=CC(=C5)F)F,4.686132779630847,O=C(/C=C/c1cc(F)cc(F)c1)N1CCC([C@@H](CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1
17210,CHEMBL455683,JWWBRTLPEUWQCU-OQECSOMKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18990568.0,IC50,=,25200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C2=CNC3=C2C=CC=N3)[C@H](CO)C4CCN(CC4)C(=O)/C=C/C5=CC(=CC(=C5)F)F,4.598599459218456,O=C(/C=C/c1cc(F)cc(F)c1)N1CCC([C@@H](CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1
17211,CHEMBL455683,JWWBRTLPEUWQCU-OQECSOMKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18990568.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C2=CNC3=C2C=CC=N3)[C@H](CO)C4CCN(CC4)C(=O)/C=C/C5=CC(=CC(=C5)F)F,4.3979400086720375,O=C(/C=C/c1cc(F)cc(F)c1)N1CCC([C@@H](CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1
17217,CHEMBL1914489,JWYIGNODXSRKGP-UHFFFAOYSA-N,AZD1981,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21944852.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C2=C(C=CC=C2N1CC(=O)O)NC(=O)C)SC3=CC=C(C=C3)Cl,5.0,CC(=O)Nc1cccc2c1c(Sc1ccc(Cl)cc1)c(C)n2CC(=O)O
17244,CHEMBL482637,JXGJTODYQBRZDL-RTIVMORXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CCCN(CC3)C(=O)N[C@H]4C[C@@H]4C5=CC=CC=C5)CC2,5.0,CS(=O)(=O)c1ccc2c(c1)CCC1(CCCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2
17252,CHEMBL2022996,JXIGVUPYYZGRRZ-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22248262.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,CC1=CC(=CC=C1)C(CC[C@H](C(=O)O)N)(C2=CC=CC=C2)C3=CC=CC=C3,4.6020599913279625,Cc1cccc(C(CC[C@@H](N)C(=O)O)(c2ccccc2)c2ccccc2)c1
17253,CHEMBL2022995,JXIGVUPYYZGRRZ-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22248262.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,CC1=CC(=CC=C1)C(CC[C@@H](C(=O)O)N)(C2=CC=CC=C2)C3=CC=CC=C3,4.6020599913279625,Cc1cccc(C(CC[C@H](N)C(=O)O)(c2ccccc2)c2ccccc2)c1
17254,CHEMBL3403824,JXJZEDILUDZDFW-HNLCVBAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)C9COC9)C)C)O)C)C(C)(C)O,5.721246399047171,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
17255,CHEMBL3403824,JXJZEDILUDZDFW-HNLCVBAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)C9COC9)C)C)O)C)C(C)(C)O,5.180456064458132,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
17258,CHEMBL159,JXLYSJRDGCGARV-CFWMRBGOSA-N,VINBLASTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,4.585026652029182,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
17275,CHEMBL2070155,JXONDSQREGQXDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=NC=CC(=C3)C4=CC=CC=C4,5.154901959985743,CCS(=O)(=O)c1ccc2nc(-c3cc(-c4ccccc4)ccn3)[nH]c2c1
17280,CHEMBL1271930,JXQLUDIGMMJLLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933409.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=NC(=NC(=C3)C)SC)C.Cl,4.698970004336019,CSc1nc(C)cc(C(=O)NCCN2CCN(c3cccc(C)c3C)CC2)n1
17296,CHEMBL2441841,JXXNQEGNWBPSSV-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)C[C@@H]3CCCN3S(=O)(=O)C4CC4)C5=C(C=C(C=C5)Cl)Cl)CN,5.522878745280337,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCN1S(=O)(=O)C1CC1)C2
17305,CHEMBL3422238,JYDYMWJEZLKIBS-CXMBCZLWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,CN1C=C(C=N1)[C@H]2C[C@H]3CSC(=N[C@]3(CO2)C4=C(C=C(C=C4)F)F)N,4.522878745280337,Cn1cc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)cn1
17306,CHEMBL1214336,JYFFQMUEOPGGBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=CN=CC=C3,5.0,CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccnc3)cc2C1
17310,CHEMBL389621,JYGXADMDTFJGBT-VWUMJDOOSA-N,HYDROCORTISONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,4.301029995663981,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
17323,CHEMBL2334759,JYSGBOOAYHHKRU-PAXLWEDBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C([C@H]4CC[C@@H](C3)N4C(=O)C)C(=N2)N5CCOC[C@@H]5C,5.136677139879544,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)[C@H]2CC[C@@H](C3)N2C(C)=O)cc1
17325,CHEMBL1682894,JYTGSYXSDJJCCR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,5700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C(C3=CN=CN3)(C(C)C)O,5.2441251443275085,CCNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
17327,CHEMBL3217170,JYUAHTUNBVFGGJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21823597.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by luceferin-based assay,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C.Cl.Cl.Cl,4.698970004336019,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2C)CC1
17329,CHEMBL1829776,JYUZCHJMXCOJJR-MRDQGFSESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCNS(=O)(=O)N)C4=CC=C(C=C4)F,4.920818753952375,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNS(N)(=O)=O)(c2ccc(F)cc2)OC1=O
17337,CHEMBL1090089,JYYLVUFNAHSSFE-UHFFFAOYSA-N,PAMAPIMOD,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21375264.0,IC50,>,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38a mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,CN1C2=NC(=NC=C2C=C(C1=O)OC3=C(C=C(C=C3)F)F)NC(CCO)CCO,4.5376020021010435,Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21
17342,CHEMBL3702716,JZAVQNHDPXFZNV-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3860.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCOC(=O)C1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.413412695328245,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(C(=O)OCC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
17343,CHEMBL377177,JZBAXRLBKQTQQE-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]([C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCCC3)C(=O)O)N4C=CN=C4)N(C)C,5.086186147616283,C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1)N(C)C
17345,CHEMBL111,JZCPYUJPEARBJL-UHFFFAOYSA-N,RIMONABANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673729.0,IC50,>,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 30 mins,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,PUBLICATION,,CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl,7.698970004336019,Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1
17348,CHEMBL412024,JZDBOFKXYADYQD-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CN(C)C,4.823908740944319,CC(C)C[C@H](NC(=O)CN(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
17351,CHEMBL3298836,JZEFDHAAEABKGE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,=,490.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCN(CC4)C5=CC=C(C=C5)F,6.309803919971486,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(F)cc3)CC2)cc1
17366,CHEMBL434936,JZIURJIEJBKSKI-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,7.0,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F
17367,CHEMBL434936,JZIURJIEJBKSKI-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,7.0,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F
17368,CHEMBL434936,JZIURJIEJBKSKI-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,7.0,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F
17369,CHEMBL3408940,JZIZUMLXHJPWJH-WQRKFILVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=NC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7N(C6=O)C,6.522878745280337,CN1CCN(c2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)N(C)c5ccccc56)ccc34)cn2)CC1
17370,CHEMBL3408940,JZIZUMLXHJPWJH-WQRKFILVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=NC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7N(C6=O)C,5.5376020021010435,CN1CCN(c2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)N(C)c5ccccc56)ccc34)cn2)CC1
17378,CHEMBL2022739,JZLFWWQOPQHUPT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22503453.0,IC50,=,64000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1CCCCNC2=NN=C(O2)C3=C(C=C(C=C3)NC(=O)C4=CC=CC=C4F)F,4.1938200260161125,O=C(Nc1ccc(-c2nnc(NCCCCN3CCOCC3)o2)c(F)c1)c1ccccc1F
17379,CHEMBL2022739,JZLFWWQOPQHUPT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22503453.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1CCCCNC2=NN=C(O2)C3=C(C=C(C=C3)NC(=O)C4=CC=CC=C4F)F,4.0,O=C(Nc1ccc(-c2nnc(NCCCCN3CCOCC3)o2)c(F)c1)c1ccccc1F
17389,CHEMBL1270335,JZQHTDKITQYMAR-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ß-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)[C@@](N=C1N)(C2=CC=C(C=C2)OC(F)F)C3=CC(=C(C=C3)F)C#CC4CC4,5.0,CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2ccc(F)c(C#CC3CC3)c2)N=C1N
17403,CHEMBL2425599,JZTFFTMPOGLVCG-CBZQJITBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC(=CC=C1)C(C)(C)C)N[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F,7.0,COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](N[C@H](C)c3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F
17431,CHEMBL3359022,JZWRBLGQVCTHKC-ZSOGYDGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25210858.0,IC50,<,46.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2CN(C[C@@H]2CC1C3=CC=CC=C3C(F)(F)F)C(=O)NC4=C(C=NC=C4)C(=O)O,7.337242168318426,O=C(O)c1cnccc1NC(=O)N1C[C@H]2CC(c3ccccc3C(F)(F)F)C[C@H]2C1
17432,CHEMBL2448706,JZXBDYCABDJUSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CN(CC(COC1=CC2=C(C=C1)C=C(C=C2)Br)O)C3CCCCC3,5.0,CN(CC(O)COc1ccc2cc(Br)ccc2c1)C1CCCCC1
17438,CHEMBL428586,JZXUGHRCBRCPON-ZKMPZPQNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN2CCN(C[C@@H]2C1)C(=O)CC3(CC3)[C@H]4CCC[C@H](N4S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,5.7447274948966935,O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN2CCCC[C@H]2C1
17442,CHEMBL2332068,KACIGJBSABVNRF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23570561.0,IC50,=,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CN(C)CCN(CC1=CC(=CC=C1)OC)C(=O)NC2=CC=C(C=C2)C3=CNN=C3,4.096910013008056,COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1
17444,CHEMBL3358934,KAEZOVLEAHIZGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=C(C=C4)F,7.0,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1
17448,CHEMBL3289803,KAHGRTFKEJELQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914738.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1C(F)(F)F)Cl)C(CN2C3=C(C=CC(=C3)C(F)(F)F)N=C2N)O,4.522878745280337,Nc1nc2ccc(C(F)(F)F)cc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl
17455,CHEMBL3682508,KAJOKEZYYKICFN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,200000.0,NM,291609,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",Metalloenzyme inhibitor compounds,,PATENT,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC(F)(F)F)O,3.6989700043360187,CC(C)C(O)c1ccc2cc(OCC(F)(F)F)ccc2c1
17456,CHEMBL3125384,KAKATSTZIXKFNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O)C=CC=C2Br,4.3979400086720375,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O
17466,CHEMBL2043325,KAPZNJYOKZDXPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
17473,CHEMBL2437426,KARTZJAENYQGIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1CN2C3=C(C=CC(=C3)F)N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC(=NC=C6)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC5CC5)c5cc(F)ccc54)CC3)CC2)ccn1
17479,CHEMBL1091778,KAWDUHFGBOIYCO-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,C[C@@H](c1cccnc1)c1c(CCN(C)C)sc2ccccc12
17480,CHEMBL1091777,KAWDUHFGBOIYCO-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,5.3979400086720375,C[C@H](c1cccnc1)c1c(CCN(C)C)sc2ccccc12
17481,CHEMBL1091776,KAWDUHFGBOIYCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,CC(c1cccnc1)c1c(CCN(C)C)sc2ccccc12
17483,CHEMBL241896,KAYCKFWCZGZEHA-WEPZFIBGSA-N,GERANYLCOUMARIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17400460.0,IC50,=,42930.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit.,Bioorg. Med. Chem.,PUBLICATION,,CC(C)/C=C/C/C(=C/COC1=CC2=C(C=C1)C=CC(=O)O2)/C,4.367239111520561,C/C(=C\COc1ccc2ccc(=O)oc2c1)C/C=C/C(C)C
17485,CHEMBL1777855,KAYILIDZNSBIOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC#CC(CC(=O)O)C1=C(C=C(C=C1)OC2=C(C=C(C=C2)C(F)(F)F)OC(F)F)F,4.301029995663981,CC#CC(CC(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1F
17487,CHEMBL1911817,KAZJACRSYJQAEE-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,13500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)C(=O)[C@@H](COCC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,4.869666231504994,CN1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
17491,CHEMBL2448743,KBAQNZRYJNJHIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,576.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCN(CC1=CN=CN1)C2=CC(=CC(=C2)C3=NC4=CC=CC=C4S3)F,6.239577516576788,CCN(Cc1cnc[nH]1)c1cc(F)cc(-c2nc3ccccc3s2)c1
17493,CHEMBL393789,KBBHXCZBVZTXQH-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,720.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCC(=O)N,6.142667503568732,CC(C)C[C@H](NCC(N)=O)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
17495,CHEMBL3358948,KBCDLIHQEVOPOI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C=C1)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)S(=O)(=O)C)(C(F)(F)F)O)C(=O)N,5.221848749616356,Cc1ccc(C(C)(C)CC(O)(Cc2cc3cc(S(C)(=O)=O)ncc3[nH]2)C(F)(F)F)c(C(N)=O)c1
17502,CHEMBL1223034,KBDZMHUBIGWJPD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673729.0,IC50,>,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 30 mins,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)(C)C1=NN=C(S1)C2=NN(C(=C2CN3C=NC=N3)C4=CC=C(C=C4)Br)C5=C(C=C(C=C5)Cl)Cl,7.698970004336019,CC(C)(C)c1nnc(-c2nn(-c3ccc(Cl)cc3Cl)c(-c3ccc(Br)cc3)c2Cn2cncn2)s1
17533,CHEMBL1077340,KBLBAKODFLPDCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)N5CCC(CC5)N6CCN(CC6)C(=O)OC,6.0,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCCn6cc(Cl)cn6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
17536,CHEMBL3354313,KBMWPOLIYQYLRJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25455487.0,IC50,=,6710.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) after 3 mins by LC-MS/MS analysis,"Serendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=NC=C(C=C1)C2=NC(=NC3=C2SC=C3)CS(=O)(=O)C4=CC(=CC=C4)Cl,5.1732774798310075,COc1ccc(-c2nc(CS(=O)(=O)c3cccc(Cl)c3)nc3ccsc23)cn1
17550,CHEMBL254912,KBQBORFEXVLABK-ZEQKJWHPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCC(CC4)N5CCCCC5,5.920818753952375,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC(N4CCCCC4)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
17551,CHEMBL2181786,KBQRHEVOBYQPPE-QGOAFFKASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)NC1=CC=C(C=C1)/C=C/C(=O)O)NC(=O)C2=CC3=C(C=C2)C(=C(N3C)C4=CC=CC=N4)C5CCCC5,5.102372908709558,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21
17552,CHEMBL596700,KBRWHYVGRXRJIC-MUJYYYPQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)C(=O)N(CC2=CC(=CC=C2)OC(F)(F)F)C3C[C@@H]4CNC[C@@H]4C3,5.0,Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)C2C[C@@H]3CNC[C@@H]3C2)c1
17554,CHEMBL2023803,KBSBJZXYFDQQMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497760.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NN(C=C1NC(=O)CC2=C(C=C(C=C2)OC3=C4C=CC(=CC4=NC=C3)OC)OC)C.OS(=O)(=O)O,5.0,COc1ccc2c(Oc3ccc(CC(=O)Nc4cn(C)nc4C)c(OC)c3)ccnc2c1
17559,CHEMBL1630,KBTNVJNLEFHBSO-UHFFFAOYSA-N,AMODIAQUINE HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,"Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate","Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O.Cl,4.552841968657781,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
17560,CHEMBL1630,KBTNVJNLEFHBSO-UHFFFAOYSA-N,AMODIAQUINE HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O.Cl,4.0,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
17561,CHEMBL1630,KBTNVJNLEFHBSO-UHFFFAOYSA-N,AMODIAQUINE HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using DEF substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O.Cl,4.552841968657781,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
17562,CHEMBL1630,KBTNVJNLEFHBSO-UHFFFAOYSA-N,AMODIAQUINE HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using PPR substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O.Cl,4.0,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
17565,CHEMBL495493,KBVAYGZXOAZDKK-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,CCNC1=NOC2=C1C=CC(=C2C3=CC4=CN=NC(=C4C=C3)N5CCOC[C@@H]5C)C,5.0,CCNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(C)ccc12
17571,CHEMBL3115188,KBZPKTMYSVUUNF-JHFJJOSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCNC(=O)C)C(=O)N[C@@H](CC[C@@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.920818753952375,CC(=O)NCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
17572,CHEMBL3115182,KBZPKTMYSVUUNF-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCNC(=O)C)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.823908740944319,CC(=O)NCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
17575,CHEMBL2347990,KCAVKWMGHFWNGD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(CO)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)F)CCC(CO)O,4.301029995663981,CC(C)(CO)NC(=O)c1c[nH]c2ncc(-c3nn(CCC(O)CO)c4cc(F)ccc34)nc12
17584,CHEMBL499026,KCCHSZZXJXIDAP-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)COC(=O)CO)N,6.920818753952375,N[C@@H](Cn1c(=O)c(-c2ccc(COC(=O)CO)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
17587,CHEMBL3133005,KCEBLEVIKCWQMU-JNSHFYNHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,MedChemComm,PUBLICATION,,C1CC(CCC1CC(=O)O)OC2=NC=C(C=C2)NC(=O)C3=NN=C(O3)NC4=CC(=C(C=C4)F)F,5.0,O=C(O)CC1CCC(Oc2ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cn2)CC1
17620,CHEMBL2057528,KCNVHXJEALIYQI-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,55.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=CO4,7.259637310505756,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncoc2c1
17621,CHEMBL3264598,KCNWFHLEERWIML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=NC=NN3)O,4.0,COc1cc2ccc(C(O)(c3ncn[nH]3)C(C)C)cc2cc1OC
17625,CHEMBL2059786,KCPUZNAAPSFNSG-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@H](C(=O)N1CCC(CC1)N2CCCCC2)NC(=O)N3CCC(CC3)N4C5=CC=CC=C5NC4=O,4.795880017344075,CC(C)C[C@@H](NC(=O)N1CCC(n2c(=O)[nH]c3ccccc32)CC1)C(=O)N1CCC(N2CCCCC2)CC1
17632,CHEMBL1092494,KCSVGYHUQTUHTM-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)Cl,5.0,C[C@@H](c1ncccc1Cl)c1c(CCN(C)C)sc2ccccc12
17633,CHEMBL480966,KCSXXVMVRJMJFA-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.7,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)NC(=O)C6CC6,9.154901959985743,Cc1cc(N2CCC(NC(=O)C3CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
17634,CHEMBL480966,KCSXXVMVRJMJFA-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)NC(=O)C6CC6,6.154901959985743,Cc1cc(N2CCC(NC(=O)C3CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
17660,CHEMBL1642897,KDERKEZKMQCRPQ-DZGCQCFKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,=,17100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CN[C@@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,4.767003889607846,CN[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
17661,CHEMBL1642896,KDERKEZKMQCRPQ-HIFRSBDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CN[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,4.6020599913279625,CN[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
17662,CHEMBL1642895,KDERKEZKMQCRPQ-UKRRQHHQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CN[C@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,4.6020599913279625,CN[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
17663,CHEMBL1642894,KDERKEZKMQCRPQ-ZFWWWQNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CN[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,4.6020599913279625,CN[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
17666,CHEMBL220660,KDHKDFONLOHKCA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1CNC2=NC=CN=C2)C(=O)OCC3=CC=CC=C3,4.657577319177793,O=C(OCc1ccccc1)N1CCC(CNc2cnccn2)CC1
17667,CHEMBL2178223,KDHZEOLHBGWCJL-PAJWBHGYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061376.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,PUBLICATION,,CC(C)(CN1C[C@@H]([C@H](C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=C(C=C3)/C=C/C(=O)NC4=CC=CC=C4N)O,5.522878745280337,CC(C)(O)CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1
17668,CHEMBL3417530,KDIHNMYGWTUGIV-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25671290.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,PUBLICATION,,C[C@@](C1CC1)(C2=CC=C(C=C2)C3=CN=C(N=C3)N)C4=NOC(=N4)C5=CN(N=C5)CCN(C)C,4.522878745280337,CN(C)CCn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1
17669,CHEMBL3237449,KDIKLUVXDINZHL-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,C[C@@H](CO)N1C2=C(C=CN=C2)C3=CN=C(N=C31)NC4=NC=C(C=C4)N5CCNCC5,5.0,C[C@@H](CO)n1c2cnccc2c2cnc(Nc3ccc(N4CCNCC4)cn3)nc21
17691,CHEMBL1778639,KDOSMMYSHYZFQE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21592791.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC(=C(C=C1)C2=C(C=CC(=C2)C(F)(F)F)OCC(=O)O)C,4.301029995663981,CCS(=O)(=O)c1ccc(-c2cc(C(F)(F)F)ccc2OCC(=O)O)c(C)c1
17695,CHEMBL206096,KDRGQJRCUVUELE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16503138.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)COC2=C(C=C(C=C2)Cl)C3=C(N=CC=C3)C4=CC(=CC=C4)C(=O)O,4.301029995663981,O=C(O)c1cccc(-c2ncccc2-c2cc(Cl)ccc2OCc2ccccc2)c1
17698,CHEMBL404401,KDTMLCXQOWKVOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NC)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,5.6777807052660805,CNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1
17699,CHEMBL567570,KDUIBMLGMZJDAG-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=CC=CC=C32)C(=O)C4=CC=CC=C4,4.3979400086720375,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccccc12
17700,CHEMBL567570,KDUIBMLGMZJDAG-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=CC=CC=C32)C(=O)C4=CC=CC=C4,4.3979400086720375,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccccc12
17709,CHEMBL3393295,KDXXYHDZDWLQGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C#N)OC2=CC=C(C=C2)C(=O)NCC3=CN=CC=C3,5.0,N#Cc1ccccc1Oc1ccc(C(=O)NCc2cccnc2)cc1
17716,CHEMBL1092118,KEDAYBZXXNOGOP-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CN=CS1)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,C[C@@H](c1cncs1)c1c(CCN(C)C)sc2ccccc12
17720,CHEMBL425519,KEERDUCTIKTUOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,39100.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,CC1=CSC=C1C2=CN=C(C=C2)F,4.407823242604133,Cc1cscc1-c1ccc(F)nc1
17721,CHEMBL425519,KEERDUCTIKTUOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,114000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,CC1=CSC=C1C2=CN=C(C=C2)F,3.9430951486635273,Cc1cscc1-c1ccc(F)nc1
17722,CHEMBL227670,KEHDIZISMAQBKX-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N(C2=O)CC3=CC=CC=C3C#N)N4CCC[C@H](C4)N,6.698970004336019,COc1ccc2nc(N3CCC[C@@H](N)C3)n(Cc3ccccc3C#N)c(=O)c2c1
17731,CHEMBL3291120,KELRBTWVTDHIHS-KGTFJIFRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CC=CC(=C4)CO)C,5.721246399047171,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cccc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
17732,CHEMBL3291120,KELRBTWVTDHIHS-KGTFJIFRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1950.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CC=CC(=C4)CO)C,5.709965388637482,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cccc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
17735,CHEMBL3236358,KENRSCUSWCVFPT-ZJTSJXPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1[C@@H]([C@H](C[C@](C1=O)(C)CC2=NNN=N2)C3=CC(=CC=C3)Cl)C4=CC=C(C=C4)Cl,5.6020599913279625,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(Cc2nn[nH]n2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
17742,CHEMBL403149,KEPLTYGEHMAOOM-DNVJHFABSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=CO1)[C@H](C(=O)N2CCC2)N3[C@@H](C(=O)N[C@@H](C3=O)C4CC5=CC=CC=C5C4)CC(C)C,4.0,Cc1nc([C@H](C(=O)N2CCC2)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1
17746,CHEMBL1671936,KEUJAGGJGBWRFC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC(=O)NC1=C(C=C(C=C1F)C(=O)NC2=NC=CS2)F,4.3979400086720375,CC(C)(C)CC(=O)Nc1c(F)cc(C(=O)Nc2nccs2)cc1F
17774,CHEMBL287400,KFCQYUZRWULLQM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CC1=CC(=C2C3=C(C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)N(C2=N1)C)C(=O)N,6.6777807052660805,Cc1cc(C(N)=O)c2c3ncnc(N4CCN(CCc5ccc(F)c(F)c5)CC4)c3n(C)c2n1
17782,CHEMBL3091545,KFEKXXFPCURVGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3ß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1NCC(=O)C2=CC=CC=C2)C3=CC=NC=C3,4.301029995663981,Cn1c(NCC(=O)c2ccccc2)nc(-c2ccncc2)cc1=O
17783,CHEMBL3422083,KFENBNGSHOHELN-BSYJTBJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,CC(C)[C@@H](C1=CC=CC=C1Cl)NC(=O)C2=CC3=C(C=C2)NN=C3C4=CC=C(C=C4)N5C6CCC5COC6,7.221848749616356,CC(C)[C@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1)c1ccccc1Cl
17784,CHEMBL3264600,KFGRUSFLKJSLMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CN=CO3)O,5.187086643357144,COc1cc2ccc(C(O)(c3cnco3)C(C)C)cc2cc1OC
17801,CHEMBL2296321,KFNVAIUTZXCDKO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of Homo sapiens (human) recombinant CYP3A4 by fluorogenic assay,,Med Chem Res,PUBLICATION,,COC1=NC2=C(C=C1)OCC23C4=CC=CC=C4N(C3=O)CC5=CC=C(O5)C(F)(F)F,5.0,COc1ccc2c(n1)C1(CO2)C(=O)N(Cc2ccc(C(F)(F)F)o2)c2ccccc21
17803,CHEMBL1921855,KFNXSASJRFOSHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21966889.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)S(=O)(=O)N(S2(=O)=O)C3=CC=C(C=C3)NC(=O)C4=CC=CC=N4,4.522878745280337,O=C(Nc1ccc(N2S(=O)(=O)c3ccccc3S2(=O)=O)cc1)c1ccccn1
17805,CHEMBL2376577,KFQWZEYUSVKRBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23545108.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=C(C=C2)OC3=CC=CC=C3)C(=O)O,4.522878745280337,Cc1ccc(S(=O)(=O)Nc2ccc(Oc3ccccc3)cc2C(=O)O)cc1
17817,CHEMBL594933,KFUFYKHPONJLKZ-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,16.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C=C(N=CC2=NN1)C3=C(N=CC(=C3)OC[C@H](CC4=CNC5=CC=CC=C54)N)C6=COC=C6,7.795880017344075,Cc1[nH]nc2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12
17822,CHEMBL242983,KFUYKTYUJHLOPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,195.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)CN2CCN(CC2)C3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,6.709965388637482,COc1ccc(CN2CCN(c3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC
17823,CHEMBL242983,KFUYKTYUJHLOPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,2480.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)CN2CCN(CC2)C3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,5.605548319173784,COc1ccc(CN2CCN(c3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC
17824,CHEMBL563956,KFVOKCIYVVCZGF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19552431.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assay,Novel small molecule bradykinin B2 receptor antagonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC=C1)CN2C=CC=C(C2=O)C(F)(F)F)COC3=CC=CC4=C(C=C(N=C43)C)C5=C(C=NN5)C,5.42021640338319,Cc1cc(-c2[nH]ncc2C)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1
17837,CHEMBL3359023,KGAYRJHUIIQQLX-QKDCVEJESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25210858.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=N1)C(=O)O)NC(=O)N2C[C@H]3CC(C[C@H]3C2)C4=CC=CC=C4C(F)(F)F,5.958607314841775,Cc1cc(NC(=O)N2C[C@H]3CC(c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)cn1
17839,CHEMBL25903,KGDYDDZERXXGQS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,1230.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C3=C(C=CN=C31)C(=O)N)N=CN=C2N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,5.910094888560602,Cn1c2nccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
17841,CHEMBL1214395,KGEABTFMCTZXTF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=CN=CC(=C3)C#N,5.0,CC(C)S(=O)(=O)NC1Cc2ccc(-c3cncc(C#N)c3)cc2C1
17844,CHEMBL219098,KGGUBHJOEDSZBC-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)OC3=CC=CC4=CC=CC=C43)C(=O)N5CC[C@H](C5)O)C(=O)N(C1=O)C,5.142667503568732,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Oc3cccc4ccccc34)sc21
17856,CHEMBL474130,KGOGIJXNFVIMTA-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CCC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,5.0,C[C@H]1CN(Cc2ccc(CCC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
17857,CHEMBL474130,KGOGIJXNFVIMTA-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CCC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,4.7447274948966935,C[C@H]1CN(Cc2ccc(CCC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
17861,CHEMBL1082053,KGOQVALOLTXUEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CCNC(=O)OCC1=CN=CS1)CCNC(=O)OCC2=NC=CS2,5.522878745280337,CCN(CCNC(=O)OCc1cncs1)CCNC(=O)OCc1nccs1
17875,CHEMBL501711,KGSZHKRKHXOAMG-HQKKAZOISA-N,HYPERFORIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20408551.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).,J. Nat. Prod.,PUBLICATION,,CC(C)C(=O)[C@]12C(=O)C(=C([C@](C1=O)(C[C@@H]([C@@]2(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)O)CC=C(C)C,5.638272163982407,CC(C)=CCC[C@]1(C)[C@@H](CC=C(C)C)C[C@@]2(CC=C(C)C)C(=O)[C@]1(C(=O)C(C)C)C(=O)C(CC=C(C)C)=C2O
17889,CHEMBL529213,KHBYHUBFGVKELV-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19320488.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1C(=O)[C@@H]2C[C@H]2C3=CC=C(C=C3)C(F)(F)F)S(=O)(=O)C4=CC(=CC(=C4)C(F)(F)F)C5=NC=NN5,5.327902142064283,O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(-c3ncn[nH]3)cc(C(F)(F)F)c2)CC1
17894,CHEMBL1290004,KHHBKFYFMHFBOI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21055936.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological characterization of 5-phenyl-2-[2-(1-piperidinylcarbonyl)phenyl]-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-ones: a new class of Neuropeptide S antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C(=O)C2=CC=CC=C2N3CN4C(=CC=C4C3=O)C5=CC=CC=C5,5.301029995663981,O=C(c1ccccc1N1Cn2c(ccc2-c2ccccc2)C1=O)N1CCCCC1
17929,CHEMBL3582240,KHPZRFSKOJGJEJ-YYHAPLCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25992974.0,IC50,=,932.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using midazolam as substrate after 1 hr by LC-MS/MS analysis,"Synthesis and Biological Evaluation of Novel Olean-28,13ß-lactams as Potential Antiprostate Cancer Agents.",J. Med. Chem.,PUBLICATION,,C[C@@]12CC[C@@H]3[C@@](C1=CC(=O)[C@@]45[C@]2(CC[C@@]6([C@H]4CC(CC6)(C)C)C(=O)N5C7CCCCC7)C)(C=C(C(=O)C3(C)C)C#N)C,6.030584087646019,CC1(C)CC[C@]23CC[C@]4(C)[C@](C(=O)C=C5[C@@]6(C)C=C(C#N)C(=O)C(C)(C)[C@@H]6CC[C@]54C)([C@@H]2C1)N(C1CCCCC1)C3=O
17930,CHEMBL3582240,KHPZRFSKOJGJEJ-YYHAPLCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25992974.0,IC50,=,2535.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using testosterone as substrate after 1 hr by LC-MS/MS analysis,"Synthesis and Biological Evaluation of Novel Olean-28,13ß-lactams as Potential Antiprostate Cancer Agents.",J. Med. Chem.,PUBLICATION,,C[C@@]12CC[C@@H]3[C@@](C1=CC(=O)[C@@]45[C@]2(CC[C@@]6([C@H]4CC(CC6)(C)C)C(=O)N5C7CCCCC7)C)(C=C(C(=O)C3(C)C)C#N)C,5.596022036330646,CC1(C)CC[C@]23CC[C@]4(C)[C@](C(=O)C=C5[C@@]6(C)C=C(C#N)C(=O)C(C)(C)[C@@H]6CC[C@]54C)([C@@H]2C1)N(C1CCCCC1)C3=O
17941,CHEMBL479084,KHTDXOMKTZIILK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC=C1)C(C2=CC=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,Cc1cccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)c1
17965,CHEMBL2041010,KICDUIMXMCSVGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(S6)C(=O)O,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)s4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
17971,CHEMBL3702781,KIFTVPULPLLOBV-JFKYFZFSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4530.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCN(CC)CCNC1=NC=C(C=C1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.343901797987169,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCCN(CC)CC)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
17982,CHEMBL3104485,KIOFMOLFMSYGIQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,4.698970004336019,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1
17983,CHEMBL3104485,KIOFMOLFMSYGIQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,4.698970004336019,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1
17984,CHEMBL456001,KIOOMMQUJQSBPZ-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC=C1Cl)C2=CC(=O)N(C3=C2C=C(C=C3)[C@](C4=CC=C(C=C4)Cl)(C5=CN=CN5C)N)C,5.886056647693163,Cc1c(Cl)cccc1-c1cc(=O)n(C)c2ccc([C@](N)(c3ccc(Cl)cc3)c3cncn3C)cc12
17998,CHEMBL3665949,KIYBJKHIYOZLEC-CABCVRRESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26602277.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(N=C1Cl)OC[C@H]2C[C@@H]2C3=CC=CC=N3)NCC4=CN(N=C4)C,5.42021640338319,Cc1c(Cl)nc(OC[C@H]2C[C@@H]2c2ccccn2)nc1NCc1cnn(C)c1
18004,CHEMBL3673954,KIYZZSWMJCJKKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320617,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CS(=O)(=O)NC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)Cl)F)N=C1,5.0,CS(=O)(=O)Nc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1
18010,CHEMBL2437416,KJAMWQZICMXSKB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4NC3=O)CC5=CC(=NC=C5)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)[nH]c5ccccc54)CC3)CC2)ccn1
18011,CHEMBL565362,KJBIXUOGFIZTTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=C(C=C(C=C3)Br)F,5.356547323513812,CC1(CC(=O)NCc2ccc(Br)cc2F)CC2(CCCCC2)OO1
18012,CHEMBL256988,KJBXOWKVXHJXGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C(N(C1)C(=O)CN2C3=CC(=C(C=C3N=CC2=O)Cl)Cl)CN4CCOCC4)C5=CC=CC=C5,6.0,O=C(Cn1c(=O)cnc2cc(Cl)c(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1
18017,CHEMBL3114738,KJFJLGNTFRFOMY-CHQNGUEUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4,6.657577319177793,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
18018,CHEMBL3605542,KJFJNOQRMGDJEA-LLVKDONJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26291341.0,IC50,=,830.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method,Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.,J. Med. Chem.,PUBLICATION,,CCN1C2=C(C=CC(=C2)C(F)(F)F)N=C1[C@@H](C)NS(=O)(=O)C3=CN=CC=C3,6.080921907623926,CCn1c([C@@H](C)NS(=O)(=O)c2cccnc2)nc2ccc(C(F)(F)F)cc21
18023,CHEMBL411095,KJFSUONZDZKWIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20971004.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC(=CC=C3)N4C=CN=C4,7.0,Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-n3ccnc3)c1)=N2
18024,CHEMBL239078,KJGSLJURFWWLOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C4=C(C=CC(=C4)F)F,5.721246399047171,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)ccc1F)O2
18046,CHEMBL1224195,KJKVVLUSAUZZBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709545.0,IC50,=,51000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted biaryl pyrazoles as sodium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NN1C2=CC=CC(=C2)C3=C(C=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)N,4.292429823902063,Cc1cc(C(N)=O)nn1-c1cccc(-c2cc(C(F)(F)F)ccc2C(F)(F)F)c1
18065,CHEMBL1092126,KJQCJXUDPPZASI-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=CC=C1)[C@H](C)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,Cc1cccnc1[C@H](C)c1c(CCN(C)C)sc2ccccc12
18078,CHEMBL398372,KJXOYJXMFGXDRR-QGZVFWFLSA-N,BMS-317180,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17973363.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180).,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C2=NN=NN2CCOC(=O)NCCCCO)N,4.0,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1CCOC(=O)NCCCCO
18091,CHEMBL1096717,KKACLEOGRMSWFM-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C(=O)CCCF,6.096910013008056,Cc1cc(N2CCN(C(=O)CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
18097,CHEMBL2070158,KKANPYOQEOCPDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CN(C(=O)C=C3)C4=CC=CC=C4,4.698970004336019,CCCS(=O)(=O)c1ccc2nc(-c3ccc(=O)n(-c4ccccc4)c3)[nH]c2c1
18113,CHEMBL236520,KKISTVNQPNAOJB-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCN,5.1938200260161125,CC(C)C[C@H](NC(=O)CCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
18116,CHEMBL14192,KKKDZZRICRFGSD-UHFFFAOYSA-N,BENZYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,77500.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC=C(C=C1)CN2C=CN=C2,4.110698297493689,c1ccc(Cn2ccnc2)cc1
18120,CHEMBL239629,KKKLWLSGVSXCDO-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@H](N([C@H](C1)C2(CC2)OC(=O)N3CCN(CC3)CCO)S(=O)(=O)C4=CC=C(C=C4)Cl)C5=CC(=CC(=C5)F)F,7.221848749616356,O=C(OC1([C@H]2CCC[C@@H](c3cc(F)cc(F)c3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1
18121,CHEMBL239629,KKKLWLSGVSXCDO-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@H](N([C@H](C1)C2(CC2)OC(=O)N3CCN(CC3)CCO)S(=O)(=O)C4=CC=C(C=C4)Cl)C5=CC(=CC(=C5)F)F,7.221848749616356,O=C(OC1([C@H]2CCC[C@@H](c3cc(F)cc(F)c3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1
18123,CHEMBL1230122,KKKRKRMVJRHDMG-UHFFFAOYSA-N,R-1487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21375264.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38a mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,CN1C2=NC(=NC=C2C=C(C1=O)OC3=C(C=C(C=C3)F)F)NC4CCOCC4,4.3979400086720375,Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21
18131,CHEMBL2018482,KKOSHWJEFBAPQK-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,=,301.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,C1[C@H](CN([C@@H]1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CC4=CN=CN4)C5=CC=CC=C5,6.521433504406157,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](c2ccccc2)CN1C(=O)Cc1cnc[nH]1
18134,CHEMBL1668898,KKQXNJWVSUWKOH-UHFFFAOYSA-M,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21211969.0,IC50,=,2.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by time-dependent inhibition assay,"Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC1=C(C=CC(=C1)C2=CN=C(C=C2)OCC)C3=C(C=CC(=C3)CC(=O)[O-])OC)C(=O)C4CC4.[Na+],8.698970004336019,CCOc1ccc(-c2ccc(-c3cc(CC(=O)[O-])ccc3OC)c(CN(CC)C(=O)C3CC3)c2)cn1
18135,CHEMBL1668898,KKQXNJWVSUWKOH-UHFFFAOYSA-M,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21211969.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC1=C(C=CC(=C1)C2=CN=C(C=C2)OCC)C3=C(C=CC(=C3)CC(=O)[O-])OC)C(=O)C4CC4.[Na+],4.301029995663981,CCOc1ccc(-c2ccc(-c3cc(CC(=O)[O-])ccc3OC)c(CN(CC)C(=O)C3CC3)c2)cn1
18143,CHEMBL411885,KKULHWAGAYCAAF-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,82.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCN1CCCC2=C1C=C(C=C2)OC[C@H]3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,7.086186147616283,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCNC(C)=O)CCC3)cc1
18145,CHEMBL411885,KKULHWAGAYCAAF-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17482464.0,IC50,=,82.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCN1CCCC2=C1C=C(C=C2)OC[C@H]3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,7.086186147616283,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCNC(C)=O)CCC3)cc1
18159,CHEMBL1077335,KLAOJPFJEJJZAC-QGOAFFKASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20185309.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)NC4(CCCC4)C(=O)NC5=CC=C(C=C5)/C=C/C(=O)O)N=C2C6=CC=CC=N6,4.522878745280337,O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccccn3)n4C3CCCCC3)CCCC2)cc1
18167,CHEMBL1683443,KLCHUAUMSZUJEX-KXBFYZLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21300546.0,IC50,=,1.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C[C@@H](CS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)F)N(C=O)O)C3=NC=C(C=N3)F,8.853871964321762,C[C@@H](C[C@@H](CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O)c1ncc(F)cn1
18170,CHEMBL3182315,KLEAARUETMFQIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C(=C(C(=N1)C)CNC(=O)C2=CC(=C(C=C2)OC)OC3CCN(CC3)C(C)C)C,4.522878745280337,CCn1nc(C)c(CNC(=O)c2ccc(OC)c(OC3CCN(C(C)C)CC3)c2)c1C
18175,CHEMBL1092765,KLFVGKSTNOVPOR-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(N=CC=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,C[C@H](c1cccnc1F)c1c(CCN(C)C)sc2ccccc12
18176,CHEMBL1086580,KLGQSVMIPOVQAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22260203.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,PUBLICATION,,C1CSCC2=C1N=C(NC2=O)C3=CC=C(C=C3)C(F)(F)F,4.301029995663981,O=c1[nH]c(-c2ccc(C(F)(F)F)cc2)nc2c1CSCC2
18186,CHEMBL2381116,KLJVDMAOKMSBQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535330.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 6beta-hydroxylase as substrate by LC-MS/MS analysis,Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=C(CN(C2=O)C3=NC(=CS3)C(=O)NC4=C(C=CN=C4)N5CCNCC5)C=C1,4.522878745280337,COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2
18187,CHEMBL2381116,KLJVDMAOKMSBQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535330.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using 6beta-hydroxylase as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by LC-MS/MS analysis,Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=C(CN(C2=O)C3=NC(=CS3)C(=O)NC4=C(C=CN=C4)N5CCNCC5)C=C1,4.522878745280337,COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2
18195,CHEMBL510538,KLOIUBZMBUJOJL-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCCC(=O)O)C4=C(C(=CC=C4)OC)F,4.5376020021010435,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCCC(=O)O)c3ccccc3)c2=O)c1F
18204,CHEMBL232801,KLSJWNVTNUYHDU-UHFFFAOYSA-N,AMITROLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=NNC(=N1)N,5.0,Nc1ncn[nH]1
18205,CHEMBL232801,KLSJWNVTNUYHDU-UHFFFAOYSA-N,AMITROLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=NNC(=N1)N,5.0,Nc1ncn[nH]1
18210,CHEMBL3093463,KLTYQAJNDLZNSD-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24215891.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H](CN1C=C(C2=CC=CC=C21)C#N)NS(=O)(=O)C3=C(C=C(C=C3Cl)Cl)N,5.236572006437063,CC[C@@H](Cn1cc(C#N)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl
18212,CHEMBL570402,KLUCUOQHRAOQQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,890.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)CN2CCN(CC2)C(=O)C34CC5CC(C3)CC(C5)(C4)C6=CC=C(C=C6)OCC(=O)NC7=CC=CC(=C7)C(=O)OC,6.050609993355088,COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7ccc(OC)cc7)CC6)(C5)C3)C4)cc2)c1
18213,CHEMBL3632721,KLUQUTDAFSUQQQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=C(C=C1)F)NC2=NC3=C(N2C)C=CC(=C3)OC4=CC(=NC=C4)C5=NC=C(N5)C(F)(F)F,5.481486060122113,Cn1c(Nc2cc(C(C)(C)C)ccc2F)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
18245,CHEMBL2436214,KMHYVPFBZOIGRL-VPRHZQQDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C)NC.Cl,5.494850021680094,CN[C@@H](C)C(=O)N[C@H]1CN(C(C)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
18249,CHEMBL1923109,KMLLEVUPKXCGML-VEEOACQBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC=CC=C5C=CO4,5.958607314841775,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC=Cc2ccccc23)C2CC2)cc(OCCOC)c1
18260,CHEMBL3287179,KMPBWZLPWZAVKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24899257.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 2 to 45 mins by LC-MS/MS analysis,Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.,J. Med. Chem.,PUBLICATION,,CCC(=O)N1CCC2=C1C=CC(=C2)C3=CN=CC4=CC=CC=C43,4.301029995663981,CCC(=O)N1CCc2cc(-c3cncc4ccccc34)ccc21
18269,CHEMBL495586,KMQZBSVCYFOFTL-WOJBJXKFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CCN(CC3)C(=O)N[C@@H]4CC[C@H](C4)C5=CC=CC=C5)CC2=O,5.0,CS(=O)(=O)c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@@H]3CC[C@@H](c4ccccc4)C3)CC1)O2
18271,CHEMBL1808645,KMTIRMHMRODSJK-FNORWQNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=C(CN1CCC3=C4C=CC=CN4N=C3)C=C(C=C2)/C=C/C(=O)NO,4.301029995663981,O=C(/C=C/c1ccc2c(c1)CN(CCc1cnn3ccccc13)C2)NO
18276,CHEMBL3622175,KMUOWVJTLAOVPK-PZJWPPBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288697.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,COCC1=CN=C(N=C1)N2CCC(CC2)[C@H]3C[C@H]3COCC4=C(C=C(C=C4)S(=O)(=O)C)F,4.3979400086720375,COCc1cnc(N2CCC([C@H]3C[C@H]3COCc3ccc(S(C)(=O)=O)cc3F)CC2)nc1
18295,CHEMBL2425614,KNBBTCRFFYVMIG-CTLVIRCOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC=CC(=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O,5.0,CC(C)(C)c1cccc(CN[C@H]2C[S@+]([O-])C[C@@H](Cc3cc(O)c(N)c(F)c3)[C@@H]2O)c1
18321,CHEMBL3393479,KNOIFPSQNXJZDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=CC=C6Cl,7.301029995663981,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(Cl)cccc3[nH]2)o1
18322,CHEMBL1779699,KNQGJTLFPWWGEW-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21570283.0,IC50,=,1075.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)CN2CCN(CC2=O)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N,5.968591535748375,COc1ccc(CN2CCN(C(=O)C[C@H](N)Cc3cc(F)c(F)cc3F)CC2=O)cc1
18330,CHEMBL3634015,KNSSBXCHRPNPDS-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26522950.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NN1)C)[C@H](C)NC(=O)COC2=NC3=C(C(=C2)C(F)(F)F)C(=NN3C)C4=CC=CC=C4,4.698970004336019,Cc1n[nH]c(C)c1[C@H](C)NC(=O)COc1cc(C(F)(F)F)c2c(-c3ccccc3)nn(C)c2n1
18334,CHEMBL3087340,KNUCAIOJOAOGJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CC(=C1)C2=CC=C(C=C2)NC(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,4.568636235841013,Cc1cc(-c2ccc(NC(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
18339,CHEMBL3702796,KNVFYUIRHGJMNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6040.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)CCO,5.218963061378868,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CCO)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
18344,CHEMBL3085388,KNWFVJXJIMAUCK-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,44000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,C1=CN(N=C1)C[C@@](C2=C(C=C(C=C2)F)F)(N3C=NC=N3)O,4.356547323513813,O[C@](Cn1cccn1)(c1ccc(F)cc1F)n1cncn1
18352,CHEMBL500422,KNZBNTANJVZDOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18479916.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=NC(=C1)C#CC2=C(C=CN=C2N)OC3=C(C=C(C=C3)NC(=O)NC(=O)CC4=CC=C(C=C4)F)F,4.431798275933005,Nc1nccc(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)c1C#Cc1ccccn1
18356,CHEMBL2013053,KOAYFGOVRZLWGD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22365751.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)N2CCC3(CCC4=C(O3)C=CC(=C4)OC5CCN(CC5)C(=O)C6CC6)CC2,4.522878745280337,O=C(C1CC1)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
18359,CHEMBL468927,KODBDIFHMBDFOH-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19419866.0,IC50,>,100000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 expressed in human hepatocytes,Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C(=O)NCC1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)C3=NN=C(O3)C4=C5C(=CC=C4)N=CS5)N,4.0,C[C@H](N)C(=O)NCc1cccc(-n2nc(C(F)(F)F)cc2-c2nnc(-c3cccc4ncsc34)o2)c1
18361,CHEMBL2437423,KODNBJZZDKPFDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)CCCC(F)(F)F)CC5=CC(=NC=C5)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCCC(F)(F)F)c5cc(F)ccc54)CC3)CC2)ccn1
18366,CHEMBL1951335,KODZKNALZQZEBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,55.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,7.259637310505756,CCNC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
18367,CHEMBL2163837,KOEVIKUFICKWKV-QKKBWIMNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,C[C@H]1CN(CCN1)C(=O)[C@H](CC2=C(C=C(C=C2)Cl)Cl)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,6.3979400086720375,C[C@H]1CN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CCN1
18368,CHEMBL2163836,KOEVIKUFICKWKV-SZNDQCEHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1)C(=O)[C@H](CC2=C(C=C(C=C2)Cl)Cl)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,6.346787486224656,C[C@@H]1CN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CCN1
18371,CHEMBL521889,KOHDMWKBUVOITI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4CCNC4=O,5.275724130399211,Cc1cccc(C)c1CNc1cc(N2CCNC2=O)cn2c(C)c(C)nc12
18372,CHEMBL521889,KOHDMWKBUVOITI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4CCNC4=O,5.187086643357144,Cc1cccc(C)c1CNc1cc(N2CCNC2=O)cn2c(C)c(C)nc12
18373,CHEMBL2381945,KOIGSPGBVAOKRC-SPEDKVCISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23701517.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.",J. Med. Chem.,PUBLICATION,,CC1([C@@H](N(C(=O)O1)C2CCC(CC2)N3C4=C(C=C(C(=C4)F)C#N)NC3=O)C5=CC=CC=C5)C,5.119186407719209,CC1(C)OC(=O)N(C2CCC(n3c(=O)[nH]c4cc(C#N)c(F)cc43)CC2)[C@H]1c1ccccc1
18374,CHEMBL1223158,KOIKIOIHIGLQAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)CC2=CC=C(C=C2)C(C3=NN=NN3CC4=CC=CC=C4)N5CCCN(CC5)C6CCC6,4.301029995663981,CN1CCN(Cc2ccc(C(c3nnnn3Cc3ccccc3)N3CCCN(C4CCC4)CC3)cc2)CC1
18378,CHEMBL1951329,KOIZCQULZQIWHY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,82.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,7.086186147616283,COC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
18390,CHEMBL1777958,KOPYHSKMDVXZJU-KAYWLYCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]3CCCC4=C3C=CC(=C4)CN5CCCCC5,4.522878745280337,Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CN4CCCCC4)ccc32)cc1
18391,CHEMBL1777958,KOPYHSKMDVXZJU-KAYWLYCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]3CCCC4=C3C=CC(=C4)CN5CCCCC5,4.522878745280337,Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CN4CCCCC4)ccc32)cc1
18393,CHEMBL1951601,KOTAQXKIRQIPRZ-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=CCN1C2=C(C(=C1N3CCC[C@@H](C3)N)C#N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5N=C4)C)C,5.522878745280337,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1cnc3ccccc3n1)c(=O)n2C
18394,CHEMBL273921,KOTITFQGTVUMBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643910.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4,Identification of a novel series of selective 5-HT7 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2=CC=CC=C2C(=O)N(C1)CCN3CCC(CC3)N4C5=C(C=C(C=C5)F)NC4=O,4.0,O=C1c2ccccc2CCCN1CCN1CCC(n2c(=O)[nH]c3cc(F)ccc32)CC1
18404,CHEMBL1172779,KOYRCBKCALKGKO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,7580.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)O,5.120330794367947,Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1O
18405,CHEMBL1172779,KOYRCBKCALKGKO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,7580.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)O,5.120330794367947,Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1O
18406,CHEMBL230262,KOZVNMWDJGMEPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17482464.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(CCCN3CCCCC(=O)OC)C=C2,4.920818753952375,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCCC(=O)OC)CCC2
18409,CHEMBL1766181,KPCAQRVDZSQEMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=C(C=C1)C2=CC=CC=N2)(C3=CN=CN3)O,5.2839966563652006,CC(C)C(O)(c1ccc(-c2ccccn2)cc1)c1cnc[nH]1
18410,CHEMBL1950084,KPCVLACNFAKGBK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)F)OC,6.522878745280337,COc1cc(C)c2nc3n[nH]c(C)c3c(C(F)c3ccncc3)c2c1
18411,CHEMBL1950084,KPCVLACNFAKGBK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)F)OC,4.920818753952375,COc1cc(C)c2nc3n[nH]c(C)c3c(C(F)c3ccncc3)c2c1
18414,CHEMBL3393482,KPFKBJLOCNHHJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,490.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=CC=C6O,6.309803919971486,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(O)cccc3[nH]2)o1
18442,CHEMBL2441567,KPLGROMQFNWKJK-QPJJXVBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 20 mins by LC/MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CN(C)C/C=C/C(=O)N1CCOC2=C1C=C3C(=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,5.0,CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21
18443,CHEMBL3664694,KPLJMMNESSARTG-JRPXNJEYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,44000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C3CC3)N4CC[C@](OC4=O)(CC(C)(C)O)C5=CC=CC=C5,4.356547323513813,C[C@@H](c1ccc(-c2ccc(=O)n(C3CC3)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
18466,CHEMBL1241998,KPSUZBNHNICQLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC(C)C,5.096910013008056,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC(C)C)ncn4-5)CC3)cccc2n1
18467,CHEMBL1241998,KPSUZBNHNICQLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC(C)C,5.096910013008056,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC(C)C)ncn4-5)CC3)cccc2n1
18474,CHEMBL164261,KPVDIIPFHYNTLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C1N=C(C=C4C)Cl,5.638272163982407,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(Cl)nc21
18475,CHEMBL164261,KPVDIIPFHYNTLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C1N=C(C=C4C)Cl,5.0915149811213505,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(Cl)nc21
18476,CHEMBL3291398,KPVIXBKIJXZQJX-FCEONZPQSA-N,LEFAMULIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,4430.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CS[C@@H]4CC[C@H](C[C@H]4O)N)C,5.3535962737769305,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
18477,CHEMBL3291398,KPVIXBKIJXZQJX-FCEONZPQSA-N,LEFAMULIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,4650.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CS[C@@H]4CC[C@H](C[C@H]4O)N)C,5.3325470471100465,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
18503,CHEMBL261288,KQAQQTRQYSXKHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18374569.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(=NC2=C(C=C(C=C2)C3=CC=CC=C3F)NC1=O)C4=CC(=CC=C4)N5C=CN=N5,5.366531544420414,O=C1CC(c2cccc(-n3ccnn3)c2)=Nc2ccc(-c3ccccc3F)cc2N1
18535,CHEMBL2448700,KQHQMFLSXREETG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16300.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCN(C1=CC=CC=C1)S(=O)(=O)C2=CC(=C(C=C2)Cl)NC(=O)CNC3CCCN(C3)C.C(=O)O,4.787812395596042,CCN(c1ccccc1)S(=O)(=O)c1ccc(Cl)c(NC(=O)CNC2CCCN(C)C2)c1
18554,CHEMBL221445,KQNYTTDHCMFOME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16950617.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)N1CCN(CC1)CC2=C(N=C3C(=C2C(=O)NN(C4=CC=CC=C4)C(=O)OC)C=CC=C3F)C5=CC=CC=C5,4.522878745280337,COC(=O)N(NC(=O)c1c(CN2CCN(C(C)(C)C)CC2)c(-c2ccccc2)nc2c(F)cccc12)c1ccccc1
18559,CHEMBL29609,KQOXLKOJHVFTRN-UHFFFAOYSA-N,PLECONARIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21907579.0,IC50,=,6309.57,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1OCCCC2=CC(=NO2)C)C)C3=NOC(=N3)C(F)(F)F,5.200000237109354,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1
18560,CHEMBL29609,KQOXLKOJHVFTRN-UHFFFAOYSA-N,PLECONARIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21907579.0,IC50,>,50118.72,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1OCCCC2=CC(=NO2)C)C)C3=NOC(=N3)C(F)(F)F,4.300000029139089,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1
18568,CHEMBL549749,KQRDVNUCOWRFLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19610616.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.",J. Med. Chem.,PUBLICATION,,CCNC(=O)C1=CC2=C(N=C(N=C2S1)N)C3=CC(=C(C=C3Cl)Cl)OCCN(CC)CC,5.0,CCNC(=O)c1cc2c(-c3cc(OCCN(CC)CC)c(Cl)cc3Cl)nc(N)nc2s1
18597,CHEMBL3104487,KQYYFXSCJMMDOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,4.698970004336019,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1
18598,CHEMBL3104487,KQYYFXSCJMMDOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,4.698970004336019,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1
18599,CHEMBL3344501,KQZKQPCMHFSLEK-ZXVPZRJPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25310383.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.,J. Med. Chem.,PUBLICATION,,CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)[C@@H](C)CN2CCN(CC2)CCOC)C)C)C,4.3979400086720375,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](C)C(=O)N(C)[C@@H]([C@@H](C)CN2CCN(CCOC)CC2)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
18608,CHEMBL3326579,KRCMLCOREROPCP-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CCC1(C[C@H](C2=C(O1)C(=CC=C2)F)NC(=O)NC3=CC=CC4=C3C=C(N=C4)C)CC,4.698970004336019,CCC1(CC)C[C@@H](NC(=O)Nc2cccc3cnc(C)cc23)c2cccc(F)c2O1
18616,CHEMBL1552719,KRIKILRRJCIWNB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22260203.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)C2=NOC(=N2)CSC3=NN=C(N3C4=CC=C(C=C4)OC)C5=CC=NC=C5,5.769551078621726,COc1ccc(-n2c(SCc3nc(-c4ccc(C)cc4)no3)nnc2-c2ccncc2)cc1
18628,CHEMBL371430,KRLGQBXIHBDUPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,3560.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CN=CC=C3,5.448550002027125,COc1ccc2ccc(-c3cccnc3)c(Cl)c2c1
18629,CHEMBL1669423,KRLJKEOQHOYBSK-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,1535.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN4C,5.813891620186794,C[C@H](C1=C(CCN(C)Cc2nccn2C)Cc2ccccc21)c1cnccn1
18631,CHEMBL1951598,KRMBZIKXHYHITN-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=CCN1C2=C(C(=C1N3CCC[C@@H](C3)N)C#N)N(C(=O)N(C2=O)CC(=O)C4=CC(=CC=C4)OC)C)C,5.522878745280337,COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCC[C@H](N)C4)n3CC=C(C)C)n(C)c2=O)c1
18639,CHEMBL2178422,KRNAOFGYEFKHPB-ANJVHQHFSA-N,RIMEGEPANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23153230.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 20 mins by fluorescence assay,"Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine.",J. Med. Chem.,PUBLICATION,,C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6,4.769551078621726,N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F
18640,CHEMBL2178422,KRNAOFGYEFKHPB-ANJVHQHFSA-N,RIMEGEPANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23153230.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using benzoylresorufin as substrate after 45 mins by fluorescence assay,"Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine.",J. Med. Chem.,PUBLICATION,,C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6,4.769551078621726,N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F
18658,CHEMBL1808643,KRVGKRFOWVTXGV-VQHVLOKHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)CCN2CC3=C(C2)C=C(C=C3)/C=C/C(=O)NO,4.301029995663981,O=C(/C=C/c1ccc2c(c1)CN(CCC1CCCCC1)C2)NO
18685,CHEMBL1957148,KSDLXGLGEFBZCB-MDWZMJQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22342630.0,IC50,>,172000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence assay,"Biotransformations of 6',7'-dihydroxybergamottin and 6',7'-epoxybergamottin by the citrus-pathogenic fungi diminish cytochrome P450 3A4 inhibitory activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C/C(=C\COC1=C(C(=CC2=C1C=CO2)O)CCC(=O)O)/CCC(C(C)(C)O)O,3.7644715530924513,C/C(=C\COc1c(CCC(=O)O)c(O)cc2occc12)CCC(O)C(C)(C)O
18693,CHEMBL243876,KSHJXDWYTZJUEI-UHFFFAOYSA-N,BMS-433771,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25941547.0,IC50,=,27500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1N2C3=C(C=NC=C3)N(C2=O)CC4=NC5=CC=CC=C5N4CCCCO,4.560667306169737,O=c1n(Cc2nc3ccccc3n2CCCCO)c2cnccc2n1C1CC1
18702,CHEMBL3672587,KSIVSAIIPBDCII-LKMBZGFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,150.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N(C)C,6.823908740944319,CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N(C)C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
18703,CHEMBL3672587,KSIVSAIIPBDCII-LKMBZGFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,330.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N(C)C,6.481486060122113,CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N(C)C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
18727,CHEMBL2181889,KSQJUIXMCGQLTA-OIFRRMEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)C[C@@H]2NC[C@H]([C@H](CC4=CC(=CC=C4)C5=CC=CC=N5)NC(=O)COC)O,6.3979400086720375,COCC(=O)N[C@@H](Cc1cccc(-c2ccccn2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
18730,CHEMBL1649682,KSRDECNQNMUKOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,C1CC(=O)N(C1)CC2=C(C=C(C=C2F)N3C4=C(COCC4)C(=N3)C(F)(F)F)F,5.0,O=C1CCCN1Cc1c(F)cc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1F
18734,CHEMBL3699082,KSUCBNRQDLUBLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,45000.0,NM,273498,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",Metalloenzyme inhibitor compounds,,PATENT,,C1=CC(=C(C=C1F)F)C(CN2C=NN=C2)(C(C3=CN=C4C=C(C=CC4=N3)Cl)(F)F)O,4.346787486224656,OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1cnc2cc(Cl)ccc2n1
18786,CHEMBL1172744,KTJHVHZJTXJNIH-QZTJIDSGSA-N,1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX),,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20527970.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,COC[C@]12C[C@]1(CCNC2)C3=CC4=CC=CC=C4C=C3,5.096910013008056,COC[C@@]12CNCC[C@]1(c1ccc3ccccc3c1)C2
18793,CHEMBL3664711,KTNRIRGXBWOYQO-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=C(C=C4)F,4.301029995663981,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O
18815,CHEMBL1951611,KTVXOJMKMNUCCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=C(C5=CC=CC=C5C=N4)C#N)C)C,5.522878745280337,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1ncc3ccccc3c1C#N)c(=O)n2C
18816,CHEMBL2387505,KTVYEQQSGWOYNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CC1=CC(=CC=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F,4.522878745280337,Cc1cccc(-c2ccc3c(c2)[nH]c(=O)c2[nH]c(-c4c(F)cccc4Cl)nc23)c1
18822,CHEMBL1917468,KTXVIHVCQVKSMA-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21944855.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of pyridazinone-phenethylamine derivatives as selective and orally bioavailable histamine H(3) receptor antagonists with robust wake-promoting activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCC2=CC=C(C=C2)C3=NN(C(=O)C=C3)C4=CC=C(C=C4)F,4.522878745280337,C[C@@H]1CCCN1CCc1ccc(-c2ccc(=O)n(-c3ccc(F)cc3)n2)cc1
18824,CHEMBL1910122,KTYRZCOFWKPJRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCN(CC3)C)C4=C(C=C(C=C4)Cl)Cl)CN,4.769551078621726,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCN(C)CC1)C2=O
18840,CHEMBL2425159,KUBYYBWHXPIUIM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=NC(=CC(=N4)OC)OC,5.0,COc1cc(OC)nc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)n1
18841,CHEMBL448656,KUCPVNZOVVPTBB-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=C(C(=CC=C4)OCCCCC(=O)O)F)N,4.443697499232712,N[C@@H](Cn1c(=O)c(-c2cccc(OCCCCC(=O)O)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
18846,CHEMBL3699341,KUEBPEWAUJGQRQ-YMJVKMAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,21700.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCCCCCCC(=O)NC1=CC=C(C=C1)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,4.663540266151471,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)CCCCCCC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
18850,CHEMBL1427458,KUELMQAVLKNHFA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC=NC=C3,6.0,Cc1ccc(Oc2ccc(C(=O)NCc3ccncc3)cc2)cc1
18864,CHEMBL2018926,KUIKUTZPAAIPGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,3560.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=C(C=C3)OCC4=CC=CC=C4,5.448550002027125,COc1ccc2nc(SCc3ccc(OCc4ccccc4)cc3)[nH]c2c1
18865,CHEMBL2448740,KUIOELMGPFXPNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCN(CC1=CN=CN1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4S3,5.3979400086720375,CCN(Cc1cnc[nH]1)c1ccc(-c2nc3ccccc3s2)cc1
18870,CHEMBL1818445,KUJKCGJIUCGPED-AAFJCEBUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550808.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC1=CSC(=N1)C23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,5.221848749616356,Cc1csc(C23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
18871,CHEMBL2057524,KUJLAGMVWGXVMF-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C#CCN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,7.3979400086720375,C#CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
18874,CHEMBL520238,KUMYJQZMYWIEHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,8500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC=NC=C3)C,5.070581074285707,CC(=O)Nc1cc(-c2ccncc2)nc(-n2nc(C)cc2C)n1
18879,CHEMBL508020,KUOHOWIMYSEGDM-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,48000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC=CC(=C1CN2C=C(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)C4=CC=CC=C4Cl)F,4.318758762624412,CS(=O)(=O)c1cccc(F)c1Cn1cc(-c2ccccc2Cl)c(=O)n(C[C@H](NCCCC(=O)O)c2ccccc2)c1=O
18903,CHEMBL377414,KUYYTTWJIWYFTJ-WXFUMESZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16821776.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4 transfected in human microsome using PPR fluorogenic substrate,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,CC(C)C[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(C=C(C=C2)F)F)C(=O)N(C)C)C3CC4=CC=CC=C4C3,4.207608310501746,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F
18904,CHEMBL377414,KUYYTTWJIWYFTJ-WXFUMESZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16821776.0,IC50,=,89000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4 transfected in human microsome using DEF fluorogenic substrate,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,CC(C)C[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(C=C(C=C2)F)F)C(=O)N(C)C)C3CC4=CC=CC=C4C3,4.050609993355088,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F
18905,CHEMBL377414,KUYYTTWJIWYFTJ-WXFUMESZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239250.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using diethoxyfluorescein as substrate,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,CC(C)C[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(C=C(C=C2)F)F)C(=O)N(C)C)C3CC4=CC=CC=C4C3,5.301029995663981,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F
18906,CHEMBL377414,KUYYTTWJIWYFTJ-WXFUMESZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239250.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,CC(C)C[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(C=C(C=C2)F)F)C(=O)N(C)C)C3CC4=CC=CC=C4C3,4.508638306165727,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F
18910,CHEMBL3087037,KUZUQSLQWYRGST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,5.327902142064283,Cc1cc(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)cc2)ccn1
18916,CHEMBL1921979,KVDGTWKQXMEUBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3CCN4C3=CN=C4,6.0,CNC(=O)c1ccc2cc(C3CCn4cncc43)ccc2c1
18923,CHEMBL515624,KVICYPUXGNRQCI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=CC3=C(C=C21)C(=CN3S(=O)(=O)C4=CC=CC=C4)Cl,4.920818753952375,O=S(=O)(c1ccccc1)n1cc(Cl)c2cc3c(cc21)CCNCC3
18924,CHEMBL515624,KVICYPUXGNRQCI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=CC3=C(C=C21)C(=CN3S(=O)(=O)C4=CC=CC=C4)Cl,4.721246399047171,O=S(=O)(c1ccccc1)n1cc(Cl)c2cc3c(cc21)CCNCC3
18927,CHEMBL2425613,KVJZSBQIJYQMHT-STZPNVHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC=CC(=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](CO)C(F)(F)F,6.045757490560675,CC(C)(C)c1cccc(CN[C@H]2C[S@+]([O-])C[C@@H](Cc3cc(F)c(N)c(O[C@H](CO)C(F)(F)F)c3)[C@@H]2O)c1
18932,CHEMBL1910119,KVNIHXPFEOWXRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCC(CC3)C(=O)N)C4=C(C=C(C=C4)Cl)Cl)CN,4.769551078621726,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCC(C(N)=O)CC1)C2=O
18933,CHEMBL1761531,KVNPGGYBLPCJSE-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC(C)(C)C(=O)O)C5CC5)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)C(=O)O)c1
18934,CHEMBL1761531,KVNPGGYBLPCJSE-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC(C)(C)C(=O)O)C5CC5)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)C(=O)O)c1
18943,CHEMBL1097187,KVNUNQVIQXLHFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,275.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=C(C=CC=C5F)F)C)OC,6.560667306169737,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1c(F)cccc1F)cc(=O)n2C)c1cncn1C
18944,CHEMBL495792,KVNUPZLQKXFWBS-IRLDBZIGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=CC=N1)C2=CC3=C(C=C2)OC4(CCN(CC4)C(=O)N[C@H]5C[C@@H]5C6=CC=CC=C6)CC3=O,5.0,Cn1nccc1-c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2
18950,CHEMBL360033,KVOPMRICDIBARO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15582422.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against Cytochrome P450 3A4,Aminothiazole inhibitors of HCV RNA polymerase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)N(C2=NC=C(S2)C(=O)O)C(=O)C3=CC=C(C=C3)OCC4=CC(=CC=C4)C(F)(F)F,4.522878745280337,O=C(O)c1cnc(N(C(=O)c2ccc(OCc3cccc(C(F)(F)F)c3)cc2)C2CCCCC2)s1
18959,CHEMBL3581143,KVTIRZWDMYIMRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=CC(=NC=C3)OC,5.080921907623926,COc1cccc(CC(=O)Nc2nc(-c3ccnc(OC)c3)cs2)c1
18962,CHEMBL1813316,KVTPLEPXMVVCIZ-CJNGLKHVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,CCN1C[C@H]2CCCC[C@]2(C1)C3=CC(=C(C=C3)Cl)Cl,5.301029995663981,CCN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1
18963,CHEMBL1813317,KVTPLEPXMVVCIZ-XJKSGUPXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,CCN1C[C@@H]2CCCC[C@@]2(C1)C3=CC(=C(C=C3)Cl)Cl,5.301029995663981,CCN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1
18965,CHEMBL3236360,KVURUXGLNAWILE-ZJTSJXPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1[C@@H]([C@H](C[C@](C1=O)(C)CC(=O)NS(=O)(=O)C(F)(F)F)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,5.42021640338319,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(=O)NS(=O)(=O)C(F)(F)F)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
18996,CHEMBL151038,KWEADCNYIUWGLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=C(C=NO2)C,4.0,CCCCOc1ccc(-c2oncc2C)cc1
19013,CHEMBL2041189,KWJTYPOQTXWLHU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CN=C4)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)O,4.301029995663981,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1cnccn1
19015,CHEMBL2158224,KWLXMAXTGKZBPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)CC4=CC=CC=N4)NC(=O)C5=NC=C(N5)C#N,5.251811972993799,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(Cc4ccccn4)CC3)cc2C2=CCCCC2)[nH]1
19027,CHEMBL520036,KWQQYOALARJKSN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCCOCC4)C,4.698970004336019,CC(=O)Nc1cc(-c2cccc(N3CCCOCC3)n2)nc(-n2nc(C)cc2C)n1
19039,CHEMBL2387603,KWSYUYDFIFYONI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CC=CS5)Cl,4.522878745280337,O=c1[nH]c2cc(-c3cccs3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
19049,CHEMBL3321850,KWWIBMICKVLCQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25082126.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(C2=CC=CC=C21)C(=O)C3(CC3)C(=O)NC4=C(C=CC(=C4)Cl)Cl,6.568636235841013,CN1CCN(C(=O)C2(C(=O)Nc3cc(Cl)ccc3Cl)CC2)c2ccccc21
19086,CHEMBL3352882,KXMQLNZZFBQWDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=CC=C4C(=O)N,5.522878745280337,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1C(N)=O
19089,CHEMBL1269676,KXNILSUQHBEFOR-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNCCC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,4.823908740944319,CCNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
19090,CHEMBL1269676,KXNILSUQHBEFOR-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNCCC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,4.7447274948966935,CCNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
19095,CHEMBL1681849,KXOXGMSSGWQNPP-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21277198.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=C(C=C(C=N4)C(=O)NCC5=CC(=C(C=C5)F)F)Cl,5.0,C[C@H]1CN(c2ncc(C(=O)NCc3ccc(F)c(F)c3)cc2Cl)CCN1C1CCN(Cc2ccc(Cl)cc2)CC1
19099,CHEMBL3702675,KXQBIJCCZVZCTA-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8CCCCC8,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCCCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
19109,CHEMBL3401131,KXTWFYBMSDHQDY-HZPDHXFCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,=,418000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3ß inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1N2CCO[C@H]3[C@H]2CCCC3)C4=C(C=NC=C4)F,3.378823718224965,Cn1c(N2CCO[C@@H]3CCCC[C@H]32)nc(-c2ccncc2F)cc1=O
19119,CHEMBL1079360,KXYUVZFKXATOCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3,5.0,CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
19123,CHEMBL2041185,KXZUNTUEDNVFLH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CN=C4OC)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,COc1nccnc1N1C(=O)N(c2ccc(-c3ccc(C(=O)O)cc3C)cc2)C(=O)C12CCN(Cc1ncccc1C)CC2
19130,CHEMBL597033,KYCWFOMNQICMSP-XQLXZJNDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)C(=O)N(CC2=CC(=CC=C2)OC(F)(F)F)C3C[C@@H]4CN(C[C@@H]4C3)CC(C5=CC=CC=C5)O,5.0,Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)C2C[C@@H]3CN(CC(O)c4ccccc4)C[C@@H]3C2)c1
19136,CHEMBL3601196,KYGDXANIBQBNCG-BAOJUYLCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=N1)C)NC2=NC=C(C(=C2)N[C@@H]3C[C@@H]([C@H]([C@H]3O)O)CO)C4=NC5=CC=CC=C5S4,4.301029995663981,Cc1cc(Nc2cc(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)c(-c3nc4ccccc4s3)cn2)cc(C)n1
19137,CHEMBL2437422,KYGYDBWEUNNQKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)CCN5CCOCC5)CC6=CC(=NC=C6)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCN5CCOCC5)c5cc(F)ccc54)CC3)CC2)ccn1
19144,CHEMBL348263,KYILADUMHVWERU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)N=CNO,4.0,CCCCOc1ccc(N=CNO)cc1
19148,CHEMBL1094511,KYIVOBNKSGAKNZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=CC=N4,5.301029995663981,CN1CCCC(c2nc3ccccc3n2Cc2ccccn2)C1
19151,CHEMBL2016938,KYKXDBASGIWWGF-XCLFUZPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNC[C@@H]([C@]1(C2=CC(=C(C=C2)F)F)O)C3=C(C(=NO3)C4=CC=CC=C4Cl)Br,4.7447274948966935,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2ccccc2Cl)c1Br
19159,CHEMBL3702744,KYMQIUAUXUGDAK-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3460.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCC(=O)OC,5.460923901207224,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCC(=O)OC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
19163,CHEMBL3260753,KYOICGKIVJTIGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=CN=C(N=C4)C)C5=CC=C(C=C5)Cl,4.3979400086720375,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnc(C)nc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
19172,CHEMBL3664684,KYQHBGDFXHLCHY-UGDMGKLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)CC(C)(C)O)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,C[C@@H](c1ccc(-c2ccn(CC(C)(C)O)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
19176,CHEMBL1270110,KYQVHOMHIXJGBI-CUGSZRRRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,=,26600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@H]1NC2=NC=C(C=C2)C#N)C(=O)OC3C4CC5CC3CC(C5)(C4)C(=O)N,4.575118363368933,N#Cc1ccc(N[C@H]2CCN(C(=O)OC3C4CC5CC3CC(C(N)=O)(C5)C4)C2)nc1
19177,CHEMBL1270001,KYQVHOMHIXJGBI-DOVRNEMHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,=,14200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1NC2=NC=C(C=C2)C#N)C(=O)OC3C4CC5CC3CC(C5)(C4)C(=O)N,4.847711655616943,N#Cc1ccc(N[C@@H]2CCN(C(=O)OC3C4CC5CC3CC(C(N)=O)(C5)C4)C2)nc1
19201,CHEMBL2057794,KYWHIBXYSUFTBJ-DQEYMECFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,69.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@@H]([C@H](CC3=CN=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)C,7.161150909262744,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@H](O)[C@H](Cc3cccnc3)NC(=O)OCc3cncs3)cc2o1
19213,CHEMBL1813476,KZCROLYCBADBTI-DLBZAZTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,2650.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,C1C[C@H]2CNC[C@]2(C1)C3=CC4=CC=CC=C4C=C3,5.576754126063192,c1ccc2cc([C@]34CCC[C@H]3CNC4)ccc2c1
19214,CHEMBL1813477,KZCROLYCBADBTI-SJORKVTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,10700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,C1C[C@@H]2CNC[C@@]2(C1)C3=CC4=CC=CC=C4C=C3,4.97061622231479,c1ccc2cc([C@@]34CCC[C@@H]3CNC4)ccc2c1
19232,CHEMBL221542,KZJWDPNRJALLNS-VJSFXXLFSA-N,BETA-SITOSTEROL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C(C)C,4.0,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C)C(C)C
19256,CHEMBL3589557,KZRCYRFDOFTBHY-BTQNPOSSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26101566.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Competitive inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C1C[C@@H]2CN(CCN2C1)C(=O)C3=CC(=C(C=C3Cl)F)S(=O)(=O)NC4=CC=CC=C4F.Cl,5.0,O=C(c1cc(S(=O)(=O)Nc2ccccc2F)c(F)cc1Cl)N1CCN2CCC[C@@H]2C1
19270,CHEMBL521347,KZYAHEIPPAPADQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,CC1=C(C(N=C(N1)C2=CC(=NC=C2)Cl)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=C(C=C5C(=C4)C=NN5)F,5.6020599913279625,CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1
19274,CHEMBL3407785,KZZIQBCUVRUILN-AQPYCOETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25422861.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,In vivo phenotypic screening for treating chronic neuropathic pain: modification of c2-arylethynyl group of conformationally constrained a3 adenosine receptor agonists.,J. Med. Chem.,PUBLICATION,,CNC1=C2C(=NC(=N1)C#CC3=CC=C(S3)Br)N(C=N2)[C@@H]4[C@H]5C[C@]5([C@H]([C@H]4O)O)C(=O)NC,5.154901959985743,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccc(Br)s4)nc31)[C@H](O)[C@@H]2O
19278,CHEMBL450061,LADNPCFYVROVIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19231183.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CNC1=C(C(=NC(=N1)C#N)N2CCOCC2)N,5.0,CC(C)CNc1nc(C#N)nc(N2CCOCC2)c1N
19282,CHEMBL496400,LAFOUUWSNUQMPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4CCCCC4=O,5.167491087293763,Cc1cccc(C)c1CNc1cc(N2CCCCC2=O)cn2c(C)c(C)nc12
19283,CHEMBL496400,LAFOUUWSNUQMPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4CCCCC4=O,4.657577319177793,Cc1cccc(C)c1CNc1cc(N2CCCCC2=O)cn2c(C)c(C)nc12
19284,CHEMBL240571,LAHUDBCXWRATGM-HRFSGMKKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@H](C)CC3=C(C=C(C=C3)Cl)F)[C@H](C(C)C)NC(=O)CNC,5.161150909262744,CNCC(=O)N[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2F)CC1)C(C)C
19286,CHEMBL606467,LAJHRQQVGFRLQL-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,790.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=COC=C4)C#N)OC[C@H](CC5=CNC6=CC=CC=C65)N,6.102372908709558,Cc1[nH]nc2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c(C#N)nc3-c3ccoc3)nc12
19289,CHEMBL1269672,LANNZQCALHSARO-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCOC)Cl)C5CC5)Cl,5.494850021680094,COCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
19300,CHEMBL3394722,LAQHWPIUUQIIKZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(N3)C=CN=C4)C5CCOCC5,5.0,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2cnccc2[nH]1
19301,CHEMBL3394722,LAQHWPIUUQIIKZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(N3)C=CN=C4)C5CCOCC5,5.0,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2cnccc2[nH]1
19367,CHEMBL239816,LBKUIYUPKQWTEX-UHFFFAOYSA-N,SR-1459,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,490.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Br)N,6.309803919971486,NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1
19373,CHEMBL456002,LBLKWZCUZFIOQX-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,1350.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,CC1=CC=CC=C1C2=CC(=O)N(C3=C2C=C(C=C3)[C@](C4=CC=C(C=C4)Cl)(C5=CN=CN5C)N)C,5.8696662315049934,Cc1ccccc1-c1cc(=O)n(C)c2ccc([C@](N)(c3ccc(Cl)cc3)c3cncn3C)cc12
19374,CHEMBL578547,LBMSLUDBQYSBBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)C(=O)OC,5.301029995663981,COC(=O)c1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1
19375,CHEMBL434317,LBNCHIKFTCJSPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,26800.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=C(C=NN2)C,4.5718652059712115,CCCCOc1ccc(-c2[nH]ncc2C)cc1
19377,CHEMBL565383,LBOFATLQBXVRSA-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=C[N+](=CC=C5)[O-],6.045757490560675,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc[n+]([O-])c3)ccc2o1
19413,CHEMBL3088176,LBTQISHPRWJOLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,J. Med. Chem.,PUBLICATION,,CC1=CSC(=N1)C(C)(C2=NN=C(S2)NC(=O)CC3=C(C=CC=C3F)F)O,4.301029995663981,Cc1csc(C(C)(O)c2nnc(NC(=O)Cc3c(F)cccc3F)s2)n1
19433,CHEMBL3291430,LCCDAYCGXSEETO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CN=C1N(C)C)CN2C=C(C3=C2C=C(C=N3)OC)C(=O)NCCO,4.301029995663981,COc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(N(C)C)c3C)c2c1
19455,CHEMBL2425148,LCGWKKYPAXXXPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=NNC(=S)N4C,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3n[nH]c(=S)n3C)cc2)cc1
19476,CHEMBL1778587,LCPOJFADYAPLKQ-LFIBNONCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550240.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C(=O)NC1=CC=C(C=C1)/C=C/C(=O)O)NC(=O)C2=CC3=C(C=C2)C(=C(N3C)C4=COC=C4)C5CCCCC5,5.060480747381382,Cn1c(-c2ccoc2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21
19478,CHEMBL3137459,LCQMERCOLHHNJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4300.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C#N)C3=CN=CC=C3)C4=CC(=C(C=C4)F)F,5.366531544420414,N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(F)c(F)c3)CC2)cc1
19498,CHEMBL539475,LCXRMOKMNODMLL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,790.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NN1CC(C2=CC=CC=C2)NC(=O)NC3CCN(CC3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F)C,6.102372908709558,Cc1cc(C)n(CC(NC(=O)NC2CCN(Cc3ccn(-c4ccc(C(F)(F)F)cc4)c3)CC2)c2ccccc2)n1
19504,CHEMBL3632717,LDACHLNBCOVNBL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=CC=C1)NC2=NC3=C(N2C)C=CC(=C3)OC4=CC(=NC=C4)C5=NC=CN5,5.7447274948966935,Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc[nH]4)c3)ccc21
19510,CHEMBL239149,LDDVFORMTQHFKD-GOSISDBHSA-N,SR-897,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)[C@@H](C4=CC=CC=C4)O,5.0,O=C([C@H](O)c1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
19523,CHEMBL1269680,LDHQAYBINPIZLI-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNCCF)Cl)C5CC5)Cl,5.136677139879544,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCCF)ccc3Cl)C3CC3)cc2)c(Cl)c1
19524,CHEMBL1269680,LDHQAYBINPIZLI-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,9900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNCCF)Cl)C5CC5)Cl,5.00436480540245,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCCF)ccc3Cl)C3CC3)cc2)c(Cl)c1
19528,CHEMBL561696,LDIUIXFIAWISPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,<,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CSC1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,4.823908740944319,CSc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
19529,CHEMBL561696,LDIUIXFIAWISPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 coincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CSC1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,4.522878745280337,CSc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
19537,CHEMBL3234567,LDKJFGZHRKASEF-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CC1=NC(=CC(=N1)N2CCC[C@H](C2)C(=O)NCCC3=CC=C(C=C3)C#N)N4CCN(CC4)C,4.6020599913279625,Cc1nc(N2CCN(C)CC2)cc(N2CCC[C@@H](C(=O)NCCc3ccc(C#N)cc3)C2)n1
19538,CHEMBL1094510,LDKQFEPUPKIHCG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CCOC4=CC=CC=C4,5.301029995663981,CN1CCCC(c2nc3ccccc3n2CCOc2ccccc2)C1
19540,CHEMBL3291348,LDMFKWUZUDRFEG-ZMZPIMSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@]12CC[C@@H](C1(C)C)C3=C2N(N(C3=O)C4=C(C=CC(=C4)Cl)Cl)C,4.6020599913279625,Cn1c2c(c(=O)n1-c1cc(Cl)ccc1Cl)[C@H]1CC[C@]2(C)C1(C)C
19547,CHEMBL3291354,LDOLONWICSGMOO-ZMZPIMSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@]12CC[C@@H](C1(C)C)C3=C2N(N(C3=O)C4=CC=CC=C4Cl)C,4.301029995663981,Cn1c2c(c(=O)n1-c1ccccc1Cl)[C@H]1CC[C@]2(C)C1(C)C
19560,CHEMBL1951602,LDQKRHYWUXCKBV-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=CCN1C2=C(C(=C1N3CCC[C@@H](C3)N)C#N)N(C(=O)N(C2=O)CC4=C(C=CC=N4)C#N)C)C,5.522878745280337,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1ncccc1C#N)c(=O)n2C
19565,CHEMBL373751,LDTAHRLHGHFHKP-UHFFFAOYSA-N,GSK-319347A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16997559.0,IC50,<,50118.72,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-epsilon kinase.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C#N)OCC4=CC=CC=C4S(=O)(=O)C)OC,4.300000029139089,COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC
19583,CHEMBL361812,LDXDSHIEDAPSSA-OAHLLOKOSA-N,RAMATROBAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2=C(C[C@@H]1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O,4.522878745280337,O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2
19590,CHEMBL2159071,LDZFSHKFVOIAHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,Adamantyl carboxamides and acetamides as potent human 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)C2(CC2)C(=O)N(C)CC3=CC=CS3,5.795880017344075,Cc1ccc(C2(C(=O)N(C)Cc3cccs3)CC2)cc1
19591,CHEMBL2159071,LDZFSHKFVOIAHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,Adamantyl carboxamides and acetamides as potent human 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)C2(CC2)C(=O)N(C)CC3=CC=CS3,5.136677139879544,Cc1ccc(C2(C(=O)N(C)Cc3cccs3)CC2)cc1
19593,CHEMBL3325537,LDZNFFGWKHAEMM-GDBMZVCRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25176194.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CC[C@@H]([C@H](C1)COC2=CC(=C(C=C2F)S(=O)(=O)NC3=NC=NS3)F)C4=CC=C(C=C4)Cl,6.853871964321762,CN1CC[C@H](c2ccc(Cl)cc2)[C@@H](COc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1
19607,CHEMBL180829,LEDOEMLBTIQWQV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,2010.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)NC)N3C=CN=C3)N(C)C,5.696803942579511,CNC(=O)C(C)(C)COc1ccc2cc(C(C(C)N(C)C)n3ccnc3)ccc2c1
19625,CHEMBL2181777,LEMKJLWZCSZLJU-GZTJUZNOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CC1=CN=C(C=C1)C2=C(C3=C(N2C)C=C(C=C3)C(=O)NC4(CCC4)C(=O)NC5=CC=C(C=C5)/C=C/C(=O)O)C6CCCC6,5.236572006437063,Cc1ccc(-c2c(C3CCCC3)c3ccc(C(=O)NC4(C(=O)Nc5ccc(/C=C/C(=O)O)cc5)CCC4)cc3n2C)nc1
19626,CHEMBL178090,LENAVORGWBTPJR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,47100.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CC=C(O2)CN,4.326979092871104,NCc1ccc(-c2cccnc2)o1
19633,CHEMBL1088290,LEPZPTOEMLDSMH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19853442.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New classes of potent and bioavailable human renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=C(C(=CC=C2)Cl)Cl)C(=O)C3=C(CCNC3)C4=CC=C(C=C4)CCCOC5=C(C=CC(=C5Cl)F)F,5.886056647693163,O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)CCNC1)N(Cc1cccc(Cl)c1Cl)C1CC1
19641,CHEMBL2086751,LETIJBVXDGOQFG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=C3/C(=C/4\N=C5C=CC(=CC5=N4)OC)/C6=CC=CC=C6)O,5.251811972993799,CCN1CCC(Nc2ccc3[nH]c(O)c(/C(=C4\N=c5ccc(OC)cc5=N4)c4ccccc4)c3c2)CC1
19651,CHEMBL1774930,LEXXECNYBXJPMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,C1C2=C(CN1C(=O)NCC(F)(F)F)N=C(N=C2C3=C(C=C(C=C3Cl)Cl)OCCN4C=C(C=N4)F)N,6.096910013008056,Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cc(F)cn3)n1)CN(C(=O)NCC(F)(F)F)C2
19656,CHEMBL808,LEZWWPYKPKIXLL-UHFFFAOYSA-N,ECONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,430.53,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,6.365996580840961,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
19657,CHEMBL808,LEZWWPYKPKIXLL-UHFFFAOYSA-N,ECONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,50.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,7.301029995663981,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
19701,CHEMBL261805,LFQVOSHWRZTZHW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6,5.468521082957745,Nc1nccn2c(C3CCC3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12
19703,CHEMBL557210,LFSBNTMFCXGIEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CCO)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,5.301029995663981,CN(CCO)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
19706,CHEMBL2436205,LFSWTUZKDFSREL-OBRDHALPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=C(C=C5)S(=O)(=O)C)NC.Cl,5.698970004336019,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(S(C)(=O)=O)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
19723,CHEMBL1949941,LFZMKXMCRKNUCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CN4C)O)OC,5.920818753952375,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cncn3C)c2c1
19724,CHEMBL1949941,LFZMKXMCRKNUCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CN4C)O)OC,5.309803919971486,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cncn3C)c2c1
19729,CHEMBL252437,LGAIRKZXPYNIQE-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,5.0,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
19731,CHEMBL3318477,LGARZUXXEONOTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2Cl)C3=C(C=CC=C3C(F)(F)F)C(F)(F)F,5.301029995663981,O=C1CC(c2c(C(F)(F)F)cccc2C(F)(F)F)CC(O)=C1Sc1ccccc1Cl
19736,CHEMBL3087339,LGBXCUAQHIUOHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CC(=C1)C2=CC=C(C=C2)NC(=O)C3=CC(=CC(=C3)Cl)Cl,4.568636235841013,Cc1cc(-c2ccc(NC(=O)c3cc(Cl)cc(Cl)c3)cc2)ccn1
19739,CHEMBL348475,LGGHDPFKSSRQNS-UHFFFAOYSA-N,TARIQUIDAR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,4.0,COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2
19740,CHEMBL348475,LGGHDPFKSSRQNS-UHFFFAOYSA-N,TARIQUIDAR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,4.0,COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2
19747,CHEMBL218375,LGJRRERRFSZFTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17266208.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8.",J. Med. Chem.,PUBLICATION,,CCOC(=O)N1CCC(CC1)NS(=O)(=O)C2=CC=C(C3=CC=CC=C32)NC(=O)C4=CC=CC=C4C,5.0,CCOC(=O)N1CCC(NS(=O)(=O)c2ccc(NC(=O)c3ccccc3C)c3ccccc23)CC1
19756,CHEMBL326796,LGMBHWQZEHFJOS-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC=C(O2)C3=CC=CC=C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=NC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,5.823908740944319,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccncc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
19760,CHEMBL1650646,LGNVIXULXLACQS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2050.0,NM,221148,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. Inhibition assay using P450 CYP enzymes.,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,PATENT,,COC1=NC=C(C=C1)C2=C(C=CC3=C2C=CC(=C3)C4=CC(=CC=C4)O)O,5.688246138944246,COc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cn1
19762,CHEMBL3115173,LGNYHLQWWSCHTL-WUNLWTINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.301029995663981,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
19767,CHEMBL389074,LGQVNFUOFPCSSQ-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC3=C(C=C(C=C3)Cl)C(=O)N2CC4=CC=CC=C4C#N)N,6.6020599913279625,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(Cl)cc2c1=O
19770,CHEMBL3702731,LGRWYGGRXLUJDO-LQJZCPKCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2510.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(C)CCO,5.600326278518962,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
19777,CHEMBL3702770,LGWHJDRHSPNXIU-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2610.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CC=C(C=C7)OC,5.583359492661719,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
19789,CHEMBL2024249,LGZMQYLGIALXSF-VHSZZVNMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2910.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,COCCCC[C@]([C@@H]1CCCN(C1)C(=O)NC[C@H](CC2CCCCC2)N)(C3=C(C(=CC=C3)Cl)F)O,5.536107011014093,COCCCC[C@@](O)(c1cccc(Cl)c1F)[C@@H]1CCCN(C(=O)NC[C@@H](N)CC2CCCCC2)C1
19797,CHEMBL1671982,LHEAAXNLFNVCGK-NDENLUEZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)/C=C\2/C(=O)NC(=O)S2)OC3=CC=C(C4=CC=CC=C43)C(=O)OC,6.096910013008056,COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c2ccccc12
19798,CHEMBL519383,LHFROBFAPLSYRB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CN=C3)OCCOC)C,4.853871964321762,COCCOc1cncc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1
19810,CHEMBL3357637,LHHLPNVJMCVRGH-YVNNLAQVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25409491.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method,A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles.,J. Med. Chem.,PUBLICATION,,CCOC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)NC(=O)/C(=C/CN(C)C)/F,5.0,CCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C
19812,CHEMBL3702736,LHIDQAMOAPBRHZ-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2530.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(C)CC7(CC7)CO,5.5968794788241825,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CC5(CO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
19847,CHEMBL191817,LHWQBUMJKGGLOH-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)N)CC4=C(C=CC=C4F)F,6.221848749616356,COc1cccc(-c2cn(Cc3c(F)cccc3F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F
19849,CHEMBL3702674,LHXHSXDYTBEHRK-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8=CC=CC=C8,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
19851,CHEMBL1090176,LHYWGVZKOTTYSZ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CN=C3OC,5.0,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(C)ccc21
19852,CHEMBL1090176,LHYWGVZKOTTYSZ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20800486.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CN=C3OC,5.0,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(C)ccc21
19857,CHEMBL2037604,LIEAKONJVOLXFZ-LSDHHAIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22578490.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,C[C@@H]1CCCN1C[C@H](C)COC2=CC=C(C=C2)C3=CC(=O)NN=C3,4.522878745280337,C[C@H](COc1ccc(-c2cn[nH]c(=O)c2)cc1)CN1CCC[C@H]1C
19861,CHEMBL3311222,LIFCTIRUKQXXCV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,53000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)F,4.275724130399211,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)cc2)cn1
19866,CHEMBL465470,LIKKKFAHHSRGPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,=,64000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=NC=C1C(=O)NCC2CCOCC2)NC3=C(C=C(C=C3)Cl)Cl,4.1938200260161125,CC(C)(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1
19868,CHEMBL3288752,LIKSGJKEDNKMAF-FTWQHDNSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24842618.0,IC50,>,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.,Bioorg. Med. Chem.,PUBLICATION,,CC1=CC2=NN(C(=O)N2C=C1Cl)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl,4.958607314841775,Cc1cc2nn(Cc3cc([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)ccc3Cl)c(=O)n2cc1Cl
19869,CHEMBL1098726,LILGMDXLRPEBNH-HFZDXXHNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20405922.0,IC50,>,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521).",J. Med. Chem.,PUBLICATION,,CN1C(=O)N(C(=O)[C@]12CN(C[C@H]2C3=CC=C(C=C3)C#N)C4=NC=C(C=C4)C(=O)O)C5=CC(=CC(=C5)Cl)Cl,4.455931955649724,CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)[C@]12CN(c1ccc(C(=O)O)cn1)C[C@H]2c1ccc(C#N)cc1
19870,CHEMBL2331772,LIMFSRUCVSKRHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1Cl)Cl)S(=O)(=O)NC2=CC(=C(C(=C2)Cl)OC3=CC(=CN=C3)Cl)Cl,5.920818753952375,O=S(=O)(Nc1cc(Cl)c(Oc2cncc(Cl)c2)c(Cl)c1)c1ccc(Cl)cc1Cl
19881,CHEMBL2386076,LINXGADXFCBIBN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CC2=C1N(C3=CC=CC=C23)CC(=O)O)C(=O)C4=CC(=CC=C4)Cl,4.301029995663981,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1cccc(Cl)c1)CC2
19889,CHEMBL1938681,LIPNXDIBECKOMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes co-incubated with testosterone,,ACS Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1)C2=CC=C(C=C2)N(CC3=CC=CC=N3)C(=O)C4=CC=C(O4)C5=CC=C(C=C5)Cl,4.698970004336019,O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1
19890,CHEMBL1938681,LIPNXDIBECKOMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 30 mins prior to substrate addition,,ACS Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1)C2=CC=C(C=C2)N(CC3=CC=CC=N3)C(=O)C4=CC=C(O4)C5=CC=C(C=C5)Cl,4.698970004336019,O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1
19892,CHEMBL2017091,LIQNVPVFYAIYPC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,>,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=CC3=NC=C(C(=C3C=C2)NC4=CC=CC=C4)C(=O)O,4.481486060122112,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3)c(C(=O)O)cnc2c1
19893,CHEMBL522689,LIQUKCBVEIEJGE-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,CC[C@H](C)NC1=C2C=CC(=CC2=CN=N1)C3=C(C=CC4=C3ON=C4NC)C,4.6020599913279625,CC[C@H](C)Nc1nncc2cc(-c3c(C)ccc4c(NC)noc34)ccc12
19896,CHEMBL3115179,LIRHQWJNEWJZFF-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN(C)C)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.853871964321762,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN(C)C)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
19897,CHEMBL2018923,LISPYUNURYPUOP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,1870.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC(=CC=C3)C4=CC=CC=C4,5.728158393463501,COc1ccc2nc(SCc3cccc(-c4ccccc4)c3)[nH]c2c1
19903,CHEMBL2397186,LIWXQSMSAZJCQT-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=NC(=NC=C3)C(C)(C)C,5.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1
19905,CHEMBL3702812,LIXAEKDRWMNILP-LFCBDPIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)C2CN(C2)C3=NC=C(C=C3)NC(=O)C4=CN(C5=C(C=CC=C45)CN6C[C@H]7N([C@H](C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,5.3872161432802645,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(N7CCN(C)CC7)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
19906,CHEMBL1081515,LIXMKOKUEJGOKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,66.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC(CC1CCCCC1)NC(=O)OCC2=CN=CS2)CC(CC3CCCCC3)NC(=O)OCC4=NC=CS4,7.180456064458132,CCN(CC(CC1CCCCC1)NC(=O)OCc1cncs1)CC(CC1CCCCC1)NC(=O)OCc1nccs1
19914,CHEMBL196945,LIYLTQQDABRNRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,48000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)Cl)Cl)F)C(=O)O,4.318758762624412,O=C(O)C1(c2ccc(-c3ccc(Cl)c(Cl)c3)c(F)c2)CC1
19917,CHEMBL2069845,LJDGJZNBWICGDO-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ß-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC(=CC=C3)C(=O)O,6.0,N[C@@H](CC(=O)N1CCN(C(=O)c2cccc(C(=O)O)c2)CC1)Cc1cc(F)c(F)cc1F
19918,CHEMBL540359,LJDOMRHCUJTSAI-ZBBHSQCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18680280.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel and long acting muscarinic acetylcholine receptor antagonists.,J. Med. Chem.,PUBLICATION,,CC(C)OC(=O)C1=CC=C(C=C1)NC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@H]3CCC[N+](C3)(C)CC4=CC(=CC=C4)O.[I-],5.0,CC(C)OC(=O)c1ccc(NC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H]2CCC[N+](C)(Cc3cccc(O)c3)C2)cc1
19924,CHEMBL3109797,LJGARRQSIYHDHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,CCC1=C(N2C=CC(=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCN(CC4)C5=CC=C(C=C5)F,4.3979400086720375,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCN(c3ccc(F)cc3)CC2)cc1
19928,CHEMBL1223002,LJHSDTNRTCEUNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)CN2C3=CC=CC=C3N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC=NC=C6,6.698970004336019,COc1cccc(Cn2c(=O)n(C3CCN(C(=O)C4CCN(Cc5ccncc5)CC4)CC3)c3ccccc32)c1
19930,CHEMBL2059799,LJKCPRJTSAUESM-JGCGQSQUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=CC=CC=C4C=C3)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,7.522878745280337,O=C(N[C@H](Cc1ccc2ccccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
19938,CHEMBL114756,LJMLRDFXBGZNOB-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852968.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC=C(O2)C3=CC=NC=C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,6.494850021680094,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccncc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
19939,CHEMBL114756,LJMLRDFXBGZNOB-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC=C(O2)C3=CC=NC=C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,6.494850021680094,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccncc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
19953,CHEMBL2165498,LJTQAIKAEMCJSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC1=NC2=CC=CC=C2N1C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCC(CC6)N(C)C,5.0,Cc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCC(N(C)C)CC3)cc2n1
19956,CHEMBL1921961,LJUABYFUJVRUSJ-FRVJLOGJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21966889.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2C=C[C@H]1[C@@H]3[C@H]2C(=O)N(C3=O)C4=C(C=C(C=C4)NC(=O)C5=CC=CC=N5)Cl,4.522878745280337,O=C(Nc1ccc(N2C(=O)[C@H]3[C@H]4C=C[C@H](C4)[C@H]3C2=O)c(Cl)c1)c1ccccn1
19960,CHEMBL594072,LJVDXVHUFXOWBO-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OC[C@H](CC5=C(NC6=CC=CC=C65)C(=O)N)N,5.3979400086720375,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C(N)=O)[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2n1
19963,CHEMBL1079712,LJXHKSLKMJASBE-UIOOFZCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,348.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CN2)C[C@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CN4,6.458420756053419,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cnc[nH]1)C[C@H](Cc1ccccc1)NC(=O)OCc1ncc[nH]1
19973,CHEMBL196875,LKBXWNYXDMSFQU-ONNFQVAWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15837312.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against human Cytochrome P450 3A4,"Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1/C=C/C(=O)NC2=C(C=C(C=C2)C3=NC4=C(O3)C=CC(=C4)CC(=O)O)F)Br,4.522878745280337,O=C(O)Cc1ccc2oc(-c3ccc(NC(=O)/C=C/c4ccc(Br)cc4)c(F)c3)nc2c1
19977,CHEMBL3261082,LKDWXLBCDHUZRF-HXPMCKFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC(=N1)N2C[C@H]3C(=O)N(C(=N[C@]3(C2)C4=C(C=CC(=C4)F)F)N)C)OC)F,4.522878745280337,COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cc(F)ccc3F)C2)nc(C)c1F
19997,CHEMBL1272046,LKJNOKVJAZHRAT-OMXLDXBASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,2.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1CCO)C)C(=O)OC2(CC2)[C@H]3COC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)CC5CC5,8.698970004336019,C[C@H]1CN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)C[C@@H](C)N1CCO
20019,CHEMBL2441836,LKKWOSVPEMTNNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CCOC)C3=C(C=C(C=C3)Cl)Cl)CN,4.853871964321762,COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
20020,CHEMBL2441836,LKKWOSVPEMTNNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CCOC)C3=C(C=C(C=C3)Cl)Cl)CN,4.638272163982407,COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
20021,CHEMBL2441836,LKKWOSVPEMTNNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CCOC)C3=C(C=C(C=C3)Cl)Cl)CN,4.5376020021010435,COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
20023,CHEMBL3422244,LKLYLZSFUBTUBW-KDQZPGIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=COC(=N1)[C@H]2C[C@H]3[C@H](SC(=N[C@]3(CO2)C4=C(C=C(C=C4)F)F)N)CF,4.522878745280337,Cc1coc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1
20033,CHEMBL461012,LKQMULLPLYLIGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=C(C=CC=C3Cl)Cl,6.154901959985743,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(Cl)cccc1Cl
20041,CHEMBL502531,LKUSYUYBQDJFNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18479916.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C#CC1=C(C=CN=C1N)OC2=C(C=C(C=C2)NC(=O)NC(=O)CC3=CC=C(C=C3)F)F,6.096910013008056,C#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N
20046,CHEMBL3601192,LKWUVRWXZPRGNM-BMZZKGLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=N1)C)NC2=NC=C(C(=N2)N[C@@H]3C[C@@H]([C@H]([C@H]3O)O)CO)C4=NC5=CC=CC=C5C=C4,4.301029995663981,Cc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)cc(C)n1
20067,CHEMBL312121,LLIPALBHLJKSHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,CN1CC2=CN=CN2CC3=CC(=C(C=C3)C#N)OC4=CC5=C(C=CC=C5N6CCC1C6=O)C=C4,5.301029995663981,CN1Cc2cncn2Cc2ccc(C#N)c(c2)Oc2ccc3cccc(c3c2)N2CCC1C2=O
20074,CHEMBL2425152,LLLIYKLRWQOPGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C(=NN=N4)C,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3nnnc3C)cc2)cc1
20104,CHEMBL324461,LLRKKARNQCFJDO-NKBKYVEPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC3=CC=CC=C3O2)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CN=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,6.318758762624412,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2cc3ccccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
20105,CHEMBL2386636,LLRNGFSFYHDPKW-MGPQQGTHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1C4CCC(CC4)CCC#N)C=CN3)O,5.173925197299173,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1C1CCC(CCC#N)CC1
20106,CHEMBL2386636,LLRNGFSFYHDPKW-MGPQQGTHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1C4CCC(CC4)CCC#N)C=CN3)O,5.0,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1C1CCC(CCC#N)CC1
20110,CHEMBL1822515,LLSXHTXXTKDPRH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21859094.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC=C(C=C2)NC3=NN4C(=CC=C4C5=CC=CC=C5OC)C=N3,5.026872146400302,COc1ccccc1-c1ccc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nn12
20111,CHEMBL3137450,LLTMFKOMKKKDNQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,COC1=CC=C(C=C1)CN2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,5.096910013008056,COc1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
20112,CHEMBL3137450,LLTMFKOMKKKDNQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,COC1=CC=C(C=C1)CN2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,4.823908740944319,COc1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
20145,CHEMBL1241738,LMIGPJJYYRXPJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C(=NN=C6CO5)C,5.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nnc(C)n4-5)CC3)cccc2n1
20146,CHEMBL1241738,LMIGPJJYYRXPJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C(=NN=C6CO5)C,5.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nnc(C)n4-5)CC3)cccc2n1
20154,CHEMBL2419491,LMMAPNCJSSIUOS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)F)C,5.346787486224656,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3)CC2)nc1C
20155,CHEMBL3264002,LMMJFBMMJUMSJS-UHFFFAOYSA-N,RG-7304,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=NC=C4)NS(=O)(=O)NC)F,4.0,CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F
20156,CHEMBL3264002,LMMJFBMMJUMSJS-UHFFFAOYSA-N,RG-7304,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=NC=C4)NS(=O)(=O)NC)F,4.0,CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F
20161,CHEMBL2059900,LMPHOXYGKFAVAU-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22732695.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CSC4=CC=CC=C43)NC(=O)N5CCC6(CC5)C(=O)NC(=N6)C7=CC=CC=C7,6.0,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC2(CC1)N=C(c1ccccc1)NC2=O
20165,CHEMBL3581141,LMRBHLOXIRMINE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,11400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,CNC1=NC=CC(=C1)C2=CSC(=N2)NC(=O)CC3=CC(=CC=C3)OC,4.943095148663527,CNc1cc(-c2csc(NC(=O)Cc3cccc(OC)c3)n2)ccn1
20172,CHEMBL1097772,LMTYJQQFAMWXIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,2345.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC=CC=C5)C)OC,5.629857152948898,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccccc1)cc(=O)n2C)c1cncn1C
20188,CHEMBL2036214,LNAWXIMKZTUGJB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,CCCCC(=O)N(CC1=CC=C(C=C1)OC(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)F,5.0,CCCCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(F)cc(-c2nn[nH]n2)c1
20193,CHEMBL3264609,LNCAMLLVHZJNDI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,>=,195000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC(F)(F)F)(C3=NNN=C3)O,3.709965388637482,CC(C)C(O)(c1ccc2cc(OCC(F)(F)F)ccc2c1)c1cn[nH]n1
20206,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,5.086186147616283,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
20207,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,33100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,4.480172006224281,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
20221,CHEMBL3287849,LNFPEBXLWIXQLF-STQMWFEESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900876.0,IC50,>,20000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.",ACS Med. Chem. Lett.,PUBLICATION,,C1CN[C@H](C[C@H]1C2=CC(=O)NO2)CC3=CC=CC=C3,1.6989700043360187,O=c1cc([C@H]2CCN[C@@H](Cc3ccccc3)C2)o[nH]1
20222,CHEMBL1080419,LNFPYTXWNUBAEF-PMACEKPBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,136.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@H](CC(C)C)NC(=O)OCC1=CN=CS1)C[C@H](CC(C)C)NC(=O)OCC2=NC=CS2,6.866461091629782,CCN(C[C@H](CC(C)C)NC(=O)OCc1cncs1)C[C@H](CC(C)C)NC(=O)OCc1nccs1
20227,CHEMBL519336,LNOMZGGJGBXFOZ-RTWAWAEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CC2)CCN(CC3)C(=O)N[C@H]4C[C@@H]4C5=CC=CC=C5,5.0,CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2
20236,CHEMBL2407950,LNPHHOCWZOSXKI-YYDJUVGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1C(C/C(=N\O)/C2=CC(=NC=C2)C)C3=CC=C(C=C3)Br,5.301029995663981,Cc1cc(/C(CC(c2ccc(Br)cc2)c2ccccc2C)=N/O)ccn1
20245,CHEMBL3298907,LNTJQFBTDQICKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,CCC1=C(N2C=CC(=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)Cl,4.3979400086720375,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(Cl)cc3)CC2)cc1
20272,CHEMBL256391,LOBKVXVGQZRYKH-DNVJHFABSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=CO1)[C@H](C(=O)N(C)CCO)N2[C@@H](C(=O)N[C@@H](C2=O)C3CC4=CC=CC=C4C3)CC(C)C,4.0,Cc1nc([C@H](C(=O)N(C)CCO)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1
20277,CHEMBL3394738,LOBWMLUMWDKDBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CN=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1
20278,CHEMBL3394738,LOBWMLUMWDKDBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CN=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1
20287,CHEMBL1766170,LOFFEKCUNLMSQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=CC(=C1)C2=CC=C(C=C2)F)(C3=CN=CN3)O,5.6777807052660805,CC(C)C(O)(c1cccc(-c2ccc(F)cc2)c1)c1cnc[nH]1
20292,CHEMBL3702685,LOFXNVBNYNYEPK-QARUCVQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)(C)CNC(=O)NC1=NC=C(C=C1)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.6595558851598815,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCC(C)(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
20306,CHEMBL495727,LOLPPWBBNUVNQZ-UHFFFAOYSA-N,AT-9283,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19143567.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",J. Med. Chem.,PUBLICATION,,C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5,5.0,O=C(Nc1cn[nH]c1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
20309,CHEMBL1224524,LOMHDTDKMKKMKY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709552.0,IC50,<,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=CN=CN3)C(F)(F)F,7.301029995663981,FC(F)(F)c1ccccc1-c1cccc(-c2cnc[nH]2)c1
20338,CHEMBL1294,LOUPRKONTZGTKE-LHHVKLHASA-N,QUINIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,4.301029995663981,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12
20352,CHEMBL3702757,LOVFQEUYPQWFHE-LQJZCPKCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6150.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCOC(=O)CNNC(=O)C1=CN(C2=C(C=CC=C12)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C,5.211124884224583,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NNCC(=O)OCC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
20355,CHEMBL230309,LOYHRPQPVDZCBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,710.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=CC=C1)NC(=N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O,6.1487416512809245,Cc1cccc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
20365,CHEMBL404646,LPCDOMMRICKOBC-JDXGNMNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC(=CC=C2)OC)CCOC3=CC=CC(=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,4.721246399047171,COc1cccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)c1
20378,CHEMBL240568,LPIMZWKKMREGHM-ZBLYBZFDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@H](C)CC3=C(C=C(C=C3)Cl)F)[C@H](C(C)C)NCCNC,5.045757490560675,CNCCN[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2F)CC1)C(C)C
20385,CHEMBL460178,LPKACSKZPXNEBK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,=,12200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,COC1CCC2=C(C1)C=CC(=C2)C3=CN=CC=C3,4.913640169325252,COC1CCc2cc(-c3cccnc3)ccc2C1
20408,CHEMBL471072,LPRPIMHDDACJHT-AWEZNQCLSA-N,(S)-6-GINGEROL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,36400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,CCCCC[C@@H](CC(=O)CCC1=CC(=C(C=C1)OC)O)O,4.438898616350944,CCCCC[C@H](O)CC(=O)CCc1ccc(OC)c(O)c1
20411,CHEMBL1651525,LPTGBERPUYIOJQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng testosterone substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=CN=CC=C4,6.096910013008056,O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
20412,CHEMBL1651525,LPTGBERPUYIOJQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng midazolam substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=CN=CC=C4,5.366531544420414,O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
20413,CHEMBL3315061,LPVOSIGKKGTQCK-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24980053.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)([C@H]1C2=C(C(=CC=C2)F)OC3=C1C=CC(=N3)C4=CC=C(C=C4)C(=O)N5CCOCC5)C(=O)NC(=O)N,4.3979400086720375,CC(C)(C(=O)NC(N)=O)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21
20429,CHEMBL464245,LQAJJWMXZBDMAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C(=C1)F)C(=O)N(CCF)CC(CNC(=O)C2=C(N(N=C2)C3=CC=C(C=C3)F)N)(C(F)(F)F)O)F,6.301029995663981,Nc1c(C(=O)NCC(O)(CN(CCF)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1
20435,CHEMBL564085,LQCLVBQBTUVCEQ-QTFUVMRISA-N,TROLEANDOMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,4.795880017344075,CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
20436,CHEMBL564085,LQCLVBQBTUVCEQ-QTFUVMRISA-N,TROLEANDOMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,4.698970004336019,CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
20437,CHEMBL564085,LQCLVBQBTUVCEQ-QTFUVMRISA-N,TROLEANDOMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,4.481486060122112,CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
20438,CHEMBL564085,LQCLVBQBTUVCEQ-QTFUVMRISA-N,TROLEANDOMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,61000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,4.214670164989233,CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
20440,CHEMBL564085,LQCLVBQBTUVCEQ-QTFUVMRISA-N,TROLEANDOMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,7998.34,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,5.0970001384638906,CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
20448,CHEMBL3233058,LQCUMLOMFBTKNQ-NWDGAFQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24520947.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,PUBLICATION,,CC1=NC(=CC=C1)NC2=CC(=NN=C2C(=O)N)N[C@@H]3CCCC[C@@H]3N,4.301029995663981,Cc1cccc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)n1
20452,CHEMBL3236363,LQFZONHTRLPWKM-ZJTSJXPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1[C@@H]([C@H](C[C@](C1=O)(C)CC(=O)N)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,5.886056647693163,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
20469,CHEMBL2016937,LQMJDFXYANXGEK-VLIAUNLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNC[C@@H]([C@]1(C2=CC(=C(C=C2)F)F)O)C3=CC(=NO3)C4=C(C=C(C=C4)F)Cl,5.154901959985743,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2ccc(F)cc2Cl)no1
20471,CHEMBL258694,LQNDDQQRHZEHDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18395443.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NN=C(O1)C2=CN3C(=C2C(C)C)C(=NC=N3)NC4=CN=C5C(=C4)C=CN5,4.3979400086720375,Cc1nnc(-c2cn3ncnc(Nc4cnc5[nH]ccc5c4)c3c2C(C)C)o1
20472,CHEMBL2023802,LQNNUQKZSZVOBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497760.0,IC50,>,8600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=C(C(=NN1)NC(=O)CC2=C(C=C(C=N2)OC3=C4C=C(C(=CC4=NC=C3)OCC)OC)OC)C,5.0655015487564325,CCOc1cc2nccc(Oc3cnc(CC(=O)Nc4n[nH]c(CC)c4C)c(OC)c3)c2cc1OC
20474,CHEMBL3092467,LQOIAHRPEWFITJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,=,18600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)N=C(C=N2)C3=CC=C(C=C3)NS(=O)(=O)C4=C(C=CC(=C4)OC)Cl,4.730487055782084,COc1ccc(Cl)c(S(=O)(=O)Nc2ccc(-c3cnc4c(C)[nH]nc4n3)cc2)c1
20475,CHEMBL3092467,LQOIAHRPEWFITJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,=,26800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)N=C(C=N2)C3=CC=C(C=C3)NS(=O)(=O)C4=C(C=CC(=C4)OC)Cl,4.5718652059712115,COc1ccc(Cl)c(S(=O)(=O)Nc2ccc(-c3cnc4c(C)[nH]nc4n3)cc2)c1
20487,CHEMBL575448,LQVXSNNAFNGRAH-QHCPKHFHSA-N,BMS-754807,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19778024.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxy-resorufin as substrate,"Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.",J. Med. Chem.,PUBLICATION,,C[C@]1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F,5.154901959985743,C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1
20488,CHEMBL575448,LQVXSNNAFNGRAH-QHCPKHFHSA-N,BMS-754807,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19778024.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.",J. Med. Chem.,PUBLICATION,,C[C@]1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F,4.3979400086720375,C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1
20491,CHEMBL1682903,LQWYAFZMARIARA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,5400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=CC3=C(C=C2C=C1)C(=O)N(C3)C)(C4=CN=CN4)O,5.267606240177032,CC(C)C(O)(c1ccc2cc3c(cc2c1)CN(C)C3=O)c1cnc[nH]1
20495,CHEMBL231350,LQYNONCEAYAGNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17084080.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Studies towards the identification of a new generation of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)NC1=C(C=C2CCN(CCC2=C1)C)NS(=O)(=O)C3=CC=C(C=C3)C4=CC=C(C=C4)Cl,5.1249387366083,CC(C)Nc1cc2c(cc1NS(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CCN(C)CC2
20501,CHEMBL1898239,LQZSHPITKSPDLC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22260203.0,IC50,=,5700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,PUBLICATION,,CC1=NN=C(N1C2=CC=C(C=C2)OC)SCC3=NC(=NO3)C4=CC=C(C=C4)OC,5.2441251443275085,COc1ccc(-c2noc(CSc3nnc(C)n3-c3ccc(OC)cc3)n2)cc1
20518,CHEMBL496263,LRECNGBVUUBJSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,15190.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C(CCC3)(C4=CC=NC=C4)O)F,4.818442226137214,COc1ccc(-c2ccc3c(c2)CCCC3(O)c2ccncc2)cc1F
20524,CHEMBL2425894,LRJXBQIWFWQGFB-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,54650.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=CC(=C3)F)C=C2)N4CCC[C@H](C4)N,4.262409833714278,CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccc(F)cc3n2)c1=O
20525,CHEMBL1089270,LRJYGHMKTIYPPQ-OMKJIRLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188553.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydroindolizinone NK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CN3C([C@@H]2C4=CC=C(C=C4)F)CC(=CC3=O)C5=CCN(CC5)C(C)(C)C,4.301029995663981,C[C@@H](O[C@H]1CN2C(=O)C=C(C3=CCN(C(C)(C)C)CC3)CC2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
20544,CHEMBL3137471,LRPTWDVRWNQMPG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC(C(=O)C)N1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3,5.301029995663981,CC(=O)C(C)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
20549,CHEMBL2425157,LRUCJVKBTVPLFN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CN=C(C=C4)N,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(N)nc3)cc2)cc1
20562,CHEMBL3103437,LRYNXQMWCWCCSO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24360604.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Synthesis and structure-activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2CC3CC1CC(C2)C3(CC4=NNN=N4)C5=CC=C(C=C5)C6=CC=CC=C6,4.3979400086720375,c1ccc(-c2ccc(C3(Cc4nn[nH]n4)C4CC5CC(C4)CC3C5)cc2)cc1
20563,CHEMBL496387,LRZALAWCYDMOCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C(=O)C=CC=N4,5.142667503568732,Cc1cccc(C)c1CNc1cc(-n2ncccc2=O)cn2c(C)c(C)nc12
20564,CHEMBL496387,LRZALAWCYDMOCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,8500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C(=O)C=CC=N4,5.070581074285707,Cc1cccc(C)c1CNc1cc(-n2ncccc2=O)cn2c(C)c(C)nc12
20577,CHEMBL2203397,LSFSILMVQQMGRP-OPRSCSRJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24328103.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Discovery of a non-estrogenic irreversible inhibitor of 17ß-hydroxysteroid dehydrogenase type 1 from 3-substituted-16ß-(m-carbamoylbenzyl)-estradiol derivatives.,J. Med. Chem.,PUBLICATION,,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@@H]([C@@H]2O)CC4=CC(=CC=C4)C(=O)N)CCC5=C3C=CC(=C5)CCBr,5.4089353929735005,C[C@]12CC[C@@H]3c4ccc(CCBr)cc4CC[C@H]3[C@@H]1C[C@H](Cc1cccc(C(N)=O)c1)[C@@H]2O
20593,CHEMBL1766191,LSNINMQJLNWRJL-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC[C@](C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,5.0,CC[C@](O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1cnc[nH]1
20594,CHEMBL1766192,LSNINMQJLNWRJL-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC[C@@](C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,5.0,CC[C@@](O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1cnc[nH]1
20595,CHEMBL1766184,LSNINMQJLNWRJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC(C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,5.0,CCC(O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1cnc[nH]1
20616,CHEMBL482034,LSSNBHGWOAHIQS-LSDHHAIUSA-N,"(8R,8'R)-4-HYDROXYCUBEBINONE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,COC1=CC(=CC(=C1O)OC)C[C@H]2COC(=O)[C@@H]2CC3=CC4=C(C(=C3)OC)OCO4,5.130768280269024,COc1cc(C[C@H]2COC(=O)[C@@H]2Cc2cc(OC)c3c(c2)OCO3)cc(OC)c1O
20633,CHEMBL567089,LSZYMWXOOBDCEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)SCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,5.346787486224656,COc1ccc2c(SCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
20634,CHEMBL567089,LSZYMWXOOBDCEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)SCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,5.154901959985743,COc1ccc2c(SCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
20645,CHEMBL408444,LTEJRLHKIYCEOX-TZMCWYRMSA-N,BMS-582664,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@@H](C)N)C,6.292429823902063,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@@H](C)N)c(C)c34)ccc2[nH]1
20646,CHEMBL408444,LTEJRLHKIYCEOX-TZMCWYRMSA-N,BMS-582664,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@@H](C)N)C,5.795880017344075,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@@H](C)N)c(C)c34)ccc2[nH]1
20659,CHEMBL1751,LTMHDMANZUZIPE-PUGKRICDSA-N,DIGOXIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,4.301029995663981,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
20695,CHEMBL487766,LTWAUSKVHLPSOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CN=CC=C3)C,4.698970004336019,CC(=O)Nc1cc(-c2cccnc2)nc(-n2nc(C)cc2C)n1
20716,CHEMBL2040895,LUCCLRBBVBPHOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)N6C=CC=N6,4.301029995663981,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-n3cccn3)cc1)C(=O)N2c1cc(=O)[nH]cn1
20717,CHEMBL1269696,LUCJQRCTXXOATA-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)OC)Cl)C5CC5)Cl,5.455931955649724,COC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
20718,CHEMBL1269696,LUCJQRCTXXOATA-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)OC)Cl)C5CC5)Cl,5.187086643357144,COC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
20725,CHEMBL1095404,LUCVGGOCKASWHT-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)N1CCN(CC1)C2=CC3=C(C(=C2)C)N=C(N3)C4=C(C=CNC4=O)NC[C@H](C5=CC(=CC=C5)Cl)O,6.0,CCOC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
20726,CHEMBL1910116,LUDLSGUXLBEWMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)NC)C3=C(C=C(C=C3)Cl)Cl)CN,4.769551078621726,CNC(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
20729,CHEMBL426789,LUDUPPNOCMHNSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,1590.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)O)N4C=CN=C4)N(C)C,5.798602875679548,CC(C(c1ccc2cc(OCc3cccc(C(=O)O)c3)ccc2c1)n1ccnc1)N(C)C
20730,CHEMBL426789,LUDUPPNOCMHNSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,3790.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)O)N4C=CN=C4)N(C)C,5.421360790031928,CC(C(c1ccc2cc(OCc3cccc(C(=O)O)c3)ccc2c1)n1ccnc1)N(C)C
20739,CHEMBL2420686,LUGXRTWVGQQQDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,2145.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC2=C1C=CC(=C2Cl)C3=CN=CN=C3)O,5.668572703479257,Oc1ccc2ccc(-c3cncnc3)c(Cl)c2c1
20754,CHEMBL1645462,LUJZZYWHBDHDQX-QFIPXVFZSA-N,AC-480,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19821562.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.",J. Med. Chem.,PUBLICATION,,CC1=C2C(=NC=NN2C=C1NC(=O)OC[C@@H]3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F,5.795880017344075,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12
20755,CHEMBL1645462,LUJZZYWHBDHDQX-QFIPXVFZSA-N,AC-480,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19821562.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled human liver microsome,"Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.",J. Med. Chem.,PUBLICATION,,CC1=C2C(=NC=NN2C=C1NC(=O)OC[C@@H]3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F,4.920818753952375,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12
20760,CHEMBL165,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,RESVERATROL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,600.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,6.221848749616356,Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
20778,CHEMBL244239,LUNFWPKHPVTQAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,1620.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,CN(CCC1=CC(=C(C=C1)OC)OC)CCNC(=O)C2=CC=CC=C2NC(=O)C3=CC4=CC=CC=C4N=C3,5.790484985457369,COc1ccc(CCN(C)CCNC(=O)c2ccccc2NC(=O)c2cnc3ccccc3c2)cc1OC
20779,CHEMBL244239,LUNFWPKHPVTQAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,7750.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,CN(CCC1=CC(=C(C=C1)OC)OC)CCNC(=O)C2=CC=CC=C2NC(=O)C3=CC4=CC=CC=C4N=C3,5.110698297493689,COc1ccc(CCN(C)CCNC(=O)c2ccccc2NC(=O)c2cnc3ccccc3c2)cc1OC
20788,CHEMBL1643773,LUSAWDRMCLUELC-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106375.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=C(N2C1)C=C(C=C3)F)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.301029995663981,CN([C@@H]1CCc2c(CC(=O)O)c3ccc(F)cc3n2C1)S(=O)(=O)c1ccc(F)cc1
20789,CHEMBL552026,LUSFVKKEBIMJTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C(=O)C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,5.301029995663981,O=C1CCCCN1C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
20792,CHEMBL578413,LUTXIHFTNWRKIR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19664922.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine derivatives as selective progesterone receptor agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NC2=C1SC3=C2C(CC(=O)N3)C4=CC=CC=C4Cl)N)C#N,5.0,Cc1c(C#N)c(N)nc2c3c(sc12)NC(=O)CC3c1ccccc1Cl
20794,CHEMBL3407814,LUVKXYMOSKKHHP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25489882.0,IC50,=,70000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,"Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)CCCNCCC2=NC(=NC=C2)N3C=CN=C3.Cl,4.154901959985743,c1cncc(CCCNCCc2ccnc(-n3ccnc3)n2)c1
20802,CHEMBL1732,LUZRJRNZXALNLM-JGRZULCMSA-N,DIHYDROERGOTAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,2999.16,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,5.523000364762793,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
20803,CHEMBL1732,LUZRJRNZXALNLM-JGRZULCMSA-N,DIHYDROERGOTAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,5.301029995663981,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
20814,CHEMBL2059117,LVCRRGONEHSFIT-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,33.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,7.481486060122113,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
20816,CHEMBL3330073,LVDNNHBINPPRBD-IMODNSLOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25164763.0,IC50,=,2250.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,C1C[C@H]2C[C@H](N([C@H]2C1)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N)C#N,5.647817481888637,N#C[C@@H]1C[C@@H]2CCC[C@@H]2N1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F
20817,CHEMBL25905,LVDUAUUVOUUFCK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,36820.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C3=C1C(=NC(=N3)COC)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)Cl,4.433916215832004,COCc1nc(N2CCN(CCc3ccc(F)c(F)c3)CC2)c2c(n1)c1c(Cl)nccc1n2C
20822,CHEMBL2017274,LVFMQRNYMLOTHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4C(C)(C)C)C(=O)N)OC,5.721246399047171,COc1cc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2cc1-c1c(C)noc1C
20829,CHEMBL3330649,LVHMCPRJISQGAK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1I)F)NC2=C(OC3=C2C=NC=C3)C(=O)NOCCO,5.0,O=C(NOCCO)c1oc2ccncc2c1Nc1ccc(I)cc1F
20830,CHEMBL3330649,LVHMCPRJISQGAK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1I)F)NC2=C(OC3=C2C=NC=C3)C(=O)NOCCO,5.0,O=C(NOCCO)c1oc2ccncc2c1Nc1ccc(I)cc1F
20840,CHEMBL1077339,LVOHHKIFPDWJJY-NLJOTIRTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6C[C@@H]7C[C@H]6CO7,6.301029995663981,Cc1cc(N2CCC(N3C[C@@H]4C[C@H]3CO4)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
20842,CHEMBL474469,LVOHHKIFPDWJJY-ONBPZOJHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6C[C@@H]7C[C@@H]6CO7,9.301029995663981,Cc1cc(N2CCC(N3C[C@@H]4C[C@@H]3CO4)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
20873,CHEMBL2380735,LWCCEQKYCZQPRK-HBFSDRIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23639544.0,IC50,=,9950.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence detection method,Synthesis of proline analogues as potent and selective cathepsin S inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H](C(=O)C1=NC2=CC=CC=C2O1)NC(=O)[C@@H]3C[C@H](CN3C(=O)C)S(=O)(=O)C4=CC=CC=C4,5.002176919254275,CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)CN1C(C)=O)C(=O)c1nc2ccccc2o1
20882,CHEMBL3629738,LWHLEVWRUZVAKD-BWAGFHJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@]2(CCOC2)[C@@H]3COC4=C(C=CC(=C4[C@@]3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,4.698970004336019,O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCC[C@]3(CCOC3)[C@@H]1COc1c(F)ccc(F)c12
20883,CHEMBL3629738,LWHLEVWRUZVAKD-BWAGFHJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@]2(CCOC2)[C@@H]3COC4=C(C=CC(=C4[C@@]3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,4.698970004336019,O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCC[C@]3(CCOC3)[C@@H]1COc1c(F)ccc(F)c12
20893,CHEMBL3664683,LWLLZFJSQXCRGM-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2F)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,C[C@@H](c1ccc(-c2cc(=O)n(C)cc2F)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
20895,CHEMBL2430983,LWMQAANXGYCZIW-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CN1C(=CC(=N1)C2=CC=NC=C2)NC(=O)[C@H](CC3=CC=CC=C3)NCC(=O)O,4.522878745280337,Cn1nc(-c2ccncc2)cc1NC(=O)[C@H](Cc1ccccc1)NCC(=O)O
20896,CHEMBL3702748,LWMQTYQSMZDRPA-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11510.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)CCNC(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,4.938924676370208,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
20898,CHEMBL2436211,LWORELOKAQNWTQ-GZAZCRCBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=NC=CN=C5)NC.Cl,5.795880017344075,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cnccn2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
20904,CHEMBL1077325,LWTKJTIPCMXHIH-GBXCKJPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,>,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CC[C@@H](C5)NC(=O)OC(C)(C)C,4.886056647693163,Cc1cc(N2CC[C@H](NC(=O)OC(C)(C)C)C2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
20906,CHEMBL2448705,LWTNFEIUOJCFKQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1=CC=C(C=C1)C2=CN=C(C=N2)C(=O)NCCC3=CN=CN3,4.795880017344075,O=C(NCCc1cnc[nH]1)c1cnc(-c2ccccc2)cn1
20913,CHEMBL3125389,LWUXPHDHNVTIOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C2=C1C(=CC=C2)Cl)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N,4.3979400086720375,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21
20914,CHEMBL2178713,LWVMTILRDSZVMA-CYFREDJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,CN1C(=O)[C@@H]2CN(C[C@@]2(N=C1N)C3=CC(=CS3)C4=CC=CC(=C4)C#N)C5=C(C=CC=N5)C#N,4.522878745280337,CN1C(=O)[C@@H]2CN(c3ncccc3C#N)C[C@]2(c2cc(-c3cccc(C#N)c3)cs2)N=C1N
20918,CHEMBL2018920,LWYPYTJNIOQAJR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,4230.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=C(C=C3)Br,5.373659632624958,COc1ccc2nc(SCc3ccc(Br)cc3)[nH]c2c1
20921,CHEMBL293391,LXBGSDVWAMZHDD-UHFFFAOYSA-N,2-METHYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,1253141.17,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC1=NC=CN1,2.9020000017125205,Cc1ncc[nH]1
20926,CHEMBL3702807,LXCBABHDWQHVDN-QCDYIZFSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6320.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)C2CCN(CC2)C3=NC=C(C=C3)NC(=O)C4=CN(C5=C(C=CC=C45)CN6C[C@H]7N([C@H](C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,5.199282921717615,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCN(C)CC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
20938,CHEMBL3601070,LXFJUSIWCMBIBJ-XTUVKROYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)OC1=NC=CC(=C1)NC2=NC=C(C(=N2)N[C@@H]3C[C@@H]([C@H]([C@H]3O)O)CO)C4=NC5=CC=CC=C5C=C4,4.301029995663981,CC(C)Oc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1
20939,CHEMBL1837037,LXHAZNJVVVBJIF-UHFFFAOYSA-N,PF-184563,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21885275.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCN(CC4)C5=CC=CC=N5)C1,4.522878745280337,CN1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1
20945,CHEMBL3112847,LXISESLTVSOLPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=C1C=C(C=C2)F)C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(F)ccc21
20946,CHEMBL3087353,LXIVCWUSTWHNJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CN1C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,4.568636235841013,Cc1nccn1-c1ccc(NS(=O)(=O)c2cc(Cl)cc(Cl)c2)cc1
20963,CHEMBL1935443,LXOHJARDVFSOPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCO4)C,5.309803919971486,Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C
20964,CHEMBL1935443,LXOHJARDVFSOPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCO4)C,5.119186407719209,Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C
20966,CHEMBL2064333,LXQCVNDYORNYIT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,CN1C2=C(C=C(C=C2)F)N=C1CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(F)ccc21
20975,CHEMBL550816,LXXCGDJSCVIHPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,16500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC(=O)NC(CN2CCOCC2)C3=CC=CC=C3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,4.782516055786093,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(CN1CCOCC1)c1ccccc1
20997,CHEMBL407246,LYDVUNMUKWQJAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)NC(=O)OCC2=CN(N=N2)C3=CC=C(C=C3)Cl,4.698970004336019,O=C(Nc1ccccc1)OCc1cn(-c2ccc(Cl)cc2)nn1
21002,CHEMBL274551,LYHMZZTVHAMCGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCC1=CN(C(=NC1=O)SCC2=CC=C(C=C2)F)CC(=O)N(CCN(CC)CC)CC3=CC=C(C=C3)C4=CC=C(C=C4)C(F)(F)F,5.301029995663981,CCCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O
21003,CHEMBL2170294,LYHNSWOZRDSWLX-MRXNPFEDSA-N,AS1940477,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22905713.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,"Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CC=CC=C1N2C(=O)C=CC(=N2)C3=C4NC[C@H](CN4N=C3C5=CC=C(C=C5)F)CO,4.0,Cc1ccccc1-n1nc(-c2c(-c3ccc(F)cc3)nn3c2NC[C@@H](CO)C3)ccc1=O
21015,CHEMBL2431463,LYKFFNSXZSUFOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC(=CC(=C1OC)C2CC2C3=CC=C(C=C3)NS(=O)(=O)C)C4=CC=CNC4=O,7.3979400086720375,COc1c(C2CC2c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C
21022,CHEMBL267865,LYNOGBKNFIHKLE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,71000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC1=CC(=C(C=C1)N=CNO)C,4.1487416512809245,CCCCc1ccc(N=CNO)c(C)c1
21023,CHEMBL267865,LYNOGBKNFIHKLE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,65400.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCC1=CC(=C(C=C1)N=CNO)C,4.184422251675732,CCCCc1ccc(N=CNO)c(C)c1
21029,CHEMBL266212,LYPHFRXCVAZTEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,3580.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)CN2CCN(CC2)C3=CC=C(C=C3)NC(=O)C4=CC=CC=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC,5.446116973356125,COc1ccc(CN2CCN(c3ccc(NC(=O)c4ccccc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC
21030,CHEMBL266212,LYPHFRXCVAZTEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,20200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)CN2CCN(CC2)C3=CC=C(C=C3)NC(=O)C4=CC=CC=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC,4.694648630553377,COc1ccc(CN2CCN(c3ccc(NC(=O)c4ccccc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC
21031,CHEMBL1214449,LYPZADYPKMLUQI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC1=CN=C(C=C1)C2=CC3=C(CC(C3)NS(=O)(=O)C(C)C)C=C2,5.0,Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)nc1
21034,CHEMBL1629855,LYTVXCQQTLUEQR-UHFFFAOYSA-N,RO-4491533,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20971004.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC=CC(=C3)C4=CC(=NC(=C4)C)C,5.318758762624412,Cc1cc(-c2cccc(C3=Nc4cc(C)c(C(F)(F)F)cc4NC(=O)C3)c2)cc(C)n1
21052,CHEMBL116772,LZAICYPRHBGZTR-XREYCITQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)COC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](CN3CCN(C[C@H]3C(=O)NC(C)(C)C)CC4=CC5=C(C=C4)OCO5)O,5.017728766960431,CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3ccc4c(c3)OCO4)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1
21062,CHEMBL249293,LZCMGTZILVEQAQ-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)C(C)(C)CO,6.301029995663981,CC(C)[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
21071,CHEMBL2043171,LZELSEPAXCUBKS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)Cl,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4Cl)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
21079,CHEMBL585191,LZGLHOVCHAQTAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC4=C(C=C3)OCCO4,5.301029995663981,CC1(CC(=O)NCc2ccc3c(c2)OCCO3)CC2(CCCCC2)OO1
21080,CHEMBL2397194,LZHWZDRNJFDAFI-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=NC(=NC=C3)C4CCC4,5.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2CCC2)n1
21082,CHEMBL3115165,LZJOGRNDENREKS-WUNLWTINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N[C@H](CC[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC3=CC=CC=C3)NC(=O)N(C)CC4=CN=CS4,7.096910013008056,CC(C)[C@H](NC(=O)N(C)Cc1cncs1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
21097,CHEMBL3702713,LZMJCQWNDIGSIP-HWHSMDOUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5040.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCN1CCN2CCN(CC2C1)C(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.297569463554475,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(CC)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
21110,CHEMBL485752,LZPFERLGKNQAQE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CCOC(=O)NC1=NC(=NC(=C1)C2=CC(=CN=C2)OC)N3C(=CC(=N3)C)C,4.698970004336019,CCOC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1
21114,CHEMBL3401132,LZPSMMDCTAIZFR-ZIAGYGMSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,=,545000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3ß inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1N2CCO[C@H]3[C@H]2COC3)C4=C(C=NC=C4)F,3.2636034977233574,Cn1c(N2CCO[C@@H]3COC[C@H]32)nc(-c2ccncc2F)cc1=O
21127,CHEMBL1077939,LZXPGRRYRBSCOY-KYJUHHDHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,49.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@@H](CN(CC2=CC=NC=C2)C[C@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,7.309803919971486,O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccncc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
21139,CHEMBL3672578,MAACKGCFQFNWKO-PIGLOVQCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N,6.721246399047171,CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
21140,CHEMBL3672578,MAACKGCFQFNWKO-PIGLOVQCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,310.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N,6.508638306165727,CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
21141,CHEMBL465941,MAAFRGFJCFJJAS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CC4=CC(=CC=C4)Cl,5.853871964321762,C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)Cc3cccc(Cl)c3)cc2)C[C@@H](C)N1
21142,CHEMBL465941,MAAFRGFJCFJJAS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CC4=CC(=CC=C4)Cl,5.823908740944319,C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)Cc3cccc(Cl)c3)cc2)C[C@@H](C)N1
21152,CHEMBL3702730,MADNMYLUHTVLOZ-ACHIHNKUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3160.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(C)C,5.5003129173815966,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
21154,CHEMBL3104490,MAEQYLYKCWECPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,5.3979400086720375,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1
21155,CHEMBL3104490,MAEQYLYKCWECPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,5.3979400086720375,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1
21156,CHEMBL3104490,MAEQYLYKCWECPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7100.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,5.1487416512809245,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1
21157,CHEMBL3104490,MAEQYLYKCWECPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,19000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,4.721246399047171,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1
21169,CHEMBL397367,MAHFSCYTEUPDKY-IYKJZBSOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,8600.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C(=O)N[C@@H](CC(C)C)C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N,5.0655015487564325,CC(C)C[C@H](NC(=O)[C@H](C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
21170,CHEMBL396434,MAHFSCYTEUPDKY-NBYOPXRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C(=O)N[C@@H](CC(C)C)C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N,5.275724130399211,CC(C)C[C@H](NC(=O)[C@@H](C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
21179,CHEMBL3706623,MAMJAUDDHCPYJQ-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852968.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC=C(O2)C3=CN=CC=C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,6.356547323513812,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3cccnc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
21180,CHEMBL3236364,MANSWCXFKVIKPE-HIJQLYNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)N,5.920818753952375,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
21181,CHEMBL3236364,MANSWCXFKVIKPE-HIJQLYNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1.83,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Homogenous Time-Resolved Fluorescence Assay (HTRF). The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",Benzoic acid derivative MDM2 inhibitor for the treatment of cancer,,PATENT,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)N,8.73754891026957,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
21187,CHEMBL1766811,MARFUFVBECBSBC-HZCBDIJESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21413799.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes.,J. Med. Chem.,PUBLICATION,,C1CC(CCC1C(=O)N2CCC(CC2)C3=CC=C(C=C3)NC(=O)C4=C(OC(=N4)C5=CC=CC=C5)C(F)(F)F)C(=O)O,4.301029995663981,O=C(Nc1ccc(C2CCN(C(=O)C3CCC(C(=O)O)CC3)CC2)cc1)c1nc(-c2ccccc2)oc1C(F)(F)F
21198,CHEMBL3137472,MAUKISZQMSQDOJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC(C(C)O)N1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3,4.698970004336019,CC(O)C(C)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
21206,CHEMBL1834661,MAYIXESJSMZIQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CCN1CCC(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,5.920818753952375,CCN1CCC(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
21207,CHEMBL1834661,MAYIXESJSMZIQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CCN1CCC(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,5.221848749616356,CCN1CCC(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
21211,CHEMBL3702680,MBBBZVXOEJXMKY-HHDOLNPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4610.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8=NC=CN=C8,5.336299074610352,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6cnccn6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
21217,CHEMBL101296,MBDCLNRSFGFOLO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC=C(C=C1)N=CNO,4.0,CCc1ccc(N=CNO)cc1
21219,CHEMBL1080973,MBEXSEUYYAPDIQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NCC2=C(C=C(C=C2)Cl)Cl)C3=CC=CC=C3,5.0,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(Cl)cc2Cl)C1
21244,CHEMBL3702758,MBMVBQUBYZAPMZ-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,17440.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NN7CCCC7,4.758453519403451,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
21247,CHEMBL3092460,MBNNXCKHRKSGSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,=,14500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C(=C1)Cl)Cl)S(=O)(=O)NC2=CC=C(C=C2)C3=NC4=NNC(=C4N=C3)N,4.838631997765025,Nc1[nH]nc2nc(-c3ccc(NS(=O)(=O)c4cccc(Cl)c4Cl)cc3)cnc12
21248,CHEMBL3092460,MBNNXCKHRKSGSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C(=C1)Cl)Cl)S(=O)(=O)NC2=CC=C(C=C2)C3=NC4=NNC(=C4N=C3)N,4.522878745280337,Nc1[nH]nc2nc(-c3ccc(NS(=O)(=O)c4cccc(Cl)c4Cl)cc3)cnc12
21251,CHEMBL1271822,MBQIBPDSTIZHQM-CTNGQTDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,0.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC1)[C@@H]2COC[C@@H](N2S(=O)(=O)C3=CC=C(C=C3)Cl)COC(=O)N4CCN(CC4)C(C)(C)CO,9.301029995663981,CC1([C@@H]2COC[C@H](COC(=O)N3CCN(C(C)(C)CO)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1
21272,CHEMBL3702794,MBXAGHYXINTFRA-JFKYFZFSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5730.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCN1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.24184537803261,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CC)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
21275,CHEMBL3261481,MBYAMJFNDALRJQ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@@H](C2)N3CCN4C5=C(C=CC=C5C3=O)C=N4,4.301029995663981,O=C1c2cccc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
21285,CHEMBL466496,MCBPNFWHHNJTGN-LLVKDONJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19364658.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,PUBLICATION,,C[C@H](C1=CC=CC=C1)NC2=C(C(=O)C2=O)NC3=CC=NC=C3,5.886056647693163,C[C@@H](Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1
21290,CHEMBL408479,MCDBKPBDTVBVTL-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18217703.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.,J. Med. Chem.,PUBLICATION,,CN(C)S(=O)(=O)N(C)[C@@H]1CCCN2C1=NC(=C(C2=O)O)C(=O)NCC3=CC=C(C=C3)F,4.0,CN(C)S(=O)(=O)N(C)[C@@H]1CCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O
21291,CHEMBL2325485,MCDNCMGVHBZICR-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23445448.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Development of Dual PLD1/2 and PLD2 Selective Inhibitors from a Common 1,3,8-Triazaspiro[4.5]decane Core: Discovery of ML298 and ML299 That Decrease Invasive Migration in U87-MG Glioblastoma Cells.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC=C1)N2CNC(=O)C23CCN(CC3)C[C@H](C)NC(=O)C4=CC=C(C=C4)Br,5.167491087293763,Cc1cccc(N2CNC(=O)C23CCN(C[C@H](C)NC(=O)c2ccc(Br)cc2)CC3)c1
21296,CHEMBL1092929,MCEPAFGIBULHLP-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by P450-Glo method,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCC3CCN(CC3)C(=O)C4=CC=CC=C4,5.0,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3ccccc3)CC2)C1
21305,CHEMBL590810,MCIPSMFHIWYOIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,5900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,C1CNCC2=C1C=CC(=C2)NC(=O)C3=CC=CC(=C3)CNC(=O)NC4=CC=C(C=C4)C#N,5.229147988357856,N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1
21306,CHEMBL590810,MCIPSMFHIWYOIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,C1CNCC2=C1C=CC(=C2)NC(=O)C3=CC=CC(=C3)CNC(=O)NC4=CC=C(C=C4)C#N,4.522878745280337,N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1
21317,CHEMBL3664675,MCLUYWYPALEDGG-WRONEBCDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)C#N)C4=CC=C(C=C4)F,4.638272163982407,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccc(F)cc2)OC1=O
21318,CHEMBL294616,MCMMCRYPQBNCPH-DVKRWUGUSA-N,DPDPE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC1([C@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(SS1)(C)C)C(=O)O)CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C,4.301029995663981,CC1(C)SSC(C)(C)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H]1C(=O)O
21325,CHEMBL1923729,MCNAJLPLCULBOJ-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22014551.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=CN(C(=O)C=C3)C,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)c2)cc1
21333,CHEMBL2420687,MCOVGPFVWGBXTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CN=CC4=CC=CC=C43,5.0,COc1ccc2ccc(-c3cncc4ccccc34)c(Cl)c2c1
21335,CHEMBL3237442,MCPPMOSBWNMSOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,C1CCC(C1)N2C3=C(C=CN=C3)C4=CN=C(N=C42)NC5=NC=C(C=C5)N6CCNCC6,6.259637310505756,c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2cn1
21342,CHEMBL543,MCTWTZJPVLRJOU-UHFFFAOYSA-N,1-METHYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,CN1C=CN=C1,5.0,Cn1ccnc1
21343,CHEMBL543,MCTWTZJPVLRJOU-UHFFFAOYSA-N,1-METHYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CN1C=CN=C1,5.0,Cn1ccnc1
21344,CHEMBL543,MCTWTZJPVLRJOU-UHFFFAOYSA-N,1-METHYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,2697739.43,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CN1C=CN=C1,2.5690000003935944,Cn1ccnc1
21349,CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,5.1249387366083,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
21350,CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,5.107905397309519,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
21351,CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,9500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,5.022276394711152,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
21355,CHEMBL604805,MCVXWPPVTYUESA-BCDXTJNWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C[C@H]2CC(C[C@H]2C1)N(CC3=CC(=CC=C3)OC(F)(F)F)C(=O)C4=CN(C=N4)C,5.0,CCN1C[C@H]2CC(N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1
21359,CHEMBL497481,MCXOBRFKSNUMRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,3643.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC2=C(C=CC(=C2)C3=CC(=C(C=C3)F)F)C(=C1)C4=CC=NC=C4.Cl,5.438540828758084,Fc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1F
21378,CHEMBL2057515,MDFDAKQXZVXGEL-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)NCCCN(C)C,6.698970004336019,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCCN(C)C)oc2c1
21383,CHEMBL559825,MDGWFKBCHGOIRO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19552431.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assay,Novel small molecule bradykinin B2 receptor antagonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC=C1)CN2C=CC=C(C2=O)C(F)(F)F)COC3=CC=CC4=C(C=C(N=C43)C)C5=CC=NN5C,5.301029995663981,Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1
21384,CHEMBL2397303,MDHMYNMBYCVKJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)CN(CC(=O)NC2=NC=C(S2)C3=CC=C(C=C3)N)C(=O)C4=CC=NC=C4,6.301029995663981,Nc1ccc(-c2cnc(NC(=O)CN(Cc3ccccc3)C(=O)c3ccncc3)s2)cc1
21386,CHEMBL2331704,MDISRFPYOOBZRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288685.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=NN=C2N1C3=C(CC2)C=C(C=C3)C4=CC(=CN=C4)C(C)(C)OC,4.301029995663981,COC(C)(C)c1cncc(-c2ccc3c(c2)CCc2nnc(C)n2-3)c1
21388,CHEMBL1766177,MDJDLHSQYRTGNB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)C)(C3=CN=CN3)O,6.0,CC(=O)Nc1ccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)cc1
21406,CHEMBL475928,MDOZGPZABUSJAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CC=C(C=C3)Cl,4.301029995663981,O=C(CNC(=O)c1ccc(Cl)cc1)NC(c1ccccc1)c1ccc(Cl)cc1
21415,CHEMBL1091790,MDTGYTUAMOVSAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1=CC=NC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,5.552841968657781,CC(c1ccncc1)c1c(CCN(C)C)sc2ccccc12
21421,CHEMBL3359021,MDWUZADCYVCQNO-ZSOGYDGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25210858.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2CN(C[C@@H]2CC1C3=CC=CC=C3C(F)(F)F)C(=O)NC4=C(C=CC=N4)C(=O)O,4.0,O=C(O)c1cccnc1NC(=O)N1C[C@H]2CC(c3ccccc3C(F)(F)F)C[C@H]2C1
21422,CHEMBL3427272,MDXDEVDOOLNVAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25941547.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1N2C3=C(C=NC=C3)N(C2=O)CC4=C(N5C=CC(=CC5=N4)Cl)CCC(=O)O,4.301029995663981,O=C(O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12
21427,CHEMBL1230001,MEAQCLPMSVEOQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25210858.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=CC=CC=C2C(F)(F)F)C(=O)NC3=CC=CC=C3C(=O)O,4.0,O=C(O)c1ccccc1NC(=O)N1CCC(c2ccccc2C(F)(F)F)CC1
21437,CHEMBL28168,MECOLUCWZLXWNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CC1=CC(=C2C3=C(C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)N(C2=N1)C)C#N,4.0,Cc1cc(C#N)c2c3ncnc(N4CCN(CCc5ccc(F)c(F)c5)CC4)c3n(C)c2n1
21444,CHEMBL3702808,MEEAYSRFSVBIAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23670.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)C9=CC=C(C=C9)C(F)(F)F,4.625801742070918,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(c7ccc(C(F)(F)F)cc7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
21450,CHEMBL1683445,MEGFCBVTRXVKDO-KKSFZXQISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21300546.0,IC50,>,10.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C[C@@](C)(CS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)F)N(C=O)O)C3=NC=C(C=N3)F,8.0,C[C@@H](C[C@@](C)(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O)c1ncc(F)cn1
21460,CHEMBL1271703,MELKFGZURAGNSX-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,0.3,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H]1COC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCNCC4,9.522878745280337,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CCNCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
21461,CHEMBL2347208,MELQHVBGGSKVJQ-YJBOKZPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23590342.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,ß-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.,J. Med. Chem.,PUBLICATION,,C[C@]1(C[C@H](OC(=N1)N)C(F)(F)F)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F,4.6020599913279625,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C[C@@H](C(F)(F)F)OC(N)=N1
21469,CHEMBL1784368,MESQXIKYNYUZRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(CS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)F)N(C=O)O,6.0,CC(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O
21485,CHEMBL3702817,MEWIHUZHSMPRNO-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11240.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,4.949233688766958,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
21486,CHEMBL449468,MEXADSOJSYPZRE-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)N)C4=CC(=CC=C4)OCCCCC(=O)O,4.657577319177793,Cc1c(-c2cccc(OCCCCC(=O)O)c2)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F
21511,CHEMBL3702785,MFDVDJXFNUJFNE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2320.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCCN8CCOCC8,5.634512015109101,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCOCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
21513,CHEMBL520419,MFFQPYYPGSJIDM-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)O,9.397940008672037,Cc1cc(N2CCC(O)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
21524,CHEMBL1910118,MFMDQBPDMCWAMW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)C(=O)CN1CC2=C(C(=C(N=C2C1=O)C)CN)C3=C(C=C(C=C3)Cl)Cl,4.769551078621726,CCN(CC)C(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
21527,CHEMBL480398,MFMYBHHGKONKNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C2=CC(=NC=C2C(=O)NCC3CCOCC3)NC4=CC(=CC=C4)Br,4.0,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Br)c2)cc1C1CC1
21583,CHEMBL3310285,MGKQPZFQZLLPPL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24939756.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH,Strategies for the modulation of phase II metabolism in a series of PKCe inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)NCCC1=CC(=CC(=C1)C2(CC2)C#N)C3=CC=NC4=NNC(=C34)C(F)(F)F,5.154901959985743,CS(=O)(=O)NCCc1cc(-c2ccnc3n[nH]c(C(F)(F)F)c23)cc(C2(C#N)CC2)c1
21591,CHEMBL3699327,MGPNHBYVGAWOLH-GTMCEHENSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,17200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC(=CC=C8)OCC9=CC=CC=C9,4.764471553092451,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OCc7ccccc7)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
21600,CHEMBL3639714,MGUFMPBNVRJNSL-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,140.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCN(C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)C,6.853871964321762,CC(C)c1nc(CN(C)C(=O)N2CCN(C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
21601,CHEMBL3639714,MGUFMPBNVRJNSL-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCN(C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)C,6.522878745280337,CC(C)c1nc(CN(C)C(=O)N2CCN(C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
21609,CHEMBL476572,MGWSCJCLMDQNGB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,74000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=C2C=CC(=CC2=NN1CC3=CC=CC=C3)N(C)C4=NC(=NC=C4)NC5=CC(=CC=C5)S(=O)(=O)N,4.130768280269024,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1Cc1ccccc1
21610,CHEMBL476572,MGWSCJCLMDQNGB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,79000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=C2C=CC(=CC2=NN1CC3=CC=CC=C3)N(C)C4=NC(=NC=C4)NC5=CC(=CC=C5)S(=O)(=O)N,4.102372908709558,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1Cc1ccccc1
21646,CHEMBL486745,MHSIRMSFRHMBDY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=C(C(=CC=C3)OC)F)C,4.698970004336019,COc1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1F
21652,CHEMBL2178250,MHVVFDUISIWISF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=N1)C2=CC(=CC=C2)Cl)NC(=O)C3=C4N=CC=CN4N=C3,5.0,Cc1cc(NC(=O)c2cnn3cccnc23)c(-c2cccc(Cl)c2)cn1
21653,CHEMBL1923116,MHVYWHNMBRDTMC-BWKNWUBXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F)C,5.301029995663981,Cc1cccc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1C
21655,CHEMBL5,MHWLWQUZZRMNGJ-UHFFFAOYSA-N,NALIDIXIC ACID,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,5.0,CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21
21656,CHEMBL5,MHWLWQUZZRMNGJ-UHFFFAOYSA-N,NALIDIXIC ACID,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,5.0,CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21
21664,CHEMBL518421,MHXCIKYXNYCMHY-AUSJPIAWSA-N,LARICIRESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,25600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,COC1=C(C=CC(=C1)C[C@H]2CO[C@@H]([C@H]2CO)C3=CC(=C(C=C3)O)OC)O,4.591760034688151,COc1cc(C[C@H]2CO[C@H](c3ccc(O)c(OC)c3)[C@H]2CO)ccc1O
21679,CHEMBL1762293,MIBQBFVAZRBAFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21354795.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin),"1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=NO1)NC(=O)N2CCCN(CC2)C(=O)C3CCOCC3,4.522878745280337,CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)C3CCOCC3)CC2)no1
21694,CHEMBL1631095,MIGUNWYRDMCMDZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106456.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC(=C1)N2C(=CC(=N2)C(=O)N)C(=O)N)C3=C(C=CC(=C3)C(F)(F)F)C(F)(F)F,4.0,NC(=O)c1cc(C(N)=O)n(-c2cccc(-c3cc(C(F)(F)F)ccc3C(F)(F)F)c2)n1
21695,CHEMBL2436218,MIHAQLKAZGVBQZ-MJFWUJRASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,9700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@H]1[C@@H](C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=C(C=CC4=CC=CC=C43)OC)NC(=O)[C@H](C)NC.Cl,5.013228265733755,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C
21700,CHEMBL3702696,MIHDVZBMEYHLOS-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCCCO,5.031517051446065,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
21701,CHEMBL3702672,MIHIASNXXPUNOB-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)N8CCOCC8,5.6595558851598815,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCOCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
21718,CHEMBL3125378,MIOMMFIKTOATBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C2=C1C(=CC=C2)Cl)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O,4.3979400086720375,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21
21724,CHEMBL3702710,MIPWODRTRBZYNE-MJPQJCIXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3980.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)CN1CCN2CCN(CC2C1)C(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.400116927926312,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(CC(C)C)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
21753,CHEMBL3259907,MIXIIJCBELCMCZ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24944749.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=NC2=CC=CC=C2C(=C1[C@@H](C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4,4.638272163982407,Cc1nc2ccccc2c(-c2ccc3c4c(ccnc24)CCO3)c1[C@H](OC(C)(C)C)C(=O)O
21754,CHEMBL3259907,MIXIIJCBELCMCZ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC1=NC2=CC=CC=C2C(=C1[C@@H](C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4,4.638272163982407,Cc1nc2ccccc2c(-c2ccc3c4c(ccnc24)CCO3)c1[C@H](OC(C)(C)C)C(=O)O
21770,CHEMBL480,MJIHNNLFOKEZEW-UHFFFAOYSA-N,LANSOPRAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,4.522878745280337,Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1
21778,CHEMBL473763,MJIOKZJYJYOUKX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19208473.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microplate-based direct fluorometric assay,"Discovery of novel non-peptidic beta-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CCC1C2=CC=CC=C2C3=CC=CC=C13)CCC(=O)N4CCN(CC4)C5=CC(=C(C=C5)F)F.Cl,5.0,CN(CCC(=O)N1CCN(c2ccc(F)c(F)c2)CC1)CCC1c2ccccc2-c2ccccc21
21790,CHEMBL3234573,MJKSBDOYJVJJGS-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CCN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCC[C@H](C3)C(=O)NCCC4=CN=C(N=C4)C#N,5.2839966563652006,CCN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4cnc(C#N)nc4)C3)nc(C(F)(F)F)n2)CC1
21793,CHEMBL3357634,MJLGATKKRYTQPD-SOFYXZRVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25409491.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method,A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles.,J. Med. Chem.,PUBLICATION,,CN(C)C/C=C(/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC)\F,5.0,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C
21816,CHEMBL2407954,MJSLGTDKVDKHMT-CCFHIKDMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1C(C/C(=N\O)/C2=CC(=NC=C2)C)C3=CC=C(C=C3)C4=CC=C(C=C4)C(=O)O,4.301029995663981,Cc1cc(/C(CC(c2ccc(-c3ccc(C(=O)O)cc3)cc2)c2ccccc2C)=N/O)ccn1
21836,CHEMBL3403821,MKBBZNXNYQBPQR-VPNNIMDCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)CCO)C)C)O)C)C(C)(C)O,5.494850021680094,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
21837,CHEMBL3403821,MKBBZNXNYQBPQR-VPNNIMDCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)CCO)C)C)O)C)C(C)(C)O,5.309803919971486,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
21839,CHEMBL391028,MKCZAMJRNWLDEF-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=CC=CC=C1N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCN,5.5376020021010435,CC(C)C[C@H](NC(=O)CCN)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
21848,CHEMBL3234571,MKHYOYUIGKEBPI-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCC[C@H](C3)C(=O)NCCC4=CN=C(C=C4)C#N,5.0,CN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)nc4)C3)nc(C(F)(F)F)n2)CC1
21850,CHEMBL2448708,MKIGMPSDMNXEHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCN(CC1=CN=CC=C1)C2=CC=CC(=C2)C3=NC4=CC=CC=C4S3,6.0,CCN(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1
21853,CHEMBL1241642,MKKLXKXAAUILMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC=C6CO5,7.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4cncn4-5)CC3)cccc2n1
21910,CHEMBL2436630,MLBBOYBRPZGZGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2CC3=C(C2)C=C(C=C3)F)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,4.522878745280337,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccc(F)cc5C4)CC3)CC2)ccn1
21911,CHEMBL253023,MLBHRXIETSMRAN-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NOC(=N4)CN(C)C(C)(C)CO,5.3979400086720375,CC[C@@H]1CCC[C@H](C2(Cc3noc(CN(C)C(C)(C)CO)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
21917,CHEMBL1938952,MLDQTQOMWDNTNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,COC1=C(C=NC=C1)C(=O)NC(=O)NC2=CC(=C(C=C2)C3=CC=CC=C3)C(F)(F)F,4.522878745280337,COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(C(F)(F)F)c1
21926,CHEMBL2171397,MLFFCILPEDOIHN-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861813.0,IC50,=,15.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel ß-amino acid derivatives as inhibitors of cathepsin A.,J. Med. Chem.,PUBLICATION,,CCOC1=CC(=NN1C2=CC=CC=C2F)C(=O)N[C@@H](CC(=O)O)C3=CC=CC=C3C,7.823908740944319,CCOc1cc(C(=O)N[C@@H](CC(=O)O)c2ccccc2C)nn1-c1ccccc1F
21930,CHEMBL1081957,MLHRKLZCJRKSHO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC(=CC=C5)C(F)(F)F,5.0,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(C(F)(F)F)c3)C2)n1C
21931,CHEMBL1081957,MLHRKLZCJRKSHO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC(=CC=C5)C(F)(F)F,5.0,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(C(F)(F)F)c3)C2)n1C
21932,CHEMBL494979,MLHUEVZLHPFKKC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,5.698970004336019,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
21933,CHEMBL494979,MLHUEVZLHPFKKC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,4.5376020021010435,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
21935,CHEMBL494979,MLHUEVZLHPFKKC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in absence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,5.698970004336019,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
21936,CHEMBL494979,MLHUEVZLHPFKKC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,4.5376020021010435,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
21938,CHEMBL2181329,MLIJDZYVRSRDJT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21604762.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.",J. Med. Chem.,PUBLICATION,,CCN(CC)CCOC1=C2COCC=CCOCC3=CC(=CC=C3)C4=NC(=NC=C4)NC(=C2)C=C1,5.552841968657781,CCN(CC)CCOc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2
21958,CHEMBL378132,MLPHGOPXOJDNLS-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]([C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCOCC3)C(=O)O)N4C=CN=C4)N(C)C,4.698970004336019,C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCOCC3)ccc2c1)n1ccnc1)N(C)C
21962,CHEMBL3609325,MLQVQPMTZJBGEY-VGEDNRJQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191364.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H](C(=O)N[C@H](C(=O)N1C[C@H]2CCCCOC3=CC=C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]4C[C@@H](CN4C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C)NC)N5C=C(COC6=CC=C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1C2)CC7=CC8=CC=CC=C8C=C7)NS(=O)(=O)C9CC9)C=C6)N=N5)CC1=CC2=CC=CC=C2C=C1)C(=O)O)C=C3)C(C)(C)C)NC,4.698970004336019,CN[C@@H](C)C(=O)N[C@H](C(=O)N1C[C@@H]2C[C@H]1C(=O)N[C@@H](Cc1ccc3ccccc3c1)C(=O)N[C@H](C(=O)O)Cc1ccc(cc1)OCCCC[C@H]1C[C@@H](C(=O)N[C@@H](Cc3ccc4ccccc4c3)C(=O)N[C@H](NS(=O)(=O)C3CC3)Cc3ccc(cc3)OCc3cn2nn3)N(C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)C1)C(C)(C)C
21963,CHEMBL2441831,MLRHWBQYYDVLMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)C3=NN(C=C3)C)C4=C(C=C(C=C4)Cl)Cl)CN,4.958607314841775,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(c1ccn(C)n1)C2
21976,CHEMBL492591,MMAIBGHDBYQYDI-UHFFFAOYSA-N,"5-CARBOXYFURO[3,2-B]PYRROLE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18455394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=COC2=C1NC(=C2)C(=O)O,5.0,O=C(O)c1cc2occc2[nH]1
21981,CHEMBL3702700,MMEGHIZPLVCKKK-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2820.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCS(=O)(=O)N1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.549750891680639,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(S(=O)(=O)CC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
21992,CHEMBL1939876,MMJPVSDTLGFIQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22017539.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins by fluorimetry,Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=CC2=C(N1)C=CC(=C2)C3=CC(=NN3C)C(=O)NCC4=CC=C(C=C4)C(=O)O,4.522878745280337,CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1
21995,CHEMBL1209853,MMKVMFVAFDJNGK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598534.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,inhibition of CYP3A4,Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=NC(=CN2C(=C1CN)C3=C(C=C(C=C3)Cl)Cl)C4=CC=CC=C4,6.0,Cc1nc2nc(-c3ccccc3)cn2c(-c2ccc(Cl)cc2Cl)c1CN
21997,CHEMBL1173335,MMMNQMIQOUFMSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,17650.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,CC(=C(C1=CC=C(C=C1)C2=CC(=C(C=C2)O)F)C3=CC=NC=C3)C,4.753255290276159,CC(C)=C(c1ccncc1)c1ccc(-c2ccc(O)c(F)c2)cc1
21999,CHEMBL2336424,MMNFZCWXLBJTKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.958607314841775,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
22000,CHEMBL2336424,MMNFZCWXLBJTKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.619788758288394,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
22001,CHEMBL454791,MMNFZCWXLBJTKN-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.221848749616356,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
22002,CHEMBL454791,MMNFZCWXLBJTKN-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.443697499232712,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
22003,CHEMBL454791,MMNFZCWXLBJTKN-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.221848749616356,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
22004,CHEMBL454791,MMNFZCWXLBJTKN-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.443697499232712,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
22016,CHEMBL2017101,MMQZUVZXVOBUEW-KOSHJBKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,45000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCC1=CC=CC=C1C2=NOC(=C2Br)[C@H]3CNCC[C@@]3(C4=CC(=C(C=C4)F)F)O,4.346787486224656,CC(=O)NCCc1ccccc1-c1noc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br
22018,CHEMBL599792,MMRPIWYTUYGTFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC=C(C=C1)NC(=O)C2=CC=CC(=C2)CNC(=O)C3=CC(=C(C=C3)OC)OC,5.0915149811213505,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC
22019,CHEMBL599792,MMRPIWYTUYGTFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC=C(C=C1)NC(=O)C2=CC=CC(=C2)CNC(=O)C3=CC(=C(C=C3)OC)OC,4.522878745280337,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC
22026,CHEMBL2013050,MMTAJJBCVXEVAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22365751.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)N2CCC3(CCC4=C(O3)C=CC(=C4)OC5CCN(CC5)S(=O)(=O)C6CC6)CC2,4.522878745280337,O=S(=O)(C1CC1)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
22037,CHEMBL3104531,MMWXEYASGQOQGV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1700.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C(=O)C4=CC=CC=C4C(F)(F)F,5.769551078621726,O=C(c1ccccc1C(F)(F)F)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
22060,CHEMBL241032,MNEZWRIUOPOINT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,670.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)OC)(C)C4=CC(=CC(=C4)F)F,6.173925197299173,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)OC)C(=O)C(C)(c1cc(F)cc(F)c1)O2
22067,CHEMBL3115187,MNHOXZBSLMSIDR-QYDYLWNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC[C@@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.853871964321762,CC(C)c1nc(CN(C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
22068,CHEMBL3115167,MNHOXZBSLMSIDR-WUNLWTINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.823908740944319,CC(C)c1nc(CN(C)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
22069,CHEMBL368883,MNHXJOCWNHZKLQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,152000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,CC1=NC=CN1C2=CN=CC=C2,3.8181564120552274,Cc1nccn1-c1cccnc1
22071,CHEMBL368883,MNHXJOCWNHZKLQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,152000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,CC1=NC=CN1C2=CN=CC=C2,3.8181564120552274,Cc1nccn1-c1cccnc1
22082,CHEMBL559168,MNIKGZYFLQZIHV-JUJAXGASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN1C(=O)[C@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)[C@@H](C(C)C)O.Cl,4.522878745280337,CCCCN1C(=O)[C@@H]([C@H](O)C(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
22086,CHEMBL1224655,MNJFIVNZRQTGJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709552.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=NC(=CS3)C(=O)N)OC(F)(F)F,4.301029995663981,NC(=O)c1csc(-c2cccc(-c3ccccc3OC(F)(F)F)c2)n1
22088,CHEMBL416146,MNJVRJDLRVPLFE-UHFFFAOYSA-N,ETORICOXIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11327589.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 CYP3A4 in human liver microsomes,"In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C,4.301029995663981,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
22093,CHEMBL235955,MNKVGJVJTHPQCA-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCCC(=O)O,4.6777807052660805,CC(C)C[C@H](NCCCC(=O)O)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
22106,CHEMBL170159,MNTVJSYTLLQKAC-WTIAOWAESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)[C@H](C)CNCCC6=CC=CC7=C6C=CN=C7)C,6.0,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2cccc3cnccc23)c1
22128,CHEMBL3287925,MODVORZURPOLGV-NDEPHWFRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24944749.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C(N=C1C2=CC=C(C=C2)C3=C(ON=C3C)C)C)[C@@H](C(=O)O)OC(C)(C)C)C4=CC=C(C=C4)Cl,4.769551078621726,Cc1noc(C)c1-c1ccc(-c2nc(C)c([C@H](OC(C)(C)C)C(=O)O)c(-c3ccc(Cl)cc3)c2C)cc1
22158,CHEMBL2420682,MOMSGXYFDHLLKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,4196.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,COC1=CN=CC(=C1)C2=C(C3=C(C=CC(=C3)O)C=C2)Cl,5.3771645204784795,COc1cncc(-c2ccc3ccc(O)cc3c2Cl)c1
22159,CHEMBL2347323,MOMUFKSOCOPXAG-GJZGRUSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23466233.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC(=C(N2)Br)C3=CC=C(C=C3)N=[N+]=[N-])NC(=O)OC,5.823908740944319,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc(N=[N+]=[N-])cc2)c(Br)[nH]1)C(C)C
22164,CHEMBL1080803,MONVGMXMCOSOEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4C=CC=CC4=O)C(=C(N3CCO)C)C,5.251811972993799,Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)n(CCO)c12
22165,CHEMBL3702698,MONWIUSEFBOZFB-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10900.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(=O)N1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,4.962573502059376,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C(C)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
22166,CHEMBL602483,MOOACFAVSYOZPW-RTWAWAEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20089400.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 muscle isoform in human liver microsomes,"Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1[C@@H](N(C2=CC=CC(=C2O1)C3=CC(=CC=C3)OC(F)(F)F)C[C@@H](C(F)(F)F)O)C4=CC(=CC=C4)OC(C(F)F)(F)F,4.0,O[C@@H](CN1c2cccc(-c3cccc(OC(F)(F)F)c3)c2OC[C@@H]1c1cccc(OC(F)(F)C(F)F)c1)C(F)(F)F
22167,CHEMBL602483,MOOACFAVSYOZPW-RTWAWAEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20089400.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 tissue isoform in human liver microsomes,"Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1[C@@H](N(C2=CC=CC(=C2O1)C3=CC(=CC=C3)OC(F)(F)F)C[C@@H](C(F)(F)F)O)C4=CC(=CC=C4)OC(C(F)F)(F)F,4.0,O[C@@H](CN1c2cccc(-c3cccc(OC(F)(F)F)c3)c2OC[C@@H]1c1cccc(OC(F)(F)C(F)F)c1)C(F)(F)F
22175,CHEMBL1668108,MOQNWTYYZUVPQT-WBMJQRKESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,99500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,COC1=C(C=CC(=C1)[C@H]2COC3=CC=CC=C3[C@@H]2O)O,4.002176919254275,COc1cc([C@H]2COc3ccccc3[C@@H]2O)ccc1O
22176,CHEMBL3127510,MOQYJMVBPKWDGC-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@H]3C[C@@H]3C4=CN=CC=C4,6.698970004336019,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1
22177,CHEMBL3127510,MOQYJMVBPKWDGC-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@H]3C[C@@H]3C4=CN=CC=C4,5.721246399047171,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1
22180,CHEMBL3127509,MOQYJMVBPKWDGC-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@@H]3C[C@H]3C4=CN=CC=C4,6.522878745280337,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1
22181,CHEMBL3127509,MOQYJMVBPKWDGC-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,960.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@@H]3C[C@H]3C4=CN=CC=C4,6.017728766960432,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1
22186,CHEMBL514241,MOSUHGCZZUVJGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=NC=CC=N2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ncccn1
22191,CHEMBL3623825,MOUHKVCNIZIARN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26403853.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,PUBLICATION,,CC(C)C(=O)NC1CCCC2=C1C=NC=C2C3=CC=C(C=C3)C#N,4.301029995663981,CC(C)C(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21
22192,CHEMBL3702798,MOURGQNCSOFJCE-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3670.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)N1CCN(CC1)C2=NC=C(C=N2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.43533393574791,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5cnc(N6CCN(C(C)C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
22212,CHEMBL3699331,MPARRWFWOOSGFT-BNLBYEDMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC(=CC=C7)C(=O)NC8=CC=C(C=C8)N9CCN(CC9)C1=CC=C(C=C1)OC,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cccc(C(=O)Nc6ccc(N7CCN(c8ccc(OC)cc8)CC7)cc6)c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
22233,CHEMBL3353337,MPFUDUPAOWHBRQ-QPEQYQDCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C(=C(N2)O)/C=C\3/C=CC4=CN=NC4=C3,5.0,Oc1[nH]c2ccccc2c1/C=c1/ccc2c(c1)N=NC=2
22234,CHEMBL62811,MPGBYGNPFRLHAO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,=,127000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,C1CC(=O)NC2=C1C=C(C=C2)C3=CN=CC=C3,3.896196279044043,O=C1CCc2cc(-c3cccnc3)ccc2N1
22237,CHEMBL3137455,MPHUQXMZMAGHLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,700.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=N4)F,6.154901959985743,Fc1cnc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)nc1
22239,CHEMBL3422017,MPIGZKVWBCATSN-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,55000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=NC(=NO5)C,4.259637310505756,Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1
22256,CHEMBL1910110,MPQHCJTZWVZDFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)C)C3=C(C=C(C=C3)Cl)Cl)CN,4.3979400086720375,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(C)C2=O
22257,CHEMBL3664670,MPRLCRDFWDNLEU-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CC1=CC(=CC(=O)N1C)C2=CC=C(C=C2)[C@H](C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(=O)n1C
22258,CHEMBL2436983,MPTRQLXNBJOFSI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,=,21800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,C1=CC2=C(C=CN2)C=C1C3=CNC4=C3C=C(C=N4)C5=CN=C(N=C5)N,4.661543506395395,Nc1ncc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1
22267,CHEMBL478230,MPYXFPRJIAJIQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC=NC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccncc1
22268,CHEMBL3581149,MPZKHCPHRLXFAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)N,5.251811972993799,COc1cccc(CC(=O)Nc2cc(-c3ccnc(N)c3)cs2)c1
22269,CHEMBL3288009,MPZREFQMQSSBPR-HJWAMQHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24785301.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD.,J. Med. Chem.,PUBLICATION,,CC1=CC=CC2=NC(=CN12)C(=O)NC3CCC(CC3)NC(=O)C4=C(N=CC(=C4)F)OC5=CC=CC(=C5)C6=CC=C(C=C6)CN7CCC(CC7)N8CCCC8,6.0,Cc1cccc2nc(C(=O)NC3CCC(NC(=O)c4cc(F)cnc4Oc4cccc(-c5ccc(CN6CCC(N7CCCC7)CC6)cc5)c4)CC3)cn12
22286,CHEMBL2178248,MQGLDOPILNOMIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)Cl)C2=C(C=CC=N2)NC(=O)C3=C4N=CC=CN4N=C3,5.0,O=C(Nc1cccnc1-c1cccc(Cl)c1)c1cnn2cccnc12
22318,CHEMBL3234566,MQTKTGBFRROXDQ-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC(=N1)N2CCC[C@H](C2)C(=O)NCCC3=CC=C(C=C3)C#N)N4CCN(CC4)C)F,5.119186407719209,Cc1nc(N2CCC[C@@H](C(=O)NCCc3ccc(C#N)cc3)C2)nc(N2CCN(C)CC2)c1F
22320,CHEMBL529,MQTOSJVFKKJCRP-BICOPXKESA-N,AZITHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,5.0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
22321,CHEMBL529,MQTOSJVFKKJCRP-BICOPXKESA-N,AZITHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,5.0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
22329,CHEMBL2436220,MQTWTRJTQGLJQD-DDUISNTDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,38000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@H]1[C@@H](C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=NOC4=CC=CC=C43)NC(=O)[C@H](C)NC.Cl,4.42021640338319,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2noc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C
22338,CHEMBL254592,MQWJGLSZBHVGLN-VBSSPFTJSA-N,FIBRAURECDYSIDE A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,C[C@H](C[C@H]([C@@](C)([C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)C)C)O)O)O)C(C)(C)O,4.0,C[C@H](C[C@@H](O)[C@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C)C(C)(C)O
22346,CHEMBL3608682,MRAPDPPDTOESHB-SECBINFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NO4)C,4.0,Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1
22354,CHEMBL2040897,MRDYEAJRUPFRFX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)C6=C(N=C(S6)C)C,4.301029995663981,Cc1nc(C)c(-c2ccc(N3C(=O)N(c4cc(=O)[nH]cn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)s1
22358,CHEMBL1271320,MREFPLHQTKDQLT-HSPRIFCFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1NC2=NC=C(C=C2)C(F)(F)F)C(=O)OC3C4CC5CC3CC(C5)(C4)C(=O)N,5.142667503568732,NC(=O)C12CC3CC(C1)C(OC(=O)N1CC[C@@H](Nc4ccc(C(F)(F)F)cn4)C1)C(C3)C2
22359,CHEMBL1269894,MREFPLHQTKDQLT-ZHLGKKDISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,=,10300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@H]1NC2=NC=C(C=C2)C(F)(F)F)C(=O)OC3C4CC5CC3CC(C5)(C4)C(=O)N,4.987162775294828,NC(=O)C12CC3CC(C1)C(OC(=O)N1CC[C@H](Nc4ccc(C(F)(F)F)cn4)C1)C(C3)C2
22362,CHEMBL238744,MRGGOQVTDADSFB-GOSISDBHSA-N,SR-889,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)[C@@H](C4=CC(=CC=C4)Cl)O,5.455931955649724,O=C([C@H](O)c1cccc(Cl)c1)N1CCN(c2ccc3[nH]ncc3c2)CC1
22371,CHEMBL2041178,MRIBBXXALNMJDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)NC,4.301029995663981,CNC(=O)c1ccc(-c2ccc(N3C(=O)N(c4cc(OC)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)cc1
22402,CHEMBL2425893,MRWKTDPDQXVRSA-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,46180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=CC(=C3)Cl)C=C2)N4CCC[C@H](C4)N,4.335546071418842,CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccc(Cl)cc3n2)c1=O
22403,CHEMBL2419494,MRWKTKIMIMOEBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)C(C)C)C,5.698970004336019,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(C(C)C)cc3)CC2)nc1C
22425,CHEMBL1097192,MRZTZDFHFHGWFU-YMGMXPECSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OC[P@@]4(=O)OCC[C@H](O4)C5=CN=CC=C5,5.5376020021010435,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccnc3)O2)c2c(c1C)Cc1scnc1-2
22444,CHEMBL1669418,MSDXVUCMHKOWGT-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,2751.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CO4,5.560509409610316,C[C@H](C1=C(CCN(C)Cc2ccco2)Cc2ccccc21)c1cnccn1
22453,CHEMBL2070947,MSHULPIKNRKAQH-QZTJIDSGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22858142.0,IC50,=,630.96,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC2=C(C=C1)N=C(S2)N3CCN(CC3)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,6.199998172182031,CS(=O)(=O)c1ccc2nc(N3CCN(C(=O)[C@@H]4CCCC[C@H]4C(=O)NC4(C#N)CC4)CC3)sc2c1
22454,CHEMBL356594,MSHWCOQQFPXUKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=NNC(=C2)C,4.0,CCCCOc1ccc(-c2cc(C)[nH]n2)cc1
22467,CHEMBL1669406,MSMKOTVNTGCTFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,4038.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3,5.393833685392379,CCCN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1
22469,CHEMBL111201,MSOUIIHPMJCUNI-LJAQVGFWSA-N,L-796568,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26709102.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)[C@H](CNCCC2=CC=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)C4=NC(=CS4)C5=CC=C(C=C5)C(F)(F)F)O,5.031517051446065,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1
22470,CHEMBL250766,MSOXUNRESBTCBO-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18294849.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@@H](N(C1)CCCOC2=CC3=CN=NC(=C3C=C2)NC4=CN(N=C4)CC(=O)NC5=C(C(=CC=C5)F)F)COP(=O)(O)O,5.214670164989233,O=C(Cn1cc(Nc2nncc3cc(OCCCN4CCC[C@@H]4COP(=O)(O)O)ccc23)cn1)Nc1cccc(F)c1F
22472,CHEMBL1093607,MSPFRPWEGPBFTC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)N3C=CN=C3,5.2839966563652006,CC(c1c(CCN(C)C)sc2ccccc12)n1ccnc1
22474,CHEMBL1829780,MSQIRKAOYTVRLM-XDBZFTIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCCNC(=O)N)C4=CC=C(C=C4)F,5.3979400086720375,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCNC(N)=O)(c2ccc(F)cc2)OC1=O
22475,CHEMBL3680984,MSRICOSVBSYAJO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5800.0,NM,253317,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",Metalloenzyme inhibitor compounds,,PATENT,,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F,5.236572006437063,OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1
22481,CHEMBL1651533,MSVRZOTYGPKRHH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,23500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng testosterone substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NC=CN=C4,4.628932137728264,O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
22482,CHEMBL1651533,MSVRZOTYGPKRHH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng midazolam substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NC=CN=C4,4.522878745280337,O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
22483,CHEMBL1271762,MSWDKLVRBJNSSU-QUCCMNQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,7.1,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)[C@@H]1COC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCC(CC3)CO,8.148741651280925,CC(C)(C)[C@@H]1COC[C@H](COC(=O)N2CCC(CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
22485,CHEMBL1215621,MSXMGTMTOVJLOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20672820.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C(C(=C(N1)CN2C=NC=N2)C(=O)OC)C3=C(C=C(C=C3)F)Cl)C#N,6.096910013008056,COC(=O)C1=C(Cn2cncn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl
22491,CHEMBL1766169,MSYJBDGOMUPKGB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=CC(=C1)C2=CC=CC=C2)(C3=CN=CN3)O,5.920818753952375,CC(C)C(O)(c1cccc(-c2ccccc2)c1)c1cnc[nH]1
22494,CHEMBL2347994,MTALYIZKNIEGKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)F)C5CCNCC5,4.301029995663981,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(C4CCNCC4)c4cc(F)ccc34)nc12
22498,CHEMBL467047,MTDBNJKMVASAKC-LNNUBQDUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19289530.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,PUBLICATION,,CC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CN(C)C/C=C\CN)O)O)N,5.301029995663981,Cc1nc(N)c2ncn([C@@H]3O[C@H](CN(C)C/C=C\CN)[C@@H](O)[C@H]3O)c2n1
22501,CHEMBL2041188,MTFKYKNIAONGHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CC=N4)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ncccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1
22504,CHEMBL2064341,MTHPQWCRVGFTAP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1CC1N2C3=C(C=C(C=C3)F)N=C2CC4=NC(=CC(=O)N4)N5CCOCC5,4.3979400086720375,O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3n2C2CC2)[nH]1
22505,CHEMBL1766005,MTHVGGMOKYRPIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21428449.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26): Synthesis and Biological Evaluation of Imidazole Methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.,J. Med. Chem.,PUBLICATION,,CC(C)(C(C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2)N4C=CN=C4)C(=O)OC,5.096910013008056,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1
22507,CHEMBL1766005,MTHVGGMOKYRPIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21838328.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26).",J. Med. Chem.,PUBLICATION,,CC(C)(C(C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2)N4C=CN=C4)C(=O)OC,7.0,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1
22514,CHEMBL2332097,MTJPSOHLRSAFBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23570561.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CN(CC1=CC(=CC=C1)OC)C(=O)NC2=CC=C(C=C2)C3=CNN=C3,4.0,COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1
22521,CHEMBL2385906,MTLOUGLEHWJVAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23324405.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CC2=C1N(C3=CC=CC=C23)CC(=O)O)C(=O)C4=CC=CC=C4,4.301029995663981,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1ccccc1)CC2
22522,CHEMBL2385906,MTLOUGLEHWJVAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CC2=C1N(C3=CC=CC=C23)CC(=O)O)C(=O)C4=CC=CC=C4,4.301029995663981,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1ccccc1)CC2
22538,CHEMBL524472,MTSGTWVVCJFRLJ-SECBINFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19364658.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,PUBLICATION,,C[C@H](C1=CC=CC=C1)NC2=C(C(=O)C2=O)NC3=CC=NN3,4.3979400086720375,C[C@@H](Nc1c(Nc2ccn[nH]2)c(=O)c1=O)c1ccccc1
22545,CHEMBL454467,MTUYBYGTWUVARZ-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N(CCOC)CCOC,9.0,COCCN(CCOC)C1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
22551,CHEMBL2152523,MTYFDEYZRYWPAI-DNQXCXABSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,19952.62,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli,,ACS Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)[C@H](C2=CC=CC=C2)[C@@H](C3=CC=CC=C3)N4CCCCC4,4.70000006855703,c1ccc([C@H]([C@@H](c2ccccc2)N2CCCCC2)N2CCCCC2)cc1
22552,CHEMBL2152522,MTYFDEYZRYWPAI-ZEQRLZLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15848.93,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli,,ACS Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)[C@@H](C2=CC=CC=C2)[C@H](C3=CC=CC=C3)N4CCCCC4,4.800000052738446,c1ccc([C@@H]([C@H](c2ccccc2)N2CCCCC2)N2CCCCC2)cc1
22553,CHEMBL1950089,MTYKIQDYUJLUDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=NC=CO4)O)Cl,6.0,Cc1cc(Cl)cc2c(C(O)c3ncco3)c3c(C)[nH]nc3nc12
22554,CHEMBL1950089,MTYKIQDYUJLUDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=NC=CO4)O)Cl,5.130768280269024,Cc1cc(Cl)cc2c(C(O)c3ncco3)c3c(C)[nH]nc3nc12
22555,CHEMBL1081504,MTYYVNZCZPYFBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=NC=NC3=C2NC(=C3C)C,5.055517327849831,Cc1cccc(C)c1CNc1ncnc2c(C)c(C)[nH]c12
22556,CHEMBL1081504,MTYYVNZCZPYFBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=NC=NC3=C2NC(=C3C)C,4.0,Cc1cccc(C)c1CNc1ncnc2c(C)c(C)[nH]c12
22562,CHEMBL359627,MUCJLTBRRVGZER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,260.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C#N)N4C=CN=C4)N(C)C,6.585026652029182,CC(C(c1ccc2cc(OCc3ccc(C#N)cc3)ccc2c1)n1ccnc1)N(C)C
22563,CHEMBL359627,MUCJLTBRRVGZER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C#N)N4C=CN=C4)N(C)C,6.494850021680094,CC(C(c1ccc2cc(OCc3ccc(C#N)cc3)ccc2c1)n1ccnc1)N(C)C
22578,CHEMBL399772,MUIOMNHOLFGIGK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17937987.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and structure-activity relationships of thieno[2,3-b]pyrroles as antagonists of the GnRH receptor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)C2=C(C3=C(N2)SC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)CCN6CCN(CC6)CC(=O)N7CCOCC7)C,7.0,Cc1cc(C)cc(-c2[nH]c3sc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2CCN2CCN(CC(=O)N3CCOCC3)CC2)c1
22585,CHEMBL386630,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,TESTOSTERONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C,5.0,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
22614,CHEMBL3702822,MUMIOWBMUUBPQQ-NWDJCJOJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)S(=O)(=O)C,5.0,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(-c5ccc(S(C)(=O)=O)cc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
22635,CHEMBL2037608,MURCULVYVOMYIO-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22578490.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=CC(=O)N(N=C3)COC,4.522878745280337,COCn1ncc(-c2ccc(OCCCN3CCC[C@H]3C)cc2)cc1=O
22639,CHEMBL3286732,MUTPWJCHZIMJSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C1CN(CCC12CNC(=O)O2)C3=NC=C(C=C3)C(=O)NC4=C(C=CC(=C4)C5=CC=CS5)N,5.0,Nc1ccc(-c2cccs2)cc1NC(=O)c1ccc(N2CCC3(CC2)CNC(=O)O3)nc1
22641,CHEMBL312238,MUULRSITXOVVFK-WGAQAMEHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12161148.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](COC4=CC=CC=C34)O)O)C(C)(C)C5=CC6=C(O5)C=CN=C6,6.508638306165727,CC(C)(C)NC(=O)[C@@H]1CN(C(C)(C)c2cc3cnccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
22644,CHEMBL2346686,MUUWFGCCXBFENT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=C(C=C4)OC(F)F)C,4.721246399047171,Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2cc(OC(F)F)ccc21
22665,CHEMBL1171987,MVDKLMQNQSJYHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,1520.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)N)C2=CC=C(C=C2)CC3=CC=NC=C3,5.818156412055227,Nc1cccc(-c2ccc(Cc3ccncc3)cc2)c1
22666,CHEMBL1171987,MVDKLMQNQSJYHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,1520.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)N)C2=CC=C(C=C2)CC3=CC=NC=C3,5.818156412055227,Nc1cccc(-c2ccc(Cc3ccncc3)cc2)c1
22685,CHEMBL3358920,MVGWUTBTXDYMND-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516790.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.,ACS Med. Chem. Lett.,PUBLICATION,,C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CC[C@@H]5CC(=O)O)C(F)(F)F,4.301029995663981,O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21
22689,CHEMBL3125655,MVIDQQZWMHRXFV-IVAHSZNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23544424.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 7 mins by LC/MS/MS analysis,Hepatitis C replication inhibitors that target the viral NS4B protein.,J. Med. Chem.,PUBLICATION,,C1CC1C2=CC3=C(C(=NN3C(=C2)C(F)(F)F)C(=O)N4CCN(C(=O)C4)[C@H]5C[C@@H]6C[C@@H]6[C@@H]5O)Cl,4.698970004336019,O=C(c1nn2c(C(F)(F)F)cc(C3CC3)cc2c1Cl)N1CCN([C@H]2C[C@@H]3C[C@@H]3[C@@H]2O)C(=O)C1
22692,CHEMBL464907,MVKOXOCIOJFWSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=C(C=CC=C3F)F,4.0,CN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F
22702,CHEMBL2158230,MVPRWLBKNHWFPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)CCN4CCOCC4)NC(=O)C5=NC=C(N5)C#N,5.42021640338319,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCN4CCOCC4)CC3)cc2C2=CCCCC2)[nH]1
22716,CHEMBL1761532,MVXIVGJQLGJBTD-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCC(C)(C)C(=O)O)C5CC5)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC(C)(C)C(=O)O)c1
22717,CHEMBL1761532,MVXIVGJQLGJBTD-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCC(C)(C)C(=O)O)C5CC5)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC(C)(C)C(=O)O)c1
22722,CHEMBL2331785,MWAFLDQEXDZJCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,360.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,CCNC(=O)C1=C(C=CC(=C1)NS(=O)(=O)C2=C(C=C(C(=C2)C)Cl)Cl)OC3=CC(=CN=C3)Cl,6.443697499232713,CCNC(=O)c1cc(NS(=O)(=O)c2cc(C)c(Cl)cc2Cl)ccc1Oc1cncc(Cl)c1
22725,CHEMBL2017277,MWCQWHMNJUFCOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4CCCCC4)C(=O)N)OC,5.214670164989233,COc1cc2c(NC3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C
22747,CHEMBL3702723,MWNNUMQFYMZPJW-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2110.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)N8CCOCC8,5.675717544702307,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N6CCOCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
22748,CHEMBL1909725,MWNVVXNYGOUFQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21924902.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-(2'-Pyridyl)-2-aminothiazoles: Alkyl amino sulfonamides and sulfamides as potent NPY(5) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)S(=O)(=O)NCCCCCNC1=NC(=CS1)C2=CC=CC=N2,5.154901959985743,CN(C)S(=O)(=O)NCCCCCNc1nc(-c2ccccn2)cs1
22758,CHEMBL1668112,MWQRAOGWLXTMIC-WZBLMQSHSA-N,(7R)-7-HYDROXYLARICIRESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,66500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,COC1=C(C=CC(=C1)[C@@H]2[C@H]([C@H](CO2)[C@H](C3=CC(=C(C=C3)O)OC)O)CO)O,4.1771783546968955,COc1cc([C@H]2OC[C@H]([C@@H](O)c3ccc(O)c(OC)c3)[C@@H]2CO)ccc1O
22763,CHEMBL214957,MWULMTACIBZPGN-UHFFFAOYSA-N,GW3430,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20951036.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=CC(=C1)N2C=NC3=C(C2=O)SC(=C3)C4=CC=C(C=C4)Cl)OCCN5CCCC5,5.795880017344075,COc1cc(-n2cnc3cc(-c4ccc(Cl)cc4)sc3c2=O)ccc1OCCN1CCCC1
22769,CHEMBL1951325,MWWLVSZLKTULPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,92.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC(=C1)Br)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,7.036212172654444,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(Br)c1
22774,CHEMBL1923111,MWXLYTROOQGXBN-VIZCGCQYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F,4.886056647693163,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)cc(OCCOC)c1
22790,CHEMBL3623290,MXDSJQHFFDGFDK-CYBMUJFWSA-N,AZD3759,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26313252.0,IC50,>,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC)C,7.301029995663981,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C
22791,CHEMBL231924,MXDWNZUMSIYAFL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17524641.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)NC2=NS(=O)(=O)C3=CC(=CC(=C3N2)O)[N+](=O)[O-])Cl,4.6020599913279625,O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Cl)N2
22796,CHEMBL1290264,MXFUQWVSPVTIIP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20952195.0,IC50,=,67000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC2=C(C1)C3=C(N2C)C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5,4.173925197299173,CN1CCc2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc3n2C)C1
22817,CHEMBL444989,MXOCHUKULSSMCN-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=C(C(=CC=C4)OCCCCCC(=O)O)F)N,4.6020599913279625,N[C@@H](Cn1c(=O)c(-c2cccc(OCCCCCC(=O)O)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
22834,CHEMBL251055,MXTLAHSTUOXGQF-UHFFFAOYSA-O,JATRORRHIZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)O)OC)OC,5.6777807052660805,COc1cc2c(cc1O)CC[n+]1cc3c(OC)c(OC)ccc3cc1-2
22836,CHEMBL2064335,MXWXREUDDBTARZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1COCCN1C2=CC(=O)NC(=N2)CC3=NC4=C(N3)C=C(C=C4)Br,4.3979400086720375,O=c1cc(N2CCOCC2)nc(Cc2nc3ccc(Br)cc3[nH]2)[nH]1
22849,CHEMBL3702725,MYADYUMYQBLDNQ-OZLPACJUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4490.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CC2CCN(C2C1)C(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.347753658996677,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC6CN(C)CC65)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
22866,CHEMBL1916282,MYHHDENZOVCZAX-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21955939.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of pyrazoles as novel FPR1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NN2C3=CC=CC=C3)C)C(=O)N[C@@H](C)C(C)(C)C,5.0,Cc1ccc(S(=O)(=O)Nc2c(C(=O)N[C@@H](C)C(C)(C)C)c(C)nn2-c2ccccc2)cc1
22871,CHEMBL482845,MYJOBXPUJPRQLF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2=CC=CC=C2C1NC(=O)N3CCC4(CC3)CC(=O)C5=CC=CC=C5O4,5.0,O=C1CC2(CCN(C(=O)NC3CCc4ccccc43)CC2)Oc2ccccc21
22874,CHEMBL207304,MYLJXYCXVOMQPS-NLFFAJNJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]([C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCCC3)C(=O)O)N4C=CN=C4)N(C)C(C)C,6.096910013008056,CC(C)N(C)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1
22881,CHEMBL1272097,MYNIAARJFHEUIK-UYAOXDASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,1.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1=O)C(=O)OC2(CC2)[C@H]3COC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)CC5CC5,8.853871964321762,CN1CCN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1=O
22898,CHEMBL8,MYSWGUAQZAJSOK-UHFFFAOYSA-N,CIPROFLOXACIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,5.0,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
22899,CHEMBL8,MYSWGUAQZAJSOK-UHFFFAOYSA-N,CIPROFLOXACIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,5.0,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
22909,CHEMBL1257965,MYTSILBAQHYOET-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN2C3=C(C=C(C=C3)OC4CCN(CC4)C(C)C)C=C2C(=O)N1CC5CC5,4.301029995663981,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@@H](C)N(CC3CC3)C2=O)CC1
22913,CHEMBL598644,MYVJXQAAFVJXRY-VIKVFOODSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,C1CC1COCC2([C@H]3[C@@H]2CNC3)C4=CC(=C(C=C4)Cl)Cl,5.3979400086720375,Clc1ccc(C2(COCC3CC3)[C@H]3CNC[C@H]32)cc1Cl
22914,CHEMBL1951597,MYVRYELIXRBEEQ-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C2=C(C(=O)N(C1=O)C)N(C(=C2C#N)N3CCC[C@@H](C3)N)CC4=CC=CC=C4,5.522878745280337,Cn1c(=O)c2c(c(C#N)c(N3CCC[C@H](N)C3)n2Cc2ccccc2)n(C)c1=O
22925,CHEMBL240069,MZAPDYQWIGAEQO-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@H](N([C@H](C1)C2(CC2)OC(=O)N3CCN(CC3)CCO)S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,6.3979400086720375,O=C(OC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1
22943,CHEMBL3218855,MZGDIKYASHMRSG-UGCQDJOBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,CN1CCN(CC1)C2=CC(=C(C=C2)C3=NC4=NC=C(C(=C4N3)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl)OC,5.070581074285707,COc1cc(N2CCN(C)CC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
22944,CHEMBL3218855,MZGDIKYASHMRSG-UGCQDJOBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,CN1CCN(CC1)C2=CC(=C(C=C2)C3=NC4=NC=C(C(=C4N3)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl)OC,4.863279432843593,COc1cc(N2CCN(C)CC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
22973,CHEMBL2397308,MZTTVVHNFDPGBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=C(C=C1)C(=O)N(CC2=CC=CC=C2)CC(=O)NC3=NC=C(S3)C4=CC=C(C=C4)N,4.823908740944319,Cc1ccc(C(=O)N(CC(=O)Nc2ncc(-c3ccc(N)cc3)s2)Cc2ccccc2)cn1
22974,CHEMBL1222649,MZTTZMXOZUZREU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,5.1249387366083,Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
22976,CHEMBL3326576,MZVVZQZAVDLFTI-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1(C[C@H](C2=C(O1)C=C(C=C2)OC(F)(F)F)NC(=O)NC3=CC=CC4=C3C=CN=C4)C,5.657577319177793,CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2ccc(OC(F)(F)F)cc2O1
22988,CHEMBL3702755,NAFGAODZJQDRCU-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2180.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCC7=CC(=NC=C7)N(C)C,5.661543506395395,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCc5ccnc(N(C)C)c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
22993,CHEMBL558339,NAGKIWFBALBSMD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2C=CC=C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,5.301029995663981,Fc1ccc(Cn2c(N3CCC(n4cccc4)CC3)nc3ccccc32)cc1
22996,CHEMBL1256004,NAHHNSMHYCLMON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26371436.0,IC50,=,5000000.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase,Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.,J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)CCN,2.3010299956639813,NCCc1cccnc1
23000,CHEMBL397583,NAHRDBPWFMIDIX-MFMCTBQISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)[C@H](CC(C)C)NC(=O)CCNC,5.468521082957745,CNCCC(=O)N[C@@H](CC(C)C)c1cc(C)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
23003,CHEMBL429459,NAJFOBIBNBUZAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,4790.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCCO)(C)C4=CC(=CC(=C4)F)F,5.319664486585436,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2
23009,CHEMBL593375,NANAONFNJKBZQE-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C=C(C=NC2=NN1)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OC[C@H](CC5=CNC6=CC=CC=C65)N,6.0,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2c1
23011,CHEMBL564144,NANQRVOKMXDMNL-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,C[C@@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12
23012,CHEMBL564144,NANQRVOKMXDMNL-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20800486.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,C[C@@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12
23013,CHEMBL1090433,NANQRVOKMXDMNL-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,C[C@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12
23014,CHEMBL1090432,NANQRVOKMXDMNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,CC(c1ccccn1)c1c(CCN(C)C)sc2ccccc12
23021,CHEMBL1761533,NASKVDWGYKOGBO-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCCC(C)(C)C(=O)O)C5CC5)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCC(C)(C)C(=O)O)c1
23022,CHEMBL1761533,NASKVDWGYKOGBO-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCCC(C)(C)C(=O)O)C5CC5)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCC(C)(C)C(=O)O)c1
23025,CHEMBL271310,NATXHFKXFMNQDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCN(C)C)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,4.5376020021010435,CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
23026,CHEMBL271310,NATXHFKXFMNQDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCN(C)C)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,4.5376020021010435,CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
23027,CHEMBL271310,NATXHFKXFMNQDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCN(C)C)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,4.431798275933005,CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
23040,CHEMBL3640258,NAXGDHGFSCZYGN-OVWNDWIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC(=N1)N2C[C@H]3C(=O)N(C(=N[C@]3(C2)C4=C(C=CC=C4F)F)N)C)OC)F,4.698970004336019,COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)cccc3F)C2)nc(C)c1F
23045,CHEMBL2435852,NAYZSSQGIKJDGG-PMERELPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24090135.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC(=N1)OC2=CC=C(C=C2)C(=O)O)CN3CCC(CC3)N4[C@@H](CN(C4=O)C5CCOCC5)C6=CC=CC=C6,4.3979400086720375,Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1
23049,CHEMBL1824230,NBCFVKKQKAXINS-TYKWCNGQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21783360.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C1CCC(CC1)C2=CC=C(C=C2)OCCCN3CCCCC3,4.301029995663981,CN(C)C1CCC(c2ccc(OCCCN3CCCCC3)cc2)CC1
23050,CHEMBL1824231,NBCFVKKQKAXINS-XUTJKUGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21783360.0,IC50,=,42600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C1CCC(CC1)C2=CC=C(C=C2)OCCCN3CCCCC3,4.370590400897281,CN(C)C1CCC(c2ccc(OCCCN3CCCCC3)cc2)CC1
23056,CHEMBL496289,NBDGMNQECKEFTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,2173.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC(C2=C(C1)C=C(C=C2)C3=CC=C(C=C3)F)C4=CC=NC=C4.Cl,5.662940273679475,Fc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1
23093,CHEMBL1094512,NBMXJNMUHLTYPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CSC(=N1)CN2C3=CC=CC=C3N=C2C4CCCN(C4)C,5.301029995663981,Cc1csc(Cn2c(C3CCCN(C)C3)nc3ccccc32)n1
23105,CHEMBL3640262,NBQUUPYPQVTUSJ-HXPMCKFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC(=N1)N2C[C@H]3C(=O)N(C(=N[C@]3(C2)C4=CC=CC=C4F)N)C)OC)F,4.522878745280337,COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3F)C2)nc(C)c1F
23107,CHEMBL3581137,NBSARUOSCYNPMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=NC=NC=C3,5.0,COc1cccc(CC(=O)Nc2nc(-c3ccncn3)cs2)c1
23117,CHEMBL469850,NBVYFPSAUFQMAK-XVCAIJIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,35500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C/C/1=C\CC(/C=C/C(=O)/C(=C/[C@@H](C1)O)/C)(C)C,4.449771646944906,C/C1=C\CC(C)(C)/C=C/C(=O)/C(C)=C/[C@H](O)C1
23119,CHEMBL2058907,NBXKPHVFWKOIHD-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CC=NC=C4)O)CC(C)C,6.698970004336019,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3ccncc3)cc2o1
23137,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,6.6020599913279625,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
23138,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,7.522878745280337,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
23146,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,7.301029995663981,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
23162,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497764.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in liver microsomes,"Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,7.0,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
23163,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23586711.0,IC50,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.,J. Med. Chem.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,6.259637310505756,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
23168,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,6.958607314841775,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
23172,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,7.795880017344075,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
23176,CHEMBL3311227,NCEHACHJIXJSPD-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,79000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OC(F)(F)F,4.102372908709558,O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OC(F)(F)F)cc2)cn1
23193,CHEMBL3125272,NCHSTBMDNNMMEJ-BEFAXECRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24450589.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.,J. Med. Chem.,PUBLICATION,,CCC1=NN(C(=C1)C(=O)N[C@@H]2C[C@H](N(C2)C(=O)C3=COC4=CC=CC=C43)C(=O)NCC)C,4.301029995663981,CCNC(=O)[C@@H]1C[C@@H](NC(=O)c2cc(CC)nn2C)CN1C(=O)c1coc2ccccc12
23204,CHEMBL408513,NCNRHFGMJRPRSK-MDZDMXLPSA-N,BELINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,5.0,O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO
23213,CHEMBL3087350,NCOYZGPRWXMZKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NOC(=N1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,4.568636235841013,Cc1noc(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)cc2)n1
23215,CHEMBL2019023,NCPZEGFWCSOTGE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CCOC1=CC2=C(C=C1)N=C(N2)SCC3=CC=CC=N3,6.3979400086720375,CCOc1ccc2nc(SCc3ccccn3)[nH]c2c1
23235,CHEMBL1098148,NCZRGOOBIMCMOT-YMGMXPECSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OC[P@@]4(=O)OCC[C@H](O4)C5=CC=CC=N5,5.075720713938118,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccccn3)O2)c2c(c1C)Cc1scnc1-2
23240,CHEMBL1270936,NDAQOTDOXUWRAJ-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ß-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC#CC1=C(C=CC(=C1)[C@@]2(C(=O)N(C(=N2)N)C)C3=CC=C(C=C3)OC(F)F)F,6.0,CC#Cc1cc([C@@]2(c3ccc(OC(F)F)cc3)N=C(N)N(C)C2=O)ccc1F
23247,CHEMBL1642906,NDCNHLIWHOBKGK-LRDDRELGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,=,20100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CNC[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,4.696803942579511,CNC[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
23248,CHEMBL1642907,NDCNHLIWHOBKGK-MLGOLLRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CNC[C@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,4.6020599913279625,CNC[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
23249,CHEMBL1642908,NDCNHLIWHOBKGK-WBMJQRKESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CNC[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,4.6020599913279625,CNC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
23255,CHEMBL1934424,NDFKHRWYNVKHBS-SLFFLAALSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22094028.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimisation of pyrazoles as novel FPR1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NN2C3CCC(CC3)OC)C)C(=O)N[C@@H](C)C(C)(C)C,5.0,COC1CCC(n2nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c2NS(=O)(=O)c2ccc(C)cc2)CC1
23265,CHEMBL2159135,NDKNVVACIYGWQY-GZXUFEOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](NC(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NC(C)(C)C)O4)C)(C)OC)C)C)O)(C)O,5.853871964321762,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NC(C)(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O
23266,CHEMBL2159135,NDKNVVACIYGWQY-GZXUFEOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](NC(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NC(C)(C)C)O4)C)(C)OC)C)C)O)(C)O,5.0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NC(C)(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O
23280,CHEMBL2334758,NDQIDSZBEUKRAW-ZAAXVRCTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C([C@H]4CC[C@@H](C3)N4S(=O)(=O)C)C(=N2)N5CCOC[C@@H]5C,5.301029995663981,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)[C@H]2CC[C@@H](C3)N2S(C)(=O)=O)cc1
23282,CHEMBL526929,NDRBDNKFYLWQEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18479916.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1CC(=O)NC(=O)NC2=CC(=C(C=C2)OC3=C(C(=NC=C3)N)C#CCN)F)F,5.7447274948966935,NCC#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N
23283,CHEMBL3087036,NDSORUPSARDZBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CN=CN=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,5.455931955649724,O=S(=O)(Nc1ccc(-c2cncnc2)cc1)c1cc(Cl)cc(Cl)c1
23290,CHEMBL1215732,NDUUGOAGHNLAIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,668.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)F)C2=CC=C(C=C2)CC3=CC=NC=C3,6.175223537524454,Fc1cccc(-c2ccc(Cc3ccncc3)cc2)c1
23291,CHEMBL1079292,NDVUCAXUMZGNKP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)N)C3=CC=CC=C3,5.0,NC(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
23309,CHEMBL3127992,NELULMBEPVQNFL-NHCYSSNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24531224.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,C1[C@@H](CN([C@@H]1C#N)C(=O)[C@H](CC2=CC3=C(C=C2Br)OCO3)N)F,5.657577319177793,N#C[C@@H]1C[C@H](F)CN1C(=O)[C@@H](N)Cc1cc2c(cc1Br)OCO2
23310,CHEMBL2419490,NEMHKCNXXRQYRF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=CC=C3)C,4.698970004336019,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccccc3)CC2)nc1C
23311,CHEMBL2436633,NEPGOHXZJPYLLQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2CC3=CC=CC=C3C4=CC=CC=C4C2)C(=O)C5(CCN(CC5)CC6=CC(=NC=C6)N)F,4.7447274948966935,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5-c5ccccc5C4)CC3)CC2)ccn1
23316,CHEMBL3699315,NEQDCWFWVYOBKX-HHDOLNPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12240.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCCCC8,4.912218582190458,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
23317,CHEMBL3699315,NEQDCWFWVYOBKX-HHDOLNPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,14700.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCCCC8,4.8326826652518236,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
23320,CHEMBL205245,NEQSVLABUJREKW-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=C(N1CC2=C(C3=C(S2)N(C(=O)N(C3=O)C)CC(C)C)C(=O)N4CC[C@H](C4)O)Cl)Cl,4.301029995663981,Cc1nc(Cl)c(Cl)n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C
23323,CHEMBL3702777,NESCTSGARYERBV-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3450.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N(C)CCO,5.462180904926726,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(C)CCO)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
23336,CHEMBL2347996,NEVNJCLJFXHCCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=C4CCCCN4C=N3,4.301029995663981,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3ncn4c3CCCC4)nc12
23346,CHEMBL2163830,NEXRPVDFTJNSMM-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C(=O)[C@H](COCC2=CC=CC=C2)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,5.657577319177793,CN1CCN(C(=O)[C@H](COCc2ccccc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
23378,CHEMBL2336420,NFKNHAHXAMZIFN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,370.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,6.431798275933005,CC(C)c1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
23383,CHEMBL1824241,NFMCJKWXWBIFGH-AFARHQOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21783360.0,IC50,=,66200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)CCCOC2=CC=C(C=C2)C3CCC(CC3)N4CCOCC4,4.1791420105603,c1cc(C2CCC(N3CCOCC3)CC2)ccc1OCCCN1CCCCC1
23394,CHEMBL252837,NFUBWILZNIMKMD-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=C(C=CC(=C1)F)Cl)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,5.698970004336019,CC(C)(C)OC(=O)N[C@H](Cc1cc(F)ccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
23396,CHEMBL567169,NFWQSVLWPXHOHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=CC=C3)C(F)(F)F,5.494850021680094,CC1(CC(=O)NCc2cccc(C(F)(F)F)c2)CC2(CCCCC2)OO1
23397,CHEMBL1077934,NFWXZIIEKXXDMY-CONSDPRKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,135.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@@H](CN(CC2=CC=CC=C2)C[C@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,6.8696662315049934,O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
23398,CHEMBL1077936,NFWXZIIEKXXDMY-FIRIVFDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@H](CN(CC2=CC=CC=C2)C[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,7.221848749616356,O=C(N[C@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
23399,CHEMBL1077935,NFWXZIIEKXXDMY-IOWSJCHKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,87.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@@H](CN(CC2=CC=CC=C2)C[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,7.060480747381382,O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
23407,CHEMBL3114732,NFZMNPXRMSSCSR-LDNVYYCDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(CC3=CC=C(C=C3)Cl)C(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.356547323513812,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccc(Cl)cc2)C(=O)OCc2cncs2)Cc2ccccc2)cs1
23421,CHEMBL230654,NGCNZPVYWSEEJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17715908.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.,J. Med. Chem.,PUBLICATION,,CCCC1=C(NC=N1)CNC2=CC3=C(C(=CN=C3C(=C2)Cl)C#N)NC4=CC(=C(C=C4)F)Cl,4.795880017344075,CCCc1nc[nH]c1CNc1cc(Cl)c2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1
23428,CHEMBL2036730,NGEBYTLALFOQKI-HDJSIYSDSA-N,AZD-3988,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22608962.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)NC(=O)C3=NN=C(O3)NC4=CC(=C(C=C4)F)F,4.522878745280337,O=C(O)CC1CCC(c2ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cc2)CC1
23436,CHEMBL3216770,NGFJLBUDBMXNIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21699209.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,PUBLICATION,,CN(C)CCN1C(=O)CCC2=C1C=CC(=C2)N=C(C3=CC=CS3)N.Cl.Cl,4.0,CN(C)CCN1C(=O)CCc2cc(N=C(N)c3cccs3)ccc21
23446,CHEMBL1956397,NGKMIRWLVJBBBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22341942.0,IC50,=,139000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsome,Wake-promoting agents: search for next generation modafinil: part II.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)CS(=O)CC(=O)N)C2=CC=C(C=C2)Cl,3.856985199745905,NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1
23447,CHEMBL1956397,NGKMIRWLVJBBBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22341942.0,IC50,=,159000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsome,Wake-promoting agents: search for next generation modafinil: part II.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)CS(=O)CC(=O)N)C2=CC=C(C=C2)Cl,3.7986028756795487,NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1
23479,CHEMBL2332065,NGOKTEXAUPRBFP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23570561.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CN(CCO)C(=O)NC2=CC=C(C=C2)C3=CNN=C3,4.455931955649724,COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1
23486,CHEMBL2397192,NGSUGGPEIWGUBD-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C4(CC4)C#N,5.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2(C#N)CC2)c1
23501,CHEMBL1078265,NGZGPRMVYQEQTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NCCC2=CC=C(C=C2)Cl)C3=CC=CC=C3,5.0,CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc(Cl)cc2)C1
23507,CHEMBL1834662,NHAXYOVOGZMIOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)CC2=CC(=CC=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,6.301029995663981,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN4CCN(C)CC4)c3)ncn2)c1Cl
23508,CHEMBL1834662,NHAXYOVOGZMIOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)CC2=CC(=CC=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,5.0,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN4CCN(C)CC4)c3)ncn2)c1Cl
23513,CHEMBL3358945,NHDBZQPHSRUJIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=CC=CC=C3S(=O)(=O)N,4.823908740944319,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1S(N)(=O)=O
23514,CHEMBL3664671,NHDUOZUJFFAZCM-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CCN1C=CC(=CC1=O)C2=CC=C(C=C2)[C@H](C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,CCn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O
23517,CHEMBL3321845,NHEYHWKFXOLIOV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25082126.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(C2=CC=CC=C21)C(=O)C3=CN=CN=C3OC4=C(C=CC(=C4)Cl)Cl,6.6020599913279625,CN1CCN(C(=O)c2cncnc2Oc2cc(Cl)ccc2Cl)c2ccccc21
23530,CHEMBL2334763,NHJAMHLWORQRFH-XWFZLUIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C[C@@H]4CC[C@H]3N4C5COC5)C(=N2)N6CCOC[C@@H]6C,5.0,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)C[C@@H]2CC[C@H]3N2C2COC2)cc1
23538,CHEMBL3597952,NHPQGZOBHSVTAQ-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26317591.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.,J. Med. Chem.,PUBLICATION,,CC1=CC(=CC(=C1)NC(=O)[C@@H]2CCCN2S(=O)(=O)C3=CC=C(C=C3)OC)C,4.823908740944319,COc1ccc(S(=O)(=O)N2CCC[C@H]2C(=O)Nc2cc(C)cc(C)c2)cc1
23539,CHEMBL3355225,NHQZPUJZMXFCFZ-SDNWHVSQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25393851.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection.",J. Med. Chem.,PUBLICATION,,CCOC1=C(C=CC(=C1)NC(=O)C2(CCC2)NC(=O)C3=CC4=C(C=C3)C(=C(N4C)C5=NC=C(C=N5)Cl)C6CCCC6)/C=C/C(=O)O,4.522878745280337,CCOc1cc(NC(=O)C2(NC(=O)c3ccc4c(C5CCCC5)c(-c5ncc(Cl)cn5)n(C)c4c3)CCC2)ccc1/C=C/C(=O)O
23543,CHEMBL1209694,NHRLPAVZBKIQPV-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)COC(C)C,7.167491087293763,CC(C)OCC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O
23544,CHEMBL1209694,NHRLPAVZBKIQPV-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)COC(C)C,6.920818753952375,CC(C)OCC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O
23561,CHEMBL247428,NHWFUZYIOHEXGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,>,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCN(CC3)CC4=CC5=C(C(=C4)F)OCC(=O)N5C,4.721246399047171,Cc1ccc2c(OCCN3CCN(Cc4cc(F)c5c(c4)N(C)C(=O)CO5)CC3)cccc2n1
23564,CHEMBL1910286,NHXKTRMFQYHBQT-PXJZQJOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)[C@H]3CNCC[C@@]3(C4=CC=CC=C4)O,5.585026652029182,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@]2(O)c2ccccc2)C2CC2)cc(OCCOC)c1
23572,CHEMBL1290150,NIAQGSGCZRZBSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20951036.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CCN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)C5=C(C=C(C=C5)Cl)Cl)C=N2,5.769551078621726,O=c1cc(-c2ccc(Cl)cc2Cl)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
23579,CHEMBL266647,NICHJJOSEXYBED-AMGIVPHBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994683.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor.",J. Med. Chem.,PUBLICATION,,C[C@H](CC1=CC=C(C=C1)Cl)C(=O)N2CCN(CC2)C3=C(C=C(C=C3)Cl)[C@H](CC(C)C)NC(=O)CCN(C)C,5.0,CC(C)C[C@H](NC(=O)CCN(C)C)c1cc(Cl)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1
23580,CHEMBL26150,NICIICGVYGSKJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,26410.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)N(C)C,4.578231598793076,CN(C)c1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C
23582,CHEMBL391056,NIDQERYOGAPSJL-MNNSJKJDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@H](C)CC3=C(C=C(C=C3)Cl)F)[C@H](C(C)C)NC(=O)CCN(C)C,5.1938200260161125,Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3F)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1
23591,CHEMBL1800137,NIFJWDNQUGBNEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21644570.0,IC50,>,8900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP 3A4,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N1CCN2C(=NC(=C2NC3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C1)N,5.050609993355088,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)cc2)C1
23609,CHEMBL213221,NIKRNNCEAFBTLC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16843659.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Identification of novel pyrazole acid antagonists for the EP1 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NN1CC2=C(C=CC(=C2)Br)OCC3=CC=CC=C3)C(=O)O,4.0,Cc1cc(C(=O)O)nn1Cc1cc(Br)ccc1OCc1ccccc1
23617,CHEMBL3234570,NINLJGBDNUJAET-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC(=NC(=C2)N3CCN(CC3)C4COC4)C(F)(F)F)C(=O)NCCC5=CC=C(C=C5)C#N,5.958607314841775,N#Cc1ccc(CCNC(=O)[C@@H]2CCCN(c3cc(N4CCN(C5COC5)CC4)nc(C(F)(F)F)n3)C2)cc1
23620,CHEMBL1945726,NIPDDLFKIMAGDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22196117.0,IC50,=,11800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of triazolopyridazinones as potent p38a inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C(=O)C(=CC2=NN=C(N21)C3=C(C=CC=C3Cl)F)C4=C(C(=CC(=C4)C(=O)NC5CC5)F)C,4.928117992693875,CCn1c(=O)c(-c2cc(C(=O)NC3CC3)cc(F)c2C)cc2nnc(-c3c(F)cccc3Cl)n21
23623,CHEMBL375248,NIQLDGOLJPELPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15566305.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.",J. Med. Chem.,PUBLICATION,,CNC(=O)N1CCN(CC1)CC2=CC(=NC=C2)NC3=NC=C(S3)C#N,4.301029995663981,CNC(=O)N1CCN(Cc2ccnc(Nc3ncc(C#N)s3)c2)CC1
23638,CHEMBL1290155,NISSGJHPJFKJDG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20952195.0,IC50,=,68000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCC2=C1NC3=C2C=CC(=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5,4.167491087293763,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c3c([nH]c2c1)CCNC3
23645,CHEMBL3702787,NIVWMBCQJMTWFL-LFCBDPIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7670.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)OCCCN8CCCCC8,5.115204636051019,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCCN6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
23647,CHEMBL3087041,NIYDALVYCLIMEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C=CC1=NC=CC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,5.346787486224656,C=Cc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
23648,CHEMBL498643,NIYOFXPODJVAGK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,3291.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,COC1=CC=C(C=C1)C2=CC3=C(C=C2)C(CC3)(C4=CC=NC=C4)O,5.482672117705627,COc1ccc(-c2ccc3c(c2)CCC3(O)c2ccncc2)cc1
23658,CHEMBL178330,NJFOVAJRFITZIG-GHXNOFRVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,>,400000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CC=C(O2)/C=N\O,3.3979400086720375,O/N=C\c1ccc(-c2cccnc2)o1
23659,CHEMBL178547,NJFOVAJRFITZIG-KPKJPENVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,>,400000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CC=C(O2)/C=N/O,3.3979400086720375,O/N=C/c1ccc(-c2cccnc2)o1
23661,CHEMBL252836,NJGHOWOIRIXDKZ-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=C(C=CC(=C1F)F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,5.4089353929735005,CC(C)(C)OC(=O)N[C@H](Cc1c(F)ccc(F)c1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
23688,CHEMBL1794074,NJQSZNSQWNSIHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=C2C=CC(=CC2=NN1C)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N.Cl.Cl,4.795880017344075,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C
23689,CHEMBL1794074,NJQSZNSQWNSIHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=C2C=CC(=CC2=NN1C)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N.Cl.Cl,4.508638306165727,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C
23690,CHEMBL1668240,NJQWANVVYVPHJE-KHOMTPLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)[C@@H](C(=O)NC2CCC(CC2)C(=O)O)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,4.301029995663981,O=C(O)C1CCC(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)CC1
23712,CHEMBL1950078,NJVOBGWGMQUPTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=C(C=C4)OC)O)OC,6.698970004336019,COc1ccc(C(O)c2c3cc(OC)cc(C)c3nc3n[nH]c(C)c23)cc1
23713,CHEMBL1950078,NJVOBGWGMQUPTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=C(C=C4)OC)O)OC,5.920818753952375,COc1ccc(C(O)c2c3cc(OC)cc(C)c3nc3n[nH]c(C)c23)cc1
23730,CHEMBL83,NKANXQFJJICGDU-QPLCGJKRSA-N,TAMOXIFEN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,4.522878745280337,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
23738,CHEMBL584261,NKBQZUQMWOWSFW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19683918.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N(N=C1C2=CN(C=N2)C(C)C)C3=CC=CC=C3Cl)C4=CC=C(C=C4)Cl,5.0,Cc1c(-c2cn(C(C)C)cn2)nn(-c2ccccc2Cl)c1-c1ccc(Cl)cc1
23746,CHEMBL3702786,NKFVGWLSONSSEH-UJGAEZNTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5800.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCCN8CCC(CC8)O,5.236572006437063,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCC(O)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
23748,CHEMBL1766171,NKGXIBYLFKGGQB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=CC(=C1)C2=CC=C(C=C2)Cl)(C3=CN=CN3)O,5.619788758288394,CC(C)C(O)(c1cccc(-c2ccc(Cl)cc2)c1)c1cnc[nH]1
23756,CHEMBL506169,NKJTYXXPGXIGTL-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)C,9.096910013008056,CC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
23759,CHEMBL3329684,NKKNQMFHKZEGQU-KQWNVCNZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25089810.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using Vivid OOMR substrate,Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.,Eur. J. Med. Chem.,PUBLICATION,,CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)/C=C\3/C4=C(C=C(C=C4)NC(=O)NC(=O)C5=C(C=C(C=C5)OC)F)NC3=O,5.0,COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]c(C)c(C(=O)NCCN3CCCC3)c2C)c(F)c1
23769,CHEMBL2381936,NKPDQKILCAOJCZ-YDHSSHFGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23701517.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.",J. Med. Chem.,PUBLICATION,,CC1([C@@H](N(C(=O)O1)C2CCC(CC2)NC(=O)C3=C4C(=NC=C3)C=C(C=N4)F)C5=CC=CC=C5)C,4.568636235841013,CC1(C)OC(=O)N(C2CCC(NC(=O)c3ccnc4cc(F)cnc34)CC2)[C@H]1c1ccccc1
23771,CHEMBL3664712,NKQLSIVCYOQHSU-UZTOHYMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CC[C@](OC3=O)(CCCO)C4=CC=C(C=C4)F,4.301029995663981,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O
23774,CHEMBL1631007,NKRSPRREAOOIMI-NSHDSACASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20974532.0,IC50,>,38000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C(F)(F)F)OC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)N2CC3=C(C2)C=C(C=C3)Cl,4.42021640338319,C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(Cl)cc2C1)C(F)(F)F
23776,CHEMBL497747,NKSITFUAIXVDAQ-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CN)N,5.040958607678906,NCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1
23777,CHEMBL1945721,NKSUTIFGDVDLOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22196117.0,IC50,=,25800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of triazolopyridazinones as potent p38a inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=CC4=NN=C(N4N(C3=O)C)C5=C(C=CC=C5Cl)F,4.58838029403677,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1cc2nnc(-c3c(F)cccc3Cl)n2n(C)c1=O
23784,CHEMBL3104250,NKUDGJUBIVEDTF-FYJGNVAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24237195.0,IC50,=,2610.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.",J. Med. Chem.,PUBLICATION,,C/C(=N\NC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCOCC2)/C3=C(C=CC(=C3)Cl)O,5.583359492661719,C/C(=N\NC(=O)c1cccc(S(=O)(=O)N2CCOCC2)c1)c1cc(Cl)ccc1O
23786,CHEMBL3091536,NKUNFNVAHJNALA-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3ß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1N2CCO[C@H](C2)C3=CC=C(C=C3)F)C4=NC=NC=C4,4.301029995663981,Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncn2)cc1=O
23787,CHEMBL3091536,NKUNFNVAHJNALA-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3ß inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1N2CCO[C@H](C2)C3=CC=C(C=C3)F)C4=NC=NC=C4,4.301029995663981,Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncn2)cc1=O
23801,CHEMBL1257138,NKZJSHCNJFDLTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCN(C(=O)C4=C3)CC5CC5,4.301029995663981,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(CC3CC3)C2=O)CC1
23807,CHEMBL1092169,NLFVFVQFPLEKDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20096577.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C(=O)C1=C(C2=CC(=C(N=C2O1)C3=CC=CC=C3Cl)C4=CC=C(C=C4)Cl)NC(=O)CO)O,4.0,CC(C)(O)C(=O)c1oc2nc(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)cc2c1NC(=O)CO
23818,CHEMBL3393472,NLJHGKLCSVZNRM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CNCC3=O)C4=CC=C(O4)SC5=NC6=CC=CC=C6N5.O.Cl,6.769551078621726,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CNC1)C2c1ccc(Sc2nc3ccccc3[nH]2)o1
23825,CHEMBL3401195,NLNMCEXQEHYXBB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25683622.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C(=O)N2C1=NC(=C2)COC3=CC=CC=C3)C4=CC=C(C=C4)F,4.698970004336019,O=C1N(c2ccc(F)cc2)CCc2nc(COc3ccccc3)cn21
23826,CHEMBL271864,NLNSEABQNGLUMD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)N4CCC(CC4)N)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,6.522878745280337,CC(C)c1c(-c2nnc(N3CCC(N)CC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
23845,CHEMBL3092198,NLTKWBJFNLWOOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(C1CCN(CC1)C(=O)C2=C(C=CC(=C2)F)S(=O)(=O)C)S(=O)(=O)C3=CC=CC(=C3)C(F)(F)F,5.0,CC(C)(C1CCN(C(=O)c2cc(F)ccc2S(C)(=O)=O)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1
23867,CHEMBL248849,NMADZMIBEVCFDZ-XLCPLWEUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17855089.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1CNS(=O)(=O)/C=C/C2=CC=C(S2)C3=CC=C(S3)Cl)C(=O)C4CCN(CC4)C5=CC=NC=C5,6.0,O=C(C1CCN(c2ccncc2)CC1)N1CC[C@@H](CNS(=O)(=O)/C=C/c2ccc(-c3ccc(Cl)s3)s2)C1
23868,CHEMBL248849,NMADZMIBEVCFDZ-XLCPLWEUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17855089.0,IC50,=,2330.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1CNS(=O)(=O)/C=C/C2=CC=C(S2)C3=CC=C(S3)Cl)C(=O)C4CCN(CC4)C5=CC=NC=C5,5.632644078973981,O=C(C1CCN(c2ccncc2)CC1)N1CC[C@@H](CNS(=O)(=O)/C=C/c2ccc(-c3ccc(Cl)s3)s2)C1
23872,CHEMBL2387590,NMAXYWKTMNUWHI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)Cl)Cl,4.522878745280337,O=c1[nH]c2cc(Cl)ccc2c2nc(-c3ccccc3Cl)[nH]c12
23885,CHEMBL563055,NMEALLMQARPNTN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2N4CCC(CC4)NCC5CCOCC5,5.301029995663981,COc1ccc(Cn2c(N3CCC(NCC4CCOCC4)CC3)nc3ccccc32)cc1
23898,CHEMBL271120,NMEUHELRRBWEPG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CC1=CN=C(N=C1)CNC2=NC(=NC(=C2)C3=CC=CC=C3)C4=CN=CC=C4,5.017728766960431,Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3cccnc3)n2)nc1
23906,CHEMBL3104486,NMIILRZYAIUZRW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,4.698970004336019,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1
23907,CHEMBL3104486,NMIILRZYAIUZRW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,4.698970004336019,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1
23908,CHEMBL3104486,NMIILRZYAIUZRW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,4.698970004336019,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1
23914,CHEMBL496605,NMKSBEVTNZMDAE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,4.886056647693163,Cc1cccc(C)c1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
23915,CHEMBL496605,NMKSBEVTNZMDAE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,48000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,4.318758762624412,Cc1cccc(C)c1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
23937,CHEMBL1094348,NMNJWRKGTYNGSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,C1OC2=C(O1)C=C(C=C2)C3=CC(=CC(=C3)C4=CC(=CC=C4)F)OCCCCCCC5=C(C(=CC=C5)OCCCC(=O)O)CCC(=O)O,5.1249387366083,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3cccc(F)c3)cc(-c3ccc4c(c3)OCO4)c2)c1CCC(=O)O
23938,CHEMBL2419516,NMNMXZAMLXAEMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=C(CN1C(=O)NCC3=CC=C(C=C3)S(=O)(=O)C4=CN=C(C=C4)N)C=NC=C2,5.0,Nc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
23939,CHEMBL2419516,NMNMXZAMLXAEMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=C(CN1C(=O)NCC3=CC=C(C=C3)S(=O)(=O)C4=CN=C(C=C4)N)C=NC=C2,5.0,Nc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
23945,CHEMBL3401117,NMRFTYLCMLGDQK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3ß inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1N2CCOC(C2)C3CCC3)C4=C(C=NC=C4)F,4.301029995663981,Cn1c(N2CCOC(C3CCC3)C2)nc(-c2ccncc2F)cc1=O
23946,CHEMBL1923124,NMRNERYMRSVGHM-RLWLMLJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=CC=NC3=CC=CC=C23)C(=O)[C@H]4CNCC[C@]45C6=CC(=C(C=C6CO5)F)F,4.508638306165727,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccnc2ccccc12)C1CC1
23948,CHEMBL1236924,NMRWDFUZLLQSBN-UHFFFAOYSA-N,INT131,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C=C(C=N2)OC3=C(C=C(C=C3Cl)NS(=O)(=O)C4=C(C=C(C=C4)Cl)Cl)Cl,4.6020599913279625,O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl
23961,CHEMBL3261407,NMWIJNGJMPMFQG-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755427.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)C)S(=O)(=O)N[C@@H](C)CNC2=C3C=NN(C3=CC=C2)C4=CC=C(C=C4)F)C,5.0,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2ccc(F)cc2)c(C)c1
23962,CHEMBL1288260,NMWLWOOLJCZPEH-ZMBIFBSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,10200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@]1(CCCN(C1)C2=CC3=C(N2CC4=C(C=CC(=C4)F)Cl)C(=O)N(C(=O)N3C)C)N.Cl,4.991399828238082,Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2Cl)n(C)c1=O
23966,CHEMBL1922933,NMYGSMGORGHTCL-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22030028.0,IC50,>,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC[C@@H](CC1=CC=C(C=C1)C(=O)NCCC(=O)O)C(=O)C2=CC3=C(N2C4=CC=CC(=C4)C(F)(F)F)C=CC(=C3)Cl,4.958607314841775,CCCCC[C@@H](Cc1ccc(C(=O)NCCC(=O)O)cc1)C(=O)c1cc2cc(Cl)ccc2n1-c1cccc(C(F)(F)F)c1
23979,CHEMBL1098147,NNBCYIMUIAZCEX-ADSBAMQRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OC[P@]4(=O)OCC[C@H](O4)C5=CC(=CC=C5)OC,6.522878745280337,COc1cccc([C@@H]2CCO[P@@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)c1
23980,CHEMBL1097507,NNBCYIMUIAZCEX-WWOZWPLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OC[P@@]4(=O)OCC[C@H](O4)C5=CC(=CC=C5)OC,6.568636235841013,COc1cccc([C@@H]2CCO[P@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)c1
23986,CHEMBL2178804,NNGCTIVKZKXWGS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,CN1C=C(C(=N1)C2=C(C=CC(=C2)Cl)Cl)NC(=O)C3=C4N=C(C=CN4N=C3)N,5.236572006437063,Cn1cc(NC(=O)c2cnn3ccc(N)nc23)c(-c2cc(Cl)ccc2Cl)n1
23990,CHEMBL593374,NNIFDNQGXRCFDV-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C=C(C=CC2=NN1)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OC[C@H](CC5=CNC6=CC=CC=C65)N,7.0,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2n[nH]c(C)c2c1
24013,CHEMBL3702801,NNTFXIZLDBUGCH-YMJVKMAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,17240.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)C9CCCC9,4.763462738511306,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C7CCCC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
24025,CHEMBL2035185,NNXDIGHYPZHXTR-ONEGZZNKSA-N,CT-1578,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22339472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.",J. Med. Chem.,PUBLICATION,,C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC=C(O4)C5=NC(=NC=C5)NC(=C3)C=C2,5.0,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1
24026,CHEMBL2035185,NNXDIGHYPZHXTR-ONEGZZNKSA-N,CT-1578,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22339472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by fluorescence detection assay,"Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.",J. Med. Chem.,PUBLICATION,,C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC=C(O4)C5=NC(=NC=C5)NC(=C3)C=C2,5.0,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1
24028,CHEMBL3112848,NNXWAJVWAVPAPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=C1C(=CC=C2)F)C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(F)cccc21
24039,CHEMBL3114714,NODXVDNUTZZZMM-APGVRMINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)CC(=O)[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4,6.552841968657781,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC(=O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
24076,CHEMBL521223,NOMOVVSYFDZGOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCC(CC4)O)C,4.698970004336019,CC(=O)Nc1cc(-c2cccc(N3CCC(O)CC3)n2)nc(-n2nc(C)cc2C)n1
24077,CHEMBL3699340,NOOTYVQYKTUNKR-CXNSMIOJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)C8=CC=C(C=C8)N(C)C,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N(C)C)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
24083,CHEMBL3702805,NOQSZIDIAUSSBW-LFCBDPIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3290.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC(CC8)N9CCC9,5.482804102050026,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
24088,CHEMBL2069801,NOTVTROJVYACLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,=,14600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)S(=O)(=O)CC2=NOC(=N2)C(=O)NCC3=CC=NC=C3,4.835647144215563,O=C(NCc1ccncc1)c1nc(CS(=O)(=O)c2ccccc2)no1
24100,CHEMBL284024,NOYHLVPSJIKFBF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,42260.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC(=NC4=C3NC5=C4C=C(C=C5[N+](=O)[O-])[N+](=O)[O-])CN6CCOCC6,4.374070507283705,O=[N+]([O-])c1cc([N+](=O)[O-])c2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)nc(CN4CCOCC4)nc3c2c1
24105,CHEMBL2151821,NPAUEGMLUVJJFP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1C2=CC(=O)NC(=N2)CC(=O)NC3=CC=C(C=C3)F,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cc1
24106,CHEMBL2151923,NPBHHSSAUGKQQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1C2=CC(=O)NC(=N2)CC(=O)NC3=CC(=CC=C3)Br,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Br)c1
24114,CHEMBL1910123,NPDHHSAKDZBURI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCCC3)C4=C(C=C(C=C4)Cl)Cl)CN,4.769551078621726,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCCC1)C2=O
24123,CHEMBL466624,NPGZZLCILZSYOC-KJUCIFOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19289530.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,PUBLICATION,,CN(C/C=C\CN)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)F)O,5.301029995663981,CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](F)[C@@H]1O
24124,CHEMBL443705,NPGZZLCILZSYOC-UNCBZGBMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19289530.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,PUBLICATION,,CN(C/C=C\CN)C[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)F)O,5.301029995663981,CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@@H](F)[C@@H]1O
24136,CHEMBL3702754,NPJQSTPHYKZFBF-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2050.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCC7=CN=C(C=C7)N(C)C,5.688246138944246,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCc5ccc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
24139,CHEMBL1078892,NPKNHWRWDNDLPC-DYESRHJHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CC[C@H](C5)N,4.7447274948966935,Cc1cc(N2CC[C@@H](N)C2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
24141,CHEMBL1078991,NPKNHWRWDNDLPC-LAUBAEHRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,>,4400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CC[C@@H](C5)N,5.356547323513812,Cc1cc(N2CC[C@H](N)C2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
24146,CHEMBL565390,NPLZSLFSOASJNF-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=C(C=C1)C(=O)NC(=N[C@H]2CCCCN(C2=O)CC(=O)N3CCCC3)NC4=CC5=C(C=C4)OC(=C5)C,5.154901959985743,Cc1ccc(C(=O)NC(=N[C@H]2CCCCN(CC(=O)N3CCCC3)C2=O)Nc2ccc3oc(C)cc3c2)cn1
24148,CHEMBL197140,NPPAGUSXMQPYGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,27000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,CC1(CC(CC(C1)(C)C)OC2=CC=C(C=C2)C3=C(C=C(C=C3)C4(CC4)C(=O)O)F)C,4.568636235841013,CC1(C)CC(Oc2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC(C)(C)C1
24152,CHEMBL2178258,NPRMPQSNJGVJOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=NC(=C(S1)NC(=O)C2=C3N=C(C=CN3N=C2)N)C4=CC(=CC=C4)Cl,5.173925197299173,Cc1nc(-c2cccc(Cl)c2)c(NC(=O)c2cnn3ccc(N)nc23)s1
24155,CHEMBL3298908,NPSUKLHLCCMRQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)Cl,4.3979400086720375,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(Cl)cc3)CC2)cc1
24156,CHEMBL498472,NPTCBAGFEZBWJN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,3231.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC(C2=C1C=C(C=C2)C3=CC=C(C=C3)F)(C4=CC=NC=C4)O,5.490663041982356,OC1(c2ccncc2)CCc2cc(-c3ccc(F)cc3)ccc21
24157,CHEMBL497480,NPTYKZWLTCILPL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,4199.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC2=C(C=CC(=C2)C3=CC=C(C=C3)F)C(=C1)C4=CC=NC=C4.Cl,5.37685412536206,Fc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1
24187,CHEMBL2057282,NQEXNUZFXBFSAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22500954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of Novel 1,2,4-Thiadiazole Derivatives as Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)).",J. Med. Chem.,PUBLICATION,,CCC1=C(C=CC=C1C2=NSC(=N2)C3=CC(=C(C=C3)OC(C)C)Cl)CCN4CCC(CC4)C(=O)O,5.0,CCc1c(CCN2CCC(C(=O)O)CC2)cccc1-c1nsc(-c2ccc(OC(C)C)c(Cl)c2)n1
24206,CHEMBL1951612,NQNTUCLHZLYJJD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,>=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC#CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=NC=CC5=CC=CC=C54)C,5.0,CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C
24207,CHEMBL364572,NQPPPAJKEZYMMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,6.3,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)N1C2=C(C=CC(=C2)C3=C(NC(=N3)C4=C(C=CC=C4F)F)C5=CC=CC=C5)N=C1N,8.200659450546418,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3nc(-c4c(F)cccc4F)[nH]c3-c3ccccc3)cc21
24215,CHEMBL3640762,NQVNWLWVULSZAV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1590.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1=CC(=CN=C1)C2=CC=C(S2)N,5.798602875679548,Nc1ccc(-c2cccnc2)s1
24219,CHEMBL429836,NQXTWVRGKUFRQC-SVFBPWRDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCC[C@H]4CO,5.045757490560675,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC[C@H]3CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
24220,CHEMBL241271,NQYWUAZXGFMIIN-UHFFFAOYSA-N,SR-715,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Br)O,5.455931955649724,O=C(C(O)c1ccc(Br)cc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
24229,CHEMBL3628934,NRDAGRURPLJETJ-QVWGJOIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC(C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=C(N=N2)[C@](C)(C(C)C)NCC3=CC4=C(C=C3)N=CS4,6.522878745280337,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncsc3c2)C(C)C)nn1
24249,CHEMBL499589,NRLWTIIVKXPCSZ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CSCC(=O)O)N,4.795880017344075,N[C@@H](Cn1c(=O)c(-c2ccc(CSCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
24252,CHEMBL1092650,NRNPLYWFPSCQAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NC=CN=C3OC,5.0,COc1nccnc1CC1=C(CCN(C)C)Cc2cc(Cl)ccc21
24255,CHEMBL557117,NROVVWMGTIZNGL-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=C(N2C1)C=CC=N3)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.522878745280337,CN([C@@H]1CCc2c(CC(=O)O)c3ncccc3n2C1)S(=O)(=O)c1ccc(F)cc1
24260,CHEMBL1829761,NRQVLVGDMUNLPF-CCLHPLFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CC[C@](OC3=O)(CCCO)C4=CC=CC=C4,4.958607314841775,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O
24262,CHEMBL577338,NRSWHXCLBQLBRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19831396.0,IC50,=,820.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=C(C=C3)O)F,6.086186147616283,Oc1cccc(-c2ccc(-c3ccc(O)c(F)c3)s2)c1
24269,CHEMBL2397347,NRWYEXCPHKZKIR-NOCBQHASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23932792.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,"Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C23CC4CC(C2)CC(C4)C3)C5=C(N=CC=C5)C#N,5.154901959985743,C[C@@H]1CN(c2cccnc2C#N)CCN1C(=O)C12CC3CC(CC(C3)C1)C2
24271,CHEMBL1671921,NRYURYQHEDZXCQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,CC(C)CC(=O)NC1=CC=C(C=C1)C(=O)NC2=NC=CS2,4.3979400086720375,CC(C)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
24276,CHEMBL509267,NSBUNJVFFBYJER-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,42000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)N(C)C)C4=C(C(=CC=C4)OCCCCC(=O)O)F,4.376750709602099,Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(C[C@@H](c2ccccc2)N(C)C)c(=O)n1Cc1c(F)cccc1C(F)(F)F
24280,CHEMBL3127905,NSFZNVJVLSAVRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24428186.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Pharmacological Evaluation of a Novel Series of Pyridopyrazine-1,6-dione ¿-Secretase Modulators.",J. Med. Chem.,PUBLICATION,,CC1=CN(C=N1)C2=CC=C3C(=O)N(CCN3C2=O)CCOC4=C(C=C(C=C4)F)C(F)(F)F,4.522878745280337,Cc1cn(-c2ccc3n(c2=O)CCN(CCOc2ccc(F)cc2C(F)(F)F)C3=O)cn1
24291,CHEMBL3331506,NSLNAFLIDKTSFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,3640.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,C1C(CN1)N(CC2=CC=C(C=C2)Cl)C3=CC=CC=C3F,5.438898616350944,Fc1ccccc1N(Cc1ccc(Cl)cc1)C1CNC1
24295,CHEMBL3639728,NSMOZFXKTHCPTQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320632,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC(=C4)F)OC)F)N=C1,5.301029995663981,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1
24296,CHEMBL3639728,NSMOZFXKTHCPTQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320676,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC(=C4)F)OC)F)N=C1,5.0,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1
24302,CHEMBL462624,NSOFETGRKBREDS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19260711.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.",J. Med. Chem.,PUBLICATION,,C1=CN(C(=O)C(=C1)C(=O)NC2=CC(=C(C=C2)OC3=C(C(=NC=C3)N)Cl)F)C4=CC=C(C=C4)F,5.3979400086720375,Nc1nccc(Oc2ccc(NC(=O)c3cccn(-c4ccc(F)cc4)c3=O)cc2F)c1Cl
24308,CHEMBL2332055,NSPKBHVNVJWICU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23570514.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.",J. Med. Chem.,PUBLICATION,,CC(C)(C)C(=O)NCCC1CCN(CC1)C2=NC=NC3=C2SC(=C3)C(=O)N,4.301029995663981,CC(C)(C)C(=O)NCCC1CCN(c2ncnc3cc(C(N)=O)sc23)CC1
24310,CHEMBL3702728,NSRQJAWPJAFMQG-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5990.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CC(C7)N8CCOCC8,5.2225731776106885,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCOCC6)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
24327,CHEMBL513868,NTBRVXRWQHXTKZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18632268.0,IC50,=,410.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC(=C1)Cl)OC2=C3C(=CC(=C2)CC4=NNC(=O)C=C4)C=CO3,6.3872161432802645,O=c1ccc(Cc2cc(Oc3cccc(Cl)c3)c3occc3c2)n[nH]1
24341,CHEMBL1287846,NTIFEVGVXWYYHK-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074434.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC2=C1N(C=C2C(=O)N3CCN4CCCC[C@H]4C3)CC5CCCCC5,5.221848749616356,COc1cccc2c(C(=O)N3CCN4CCCC[C@H]4C3)cn(CC3CCCCC3)c12
24358,CHEMBL118258,NTPLIHVIDFWRGV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177482.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC(CC1)(C2=CN(C(=N2)C3=CC(=CC=C3)C(F)(F)F)C4=NC(=NC=C4)NC5CCCC5)O,5.698970004336019,CN1CCC(O)(c2cn(-c3ccnc(NC4CCCC4)n3)c(-c3cccc(C(F)(F)F)c3)n2)CC1
24369,CHEMBL2043324,NTUAWRQDBAVJLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)F,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4F)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
24375,CHEMBL375812,NTVBAWSNQRKVKF-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17274610.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.",J. Med. Chem.,PUBLICATION,,C1CCC2=C(C1)N=C(S2)C3=CC=C(C=C3)OCCCOC4=CC5=C(C=C4)[C@@H](CC5)CC(=O)O,5.0,O=C(O)C[C@@H]1CCc2cc(OCCCOc3ccc(-c4nc5c(s4)CCCC5)cc3)ccc21
24382,CHEMBL3407821,NTYRNOKRWWTRNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25489882.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,"Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.",J. Med. Chem.,PUBLICATION,,CC1=CN=CN1C2=NC=CC(=N2)CCNCCCC3=CC(=CC=C3)F.Cl,6.045757490560675,Cc1cncn1-c1nccc(CCNCCCc2cccc(F)c2)n1
24384,CHEMBL236732,NUALMFMLNXDIHK-AZGAKELHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N,6.657577319177793,CC(C)C[C@H](N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
24385,CHEMBL3702708,NUBFJAZVCPPPLP-HNNLUAMWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6600.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN8CCCC8C7,5.180456064458132,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCCC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
24389,CHEMBL2165509,NUEWJDROHKEDES-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2N1)C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCN(CC6)C(C)(C)C(=O)N,7.0,Cc1cc2c(-c3nc(N4CCOCC4)c4sc(CN5CCN(C(C)(C)C(N)=O)CC5)cc4n3)cccc2[nH]1
24401,CHEMBL3401116,NUIXEUAEKRDSJR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3ß inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC1CN(CCO1)C2=NC(=CC(=O)N2C)C3=C(C=NC=C3)F,4.301029995663981,CCCCC1CN(c2nc(-c3ccncc3F)cc(=O)n2C)CCO1
24425,CHEMBL3261425,NUUMMLYSKRRLTQ-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755427.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NN1C2CCCC2)C)S(=O)(=O)N[C@@H](C)CNC3=C4C=NN(C4=CC=C3)C5=CN=C(C=C5)F,4.657577319177793,Cc1nn(C2CCCC2)c(C)c1S(=O)(=O)N[C@@H](C)CNc1cccc2c1cnn2-c1ccc(F)nc1
24426,CHEMBL496426,NUUQKRDJXWZEIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CC=CO4,5.823908740944319,Cc1cccc(C)c1CNc1cc(-c2ccco2)cn2c(C)c(C)nc12
24427,CHEMBL496426,NUUQKRDJXWZEIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CC=CO4,5.7447274948966935,Cc1cccc(C)c1CNc1cc(-c2ccco2)cn2c(C)c(C)nc12
24428,CHEMBL205692,NUWCFGTWEDHTKQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,C1CN(CCC1NC(=O)CC2=CC=CC=C2)CC3=CC(=CC=C3)OC4=CC=CC=C4,5.0,O=C(Cc1ccccc1)NC1CCN(Cc2cccc(Oc3ccccc3)c2)CC1
24433,CHEMBL240889,NVABFHSNHQWIJY-IBGZPJMESA-N,SR-1452,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)[C@H](CC4=CC=CC=C4)N,6.0,N[C@@H](Cc1ccccc1)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
24434,CHEMBL1921982,NVALCPKQWJAPMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,CCNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O,5.0,CCNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
24437,CHEMBL2420676,NVDJGCDUAXDWHH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,1262.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=C(C3=C(C=CC(=C3)O)C=C2)F,5.898940645091884,Oc1ccc2ccc(-c3cccnc3)c(F)c2c1
24438,CHEMBL2425958,NVEBAMFLYZFKKW-CSKARUKUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23905680.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using Vivid BOMR as substrate,Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.,J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=CC(=C2)/C=C/C(=O)NO)C(=O)N1CCC3=CC=CC=C3,5.187086643357144,Cc1nc2cc(/C=C/C(=O)NO)ccc2c(=O)n1CCc1ccccc1
24454,CHEMBL2448693,NVHVFITXPIZHCV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1=CC=C(C=C1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4C(=O)N3CC5=CN=CC=C5,4.698970004336019,O=c1c2ccccc2nc(-c2ccc(-c3ccccc3)cc2)n1Cc1cccnc1
24455,CHEMBL2386079,NVIBILUEGHHNNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CC2=C1N(C3=CC=CC=C23)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54,4.301029995663981,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1cccc3ccccc13)CC2
24464,CHEMBL253660,NVLCLKSNVBSVHX-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1OC(F)(F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,5.886056647693163,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1OC(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
24465,CHEMBL2181896,NVMABPBDYKXNKD-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)C[C@@H]2NC[C@H]([C@H](CC4=CC(=CC=C4)C#C)NC(=O)COC)O,7.522878745280337,C#Cc1cccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)c1
24477,CHEMBL2436626,NVORSIAIADQRIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2CCNC3=CC=CC=C3C2)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,4.522878745280337,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCNc5ccccc5C4)CC3)CC2)ccn1
24480,CHEMBL2035186,NVQBQWBWTJVBDD-ONEGZZNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22339472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.",J. Med. Chem.,PUBLICATION,,C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC(=CO4)C5=NC(=NC=C5)NC(=C3)C=C2,5.0,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2coc(c2)COC/1
24483,CHEMBL2420675,NVRWXGKJXOBEQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)C=CC(=C2F)C3=CN=CC=C3,5.0,COc1ccc2ccc(-c3cccnc3)c(F)c2c1
24486,CHEMBL453246,NVTYARUVRYHLSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=N4,5.6777807052660805,Cc1cccc(C)c1CNc1cc(-n2cccn2)cn2c(C)c(C)nc12
24487,CHEMBL453246,NVTYARUVRYHLSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=N4,5.5376020021010435,Cc1cccc(C)c1CNc1cc(-n2cccn2)cn2c(C)c(C)nc12
24490,CHEMBL2058904,NVWBTVGTFCSKEI-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,52.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)C,7.2839966563652006,Cc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
24516,CHEMBL430724,NWGCADAPGOPMCR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,17850.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=NC=C2)C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,4.748361779551788,Cn1c2ccncc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
24542,CHEMBL3092419,NWLPPUYKURFGOD-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)C3=CC4=NC=NN4C=C3)F,4.698970004336019,CC(=O)NC[C@H]1CN(c2ccc(-c3ccn4ncnc4c3)c(F)c2)C(=O)O1
24551,CHEMBL3112854,NWRXYTMCKVBTKP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=C1C(=CC=C2)OC(F)(F)F)C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(OC(F)(F)F)cccc21
24580,CHEMBL3114728,NXFTYHPDFHJIBT-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,1840.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N2CCC(CC2)NC(=O)OCC3=CN=CS3,5.735182176990463,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N2CCC(NC(=O)OCc3cncs3)CC2)C(C)C)cs1
24599,CHEMBL1671922,NXJOSCHYVJGECZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC(=O)NC1=CC=C(C=C1)C(=O)NC2=NC=CS2,4.3979400086720375,CC(C)(C)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
24600,CHEMBL256195,NXJWRSVRPJAYKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)OCC(C)N)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,4.3979400086720375,CC(N)COc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1
24609,CHEMBL1209016,NXOJBDCDDRAJDO-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)CCN6CCN(CC6)C)C(=O)N,6.698970004336019,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
24610,CHEMBL1209016,NXOJBDCDDRAJDO-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)CCN6CCN(CC6)C)C(=O)N,5.721246399047171,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
24612,CHEMBL2070149,NXOWVMXRWKZXSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=C3Cl)C4=CC=CC=C4,5.42021640338319,CCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)c3Cl)[nH]c2c1
24615,CHEMBL1087758,NXPLYKRKIFPEOA-BLLLJJGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,56.23,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as ratio of IC50 at 0 mins to IC50 at 10 mins using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1C[C@@H]1CN2C(=C(C3=CN=NC(=C32)OCC4=CC=C(C=C4)F)C)C,7.250031916490597,Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12
24616,CHEMBL1087758,NXPLYKRKIFPEOA-BLLLJJGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1C[C@@H]1CN2C(=C(C3=CN=NC(=C32)OCC4=CC=C(C=C4)F)C)C,5.221848749616356,Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12
24617,CHEMBL1087758,NXPLYKRKIFPEOA-BLLLJJGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1C[C@@H]1CN2C(=C(C3=CN=NC(=C32)OCC4=CC=C(C=C4)F)C)C,4.853871964321762,Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12
24623,CHEMBL1276678,NXWASIVXQMMPLM-ZXMXYHOLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CN[C@@H](C[C@H]1CCCOC1)CNC(=O)N2CCC[C@H](C2)[C@H](C3=CC(=CC=C3)Cl)OCCNC(=O)OC,4.522878745280337,CN[C@H](CNC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1)C[C@H]1CCCOC1
24626,CHEMBL2041186,NYAAHHZTIZKYSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CN=C4C)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3nccnc3C)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1
24629,CHEMBL1916224,NYDGEZQQIMDHCY-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21930376.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Development of a highly selective, orally bioavailable and CNS penetrant M(1) agonist derived from the MLPCN probe ML071.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)N1CCC(CC1)N2CCC[C@H](C2)NC(=O)C3=CC=CC=C3C,4.6020599913279625,CCOC(=O)N1CCC(N2CCC[C@@H](NC(=O)c3ccccc3C)C2)CC1
24646,CHEMBL3673935,NYJZMHUFDZQMKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320638,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=C(C=C(C=N1)F)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl,5.0,COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(Cl)cc23)cn1
24647,CHEMBL3673935,NYJZMHUFDZQMKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320682,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=C(C=C(C=N1)F)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl,5.0,COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(Cl)cc23)cn1
24667,CHEMBL564920,NYOPRXQTXYICBQ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C1)N3C=CC=CC3=C2CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.522878745280337,CN([C@@H]1CCc2c(CC(=O)O)c3ccccn3c2C1)S(=O)(=O)c1ccc(F)cc1
24676,CHEMBL3702813,NYWLSHWADDPCKK-YMJVKMAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2560.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CC(C8)N9CCC(CC9)OC,5.59176003468815,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(N7CCC(OC)CC7)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
24678,CHEMBL1277126,NYWUAMYWDNANQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,C1CC2(CC1N3CCC(=CC3)C(=O)O)CC4=CC=CC=C4OC5=CC=CC=C25,5.0,O=C(O)C1=CCN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)CC1
24695,CHEMBL3353347,NZBZBQUHFXSFOR-VXPCJWDYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC=C(C=C1)/C=C/C2=NNC3=C2C=CC(=C3)[C@@H]4C[C@]45C6=CC=CC=C6NC5=O,5.0,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1
24696,CHEMBL3353347,NZBZBQUHFXSFOR-VXPCJWDYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC=C(C=C1)/C=C/C2=NNC3=C2C=CC(=C3)[C@@H]4C[C@]45C6=CC=CC=C6NC5=O,5.301029995663981,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1
24697,CHEMBL3353347,NZBZBQUHFXSFOR-VXPCJWDYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC=C(C=C1)/C=C/C2=NNC3=C2C=CC(=C3)[C@@H]4C[C@]45C6=CC=CC=C6NC5=O,5.0,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1
24733,CHEMBL2165500,NZLCSWCXKHCYFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CCC1=NC2=CC=CC=C2N1C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCN(CC6)S(=O)(=O)C,5.0,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(S(C)(=O)=O)CC3)cc2n1
24744,CHEMBL16596,NZOONKHCNQFYCI-UHFFFAOYSA-N,QUIFLAPON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,=,5.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)O,8.236572006437063,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12
24746,CHEMBL16596,NZOONKHCNQFYCI-UHFFFAOYSA-N,QUIFLAPON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19914828.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)O,5.2839966563652006,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12
24755,CHEMBL270361,NZSRSKNDCCSSGY-KAVGSWPWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,64900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)/C=C\2/C(=O)/C(=C/C3=CC(=C(C=C3)O)OC)/CC2)O,4.187755303199631,COc1cc(/C=C2\CC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O
24756,CHEMBL270361,NZSRSKNDCCSSGY-KAVGSWPWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,64863443.35,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)/C=C\2/C(=O)/C(=C/C3=CC(=C(C=C3)O)OC)/CC2)O,1.188000000032298,COc1cc(/C=C2\CC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O
24759,CHEMBL253968,NZUICIGFUCOURS-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18294849.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@@H](N(C1)CCCOC2=CC3=CN=NC(=C3C=C2)NC4=CN(N=C4)CC(=O)NC5=C(C(=CC=C5)F)F)CO,5.0,O=C(Cn1cc(Nc2nncc3cc(OCCCN4CCC[C@@H]4CO)ccc23)cn1)Nc1cccc(F)c1F
24767,CHEMBL2409710,NZWCKNGEMCPIOP-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810497.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Hydantoin based inhibitors of MMP13-Discovery of AZD6605.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@]1(C(=O)NC(=O)N1)CS(=O)(=O)N2CCC(CC2)OC3=CC=C(C=C3)C(F)(F)F,4.3979400086720375,C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(C(F)(F)F)cc3)CC2)NC(=O)NC1=O
24776,CHEMBL522211,NZZBOICLIUBLLK-MJGOQNOKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2(CCN(CC2)C(=O)N[C@H]3C[C@@H]3C4=CC=CC=C4)OC5=C1N=CC=C5,5.0,O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3ncccc3O2)CC1
24796,CHEMBL3422241,OAFBAMRSEZLVDJ-CKMNQQOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,C[C@@H]1[C@@H]2C[C@@H](OC[C@@]2(N=C(S1)N)C3=C(C=C(C=C3)F)F)C4=NC(=CO4)C,4.522878745280337,Cc1coc([C@H]2C[C@H]3[C@@H](C)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1
24797,CHEMBL2086755,OAFIHAHWHDARSB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=C3C(=C4N=C5C=CC=CC5=N4)C6=CC=C(C=C6)OC)O,5.045757490560675,CCN1CCC(Nc2ccc3[nH]c(O)c(C(=C4N=c5ccccc5=N4)c4ccc(OC)cc4)c3c2)CC1
24801,CHEMBL3359024,OAIRCWVKNKXXQY-XYYAHUGASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25210858.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2CN(C[C@@H]2CC1C3=CC=CC=C3C(F)(F)F)C(=O)NC4=CN=NC=C4C(=O)O,4.920818753952375,O=C(O)c1cnncc1NC(=O)N1C[C@H]2CC(c3ccccc3C(F)(F)F)C[C@H]2C1
24808,CHEMBL3408526,OAMJWPLGTPOCHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,CCOC1(C2=NOC(=O)N2C3=CC=CC=C3S1)C4=CC=C(C=C4)Br,4.698970004336019,CCOC1(c2ccc(Br)cc2)Sc2ccccc2-n2c1noc2=O
24809,CHEMBL3408526,OAMJWPLGTPOCHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,CCOC1(C2=NOC(=O)N2C3=CC=CC=C3S1)C4=CC=C(C=C4)Br,4.698970004336019,CCOC1(c2ccc(Br)cc2)Sc2ccccc2-n2c1noc2=O
24810,CHEMBL3582478,OAMLIJKKGZLNHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26005536.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=CN=CC(=C1)C2=NC3=C(N2C4CC4)C=C(C=C3)F)O,4.301029995663981,CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1
24817,CHEMBL1910115,OAPPTAHHCBBEDY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N)C3=C(C=C(C=C3)Cl)Cl)CN,4.769551078621726,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(N)=O)C2=O
24818,CHEMBL389608,OAQMOBFXPMYRII-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)C5=CN=CC=C5)N(C2=O)CC6=CC=CC=C6F,5.958607314841775,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cccnc5)cc4)CC3)C2=O)c1
24828,CHEMBL3357391,OAYGNQGEUIFBFA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25499880.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)CC1=NC2=C(N1CCN(C)C)C=CC(=C2)S(=O)(=O)C3CN(C3)CCO,5.522878745280337,CN(C)CCn1c(CC(C)(C)C)nc2cc(S(=O)(=O)C3CN(CCO)C3)ccc21
24833,CHEMBL1671971,OBBIOCQFTMNSJI-PXNMLYILSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)/C=C\2/C(=O)NC(=O)S2)OC3=C(C=C(C=C3)C#N)C(F)(F)F,5.0,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C#N)cc1C(F)(F)F
24834,CHEMBL387552,OBBPMZQSYHHZLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,C1CC(CN(C1)C2=NC3=C(C=CC=C3Cl)C(=O)N2CC4=CC=CC=C4C#N)N,6.886056647693163,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2c(Cl)cccc2c1=O
24850,CHEMBL1643512,OBKCQTGBMZHBFE-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21095126.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C2=CC=CC=C2[C@@H]1N)C3=CC(=C(C=C3)Cl)Cl,4.6020599913279625,N[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
24854,CHEMBL579200,OBMNRUUTVNRXAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=C(C(=C3)OC)OC)OC,5.721246399047171,COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1OC
24873,CHEMBL3120505,OBULGMCFXOTNNK-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,CCC1=CC2=C(C=C1F)C(=C(N2C3=NC=CC=N3)C4=NC=C(C=C4)S(=O)(=O)N[C@@H](C)C(F)(F)F)C#N,5.0,CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccn1
24879,CHEMBL80702,OBXLXUGOZZWQOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CN2C3=CC=CC4=C3C=C(C=C4)OC5=C(C=CC(=C5)CN6C=NC=C6CCNC1C2=O)C#N,6.221848749616356,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCCc3cncn3C2)C1=O
24880,CHEMBL80702,OBXLXUGOZZWQOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CN2C3=CC=CC4=C3C=C(C=C4)OC5=C(C=CC(=C5)CN6C=NC=C6CCNC1C2=O)C#N,5.221848749616356,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCCc3cncn3C2)C1=O
24881,CHEMBL3702717,OBYFMRYTDUFAQC-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4970.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)C(=O)N(C)CCN(C)C,5.303643611266668,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(C(=O)N(C)CCN(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
24882,CHEMBL1269683,OBZVMSKEVPNTKM-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCC(=O)NC)Cl)C5CC5)Cl,5.5376020021010435,CNC(=O)CCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
24883,CHEMBL1269683,OBZVMSKEVPNTKM-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCC(=O)NC)Cl)C5CC5)Cl,5.050609993355088,CNC(=O)CCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
24888,CHEMBL277535,OCAPBUJLXMYKEJ-UHFFFAOYSA-N,BIFONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,800.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=CC=C3)N4C=CN=C4,6.096910013008056,c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1
24900,CHEMBL3128180,OCDCTMROVJZCQS-FBHSLPMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24437735.0,IC50,=,41800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective ß3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(S1)CC[C@H]2C(=O)NC3=CC=C(C=C3)C[C@@H]4CC[C@@H](N4)[C@@H](C5=CN=CC=C5)O,4.3788237182249645,Cc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1
24912,CHEMBL2048061,OCEZDSXYNMWVGV-AZOIQLNYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,9200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ß-peptides.,J. Med. Chem.,PUBLICATION,,C1[C@H]([C@@H]([C@H](CS1(=O)=O)NCC2=CC(=CC=C2)OC(F)(F)F)O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,5.036212172654444,Nc1c(F)cc(C[C@@H]2CS(=O)(=O)C[C@H](NCc3cccc(OC(F)(F)F)c3)[C@H]2O)cc1OC(C(F)(F)F)C(F)(F)F
24919,CHEMBL3325526,OCGIYHGXHMLCPX-UKRRQHHQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25176194.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNC[C@@H]([C@H]1C2=CC=C(C=C2)Cl)COC3=CC(=C(C=C3F)S(=O)(=O)NC4=NC=NS4)F,6.823908740944319,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@H]2CNCC[C@@H]2c2ccc(Cl)cc2)cc1F
24925,CHEMBL2059123,OCHINVHFVKJXGW-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,92.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCN(CC5)C,7.036212172654444,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCN(C)CC3)oc2c1
24926,CHEMBL3236362,OCIDJOZAAORGQC-RRYSNUMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1[C@@H]([C@H](C[C@](C1=O)(C)CC(=O)CO)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,6.154901959985743,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(=O)CO)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
24927,CHEMBL281326,OCIIEYOWWOUETK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,18480.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)NCC6=CC=CC=N6,4.733298033115912,Cn1c2ccnc(NCc3ccccn3)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
24929,CHEMBL600058,OCJFISAERVJZBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153655.0,IC50,=,97000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC,Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway.,Bioorg. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1C)N(C(=N2)NCCCOC)CC(=O)C3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C,4.013228265733755,COCCCNc1nc2cc(C)c(C)cc2n1CC(=O)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
24930,CHEMBL1214447,OCJKHBCJMIOPJS-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC1=NC=C(C=C1)C2=CC3=C(C[C@@H](C3)NS(=O)(=O)C(C)C)C=C2,5.0,Cc1ccc(-c2ccc3c(c2)C[C@@H](NS(=O)(=O)C(C)C)C3)cn1
24931,CHEMBL1214397,OCJKHBCJMIOPJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC1=NC=C(C=C1)C2=CC3=C(CC(C3)NS(=O)(=O)C(C)C)C=C2,5.0,Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)cn1
24939,CHEMBL3408192,OCKDTDFLJPUWIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25680029.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.",J. Med. Chem.,PUBLICATION,,C1CNC(=O)C12CCN(CC2)C3=C(C=NC=C3C4=CC=C(C=C4)N5CCOCC5)Cl,5.6777807052660805,O=C1NCCC12CCN(c1c(Cl)cncc1-c1ccc(N3CCOCC3)cc1)CC2
24949,CHEMBL2425161,OCMTUPKQSOGIPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CN=C(C=C4)OCC5=CC=CC=C5,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(OCc4ccccc4)nc3)cc2)cc1
24950,CHEMBL482088,OCNLJCSEDBMGNF-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.9,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)OCCOC,9.045757490560675,COCCOC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
24957,CHEMBL1214739,OCQPVXWUPNNJIV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,1140.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC4=C(C=C3)C=C(C=C4)O,5.943095148663527,Oc1ccc2cc(-c3ccc(Cc4ccncc4)cc3)ccc2c1
24969,CHEMBL271624,OCSFKRCNTJAHRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CCN1C(=NN=C1SCC2=CC=C(C=C2)OC)C3=CC=NC=C3,4.552841968657781,CCn1c(SCc2ccc(OC)cc2)nnc1-c1ccncc1
24986,CHEMBL3702694,OCZUEDNFZLWPEY-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9120.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCOC,5.0400051616715835,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCOC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
25013,CHEMBL1485,ODKSFYDXXFIFQN-BYPYZUCNSA-N,ARGININE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C(C[C@@H](C(=O)O)N)CN=C(N)N,5.0,NC(N)=NCCC[C@H](N)C(=O)O
25014,CHEMBL1485,ODKSFYDXXFIFQN-BYPYZUCNSA-N,ARGININE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C(C[C@@H](C(=O)O)N)CN=C(N)N,5.0,NC(N)=NCCC[C@H](N)C(=O)O
25036,CHEMBL2181897,ODTHBEGKDAPUFY-HZFUHODCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC#CC1=CC=CC(=C1)C[C@@H]([C@@H](CN[C@H]2CC3(CCC3)OC4=C2C=C(C=N4)CC(C)(C)C)O)NC(=O)COC,7.522878745280337,CC#Cc1cccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)c1
25045,CHEMBL476762,ODVRVGNZEWQPJY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)CC(=O)NCC(=O)NC(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,4.301029995663981,O=C(Cc1ccccc1)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1
25051,CHEMBL452808,ODYPAHVIPOBHBB-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@H](CN1CCOCC1)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)CN4C(=O)COC5=CC(=C(C=C54)Cl)Cl,5.376750709602099,CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)[C@H](CN1CCOCC1)c1ccc(-c2ccccc2)cc1
25052,CHEMBL453075,ODYPAHVIPOBHBB-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H](CN1CCOCC1)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)CN4C(=O)COC5=CC(=C(C=C54)Cl)Cl,5.040958607678906,CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)[C@@H](CN1CCOCC1)c1ccc(-c2ccccc2)cc1
25053,CHEMBL453074,ODYPAHVIPOBHBB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C(CN1CCOCC1)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)CN4C(=O)COC5=CC(=C(C=C54)Cl)Cl,5.337242168318426,CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1
25069,CHEMBL495882,OEBZYYGQPIDGKZ-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CO)N,6.096910013008056,N[C@@H](Cn1c(=O)c(-c2ccc(CO)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
25072,CHEMBL2018915,OEFRKYNZBGSTRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,>,80.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=CC=C3,7.096910013008056,COc1ccc2nc(SCc3ccccc3)[nH]c2c1
25081,CHEMBL1209015,OENQIJZSDDCZNC-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)CCN6CCOCC6)C(=O)N,5.6777807052660805,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
25090,CHEMBL2331689,OESWUISVDCHYDK-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4=NC(=NC=C4)C)C(=N2)N5CCOC[C@@H]5C,5.481486060122113,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ccnc(C)n2)C3)cc1
25091,CHEMBL2336411,OEUDGDKDYOXFHU-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=NNN=C12)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.136677139879544,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2n[nH]nc12
25092,CHEMBL2336411,OEUDGDKDYOXFHU-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=NNN=C12)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.3979400086720375,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2n[nH]nc12
25105,CHEMBL2181618,OEYHZQYPYDAJBL-QGOAFFKASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=CC=CC=N5)C6CCCC6,5.200659450546418,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21
25112,CHEMBL3359272,OEYYOVRNPJSWTO-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25423411.0,IC50,=,10100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM).",J. Med. Chem.,PUBLICATION,,CC(C)N1CCC[C@H]1CNC(=O)C2=CN(C(=O)C3=C2C4=CC=CC=C4N3C)C5CCCC5,4.995678626217358,CC(C)N1CCC[C@H]1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C
25129,CHEMBL1467,OFCNXPDARWKPPY-UHFFFAOYSA-N,ALLOPURINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=NNC2=C1C(=O)NC=N2,5.0,O=c1[nH]cnc2[nH]ncc12
25130,CHEMBL1467,OFCNXPDARWKPPY-UHFFFAOYSA-N,ALLOPURINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=NNC2=C1C(=O)NC=N2,5.0,O=c1[nH]cnc2[nH]ncc12
25137,CHEMBL2425602,OFDBSOZDYKJEFG-CAALGAHQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=CC=CC(=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F)O,5.619788758288394,COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)O)c3)[C@H]2O)cc(F)c1N)C(F)(F)F
25139,CHEMBL179763,OFDVABAUFQJWEZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,64700.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CN=CC=C2,4.189095719331299,c1cncc(-c2cccnc2)c1
25141,CHEMBL522196,OFEDZXBACHVRIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C=C5)F)F,5.1938200260161125,COc1ccc2c(OCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1
25142,CHEMBL522196,OFEDZXBACHVRIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C=C5)F)F,4.301029995663981,COc1ccc2c(OCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1
25173,CHEMBL391914,OFNOTFBPXMBPPC-AZGAKELHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=CC=CC=C1N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N,6.920818753952375,CC(C)C[C@H](N)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
25220,CHEMBL519761,OFWDHNGVKNRLFY-LHZKXVGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,14400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)OC(=O)C)OC(=O)C)OC(=O)C,4.841637507904751,CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O
25247,CHEMBL399512,OGFXBIXJCWAUCH-KPHUOKFYSA-N,ISOLARICIRESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,COC1=C(C=C2[C@@H]([C@H]([C@@H](CC2=C1)CO)CO)C3=CC(=C(C=C3)O)OC)O,4.0,COc1cc([C@H]2c3cc(O)c(OC)cc3C[C@@H](CO)[C@@H]2CO)ccc1O
25260,CHEMBL9,OGJPXUAPXNRGGI-UHFFFAOYSA-N,NORFLOXACIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,4.301029995663981,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21
25266,CHEMBL1784355,OGLLJVIOQHNPQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)(CS(=O)(=O)N2CCN(CC2)C3=CC=C(C=C3)F)N(C=O)O,5.721246399047171,O=CN(O)C1(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)CCC1
25281,CHEMBL1669416,OGQADGYHVAQLNE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,1405.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CC1(F)F)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,5.8523236757589014,FC1(F)CCN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
25282,CHEMBL3087348,OGQIHASBDUUYTP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=COC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,4.886056647693163,O=S(=O)(Nc1ccc(-c2ccco2)cc1)c1cc(Cl)cc(Cl)c1
25289,CHEMBL3236365,OGTCBKWJBDPSAX-PAHOUZJPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CS(=O)(=O)N,6.301029995663981,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CS(N)(=O)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
25290,CHEMBL1669409,OGTGPRXXTIEASF-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC#N,5.0,C[C@H](C1=C(CCN(C)CC#N)Cc2ccccc21)c1cnccn1
25355,CHEMBL395426,OHOPDRRPSWGLIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276063.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(C(CN1C2=NC=NC(=C2)C3=CSC=C3)N)C4=CC(=C(C=C4F)F)F,5.0,NC1CN(c2cc(-c3ccsc3)ncn2)CC1c1cc(F)c(F)cc1F
25356,CHEMBL1643789,OHOXPFJGCQEEJL-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106375.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2=C(C3=CC=CC=C3N2C[C@@H]1N(CC4=CC=C(C=C4)F)S(=O)(=O)C5=CC=C(C=C5)F)CC(=O)O,4.301029995663981,O=C(O)Cc1c2n(c3ccccc13)C[C@H](N(Cc1ccc(F)cc1)S(=O)(=O)c1ccc(F)cc1)CC2
25385,CHEMBL440964,OIEZHHIBUVJWBU-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)N[C@@H](CC4=CC=CC=C4)CO)C5=CC=C(C=C5)OC,5.167491087293763,COc1ccc(-c2cc(C)c3nc(-c4c(N[C@H](CO)Cc5ccccc5)cc[nH]c4=O)[nH]c3c2)cc1
25387,CHEMBL3640785,OIFZZHGYNVANQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,400000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1=CC(=CN=C1)C2=CC=C(O2)CN=O,3.3979400086720375,O=NCc1ccc(-c2cccnc2)o1
25393,CHEMBL519549,OIGKTTFTKCPYQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)OC)C3=CC(=CN=C3)OC)C,4.795880017344075,COC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1
25403,CHEMBL1171786,OIGUMNDUYFBXEM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20627722.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)C(=O)O)OC2=C(C=C(C=C2)Cl)NS(=O)(=O)C3=CC(=C(C=C3)Cl)Cl,5.0,O=C(O)c1ccccc1Oc1ccc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1
25428,CHEMBL209350,OIZAFWVARZBXFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,CCN1CCC(CC1)(C2=CC=CC=C2)C(=O)NC3CCN(CC3)CC4=CC(=CC=C4)OC5=CC=CC=C5OC,5.0,CCN1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4OC)c3)CC2)(c2ccccc2)CC1
25450,CHEMBL2069844,OJEKLVGMWTUETI-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ß-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)C(=O)O,6.0,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(C(=O)O)cc2)CC1)Cc1cc(F)c(F)cc1F
25456,CHEMBL1778387,OJEQIOOQKHUSKG-CRAIPNDOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21515053.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=C(C=C1)F)C(=O)N(C)[C@@H]2CCC3=C(C4=CC=CC=C4N3C2)CC(=O)O,4.301029995663981,C[C@@H](C(=O)N(C)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)c1ccc(F)cc1
25459,CHEMBL3104525,OJFZYAQGMWSUID-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)[C@H](C3=CC=C(C=C3)Cl)C4=CN=CC=C4,4.769551078621726,O=C([C@H](c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
25460,CHEMBL3104526,OJFZYAQGMWSUID-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)[C@@H](C3=CC=C(C=C3)Cl)C4=CN=CC=C4,4.823908740944319,O=C([C@@H](c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
25461,CHEMBL3104376,OJFZYAQGMWSUID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,4.795880017344075,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
25462,CHEMBL3104376,OJFZYAQGMWSUID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1200.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,5.920818753952375,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
25463,CHEMBL3104376,OJFZYAQGMWSUID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7400.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,5.130768280269024,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
25464,CHEMBL3104376,OJFZYAQGMWSUID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,4.698970004336019,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
25468,CHEMBL3298910,OJICYBSWSZGRFB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)OC(F)(F)F,4.0,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1
25489,CHEMBL398584,OJPCZEDCYHLAEY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C4=CC(=CC(=C4)F)F,6.0655015487564325,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2
25490,CHEMBL3326580,OJPHAHBZLDUZLU-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CCCC1(C[C@H](C2=C(O1)C(=CC=C2)F)NC(=O)NC3=CC=CC4=C3C=C(N=C4)C)CCC,4.698970004336019,CCCC1(CCC)C[C@@H](NC(=O)Nc2cccc3cnc(C)cc23)c2cccc(F)c2O1
25513,CHEMBL2418359,OJVHRVLPSCDXSQ-CALCHBBNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23932792.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,"Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC2(C1)CCN(C2)C(=O)N3C[C@H]4CN(C[C@H]4C3)C5=CC=CC=N5,4.522878745280337,O=C(N1C[C@@H]2CN(c3ccccn3)C[C@@H]2C1)N1CCC2(CCCC2)C1
25524,CHEMBL502908,OKAPKQMESLLPQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18855374.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,"Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).",J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)O)C2=CC=C(C=C2)C3=CC(=CC=C3)O,5.6777807052660805,Oc1cccc(-c2ccc(-c3cccc(O)c3)cc2)c1
25525,CHEMBL205345,OKAUHDJQKYCWBT-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,14.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCN1C(=O)COC2=C1C=C(C=C2)SC[C@H]3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,7.853871964321762,COCCCN1C(=O)COc2ccc(SC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21
25533,CHEMBL2437429,OKCJFCOBXGHPBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)C5=CC(=C(C=C5)F)F)CC6=CC(=NC=C6)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ccc(F)c(F)c5)c5cc(F)ccc54)CC3)CC2)ccn1
25535,CHEMBL2448699,OKEDBMJLEWWRHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1=CC=C(C=C1)C2=NC=C(C=N2)C(=O)NC3=C(C=CC(=C3)C#N)N4C=CN=C4,4.698970004336019,N#Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
25537,CHEMBL3099819,OKFARBMRDHCVLP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation and testosterone 6beta-hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)C(C2=NN=NN2C(C)(C)C)NCCNC3=C4C=CC(=CC4=NC=C3)Cl,6.769551078621726,Cc1ccc(C(NCCNc2ccnc3cc(Cl)ccc23)c2nnnn2C(C)(C)C)cc1
25544,CHEMBL453384,OKGGBPZMSDNNFA-UHFFFAOYSA-N,TCMDC-135909,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Activation of human CYP3A4 using DEF substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,CC(C)(C)NCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)F,4.0,CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1F
25548,CHEMBL337301,OKGPFTLYBPQBIX-CQSZACIVSA-N,BMS-377806,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=NC=CC(=C23)OC)C(=O)C4=CC=CC=C4,4.3979400086720375,COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)C[C@H]3C)c12
25549,CHEMBL337301,OKGPFTLYBPQBIX-CQSZACIVSA-N,BMS-377806,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=NC=CC(=C23)OC)C(=O)C4=CC=CC=C4,4.3979400086720375,COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)C[C@H]3C)c12
25551,CHEMBL605360,OKHVXBABEFQOCR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by LCMS/MS assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NC3=CC=C(C=C3)CO)OC,4.522878745280337,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CO)cc3)c2)cc1OC
25553,CHEMBL3128194,OKIOQHRDFOXEBF-DZCCDHAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24437735.0,IC50,=,86000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective ß3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,PUBLICATION,,C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=C3N=C(S4)N)[C@@H](C5=CC=CC=C5)O,4.0655015487564325,Nc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1
25558,CHEMBL321051,OKLABFVDVTVNBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCCCC1=CC=C(C=C1)N=CNO,4.301029995663981,CCCCCCc1ccc(N=CNO)cc1
25560,CHEMBL29743,OKLXZLLQLHWOGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,5780.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3N(C5=C4C(=CC=C5)[N+](=O)[O-])CC6=CC=NC=C6,5.2380721615794705,O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1ccncc1
25564,CHEMBL2058902,OKOGYZXIHINVRK-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)NC5CCN(CC5)C,5.568636235841013,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NC3CCN(C)CC3)oc2c1
25566,CHEMBL3288755,OKQVIDODFGYTAX-IFPLKCGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24842618.0,IC50,>,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.,Bioorg. Med. Chem.,PUBLICATION,,CCN1C(=O)CN(C1=O)C2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl,4.958607314841775,CCN1C(=O)CN(c2ccc(Cc3cc([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)ccc3Cl)cc2)C1=O
25570,CHEMBL2435858,OKRZBWWJVVVKHT-PMERELPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24090135.0,IC50,>,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC(=N1)OC2=CC=C(C=C2)C(=O)N)CN3CCC(CC3)N4[C@@H](CN(C4=O)C5CCOCC5)C6=CC=CC=C6,4.585026652029182,Cc1nc(Oc2ccc(C(N)=O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1
25580,CHEMBL2165317,OKZQWDIOWQYOGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861193.0,IC50,=,90000.0,NM,,,,,,,,,,,,,,,Inhibition of hepatic CYP3A4,Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.,J. Med. Chem.,PUBLICATION,,CCOC1=C(C=C2CCC(=O)N(C2=C1)C)C3=CN=CC=C3,4.045757490560675,CCOc1cc2c(cc1-c1cccnc1)CCC(=O)N2C
25581,CHEMBL1917464,OLADFXRHWWGOMN-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21944855.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of pyridazinone-phenethylamine derivatives as selective and orally bioavailable histamine H(3) receptor antagonists with robust wake-promoting activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCC2=CC=C(C=C2)C3=NN(C(=O)C=C3)C,4.522878745280337,C[C@@H]1CCCN1CCc1ccc(-c2ccc(=O)n(C)n2)cc1
25592,CHEMBL521724,OLCABARHEDJPQC-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)N[C@H]3CCC4=CC=CC=C34)N5C=CC=CC5=O)C,4.7447274948966935,Cc1nc2c(N[C@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C
25593,CHEMBL521724,OLCABARHEDJPQC-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,86000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)N[C@H]3CCC4=CC=CC=C34)N5C=CC=CC5=O)C,4.0655015487564325,Cc1nc2c(N[C@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C
25594,CHEMBL496402,OLCABARHEDJPQC-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)N[C@@H]3CCC4=CC=CC=C34)N5C=CC=CC5=O)C,4.886056647693163,Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C
25595,CHEMBL496402,OLCABARHEDJPQC-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)N[C@@H]3CCC4=CC=CC=C34)N5C=CC=CC5=O)C,4.443697499232712,Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C
25600,CHEMBL1209686,OLDDAHJZTORONS-ONTIZHBOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP1A2,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H](C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCCC3)NC(=O)[C@@H]4[C@H](CCN4)O,5.301029995663981,CC[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1
25616,CHEMBL3393063,OLIKAINVOFFOAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C#N)OC2=CC=C(C=C2)C(=O)NCC3=NC=NC=C3,5.0,N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccncn2)cc1
25622,CHEMBL601031,OLJMSYJNZOXIEK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20074949.0,IC50,>=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCN(CC1)C(=O)CN2C3=C(C=CC(=C3)C(=O)O)C(=C2C4=COC=C4)C5CCCCC5,5.096910013008056,CC(C)N1CCN(C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1
25623,CHEMBL1327969,OLJPUMGNYIOTFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23867602.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Lead identification of novel and selective TYK2 inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,C1=CC(=C(C(=C1)Cl)C(=O)NC2=CC=NC=C2)Cl,5.327902142064283,O=C(Nc1ccncc1)c1c(Cl)cccc1Cl
25624,CHEMBL3629743,OLJWGKMQUSBBIA-BWAGFHJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@]2(CCN(C2)S(=O)(=O)C(F)(F)F)[C@@H]3COC4=C(C=CC(=C4[C@@]3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,4.698970004336019,O=S(=O)(N1CC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)C1)C(F)(F)F
25625,CHEMBL3629743,OLJWGKMQUSBBIA-BWAGFHJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@]2(CCN(C2)S(=O)(=O)C(F)(F)F)[C@@H]3COC4=C(C=CC(=C4[C@@]3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,4.522878745280337,O=S(=O)(N1CC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)C1)C(F)(F)F
25626,CHEMBL213743,OLLCPXMBOYVHAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16759855.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,"1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)CC2=CC3=C(CC4=C3NN=C4C5=CSC=C5)C=C2,5.0,CN1CCN(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)CC1
25627,CHEMBL236521,OLLQZYNQBYGVCQ-IGYGKHONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)[C@H](CC(C)C)NC(=O)CCN(C)C,5.221848749616356,Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@H](CC(C)C)NC(=O)CCN(C)C)c1
25628,CHEMBL1668243,OLLRSJLKNAIFCJ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)[C@@H](C(=O)NC2=C(C=C(C=C2)C(=O)O)Cl)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,4.638272163982407,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(Cl)c1
25639,CHEMBL496288,OLPCUEGEMPLTMM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,1093.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC2=C(C1C3=CC=NC=C3)C=CC(=C2)C4=CC=C(C=C4)F.Cl,5.961379838050298,Fc1ccc(-c2ccc3c(c2)CCC3c2ccncc2)cc1
25643,CHEMBL3673958,OLQODSJHRJYJIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320627,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=C2C(=CNC2=NC=C1)CC3=C(N=C(C=C3)NCC4=CC=C(C=C4)Cl)F,5.301029995663981,COc1ccnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c12
25644,CHEMBL3673958,OLQODSJHRJYJIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320671,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=C2C(=CNC2=NC=C1)CC3=C(N=C(C=C3)NCC4=CC=C(C=C4)Cl)F,5.0,COc1ccnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c12
25659,CHEMBL2018917,OLVGVEZGCNJPGR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,8340.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CC(C)C1=CC=C(C=C1)CSC2=NC3=C(N2)C=C(C=C3)OC,5.078833949362261,COc1ccc2nc(SCc3ccc(C(C)C)cc3)[nH]c2c1
25661,CHEMBL2165506,OLVSLQHNMMFQPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=CNC5=CC(=C4)F)N6CCOCC6,6.292429823902063,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cc(F)cc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
25673,CHEMBL2041174,OLZGEKRJAPMKEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC7=C(C=C6)N=CN7,4.7447274948966935,COc1cc(N2C(=O)N(c3ccc(-c4ccc5nc[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
25676,CHEMBL455126,OMBSMQLLFJMMRZ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18701276.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Highly functionalized 7-azaindoles as selective PPAR gamma modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C2=C(N1CC3=CC(=CC=C3)O[C@@H](C)C(=O)O)N=CC=C2)C(=O)C4=CC=C(C=C4)OC,4.0,COc1ccc(C(=O)c2c(C)n(Cc3cccc(O[C@@H](C)C(=O)O)c3)c3ncccc23)cc1
25683,CHEMBL249087,OMDLVUGUASZVGG-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)[C@H]3CCC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5=CC(=CC(=C5)F)F,6.3979400086720375,CC(C)(CO)N1CCN(C(=O)OC2([C@H]3CCC[C@@H](c4cc(F)cc(F)c4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
25687,CHEMBL482089,OMEGCBMNQDIBMF-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,1.3,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)OCCO,8.886056647693163,Cc1cc(N2CCC(OCCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
25692,CHEMBL3092417,OMGYQMYQUBRDBB-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)C3=CC4=NC=CN4C=C3)F,4.698970004336019,CC(=O)NC[C@H]1CN(c2ccc(-c3ccn4ccnc4c3)c(F)c2)C(=O)O1
25709,CHEMBL2181880,OMMVFRZSBCRMQD-LJYZBVLISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,C[C@H](C(=O)N[C@@H](CC1=CC2=C(C=C1)OCO2)[C@@H](CN[C@H]3CC4(CCC4)OC5=C3C=C(C=N5)CC(C)(C)C)O)OC,7.301029995663981,CO[C@H](C)C(=O)N[C@@H](Cc1ccc2c(c1)OCO2)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
25711,CHEMBL499442,OMNLHFZYIBOWOH-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NC)C4=C(C(=CC=C4)OCCCNCC(=O)O)F,4.481486060122112,CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCNCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
25732,CHEMBL2385901,OMXKUEXZCQUFSZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)CC4=CC=CC5=CC=CC=C54,4.301029995663981,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)Cc1cccc3ccccc13)CC2
25751,CHEMBL2057522,ONFQJVPTMPUNDQ-XZWHSSHBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)CN(C[C@H]([C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)O)C(=O)C4=CC5=C(C=C4)N=C(O5)N6CCCC6,7.585026652029182,O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CC1CCCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1
25758,CHEMBL3321846,ONHFEABHFHNJOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25082126.0,IC50,=,260.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(C2=CC=CC=C21)C(=O)C3=C(NC(=O)N=C3)OC4=C(C=CC(=C4)Cl)Cl,6.585026652029182,CN1CCN(C(=O)c2cnc(=O)[nH]c2Oc2cc(Cl)ccc2Cl)c2ccccc21
25766,CHEMBL520229,ONJXHXVTYOPVIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCOCC4)C,4.698970004336019,CC(=O)Nc1cc(-c2cccc(N3CCOCC3)n2)nc(-n2nc(C)cc2C)n1
25770,CHEMBL3673965,ONKIUNVOKOYXEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320634,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CN=C(C=C4)OC)N=C1,5.0,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cn1
25771,CHEMBL3673965,ONKIUNVOKOYXEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320678,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CN=C(C=C4)OC)N=C1,5.0,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cn1
25783,CHEMBL2375371,ONNNBBBPFLLYHY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23545108.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)OC2=CC(=C(C=C2)NS(=O)(=O)C3=C(C=C(C=C3)Br)F)C(=O)O,4.585026652029182,O=C(O)c1cc(Oc2ccccc2)ccc1NS(=O)(=O)c1ccc(Br)cc1F
25784,CHEMBL349638,ONPNRCWCFNPMNG-BKLRJVBYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)[C@H](C)CNCCC6=CC7=C(C=C6)N=C(N7)C)C,5.301029995663981,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3nc(C)[nH]c3c2)c1
25786,CHEMBL512127,ONRDKYMCESZKKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=CC=CC=C3S(=O)(=O)C,5.522878745280337,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1S(C)(=O)=O
25787,CHEMBL393363,ONRGYKGRPVMXIR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C4=CC(=CC=C4)C(F)(F)F,6.920818753952375,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cccc(C(F)(F)F)c1)O2
25789,CHEMBL1089866,ONVFZPXWBQZKQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20218619.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,CCN1C2=C(C=C(C1=O)C3=C(C=CC(=C3)C(=O)NC4CC4)C)C=NN2C5=C(C=C(C=C5)F)F,5.795880017344075,CCn1c(=O)c(-c2cc(C(=O)NC3CC3)ccc2C)cc2cnn(-c3ccc(F)cc3F)c21
25798,CHEMBL565361,ONWYPTYCJIAWIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=CC=C3)OC,5.431798275933005,COc1cccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)c1
25800,CHEMBL436817,ONXROKMQGCSOMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17715908.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.,J. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1NC2=C3C=C(C=C(C3=NC=C2C#N)Cl)NCC4=CN=CN4)Cl)F,5.045757490560675,N#Cc1cnc2c(Cl)cc(NCc3cnc[nH]3)cc2c1Nc1ccc(F)c(Cl)c1
25808,CHEMBL2146750,ONYWALXTZFPKAS-XHCCPWGMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,35000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CC1CCN(CC1)[C@H](C2=CC=C(C=C2)F)C3=C(C=C(C=C3)[C@@H](C)C(=O)O)C4=CC=C(C=C4)C(F)(F)F,4.455931955649724,CC1CCN([C@H](c2ccc(F)cc2)c2ccc([C@@H](C)C(=O)O)cc2-c2ccc(C(F)(F)F)cc2)CC1
25823,CHEMBL2048492,OODHRJXTEITBEQ-JQGGBATGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,36600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2)OCC)[C@@H]3C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO,4.436518914605589,CCOc1ccc(Cc2ccc(CC)cc2)cc1[C@@H]1C[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
25824,CHEMBL2048492,OODHRJXTEITBEQ-JQGGBATGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2)OCC)[C@@H]3C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO,4.301029995663981,CCOc1ccc(Cc2ccc(CC)cc2)cc1[C@@H]1C[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
25844,CHEMBL219060,OOIJMSVOEKAGEL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1CNC2=CC=NC=C2)C(=O)OCC3=CC=CC=C3,4.6020599913279625,O=C(OCc1ccccc1)N1CCC(CNc2ccncc2)CC1
25849,CHEMBL1077334,OOLQOYHCEMONID-XNTDXEJSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20185309.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)NC4(CCCC4)C(=O)NC5=CC=C(C=C5)/C=C/C(=O)O)N=C2C6=COC=C6,4.522878745280337,O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccoc3)n4C3CCCCC3)CCCC2)cc1
25853,CHEMBL2425604,OOOLZCKPVRMIHJ-QKDGCWAWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC[C@H](C(F)(F)F)OC1=C(C(=CC(=C1)C[C@@H]2C[S@@](=O)C[C@@H]([C@H]2O)NCC3=CC(=CC=C3)OC(F)(F)F)F)N,5.327902142064283,COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(OC(F)(F)F)c3)[C@H]2O)cc(F)c1N)C(F)(F)F
25856,CHEMBL261592,OOQXPATWSOGSAV-UHFFFAOYSA-N,BMS-645737,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18395443.0,IC50,=,11500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=CC(=CN=C2N1)NC3=NC=NN4C3=C(C(=C4)C5=NN=C(O5)C)C(C)C,4.939302159646388,Cc1cc2cc(Nc3ncnn4cc(-c5nnc(C)o5)c(C(C)C)c34)cnc2[nH]1
25857,CHEMBL495993,OORIVESIQGRNJV-SJORKVTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC12CC(=O)C3=C(O2)C=CC=N3)C(=O)N[C@H]4C[C@@H]4C5=CC=CC=C5,5.0,O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2cccnc21
25859,CHEMBL460491,OOSUDWRRWZVFEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19053768.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.,J. Med. Chem.,PUBLICATION,,CC1(CN2C(=CSC2=N1)CSC(=NC3CCCCC3)NC4CCCCC4)C,5.0,CC1(C)CN2C(CSC(=NC3CCCCC3)NC3CCCCC3)=CSC2=N1
25873,CHEMBL390642,OOXSSXPKHGFWIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17482464.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(CCCN3CCC(=O)OC)C=C2,5.0,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCC(=O)OC)CCC2
25884,CHEMBL193247,OPHKHUCQAYSHKT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)O.CS(=O)(=O)O.C1CCC(C1)S(=O)(=O)N2C3=C(C=CC(=C3)C4=C(NC(=N4)C5=C(C=CC=C5F)F)C6=CC=CC=C6)N=C2N,4.886056647693163,Nc1nc2ccc(-c3nc(-c4c(F)cccc4F)[nH]c3-c3ccccc3)cc2n1S(=O)(=O)C1CCCC1
25885,CHEMBL230043,OPICGPYWGONRDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C5=NCCCN5,4.795880017344075,Cc1cc(C2=NCCCN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
25887,CHEMBL216884,OPIYGGWYEOSIPY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17107790.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)CNCC2=CN=C(C=C2)C3=CC=C(S3)C(=O)NO,4.585026652029182,O=C(NO)c1ccc(-c2ccc(CNCc3ccccc3)cn2)s1
25895,CHEMBL487765,OPNAWTWHKNBYIX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,43000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC=CC=C3)C,4.366531544420414,CC(=O)Nc1cc(-c2ccccc2)nc(-n2nc(C)cc2C)n1
25901,CHEMBL3264595,OPPFLHFMEGQSGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CC=NN3)O,5.7447274948966935,COc1cc2ccc(C(O)(c3ccn[nH]3)C(C)C)cc2cc1OC
25922,CHEMBL2448733,OPTBYDHXCQHIPH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCN(CC1=CN=CC=C1)C2=C(C=C(C=C2)C3=CC=C(C=C3)F)F,6.0,CCN(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F
25926,CHEMBL1272045,OPVSCKBPGHIATG-UPSGKMMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,3.2,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C[C@@H]2COC[C@@H](N2S(=O)(=O)C3=CC=C(C=C3)Cl)C4(CC4)OC(=O)N5CC6CC5CN6CCO,8.494850021680094,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CC1CN2CCO
25943,CHEMBL230964,OPZCLJWDQNPUHB-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,C1[C@@H](OC(=O)N1C2=CC(=C(C=C2)C3=CN=C(C=C3)C(=O)CN4C=CN=C4)F)CN5C=CN=N5,6.522878745280337,O=C(Cn1ccnc1)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1
25965,CHEMBL482101,OQEBLEZRSCIFJK-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.7,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC6(CC5)OCCO6,9.154901959985743,Cc1cc(N2CCC3(CC2)OCCO3)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
25966,CHEMBL482101,OQEBLEZRSCIFJK-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC6(CC5)OCCO6,6.154901959985743,Cc1cc(N2CCC3(CC2)OCCO3)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
25971,CHEMBL1682899,OQFYRLCZKWVBHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC(=C2)C(C3=CN=CN3)(C(C)C)O)C=C1C(=O)NC,5.443697499232713,CNC(=O)c1cc2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2cc1C
25972,CHEMBL465948,OQGNJLWZKFTRPB-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CS(=O)(=O)C4=CC=CC=C4,5.522878745280337,C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)CS(=O)(=O)c3ccccc3)cc2)C[C@@H](C)N1
25973,CHEMBL465948,OQGNJLWZKFTRPB-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CS(=O)(=O)C4=CC=CC=C4,5.050609993355088,C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)CS(=O)(=O)c3ccccc3)cc2)C[C@@H](C)N1
25977,CHEMBL86932,OQHPRXYGKQHOKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN(N=C5)C,5.301029995663981,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
25987,CHEMBL25105,OQLKNTOKMBVBKV-UHFFFAOYSA-N,HEXAMIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC(=CC=C1C(=N)N)OCCCCCCOC2=CC=C(C=C2)C(=N)N,5.0,N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1
25988,CHEMBL25105,OQLKNTOKMBVBKV-UHFFFAOYSA-N,HEXAMIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CC(=CC=C1C(=N)N)OCCCCCCOC2=CC=C(C=C2)C(=N)N,5.0,N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1
25990,CHEMBL270368,OQLQJPJMZFAIDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)OCC4CCNCC4)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,5.119186407719209,CC(C)c1c(-c2nnc(OCC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
26017,CHEMBL1669415,OQSOOFROGDVPSV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,3871.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=CC=CC=C2C(=C1CCN3CC(C3)(F)F)CC4=NC=CN=C4,5.412176828681045,FC1(F)CN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
26026,CHEMBL25948,OQWKEEOHDMUXEO-BQYQJAHWSA-N,SHOGAOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,77700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,CCCCC/C=C/C(=O)CCC1=CC(=C(C=C1)O)OC,4.1095789811990855,CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1
26030,CHEMBL3408955,OQYLKJLEFFUOSP-AFYCESQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O)C)C,5.795880017344075,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5[C@@H](C)CN(C)C[C@H]5C)cc4)n[nH]c3c1)C(=O)N2
26031,CHEMBL3408955,OQYLKJLEFFUOSP-AFYCESQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O)C)C,5.0,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5[C@@H](C)CN(C)C[C@H]5C)cc4)n[nH]c3c1)C(=O)N2
26032,CHEMBL2448745,OQYZVVJUKASDLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CS(=O)(=O)N(CC1=CN=CN1)C2=C(C=C(C=C2)C3=CC=C(C=C3)F)F,6.0,CS(=O)(=O)N(Cc1cnc[nH]1)c1ccc(-c2ccc(F)cc2)cc1F
26035,CHEMBL2043328,OQZGBAAWFMGASB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)N6CCC6=O,4.301029995663981,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(N3CCC3=O)cc1)C(=O)N2c1cc(=O)[nH]cn1
26036,CHEMBL276140,OQZOXHCRSXYSPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9357513.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human Cytochrome P450 3A at 100 uM,6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.,J. Med. Chem.,PUBLICATION,,CSC1=C(C=C2C(=C1)CCN2C(=O)NC3=CN=CC=C3)C(F)(F)F,4.0,CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2
26037,CHEMBL276140,OQZOXHCRSXYSPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,10737744.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human cytochrome P450 3A4,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,PUBLICATION,,CSC1=C(C=C2C(=C1)CCN2C(=O)NC3=CN=CC=C3)C(F)(F)F,4.0,CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2
26054,CHEMBL2364618,ORDHXXHTBUZRCN-NTEUORMPSA-N,MAVATREP,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25850459.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep).,J. Med. Chem.,PUBLICATION,,CC(C)(C1=CC=CC=C1C2=CC3=C(C=C2)N=C(N3)/C=C/C4=CC=C(C=C4)C(F)(F)F)O,4.6020599913279625,CC(C)(O)c1ccccc1-c1ccc2nc(/C=C/c3ccc(C(F)(F)F)cc3)[nH]c2c1
26059,CHEMBL3218857,ORFGUEWOGJKLFU-XOSANVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)C4=NC5=NC=C(C(=C5N4)N[C@@H]6[C@@H]7C[C@H]([C@@H]6C(=O)N)C=C7)Cl)OC,4.522878745280337,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
26060,CHEMBL3218857,ORFGUEWOGJKLFU-XOSANVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)C4=NC5=NC=C(C(=C5N4)N[C@@H]6[C@@H]7C[C@H]([C@@H]6C(=O)N)C=C7)Cl)OC,4.522878745280337,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
26072,CHEMBL1271520,ORJWZBKFHYBQDC-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@@H](C2)NC(=O)C3=C4C(=CC=C3)OC(=N4)N5CCOCC5,4.0,O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(N3CCOCC3)nc12
26074,CHEMBL3287851,ORLPPUHANSFJCS-VHSXEESVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900876.0,IC50,>,20000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.",ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C[C@H]1C[C@H](CCN1)C2=CC(=O)NO2,1.6989700043360187,CC(C)(C)C[C@H]1C[C@@H](c2cc(=O)[nH]o2)CCN1
26094,CHEMBL247609,ORRRWUZIONHTFN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,>,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCN(CC3)CC4=C(C5=C(C=C4)OCC(=O)N5C)F,4.795880017344075,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4F)N(C)C(=O)CO5)CC3)cccc2n1
26097,CHEMBL610795,ORUPHFRKUPILCN-IOASZLSFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,C1CC1COC[C@@H]2[C@@H]3[C@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,5.0,Clc1ccc([C@@]23CNC[C@@H]2[C@H]3COCC2CC2)cc1Cl
26098,CHEMBL3699335,ORURZZOCXOQQIN-QCDYIZFSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NN8CCN(CC8)C9=CC=CC=N9,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NN6CCN(c7ccccn7)CC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
26102,CHEMBL395573,ORVPEVIDEJOHIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17715908.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.,J. Med. Chem.,PUBLICATION,,C1=CC=[N+](C(=C1)CNC2=CC3=C(C(=CN=C3C(=C2)Cl)C#N)NC4=CC(=C(C=C4)F)Cl)[O-],4.7447274948966935,N#Cc1cnc2c(Cl)cc(NCc3cccc[n+]3[O-])cc2c1Nc1ccc(F)c(Cl)c1
26111,CHEMBL3325460,ORYICUWIPUTJGI-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4)C(F)(F)F)(C)C)C=N1,4.698970004336019,Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4cc(C(F)(F)F)ccc43)cccc2cn1
26112,CHEMBL1208958,ORZOCBRCPCCQDN-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCN(CC6)C)C(=O)N,5.958607314841775,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
26113,CHEMBL1208958,ORZOCBRCPCCQDN-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCN(CC6)C)C(=O)N,4.568636235841013,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
26165,CHEMBL446545,OSJROQUTACPGAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18662879.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery of piperidine carboxamide TRPV1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)NC2=CC3=C(C=C2)OC(C(=O)N3)CCO)C4=CC(=C(C(=C4)F)F)F,5.431798275933005,O=C(Nc1ccc2c(c1)NC(=O)C(CCO)O2)C1CCN(c2cc(F)c(F)c(F)c2)CC1
26193,CHEMBL283438,OSTWYWCXYVRVGR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,1360.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3NC5=CC=CC(=C54)C(=O)N,5.866461091629782,NC(=O)c1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12
26194,CHEMBL2178251,OSUIVZWZMLHYTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,CN1C=C(C(=N1)NC(=O)C2=C3N=CC=CN3N=C2)C4=CC(=CC=C4)Cl,5.0,Cn1cc(-c2cccc(Cl)c2)c(NC(=O)c2cnn3cccnc23)n1
26209,CHEMBL3298431,OSVVWQSAPRHYFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24835202.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1OC2=NC=NC3=C2C=CN3)F,4.698970004336019,Fc1ccc(Oc2ncnc3[nH]ccc23)cc1
26229,CHEMBL510171,OSZOMNDRPGGELA-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)N[C@@H]3CCC4=CC=CC=C34)N5C=NC=N5)C,5.292429823902063,Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3cncn3)cn2c1C
26230,CHEMBL510171,OSZOMNDRPGGELA-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)N[C@@H]3CCC4=CC=CC=C34)N5C=NC=N5)C,5.259637310505756,Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3cncn3)cn2c1C
26234,CHEMBL1829764,OTARHPTVFRBZQX-XRHLQHRESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCCO)C4=CC=C(C=C4)F,4.522878745280337,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O
26236,CHEMBL2059515,OTAYFQWOFJKZFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22500954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of Novel 1,2,4-Thiadiazole Derivatives as Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)).",J. Med. Chem.,PUBLICATION,,CCC1=C(C=CC=C1C2=NOC(=N2)C3=CC(=C(C=C3)OC(C)C)C#N)CCCC(=O)O,5.0,CCc1c(CCCC(=O)O)cccc1-c1noc(-c2ccc(OC(C)C)c(C#N)c2)n1
26240,CHEMBL331186,OTDBMSDSGGUFDP-GSFCIGPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=NC=C(S1)COC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](CN3CCN(C[C@H]3C(=O)NC(C)(C)C)CC4=CC(=C(C=C4)OC)OC)O,4.455931955649724,CCc1ncc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3ccc(OC)c(OC)c3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)s1
26250,CHEMBL3699337,OTFUCMLNWGKDEZ-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)C8=CC=CC=C8,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
26253,CHEMBL3422013,OTGOCKFNIHTQCV-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C(F)(F)F,4.0,C[C@@H]1c2nnc(-c3csc(C(F)(F)F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1
26254,CHEMBL1643783,OTGREDPOEXITQK-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106375.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=C(N2C1)C(=CC=C3)F)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.301029995663981,CN([C@@H]1CCc2c(CC(=O)O)c3cccc(F)c3n2C1)S(=O)(=O)c1ccc(F)cc1
26275,CHEMBL1081867,OTKZOEOQKWTXMD-GHTZIAJQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19891474.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,PUBLICATION,,CN1C(=NN=C1SCCCN2C[C@@H]3C[C@@]3(C2)C4=CC=C(C=C4)C(F)(F)F)C5=CN=NC=C5,5.0,Cn1c(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccnnc1
26287,CHEMBL1684058,OTPNHPXNYRVULV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21310612.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N(C)C.Cl,4.6020599913279625,CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
26291,CHEMBL230686,OTTCBLPTHPBEEX-UHFFFAOYSA-N,TG-100435,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17113292.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N=N2)NC3=CC=C(C=C3)OCCN4CCCC4)C5=C(C=CC=C5Cl)Cl,4.207608310501746,Cc1cc(-c2c(Cl)cccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
26296,CHEMBL2409564,OTWNXWHEBKCAMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810496.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC4=C(N3)C=C(C=C4)NC(=O)C5=C(OC(=N5)C6=CC=CC=C6)C(F)(F)F,4.0,O=C(O)CC1CCC(c2ccc(-c3nc4ccc(NC(=O)c5nc(-c6ccccc6)oc5C(F)(F)F)cc4[nH]3)cc2)CC1
26313,CHEMBL3291345,OUANOAMFFAKLPS-XIKOKIGWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,=,22600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@]12CC[C@@H](C1(C)C)C3=C2N(N(C3=O)C4=CC=CC=C4C(F)(F)F)C,4.645891560852599,Cn1c2c(c(=O)n1-c1ccccc1C(F)(F)F)[C@H]1CC[C@]2(C)C1(C)C
26315,CHEMBL2436945,OUAYPLUHINPFJL-MWLCHTKSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24042009.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=NC2=C(C=CNC2=O)C(=N1)N[C@@H]3CCC[C@@H]3C#N,5.0,CCc1nc(N[C@@H]2CCC[C@@H]2C#N)c2cc[nH]c(=O)c2n1
26331,CHEMBL179529,OUEHWWLIEPNPDR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,CNC1=CC=C(S1)C2=CN=CC=C2,5.200659450546418,CNc1ccc(-c2cccnc2)s1
26332,CHEMBL1272072,OUENCNZMGZDHGX-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C2=NC3=C(C=CC=C3O2)C(=O)N[C@@H]4CN5CCC4CC5,4.0,O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(C3CC3)nc12
26334,CHEMBL1950087,OUEWVUKWTPRXNZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=CC=N4)O)Cl,5.7447274948966935,Cc1cc(Cl)cc2c(C(O)c3ccccn3)c3c(C)[nH]nc3nc12
26335,CHEMBL1950087,OUEWVUKWTPRXNZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,12200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=CC=N4)O)Cl,4.913640169325252,Cc1cc(Cl)cc2c(C(O)c3ccccn3)c3c(C)[nH]nc3nc12
26351,CHEMBL1951322,OUJNTZAPROXXHI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4)Cl,6.221848749616356,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1ccccc1Cl
26363,CHEMBL2036757,OULRKKBJQGZFKL-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22608963.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@H](CN(C1)C2CC2)CN3CCN(CC3)C(=O)NC4=CC(=C(C=C4)Cl)Cl,5.795880017344075,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
26367,CHEMBL1761849,OULYTLMMUGPJHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21439819.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11ß-hydroxysteroid-dehydrogenase type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)C2CCN(CC2)C(=O)N3CCCC4=CC=CC=C43,5.0,Cn1cc(C2CCN(C(=O)N3CCCc4ccccc43)CC2)cn1
26373,CHEMBL311561,OUQYWOOMZNKZCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CN2CC3=C(C=CC(=C3)OC4=C(C=CC(=C4)CN5C=NC=C5CNC1C2=O)C#N)Br,5.214670164989233,N#Cc1ccc2cc1Oc1ccc(Br)c(c1)CN1CCC(NCc3cncn3C2)C1=O
26375,CHEMBL2159138,OUSUKMPOOBFKCG-UTZFUXNDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NCC)O4)C)(C)OC)C)C)O)(C)O,5.5376020021010435,CCN=C1O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)OC)O[C@H](C)C[C@@H]2N1C
26378,CHEMBL1784346,OUTUIYKUSHWASL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)CCC2CCN(CC2)S(=O)(=O)CC3(CCC(CC3)(F)F)N(C=O)O,5.0,Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCC(F)(F)CC2)CC1
26386,CHEMBL2018918,OUXJOASRGMYGSX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,12300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC=C(C=C1)CSC2=NC3=C(N2)C=C(C=C3)OC,4.910094888560602,COc1ccc2nc(SCc3ccc(C(C)(C)C)cc3)[nH]c2c1
26391,CHEMBL3640016,OUYYYTDFXFTOMC-AIQPRDSRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7400.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CC=C(C=C7)CCO,5.130768280269024,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(CCO)cc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
26399,CHEMBL682,OVCDSSHSILBFBN-UHFFFAOYSA-N,AMODIAQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,4.301029995663981,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
26401,CHEMBL1935601,OVDCCBDDPCBOAW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153937.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel brain penetrant benzofuropiperidine 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2(COC1)C3=C(CCN2)C4=C(O3)C=C(C=C4)S(=O)(=O)C5=CC=CC(=C5)F,4.522878745280337,O=S(=O)(c1cccc(F)c1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3
26402,CHEMBL3358931,OVDGYTOZNODCOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=C(C=CC(=C3)F)OC,5.698970004336019,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F
26419,CHEMBL1760428,OVHGVXGIHHVKIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21414782.0,IC50,>,3162.28,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Phenoxyacetic acids as PPARd partial agonists: synthesis, optimization, and in vivo efficacy.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN(C1=CC=CC(=C1Cl)C2=CC=C(C=C2)C(F)(F)F)S(=O)(=O)C3=C(C(=C(C=C3)OC(C)C(=O)O)C)C,5.499999678657065,CCCCN(c1cccc(-c2ccc(C(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C
26420,CHEMBL150653,OVHOEGWGUASELU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CC=CC=N2,4.0,CCCCOc1ccc(-c2ccccn2)cc1
26432,CHEMBL2070141,OVLFWNCKGOPFPU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=C(C=C3)C4=CC=CC=C4,5.5376020021010435,CCCS(=O)(=O)c1ccc2nc(-c3ccc(-c4ccccc4)cc3)[nH]c2c1
26434,CHEMBL1209842,OVNJVYZXVSMONK-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)C)C(=O)N,6.698970004336019,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
26435,CHEMBL1209842,OVNJVYZXVSMONK-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)C)C(=O)N,6.698970004336019,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
26436,CHEMBL1223259,OVNVZWSCIAIPJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673729.0,IC50,>,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 30 mins,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)(C)C1=NN=C(S1)C2=NN(C(=C2CN3C=NC=N3)C4=CC=C(C=C4)Br)C5=CC=CC=C5Cl,7.698970004336019,CC(C)(C)c1nnc(-c2nn(-c3ccccc3Cl)c(-c3ccc(Br)cc3)c2Cn2cncn2)s1
26446,CHEMBL1092767,OVTUKEYYZWXZMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)C3=NC=CS3,5.0,CC(c1nccs1)c1c(CCN(C)C)sc2ccccc12
26454,CHEMBL1765101,OVYVQHHATBRNQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=CC(=C1)C2=CC=C(C=C2)OC)(C3=CN=CN3)O,5.698970004336019,COc1ccc(-c2cccc(C(O)(c3cnc[nH]3)C(C)C)c2)cc1
26466,CHEMBL3121804,OWCPJSPQYMOCLB-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,CCC1=CC2=C(C=C1F)C(=C(N2C3=NC=C(C=N3)F)C4=NC=C(C=C4)S(=O)(=O)N[C@@H](C)C(F)(F)F)C#N,5.0,CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncc(F)cn1
26477,CHEMBL1437764,OWEGWHBOCFMBLP-UHFFFAOYSA-N,CLIMBAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,100.0,NM,,,,binding,,,,,,,,,,,,,,,,CC(C)(C)C(=O)C(N1C=CN=C1)OC2=CC=C(C=C2)Cl,7.0,CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1
26478,CHEMBL1437764,OWEGWHBOCFMBLP-UHFFFAOYSA-N,CLIMBAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,100.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CC(C)(C)C(=O)C(N1C=CN=C1)OC2=CC=C(C=C2)Cl,7.0,CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1
26479,CHEMBL1437764,OWEGWHBOCFMBLP-UHFFFAOYSA-N,CLIMBAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,47500.0,NM,,,,binding,,,,,,,,,,,,,,,,CC(C)(C)C(=O)C(N1C=CN=C1)OC2=CC=C(C=C2)Cl,4.323306390375134,CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1
26496,CHEMBL3291127,OWLSZODKAZOOLP-PLQLVBBOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,44.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)N)C,7.35261702988538,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(N)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
26497,CHEMBL3291127,OWLSZODKAZOOLP-PLQLVBBOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,135.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)N)C,6.8696662315049934,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(N)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
26498,CHEMBL1092663,OWMBYQVIMDTSAW-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CN=C3,5.0,Cc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1cnccn1
26509,CHEMBL1208959,OWRZQDDNDUUITK-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCN(CC6)C)C(=O)N,6.3979400086720375,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
26510,CHEMBL1208959,OWRZQDDNDUUITK-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCN(CC6)C)C(=O)N,5.721246399047171,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
26511,CHEMBL3114723,OWSUPSVMUSHQHC-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23746300.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,,,,,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)NCCCCNC(=O)OCC2=CN=CS2,4.823908740944319,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCCCNC(=O)OCc2cncs2)C(C)C)cs1
26514,CHEMBL3114723,OWSUPSVMUSHQHC-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,870.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)NCCCCNC(=O)OCC2=CN=CS2,6.060480747381382,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCCCNC(=O)OCc2cncs2)C(C)C)cs1
26515,CHEMBL2181891,OWSUWCSVFOZIGR-HZFUHODCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)C[C@@H]2NC[C@H]([C@H](CC4=CC(=CC=C4)C5=NC=CN5C)NC(=O)COC)O,7.301029995663981,COCC(=O)N[C@@H](Cc1cccc(-c2nccn2C)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
26517,CHEMBL2017269,OWUQUQCSBQATFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=CC3=NC=C(C(=C3C=C2)NC4=CC=CC=C4C(C)(C)C)C(=O)O,4.886056647693163,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(=O)O)cnc2c1
26518,CHEMBL2017269,OWUQUQCSBQATFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=CC3=NC=C(C(=C3C=C2)NC4=CC=CC=C4C(C)(C)C)C(=O)O,4.886056647693163,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(=O)O)cnc2c1
26524,CHEMBL3109801,OWWOVESWHWBLEI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCCF)N=C1,4.301029995663981,COc1ncnc(Cn2cc(C(=O)NCCF)c3ncc(C)cc32)c1C
26529,CHEMBL205862,OWYKGJWNYSCISK-NLFFAJNJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,1010.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)[C@H](C)[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCCC3)C(=O)O)N4C=CN=C4,5.995678626217358,CCN(CC)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1
26533,CHEMBL1765107,OWYXGQALIALHJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21413798.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)NC(=O)C2=NC(=CN=C2N)C3=CN=CC=C3,5.698970004336019,Nc1ncc(-c2cccnc2)nc1C(=O)Nc1ccccc1
26548,CHEMBL2059516,OXGQQGFOOMMLIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22500954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of Novel 1,2,4-Thiadiazole Derivatives as Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)).",J. Med. Chem.,PUBLICATION,,CCC1=C(C=CC=C1C2=NN=C(S2)C3=CC(=C(C=C3)OC(C)C)C#N)CCCC(=O)O,5.0,CCc1c(CCCC(=O)O)cccc1-c1nnc(-c2ccc(OC(C)C)c(C#N)c2)s1
26551,CHEMBL218583,OXHYIGFIYVMDLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17201408.0,IC50,=,55000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=CC=CC3=C(C(=C(N=C32)C4=CC=C(C=C4)Cl)O)C(=O)O,4.259637310505756,O=C(O)c1c(O)c(-c2ccc(Cl)cc2)nc2c(-c3ccccc3)cccc12
26563,CHEMBL3358952,OXLAICHJWSSTJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=CC=CC4=C3S(=O)(=O)CC4,5.698970004336019,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1cccc2c1S(=O)(=O)CC2
26571,CHEMBL3358946,OXRSLCFSOLYHEH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=C(C=C(C=C3)F)C(=O)N,5.522878745280337,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1C(N)=O
26583,CHEMBL2448711,OXXAKVXIIVFFEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1400.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1CC1C(=O)N(CC2=CN=CC=C2)C3=CC=CC(=C3)C4=NC5=CC=CC=C5S4,5.853871964321762,O=C(C1CC1)N(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1
26595,CHEMBL476360,OYAZNQWKGGEAGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CSC=C3,4.301029995663981,O=C(CNC(=O)c1ccsc1)NC(c1ccccc1)c1ccc(Cl)cc1
26602,CHEMBL1766173,OYDIXDAQFNMWOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=C(C=C1)C2=CC=C(C=C2)OC)(C3=CN=CN3)O,5.309803919971486,COc1ccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)cc1
26606,CHEMBL456379,OYFRXCWZMBHNHW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18855374.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,"Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).",J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)O)C2=CN=C(S2)C3=CC(=CC=C3)O,6.096910013008056,Oc1cccc(-c2cnc(-c3cccc(O)c3)s2)c1
26628,CHEMBL227954,OYNURZXTLNNKAP-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC3=CC=CC=C3C(=O)N2CC4=CC=CC=C4C#N)N,5.698970004336019,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccccc2c1=O
26648,CHEMBL3128178,OYURTPRHVJSKRC-DZCCDHAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24437735.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective ß3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,PUBLICATION,,C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=C3N=CS4)[C@@H](C5=CN=CC=C5)O,4.0,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2scnc21
26649,CHEMBL3128178,OYURTPRHVJSKRC-DZCCDHAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26709102.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,PUBLICATION,,C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=C3N=CS4)[C@@H](C5=CN=CC=C5)O,4.0,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2scnc21
26654,CHEMBL601821,OYZYVBKQMLQLPM-UHFFFAOYSA-N,GNF-PF-5069,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21644570.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP 3A4,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,J. Med. Chem.,PUBLICATION,,C1CN2C(=NC(=C2NC3=CC4=C(C=C3)OCO4)C5=CC=CC=C5)CN1C(=O)CN,5.0,NCC(=O)N1CCn2c(nc(-c3ccccc3)c2Nc2ccc3c(c2)OCO3)C1
26655,CHEMBL2448719,OZACJYWNJRCVMB-CVKSISIWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C/C(=N\OC)/C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CC=C(S3)C4=CC=CC=N4,5.698970004336019,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccn3)s2)c1
26657,CHEMBL2436208,OZBOMLNKMBJQDW-QDMMYLPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,10200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=CC=CC=C43)OC)C(=O)C5=CC=C(C=C5)N)NC.Cl,4.991399828238082,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(N)cc2)c2ccccc2N(Cc2c(OC)ccc3ccccc23)C1=O
26658,CHEMBL3609819,OZBPEBNJOSXIBE-SKYBXZRDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26231163.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1'-hydroxylation by LC-MS/MS method,Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(=O)O[C@]1(C[C@H]2CCC[C@@H]1C3=CC=CC=C23)CCN(C)CCCC4=NC5=C(N4)C=CC=C5OC,5.522878745280337,COc1cccc2[nH]c(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)nc12
26659,CHEMBL3609819,OZBPEBNJOSXIBE-SKYBXZRDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26231163.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation by LC-MS/MS method,Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(=O)O[C@]1(C[C@H]2CCC[C@@H]1C3=CC=CC=C23)CCN(C)CCCC4=NC5=C(N4)C=CC=C5OC,5.259637310505756,COc1cccc2[nH]c(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)nc12
26660,CHEMBL3609819,OZBPEBNJOSXIBE-SKYBXZRDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26231163.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method,Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(=O)O[C@]1(C[C@H]2CCC[C@@H]1C3=CC=CC=C23)CCN(C)CCCC4=NC5=C(N4)C=CC=C5OC,4.468521082957745,COc1cccc2[nH]c(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)nc12
26664,CHEMBL1916704,OZCSUWJJBCTGGK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958540.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of a biphenylacetic acid series of prostaglandin D(2) receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=CC(=C2)CC(=O)O)OC)C(=O)OC,4.522878745280337,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OC
26669,CHEMBL2017097,OZFKVMALEJNYGS-ODXCJYRJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNC[C@@H]([C@]1(C2=CC(=C(C=C2)F)F)O)C3=C(C(=NO3)C4=C(C(=CC=C4)Cl)Cl)Br,4.721246399047171,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2cccc(Cl)c2Cl)c1Br
26675,CHEMBL1615153,OZGKPOZAIWDSQB-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)[C@@H](C(=O)NC2=CC=C(C=C2)C(=O)O)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,4.431798275933005,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)cc1
26682,CHEMBL3125375,OZIKWNBSDOTXBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N)C=CC(=C2)F,7.3979400086720375,CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O
26690,CHEMBL3702820,OZOANGRWDJQHKF-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3850.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)OC,5.414539270491499,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)OC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
26692,CHEMBL2048060,OZOLBCYZUXLXMZ-WVBUVRCRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ß-peptides.,J. Med. Chem.,PUBLICATION,,CC1(C2=C(CO1)C=CC(=C2)CN[C@H]3CS(=O)(=O)C[C@H]([C@@H]3O)CC4=CC(=C(C(=C4)F)N)OC(C(F)(F)F)C(F)(F)F)C,6.154901959985743,CC1(C)OCc2ccc(CN[C@H]3CS(=O)(=O)C[C@@H](Cc4cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c4)[C@@H]3O)cc21
26693,CHEMBL3084777,OZOLNJQERDKPFN-OSYLJGHBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1[C@@H]2CCC[C@H]1CC(C2)NC(=O)C3=C4C(=CC=C3)OC(=N4)C5=CC=CC=C5OC,5.958607314841775,COc1ccccc1-c1nc2c(C(=O)NC3C[C@@H]4CCC[C@H](C3)N4C)cccc2o1
26699,CHEMBL1921985,OZPFIJIOIVJZMN-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)[C@@]3(CCN4C3=CN=C4)O,5.0,CNC(=O)c1ccc2cc([C@]3(O)CCn4cncc43)ccc2c1
26700,CHEMBL1921976,OZPFIJIOIVJZMN-SFHVURJKSA-N,ORTERONEL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)[C@]3(CCN4C3=CN=C4)O,5.0,CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1
26701,CHEMBL1921976,OZPFIJIOIVJZMN-SFHVURJKSA-N,ORTERONEL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human B-lymphoblastoid cell microsomal CYP3A4 assessed as testosterone 6beta-hydroxylation preincubated for 5 mins with substrate,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)[C@]3(CCN4C3=CN=C4)O,4.522878745280337,CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1
26702,CHEMBL1921977,OZPFIJIOIVJZMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O,5.0,CNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
26722,CHEMBL493,OZVBMTJYIDMWIL-AYFBDAFISA-N,BROMOCRIPTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,2999.16,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,5.523000364762793,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
26723,CHEMBL493,OZVBMTJYIDMWIL-AYFBDAFISA-N,BROMOCRIPTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,5.698970004336019,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
26728,CHEMBL1910126,OZVWHEGOMPUFMZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)NCC3=CN=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,5.154901959985743,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)NCc1cccnc1)C2=O
26732,CHEMBL362489,OZXGHWIQASWJQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,1835.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)N)N3C=CN=C3)N(C)C,5.7363639314118915,CC(C(c1ccc2cc(OCC(C)(C)C(N)=O)ccc2c1)n1ccnc1)N(C)C
26733,CHEMBL2064331,OZYPJCFRMNJWPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1COCCN1C2=CC(=O)NC(=N2)CC3=NC4=C(N3)C=C(C=C4)F,4.3979400086720375,O=c1cc(N2CCOCC2)nc(Cc2nc3ccc(F)cc3[nH]2)[nH]1
26734,CHEMBL292759,OZYPUQNRUYTZDI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9925723.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4 as total cyclosporin oxidation (1 uM),"5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=C(C=CC(=C2)NS(=O)(=O)C3=CC=C(C=C3)Br)OC,5.221848749616356,COc1ccc(NS(=O)(=O)c2ccc(Br)cc2)cc1N1CCN(C)CC1
26735,CHEMBL218468,OZYYOJGDGOAPBJ-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CC3=C4C=C(C=CC4=NC=C3)F)C(=O)N5CC[C@H](C5)O)C(=O)N(C1=O)C,4.301029995663981,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccc(F)cc34)sc21
26742,CHEMBL245585,PAEWYHLNDGOPKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276063.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(C(CN1C2=NC=NC(=C2)C3=CC(=CC=C3)C(=O)O)N)C4=CC(=C(C=C4F)F)F,5.0,NC1CN(c2cc(-c3cccc(C(=O)O)c3)ncn2)CC1c1cc(F)c(F)cc1F
26762,CHEMBL603691,PAJUEHORDWKTSQ-ACDBMABISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)C(=O)N(CC2=CC(=CC=C2)OC3CCCC3)C4C[C@@H]5CNC[C@@H]5C4,5.0,Cn1cnc(C(=O)N(Cc2cccc(OC3CCCC3)c2)C2C[C@@H]3CNC[C@@H]3C2)c1
26773,CHEMBL1949693,PARCWEQRCVIVGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=C(C=NC5=CC=CC=C54)C#N)C)C,5.522878745280337,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1c(C#N)cnc3ccccc13)c(=O)n2C
26775,CHEMBL1825096,PARUULGUCQEWNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798738.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxy-4(trifluoromethyl)-coumarin,"Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)NC1=NC=C(C=C1)NC2=NC=C3C=NN(C3=N2)C4CCCCCC4,5.0,CS(=O)(=O)Nc1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cn1
26776,CHEMBL1825096,PARUULGUCQEWNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798738.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxyquinoline,"Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)NC1=NC=C(C=C1)NC2=NC=C3C=NN(C3=N2)C4CCCCCC4,5.0,CS(=O)(=O)Nc1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cn1
26784,CHEMBL2086758,PAUHYDQXWBOZBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC=CC=C4)C5=NC=CN5,4.6020599913279625,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccccc2)c2ncc[nH]2)C(=O)N3)CC1
26787,CHEMBL2147070,PAVGMVFHWIYGKG-PKLMIRHRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22938786.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)O)C3=C(C1=O)N(C(=N3)N4CCC[C@H](C4)N)CC5=C(C=CC(=C5)F)Cl.Cl,4.301029995663981,Cn1c(=O)c2c(nc(N3CCC[C@@H](N)C3)n2Cc2cc(F)ccc2Cl)c2ccc(C(=O)O)cc21
26790,CHEMBL2387588,PAWQBUAAGSRLHH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC(=C(C(=C1)Cl)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CC=C(C=C5)Cl)F,4.522878745280337,O=c1[nH]c2cc(-c3ccc(Cl)cc3)ccc2c2nc(-c3c(F)cccc3Cl)[nH]c12
26801,CHEMBL1224194,PBADEQPCYAGBIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709545.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted biaryl pyrazoles as sodium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NN1C2=CC=CC(=C2)C3=C(C=C(C=C3)C(F)(F)F)C(F)(F)F)C(=O)N,4.0,Cc1cc(C(N)=O)nn1-c1cccc(-c2ccc(C(F)(F)F)cc2C(F)(F)F)c1
26814,CHEMBL1911820,PBCZOAJIAODBER-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=C(O1)COC[C@H](C(=O)N2CCN(CC2)C)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,4.698970004336019,Cc1ncc(COC[C@@H](NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C(=O)N2CCN(C)CC2)o1
26825,CHEMBL208528,PBIBEWTURATALQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16495056.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,5.102372908709558,CCCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
26850,CHEMBL2059790,PBOUVYGTCAXBDO-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC=C(C=C3)O)NC(=O)N4CCC(CC4)N5C6=CC=CC=C6NC5=O,4.3979400086720375,O=C(N[C@H](Cc1ccc(O)cc1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
26852,CHEMBL3125390,PBQDTIVOGGGFGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C2=C1C(=CC=C2)Br)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N,4.3979400086720375,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21
26869,CHEMBL2048485,PCAUEUWLOMHNGF-VLQCVTHLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,COC1=CC=C(C=C1)CC2=CC(=CC=C2)[C@@H]3C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO,4.301029995663981,COc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1
26870,CHEMBL2048485,PCAUEUWLOMHNGF-VLQCVTHLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,COC1=CC=C(C=C1)CC2=CC(=CC=C2)[C@@H]3C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO,4.301029995663981,COc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1
26877,CHEMBL462360,PCBPNOBJASOPBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCCNC3=C4C=CC(=CC4=NC=C3)Cl,6.0,CC1(CC(=O)NCCNc2ccnc3cc(Cl)ccc23)CC2(CCCCC2)OO1
26879,CHEMBL474484,PCCGUZVUPBIHJH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19231183.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CNC1=C(C(=NC(=N1)C#N)N2CCNCC2)N,5.0,CC(C)CNc1nc(C#N)nc(N2CCNCC2)c1N
26896,CHEMBL563791,PCLLBFUYVTXKME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,13400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC(=O)NC(C2=CC=CC=C2)C3=NC=CN3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,4.872895201635193,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(c1ccccc1)c1ncc[nH]1
26899,CHEMBL502560,PCMOPVSFMUOUFR-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CN2CC3=CC(=CC=C3)OC4=C(C=CC(=C4)CN5C=NC=C5CN[C@H]1C2=O)C#N,5.050609993355088,N#Cc1ccc2cc1Oc1cccc(c1)CN1CC[C@@H](NCc3cncn3C2)C1=O
26901,CHEMBL2048199,PCMUEDIHLGLRQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCNC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=C(N2CC(=O)O)C=CC(=C3)F,5.3979400086720375,CCCCNC(=O)c1ccc(OC)c(CSc2nc3cc(F)ccc3n2CC(=O)O)c1
26902,CHEMBL2048199,PCMUEDIHLGLRQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCNC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=C(N2CC(=O)O)C=CC(=C3)F,5.154901959985743,CCCCNC(=O)c1ccc(OC)c(CSc2nc3cc(F)ccc3n2CC(=O)O)c1
26904,CHEMBL451916,PCOIOMHQQCRCRU-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NC)C4=C(C(=CC=C4)OCCCCC(=O)O)F,4.886056647693163,CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
26923,CHEMBL3289023,PCTUHSSCHRLPLB-MXVIHJGJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24794746.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.",Bioorg. Med. Chem.,PUBLICATION,,C1CC(CCC1N)NC(=O)C2=CC(=CC(=C2)OC3=CC=C(C=C3)C(=N)N)OC4=CC=C(C=C4)C(=N)N,4.522878745280337,N=C(N)c1ccc(Oc2cc(Oc3ccc(C(=N)N)cc3)cc(C(=O)NC3CCC(N)CC3)c2)cc1
26925,CHEMBL494947,PCWGGOVOEWHPMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19246199.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1)C2=CN=CC(=N2)OCC3=CC(=CC=C3)Cl,4.301029995663981,Clc1cccc(COc2cncc(N3CCNCC3)n2)c1
26946,CHEMBL3692706,PDBQDSXSCZPLNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27017115.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC2=C1COC2=O)CCN3CCN(CC3)C(=O)CC4=CN=C(C=C4)N5C=NN=N5,4.301029995663981,Cc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O
26948,CHEMBL1829759,PDBVUENMKQBWQZ-UZTOHYMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCCO)C4=CC=CC=C4,4.853871964321762,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O
26949,CHEMBL1258079,PDDXKTLXEAXUKO-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CN(C(=O)C2=CC3=CC(=C(C=C3N12)Br)OC4CCN(CC4)C(C)C)CC5CC5,4.301029995663981,CC(C)N1CCC(Oc2cc3cc4n(c3cc2Br)[C@@H](C)CN(CC2CC2)C4=O)CC1
26950,CHEMBL103163,PDFBPLZTOXIMKS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC=C(C=C1)N=CNO,4.0,CC(C)(C)c1ccc(N=CNO)cc1
26973,CHEMBL2001019,PDMUGYOXRHVNMO-UHFFFAOYSA-N,PF-04217903,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22924734.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.",J. Med. Chem.,PUBLICATION,,C1=CC2=C(C=CC(=C2)CN3C4=NC(=CN=C4N=N3)C5=CN(N=C5)CCO)N=C1,4.522878745280337,OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1
26984,CHEMBL235882,PDQQOEIEIIKGPR-PKTZIBPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)F)[C@H]2CN(C[C@@H]2C(=O)N(C)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)C4=NC=C(N=C4)C,4.958607314841775,Cc1cnc(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)cn1
27004,CHEMBL2441952,PECDPZCIECMGCM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)N(C)C)C3=C(C=C(C=C3)Cl)Cl)CN,4.886056647693163,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N(C)C)C2
27005,CHEMBL2441952,PECDPZCIECMGCM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)N(C)C)C3=C(C=C(C=C3)Cl)Cl)CN,4.443697499232712,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N(C)C)C2
27006,CHEMBL502824,PECISPDQTYCDOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672861.0,IC50,=,9070.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,PUBLICATION,,CC(=O)C1=CN=CC(=C1)C2=CC3=C(C=C2)C=C(C=C3)OC,5.042392712939905,COc1ccc2cc(-c3cncc(C(C)=O)c3)ccc2c1
27016,CHEMBL1270661,PEFPYUBFXFOFOB-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)C,5.130768280269024,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1
27017,CHEMBL1270661,PEFPYUBFXFOFOB-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)C,4.958607314841775,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1
27018,CHEMBL1270661,PEFPYUBFXFOFOB-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)C,5.154901959985743,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1
27030,CHEMBL1077937,PEKRVEUKQJQVHP-IOWSJCHKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)CN(C[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)C[C@@H](CC4=CC=CC=C4)NC(=O)OCC5=NC=CS5,7.301029995663981,COc1cccc(CN(C[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C[C@@H](Cc2ccccc2)NC(=O)OCc2nccs2)c1
27035,CHEMBL3260742,PEMIFSRCWZWBKB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=CN=C(C=C3)C(F)(F)F)C4=CC=NC=C4)C5=CC=C(C=C5)Cl,4.7447274948966935,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O
27049,CHEMBL467633,PEUFWNJXEBOKMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=C(C=CC=C3F)F,5.698970004336019,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F
27051,CHEMBL270978,PEVWUDKTVWGCGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,CC1=NOC(=C1)NC(=O)C2=CC=CC3=C2C=CC(=C3)OC4=C5C=C(C(=CC5=NC=C4)OC)OC,4.3979400086720375,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5cc(C)no5)cccc4c3)c2cc1OC
27072,CHEMBL113227,PFAUOLMRDJNYLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,344.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1N2C=CN=C2)OCCCC3=CC=NC=C3,6.46344155742847,c1cc(CCCOc2ccc(-n3ccnc3)cc2)ccn1
27076,CHEMBL2057525,PFEFYYZIBALVTE-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)(C)O,6.853871964321762,CCN(C)c1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)O)cc2o1
27078,CHEMBL3672577,PFESJDCERSQSIQ-ROJLCIKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)NC2(CCN(CC2)C)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.721246399047171,CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCN(C)CC2)cs1
27079,CHEMBL3672577,PFESJDCERSQSIQ-ROJLCIKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,340.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)NC2(CCN(CC2)C)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.468521082957745,CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCN(C)CC2)cs1
27102,CHEMBL2419524,PFMSCDXGGGWGEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4)C5COC5,5.0,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3COC3)CC2)cc1)N1Cc2ccncc2C1
27103,CHEMBL2419524,PFMSCDXGGGWGEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4)C5COC5,5.0,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3COC3)CC2)cc1)N1Cc2ccncc2C1
27113,CHEMBL2058905,PFOCQARJLIDBDQ-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,24.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)C5=CC=CC=C5,7.619788758288394,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(-c3ccccc3)oc2c1
27114,CHEMBL234940,PFODPHDNBFSMOX-UHFFFAOYSA-N,GW848687,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19036582.0,IC50,=,89000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(=C(C1)C2=C(C=CC(=C2)Cl)OCC3=C(C=C(C=C3)F)F)C4=NC(=CC=C4)C(=O)O,4.050609993355088,O=C(O)c1cccc(C2=C(c3cc(Cl)ccc3OCc3ccc(F)cc3F)CCC2)n1
27136,CHEMBL214335,PFTJCYRHNKTTTO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20471260.0,IC50,=,194000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,3.712198270069774,COc1ccccc1CC(c1ccccc1)N1CCNCC1
27137,CHEMBL418382,PFTRTEKHKPGIAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,20030.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C3=C1C(=NC(=N3)CN4CCOCC4)N5CCN(CC5)CCC6=CC(=C(C=C6)F)F)C(=NC=C2)Cl,4.698319050706424,Cn1c2ccnc(Cl)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
27138,CHEMBL557263,PFTYUXPUTSSSAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC(=O)NC(CN2C=CN=C2)C3=CC=CC=C3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,7.3979400086720375,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1ccnc1)c1ccccc1
27147,CHEMBL1951575,PFWVGKROPKKEDW-UHFFFAOYSA-N,VIDUPIPRANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22930276.0,IC50,>=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 30 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CC(C)(C)NC(=O)C1=CC(=C(C=C1)OC2=C(C=C(C(=C2)F)CC(=O)O)Cl)NS(=O)(=O)C3=C(C=C(C=C3)C4CC4)Cl,4.522878745280337,CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1
27148,CHEMBL1951575,PFWVGKROPKKEDW-UHFFFAOYSA-N,VIDUPIPRANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22930276.0,IC50,>=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 to 30 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CC(C)(C)NC(=O)C1=CC(=C(C=C1)OC2=C(C=C(C(=C2)F)CC(=O)O)Cl)NS(=O)(=O)C3=C(C=C(C=C3)C4CC4)Cl,4.522878745280337,CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1
27155,CHEMBL476775,PFYPNHSILULSMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1C(C2=CC=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,Cc1ccccc1C(NC(=O)CNC(=O)c1ccc(F)cc1)c1ccccc1
27157,CHEMBL3408529,PFZOBHSCNYUKMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)N3C(=NOC3=O)C(S2)(C4=CC=C(C=C4)Br)OCC(F)(F)F,4.698970004336019,O=c1onc2n1-c1ccccc1SC2(OCC(F)(F)F)c1ccc(Br)cc1
27158,CHEMBL3408529,PFZOBHSCNYUKMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)N3C(=NOC3=O)C(S2)(C4=CC=C(C=C4)Br)OCC(F)(F)F,4.698970004336019,O=c1onc2n1-c1ccccc1SC2(OCC(F)(F)F)c1ccc(Br)cc1
27162,CHEMBL207293,PGBMWNVGYFSLII-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16503138.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)COC2=C(C=C(C=C2)Cl)C3=CN=CN3C4=CC=CC(=C4)C(=O)O,6.0,O=C(O)c1cccc(-n2cncc2-c2cc(Cl)ccc2OCc2ccccc2)c1
27163,CHEMBL252616,PGCKAECGLQMGNP-SJLPKXTDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NC(=NO4)C,4.522878745280337,CC[C@@H]1CCC[C@H](C2(Cc3nc(C)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
27167,CHEMBL559101,PGDZKICIZRFRTP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1N2C=CC=N2)C(=O)NC3CC3C4=CC=CC=C4,5.0,O=C(NC1CC1c1ccccc1)N1CCC(n2cccn2)CC1
27175,CHEMBL3409588,PGGLRAWFUJMQBN-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25603482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.",J. Med. Chem.,PUBLICATION,,C1COCCC1NC2=NC=CC(=N2)C3=CC(=O)N(C=C3)[C@H](CO)C4=CC(=C(C=C4)Cl)F,5.0,O=c1cc(-c2ccnc(NC3CCOCC3)n2)ccn1[C@H](CO)c1ccc(Cl)c(F)c1
27182,CHEMBL481839,PGINMPJZCWDQNT-GJZGRUSLSA-N,ESCHOLTZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16562853.0,IC50,=,13400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,CN1[C@H]2CC3=CC4=C(C=C3[C@@H]1CC5=CC6=C(C=C25)OCO6)OCO4,4.872895201635193,CN1[C@H]2Cc3cc4c(cc3[C@@H]1Cc1cc3c(cc12)OCO3)OCO4
27191,CHEMBL1221512,PGOKBMWPBDRDGN-IBXSQZDTSA-N,L-744832,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)OC(C)C)NC[C@H](CS)N,5.522878745280337,CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS
27196,CHEMBL3645534,PGQZLXAQNFHWTD-AFMDSPMNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=NN(C(=O)C=C2)C)N3CC[C@](OC3=O)(CCCO)C4=CC=CC=C4,4.301029995663981,C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O
27238,CHEMBL256989,PHGQFDGZFPQJNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CC2C(CCCN2C(=O)CN3C4=CC(=C(C=C4N=CC3=O)Cl)Cl)C5=CC=CC=C5,5.920818753952375,O=C(Cn1c(=O)cnc2cc(Cl)c(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1
27250,CHEMBL227089,PHJKYNSEJIZCAD-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,COC1=C(C=C2C(=C1)C(=O)N(C(=N2)N3CCC[C@H](C3)N)CC4=CC=CC=C4C#N)OC,6.301029995663981,COc1cc2nc(N3CCC[C@@H](N)C3)n(Cc3ccccc3C#N)c(=O)c2cc1OC
27263,CHEMBL1808644,PHMSOOBTXSCMBO-SOFGYWHQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=C(CN1CCC3=CNC4=CC=CC=C43)C=C(C=C2)/C=C/C(=O)NO,5.0,O=C(/C=C/c1ccc2c(c1)CN(CCc1c[nH]c3ccccc13)C2)NO
27264,CHEMBL3127906,PHNBVYLTLRRMHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24428186.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Pharmacological Evaluation of a Novel Series of Pyridopyrazine-1,6-dione ¿-Secretase Modulators.",J. Med. Chem.,PUBLICATION,,CC1=CN(C=N1)C2=CC=C3C(=O)N(CCN3C2=O)CCOC4=C(C=C(C=C4)Cl)C(F)(F)F,4.522878745280337,Cc1cn(-c2ccc3n(c2=O)CCN(CCOc2ccc(Cl)cc2C(F)(F)F)C3=O)cn1
27267,CHEMBL2041193,PHOCCMVBRLGOKP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=NC=C4)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ccncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1
27277,CHEMBL272693,PHUIVAKJVUJLDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=NC=C5,7.0,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccncc5)cccc4c3)c2cc1OC
27278,CHEMBL3291346,PHUJLIRGKVQXJQ-OSPHWJPCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@]12CC[C@@H](C1(C)C)C3=C2N(N(C3=O)C4=C(C=C(C=C4)F)F)CC5=CC=CC=C5,5.214670164989233,CC1(C)[C@@H]2CC[C@@]1(C)c1c2c(=O)n(-c2ccc(F)cc2F)n1Cc1ccccc1
27279,CHEMBL3358928,PHUOGFXDMSBGIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)OC(C)C)(C(F)(F)F)O,6.522878745280337,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(OC(C)C)ncc2[nH]1)C(F)(F)F
27289,CHEMBL595154,PHVWYDDIUNHCKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20004097.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1OC2=CC=CC=C2C(F)(F)F)C3=NN=C(C=C3)N4C=CN=C4,6.3979400086720375,FC(F)(F)c1ccccc1OC1CCN(c2ccc(-n3ccnc3)nn2)CC1
27293,CHEMBL833,PHWBOXQYWZNQIN-UHFFFAOYSA-N,TICLOPIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,32700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,4.485452247339714,Clc1ccccc1CN1CCc2sccc2C1
27305,CHEMBL2437430,PHYADSPDZPCYNR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)C5=CC(=CC(=C5)F)F)CC6=CC(=NC=C6)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5cc(F)cc(F)c5)c5cc(F)ccc54)CC3)CC2)ccn1
27313,CHEMBL2036268,PIAOYGXDXCCGEO-KAECKJJSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22420844.0,IC50,=,57300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,CNC1CCC(CC1)C2=CNC3=C2C=C(C=C3)N=C(C4=CC=CS4)N.Cl,4.24184537803261,CNC1CCC(c2c[nH]c3ccc(N=C(N)c4cccs4)cc23)CC1
27314,CHEMBL1835772,PIBBQKCYYNVLJZ-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NN(C(=O)C4=C3SC=C4)C(C)C,4.522878745280337,CC(C)n1nc(-c2ccc(OCCCN3CCC[C@H]3C)cc2)c2sccc2c1=O
27315,CHEMBL1923127,PIBCEYLKROLZIT-SJHOIFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=C(C(=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F)Cl)CCCN6CCOCC6,5.585026652029182,COCCCc1cc(CCCN2CCOCC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1
27327,CHEMBL2170606,PIFFTSRNYNUHHY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,CC(C)C(=O)N1CCC(CC1)C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F,6.3979400086720375,CC(C)C(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
27331,CHEMBL1090175,PIHREWZGYZJCNQ-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=C2C=CC(=C3)OC)CCN(C)C,5.0,COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1cnccn1
27332,CHEMBL1821837,PIHRJUVRNRHPAG-LJQANCHMSA-N,GSK1997132B,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798739.0,IC50,=,45000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DEF substrate,Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPAR¿ partial agonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@H](C1=CC=CC=C1)NC(=O)C2=CC3=C(C=C2)N(C=N3)CC4=C(C=C(C=N4)F)F,4.346787486224656,CC[C@@H](NC(=O)c1ccc2c(c1)ncn2Cc1ncc(F)cc1F)c1ccccc1
27333,CHEMBL1821837,PIHRJUVRNRHPAG-LJQANCHMSA-N,GSK1997132B,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798739.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPAR¿ partial agonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@H](C1=CC=CC=C1)NC(=O)C2=CC3=C(C=C2)N(C=N3)CC4=C(C=C(C=N4)F)F,4.0,CC[C@@H](NC(=O)c1ccc2c(c1)ncn2Cc1ncc(F)cc1F)c1ccccc1
27344,CHEMBL1080787,PIKCALBGLDBAKK-NSHDSACASA-N,PF-184298,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19647430.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using felodipine as a substrate,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,4.522878745280337,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1
27345,CHEMBL1080787,PIKCALBGLDBAKK-NSHDSACASA-N,PF-184298,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19647430.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as a substrate,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,4.522878745280337,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1
27346,CHEMBL1080787,PIKCALBGLDBAKK-NSHDSACASA-N,PF-184298,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19647430.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as a substrate,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,4.522878745280337,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1
27351,CHEMBL2325940,PILAMBNAJPBLFA-RWXRFDSASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23317569.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=C(C=C(C=C4)OC5=CC=CC=C5)OC)O,4.698970004336019,COc1cc(Oc2ccccc2)ccc1-c1nc(C2CC(C)(O)C2)n2ccnc(N)c12
27353,CHEMBL3702676,PILJPIHRKFJABP-CXNSMIOJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10500.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NCCC8=CC=CC=C8,4.978810700930062,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCCc6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
27354,CHEMBL536743,PIMBSDCVZVPYEY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17118654.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)CC5CCCCC5.Cl,5.031517051446065,CCCCN1C(=O)C(CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
27355,CHEMBL536743,PIMBSDCVZVPYEY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)CC5CCCCC5.Cl,5.031517051446065,CCCCN1C(=O)C(CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
27370,CHEMBL3702759,PIPXSGQNTFVPRN-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4780.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NN7CCCCC7,5.320572103387881,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCCCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
27371,CHEMBL3116160,PIRBVHZKYOUJCV-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@](C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC(=C(S4)Br)C(F)(F)F,4.3979400086720375,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)c(Br)s2)c2ccc(Cl)cn2)c1
27372,CHEMBL3116160,PIRBVHZKYOUJCV-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@](C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC(=C(S4)Br)C(F)(F)F,4.3979400086720375,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)c(Br)s2)c2ccc(Cl)cn2)c1
27375,CHEMBL566242,PITVIIACVFAXRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C=C5)F)F,5.040958607678906,COc1cnc2c(NCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1
27376,CHEMBL566242,PITVIIACVFAXRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C=C5)F)F,4.301029995663981,COc1cnc2c(NCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1
27381,CHEMBL3234575,PIWZTMSNVDVOEQ-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCC[C@H]3C(=O)NCCC4=CC=C(C=C4)C#N,5.657577319177793,CN1CCN(c2cc(N3CCC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1
27382,CHEMBL3234576,PIWZTMSNVDVOEQ-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCC[C@@H]3C(=O)NCCC4=CC=C(C=C4)C#N,6.154901959985743,CN1CCN(c2cc(N3CCC[C@@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1
27385,CHEMBL480296,PIYHDSUVUSVLGU-HSQXHLSASA-N,(-)-CUBEBININ,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,COC1=CC(=CC(=C1OC)OC)C[C@H]2COC([C@@H]2CC3=CC(=C(C(=C3)OC)OC)OC)O,4.823908740944319,COc1cc(C[C@H]2COC(O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC
27388,CHEMBL3104529,PJARPEFKLCVCAE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1900.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC(C)(C)C(=O)N1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3,5.721246399047171,CC(C)(C)C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
27391,CHEMBL2385904,PJEVQOJEJXZQAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)N3CCC4=C(C3)C5=CC=CC=C5N4CC(=O)O,4.301029995663981,CCc1ccc(-c2ccc(C(=O)N3CCc4c(c5ccccc5n4CC(=O)O)C3)cc2)cc1
27403,CHEMBL534958,PJJQGSLLJOVYBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.Cl,4.0,N#Cc1ccc(C(=O)N2CCN(c3ccc(OCCCN4CCCCC4)cc3)C(=O)C2)cc1
27419,CHEMBL585182,PJNOYUGDEFSKQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19842661.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.",J. Med. Chem.,PUBLICATION,,CN(C)CC1=NC2=C(C(=O)N1)SC3=C2C=C(C=C3)C4=CC=C(C=C4)O,4.698970004336019,CN(C)Cc1nc2c(sc3ccc(-c4ccc(O)cc4)cc32)c(=O)[nH]1
27428,CHEMBL2170754,PJRMJIREEYPPSW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22277094.0,IC50,=,54000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17ß-HSD1.,J. Med. Chem.,PUBLICATION,,CC1=C(C=C(C=C1)C(=O)C2=NC3=C(S2)C=C(C=C3)O)O,4.267606240177032,Cc1ccc(C(=O)c2nc3ccc(O)cc3s2)cc1O
27469,CHEMBL2380641,PKGINCVLUORIEU-DTZVNRBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)N1CCN(CC1)C2=CN=C(N=C2)N3CCN(C4=CC=CC=C43)C(=O)NC5C6CC7CC5CC(C7)(C6)O,5.0,CS(=O)(=O)N1CCN(c2cnc(N3CCN(C(=O)NC4C5CC6CC4CC(O)(C6)C5)c4ccccc43)nc2)CC1
27496,CHEMBL565195,PKOKKGWFSDPGGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,4.698970004336019,CS(=O)(=O)c1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
27497,CHEMBL565195,PKOKKGWFSDPGGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 coincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,4.522878745280337,CS(=O)(=O)c1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
27498,CHEMBL1090528,PKONXOYDGGORHO-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CS3,5.0,Cc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccs1
27500,CHEMBL1079245,PKPQLLBQJIRCMS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)NC3=NNNN3)C4=CC=CC=C4,5.0,O=C(CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1)NC1=NNNN1
27503,CHEMBL2448718,PKRLJALWWJCHMA-MTDXEUNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C/C(=N\OC)/C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CC=C(C=C3)C4=CC=CC=C4,5.522878745280337,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccc3)cc2)c1
27518,CHEMBL3664686,PKVHOLANSOCZKZ-QNBVUBCUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)CC(C)CO)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,CC(CO)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O
27560,CHEMBL289228,PLHJCIYEEKOWNM-HHHXNRCGSA-N,TIPIFARNIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,CN1C=NC=C1[C@@](C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N,5.769551078621726,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C
27561,CHEMBL289228,PLHJCIYEEKOWNM-HHHXNRCGSA-N,TIPIFARNIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,4060.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,CN1C=NC=C1[C@@](C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N,5.391473966422806,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C
27566,CHEMBL1078755,PLHSBHYVGMRRQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC#N)C3=CC=CC=C3,5.0,N#CCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
27570,CHEMBL296580,PLITYYGQMDTHMM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,>,3750.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)NC(=N2)SCC3=CC=CC=N3,5.425968732272281,c1ccc(CSc2nc3ccccc3[nH]2)nc1
27574,CHEMBL586213,PLPFIMGOJTYGRW-UHFFFAOYSA-N,TCMDC-139046,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate incubated for 30 mins prior to substrate addition measured up to 10 mins by fluorimetry,,ACS Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C2C(=C1)CCN2C(=O)NC3=CC(=CC(=C3)C4=CN=CC=C4)OC(F)(F)F)C(F)(F)F,4.301029995663981,COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(OC(F)(F)F)cc(-c3cccnc3)c1)CC2
27575,CHEMBL3664662,PLRIPZFMRUQNKJ-SVEHJYQDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CC[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,CC[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
27578,CHEMBL1910120,PLSOUKNNDKPEQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCN(CC3)C(=O)C)C4=C(C=C(C=C4)Cl)Cl)CN,4.769551078621726,CC(=O)N1CCN(C(=O)CN2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)CC1
27581,CHEMBL2018484,PLUJPPMSHJDKIV-RLWLMLJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,C1[C@H](CN([C@@H]1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CN4C=NC=N4)CC5=CC=CC=C5,4.698970004336019,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccccc2)CN1C(=O)Cn1cncn1
27583,CHEMBL429736,PLVGDGRBPMVYPB-FDUHJNRSSA-N,RETOSIBAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=COC(=N2)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4,4.0,CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1coc(C)n1
27584,CHEMBL401858,PLVGDGRBPMVYPB-JUJUEEDWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=COC(=N2)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4,4.0,CC[C@@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1coc(C)n1
27586,CHEMBL3400443,PLWCLTNJVOKTLA-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NC(=O)CC2CCOCC2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,5.0,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)CC2CCOCC2)C(C)C)ccc1OC
27587,CHEMBL377286,PLXKSCLQIJZCDI-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC(CC)(COC1=CC2=C(C=C1)C=C(C=C2)[C@H]([C@@H](C)N(C)C)N3C=CN=C3)C(=O)O,5.275724130399211,CCC(CC)(COc1ccc2cc([C@H]([C@@H](C)N(C)C)n3ccnc3)ccc2c1)C(=O)O
27588,CHEMBL401910,PLXQKDCMQVUJJI-DNVJHFABSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=CO1)[C@H](C(=O)NC(C)C)N2[C@@H](C(=O)N[C@@H](C2=O)C3CC4=CC=CC=C4C3)CC(C)C,4.0,Cc1nc([C@H](C(=O)NC(C)C)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1
27589,CHEMBL3409857,PLXRFUMPYLQAFR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)OC)C2CC(C(=O)N2CC3=CC=C(C=C3)OC(F)(F)F)(F)F,5.2839966563652006,COc1cccc(OC)c1C1CC(F)(F)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
27600,CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5.0,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
27601,CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5.187086643357144,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
27603,CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19933795.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 30 mins,"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.",Antimicrob. Agents Chemother.,PUBLICATION,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5.180456064458132,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
27604,CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22205779.0,IC50,=,1450.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated for 15 mins before substrate addition by LC-MS method,Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.,Drug Metab. Dispos.,PUBLICATION,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5.838631997765025,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
27605,CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22205779.0,IC50,=,2060.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation after 7.5 mins by LC-MS method,Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.,Drug Metab. Dispos.,PUBLICATION,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,5.686132779630847,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
27622,CHEMBL3422085,PMDUMOUXISSZED-BTOOTBGFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1CC1[C@H](C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6COC7,5.853871964321762,O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
27623,CHEMBL1671967,PMEAQKGKOGFUOS-CHHVJCJISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)/C=C\2/C(=O)NC(=O)S2)OC3=C(C=C(C=C3)C(F)(F)F)Br,5.42021640338319,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C(F)(F)F)cc1Br
27629,CHEMBL507614,PMHDSACGRKBACK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18455394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CSC2=C1NC(=C2)C(=O)O,5.0,O=C(O)c1cc2sccc2[nH]1
27630,CHEMBL2425607,PMIMNVFAGLMWQP-NNWAQCLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=NC=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F,5.795880017344075,COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(C(C)(C)C)ccn3)[C@H]2O)cc(F)c1N)C(F)(F)F
27636,CHEMBL2381071,PMJFHEYTYKKNJY-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535328.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NC(=N1)NC[C@@H]2CC3(CC3)CN2C(=O)C4=C(SC(=N4)C)C5=CC=CC=C5)C,5.102372908709558,Cc1cc(C)nc(NC[C@@H]2CC3(CC3)CN2C(=O)c2nc(C)sc2-c2ccccc2)n1
27649,CHEMBL478870,PMMKHGYQMNVMIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=CC3=C(C=C21)C(=CN3S(=O)(=O)C4=CC(=CC=C4)Cl)Cl,4.920818753952375,O=S(=O)(c1cccc(Cl)c1)n1cc(Cl)c2cc3c(cc21)CCNCC3
27650,CHEMBL478870,PMMKHGYQMNVMIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=CC3=C(C=C21)C(=CN3S(=O)(=O)C4=CC(=CC=C4)Cl)Cl,4.698970004336019,O=S(=O)(c1cccc(Cl)c1)n1cc(Cl)c2cc3c(cc21)CCNCC3
27668,CHEMBL2036635,PMRJMYCLQDPGBL-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450133.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C(=O)CN3CCN(CC3)C(=O)C4=CC=CC=C4,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCN(C(=O)c3ccccc3)CC2)cc1
27669,CHEMBL1515,PMRYVIKBURPHAH-UHFFFAOYSA-N,METHIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,CN1C=CNC1=S,5.0,Cn1cc[nH]c1=S
27670,CHEMBL1515,PMRYVIKBURPHAH-UHFFFAOYSA-N,METHIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CN1C=CNC1=S,5.0,Cn1cc[nH]c1=S
27676,CHEMBL464234,PMSFEOUVENKQAA-AMVBQIFNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19014886.0,IC50,=,13600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 green,"Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)C[C@@]34CC[C@@H](C3(C)C)C[C@@H]4O,4.866461091629782,C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](C[C@@H]2O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F
27677,CHEMBL464234,PMSFEOUVENKQAA-AMVBQIFNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19014886.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 red,"Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)C[C@@]34CC[C@@H](C3(C)C)C[C@@H]4O,4.6020599913279625,C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](C[C@@H]2O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F
27692,CHEMBL550652,PMWSGFIJYUECNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,CN1C=NN=C1C2CCN(CC2)C(=O)NC3CC3C4=CC=CC=C4,5.0,Cn1cnnc1C1CCN(C(=O)NC2CC2c2ccccc2)CC1
27719,CHEMBL2023124,PNDYJPUJHZPECK-NHTMILBNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CNC[C@H](CC1CCOCC1)NC(=O)N2CCC[C@H](C2)[C@H](C3=CC(=CC=C3)Cl)OCCNC(=O)OC,4.522878745280337,CNC[C@H](CC1CCOCC1)NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1
27737,CHEMBL2436327,PNJRQMGMROTWQX-OWEKSZQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,CC1=C(C2=CC=CC=C2C=C1)CN3C4=CC=CC=C4N(C[C@@H](C3=O)NC(=O)[C@H](C)NC)C(=O)CC(C)C.Cl,5.886056647693163,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(C)ccc3ccccc23)C1=O
27742,CHEMBL270655,PNLGKAIYTKSYNF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC1=C(C=C(C=C1)CC(=O)NC2=CC(=NC(=N2)C3=CC=CC=N3)N4C(=CC(=N4)C)C)OC,5.154901959985743,CCOc1ccc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc1OC
27745,CHEMBL2017105,PNONWZINZRBQGI-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCC1=CC=CC=C1C2=CC(=NO2)[C@H]3CNCC[C@@]3(C4=CC(=C(C=C4)F)F)O,4.494850021680094,CC(=O)NCCc1ccccc1-c1cc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)no1
27750,CHEMBL248407,PNQPSLZAXAGIOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCN(CC3)CC4=CC5=C(C=C4)OCC(=O)N5CCC6=CC=CC=C6,5.045757490560675,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(CCc4ccccc4)C(=O)CO5)CC3)cccc2n1
27752,CHEMBL3601403,PNRKMBJQIFDKIH-BXKNEMSHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26181851.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.,J. Med. Chem.,PUBLICATION,,CC(C)OC1=C(C=C2CC(=O)N([C@H](C2=C1)C3=CC=C(C=C3)Cl)C4=CN=C(C=N4)N(C)CC5CCC(CC5)N6CCN(C(=O)C6)C)OC,4.698970004336019,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1cnc(N(C)CC3CCC(N4CCN(C)C(=O)C4)CC3)cn1)C(=O)C2
27753,CHEMBL372846,PNSGYWXRFOWVFA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,58000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)C4=CC=C(C=C4)O)F)F)C(=O)O,4.236572006437063,O=C(O)C1(c2ccc(-c3ccc(-c4ccc(O)cc4)c(F)c3)c(F)c2)CC1
27754,CHEMBL1669407,PNSJAJNXVSKCBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3)CCF,5.0,CN(CCF)CCC1=C(Cc2cnccn2)c2ccccc2C1
27759,CHEMBL3311221,PNUGCHCVDNISAD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,72000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1F)F)C(CN2C=NN=N2)(C(C3=NC=C(C=C3)OCC(F)(F)F)(F)F)O,4.142667503568732,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(OCC(F)(F)F)cn1
27771,CHEMBL3393294,PNXHUKPFSGHNBN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)CNC(=O)C2=CC=C(C=C2)OC3=CC=CC=C3C#N,5.0,N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccccc2)cc1
27784,CHEMBL2048846,POKKSIROKFEGGD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727639.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CSC(=N1)N(C)C(=O)CSC2=NN=C(C=C2)C3=CC=CC=C3,4.522878745280337,Cc1csc(N(C)C(=O)CSc2ccc(-c3ccccc3)nn2)n1
27799,CHEMBL3289813,POQVSNVXDFTBIQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914738.0,IC50,=,20300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,PUBLICATION,,CC(C(F)(F)F)OC1=NC2=C(C=C1)N=C(N2CC(C3=C(C=C(C=C3)C(F)(F)F)Cl)O)N,4.692503962086787,CC(Oc1ccc2nc(N)n(CC(O)c3ccc(C(F)(F)F)cc3Cl)c2n1)C(F)(F)F
27806,CHEMBL3673948,POUGJCUMNASOCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320626,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC=C(C=C4)Cl)F)N=C1,5.0,COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c2c1
27807,CHEMBL3673948,POUGJCUMNASOCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320670,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC=C(C=C4)Cl)F)N=C1,5.0,COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c2c1
27815,CHEMBL590850,POVKMUXXHHNJIG-CECLQJIQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19945870.0,IC50,=,12300.0,NM,,,,,,,,,,,,,,,Inhibition of human liver CYP3A4,Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C(=O)NC1=CC=C(C=C1)/C=C/C(=O)O)NC(=O)C2=CC3=C(C=C2)N(C(=N3)C4=COC=C4)C5CCCCC5,4.910094888560602,C[C@@H](NC(=O)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1)C(=O)Nc1ccc(/C=C/C(=O)O)cc1
27819,CHEMBL3702715,POYVJUSYLIGQCQ-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)OC,5.481486060122113,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(OC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
27823,CHEMBL1479,POZRVZJJTULAOH-LHZXLZLDSA-N,DANAZOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,4.522878745280337,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
27833,CHEMBL1762429,POZVWZHXRTXSAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21354795.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin),"1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=NO1)NC(=O)N2CCCN(CC2)C(=O)N3CCS(=O)(=O)CC3,4.522878745280337,CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)N3CCS(=O)(=O)CC3)CC2)no1
27843,CHEMBL1643881,PPGYKWQFGNLYIY-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21146988.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@H](C2)N3CC4=C5C(=NN4)C=CC=C5C3=O,5.0,O=C1c2cccc3n[nH]c(c23)CN1[C@H]1CN2CCC1CC2
27844,CHEMBL264961,PPIFUYCFGJGTGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18378449.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CNC(=O)C1=CC=C(C=C1)CN2CCC(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N,5.0,CNC(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1
27845,CHEMBL399731,PPILOQQTEQXAMT-HSWSLHEESA-N,FIBRAURINOSIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,C[C@@]12CC=C3C(=O)O[C@H](C[C@]3([C@@H]1[C@H]4[C@H]5[C@@H]([C@@]2(C(=O)O4)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O5)C)C7=COC=C7,4.0,C[C@@]12C[C@H](c3ccoc3)OC(=O)C1=CC[C@]1(C)[C@H]2[C@@H]2OC(=O)[C@@]1(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1O[C@@H]21
27852,CHEMBL480295,PPKABVGOUVBEEX-HSQXHLSASA-N,ETHOXYCLUSIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,CCOC1=CC(=CC2=C1OCO2)C[C@H]3COC([C@@H]3CC4=CC(=C(C(=C4)OC)OC)OC)O,6.356547323513812,CCOc1cc(C[C@H]2COC(O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc2c1OCO2
27853,CHEMBL2059126,PPKRNTJCUJJRGN-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(C)C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,6.958607314841775,CCN(C)c1nc2ccc(C(=O)N(C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
27860,CHEMBL3109356,PPPOUAQYRUUFNJ-GHTZIAJQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC2=NC=C(N2C=C1)C3=NC4=C(C=CC=C4O[C@@H]5CCNC[C@@H]5F)C=C3,5.0,COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@@H]5F)c4n3)cnc2c1
27861,CHEMBL3109338,PPPOUAQYRUUFNJ-RXVVDRJESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC2=NC=C(N2C=C1)C3=NC4=C(C=CC=C4O[C@H]5CCNC[C@@H]5F)C=C3,5.0,COCCOc1ccn2c(-c3ccc4cccc(O[C@H]5CCNC[C@@H]5F)c4n3)cnc2c1
27862,CHEMBL3109337,PPPOUAQYRUUFNJ-WIYYLYMNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC2=NC=C(N2C=C1)C3=NC4=C(C=CC=C4O[C@@H]5CCNC[C@H]5F)C=C3,5.0,COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@H]5F)c4n3)cnc2c1
27863,CHEMBL40583,PPQNQXQZIWHJRB-UHFFFAOYSA-N,3-METHYLCHOLANTHRENE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,5.0,Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3
27864,CHEMBL40583,PPQNQXQZIWHJRB-UHFFFAOYSA-N,3-METHYLCHOLANTHRENE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,5.0,Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3
27873,CHEMBL3608680,PPSNFPASKFYPMN-SECBINFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,=,90000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C,4.045757490560675,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1
27882,CHEMBL551058,PPZAIZWNHZKGPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CC=C(C=C1)C2=NOC(=N2)C3CCN(CC3)C(=O)NC4CC4C5=CC=CC=C5,5.0,CS(=O)(=O)c1ccc(-c2noc(C3CCN(C(=O)NC4CC4c4ccccc4)CC3)n2)cc1
27884,CHEMBL223079,PPZQHODYVASSTK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17352462.0,IC50,>,100000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect cells,"Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).",J. Med. Chem.,PUBLICATION,,C1CN(CCC1N2CC(NC2=O)(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)CC5=CC(=CC=C5)Cl,4.0,O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2cccc(Cl)c2)CC1
27889,CHEMBL1504335,PQAOSMFYTVFYMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1CC2=CC=CC=C2)CC3=NN=C(O3)C4=CC=CC=C4,4.698970004336019,c1ccc(CN2CCN(Cc3nnc(-c4ccccc4)o3)CC2)cc1
27891,CHEMBL2069846,PQBMPUQYJGLDHI-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ß-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)C2=CC=C(C=C2)C(=O)N3CCN(CC3)C(=O)C[C@@H](CC4=CC(=C(C=C4F)F)F)N,6.0,CN1CCN(c2ccc(C(=O)N3CCN(C(=O)C[C@H](N)Cc4cc(F)c(F)cc4F)CC3)cc2)CC1
27921,CHEMBL2436328,PQJFVYVHOIOJEX-OGZMHEHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=CC=CC=C43)OC)C(=O)CC(C)C)NC.Cl,5.823908740944319,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(OC)ccc3ccccc23)C1=O
27928,CHEMBL2021582,PQMJWYCYCSXLGZ-JYAVWHMHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,CCOCC1([C@H]2[C@@H]1CCC2)C3=CC(=C(C=C3)Cl)Cl,5.301029995663981,CCOCC1(c2ccc(Cl)c(Cl)c2)[C@H]2CCC[C@H]21
27932,CHEMBL261253,PQOGAQAOZACONT-LSNLESRRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1COCCN1CC2CC(C2)C3=NC(=C4N3C=CN=C4N)C5=CC6=C(C=C5)C=CC(=N6)C7=CC=CC=C7,4.698970004336019,Nc1nccn2c(C3CC(CN4CCOCC4)C3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12
27933,CHEMBL411074,PQOGAQAOZACONT-RZJSWYKGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1COCCN1CC2CC(C2)C3=NC(=C4N3C=CN=C4N)C5=CC6=C(C=C5)C=CC(=N6)C7=CC=CC=C7,4.698970004336019,Nc1nccn2c(C3CC(CN4CCOCC4)C3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12
27935,CHEMBL1098230,PQPVHIHIJVIEQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20384344.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect cell microsome after 30 mins by fluorescence assay,Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC=C(C=C1)SCCC2=CN=CN2,6.327902142064283,CC(C)(C)c1ccc(SCCc2cnc[nH]2)cc1
27936,CHEMBL1098230,PQPVHIHIJVIEQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20690643.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC=C(C=C1)SCCC2=CN=CN2,6.327902142064283,CC(C)(C)c1ccc(SCCc2cnc[nH]2)cc1
27940,CHEMBL1808424,PQQHOBXFKJXQAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21724392.0,IC50,=,14700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CC(=C(C1)Cl)C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4,4.8326826652518236,CN1CC(Cl)=C(c2cn(S(=O)(=O)c3ccccc3)c3ccccc23)C1
27948,CHEMBL495084,PQVHRPXGPBDRRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,CC1=C(C2=C(C=C1)C(=NO2)NC3CC3)C4=CC5=CN=NC(=C5C=C4)C6=CC=CC=C6C,5.7447274948966935,Cc1ccccc1-c1nncc2cc(-c3c(C)ccc4c(NC5CC5)noc34)ccc12
27963,CHEMBL1761518,PRAXUIQVVJSJMP-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC#N)C6CC6)Cl,5.853871964321762,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC#N)CC2)c1
27964,CHEMBL1761518,PRAXUIQVVJSJMP-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,19600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC#N)C6CC6)Cl,4.707743928643524,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC#N)CC2)c1
27977,CHEMBL3702809,PREDGFPQLQFLSQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)C9=CC=CC=C9OC,4.6020599913279625,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(c7ccccc7OC)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
27978,CHEMBL3581132,PRIKHRTWFXDNDC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC=NC=C3,6.318758762624412,COc1cccc(CC(=O)Nc2cc(-c3ccncc3)cs2)c1
27979,CHEMBL1950080,PRIVQPMFDOJWFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C#N)C4=CC=CC=C4)OC,6.096910013008056,COc1cc(C)c2nc3n[nH]c(C)c3c(C(C#N)c3ccccc3)c2c1
27980,CHEMBL1950080,PRIVQPMFDOJWFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C#N)C4=CC=CC=C4)OC,4.698970004336019,COc1cc(C)c2nc3n[nH]c(C)c3c(C(C#N)c3ccccc3)c2c1
28002,CHEMBL127589,PRPIEBUSWYMLSB-KRXYOAFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CN(C=C2)C3=CC=C(C=C3)Cl)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CN=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,7.301029995663981,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3ccc(Cl)cc3)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
28003,CHEMBL498662,PRQQBVJPRNDIGX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,159.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1C=C(C2=C1C=C(C=C2)C3=CC=C(C=C3)F)C4=CC=NC=C4.Cl,6.798602875679548,Fc1ccc(-c2ccc3c(c2)CC=C3c2ccncc2)cc1
28013,CHEMBL1923118,PRVWMJVSFWNIFV-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=C(C(=CC=C2)C(F)(F)F)Cl)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F,5.443697499232713,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc(C(F)(F)F)c1Cl)C1CC1
28015,CHEMBL2441340,PRWSIEBRGXYXAJ-UHFFFAOYSA-N,GSK2656157,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,19700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,CC1=NC(=CC=C1)CC(=O)N2CCC3=C2C=CC(=C3F)C4=CN(C5=NC=NC(=C45)N)C,4.705533773838407,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1
28016,CHEMBL2441340,PRWSIEBRGXYXAJ-UHFFFAOYSA-N,GSK2656157,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,CC1=NC(=CC=C1)CC(=O)N2CCC3=C2C=CC(=C3F)C4=CN(C5=NC=NC(=C45)N)C,4.6020599913279625,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1
28017,CHEMBL2441340,PRWSIEBRGXYXAJ-UHFFFAOYSA-N,GSK2656157,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,,25000.0,NM,,inhibition,tissue,functional,,,,,0.01-30,UM,,=,0.1-0.5,MG-ML,,,ACS MED. CHEM. LETT.,PUBLICATION,,CC1=NC(=CC=C1)CC(=O)N2CCC3=C2C=CC(=C3F)C4=CN(C5=NC=NC(=C45)N)C,4.6020599913279625,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1
28018,CHEMBL26599,PRXCGBDDTBLDKY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998323.0,IC50,=,45800.0,NM,,,,,,,,,,,,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CCN2C(=C(C3=C2C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=O)N)C1,4.33913452199613,NC(=O)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2
28019,CHEMBL2181894,PRYJXFKQLNPQBU-UNCTUWKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)C[C@@H]2NC[C@H]([C@H](CC4=CC(=CC=C4)C5=CSC=N5)NC(=O)COC)O,7.0,COCC(=O)N[C@@H](Cc1cccc(-c2cscn2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
28026,CHEMBL1784350,PSAIRTKPKUWNNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)CCC2CCN(CC2)S(=O)(=O)CC3(CCOC(C3)(C)C)N(C=O)O,5.0,Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCOC(C)(C)C2)CC1
28033,CHEMBL550068,PSCSTQNZPOWDJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,2490.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC(=O)N2CCN3C=CC=C3C2C4=CC=CC=C4)CC5=CN(C=C5)C6=CC=C(C=C6)C(F)(F)F,5.603800652904264,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCn2cccc2C1c1ccccc1
28052,CHEMBL468671,PSHCEXAQPYCQDU-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)C5CCN(CC5)CCOC,4.958607314841775,COCCN1CCC(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
28064,CHEMBL2448748,PSJMEQMCCNLCBN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCN(CC1=CN=CN1)C2=C(C=C(C=C2)C3=CC=C(C=C3)F)F,5.3979400086720375,CCN(Cc1cnc[nH]1)c1ccc(-c2ccc(F)cc2)cc1F
28088,CHEMBL559945,PSQYTAPXSHCGMF-BQYQJAHWSA-N,BETA-IONONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,CC1=C(C(CCC1)(C)C)/C=C/C(=O)C,5.0,CC(=O)/C=C/C1=C(C)CCCC1(C)C
28089,CHEMBL559945,PSQYTAPXSHCGMF-BQYQJAHWSA-N,BETA-IONONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CC1=C(C(CCC1)(C)C)/C=C/C(=O)C,5.0,CC(=O)/C=C/C1=C(C)CCCC1(C)C
28093,CHEMBL3673979,PSQZATYJDUBZGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320657,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,C1=CC(=NC=C1CNC2=C(C=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl)F)C(F)(F)F,5.0,Fc1cc(Cc2c[nH]c3ncc(Cl)cc23)cnc1NCc1ccc(C(F)(F)F)nc1
28105,CHEMBL358216,PSSBWTPALOUROH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,58100.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CN=CO2,4.235823867609669,CCCCOc1ccc(-c2cnco2)cc1
28107,CHEMBL3702797,PSSSYLPWYZVQRS-UJGAEZNTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6120.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.213248577854439,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)C)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
28111,CHEMBL2158231,PSWOVPWZYVUKKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)C4=CN=CC=C4)NC(=O)C5=NC=C(N5)C#N,5.214670164989233,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)c4cccnc4)CC3)cc2C2=CCCCC2)[nH]1
28121,CHEMBL1801364,PTCZOYHYJOCZIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20634071.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyflourescein as a substrate,Synthesis and biological activity of a series of tetrasubstituted-imidazoles as P2X(7) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N(C(=N1)C2=C(C=C(C=C2)F)F)C)CC(=O)NCC3=C(C=C(C=C3)F)Cl.Cl,5.259637310505756,Cc1nc(-c2ccc(F)cc2F)n(C)c1CC(=O)NCc1ccc(F)cc1Cl
28123,CHEMBL523565,PTFJFPDNCOEVNS-DVKDBIPTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC12CC(C3=C(O2)C=CC=N3)O)C(=O)N[C@H]4C[C@@H]4C5=CC=CC=C5,5.0,O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CC1)CC(O)c1ncccc1O2
28130,CHEMBL2322875,PTHJVFQTMJMDKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23374868.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Competitive inhibition of CYP3A4 (unknown origin),1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NN1CC(=O)N2CCN(CC2)C3=CC(=C(C=C3)Cl)OC)C(F)(F)F)Cl,5.0,COc1cc(N2CCN(C(=O)Cn3nc(C(F)(F)F)c(Cl)c3C)CC2)ccc1Cl
28147,CHEMBL2178718,PTLJUNIICOHEHE-JTSKRJEESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22989333.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated with substrate,Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor a Bioactive Conformation.,J. Med. Chem.,PUBLICATION,,CN1C(=O)[C@@H]2CN(C[C@@]2(N=C1N)C3=CC(=CS3)C4=CC=CC(=C4)C#N)C5=NC=C(C=N5)F,5.721246399047171,CN1C(=O)[C@@H]2CN(c3ncc(F)cn3)C[C@]2(c2cc(-c3cccc(C#N)c3)cs2)N=C1N
28148,CHEMBL2178718,PTLJUNIICOHEHE-JTSKRJEESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22989333.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 coincubated with substrate,Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor a Bioactive Conformation.,J. Med. Chem.,PUBLICATION,,CN1C(=O)[C@@H]2CN(C[C@@]2(N=C1N)C3=CC(=CS3)C4=CC=CC(=C4)C#N)C5=NC=C(C=N5)F,4.522878745280337,CN1C(=O)[C@@H]2CN(c3ncc(F)cn3)C[C@]2(c2cc(-c3cccc(C#N)c3)cs2)N=C1N
28150,CHEMBL2178718,PTLJUNIICOHEHE-JTSKRJEESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,CN1C(=O)[C@@H]2CN(C[C@@]2(N=C1N)C3=CC(=CS3)C4=CC=CC(=C4)C#N)C5=NC=C(C=N5)F,5.920818753952375,CN1C(=O)[C@@H]2CN(c3ncc(F)cn3)C[C@]2(c2cc(-c3cccc(C#N)c3)cs2)N=C1N
28156,CHEMBL1668909,PTMZDVIBDZFFRW-JCMHNJIXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21211972.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)C1=C(C2=C(S1)C=NC=C2)NC3=CC4=C(C=C3)/C(=N\O)/CC4,7.301029995663981,CCOC(=O)c1sc2cnccc2c1Nc1ccc2c(c1)CC/C2=N/O
28157,CHEMBL2397313,PTNNLDBOIACISQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)CC2=NC(=C(O2)C)C3=CC=CC=C3)C4=CN=C(C=C4)N,5.113509274827518,Cc1nc(NC(=O)Cc2nc(-c3ccccc3)c(C)o2)sc1-c1ccc(N)nc1
28160,CHEMBL2436624,PTPOPPWALKSUMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=C(CCCN(C2)C3CCN(CC3)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F)C=C1,4.522878745280337,COc1ccc2c(c1)CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CCC2
28174,CHEMBL3114737,PUCUZOUCEHETGM-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N2CCN(CC2)C(=O)OCC3=CN=CS3,5.853871964321762,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N2CCN(C(=O)OCc3cncs3)CC2)C(C)C)cs1
28176,CHEMBL368347,PUETUDUXMCLALY-HOTGVXAUSA-N,(+)-SECOISOLARICIRESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,47300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,COC1=C(C=CC(=C1)C[C@@H](CO)[C@@H](CC2=CC(=C(C=C2)O)OC)CO)O,4.325138859262188,COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O
28178,CHEMBL1830424,PUFPSZILMLJFEU-ZRDIBKRKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,=,330.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,CCCCCCC1=NC2=C(N1CCN(C)C)C=CC(=C2)/C=C/C(=O)NO,6.481486060122113,CCCCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(C)C
28179,CHEMBL1830424,PUFPSZILMLJFEU-ZRDIBKRKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,CCCCCCC1=NC2=C(N1CCN(C)C)C=CC(=C2)/C=C/C(=O)NO,4.6020599913279625,CCCCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(C)C
28182,CHEMBL355905,PUHRPYOPXGWCTE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14584934.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC,"Identification of a potent and selective 5-HT(6) antagonist: one-step synthesis of (E)-3-(benzenesulfonyl)-2- (methylsulfanyl)pyrido[1,2-a]pyrimidin-4-ylidenamine from 2-(benzenesulfonyl)-3,3-bis(methylsulfanyl)acrylonitrile.",J. Med. Chem.,PUBLICATION,,CSC1=C(C(=N)N2C=CC=CC2=N1)S(=O)(=O)C3=CC=CC=C3,4.3979400086720375,CSc1nc2ccccn2c(=N)c1S(=O)(=O)c1ccccc1
28183,CHEMBL355905,PUHRPYOPXGWCTE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14584934.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BzRes,"Identification of a potent and selective 5-HT(6) antagonist: one-step synthesis of (E)-3-(benzenesulfonyl)-2- (methylsulfanyl)pyrido[1,2-a]pyrimidin-4-ylidenamine from 2-(benzenesulfonyl)-3,3-bis(methylsulfanyl)acrylonitrile.",J. Med. Chem.,PUBLICATION,,CSC1=C(C(=N)N2C=CC=CC2=N1)S(=O)(=O)C3=CC=CC=C3,4.3979400086720375,CSc1nc2ccccn2c(=N)c1S(=O)(=O)c1ccccc1
28194,CHEMBL1241736,PUOXMWOHHZDZBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)C,5.301029995663981,CC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
28195,CHEMBL1241736,PUOXMWOHHZDZBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)C,5.301029995663981,CC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
28198,CHEMBL2010601,PURKAOJPTOLRMP-UHFFFAOYSA-N,IVACAFTOR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25441013.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a Potent and Orally Bioavailable CFTR Potentiator.",J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C,4.698970004336019,CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O
28206,CHEMBL562894,PUYPQZLPNDWKQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)OC,5.301029995663981,COc1ccc(Cn2c(N3CCC(n4cc(C)cn4)CC3)nc3ccccc32)cc1
28218,CHEMBL206884,PVEQEQGWTRAWFX-IERDGZPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]([C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC3(CC3)C(=O)O)N4C=CN=C4)N(C)C,5.1249387366083,C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CC3)ccc2c1)n1ccnc1)N(C)C
28220,CHEMBL2338474,PVGMGRKQQQTCKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C=C(C=N2)OC3=C(C=C(C=C3Cl)NS(=O)(=O)C4=C(C=C(C=C4)C(F)(F)F)Cl)Cl,5.638272163982407,O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(C(F)(F)F)cc1Cl
28236,CHEMBL260259,PVISFTMIHRDVDS-ROUUACIJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18387300.0,IC50,>,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=CC(=C1)Cl)O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,4.5376020021010435,COc1cc(Cl)ccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
28237,CHEMBL94454,PVLJETXTTWAYEW-UHFFFAOYSA-N,MIZOLASTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5,5.301029995663981,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
28249,CHEMBL2437421,PVPHPEBVXPEONF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CCN5CCOCC5)CC6=CC(=NC=C6)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCN5CCOCC5)c5ccccc54)CC3)CC2)ccn1
28251,CHEMBL2163822,PVRCCDCVZYOJAG-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1O)C(=O)[C@H](CC2=CC=C(C=C2)Br)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,5.886056647693163,O=C([C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1)N1CCC(O)CC1
28256,CHEMBL577470,PVSATFACFVIGLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)C(=O)O,5.301029995663981,CC1(CC(=O)NCc2ccc(C(=O)O)cc2)CC2(CCCCC2)OO1
28283,CHEMBL3577955,PWDBREUBRYUEGC-BTJKTKAUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25893048.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCN(CC1)C(=O)C2=CC=C(C=C2)CN3CCOCC3.C(=C\C(=O)O)\C(=O)O,4.3979400086720375,CC(C)N1CCN(C(=O)c2ccc(CN3CCOCC3)cc2)CC1
28309,CHEMBL3699344,PWOQCDXDGLGZLQ-ZYBCLOSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCN(CC)C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N(CC)CC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
28314,CHEMBL2064336,PWPZIVZLHIOULY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1COCCN1C2=CC(=O)NC(=N2)CC3=NC4=C(N3)C=C(C=C4)Cl,4.3979400086720375,O=c1cc(N2CCOCC2)nc(Cc2nc3ccc(Cl)cc3[nH]2)[nH]1
28346,CHEMBL1270630,PWZLUGHNDYWEDU-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ß-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)[C@]2(C(=O)N(C(=N2)N)C)C3=CC=CC(=C3)C#CC4CC4)OC(F)F,7.0,Cc1cc([C@]2(c3cccc(C#CC4CC4)c3)N=C(N)N(C)C2=O)ccc1OC(F)F
28351,CHEMBL454515,PXCKFKLPESDHTQ-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)N7CCN(CC7)C,7.3979400086720375,Cc1cc(N2CCC(N3CCN(C(=O)N4CCN(C)CC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
28365,CHEMBL113018,PXFGMZGVHWPLCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,5670.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1CCOC2=CC=C(C=C2)N3C=CN=C3,5.246416941107094,c1cn(-c2ccc(OCCN3CCOCC3)cc2)cn1
28367,CHEMBL519680,PXFUWAWMHRRZOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,CC1=C(C(N=C(N1)C2=CC=CC=C2)C3=CC=C(C=C3)F)C(=O)NC4=CC5=C(C=C4)NN=C5,6.455931955649724,CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccccc2)N1
28374,CHEMBL3137391,PXISBMZXCKNRIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CN=C4,4.7447274948966935,O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
28390,CHEMBL3409855,PXNXLOMDHVIHNB-GJZGRUSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)OC)[C@@H]2C[C@@H](C(=O)N2CC3=CC=C(C=C3)OC(F)(F)F)F,5.0,COc1cccc(OC)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
28391,CHEMBL496286,PXOBFFWELDGRSQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,2114.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC2=C(C=CC(=C2)C3=CC(=C(C=C3)O)F)C(=C1)C4=CC=NC=C4.Br,5.674895017028592,Oc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1F
28404,CHEMBL557461,PXUAIMJAHKAYPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19524437.0,IC50,>,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1CCN(CC1)C(=O)C2=CC3=C(C=C2)C=C(C=C3)OCCCN4CCCCC4,4.920818753952375,CC1CCN(C(=O)c2ccc3cc(OCCCN4CCCCC4)ccc3c2)CC1
28413,CHEMBL1935100,PXYUUQSMMYUYSP-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22142542.0,IC50,>,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"4,5-dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)CC3,4.958607314841775,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)CC2)cc1
28414,CHEMBL2387594,PXZRQATTWSLRPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,4.522878745280337,CCc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
28420,CHEMBL3632718,PYBNNACSMHESLC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=CC=C1)NC2=NC3=C(N2C)C=CC(=C3)OC4=CC(=NC=C4)C5=NC=C(N5)C6=CC=CC=C6,5.1487416512809245,Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc(-c5ccccc5)[nH]4)c3)ccc21
28425,CHEMBL3673937,PYDGBRKMKPMMFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320648,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=C(C=C4)OC)OC)F)N=C1,5.301029995663981,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(OC)n1
28426,CHEMBL3673937,PYDGBRKMKPMMFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320692,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=C(C=C4)OC)OC)F)N=C1,5.301029995663981,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(OC)n1
28438,CHEMBL1822525,PYEVUJXYLLDVLP-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21859094.0,IC50,>,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,C[C@@H](CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NN4C(=CC=C4C5=CC=CC=C5N(C)S(=O)(=O)C)C=N3)OC)O,4.920818753952375,COc1cc(N2CCN(C[C@H](C)O)CC2)ccc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1
28440,CHEMBL514794,PYFRREJCFXFNRR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC(=C1)CNC(=O)C2=CC(=NC=N2)C(=O)NCC3=CC(=C(C=C3)F)C)F,4.698970004336019,Cc1cc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(C)c3)ncn2)ccc1F
28441,CHEMBL514794,PYFRREJCFXFNRR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC(=C1)CNC(=O)C2=CC(=NC=N2)C(=O)NCC3=CC(=C(C=C3)F)C)F,4.698970004336019,Cc1cc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(C)c3)ncn2)ccc1F
28444,CHEMBL3137394,PYHNKTKVQRGVDZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1CC2=CC=CC=C2C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,4.823908740944319,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(Cc2ccccc2C(F)(F)F)CC1
28450,CHEMBL47529,PYKJFEPAUKAXNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=CC=C(C2=N1)OCC3=CC=CC=C3)CC#N,5.045757490560675,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N
28451,CHEMBL47529,PYKJFEPAUKAXNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=CC=C(C2=N1)OCC3=CC=CC=C3)CC#N,4.920818753952375,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N
28459,CHEMBL427548,PYLGXNLJVJXKBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,38000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)C4=CC=C(C=C4)F)F)F)C(=O)O,4.42021640338319,O=C(O)C1(c2ccc(-c3ccc(-c4ccc(F)cc4)c(F)c3)c(F)c2)CC1
28470,CHEMBL398472,PYRTUYSUPAFERK-HIKGYAAUSA-N,FIBRAURETIN A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,C[C@@]12C[C@@H](OC(=O)[C@@H]1[C@H](C[C@@]3([C@H]2[C@H]4[C@H]5[C@@H]([C@@]3(C(=O)O4)O)O5)C)O)C6=COC=C6,4.0,C[C@@]12C[C@H](c3ccoc3)OC(=O)[C@@H]1[C@@H](O)C[C@]1(C)[C@H]2[C@@H]2OC(=O)[C@@]1(O)[C@H]1O[C@@H]21
28478,CHEMBL522228,PYVRRGZFIYKCIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,632.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC(C2=C(C1)C=C(C=C2)C3=CC(=C(C=C3)O)O)C4=CC=NC=C4.Br,6.199282921717615,Oc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1O
28498,CHEMBL3617983,PYZSBQQHZCMXFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26365710.0,IC50,=,1170.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay,"Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC1=NN(C(=C1C(=O)NC(CN2C=CN=C2)C(=O)OC)Cl)C3=CC=CC=C3,5.931814138253839,COC(=O)C(Cn1ccnc1)NC(=O)c1c(C)nn(-c2ccccc2)c1Cl
28499,CHEMBL2069838,PZADYECUTZNBBF-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ß-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=CC=C3,6.0,N[C@@H](CC(=O)N1CCN(C(=O)c2ccccc2)CC1)Cc1cc(F)c(F)cc1F
28502,CHEMBL1760794,PZAIZRLLCHXVBJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21334894.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenyl triazoles as selective inhibitors of 11ß-Hydroxysteroid Dehydrogenase Type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=NN=C1C2(CCC2)C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)C5=NC=CN=C5,5.0,Cn1c(-c2ccc(-c3cnccn3)cc2)nnc1C1(c2ccc(Cl)cc2)CCC1
28519,CHEMBL257767,PZHLUEBYOAPSNB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CC2C(CCCN2C(=O)CN(CC#N)C3=CC(=C(C=C3)Cl)Cl)C4=CC=CC=C4,5.958607314841775,N#CCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1
28525,CHEMBL487572,PZIMFNJQILPVJP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N(C)C)C,4.6020599913279625,CC(=O)Nc1cc(-c2cccc(N(C)C)n2)nc(-n2nc(C)cc2C)n1
28526,CHEMBL2425600,PZJIORSTWTVMPM-UZRFBLNJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=C(C=C1)F)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F,7.0,COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(C(C)(C)C)ccc3F)[C@H]2O)cc(F)c1N)C(F)(F)F
28532,CHEMBL237364,PZLVUHVHOCIJNX-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCN,5.050609993355088,CC(C)C[C@H](NCCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
28553,CHEMBL268764,PZUQQORPORVJNV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C(=CC(=O)N=C3SCC4=CC=C(C=C4)F)C,4.657577319177793,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(C)cc(=O)nc1SCc1ccc(F)cc1
28567,CHEMBL2177582,PZYNOSYZPXJRNG-NAHVQIJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061376.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,PUBLICATION,,CN1C[C@@H]([C@H](C1)C(=O)NC2=CC=C(C=C2)Cl)C3=C(C=C(C=C3)/C=C/C(=O)NC4=CC=CC=C4N)F,5.3979400086720375,CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2F)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1
28591,CHEMBL1852688,QADPYRIHXKWUSV-UHFFFAOYSA-N,INFIGRATINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,21936542.0,IC50,>,10000.0,NM,,inhibition,biochemical,functional,enzyme_activity,,fluoresecence,,,,7-BENZYLOXY-4-(TRIFLUOROMETHYL)-COUMARIN,,,,INHIBITION OF HUMAN CYP3A4 IN PRESENCE OF NADPH,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,5.0,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
28592,CHEMBL1852688,QADPYRIHXKWUSV-UHFFFAOYSA-N,INFIGRATINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,21936542.0,IC50,>,10000.0,NM,,inhibition,biochemical,functional,enzyme_activity,,fluoresecence,,,,DIBENZYLFLUORESCEIN,,,,INHIBITION OF HUMAN CYP3A4 IN PRESENCE OF NADPH,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,5.0,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
28593,CHEMBL2441342,QAEKSWBVYBVLNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,CN1C=C(C2=C(N=CN=C21)N)C3=C(C4=C(C=C3)N(CC4)C(=O)CC5=NC(=CC=C5)C(F)(F)F)F,5.130768280269024,Cn1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2cccc(C(F)(F)F)n2)c2c(N)ncnc21
28594,CHEMBL2441342,QAEKSWBVYBVLNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,9090.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,CN1C=C(C2=C(N=CN=C21)N)C3=C(C4=C(C=C3)N(CC4)C(=O)CC5=NC(=CC=C5)C(F)(F)F)F,5.041436116778033,Cn1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2cccc(C(F)(F)F)n2)c2c(N)ncnc21
28596,CHEMBL584,QAGYKUNXZHXKMR-HKWSIXNMSA-N,NELFINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,6.259637310505756,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
28603,CHEMBL584,QAGYKUNXZHXKMR-HKWSIXNMSA-N,NELFINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,5.698970004336019,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
28609,CHEMBL1761536,QAIDCNOXZMESAW-JMUKJWEXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC[C@@](C)(C(=O)O)OC)C5CC5)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC[C@](C)(OC)C(=O)O)c1
28610,CHEMBL1761536,QAIDCNOXZMESAW-JMUKJWEXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC[C@@](C)(C(=O)O)OC)C5CC5)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC[C@](C)(OC)C(=O)O)c1
28620,CHEMBL3289811,QAKLYMPRDNHSCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914738.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,PUBLICATION,,C1COCC1OC2=NC3=C(C=C2)N=C(N3CC(C4=C(C=C(C=C4)C(F)(F)F)Cl)O)N,5.619788758288394,Nc1nc2ccc(OC3CCOC3)nc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl
28637,CHEMBL228792,QANMHLXAZMSUEX-UHFFFAOYSA-N,KINETIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=COC(=C1)CNC2=NC=NC3=C2NC=N3,5.0,c1coc(CNc2ncnc3nc[nH]c23)c1
28638,CHEMBL228792,QANMHLXAZMSUEX-UHFFFAOYSA-N,KINETIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=COC(=C1)CNC2=NC=NC3=C2NC=N3,5.0,c1coc(CNc2ncnc3nc[nH]c23)c1
28657,CHEMBL236519,QASNNAVCCMXYPS-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCN,5.200659450546418,CC(C)C[C@H](NCCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
28661,CHEMBL3409859,QAUTYBBMQXPFIE-LSDHHAIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)OC)[C@@H]2C[C@H](C(=O)N2CC3=CC=C(C=C3)OC(F)(F)F)O,4.6020599913279625,COc1cccc(OC)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
28681,CHEMBL84894,QBBSJLRQRYQJOI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,<,500.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C(=O)CN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN=C(N=C5)OC,6.301029995663981,COc1ncc(Cc2cn(CC(=O)N(CC(=O)N(C)C)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
28682,CHEMBL2385886,QBCRLDPMQHPGIM-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23718281.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 15 mins prior to NADPH addition measured after 8 mins by LC/MS/MS analysis,"Discovery of (R)-(2-Fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-Hydroxypiperidin-1-yl)methanone (ML337), An mGlu3 Selective and CNS Penetrant Negative Allosteric Modulator (NAM).",J. Med. Chem.,PUBLICATION,,COC1=CC=C(C=C1)C#CC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C3)O)F,4.522878745280337,COc1ccc(C#Cc2ccc(C(=O)N3CCC[C@@H](O)C3)c(F)c2)cc1
28700,CHEMBL2436331,QBGRYKLTKRKXQV-GYUFFBBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=C(C=C5)F)NC.Cl,5.823908740944319,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(F)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
28712,CHEMBL2165315,QBIRRYYRDPYJNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861193.0,IC50,=,90000.0,NM,,,,,,,,,,,,,,,Inhibition of hepatic CYP3A4,Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.,J. Med. Chem.,PUBLICATION,,CN1C(=O)CCC2=CC(=C(C=C21)OC)C3=CN=CC=C3,4.045757490560675,COc1cc2c(cc1-c1cccnc1)CCC(=O)N2C
28720,CHEMBL399590,QBLLJHIEFPUVNM-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCCCC4,5.585026652029182,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
28732,CHEMBL3322590,QBOWGZQRUNUQGL-ZDLGFXPLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25036791.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using Vivid OOMR substrate,Bioisosteric replacement of an acylureido moiety attached to an indolin-2-one scaffold with a malonamido or a 2/4-pyridinoylamido moiety produces a selectively potent Aurora-B inhibitor.,Eur. J. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C2=CNC=C(C2=O)C(=O)NC3=CC4=C(C=C3)/C(=C/C5=CC=CN5)/C(=O)N4)F,5.0,O=C1Nc2cc(NC(=O)c3c[nH]cc(-c4ccccc4F)c3=O)ccc2/C1=C/c1ccc[nH]1
28733,CHEMBL276856,QBOWMQHTHPHCEL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCO)CC4=CC=C(C=C4)C5=CC=C(C=C5)Cl,4.721246399047171,Cn1cc(Cc2cn(CC(=O)N(CCO)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
28734,CHEMBL3114718,QBOYRTIWRZBXKC-HFASVGIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC[C@@H](CC[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)NC(=O)[C@H](C(C)C)NC(=O)N(C)CC3=CSC(=N3)C(C)C,6.886056647693163,CCC[C@@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C
28743,CHEMBL2419525,QBTMLSOSPORBBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4)C5CCOCC5,5.0,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)N1Cc2ccncc2C1
28744,CHEMBL2419525,QBTMLSOSPORBBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4)C5CCOCC5,5.0,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)N1Cc2ccncc2C1
28768,CHEMBL150999,QBXIGUJIZJQJQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,44300.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=NC=CN2,4.3535962737769305,CCCCOc1ccc(-c2ncc[nH]2)cc1
28769,CHEMBL28629,QBYAEFPHWWOQHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,20800.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)N6CCOCC6,4.681936665037238,Cn1c2ccnc(N3CCOCC3)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
28770,CHEMBL2159133,QBYDJDSGARUEAH-VOWYRPGRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)N[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NC(C)C)O4)C)(C)OC)C)C)O)(C)O,6.0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NC(C)C)N3C)[C@](C)(OC)C[C@@H](C)NC(=O)[C@H](C)[C@@H](O)[C@]1(C)O
28771,CHEMBL2159133,QBYDJDSGARUEAH-VOWYRPGRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)N[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NC(C)C)O4)C)(C)OC)C)C)O)(C)O,5.0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NC(C)C)N3C)[C@](C)(OC)C[C@@H](C)NC(=O)[C@H](C)[C@@H](O)[C@]1(C)O
28774,CHEMBL1289283,QBYYFLZCKXHEJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20952195.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CCN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5)C=N2,5.0,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
28775,CHEMBL1289283,QBYYFLZCKXHEJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20961756.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CCN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5)C=N2,5.0,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
28776,CHEMBL409493,QBZHGWVJIIGZNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18378449.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1NC(=O)C2=CC=C(C=C2)CN3CCC(CC3)C4=CC=C(C=C4)C(=O)NC5=CC=CC=C5N,5.0,Nc1ccccc1NC(=O)c1ccc(C2CCN(Cc3ccc(C(=O)NC4CC4)cc3)CC2)cc1
28781,CHEMBL1080046,QCDCMDPVHPUROA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC1=CC=C(C=C1)S(=O)(=O)NC2=CC3=C(CCN(CC3)CC4=CC=NN4)C=C2,6.096910013008056,CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2ccn[nH]2)CC3)cc1
28782,CHEMBL1080046,QCDCMDPVHPUROA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC1=CC=C(C=C1)S(=O)(=O)NC2=CC3=C(CCN(CC3)CC4=CC=NN4)C=C2,5.721246399047171,CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2ccn[nH]2)CC3)cc1
28786,CHEMBL2387589,QCEDWPSURNZKTH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,4.522878745280337,O=c1[nH]c2ccccc2c2nc(-c3ccccc3Cl)[nH]c12
28828,CHEMBL2425891,QCTNBSORTFEAEF-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,46240.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=C2)C=C(C=C3)C)N4CCC[C@H](C4)N,4.334982174587528,CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(C)ccc3n2)c1=O
28833,CHEMBL3114736,QCYOPAQQXNLZEV-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)NCCNC(=O)OCC2=CN=CS2,5.958607314841775,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCNC(=O)OCc2cncs2)C(C)C)cs1
28834,CHEMBL3601402,QCZBNRNLGNLUDF-YFMCWZQFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26181851.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.,J. Med. Chem.,PUBLICATION,,CC(C)OC1=C(C=C2CC(=O)N([C@H](C2=C1)C3=CC=C(C=C3)Cl)C4=NC=C(C=C4)N(C)CC5CCC(CC5)N6CCN(C(=O)C6)C)OC,4.698970004336019,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)CC3CCC(N4CCN(C)C(=O)C4)CC3)cn1)C(=O)C2
28857,CHEMBL568242,QDHOZPCLAACLAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=CC=C3OC(F)(F)F,5.376750709602099,CC1(CC(=O)NCc2ccccc2OC(F)(F)F)CC2(CCCCC2)OO1
28858,CHEMBL1829773,QDIAPKPZNBARDD-XDBZFTIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCNC(=O)NC)C4=CC=C(C=C4)F,6.0,CNC(=O)NCC[C@]1(c2ccc(F)cc2)CCN([C@@H](C)c2ccc(-c3ccc(F)cc3F)cc2)C(=O)O1
28864,CHEMBL1097032,QDKVMCOVHGDSAE-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C(=O)OC,6.154901959985743,COC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
28871,CHEMBL3358932,QDMKBJCCHCGTOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=CC=C4,7.0,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1
28872,CHEMBL2144409,QDMXVKKPYBGIAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25415535.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Inhibitors of c-Jun N-terminal kinases: an update.,J. Med. Chem.,PUBLICATION,,CC1=NC=C(C=C1)C2=NN(C=N2)C3=CC=C(C=C3)NC4=NC=CC(=N4)C5=CC(=CC=C5)N6CCOCC6,4.301029995663981,Cc1ccc(-c2ncn(-c3ccc(Nc4nccc(-c5cccc(N6CCOCC6)c5)n4)cc3)n2)cn1
28873,CHEMBL1761524,QDNROJXIPJKYJU-CEBSZYIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)[C@H]1C[C@@H]1COC2=CC(=CC(=C2)CN(C3CC3)C(=O)[C@H]4CNCC[C@@H]4C5=CC=C(C=C5)OCCOC6=C(C=C(C=C6Cl)C)Cl)CCCOC,5.853871964321762,CCOC(=O)[C@H]1C[C@@H]1COc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
28874,CHEMBL1761524,QDNROJXIPJKYJU-CEBSZYIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,19300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)[C@H]1C[C@@H]1COC2=CC(=CC(=C2)CN(C3CC3)C(=O)[C@H]4CNCC[C@@H]4C5=CC=C(C=C5)OCCOC6=C(C=C(C=C6Cl)C)Cl)CCCOC,4.714442690992226,CCOC(=O)[C@H]1C[C@@H]1COc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
28906,CHEMBL2441834,QDXBXMYNKPMRPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CC3=NC=CO3)C4=C(C=C(C=C4)Cl)Cl)CN,5.113509274827518,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ncco1)C2
28911,CHEMBL2387500,QEECLILKOYZESR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CC1=C(C(=CC=C1)Cl)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CC=CC=C5,4.522878745280337,Cc1cccc(Cl)c1-c1nc2c([nH]1)c(=O)[nH]c1cc(-c3ccccc3)ccc12
28919,CHEMBL1079437,QEHHTVFVEDPISA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)C4=CC=CC(=O)N4)C(=C(N3)C)C,5.886056647693163,Cc1cccc(C)c1CNc1nc(-c2cccc(=O)[nH]2)cc2c(C)c(C)[nH]c12
28920,CHEMBL1079437,QEHHTVFVEDPISA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)C4=CC=CC(=O)N4)C(=C(N3)C)C,5.657577319177793,Cc1cccc(C)c1CNc1nc(-c2cccc(=O)[nH]2)cc2c(C)c(C)[nH]c12
28925,CHEMBL2385096,QEKANLQOSSFFGI-MXWKQRLJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1[C@H]4CC[C@H](C4)NCC(F)(F)F)C=CN3)O,5.0,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@@H](NCC(F)(F)F)C1
28926,CHEMBL2385096,QEKANLQOSSFFGI-MXWKQRLJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1[C@H]4CC[C@H](C4)NCC(F)(F)F)C=CN3)O,5.0,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@@H](NCC(F)(F)F)C1
28929,CHEMBL555563,QEKKZTBXSULKCC-IBGZPJMESA-N,VER-156084,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22209458.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C(=O)N2CC(C2)O[C@@H](C3=CC=C(C=C3)Cl)C4=C(N=CC=C4)Cl,5.0,O=C(N1CCCCC1)N1CC(O[C@@H](c2ccc(Cl)cc2)c2cccnc2Cl)C1
28942,CHEMBL1270215,QEMGBPOATYALAI-OBYDGYHJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@@H]1CCN(C1)C(=O)OC2C3CC4CC(C3)CC2C4,4.522878745280337,CC(C)(C)OC(=O)N[C@@H]1CCN(C(=O)OC2C3CC4CC(C3)CC2C4)C1
28944,CHEMBL17350,QEMSVZNTSXPFJA-HNAYVOBHSA-N,TRAXOPRODIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21524576.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Iinhibition of CYP3A4,"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]([C@H](C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O,4.698970004336019,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1
28946,CHEMBL239495,QENBZBQERGRPHC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(CC)CC,5.522878745280337,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(CC)O2
28949,CHEMBL2021600,QENXTKAMWKICNF-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20491477.0,IC50,>,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.",J. Med. Chem.,PUBLICATION,,C[C@@H](C(C)(C)C)OC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)N2CCN(CC2)C3=C(C=C(C=N3)C(F)(F)F)F,4.619788758288394,C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(C)(C)C
28951,CHEMBL2442495,QEOBCNBMVHTMBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24252546.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N(N=C1C2=CC=CC=C2)C3=NC(=CS3)C(=O)O)C4=CC=CC=C4,5.0,Cc1c(-c2ccccc2)nn(-c2nc(C(=O)O)cs2)c1-c1ccccc1
28962,CHEMBL406832,QERIBPHEBTWPBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CC1=CN=C(N=C1)CNC2=NC(=NC(=C2)C3=CC=CC=C3)C4=CC=CC=N4,4.3979400086720375,Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3ccccn3)n2)nc1
28964,CHEMBL222460,QESHSZWKJULSAR-UHFFFAOYSA-N,BMS-223131,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy-4-trifluoromethylcoumarin,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2)CCO)C3=C(C=CC(=C3)Cl)O,5.0915149811213505,O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO
28965,CHEMBL222460,QESHSZWKJULSAR-UHFFFAOYSA-N,BMS-223131,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzylether,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2)CCO)C3=C(C=CC(=C3)Cl)O,4.0,O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO
28982,CHEMBL1935416,QEWJHGKQGHFKCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153342.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)CCCOC1=CC2=C(C=C1)OC3(CC2)CCN(CC3)C4CCC4,4.522878745280337,CS(=O)(=O)CCCOc1ccc2c(c1)CCC1(CCN(C3CCC3)CC1)O2
28983,CHEMBL1222798,QEXOFWNDNHZFRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CCOC5=CC=CC=C5)CC6=CC=NC=C6,5.045757490560675,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCOc3ccccc3)c3ccccc32)CC1
28987,CHEMBL114297,QEYKJWXDJGDHTK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCCOC1=CC=C(C=C1)N2C=CN=C2,4.4089353929735005,CN(C)CCCOc1ccc(-n2ccnc2)cc1
28998,CHEMBL3669002,QEZRYOVBHVLYKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320644,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=NC(=CC=C1)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)C,5.301029995663981,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(C)n4)nc3)c2c1
28999,CHEMBL3669002,QEZRYOVBHVLYKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320688,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=NC(=CC=C1)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)C,5.301029995663981,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(C)n4)nc3)c2c1
29016,CHEMBL413,QFJCIRLUMZQUOT-HPLJOQBZSA-N,SIROLIMUS,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,5.698970004336019,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
29029,CHEMBL3112858,QFOFHWPQHOESHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=CC=CC(=C21)C3=CC=NC=C3)C(=O)CC4=NC(=CC(=O)N4)N5CCOCC5,4.508638306165727,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccncc3)cccc21
29038,CHEMBL494948,QFPUYOAZKKYGQE-CHWSQXEVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19246199.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CNCCN1C2=NC=C(C(=N2)O[C@H](C)CC3=CC(=CC=C3)F)F,5.309803919971486,C[C@H](Cc1cccc(F)c1)Oc1nc(N2CCNC[C@H]2C)ncc1F
29039,CHEMBL2387587,QFQMKJXIFPLCNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)Cl)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F,4.522878745280337,O=c1[nH]c2cc(-c3cccc(Cl)c3)ccc2c2nc(-c3c(F)cccc3Cl)[nH]c12
29050,CHEMBL2048486,QFTZJLCYYMSCKG-TWGBQZSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)CC2=CC(=CC=C2)[C@@H]3C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO,4.301029995663981,CCc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1
29051,CHEMBL2048486,QFTZJLCYYMSCKG-TWGBQZSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)CC2=CC(=CC=C2)[C@@H]3C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO,4.301029995663981,CCc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1
29069,CHEMBL3115175,QFYWEWHEOQPTQQ-XMOVUWPTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CN(C)C)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.853871964321762,CC(C)c1nc(CN(C)C(=O)NC(CN(C)C)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
29085,CHEMBL147587,QGFYFOHMBDMGBZ-UHFFFAOYSA-N,ISOQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,CCN(CC)CC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,4.0,CCN(CC)Cc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O
29087,CHEMBL147587,QGFYFOHMBDMGBZ-UHFFFAOYSA-N,ISOQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Activation of human CYP3A4 using DEF substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,CCN(CC)CC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,4.0,CCN(CC)Cc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O
29094,CHEMBL385517,QGJUIPDUBHWZPV-SGTAVMJGSA-N,SAXAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16033281.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against Cytochrome P450 3A4,"Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N,4.0,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2
29096,CHEMBL385517,QGJUIPDUBHWZPV-SGTAVMJGSA-N,SAXAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 3 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N,4.301029995663981,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2
29097,CHEMBL385517,QGJUIPDUBHWZPV-SGTAVMJGSA-N,SAXAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N,4.301029995663981,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2
29098,CHEMBL385517,QGJUIPDUBHWZPV-SGTAVMJGSA-N,SAXAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N,4.301029995663981,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2
29099,CHEMBL385517,QGJUIPDUBHWZPV-SGTAVMJGSA-N,SAXAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N,4.301029995663981,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2
29107,CHEMBL380957,QGLWIDUCGVENCV-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCN5CC[C@@H](C5)O)C,5.0,Cc1cc2c(F)c(Oc3ncnn4cc(OCCN5CC[C@H](O)C5)c(C)c34)ccc2[nH]1
29118,CHEMBL2170633,QGOFFPIIAILOFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CC=CC(=C1)C(=O)N2CCC(CC2)C3=C(C=C(C=C3)C(=O)N=C(N)N)C(F)(F)F,4.522878745280337,CS(=O)(=O)c1cccc(C(=O)N2CCC(c3ccc(C(=O)N=C(N)N)cc3C(F)(F)F)CC2)c1
29121,CHEMBL3407575,QGOICCMBEDDFCI-NXQGQTBASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,0.33,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Homogenous Time-Resolved Fluorescence Assay (HTRF). The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",Benzoic acid derivative MDM2 inhibitor for the treatment of cancer,,PATENT,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC(=C(C=C3)Cl)F)C4=CC(=CC=C4)Cl)CC(=O)NC5=CC(=C(C=C5)C(=O)O)OC,9.481486060122112,COc1cc(NC(=O)C[C@@]2(C)C[C@H](c3cccc(Cl)c3)[C@@H](c3ccc(Cl)c(F)c3)N([C@H](CS(=O)(=O)C(C)(C)C)C3CC3)C2=O)ccc1C(=O)O
29123,CHEMBL3358935,QGPHIACZTUTSAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=C(C=CC(=C4)F)OC,6.698970004336019,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F
29130,CHEMBL3417525,QGPXEIMWTKWHMH-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25671290.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,PUBLICATION,,C[C@@](C1CC1)(C2=CC=C(C=C2)C3=CN=C(N=C3)N)C4=NOC(=N4)C5=CN(N=C5)CC(=O)N(C)C,4.522878745280337,CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1
29133,CHEMBL469431,QGPZJURATJCKHO-KNRSITRYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,59000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)OC(=O)C)O)O,4.229147988357856,CC(=O)O[C@H]1[C@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)O[C@@H](C)[C@H](O)[C@H]1O
29137,CHEMBL3673962,QGQODCDKRMKJDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320630,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=C(C=CC=N1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=CC=N4)F,5.301029995663981,COc1ncccc1CNc1ccc(Cc2c[nH]c3ncccc23)c(F)n1
29138,CHEMBL3673962,QGQODCDKRMKJDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320674,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=C(C=CC=N1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=CC=N4)F,5.0,COc1ncccc1CNc1ccc(Cc2c[nH]c3ncccc23)c(F)n1
29149,CHEMBL196478,QGSYCKKZFPLTMQ-UBFVSLLYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(C=C(C=C2)F)F)C(=O)NC(C)C)C3CC4=CC=CC=C4C3,5.3979400086720375,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(F)cc1F
29151,CHEMBL2425154,QGUGSIVNZPWVQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=NN=N4,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnn3)cc2)cc1
29152,CHEMBL2413849,QGUMEWLTIYRZFH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23845281.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using nifedipine as substrate,"Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: A novel, potent and selective type 5 17ß-hydroxysteroid dehydrogenase inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1)NC(=C2)C(=O)N3CCC(CC3)CC(C)(C)O,4.0,Cc1ccc2[nH]c(C(=O)N3CCC(CC(C)(C)O)CC3)cc2c1
29168,CHEMBL3326581,QGYOUMYRQKOXET-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4)F)(C)C)C=N1,4.698970004336019,Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4cc(F)ccc43)cccc2cn1
29197,CHEMBL3601400,QHQFWUOURSTSOD-BXKNEMSHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26181851.0,IC50,=,13200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.,J. Med. Chem.,PUBLICATION,,CC(C)OC1=C(C=C2CC(=O)N([C@H](C2=C1)C3=CC=C(C=C3)Cl)C4=CN=C(C=C4)N(C)CC5CCC(CC5)N6CC(=O)N(C6)C)OC,4.87942606879415,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)CC3CCC(N4CC(=O)N(C)C4)CC3)nc1)C(=O)C2
29201,CHEMBL3702703,QHRIPYHARJRXIH-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8170.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CC8CCNCC8,5.087777943467584,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC6CCNCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
29202,CHEMBL1188,QHSMEGADRFZVNE-UHFFFAOYSA-N,ALPHA-HYDROXY-MIDAZOLAM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,2700.0,NM,,inhibition,tissue,binding,,,,,,,,,,,,,,,,C1C2=CN=C(N2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4F)CO,5.568636235841013,OCc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
29203,CHEMBL1188,QHSMEGADRFZVNE-UHFFFAOYSA-N,ALPHA-HYDROXY-MIDAZOLAM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=CN=C(N2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4F)CO,5.0,OCc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
29206,CHEMBL3702702,QHSQTDUGXXBHGV-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CC8CCCC8,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC6CCCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
29207,CHEMBL2338475,QHTHSQXFWCRPEY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,CC(=O)C1=C(C=CC(=C1)NS(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)OC3=CC4=CC=CC=C4N=C3,5.522878745280337,CC(=O)c1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc1cnc2ccccc2c1
29218,CHEMBL1089793,QIBDSCJTWMYQTC-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by P450-Glo method,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=C(C=CC(=C4)F)F,5.0,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3cc(F)ccc3F)CC2)C1
29220,CHEMBL205993,QIDWKMNIWOOQON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)O)N1CCC(C1)(C2=CC=CC=C2)C(=O)NC3CCN(CC3)CC4=CC(=CC=C4)OC5=CC=CC=C5Cl,5.0,CC(C)(C(=O)O)N1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)C1
29221,CHEMBL1098711,QIEKBURWQYYQLT-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C(=O)C,5.958607314841775,CC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
29228,CHEMBL2425890,QIHMOUKJDLOSDC-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,58280.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=C2)C=C(C=C3)F)N4CCC[C@H](C4)N,4.234480456902047,CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(F)ccc3n2)c1=O
29236,CHEMBL476567,QIIVIPMIUSRDGT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCC(=O)NC(C1=CC=CC=C1)C2=CC=C(C=C2)Cl,4.301029995663981,CC(=O)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1
29238,CHEMBL2181775,QIKHXKPKHSBWTR-GIJQJNRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=CC=C(C=C5)Cl)C6CCCC6,5.080921907623926,Cn1c(-c2ccc(Cl)cc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21
29245,CHEMBL410503,QIMASXGTWQEFGS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)OCC1COC(O1)(CN2C=NC=N2)C3=C(C=C(C=C3)Cl)Cl,5.113509274827518,CS(=O)(=O)OCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1
29247,CHEMBL565983,QIMHTADQASRTKL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)OC(F)(F)F,5.5376020021010435,CC1(CC(=O)NCc2ccc(OC(F)(F)F)cc2)CC2(CCCCC2)OO1
29251,CHEMBL3664673,QIMKZFAYADXKFW-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,28000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)CC(F)(F)F)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.552841968657781,C[C@@H](c1ccc(-c2ccc(=O)n(CC(F)(F)F)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
29254,CHEMBL1668249,QIOGTBSZDDTWRV-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)[C@@H](C(=O)NC2=C(C=C(C=C2)OC3(CC3)C(=O)O)F)N4C5=CC(=C(C=C5N=C4C6=CC=C(C=C6)Cl)F)F,4.301029995663981,O=C(Nc1ccc(OC2(C(=O)O)CC2)cc1F)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21
29261,CHEMBL584554,QIPWTYSOANVUKJ-WZONZLPQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19783143.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5,5.0,CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1
29275,CHEMBL54976,QIVBCDIJIAJPQS-VIFPVBQESA-N,TRYPTOPHAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N,5.0,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O
29276,CHEMBL54976,QIVBCDIJIAJPQS-VIFPVBQESA-N,TRYPTOPHAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N,5.0,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O
29286,CHEMBL396432,QIYPSKLPQCIXMB-XDFJSJKPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN[C@@H](CC(C)C)C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O,4.431798275933005,CCN(CC)CCN[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
29288,CHEMBL2069804,QIZIZVBSJUAZHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,C1CCC(CC1)C2=NN=C(O2)C3=CC=NC=C3,4.698970004336019,c1cc(-c2nnc(C3CCCCC3)o2)ccn1
29298,CHEMBL402805,QJEQMNOHVFVNGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,770.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC(=O)N1CCCC(C1CN2CCOCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,6.113509274827518,CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1
29304,CHEMBL209864,QJFALSJVPBJZRP-GMKZXUHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(O1)[C@H](C(=O)NC(C)C)N2[C@@H](C(=O)N[C@@H](C2=O)C3CC4=CC=CC=C4C3)CC(C)C,5.154901959985743,Cc1ccc([C@H](C(=O)NC(C)C)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)o1
29323,CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22205779.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated with compound before substrate addition by LC-MS method,Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.,Drug Metab. Dispos.,PUBLICATION,,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,6.920818753952375,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
29324,CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22205779.0,IC50,=,620.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation by LC-MS method,Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.,Drug Metab. Dispos.,PUBLICATION,,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,6.2076083105017466,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
29332,CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,6.0,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
29342,CHEMBL3422007,QJNHNXFWOFSZPP-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,45000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CC=CC(=N5)C,4.346787486224656,Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1
29349,CHEMBL297784,QJQORSLQNXDVGE-UHFFFAOYSA-N,SB-206553,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9357513.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human Cytochrome P450 3A at 1 uM,6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.,J. Med. Chem.,PUBLICATION,,CN1C=CC2=CC3=C(CCN3C(=O)NC4=CN=CC=C4)C=C21,4.0,Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1
29356,CHEMBL3310995,QJSIDAFXZGMWSO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,136000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=NC(=C1)C(C(CN2C=NN=N2)(C3=C(C=C(C=C3)F)F)O)(F)F,3.8664610916297826,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccccn1
29362,CHEMBL1214452,QJVMDGUSBHUPRY-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)N[C@H]1CC2=C(C1)C=C(C=C2)C3=NC=C(C=C3)F,5.0,CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)cn3)cc2C1
29363,CHEMBL1214448,QJVMDGUSBHUPRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=NC=C(C=C3)F,5.0,CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)cn3)cc2C1
29368,CHEMBL112532,QJWFZZZHWWOBNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,348.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)N2C=CN=C2,6.458420756053419,CCCCOc1ccc(-n2ccnc2)cc1
29369,CHEMBL112532,QJWFZZZHWWOBNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,348.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCOC1=CC=C(C=C1)N2C=CN=C2,6.458420756053419,CCCCOc1ccc(-n2ccnc2)cc1
29374,CHEMBL228814,QJZRFPJCWMNVAV-HHHXNRCGSA-N,ISPINESIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22248262.0,IC50,=,4100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)C(=O)N(CCCN)[C@@H](C2=NC3=C(C=CC(=C3)Cl)C(=O)N2CC4=CC=CC=C4)C(C)C,5.3872161432802645,Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1
29377,CHEMBL2448724,QKAQPMIIFZVJKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1=CC=C(C=C1)C2=NC=C(S2)C(=O)NC3=CC=CC=C3N4C=CN=C4,5.698970004336019,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)s1
29386,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,6095.37,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,5.214999926783721,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
29398,CHEMBL2058903,QKFSCFHGGPCBMY-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,44.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CC5=C(C=C4)OCO5)O)CC(C)C,7.356547323513813,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3ccc4c(c3)OCO4)cc2o1
29409,CHEMBL501119,QKIQAUSGMKJYFS-CWFCOSEVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,98200.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,CC1=C[C@H]([C@]23[C@H]1CC4=C(C(=O)O[C@H]4C[C@]2(O3)C)C)O,4.00788851221305,CC1=C[C@@H](O)[C@@]23O[C@]2(C)C[C@@H]2OC(=O)C(C)=C2C[C@@H]13
29411,CHEMBL2436978,QKKIWEILHCXECO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,=,16200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)CC2=CC=C(C=C2)C3=CC4=C(NC=C4C5=CC6=C(C=C5)NC=C6)N=C3,4.790484985457369,CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1
29424,CHEMBL479628,QKRGRWXDVSZBQO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C2=CC(=NC=C2C(=O)NCC3CCOCC3)NC4=C(C=CC(=C4)Cl)Cl,4.0,O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)ccc2Cl)cc1C1CC1
29433,CHEMBL1669426,QLDMAQDSTHZTSU-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN=C4,5.0,C[C@H](C1=C(CCN(C)Cc2cnccn2)Cc2ccccc21)c1cnccn1
29436,CHEMBL1269858,QLFGDTPACJHLRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20850301.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorometric assay,Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C1=NC(=NC=C1)NC2=CC(=CC(=C2)N3CCOCC3)N4CCOCC4)C5=CC=CC6=C5C=NN6,5.301029995663981,CN(c1ccnc(Nc2cc(N3CCOCC3)cc(N3CCOCC3)c2)n1)c1cccc2[nH]ncc12
29445,CHEMBL478035,QLHPJXQAKQNIOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C2C(=C1)C(C3=C(S2)C=CC(=C3)Cl)CNC(=O)CNC(=O)C4=CC=C(C=C4)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2Sc2ccc(Cl)cc21
29448,CHEMBL1669410,QLIYPKVJEXOVDM-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCC#N,5.0,C[C@H](C1=C(CCN(C)CCC#N)Cc2ccccc21)c1cnccn1
29458,CHEMBL3288450,QLKVYUYEIZLSOY-QAJMXTGNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)[C@@]3(CCCN([C@@H]3CC(CO)O)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,5.1249387366083,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CC(O)CO)CC1
29459,CHEMBL3288450,QLKVYUYEIZLSOY-QAJMXTGNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)[C@@]3(CCCN([C@@H]3CC(CO)O)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,4.522878745280337,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CC(O)CO)CC1
29480,CHEMBL220360,QLYKJCMUNUWAGO-GAJHUEQPSA-N,TARANABANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673729.0,IC50,>,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 30 mins,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,PUBLICATION,,C[C@@H]([C@@H](CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F,7.698970004336019,C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1
29511,CHEMBL2170610,QMHRLXNEGYTSRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCC(CC1)C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F,4.522878745280337,CC(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
29516,CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC(=CC=C1)N2CCOCC2)NC(=O)/C=C/C3=CC=CC=C3,4.657577319177793,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1
29517,CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin],Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC(=CC=C1)N2CCOCC2)NC(=O)/C=C/C3=CC=CC=C3,4.568636235841013,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1
29518,CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC(=CC=C1)N2CCOCC2)NC(=O)/C=C/C3=CC=CC=C3,4.481486060122112,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1
29519,CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC(=CC=C1)N2CCOCC2)NC(=O)/C=C/C3=CC=CC=C3,4.207608310501746,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1
29520,CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,76000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with Benzoylresorufin,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC(=CC=C1)N2CCOCC2)NC(=O)/C=C/C3=CC=CC=C3,4.119186407719209,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1
29521,CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,96000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC(=CC=C1)N2CCOCC2)NC(=O)/C=C/C3=CC=CC=C3,4.017728766960431,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1
29539,CHEMBL2177818,QMMOUPNLBRDPCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22533986.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins,"Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors.",J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)NC(=O)CC2=CC=C(C=C2)N3C4=C(C=CC=N4)N=C3C5=C(N=CC=C5)N,5.0,Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1
29545,CHEMBL3702688,QMNHISFQHZSZCX-JUKUECOXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3420.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(O7)C(=O)N(C)C,5.465973893943865,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N(C)C)o5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
29546,CHEMBL2165507,QMOQTGNDEOUYLC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=CNC5=CC(=C4)C#N)N6CCOCC6,5.920818753952375,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cc(C#N)cc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
29560,CHEMBL520413,QMSZYSVYDVBLRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,=,57000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C2=CC(=NC=C2C(=O)NCC3CCOCC3)NC4=CC(=CC=C4)OC(F)(F)F,4.2441251443275085,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(OC(F)(F)F)c2)cc1C1CC1
29564,CHEMBL566685,QMWKLCXWSJTEFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NSC(=C1)C2=NN3C(=NN=C3CNC4=C5C(=NC=C4)C=C(C=N5)OC)C=C2,4.585026652029182,COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
29565,CHEMBL566685,QMWKLCXWSJTEFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NSC(=C1)C2=NN3C(=NN=C3CNC4=C5C(=NC=C4)C=C(C=N5)OC)C=C2,4.301029995663981,COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
29567,CHEMBL566685,QMWKLCXWSJTEFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in absence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,CC1=NSC(=C1)C2=NN3C(=NN=C3CNC4=C5C(=NC=C4)C=C(C=N5)OC)C=C2,4.585026652029182,COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
29568,CHEMBL566685,QMWKLCXWSJTEFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,CC1=NSC(=C1)C2=NN3C(=NN=C3CNC4=C5C(=NC=C4)C=C(C=N5)OC)C=C2,4.301029995663981,COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
29584,CHEMBL404229,QNAWNEAEBOQURR-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1(C2=CC=CC=C2)N3C(=NC4=C3N=CC=C4)CNC(=O)[C@@H](CC5=C(C=CC=C5F)F)NC(=O)C6(CC6)C(F)(F)F,4.698970004336019,O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1c(F)cccc1F)NC(=O)C1(C(F)(F)F)CC1
29609,CHEMBL189164,QNIZBEIHYCQTEQ-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,160.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=CC=C4Cl)N,6.795880017344075,N[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
29611,CHEMBL1668022,QNNBMSGFNQRUEH-OCPPCWRMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN1C(=O)[C@@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)[C@H](C5CCCCC5)O.Cl,4.522878745280337,CCCCN1C(=O)[C@H]([C@@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
29612,CHEMBL1668019,QNNBMSGFNQRUEH-PQQSRXGVSA-N,APLAVIROC HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN1C(=O)[C@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)[C@@H](C5CCCCC5)O.Cl,4.522878745280337,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
29613,CHEMBL1668021,QNNBMSGFNQRUEH-QBYKQQEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN1C(=O)[C@@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)[C@@H](C5CCCCC5)O.Cl,4.522878745280337,CCCCN1C(=O)[C@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
29614,CHEMBL1668020,QNNBMSGFNQRUEH-XZVFQGBBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN1C(=O)[C@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)[C@H](C5CCCCC5)O.Cl,4.522878745280337,CCCCN1C(=O)[C@@H]([C@@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
29616,CHEMBL3393469,QNOOVTZVMOOSAW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,190.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=CC=CC=C6N5,6.721246399047171,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3ccccc3[nH]2)o1
29629,CHEMBL448743,QNSOPUXDEXJMIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,<,200000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,C1CC(=O)C2=C1C=C(C=C2)C3=CN=CC=C3,3.6989700043360187,O=C1CCc2cc(-c3cccnc3)ccc21
29645,CHEMBL3104488,QODANUKDEHILIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,5.154901959985743,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
29646,CHEMBL3104488,QODANUKDEHILIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6600.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,5.180456064458132,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
29647,CHEMBL3104488,QODANUKDEHILIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,5.154901959985743,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
29648,CHEMBL3104488,QODANUKDEHILIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,4.698970004336019,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
29652,CHEMBL1909988,QOGSEZRHWWWULE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,5.920818753952375,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccccc1)C2=O
29675,CHEMBL567487,QOJWZANXROFNQS-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)Cl,5.096910013008056,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(Cl)nc3)ccc2o1
29688,CHEMBL391963,QOPIOMWNHRCPAA-RPBOFIJWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CCC(CC1)C(=O)N2C[C@@H]([C@H](C2)C(=O)N(C)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=CC=CC=C4,4.7447274948966935,CC(=O)N1CCC(C(=O)N2C[C@H](c3ccccc3)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1
29689,CHEMBL2178252,QOQWGXFCUOWNQI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,CN1C=C(C(=N1)C2=CC(=CC=C2)Cl)NC(=O)C3=C4N=CC=CN4N=C3,5.0,Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cccc(Cl)c2)n1
29690,CHEMBL1669425,QORUSIWOKHYRCP-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,1281.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=NC=C4,5.892450870255313,C[C@H](C1=C(CCN(C)Cc2ccncc2)Cc2ccccc21)c1cnccn1
29694,CHEMBL1951914,QOSMEMHKXNNIGG-SSEXGKCCSA-N,AZD5672,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22266038.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C1CCN(CC1)CC[C@H](C2CCN(CC2)S(=O)(=O)C)C3=CC(=CC(=C3)F)F)C(=O)CC4=CC=C(C=C4)S(=O)(=O)C,5.045757490560675,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1
29697,CHEMBL603695,QOTDZEUUPREESE-MUJYYYPQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C[C@H]2CC(C[C@H]2C1)N(CC3=CC(=C(C=C3)F)C(F)(F)F)C(=O)C4=CN(C=N4)C,5.0,CN1C[C@H]2CC(N(Cc3ccc(F)c(C(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1
29698,CHEMBL461422,QOTMLIIRYJJNCS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)C5CCN(CC5)C,4.3979400086720375,Cc1cc(C2CCN(C)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12
29709,CHEMBL3702793,QOWBPCJXESFQOP-VBXQXZIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7600.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.119186407719209,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
29717,CHEMBL3403817,QOZFSPYDMIHYGH-HNLCVBAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,54000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)C9CCC9)C)C)O)C)C(C)(C)O,4.267606240177032,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
29718,CHEMBL3403817,QOZFSPYDMIHYGH-HNLCVBAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)C9CCC9)C)C)O)C)C(C)(C)O,4.0,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
29741,CHEMBL2017098,QPHJBQDZTCDVEK-ZHRRBRCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C2=NOC(=C2Br)[C@H]3CNCC[C@@]3(C4=CC(=C(C=C4)F)F)O)C,4.698970004336019,Cc1cccc(-c2noc([C@H]3CNCC[C@]3(O)c3ccc(F)c(F)c3)c2Br)c1C
29744,CHEMBL3318997,QPIAIQHJZYBDGV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25050172.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C#N)N=C(N2)C3CCN(CC3)CCN4C(=O)C=CC5=C4C=C(C=N5)OC,5.026872146400302,COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1
29749,CHEMBL2420310,QPJUVRIRYLMERM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23855836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.",J. Med. Chem.,PUBLICATION,,C1CN(CCN1CCO)CC(=O)NC2=C3C4=CC=CC=C4SC3=C(C=C2)C5=CC=CC6=C5OC(=CC6=O)N7CCOCC7,5.0,O=C(CN1CCN(CCO)CC1)Nc1ccc(-c2cccc3c(=O)cc(N4CCOCC4)oc23)c2sc3ccccc3c12
29755,CHEMBL1254079,QPLQDYDXYCUKKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=C(N2)C=NC=C3)(C(F)(F)F)O,7.0,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F
29773,CHEMBL227464,QPRAFCFDOZPSSH-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC3=C(C(=CC=C3)F)C(=O)N2CC4=CC=CC=C4C#N)N,6.301029995663981,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cccc(F)c2c1=O
29774,CHEMBL2158225,QPSVRPUGGFUWCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)CCO)NC(=O)C4=NC=C(N4)C#N,5.0,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCO)CC3)cc2C2=CCCCC2)[nH]1
29797,CHEMBL390002,QQDQTWDEUJPACU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1CN=C(N1)C2=CC3=C(C(=C2)C)N=C(N3)C4=C(C=CNC4=O)NCC(C5=CC(=CC=C5)Cl)O,5.366531544420414,Cc1cc(C2=NCC(C)N2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
29799,CHEMBL2181893,QQEJGTCLITVFBA-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)C[C@@H]2NC[C@H]([C@H](CC4=CC(=CC=C4)C5=CN=CS5)NC(=O)COC)O,7.522878745280337,COCC(=O)N[C@@H](Cc1cccc(-c2cncs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
29848,CHEMBL3673964,QQYBNPCNVNQSRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320633,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)OC)F)N=C1,5.301029995663981,COc1ncccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1
29849,CHEMBL3673964,QQYBNPCNVNQSRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320677,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)OC)F)N=C1,5.301029995663981,COc1ncccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1
29854,CHEMBL3358963,QRAMNBZTYLSISP-MGPLVRAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,51000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NN=C2)(C3=C(C=C(C=C3)F)F)O,4.292429823902063,C[C@@H](c1ncncc1F)[C@](O)(Cn1cnnc1)c1ccc(F)cc1F
29880,CHEMBL3288011,QRGFWLQABJUBCF-FLSDQSJTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24785301.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC(=CC=C3)OC4=C(C=C(C=N4)F)C(=O)NC5CCC(CC5)NC(=O)C6=CN7C(=CC=CC7=N6)C,6.0,Cc1cccc2nc(C(=O)NC3CCC(NC(=O)c4cc(F)cnc4Oc4cccc(-c5ccc(CN6C[C@H](C)N[C@H](C)C6)cc5)c4)CC3)cn12
29881,CHEMBL1801250,QRGHOAATPOLDPF-VQFNDLOPSA-N,CHR-3996,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21080647.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2[C@@H](C2NCC3=NC4=C(C=C3)C=C(C=C4)F)CN1C5=NC=C(C=N5)C(=O)NO,5.0,O=C(NO)c1cnc(N2C[C@H]3C(NCc4ccc5cc(F)ccc5n4)[C@H]3C2)nc1
29891,CHEMBL1262,QRJJEGAJXVEBNE-HKOYGPOVSA-N,OXICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,90.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl,7.045757490560675,Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
29893,CHEMBL2407951,QRJKRUIJMCAZBY-DARPEHSRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1C(C/C(=N\O)/C2=CN(C(=O)C=C2)C)C3=CC=C(C=C3)Br,4.301029995663981,Cc1ccccc1C(C/C(=N\O)c1ccc(=O)n(C)c1)c1ccc(Br)cc1
29927,CHEMBL1271489,QRWIMPDPKYXNEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933413.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DEF substrate by CYPEX bactosome P450 inhibition assay,"2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: a new class of selective orexin 2 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)NC(=O)CSC2=NN=C(N2CC3=CC=CO3)C4=C(OC=C4)C)C,5.698970004336019,Cc1cc(C)cc(NC(=O)CSc2nnc(-c3ccoc3C)n2Cc2ccco2)c1
29928,CHEMBL1271489,QRWIMPDPKYXNEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933413.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 by CYPEX bactosome P450 inhibition assay,"2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: a new class of selective orexin 2 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)NC(=O)CSC2=NN=C(N2CC3=CC=CO3)C4=C(OC=C4)C)C,5.301029995663981,Cc1cc(C)cc(NC(=O)CSc2nnc(-c3ccoc3C)n2Cc2ccco2)c1
29951,CHEMBL1257487,QRYUISZNMDTTDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCN(C(=O)C4=C3)CC5=CC=NC=C5,5.221848749616356,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(Cc3ccncc3)C2=O)CC1
29955,CHEMBL1672633,QRZYIOBBNKOVAA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CN=CO3)C4=C(C=NC=C4)F,5.301029995663981,O=C(Nc1cnc(-c2ccncc2F)c(-c2cnco2)n1)C1CC1
29963,CHEMBL2170642,QSBOEASQKPQRPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=CC=C3,4.522878745280337,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccccc3)CC2)c(C(F)(F)F)c1
29977,CHEMBL2419492,QSJSWBPRIPCKFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)OC)C,4.769551078621726,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(OC)cc3)CC2)nc1C
29978,CHEMBL3672585,QSJUJJFEVZDXSW-FIRIVFDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,150.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)NC2(CCNCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.823908740944319,CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCNCC2)cs1
29979,CHEMBL3672585,QSJUJJFEVZDXSW-FIRIVFDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,340.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)NC2(CCNCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.468521082957745,CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCNCC2)cs1
29985,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4322.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,5.364315237452778,CNCCCC12CCC(c3ccccc31)c1ccccc12
29992,CHEMBL1761522,QSMZHNDKHVVMTF-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC(=O)NCCCOC1=CC(=CC(=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)CCCOC,5.619788758288394,CCNC(=O)NCCCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
29993,CHEMBL1761522,QSMZHNDKHVVMTF-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC(=O)NCCCOC1=CC(=CC(=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)CCCOC,5.200659450546418,CCNC(=O)NCCCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
30004,CHEMBL496806,QSPSYONCWQHOSB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CNC(=O)NC4=O,5.769551078621726,Cc1cccc(C)c1CNc1cc(-c2c[nH]c(=O)[nH]c2=O)cn2c(C)c(C)nc12
30005,CHEMBL496806,QSPSYONCWQHOSB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CNC(=O)NC4=O,5.585026652029182,Cc1cccc(C)c1CNc1cc(-c2c[nH]c(=O)[nH]c2=O)cn2c(C)c(C)nc12
30019,CHEMBL2086753,QSWVENZGENITTQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=C3C(=C4N=C5C=CC=CC5=N4)C6=CC=CC=C6)O,5.522878745280337,CCN1CCC(Nc2ccc3[nH]c(O)c(C(=C4N=c5ccccc5=N4)c4ccccc4)c3c2)CC1
30029,CHEMBL1090479,QTBWCSQGBMPECM-UHFFFAOYSA-N,GSK-1070916,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20420387.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate,"Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.",J. Med. Chem.,PUBLICATION,,CCN1C=C(C(=N1)C2=CC=C(C=C2)NC(=O)N(C)C)C3=C4C=C(NC4=NC=C3)C5=CC=CC(=C5)CN(C)C,4.823908740944319,CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1
30031,CHEMBL1910117,QTCAWQMHWREMFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N(C)C)C3=C(C=C(C=C3)Cl)Cl)CN,4.769551078621726,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N(C)C)C2=O
30033,CHEMBL564547,QTDLNCWVZXZPRJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,CC1=NOC(=N1)C2CCN(CC2)C(=O)NC3CC3C4=CC=CC=C4,5.0,Cc1noc(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)n1
30034,CHEMBL3326909,QTDRSEIGXUBECZ-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC=C4F)(CF)CF)C=N1,4.698970004336019,Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4c(F)cccc43)cccc2cn1
30039,CHEMBL3359020,QTEQNMQSANNRQL-QKDCVEJESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25210858.0,IC50,=,42000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CC(=C(C=C1)NC(=O)N2C[C@H]3CC(C[C@H]3C2)C4=CC=CC=C4C(F)(F)F)C(=O)O,4.376750709602099,CS(=O)(=O)c1ccc(NC(=O)N2C[C@H]3CC(c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)c1
30040,CHEMBL445162,QTFCKBFCXDAZIU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20850301.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorometric assay,Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC=CC(=C1)NC2=NC=CC(=N2)NC3=C(C=CC4=C3OCO4)Cl,5.585026652029182,CS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4c3OCO4)n2)c1
30044,CHEMBL1916708,QTGFRLQHUVFSMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958540.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of a biphenylacetic acid series of prostaglandin D(2) receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=CC(=C2)CC(=O)O)OC)C(=O)OCC3=CC=C(C=C3)Cl,4.6777807052660805,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccc(Cl)cc1
30048,CHEMBL486950,QTJDEJXKPAATAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,740.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CC=C3)OC)C,6.130768280269024,COc1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1
30058,CHEMBL238945,QTKVIRZNRGRMSC-OAHLLOKOSA-N,SR-895,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@H](C(=O)N1CCN(CC1)C2=CC3=C(C=C2)NN=C3)O,5.0,CC(C)[C@@H](O)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1
30059,CHEMBL3326586,QTLBTSMPTYIABU-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=C(C=C4)F)(CF)CF)C=N1,4.823908740944319,Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4ccc(F)cc43)cccc2cn1
30062,CHEMBL2347159,QTLWLBUJOKPYEQ-IRXDYDNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23466233.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)N=[N+]=[N-])NC(=O)OC,5.292429823902063,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(N=[N+]=[N-])cc2)[nH]1)C(C)C
30085,CHEMBL3604701,QTUZZGDVIHVSHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C=CC=C(C3=NC(=C2)C)C(=O)N,5.0,Cc1cc(NCc2c(C)cccc2C)c2cccc(C(N)=O)c2n1
30094,CHEMBL1939697,QTVDULQPUXPKEL-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,27.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,C[C@H](C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)O)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,7.568636235841013,C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1
30095,CHEMBL1939697,QTVDULQPUXPKEL-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,68.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,C[C@H](C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)O)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,7.167491087293763,C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1
30096,CHEMBL1939697,QTVDULQPUXPKEL-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,650.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,C[C@H](C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)O)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,6.187086643357144,C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1
30097,CHEMBL1939697,QTVDULQPUXPKEL-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,C[C@H](C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)O)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,5.6777807052660805,C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1
30123,CHEMBL377512,QUBCQRMRMDXUHX-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,18.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N(C)CCN1CCCC2=C1C=C(C=C2)OC[C@H]3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,7.7447274948966935,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN(C)C(C)=O)CCC3)cc1
30128,CHEMBL1091356,QUBPQLLMMSZSGD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223663.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5C6CCC5COC6)C7CCOCC7,4.522878745280337,CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1
30131,CHEMBL1910113,QUDCMYBYHAHRMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CCO)C3=C(C=C(C=C3)Cl)Cl)CN,4.3979400086720375,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CCO)C2=O
30163,CHEMBL559565,QUNIRDORWCGMDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19552431.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assay,Novel small molecule bradykinin B2 receptor antagonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC=C1)CNC(=O)C2CCCCC2)COC3=CC=CC4=C(C=C(N=C43)C)C5=CC=NN5C,5.6020599913279625,Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3CNC(=O)C3CCCCC3)c2n1
30164,CHEMBL2170615,QUNSHWVUJWWFTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=C(C=C3)S(=O)(=O)N,4.619788758288394,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccc(S(N)(=O)=O)cc3)CC2)c(C(F)(F)F)c1
30171,CHEMBL2017108,QUOFNJSDYRDJLR-WSXYJJAVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1=C(ON=C1[C@H]2CNCC[C@@]2(C3=CC(=C(C=C3)F)F)O)C4=CC=CC=C4CCNC(=O)C)O,4.301029995663981,CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1C(C)O
30179,CHEMBL1080244,QURAXYQDHTYNMN-KBPBESRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@H](C)NC(=O)OCC1=CN=CS1)C[C@H](C)NC(=O)OCC2=NC=CS2,5.522878745280337,CCN(C[C@H](C)NC(=O)OCc1cncs1)C[C@H](C)NC(=O)OCc1nccs1
30180,CHEMBL1080417,QURAXYQDHTYNMN-UONOGXRCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,1790.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@H](C)NC(=O)OCC1=CN=CS1)C[C@@H](C)NC(=O)OCC2=NC=CS2,5.747146969020107,CCN(C[C@H](C)NC(=O)OCc1cncs1)C[C@@H](C)NC(=O)OCc1nccs1
30181,CHEMBL1080418,QURAXYQDHTYNMN-ZIAGYGMSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,1330.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@@H](C)NC(=O)OCC1=CN=CS1)C[C@@H](C)NC(=O)OCC2=NC=CS2,5.876148359032914,CCN(C[C@@H](C)NC(=O)OCc1cncs1)C[C@@H](C)NC(=O)OCc1nccs1
30182,CHEMBL3114726,QUSGSABPASEHDF-PPTMTGTBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CCN(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.522878745280337,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCN(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
30188,CHEMBL381717,QUUUOVGZDVVVGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16297617.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCCOC1=CC=C(C=C1)CN2CCCCC2,4.522878745280337,CN(C)CCCOc1ccc(CN2CCCCC2)cc1
30203,CHEMBL3114715,QUZLDZPTAVNVTK-RVXMEZTNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)/C=C/[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4,6.823908740944319,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](/C=C/[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
30219,CHEMBL3091531,QVCOEHDVYXQCHW-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3ß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(N=C1N2CCO[C@H](C2)C3=CC=C(C=C3)F)C4=C(C=NC=C4)F,4.301029995663981,Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncc2F)cc1=O
30228,CHEMBL2062809,QVEWCURGCSBRER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22594690.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779.",J. Med. Chem.,PUBLICATION,,CN1CCC(CC1)C2=CC(=CC=C2)NC3=NN4C=CC=C(C4=N3)C5=CC=C(C=C5)S(=O)(=O)C,4.619788758288394,CN1CCC(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1
30251,CHEMBL393941,QVNUOJRVQDGJQW-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)[C@H]3CCC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,6.3979400086720375,CC(C)(CO)N1CCN(C(=O)OC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
30252,CHEMBL393941,QVNUOJRVQDGJQW-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)[C@H]3CCC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,6.3979400086720375,CC(C)(CO)N1CCN(C(=O)OC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
30265,CHEMBL1835783,QVUQXLNBQGFHKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C2=C(CCC2)C(=N1)C3=CC=C(C=C3)OCCCN4CCCCC4,4.522878745280337,Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2c(c1=O)CCC2
30278,CHEMBL391964,QVYOBGVPVVZIAA-FTJBHMTQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)F)[C@H]2CN(C[C@@H]2C(=O)N(C)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)C4CCN(CC4)C(=O)C,4.958607314841775,CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1
30283,CHEMBL900,QVYRGXJJSLMXQH-UHFFFAOYSA-N,ORPHENADRINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,4.522878745280337,Cc1ccccc1C(OCCN(C)C)c1ccccc1
30296,CHEMBL114,QWAXKHKRTORLEM-UGJKXSETSA-N,SAQUINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,5.823908740944319,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
30307,CHEMBL2425147,QWBIFVYQZVMANV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=NN=C4,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnc3)cc2)cc1
30308,CHEMBL252001,QWBIJZNHHTVJRM-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NC(=NO4)CN(C)C(C)(C)CO,6.522878745280337,CC[C@@H]1CCC[C@H](C2(Cc3nc(CN(C)C(C)(C)CO)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
30343,CHEMBL2017089,QWDANQMCVSOTGM-UHFFFAOYSA-N,GW694481,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=CC3=NC=C(C(=C3C=C2)NC4=CC=CC=C4)C(=O)N,4.769551078621726,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3)c(C(N)=O)cnc2c1
30344,CHEMBL2437425,QWEGNKRBUGIZBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)CC(F)(F)F)CC5=CC(=NC=C5)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC(F)(F)F)c5cc(F)ccc54)CC3)CC2)ccn1
30345,CHEMBL515387,QWEWGXUTRTXFRF-KBPBESRZSA-N,GOSOGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19275964.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CC1(F)F)C(=O)[C@@H]2C[C@@H](CN2)N3CCN(CC3)C4=NC=CC=N4,4.522878745280337,O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1
30347,CHEMBL3702740,QWFNQVFYLFOPLC-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,17890.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCN(C)C,4.747389659432627,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
30356,CHEMBL1837040,QWHITGKBRLEYSC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21885275.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCN(CC4)C5=CC=CC=N5)C1,4.522878745280337,CC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1
30367,CHEMBL1080717,QWOUZMOGMXMQHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=NC=CN3C2=CC(=C3C)C,5.795880017344075,Cc1cccc(C)c1CNc1nccn2c(C)c(C)cc12
30368,CHEMBL1080717,QWOUZMOGMXMQHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=NC=CN3C2=CC(=C3C)C,5.327902142064283,Cc1cccc(C)c1CNc1nccn2c(C)c(C)cc12
30371,CHEMBL568438,QWQVLGPEHGKMST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=CC=N3,5.301029995663981,CC1(CC(=O)NCc2ccccn2)CC2(CCCCC2)OO1
30380,CHEMBL1795039,QWWBEGGBLMBTSG-LCDQZUQSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,51900.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CC=C(O2)/C=N/O.C1=CC(=CN=C1)C2=CC=C(O2)/C=N\O,4.284832642151542,O/N=C/c1ccc(-c2cccnc2)o1
30381,CHEMBL1215623,QWWNXNFWXOZGLJ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20672820.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,PUBLICATION,,CC1=C([C@H](C(=C(N1)CN2C=NN=N2)C(=O)OC)C3=C(C=C(C=C3)F)Cl)C#N,5.0,COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)[C@H]1c1ccc(F)cc1Cl
30382,CHEMBL1215622,QWWNXNFWXOZGLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20672820.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C(C(=C(N1)CN2C=NN=N2)C(=O)OC)C3=C(C=C(C=C3)F)Cl)C#N,5.920818753952375,COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl
30405,CHEMBL3695718,QXEIYUPKPSVTRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26602277.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)C)CNC2=CC(=NC3=CC=NN32)C4CC4,4.301029995663981,Cc1nc(C)c(CNc2cc(C3CC3)nc3ccnn23)s1
30413,CHEMBL1289614,QXIJKQBZACKAMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20951036.0,IC50,<,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)CCCN(C2CCC3(C2C3)C4=CC=C(C=C4)C#N)C(=O)NC5=CC(=C(C=C5)F)C(F)(F)F,7.301029995663981,CN1CCN(CCCN(C(=O)Nc2ccc(F)c(C(F)(F)F)c2)C2CCC3(c4ccc(C#N)cc4)CC23)CC1
30425,CHEMBL3702782,QXKIAKSRFIMLSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4050.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)N(CCNC1=NC=C(C=C1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C)C(C)C,5.392544976785332,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN(C(C)C)C(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
30437,CHEMBL1951347,QXOYUYUTBFDIFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CNC2=NC=NC(=C12)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(=O)NC(C)C,5.337242168318426,CCc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12
30438,CHEMBL3218858,QXOZRBMOILEYGU-QMKUDKLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,COC1=C(C=CC(=C1)CN2CCOCC2)C3=NC4=NC=C(C(=C4N3)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl,4.522878745280337,COc1cc(CN2CCOCC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
30439,CHEMBL3218858,QXOZRBMOILEYGU-QMKUDKLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,COC1=C(C=CC(=C1)CN2CCOCC2)C3=NC4=NC=C(C(=C4N3)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl,4.522878745280337,COc1cc(CN2CCOCC2)ccc1-c1nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c2[nH]1
30444,CHEMBL3673981,QXPPFGDYXVBPPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320620,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)F,5.301029995663981,Fc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
30445,CHEMBL3673981,QXPPFGDYXVBPPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320664,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)F,5.301029995663981,Fc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
30450,CHEMBL1214399,QXQSUBKWSHMXDP-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)N[C@H]1CC2=C(C1)C=C(C=C2)C3=CN=C(C=C3)F,5.0,CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)nc3)cc2C1
30451,CHEMBL1214338,QXQSUBKWSHMXDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=CN=C(C=C3)F,5.0,CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)nc3)cc2C1
30468,CHEMBL391615,QXYXAFHTANBIQX-SXOMAYOGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,49000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)F)[C@H]2CN(C[C@@H]2C(=O)N(C)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)C4CCN(CC4)C(=O)C,4.309803919971486,CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)C(C)(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1
30480,CHEMBL1287901,QYFPABITTUFHKR-ZMBIFBSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,11900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)CN2C(=CC3=C2C(=O)N(C=N3)C)N4CCC[C@@](C4)(C)N.Cl,4.924453038607469,Cc1ccc(F)cc1Cn1c(N2CCC[C@@](C)(N)C2)cc2ncn(C)c(=O)c21
30482,CHEMBL230204,QYHQSWFHKDOPJR-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)N[C@@H](CC4=CC=CC=C4)CO)N5C=CN=C5,7.221848749616356,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12
30486,CHEMBL2070139,QYIHIOVAOFXKMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC=C3C4=CC=CC=C4,4.958607314841775,CCCS(=O)(=O)c1ccc2nc(-c3ccccc3-c3ccccc3)[nH]c2c1
30495,CHEMBL392525,QYKHWEFPFAGNEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17933533.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C1=CC=C(C=C1)C2=NC3=NC=C(C(=C3N2)N4CCN(CC4)CC(=O)NC5=NC=CS5)Cl,5.0,CN(C)c1ccc(-c2nc3ncc(Cl)c(N4CCN(CC(=O)Nc5nccs5)CC4)c3[nH]2)cc1
30498,CHEMBL561379,QYMLHNYPNZUQCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NN=CO2)C(=O)NC3CC3C4=CC=CC=C4,5.0,O=C(NC1CC1c1ccccc1)N1CCC(c2nnco2)CC1
30506,CHEMBL375508,QYOZNVCKISSENR-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,COC1=C(C=C2C(=C1)C(=O)N(C(=N2)N3CCC[C@H](C3)N)CC4=CC=CC=C4C#N)F,6.6020599913279625,COc1cc2c(=O)n(Cc3ccccc3C#N)c(N3CCC[C@@H](N)C3)nc2cc1F
30527,CHEMBL1077932,QYQNOMZLEZZSFR-NSOVKSMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,52.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1CN(C[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)C[C@H](CC4=CC=CC=C4)NC(=O)OCC5=NC=CS5,7.2839966563652006,O=C(N[C@@H](Cc1ccccc1)CN(CC1CC1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
30528,CHEMBL1778524,QYRBBRRASAPCLC-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21515053.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)C(=O)C4(CCC4)C5=CC=C(C=C5)F,4.301029995663981,CN(C(=O)C1(c2ccc(F)cc2)CCC1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1
30530,CHEMBL527,QYSPLQLAKJAUJT-UHFFFAOYSA-N,PIROXICAM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,1000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,3.0,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
30538,CHEMBL1760809,QYSSEJDAEHAKCS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21334894.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenyl triazoles as selective inhibitors of 11ß-Hydroxysteroid Dehydrogenase Type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=NN=C1C2(CC(C2)F)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)C5=NC=CN=C5)Cl,4.443697499232712,Cn1c(-c2ccc(-c3cnccn3)cc2Cl)nnc1C1(c2ccc(Cl)cc2)CC(F)C1
30555,CHEMBL3112856,QYWBMAVBPPCNAD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=CC=CC(=C21)C3=CC=CC=N3)C(=O)CC4=NC(=CC(=O)N4)N5CCOCC5,4.958607314841775,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccn3)cccc21
30560,CHEMBL524992,QYZZTCYPDDNZDI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2(CCN(CC2)C(=O)C3=CC=C(C=C3)C(F)(F)F)OC4=CC=CC=C41,5.0,O=C(c1ccc(C(F)(F)F)cc1)N1CCC2(CCc3ccccc3O2)CC1
30582,CHEMBL1272016,QZEXFNKCPOFGAE-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC=C1C2=NC3=C(C=CC=C3O2)C(=O)N[C@@H]4CN5CCC4CC5,4.301029995663981,COc1ccccc1-c1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1
30607,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,46300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,4.334419008982047,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
30644,CHEMBL3612810,QZUKGDYPSXQBSQ-VXKWHMMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191360.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC2=C1COC2=O)[C@H](CN3CCN(CC3)C[C@@H](C4=NC=C(C(=C4)OC)C#N)O)O,4.301029995663981,COc1cc([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N
30664,CHEMBL2069839,RABCMFOALSUEDW-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ß-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)F,6.0,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(F)cc2)CC1)Cc1cc(F)c(F)cc1F
30670,CHEMBL240185,RAGNKICHAZGMOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O,4.0,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
30671,CHEMBL240185,RAGNKICHAZGMOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using diethoxyfluorescein substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O,4.0,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
30674,CHEMBL1397,RAGOYPUPXAKGKH-XAKZXMRKSA-N,POSACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,6.455931955649724,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O
30675,CHEMBL1397,RAGOYPUPXAKGKH-XAKZXMRKSA-N,POSACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,82.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,7.086186147616283,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O
30676,CHEMBL1397,RAGOYPUPXAKGKH-XAKZXMRKSA-N,POSACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,50.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,7.301029995663981,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O
30697,CHEMBL3673973,RALYGEAWFFXYBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320653,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,5.0,Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1
30698,CHEMBL3673973,RALYGEAWFFXYBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320697,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,5.0,Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1
30733,CHEMBL2069806,RAWYQCOIQXDLOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,C1CCC(CC1)NC(=O)C2=NN=C(O2)CS(=O)(=O)C3=CC=CC=C3,4.698970004336019,O=C(NC1CCCCC1)c1nnc(CS(=O)(=O)c2ccccc2)o1
30735,CHEMBL345544,RAXPHFURDFRYJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)N2C=NC=N2,4.0,CCCCOc1ccc(-n2cncn2)cc1
30736,CHEMBL540,RAXXELZNTBOGNW-UHFFFAOYSA-N,IMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CN=CN1,5.0,c1c[nH]cn1
30737,CHEMBL540,RAXXELZNTBOGNW-UHFFFAOYSA-N,IMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CN=CN1,5.0,c1c[nH]cn1
30739,CHEMBL2048490,RAYPQIFWKYQIKX-HTKBXHQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2)OC)[C@@H]3C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO,4.301029995663981,CCc1ccc(Cc2ccc(OC)c([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1
30740,CHEMBL2048490,RAYPQIFWKYQIKX-HTKBXHQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2)OC)[C@@H]3C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO,4.301029995663981,CCc1ccc(Cc2ccc(OC)c([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1
30745,CHEMBL2337981,RAZOFRCGTLUGNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23200256.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)NC(=O)NCCN1CCC(CC1)(CNC(=O)C2=CC(=CC(=C2)Cl)Cl)CO,5.0,CC(C)(C)NC(=O)NCCN1CCC(CO)(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1
30758,CHEMBL2177819,RBDDOEXDQAPTRT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22533986.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins,"Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors.",J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C(=O)NCC2=CC=C(C=C2)N3C4=C(C=CC=N4)N=C3C5=C(N=CC=C5)N,5.0,Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1
30760,CHEMBL2334082,RBDSYHYBFFEKPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23317570.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1COC2=CC=CC(=C2)C(=O)O)C3=NC=C(C=C3)NC(=O)C4=CC(=CC=C4)OC5=CC=CC=C5,5.301029995663981,O=C(O)c1cccc(OCC2CCN(c3ccc(NC(=O)c4cccc(Oc5ccccc5)c4)cn3)CC2)c1
30761,CHEMBL3215864,RBEWBQVBFXYCLE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21823597.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by luceferin-based assay,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC5=C(C=C4)OCCO5)C)C.Cl.Cl,4.698970004336019,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccc5c(c4)OCCO5)c3C)CC2)c1C
30770,CHEMBL3408942,RBHLIUIZXOCECI-WCJYFFLOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CN1C2=CC=CC=C2[C@@]3(C1=O)C[C@H]3C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=C(C=C6)CN(C)C,5.638272163982407,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)N(C)c4ccccc45)ccc23)cc1
30771,CHEMBL3408942,RBHLIUIZXOCECI-WCJYFFLOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CN1C2=CC=CC=C2[C@@]3(C1=O)C[C@H]3C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=C(C=C6)CN(C)C,6.0,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)N(C)c4ccccc45)ccc23)cc1
30772,CHEMBL3264599,RBHSEBMDGMNLDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,770.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CN=CS3)O,6.113509274827518,COc1cc2ccc(C(O)(c3cncs3)C(C)C)cc2cc1OC
30779,CHEMBL435316,RBKBGIONDAWNLO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1CNC2=NC=CC=N2)C(=O)OCC3=CC=CC=C3,4.6020599913279625,O=C(OCc1ccccc1)N1CCC(CNc2ncccn2)CC1
30780,CHEMBL361364,RBKCNBISIDBWKZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,79200.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,CCN1C=C(N=C1)C2=CN=CC=C2,4.101274818410507,CCn1cnc(-c2cccnc2)c1
30790,CHEMBL2441835,RBLWOLKKTLUERQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=CC(=NO1)CN2CC3=NC(=C(C(=C3C2=O)C4=C(C=C(C=C4)Cl)Cl)CN)C,5.327902142064283,Cc1cc(CN2Cc3nc(C)c(CN)c(-c4ccc(Cl)cc4Cl)c3C2=O)no1
30792,CHEMBL218628,RBMGZPYCDQPSLS-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CN3C4=CC=CC=C4N=C3NC)C(=O)N5C[C@@H](CO5)O)C(=O)N(C1=O)C,4.657577319177793,CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1C[C@H](O)CO1)c(=O)n(C)c(=O)n2CC(C)C
30793,CHEMBL3353354,RBNRSVPXZPBXCD-LUCHDKOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,C1COCCN1CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7NC6=O,6.0,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
30794,CHEMBL3353354,RBNRSVPXZPBXCD-LUCHDKOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C1COCCN1CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7NC6=O,5.568636235841013,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
30795,CHEMBL3353354,RBNRSVPXZPBXCD-LUCHDKOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C1COCCN1CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7NC6=O,5.200659450546418,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
30801,CHEMBL3664707,RBRPBISFBWYXBR-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,33000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)CCF)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.481486060122112,C[C@@H](c1ccc(-c2ccn(CCF)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
30813,CHEMBL3264603,RBYAUFGMTNJMOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=NC=NC=C3)O,4.7447274948966935,COc1cc2ccc(C(O)(c3ccncn3)C(C)C)cc2cc1OC
30822,CHEMBL2059127,RCDVRXHRLWGUQK-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)C2=NC3=C(O2)C=C(C=C3)C(=O)N(CCN4CCOCC4)C[C@H]([C@H](CC5=CC=CC=C5)NC(=O)OCC6=CN=CS6)O,6.920818753952375,O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CCN1CCOCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1
30840,CHEMBL1813484,RCJIOMDJRBCHJE-RISCZKNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,CN1C[C@H]2CCC[C@]2(C1)C3=CC(=C(C=C3)Cl)Cl,4.6020599913279625,CN1C[C@H]2CCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1
30841,CHEMBL1813478,RCJIOMDJRBCHJE-SMDDNHRTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,12700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,CN1C[C@@H]2CCC[C@@]2(C1)C3=CC(=C(C=C3)Cl)Cl,4.896196279044043,CN1C[C@@H]2CCC[C@]2(c2ccc(Cl)c(Cl)c2)C1
30848,CHEMBL27257,RCMQDUQWTWKKOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,2530.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,COC(=O)C1=CC2=C(C=C1)NC3=C2N=CN=C3N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,5.5968794788241825,COC(=O)c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1
30850,CHEMBL476954,RCMVHXAYSDWNBI-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18625557.0,IC50,=,17900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(=O)N(CC1=C(C(=CC=C1)Cl)Cl)[C@H]2CCNC2,4.747146969020107,CC(C)C(=O)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1
30863,CHEMBL2336415,RCQSJUJRWTWZNW-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C(=C3)I)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.259637310505756,O=C(N[C@H](Cc1cc(I)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
30864,CHEMBL2336415,RCQSJUJRWTWZNW-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C(=C3)I)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.494850021680094,O=C(N[C@H](Cc1cc(I)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
30866,CHEMBL596073,RCRPFFUFPBVPHF-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)C=CC(=N2)C3=C(N=CC(=C3)OC[C@H](CC4=CNC5=CC=CC=C54)N)C6=COC=C6,7.0,Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12
30875,CHEMBL2441955,RCUCVXSPMYHBOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)N3CCCCC3)C4=C(C=C(C=C4)Cl)Cl)CN,5.086186147616283,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N1CCCCC1)C2
30881,CHEMBL326849,RCVJADBDODGTDD-RMERSUQASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC3C=CSC3S2)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=NC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,6.327902142064283,O=C(NCC(F)(F)F)[C@@H]1CN(CC2=CC3C=CSC3S2)CCN1C[C@@H](O)C[C@@H](Cc1ccncc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
30888,CHEMBL419409,RCXVRYYLBZGIFP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177483.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C#CC1=CC(=C(C=C1)OC)C(=O)C2=CC=C(C=C2)NC3=C(C=C(C=C3)F)F)N,5.698970004336019,COc1ccc(C#CC(C)(C)N)cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1
30893,CHEMBL2387598,RCYUPGBXIPSPFZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CCCCCCC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,4.522878745280337,CCCCCCc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
30895,CHEMBL3702746,RCZWSYNLXPXMAE-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8500.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCN7CCOCC7,5.070581074285707,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
30907,CHEMBL1269671,RDCUZWVELSAOBC-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCCOC)Cl)C5CC5)Cl,5.318758762624412,COCCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
30908,CHEMBL1269671,RDCUZWVELSAOBC-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCCOC)Cl)C5CC5)Cl,5.0915149811213505,COCCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
30913,CHEMBL2036209,RDDJIRJLHGHBFB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,CCC(=O)N(CC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC(=C2)C3=NNN=N3,5.0,CCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cccc(-c2nn[nH]n2)c1
30921,CHEMBL3581142,RDGXFPSQNSIWHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,CN(C)C1=NC=CC(=C1)C2=CSC(=N2)NC(=O)CC3=CC(=CC=C3)OC,5.455931955649724,COc1cccc(CC(=O)Nc2nc(-c3ccnc(N(C)C)c3)cs2)c1
30929,CHEMBL2159075,RDHPRHXSDFSWKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,Adamantyl carboxamides and acetamides as potent human 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CN(CC1=CC=CS1)C(=O)C23CC4CC(C2)CC(C4)C3,5.0,CN(Cc1cccs1)C(=O)C12CC3CC(CC(C3)C1)C2
30933,CHEMBL407944,RDIYHPCEDLSJLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCNC1=NN=C(O1)C2=CN3C(=C2C(C)C)C(=NC=N3)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,6.3979400086720375,CCCNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1
30936,CHEMBL2019025,RDJRSUIPIPBMAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,10700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,C1=CC=NC(=C1)CSC2=NC3=C(N2)C=C(C=C3)OC(F)F,4.97061622231479,FC(F)Oc1ccc2nc(SCc3ccccn3)[nH]c2c1
30943,CHEMBL26678,RDMBCGVGRBUTKT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,260.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=CC=CC(=C2C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=O)N,6.585026652029182,Cn1c2cccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
30956,CHEMBL1093747,RDPYDEGIIXRWPN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20189807.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCC(=O)NC1=NNC2=CC(=C(C=C21)Br)C3=CC=C(C=C3)O,5.0,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(Br)cc12
30984,CHEMBL2041179,RDZUCMBSXVPKNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)N(C)C,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)N(C)C)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
30985,CHEMBL2436330,RDZYMACFEJTPOY-QDMMYLPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=CC=C5)NC.Cl,5.920818753952375,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccccc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
30995,CHEMBL3632724,RECKFDASWBRPIB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=CN=C(N1)C2=NC=CC(=C2)OC3=CC4=C(C=C3)N(C(=N4)NC5=C(C=CC(=C5)C(F)(F)F)F)C,5.468521082957745,Cc1cnc(-c2cc(Oc3ccc4c(c3)nc(Nc3cc(C(F)(F)F)ccc3F)n4C)ccn2)[nH]1
30996,CHEMBL1079361,RECUJGQMLDHPOK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NC2=NOC3=CC=CC=C32)C4=CC=CC=C4,5.0,CC1(c2ccccc2)CCCN(C(=O)Nc2noc3ccccc23)C1
31006,CHEMBL2059115,REFJKRWNHNILNV-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,23.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=CS4,7.638272163982407,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncsc2c1
31007,CHEMBL50,REFJWTPEDVJJIY-UHFFFAOYSA-N,QUERCETIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,2110.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,5.675717544702307,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
31013,CHEMBL3702706,REGJPCAIWDVDNX-QARUCVQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2480.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NN7CCN(CC7)C8=CC=CC=N8,5.605548319173784,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCN(c6ccccn6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
31014,CHEMBL3407778,REGVNYFRZZOKQV-NQWXTVAOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25422861.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,In vivo phenotypic screening for treating chronic neuropathic pain: modification of c2-arylethynyl group of conformationally constrained a3 adenosine receptor agonists.,J. Med. Chem.,PUBLICATION,,CNC1=C2C(=NC(=N1)C#CC3=CC=CO3)N(C=N2)[C@@H]4[C@H]5C[C@]5([C@H]([C@H]4O)O)C(=O)NC,5.0,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccco4)nc31)[C@H](O)[C@@H]2O
31017,CHEMBL235421,REJCISYQMOGOHG-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CN,5.443697499232713,CC(C)C[C@H](NC(=O)CN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
31018,CHEMBL371145,REKGBSFMGZYROU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,CC(C)CN1CCC(CC1)C2=NC(=C(N2)C3=CC=CC=C3)C4=CC5=C(C=C4)N=C(N5S(=O)(=O)C(C)C)N,5.275724130399211,CC(C)CN1CCC(c2nc(-c3ccc4nc(N)n(S(=O)(=O)C(C)C)c4c3)c(-c3ccccc3)[nH]2)CC1
31020,CHEMBL3298760,RELPPOJGGXOECP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24835202.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1F)F)OC2=NC=CC3=C2C=CN3,4.698970004336019,Fc1ccc(Oc2nccc3[nH]ccc23)c(F)c1
31025,CHEMBL3582243,REMZATIPDXZDEV-CXFHPJBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25992974.0,IC50,=,2740.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using testosterone as substrate after 1 hr by LC-MS/MS analysis,"Synthesis and Biological Evaluation of Novel Olean-28,13ß-lactams as Potential Antiprostate Cancer Agents.",J. Med. Chem.,PUBLICATION,,CC(=O)[C@@]12CC[C@@]3([C@@H]([C@@H]1CC(CC2)(C)C)C(=O)C=C4[C@]3(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)C,5.562249437179612,CC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2
31026,CHEMBL3582243,REMZATIPDXZDEV-CXFHPJBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25992974.0,IC50,=,4780.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using midazolam as substrate after 1 hr by LC-MS/MS analysis,"Synthesis and Biological Evaluation of Novel Olean-28,13ß-lactams as Potential Antiprostate Cancer Agents.",J. Med. Chem.,PUBLICATION,,CC(=O)[C@@]12CC[C@@]3([C@@H]([C@@H]1CC(CC2)(C)C)C(=O)C=C4[C@]3(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)C,5.320572103387881,CC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2
31027,CHEMBL2436221,RENIROBQFCXXQO-DZOOXPAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@H]1[C@@H](C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=NN(C4=CC=CC=C43)C)NC(=O)[C@H](C)NC.Cl,4.301029995663981,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2nn(C)c3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C
31032,CHEMBL1829475,REOJELNRUGHANJ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22142542.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"4,5-dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3C,4.522878745280337,Cc1cc(=O)[nH]nc1-c1ccc(OCCCN2CCC[C@H]2C)cc1
31050,CHEMBL3582336,RETOYYSEVCBIRN-JIPXPUAJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26005524.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CCN1C=C(C=N1)[C@@]2(C3=C(C[C@@H](N2)C4=NC=C(N4)C5=NC=C(C=C5)F)C6=CC=CC=C6N3)C7=NN(C(=O)O7)C,5.0,CCn1cc([C@@]2(c3nn(C)c(=O)o3)N[C@@H](c3ncc(-c4ccc(F)cn4)[nH]3)Cc3c2[nH]c2ccccc32)cn1
31052,CHEMBL2170631,REUPOOSGSYNYCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=CC=C3C#N,4.522878745280337,N#Cc1ccccc1C(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
31077,CHEMBL2057527,RFCMNSUTICBGFR-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,27.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,7.568636235841013,CC(C)(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
31078,CHEMBL3393478,RFCYJLIYROYRBL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(C(=C(C=C6N5)F)F)F,4.638272163982407,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)c(F)c(F)cc3[nH]2)o1
31080,CHEMBL479071,RFDAXGBKSBMVFF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC(=CC=C2)C(F)(F)F)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccc(C(F)(F)F)c1
31084,CHEMBL409442,RFENYOLLCXWBKT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18395443.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=CC(=CN=C2N1)NC3=NC=NN4C3=C(C(=C4)C5=NN=C(O5)NC)C(C)C,5.1938200260161125,CNc1nnc(-c2cn3ncnc(Nc4cnc5[nH]c(C)cc5c4)c3c2C(C)C)o1
31085,CHEMBL1081870,RFFMAFBDIYXZRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2N=C(N3C)C,4.920818753952375,Cc1cccc(C)c1CNc1nccc2c1nc(C)n2C
31086,CHEMBL1081870,RFFMAFBDIYXZRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2N=C(N3C)C,4.6777807052660805,Cc1cccc(C)c1CNc1nccc2c1nc(C)n2C
31092,CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,8000.0,NM,,inhibition,tissue,binding,,,,,,,,,,,,,,,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,5.096910013008056,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
31093,CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,5.0,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
31094,CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,5.0,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
31095,CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,25003.45,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,4.602000062824431,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
31099,CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8000.0,NM,273499,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",Metalloenzyme inhibitor compounds,,PATENT,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,5.096910013008056,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
31107,CHEMBL429734,RFKDHOWUSOAINF-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC(=CC=C2)Cl)CCOC3=CC=CC(=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,4.698970004336019,Cc1oc(-c2cccc(Cl)c2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1
31112,CHEMBL2401834,RFKWZWJQRQCLJF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23773865.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CP3A4 (unknown origin),"Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C3C(=CN=C2N)C(=CO3)C4=CN(N=C4)C5CCNCC5,4.698970004336019,CC(Oc1c(N)ncc2c(-c3cnn(C4CCNCC4)c3)coc12)c1c(Cl)ccc(F)c1Cl
31143,CHEMBL1934426,RFWSNJBXMGANOQ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22094028.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimisation of pyrazoles as novel FPR1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NN(C(=C1C(=O)N[C@@H](C)C(C)(C)C)NS(=O)(=O)C2=CC=C(C=C2)C3CC3)C4CCOCC4,5.0,Cc1nn(C2CCOCC2)c(NS(=O)(=O)c2ccc(C3CC3)cc2)c1C(=O)N[C@@H](C)C(C)(C)C
31144,CHEMBL3330650,RFWVETIZUQEJEF-UHFFFAOYSA-N,RG-7420,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1I)F)NC2=C(C=CC3=CN=CN32)C(=O)NOCCO,5.0,O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F
31145,CHEMBL3330650,RFWVETIZUQEJEF-UHFFFAOYSA-N,RG-7420,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1I)F)NC2=C(C=CC3=CN=CN32)C(=O)NOCCO,5.0,O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F
31152,CHEMBL2205775,RFXXESOWGZZTJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727372.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)(C(C1=CC=C(C=C1)NC2=CC=CC=C2)N3C=NC=N3)C(=O)OC,6.698970004336019,COC(=O)C(C)(C)C(c1ccc(Nc2ccccc2)cc1)n1cncn1
31154,CHEMBL2062804,RFZKSQIFOZZIAQ-UHFFFAOYSA-N,CEP-33779,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22594690.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC=CC(=C2)NC3=NN4C=CC=C(C4=N3)C5=CC=C(C=C5)S(=O)(=O)C,4.958607314841775,CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1
31167,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,13900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,4.856985199745905,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
31173,CHEMBL590078,RGCZEETYNQZRTH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20022752.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=CC=C1)N3CCNCC3NC2=O,4.3979400086720375,Cc1cccc2c1C(=O)NC1CNCCN21
31175,CHEMBL162383,RGDXKPQBVYZPLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C1N=C(C=C4C)F,5.6020599913279625,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(F)nc21
31176,CHEMBL162383,RGDXKPQBVYZPLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C1N=C(C=C4C)F,5.0,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(F)nc21
31183,CHEMBL2347989,RGIPZCBZGRZGDB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)F)CCCS(=O)(=O)C,4.301029995663981,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCCS(C)(=O)=O)c4cc(F)ccc34)nc12
31184,CHEMBL2331680,RGJOJUGRHPQXGF-INIZCTEOSA-N,RG-7603,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4COC4)C(=N2)N5CCOC[C@@H]5C,5.0,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C2COC2)C3)cc1
31199,CHEMBL1829775,RGMQKUNJMKQDMC-XRHLQHRESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCNS(=O)(=O)C)C4=CC=C(C=C4)F,5.045757490560675,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNS(C)(=O)=O)(c2ccc(F)cc2)OC1=O
31220,CHEMBL2058910,RGTBBKSFLZZHLT-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,31.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)C,7.508638306165727,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
31221,CHEMBL2058665,RGTBBKSFLZZHLT-UIOOFZCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,22.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)C,7.657577319177793,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
31242,CHEMBL270869,RHBYGIDSEIHDRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCC(C)(C)CN)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,5.853871964321762,CC(C)c1c(-c2nnc(NCC(C)(C)CN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
31259,CHEMBL495793,RHJMBQWXWMOCDA-IRLDBZIGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=CC=N1)NC2=CC3=C(C=C2)OC4(CCN(CC4)C(=O)N[C@H]5C[C@@H]5C6=CC=CC=C6)CC3=O,5.0,Cn1nccc1Nc1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2
31265,CHEMBL3664689,RHLRKYZMELKWGC-WRGVRERRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C3CC3)N4CC[C@](OC4=O)(CC(C)(C)O)C5=CC=CC=C5F,4.301029995663981,C[C@@H](c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O
31271,CHEMBL1761869,RHSTYEXBNNRSAD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,<,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)C2=CN=C(N=C2)N3CCN(C4=CC=CC=C43)C(=O)N5CCC(C5)C6=CNN=C6,6.522878745280337,COc1ccc(-c2cnc(N3CCN(C(=O)N4CCC(c5cn[nH]c5)C4)c4ccccc43)nc2)cc1
31284,CHEMBL3114967,RHVXEPUOLMPDCV-YPGOJHLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24461352.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)S(=O)(=O)N2C[C@@H]3[C@H](C2)C3(CNC(=O)C4=C(C=C(C=C4)Cl)Cl)C5=CC=CC=N5,4.522878745280337,Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)C3(CNC(=O)c2ccc(Cl)cc2Cl)c2ccccn2)c1
31288,CHEMBL1229211,RHWKPHLQXYSBKR-BMIGLBTASA-N,DOLUTEGRAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23132334.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Metabolism-dependent inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,4.481486060122112,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21
31289,CHEMBL1229211,RHWKPHLQXYSBKR-BMIGLBTASA-N,DOLUTEGRAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23132334.0,IC50,=,54000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,4.267606240177032,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21
31290,CHEMBL1229211,RHWKPHLQXYSBKR-BMIGLBTASA-N,DOLUTEGRAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23132334.0,IC50,=,65000.0,NM,,,,,,,,,,,,,,,Metabolism-dependent inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,4.187086643357144,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21
31291,CHEMBL1229211,RHWKPHLQXYSBKR-BMIGLBTASA-N,DOLUTEGRAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23132334.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,4.0,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21
31293,CHEMBL2336422,RHWMJBIOLRHWNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C(=C3)Cl)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,6.7447274948966935,O=C(NC(Cc1cc(Cl)c2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
31294,CHEMBL2336422,RHWMJBIOLRHWNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C(=C3)Cl)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.886056647693163,O=C(NC(Cc1cc(Cl)c2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
31308,CHEMBL314768,RIDDCLHNDOXTES-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCN4CCCCC4)CC5=CC=C(C=C5)C6=CC=C(C=C6)C(F)(F)F,5.0,Cn1cc(Cc2cn(CC(=O)N(CCN3CCCCC3)Cc3ccc(-c4ccc(C(F)(F)F)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
31309,CHEMBL2436212,RIFATYMCUSPMBX-RIAYWLAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,CC1=CC=C(O1)C(=O)N2C[C@@H](C(=O)N(C3=CC=CC=C32)CC4=C(C=CC5=C4C=CC(=C5)Br)OC)NC(=O)[C@H](C)NC.Cl,5.721246399047171,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C)o2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
31311,CHEMBL1079290,RIFYAWGYIHDAHH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCO)C3=CC=CC=C3,5.0,O=C(Nc1ccc(Cl)cc1)N1CCCC(CCO)(c2ccccc2)C1
31324,CHEMBL1270934,RIIMHERUTFJZHJ-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ß-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC#CC1=CC(=CC=C1)[C@@]2(C(=O)N(C(=N2)N)C)C3=CC=C(C=C3)OC(F)F,7.0,CC#Cc1cccc([C@@]2(c3ccc(OC(F)F)cc3)N=C(N)N(C)C2=O)c1
31325,CHEMBL3301607,RIJLVEAXPNLDTC-UHFFFAOYSA-N,FILGOTINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369270.0,IC50,>,70000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634.,J. Med. Chem.,PUBLICATION,,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,4.154901959985743,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
31329,CHEMBL2163835,RIJSQWHSYPOPOZ-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,C1CC1(C2=C(C=C(C=C2)Cl)Cl)C(=O)N[C@@H](CC3=C(C=C(C=C3)Cl)Cl)C(=O)N4CCNCC4,6.698970004336019,O=C([C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1)N1CCNCC1
31338,CHEMBL1911821,RIMDJKXHMLJROO-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)C(=O)[C@@H](COCC2=CC=NC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,5.698970004336019,CN1CCN(C(=O)[C@@H](COCc2ccncc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
31353,CHEMBL327919,RIOXQFHNBCKOKP-UHFFFAOYSA-N,BENOMYL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,CCCCNC(=O)N1C2=CC=CC=C2N=C1NC(=O)OC,5.0,CCCCNC(=O)n1c(NC(=O)OC)nc2ccccc21
31354,CHEMBL327919,RIOXQFHNBCKOKP-UHFFFAOYSA-N,BENOMYL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CCCCNC(=O)N1C2=CC=CC=C2N=C1NC(=O)OC,5.0,CCCCNC(=O)n1c(NC(=O)OC)nc2ccccc21
31359,CHEMBL2397317,RITGMCAEZVMEQO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(C(=NN2C(=C1)NCCN3CCOCC3)C)C4=CC(=C(C=C4)OC)OC,4.522878745280337,COc1ccc(-c2c(C)nn3c(NCCN4CCOCC4)cc(C)nc23)cc1OC
31368,CHEMBL1738805,RIVRSBWWXQQZLY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,CC(CNC(=O)N1CC2=C(C1)N=C(N=C2C3=C(C=C(C=C3Cl)Cl)OCCN4C=CC=N4)N)(F)F,5.481486060122113,CC(F)(F)CNC(=O)N1Cc2nc(N)nc(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)c2C1
31370,CHEMBL2170750,RIYCHKQKHFIRTQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22277094.0,IC50,=,54000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17ß-HSD1.,J. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1C(=O)C2=NC3=C(S2)C=C(C=C3)O)O)F,4.267606240177032,O=C(c1ccc(F)c(O)c1)c1nc2ccc(O)cc2s1
31371,CHEMBL2418364,RIYSYRWQPZAUDK-CAZKFNJPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23932792.0,IC50,=,6200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,"Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1[C@@H]2CN(C[C@@H]2CN1C3=CC=CC=N3)C(=O)C45CC6CC(C4)CC(C6)C5,5.2076083105017466,O=C(N1C[C@@H]2CN(c3ccccn3)C[C@@H]2C1)C12CC3CC(CC(C3)C1)C2
31376,CHEMBL1092652,RJAXVZUSTIFVGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NN=CC=C3,5.0,CN(C)CCC1=C(Cc2cccnn2)c2ccc(Cl)cc2C1
31378,CHEMBL309061,RJCJVIFSIXKSAH-UHFFFAOYSA-N,ERMANIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,21800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,COC1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC,4.661543506395395,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2OC)cc1
31380,CHEMBL3137442,RJDGBMFJYVXZDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2900.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC1=C(SC=N1)C(=O)N2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,5.5376020021010435,Cc1ncsc1C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
31390,CHEMBL1223003,RJIDHAYRLDHKFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC=NC=C6,6.3979400086720375,COc1ccc(Cn2c(=O)n(C3CCN(C(=O)C4CCN(Cc5ccncc5)CC4)CC3)c3ccccc32)cc1
31406,CHEMBL3326589,RJKMYWXQAHKXOZ-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4)C5CC5)(CF)CF)C=N1,4.698970004336019,Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4cc(C5CC5)ccc43)cccc2cn1
31424,CHEMBL2204359,RJOWFEDJGNNCDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,C1CN(CCN1)C2=CC=CC=C2SC3=C(C=C(C=C3)Cl)Cl.Cl,5.356547323513812,Clc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1
31428,CHEMBL478402,RJSWFGJQETZYIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CN1C=C2C=CC(=CC2=N1)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,5.4089353929735005,CN(c1ccc2cn(C)nc2c1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1
31429,CHEMBL478402,RJSWFGJQETZYIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,CN1C=C2C=CC(=CC2=N1)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,5.327902142064283,CN(c1ccc2cn(C)nc2c1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1
31431,CHEMBL2331648,RJTJMAVCPOTSLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CCNC1=NC2=C(CN(CC2)C(=O)CCC3=CC=C(C=C3)OC(F)(F)F)C(=N1)C(=O)N,4.522878745280337,CCNc1nc2c(c(C(N)=O)n1)CN(C(=O)CCc1ccc(OC(F)(F)F)cc1)CC2
31437,CHEMBL3353338,RJUIETDWZAGQNR-GUYCJALGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,C1[C@H]([C@@]12C3=CC=CC=C3NC2=O)C4=CC5=C(C=C4)C=NN5,5.0,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2cn[nH]c2c1
31449,CHEMBL504522,RJWYZBZWLAFKBF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18632268.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC(=C1)Cl)CC2=C3C(=CC(=C2)CC4=NNC(=O)C=C4)C=CO3,6.7447274948966935,O=c1ccc(Cc2cc(Cc3cccc(Cl)c3)c3occc3c2)n[nH]1
31452,CHEMBL230367,RJXJBPIINHJDPV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17482464.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(CCCN3CCNC(=O)C)C=C2,5.096910013008056,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)CCC2
31463,CHEMBL260200,RKDSFEZOQXKQOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18378449.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C(=O)C1=CC=C(C=C1)CN2CCC(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N,5.0,CN(C)C(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1
31465,CHEMBL3326578,RKEWSEJJSIVUTE-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CCC1(C[C@H](C2=C(O1)C=CC(=C2)F)NC(=O)NC3=CC=CC4=C3C=C(N=C4)C)CC,4.698970004336019,CCC1(CC)C[C@@H](NC(=O)Nc2cccc3cnc(C)cc23)c2cc(F)ccc2O1
31467,CHEMBL333306,RKFAZBXYICVSKP-AATRIKPKSA-N,TRANS-ASARONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,92300.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,C/C=C/C1=CC(=C(C=C1OC)OC)OC,4.034798298974088,C/C=C/c1cc(OC)c(OC)cc1OC
31468,CHEMBL2448689,RKHFQOOMHRJYJM-OGLMXYFKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C/C(=N\OC)/C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(C=C3)C4=CC=CC=C4,5.3979400086720375,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccc3)nc2)c1
31472,CHEMBL3237703,RKILQDBEPHSTGP-IYARVYRRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,CC1CCC(CC1)N2C3=C(C=CN=C3)C4=CN=C(N=C42)NC5=NC=C(C=C5)N6CCNCC6,5.0,CC1CCC(n2c3cnccc3c3cnc(Nc4ccc(N5CCNCC5)cn4)nc32)CC1
31498,CHEMBL1242345,RKTWFMDUKBINRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NCC7CC7,5.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NCC6CC6)ncn4-5)CC3)cccc2n1
31499,CHEMBL1242345,RKTWFMDUKBINRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NCC7CC7,5.0,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NCC6CC6)ncn4-5)CC3)cccc2n1
31537,CHEMBL3359523,RLGFHVZCVPTTLP-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516794.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.",ACS Med. Chem. Lett.,PUBLICATION,,CC(C)OC1=C(C=C(C=C1)COC2=CC3=C(C=C2)N4CC[C@@H](C4=C3Cl)CC(=O)O)C(F)(F)F,4.301029995663981,CC(C)Oc1ccc(COc2ccc3c(c2)c(Cl)c2n3CC[C@@H]2CC(=O)O)cc1C(F)(F)F
31547,CHEMBL3104473,RLKGUNQJMYDNRM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CN=C(C=C4)C(F)(F)F,4.795880017344075,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1
31548,CHEMBL3104473,RLKGUNQJMYDNRM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CN=C(C=C4)C(F)(F)F,4.795880017344075,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1
31550,CHEMBL3608688,RLKUYZTZCXMODG-MRVPVSSYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C(F)(F)F,4.0,C[C@@H]1c2nnc(-c3nc(C(F)(F)F)ns3)n2CCN1C(=O)c1ccc(F)cc1
31551,CHEMBL2448696,RLLQZNKWXMDKBR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5830.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCN(C1=CC=CC=C1)S(=O)(=O)C2=CC(=C(C=C2)Cl)NC(=O)C3=CC4=C(CNCC4)C=C3,5.2343314452409855,CCN(c1ccccc1)S(=O)(=O)c1ccc(Cl)c(NC(=O)c2ccc3c(c2)CCNC3)c1
31561,CHEMBL274189,RLQYRXCUPVKSAW-UHFFFAOYSA-M,PALMATINE CHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)OC)OC)OC.[Cl-],6.045757490560675,COc1cc2c(cc1OC)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2
31564,CHEMBL252200,RLRBZKLERUDUCY-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NC(=NO4)CN5CCCC5,6.154901959985743,CC[C@@H]1CCC[C@H](C2(Cc3nc(CN4CCCC4)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
31580,CHEMBL465925,RLWXMWFCYVZNBY-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)CC5=CC=C(C=C5)F,5.251811972993799,C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
31581,CHEMBL465925,RLWXMWFCYVZNBY-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)CC5=CC=C(C=C5)F,4.886056647693163,C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
31606,CHEMBL596809,RMFDASBXQBLDIL-OUJBWJOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,COC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,5.221848749616356,COC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
31609,CHEMBL3353355,RMGQWXVHWUUVLJ-DSUKGUNVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)NC(=O)[C@@]23C[C@H]3C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=C(C=C6)CN7CCOCC7,6.0,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2
31610,CHEMBL3353355,RMGQWXVHWUUVLJ-DSUKGUNVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)NC(=O)[C@@]23C[C@H]3C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=C(C=C6)CN7CCOCC7,5.619788758288394,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2
31611,CHEMBL3353355,RMGQWXVHWUUVLJ-DSUKGUNVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)NC(=O)[C@@]23C[C@H]3C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CC=C(C=C6)CN7CCOCC7,5.1938200260161125,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2
31633,CHEMBL1017,RMMXLENWKUUMAY-UHFFFAOYSA-N,TELMISARTAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,4.301029995663981,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1
31640,CHEMBL1093802,RMNQHMQKUFGTQZ-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by P450-Glo method,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=CC=CC=C4F,5.0,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3F)CC2)C1
31646,CHEMBL1940308,RMPYEISUTHEMLW-NDEPHWFRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153941.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC(CC1)NC(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)C#C[C@@]4(CN5CCC4CC5)O,5.0,CN1CCC(NC(=O)c2ccc(Oc3ccc(C#C[C@]4(O)CN5CCC4CC5)cc3)cc2)CC1
31653,CHEMBL2057792,RMSUKSHEEMXBPN-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N(C)CC#C,7.522878745280337,C#CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
31659,CHEMBL1089,RMUCZJUITONUFY-UHFFFAOYSA-N,PHENELZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C1=CC=C(C=C1)CCNN,5.698970004336019,NNCCc1ccccc1
31665,CHEMBL1290041,RMUWRXSDAOJENI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20951036.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CCN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)C5=CC=C(C=C5)C(F)(F)F)C=N2,5.698970004336019,O=c1cc(-c2ccc(C(F)(F)F)cc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
31667,CHEMBL169620,RMVSZBRIILAXIH-WUXOVTSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)[C@H](C)CNCCC6=CC7=NSN=C7C=C6)C,6.0,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3nsnc3c2)c1
31672,CHEMBL542139,RMXZRJYGJMSDQK-UHFFFAOYSA-N,SB-271046A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9925723.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4 as total cyclosporin oxidation (1 uM),"5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.",J. Med. Chem.,PUBLICATION,,CC1=C(SC2=C1C=C(C=C2)Cl)S(=O)(=O)NC3=CC(=C(C=C3)OC)N4CCNCC4.Cl,4.3979400086720375,COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1
31673,CHEMBL3422014,RMYVKGFVSAOUKW-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C(C)C,4.455931955649724,CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1
31705,CHEMBL1766759,RNMJNHVCCXRKJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21413798.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=CN=C(C(=N2)C(=O)NC3=CC=CC=C3)N,4.0,Nc1ncc(-c2ccccc2)nc1C(=O)Nc1ccccc1
31722,CHEMBL240566,RNPYGOUJOKJBQI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(C)CC,4.522878745280337,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(CC)O2
31728,CHEMBL461198,RNSWXWFQTKBNOT-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)C5CCN(CC5)C,4.853871964321762,Cc1cc(C2CCN(C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
31737,CHEMBL470996,RNXCYTSKNUJZDX-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,CN1C=NC=C1[C@@](C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC=CC6=CC=CC=C65)C)N,6.259637310505756,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc3ccccc13)cc(=O)n2C
31757,CHEMBL475926,ROCIAHLXAQYEAV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccc(Cl)cc1
31769,CHEMBL2441843,ROEPADSSTIFTHQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CCOC(=O)N1CC2=NC(=C(C(=C2C1=O)C3=C(C=C(C=C3)Cl)Cl)CN)C,5.1938200260161125,CCOC(=O)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
31780,CHEMBL2436622,ROIWDPBJIDVJNS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2CCC3=CC=CC=C3CC2)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,4.522878745280337,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCc5ccccc5CC4)CC3)CC2)ccn1
31783,CHEMBL3330060,ROKKOEGCWJIYBM-AXFHLTTASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25164763.0,IC50,=,56490.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,C1[C@@H](CN([C@@H]1C#N)C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N)F,4.248028425263673,N#C[C@@H]1C[C@H](F)CN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F
31789,CHEMBL549534,ROMRTXMEQJYJJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19552431.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assay,Novel small molecule bradykinin B2 receptor antagonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC=C1)CN2C=CC=C(C2=O)C(F)(F)F)COC3=CC=CC4=C(C=C(N=C43)C)C5=C(SC=N5)Cl,6.522878745280337,Cc1cc(-c2ncsc2Cl)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1
31792,CHEMBL467114,ROPHIKMBWGQPQO-UHFFFAOYSA-M,GSK269984A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19332369.0,IC50,>=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC(=C1)C(=O)[O-])CC2=C(C=CC(=C2)Cl)OCC3=C(C=C(C=C3)Cl)F.[Na+],4.0,O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(Cl)cc2F)n1
31793,CHEMBL2041192,ROQKQYJTPICBKQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=NC=C4)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)O,4.301029995663981,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ccncn1
31799,CHEMBL3114905,ROTBIIANJMNEBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412066.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N1CCC(CC1)N2C3=C(C=N2)C(=NC=N3)OC4=CC=C(C=C4)S(=O)(=O)C,5.508638306165727,CC(C)(C)OC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1
31816,CHEMBL1078232,RPEDWPSRPWEPAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)N3CCOCC3)C4=CC=CC=C4,5.0,O=C(CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1)N1CCOCC1
31829,CHEMBL1829781,RPFNAAPDFSAIEH-ADXZGYQBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCCNC(=O)NC)C4=CC=C(C=C4)F,6.221848749616356,CNC(=O)NCCC[C@]1(c2ccc(F)cc2)CCN([C@@H](C)c2ccc(-c3ccc(F)cc3F)cc2)C(=O)O1
31837,CHEMBL2420679,RPIYHUIWRDPDMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CC(=CN=C3)F,5.0,COc1ccc2ccc(-c3cncc(F)c3)c(Cl)c2c1
31846,CHEMBL87355,RPMBWDUTWZVOBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCCN(C)C)CC4=CC=C(C=C4)C5=CC=C(C=C5)Cl,4.769551078621726,CN(C)CCCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
31850,CHEMBL2151925,RPNYSADTAYSTDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)NC(=O)CC2=NC(=CC(=O)N2)N3CCOCC3)F,4.3979400086720375,Cc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F
31851,CHEMBL2448704,RPOKISRPDRUXOJ-LQKURTRISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C/C(=N\OC)/C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(N=C3)C4=CC=CC=C4,4.7447274948966935,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
31884,CHEMBL3664718,RPXPOAJHLVZLCE-CHJDUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C(C)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,CC(C)n1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O
31885,CHEMBL2315243,RPXSHXJWFUDNDF-FYGBZDAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294255.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Trichoplusia ni BTI-TN-5B1-4 cells preincubated for 15 mins measured after 30 mins by spectrofluorimetry,Development of new cyclic plasmin inhibitors with excellent potency and selectivity.,J. Med. Chem.,PUBLICATION,,C1CN2CCN(CCC(=O)NC3=CC=C(C[C@H](NC(=O)[C@@H](CC4=CC=C(C=C4)NC1=O)NS(=O)(=O)CC5=CC=CC=C5)C(=O)NCC6=CC=C(C=C6)C(=N)N)C=C3)CC2.C(=O)(C(F)(F)F)O,5.0,N=C(N)c1ccc(CNC(=O)[C@@H]2Cc3ccc(cc3)NC(=O)CCN3CCN(CCC(=O)Nc4ccc(cc4)C[C@@H](NS(=O)(=O)Cc4ccccc4)C(=O)N2)CC3)cc1
31892,CHEMBL562317,RQDDHVVAAJVVKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19630403.0,IC50,=,450000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=C(C=C3)C4=C(C=NN4)CC5=CC=NC=C5,3.3467874862246565,c1ccc2nc(COc3ccc(-c4[nH]ncc4Cc4ccncc4)cc3)ccc2c1
31893,CHEMBL562869,RQDRWTLKQRNDSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,CN1C=C(N=N1)C2CCN(CC2)C(=O)NC3CC3C4=CC=CC=C4,5.0,Cn1cc(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)nn1
31894,CHEMBL568456,RQERHAIDHUSWSQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)S(=O)(=O)N,5.301029995663981,CC1(CC(=O)NCc2ccc(S(N)(=O)=O)cc2)CC2(CCCCC2)OO1
31921,CHEMBL3640275,RQQNLWISWSTQLK-RLBGWGEZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC(=N1)N2C[C@H]3C(=O)N(C(=N[C@]3(C2)C4=C(C(=C(C=C4F)F)F)F)N)C)OC)F,4.522878745280337,COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)cc(F)c(F)c3F)C2)nc(C)c1F
31923,CHEMBL2171396,RQQTYVIPHKLYFS-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861813.0,IC50,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel ß-amino acid derivatives as inhibitors of cathepsin A.,J. Med. Chem.,PUBLICATION,,CC1=CC=CC=C1[C@H](CC(=O)O)NC(=O)C2=NN(C(=C2)OC)C3=CC=CC=C3F,7.585026652029182,COc1cc(C(=O)N[C@@H](CC(=O)O)c2ccccc2C)nn1-c1ccccc1F
31927,CHEMBL3702771,RQTZYFHLPCPBEQ-KNPJQLEMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2160.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)OC,5.665546248849069,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(OC)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
31931,CHEMBL391070,RQVOZSFAHBOBFK-AABGKKOBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17418568.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC=C1)[C@H]2CN3CCC4=CC(=C(C=C4[C@@H]3C[C@@H]2N)OC)OC,4.301029995663981,COc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](c3cccc(C)c3)CN1CC2
31934,CHEMBL445734,RQXGWBAZTYRGOW-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC1=CC(=C(C(=C1)N2CCCC2=O)F)C(=O)N[C@@H](CC3=CC=CC=C3)[C@@H](CNCC4=CC(=CC=C4)C(F)(F)F)O,5.200659450546418,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCC2=O)c1
31935,CHEMBL445734,RQXGWBAZTYRGOW-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,=,75000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC1=CC(=C(C(=C1)N2CCCC2=O)F)C(=O)N[C@@H](CC3=CC=CC=C3)[C@@H](CNCC4=CC(=CC=C4)C(F)(F)F)O,4.1249387366083,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCC2=O)c1
31938,CHEMBL1951451,RQYBGHZNFDAJIM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1CNC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4)F,6.552841968657781,O=C(NCc1ccc(F)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
31945,CHEMBL1834345,RQYRFYXSSOVCAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21866910.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP 3A4,"N'-(Arylsulfonyl)pyrazoline-1-carboxamidines as Novel, Neutral 5-Hydroxytryptamine 6 Receptor (5-HT(6)R) Antagonists with Unique Structural Features.",J. Med. Chem.,PUBLICATION,,CCN=C(NS(=O)(=O)C1=CC(=CC=C1)Cl)N2CC(C=N2)(C)C,5.0,CCN=C(NS(=O)(=O)c1cccc(Cl)c1)N1CC(C)(C)C=N1
31966,CHEMBL179704,RRFCTHIOMKUJRQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,80900.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,CC1=CSC=C1C2=CN=CC=C2,4.092051478387727,Cc1cscc1-c1cccnc1
31968,CHEMBL179704,RRFCTHIOMKUJRQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,CC1=CSC=C1C2=CN=CC=C2,4.6020599913279625,Cc1cscc1-c1cccnc1
31982,CHEMBL1682891,RRHVEQWMOKQMRJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)OC)(C3=CN=CN3)O,5.853871964321762,COC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
31991,CHEMBL14276,RRJLJKRFFRZRAF-UHFFFAOYSA-N,SB-228357,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,10737744.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human cytochrome P450 3A4,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,PUBLICATION,,COC1=C(C=C2C(=C1)CCN2C(=O)NC3=CC(=CC(=C3)C4=CN=CC=C4)F)C(F)(F)F,5.045757490560675,COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(F)cc(-c3cccnc3)c1)CC2
32001,CHEMBL2019024,RRLQDVNNRUSNKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,3610.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1)N=C(N2)SCC3=CC=CC=N3,5.442492798094342,Cc1ccc2nc(SCc3ccccn3)[nH]c2c1
32003,CHEMBL239772,RRMIJFINKILIRL-GOSISDBHSA-N,SR-887,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)[C@@H](C4=CC=CC=C4Cl)O,5.096910013008056,O=C([C@H](O)c1ccccc1Cl)N1CCN(c2ccc3[nH]ncc3c2)CC1
32006,CHEMBL3109340,RROPCZKHYUPTGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC2=NC=C(N2C=C1)C3=NC4=C(C=CC=C4OC5CCNCC5)C=C3,5.0,COCCOc1ccn2c(-c3ccc4cccc(OC5CCNCC5)c4n3)cnc2c1
32013,CHEMBL3394201,RRQQEAJYJXDKQC-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25699143.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NC=N1)C2=CC3=C(C=C2)[C@@H](CC3)N4CC5(C4)CCN(CC5)C(=O)CC6=C(C=C(C=C6)OC)C(=O)N,4.522878745280337,COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5cc(C)ncn5)ccc42)C3)c(C(N)=O)c1
32044,CHEMBL367357,RSDPLFJFCIEHAP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,2032.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)N(C)C)N3C=CN=C3)N(C)C,5.692076296388119,CC(C(c1ccc2cc(OCC(C)(C)C(=O)N(C)C)ccc2c1)n1ccnc1)N(C)C
32065,CHEMBL495601,RSJUYPGFGAQOLP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2=CC=CC=C2CC1NC(=O)N3CCC4(CC3)CC(=O)C5=CC=CC=C5O4,5.0,O=C1CC2(CCN(C(=O)NC3CCc4ccccc4C3)CC2)Oc2ccccc21
32080,CHEMBL3628939,RSSMYFQRFUEXTN-JKDDQTOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@](C1CCCC1)(C2=CN(N=N2)C(CCS(=O)(=O)C)C(=O)COC3=C(C(=CC(=C3F)F)F)F)NCC4=CC5=C(C=C4)N=CS5,6.698970004336019,C[C@@](NCc1ccc2ncsc2c1)(c1cn(C(CCS(C)(=O)=O)C(=O)COc2c(F)c(F)cc(F)c2F)nn1)C1CCCC1
32083,CHEMBL244403,RSUMDJRTAFBISX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17630726.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.",J. Med. Chem.,PUBLICATION,,CCCCCOC1=CC=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43,3.6989700043360187,CCCCCOc1ccc(C(=O)c2cccc3ccccc23)c2ccccc12
32087,CHEMBL410242,RSVOVHDOLNWYER-RYZVYYIHSA-N,16BETA-(M-CARBAMOYLBENZYL)ESTRADIOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24328103.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Discovery of a non-estrogenic irreversible inhibitor of 17ß-hydroxysteroid dehydrogenase type 1 from 3-substituted-16ß-(m-carbamoylbenzyl)-estradiol derivatives.,J. Med. Chem.,PUBLICATION,,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@@H]([C@@H]2O)CC4=CC(=CC=C4)C(=O)N)CCC5=C3C=CC(=C5)O,5.823908740944319,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@H](Cc1cccc(C(N)=O)c1)[C@@H]2O
32100,CHEMBL2316385,RSYSXDBUOKOFIE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,>,20000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,CS(=O)CC1=CC=C(C2=CC=CC=C12)C(=O)NC3=NC=CN=C3C(=O)NCC4CCC4,4.698970004336019,C[S+]([O-])Cc1ccc(C(=O)Nc2nccnc2C(=O)NCC2CCC2)c2ccccc12
32103,CHEMBL3260754,RSYWEFIQLHVGST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=C(C=NC=C4)F)C5=CC=C(C=C5)Cl,5.154901959985743,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3F)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
32112,CHEMBL517646,RSZNJMNZSVCMKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C2=CC(=NC=C2C(=O)NCC3CCOCC3)NC4=C(C=C(C=C4)Cl)Cl,4.0,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)cc1C1CC1
32116,CHEMBL3706621,RTAOSKPTWQTCBX-GIWSTSDLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852969.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=NC=C(O1)C2=CC=CC=N2)N3CCN([C@@H](C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,5.301029995663981,CC(C)(c1ncc(-c2ccccn2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1
32120,CHEMBL150681,RTCYVSYLJFBKLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CC=NO2,4.0,CCCCOc1ccc(-c2ccno2)cc1
32121,CHEMBL1209674,RTDGHNXXZKSIDE-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC=NC=C5)C(=O)N,7.0,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccncc4)ccc32)sc1C(N)=O)c1ccccc1Cl
32127,CHEMBL2316382,RTEBTDAJVQZWBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,=,8800.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,COC1=NC(=C(C=C1)NC(=O)C2=CC=C(C3=CC=CC=C32)CS(=O)C)C(=O)NCC4CCOCC4,5.055517327849831,COc1ccc(NC(=O)c2ccc(C[S+](C)[O-])c3ccccc23)c(C(=O)NCC2CCOCC2)n1
32129,CHEMBL2022570,RTGBSTJGKOHKPO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NN1)C(=O)O)CC2=CC(=CC=C2)C3=CC=C(C=C3)F,5.0,Cc1[nH]nc(C(=O)O)c1Cc1cccc(-c2ccc(F)cc2)c1
32138,CHEMBL3673945,RTGVPSAXYOKKJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320623,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)OC)F)N=C1,5.301029995663981,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cn1
32139,CHEMBL3673945,RTGVPSAXYOKKJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320667,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)OC)F)N=C1,5.301029995663981,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cn1
32171,CHEMBL117,RTIXKCRFFJGDFG-UHFFFAOYSA-N,CHRYSIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20832301.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O,4.301029995663981,O=c1cc(-c2ccccc2)oc2cc(O)cc(O)c12
32189,CHEMBL513372,RTKZIRJGSBHFAV-BKHUMSDISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,42600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C/C/1=C\[C@@H](C[C@]2([C@H](O2)CC(/C=C/C1=O)(C)C)C)O,4.370590400897281,C/C1=C\[C@H](O)C[C@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O
32191,CHEMBL503727,RTKZIRJGSBHFAV-VLROITNISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,62500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C/C/1=C\[C@@H](C[C@@]2([C@H](O2)CC(/C=C/C1=O)(C)C)C)O,4.204119982655925,C/C1=C\[C@H](O)C[C@@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O
32192,CHEMBL1682902,RTMHSNZDMYWGTC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=CC3=C(C=C2C=C1)C(=O)NC3)(C4=CN=CN4)O,5.0,CC(C)C(O)(c1ccc2cc3c(cc2c1)CNC3=O)c1cnc[nH]1
32199,CHEMBL2403549,RTNOWHVTNCEMDM-GHTZIAJQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23769643.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Synthesis, characterization, and biological assessment of the four stereoisomers of the H3 receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CCCN1[C@@H]2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(C=CC(=C4)F)C)C,4.522878745280337,Cc1cc(N2CC[C@@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C
32200,CHEMBL2403548,RTNOWHVTNCEMDM-NQIIRXRSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23769643.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Synthesis, characterization, and biological assessment of the four stereoisomers of the H3 receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1[C@H]2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(C=CC(=C4)F)C)C,4.522878745280337,Cc1cc(N2CC[C@H](N3CCC[C@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C
32201,CHEMBL2403550,RTNOWHVTNCEMDM-RXVVDRJESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23769643.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Synthesis, characterization, and biological assessment of the four stereoisomers of the H3 receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CCCN1[C@H]2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(C=CC(=C4)F)C)C,4.522878745280337,Cc1cc(N2CC[C@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C
32202,CHEMBL2403551,RTNOWHVTNCEMDM-WIYYLYMNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23769643.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Synthesis, characterization, and biological assessment of the four stereoisomers of the H3 receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1[C@@H]2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(C=CC(=C4)F)C)C,4.522878745280337,Cc1cc(N2CC[C@@H](N3CCC[C@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C
32203,CHEMBL2013051,RTNZBEUCZIJXRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22365751.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CCC(CC1)OC2=CC3=C(C=C2)OC4(CC3)CCN(CC4)C5CCC5,4.522878745280337,CC(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
32206,CHEMBL240867,RTOURUVDFOKSFN-UHFFFAOYSA-N,SR-1362,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,410.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Br)N,6.3872161432802645,NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1
32209,CHEMBL497829,RTSHWIRSEUIDML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CC2)CCN(CC3)C(=O)CC4=C(C=C(C=C4)Cl)Cl,5.0,CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)Cc3ccc(Cl)cc3Cl)CC1)O2
32213,CHEMBL2448707,RTSPQNYEIWFBCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CC(C)N(C)CC(COC1=CC2=C(C=C1)C=C(C=C2)Br)O,4.698970004336019,CC(C)N(C)CC(O)COc1ccc2cc(Br)ccc2c1
32216,CHEMBL2165666,RTUFGGWXEZHNNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CN(C)C1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C(C=CC5=C4C=CN5)F)N6CCOCC6,5.040958607678906,CN(C)C1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
32220,CHEMBL3104489,RTVDDYYSYFIYFB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,4.698970004336019,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1
32221,CHEMBL3104489,RTVDDYYSYFIYFB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,4.698970004336019,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1
32224,CHEMBL1271652,RTYAFVHSTJOJEK-ZHAWHOEGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,6.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H]1COC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CC5CNCC5C4,8.193820026016112,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC4CNCC4C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
32231,CHEMBL1208961,RTYHQIZCRYJKBV-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NCCN(C)C)C(=O)N,6.096910013008056,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
32232,CHEMBL1208961,RTYHQIZCRYJKBV-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NCCN(C)C)C(=O)N,4.568636235841013,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
32262,CHEMBL2165501,RUHKZUQCHSCKRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CCC1=NC2=CC=CC=C2N1C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCC(CC6)C(C)(C)O,5.0,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCC(C(C)(C)O)CC3)cc2n1
32266,CHEMBL2336413,RUIONSFUCOPZLD-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C=C3Cl)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.301029995663981,O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Cl)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
32267,CHEMBL2336413,RUIONSFUCOPZLD-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C=C3Cl)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.3979400086720375,O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Cl)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
32278,CHEMBL557032,RUMNCJSUPKAMTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC(=NO2)C3=NC=CN=C3)C(=O)NC4CC4C5=CC=CC=C5,5.0,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cnccn3)no2)CC1
32279,CHEMBL2048059,RUMOYGYSWPCFLL-WVBUVRCRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ß-peptides.,J. Med. Chem.,PUBLICATION,,CC(C)(CO)C1=CC=CC(=C1)CN[C@H]2CS(=O)(=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,6.096910013008056,CC(C)(CO)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1
32281,CHEMBL601030,RUNGOSGEIDQARZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20074949.0,IC50,>=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCN(CC1)C(=O)CN2C3=C(C=CC(=C3)C(=O)O)C(=C2C4=COC=C4)C5CCCCC5,4.795880017344075,CCN1CCN(C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1
32282,CHEMBL3287854,RUNJHXCAYKNYJM-KBPBESRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900876.0,IC50,>,20000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.",ACS Med. Chem. Lett.,PUBLICATION,,C1CN[C@H](C[C@H]1C2=CC(=O)NO2)CCC3=CC=CC=C3,1.6989700043360187,O=c1cc([C@H]2CCN[C@@H](CCc3ccccc3)C2)o[nH]1
32291,CHEMBL2170639,RUPPNUAUXUYUMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CNC(=O)C=C3,4.522878745280337,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccc(=O)[nH]c3)CC2)c(C(F)(F)F)c1
32320,CHEMBL599791,RUVNTEGYLMYXCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,CN1CCC2=C(C1)C=C(C=C2)NC(=O)C3=CC=CC(=C3)CNC(=O)C4=CC(=C(C=C4)OC)OC,5.769551078621726,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC
32321,CHEMBL599791,RUVNTEGYLMYXCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,CN1CCC2=C(C1)C=C(C=C2)NC(=O)C3=CC=CC(=C3)CNC(=O)C4=CC(=C(C=C4)OC)OC,4.522878745280337,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC
32322,CHEMBL2151922,RUVSRIAGPJOKFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)NC(=O)CC2=NC(=CC(=O)N2)N3CCOCC3,4.3979400086720375,COc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1
32323,CHEMBL1801233,RUVXTVKADDBLBK-BWTSREIZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21080647.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2[C@@H](C2NCC3=CC4=CC=CC=C4C=C3)CN1C5=NC=C(C=N5)C(=O)NO,4.301029995663981,O=C(NO)c1cnc(N2C[C@H]3C(NCc4ccc5ccccc5c4)[C@H]3C2)nc1
32359,CHEMBL3407784,RVLAHZAHALVQKF-AQPYCOETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25422861.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,In vivo phenotypic screening for treating chronic neuropathic pain: modification of c2-arylethynyl group of conformationally constrained a3 adenosine receptor agonists.,J. Med. Chem.,PUBLICATION,,CNC1=C2C(=NC(=N1)C#CC3=CC=C(S3)Cl)N(C=N2)[C@@H]4[C@H]5C[C@]5([C@H]([C@H]4O)O)C(=O)NC,5.0,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccc(Cl)s4)nc31)[C@H](O)[C@@H]2O
32360,CHEMBL10501,RVLMCLGUQRGIEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C4=C(CCCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,5.301029995663981,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCCC2
32382,CHEMBL3408957,RVUPIRNDZZGAJU-KTYYFCFMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7NC6=O,5.795880017344075,CC(C)N1CCC(Oc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1
32383,CHEMBL3408957,RVUPIRNDZZGAJU-KTYYFCFMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=CC=CC=C7NC6=O,6.0,CC(C)N1CCC(Oc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1
32387,CHEMBL3633943,RVWOJJBVBVIEID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26475522.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CCCN2C1=CC(=N2)COC3=CC=CC=C3,4.522878745280337,CC(=O)N1CCCn2nc(COc3ccccc3)cc21
32388,CHEMBL3104479,RVXOAGNZYPWFFX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CN=C3)C4=NC=C(C=C4)C(F)(F)F,5.200659450546418,FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
32389,CHEMBL3104479,RVXOAGNZYPWFFX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6300.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CN=C3)C4=NC=C(C=C4)C(F)(F)F,5.200659450546418,FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
32390,CHEMBL1682999,RVYDMYJAWLDQQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21295471.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome measured after 30 mins preincubation in presence of NADPH,"A new structural alert for benzimidazoles: 2,6-dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)C2=NC3=C(N2)C=C(C=C3)C(=O)NC4=NC5=CC=CC=C5C=C4,5.568636235841013,Cc1cccc(C)c1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1
32391,CHEMBL1682999,RVYDMYJAWLDQQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21295471.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"A new structural alert for benzimidazoles: 2,6-dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)C2=NC3=C(N2)C=C(C=C3)C(=O)NC4=NC5=CC=CC=C5C=C4,5.136677139879544,Cc1cccc(C)c1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1
32405,CHEMBL151974,RWCVRTQNDKYRGG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=NC=NC=C2,4.0,CCCCOc1ccc(-c2ccncn2)cc1
32426,CHEMBL2377663,RWLTWYHWMURBOO-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23584544.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,PUBLICATION,,COC(=S)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2)F)N3CCNN(CC3)C(=O)CO)F,4.698970004336019,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1
32438,CHEMBL2331678,RWSCHRBISRWGQQ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C(C)C)C(=N2)N4CCOC[C@@H]4C,5.0,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C(C)C)C3)cc1
32439,CHEMBL2163833,RWTBFMYLCXHAKG-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,760.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C(=O)[C@H](CC2=CC=C(C=C2)Cl)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,6.119186407719209,CN1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
32457,CHEMBL2087461,RWZBARRAYNKEQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1I)F)NC2=C(C=CC3=C2SN=C3)C(=O)NOCCO,5.045757490560675,O=C(NOCCO)c1ccc2cnsc2c1Nc1ccc(I)cc1F
32458,CHEMBL2087461,RWZBARRAYNKEQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1I)F)NC2=C(C=CC3=C2SN=C3)C(=O)NOCCO,5.045757490560675,O=C(NOCCO)c1ccc2cnsc2c1Nc1ccc(I)cc1F
32466,CHEMBL2057788,RXCTZJFVSOGEKG-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,37.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)(C)C,7.431798275933005,CCN(C)c1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)C)cc2o1
32472,CHEMBL3084761,RXDWERDONCYTQT-PHZGNYQRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1[C@@H]2CCC[C@H]1CC(C2)NC(=O)C3=C4C(=CC=C3)OC(=N4)N5CCOCC5,4.301029995663981,CN1[C@H]2CCC[C@@H]1CC(NC(=O)c1cccc3oc(N4CCOCC4)nc13)C2
32474,CHEMBL3093461,RXEIQMFFHIVGLD-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24215891.0,IC50,=,570.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H](CN1C=CC2=CC=CC=C21)NS(=O)(=O)C3=C(C=C(C=C3Cl)Cl)N,6.2441251443275085,CC[C@@H](Cn1ccc2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl
32484,CHEMBL1208835,RXHOSXWWMGMFAO-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N)C(=O)N,5.187086643357144,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
32488,CHEMBL1922663,RXIYTLYKWJVLSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22059882.0,IC50,=,5.5,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CN=C(C=C1)COC2=CC3=C(C=C2)N(C(=C3SC(C)(C)C)CC(C)(C)C(=O)O)CC4=CC=C(C=C4)C5=NC=C(C=C5)F,8.259637310505756,Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(F)cn3)cc2)nc1
32513,CHEMBL523374,RXQPWAXTLUQACC-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,C[C@H]1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC)C,4.6020599913279625,CNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(C)ccc12
32514,CHEMBL493496,RXQPWAXTLUQACC-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,C[C@@H]1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC)C,4.6020599913279625,CNc1noc2c(-c3ccc4c(N5CCOC[C@H]5C)nncc4c3)c(C)ccc12
32521,CHEMBL3617655,RXRVCJFGSOVYLG-LLVKDONJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26335039.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by cocktail assay,Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C(=O)C2=CC(=NN12)COC3=NC=C(C=C3)Cl)C4=C(N=CC=C4)F,4.522878745280337,C[C@@H]1CN(c2cccnc2F)C(=O)c2cc(COc3ccc(Cl)cn3)nn21
32532,CHEMBL3114719,RXURCMJQURPYAA-JTAQYXEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,190.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H](CC[C@H](CC)NC(=O)OCC1=CN=CS1)NC(=O)[C@H](C(C)C)NC(=O)N(C)CC2=CSC(=N2)C(C)C,6.721246399047171,CC[C@@H](CC[C@H](CC)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1
32546,CHEMBL3115189,RXXJTASWFDWOMQ-QYDYLWNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N[C@@H](CC[C@@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC3=CC=CC=C3)NC(=O)N(C)CC4=CSC=N4,6.920818753952375,CC(C)[C@H](NC(=O)N(C)Cc1cscn1)C(=O)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
32547,CHEMBL3115163,RXXJTASWFDWOMQ-WUNLWTINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N[C@H](CC[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC3=CC=CC=C3)NC(=O)N(C)CC4=CSC=N4,6.853871964321762,CC(C)[C@H](NC(=O)N(C)Cc1cscn1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
32563,CHEMBL392760,RYBOXBBYCVOYNO-UHFFFAOYSA-N,WAY-181187,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17948978.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.",J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C(=CN2S(=O)(=O)C3=C(N=C4N3C=CS4)Cl)CCN,4.481486060122112,NCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2ccccc12
32572,CHEMBL25867,RYGJKZCQNUAGKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,12580.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3NC5=C4C=C(C=C5)[N+](=O)[O-],4.90031935889075,O=[N+]([O-])c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1
32574,CHEMBL179621,RYGQGRAICBWYPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,39080.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,CC1=C(SC=C1)C2=CN=C(C=C2)F,4.408045444953265,Cc1ccsc1-c1ccc(F)nc1
32576,CHEMBL3104532,RYGYILSFRDCTJT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)CC4=CC=CC=C4C(F)(F)F,4.698970004336019,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3ccccc3C(F)(F)F)CC2)cc1
32578,CHEMBL1643513,RYIJMRFACOYPNH-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21095126.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN[C@@H]1CCN(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,4.6020599913279625,CN[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
32579,CHEMBL1643511,RYIJMRFACOYPNH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21095126.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CNC1CCN(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,4.6020599913279625,CNC1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
32593,CHEMBL1064,RYMZZMVNJRMUDD-HGQWONQESA-N,SIMVASTATIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,4.522878745280337,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
32617,CHEMBL1649667,RYUIVLRQMHWMSE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,C1CCC2=C(C1)C(=NN2C3=CC=C(C=C3)C4(CC4)C(=O)N5CCCC5)C(F)(F)F,5.221848749616356,O=C(N1CCCC1)C1(c2ccc(-n3nc(C(F)(F)F)c4c3CCCC4)cc2)CC1
32632,CHEMBL1672611,RZDRIXVHILKLLP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CC=CO3)C4=CC=NC=C4,4.6020599913279625,O=C(Nc1cnc(-c2ccncc2)c(-c2ccco2)n1)C1CC1
32643,CHEMBL498373,RZFRGTCAMDRPMQ-BGPOSVGRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,38300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,COC1=CC(=CC(=C1O)OC)/C=C\2/C(=O)/C(=C/C3=CC(=C(C(=C3)OC)O)OC)/CC2,4.416801226031377,COc1cc(/C=C2\CC/C(=C\c3cc(OC)c(O)c(OC)c3)C2=O)cc(OC)c1O
32644,CHEMBL498373,RZFRGTCAMDRPMQ-BGPOSVGRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,38282474.33,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,COC1=CC(=CC(=C1O)OC)/C=C\2/C(=O)/C(=C/C3=CC(=C(C(=C3)OC)O)OC)/CC2,1.4170000000190845,COc1cc(/C=C2\CC/C(=C\c3cc(OC)c(O)c(OC)c3)C2=O)cc(OC)c1O
32655,CHEMBL263664,RZIDZIGAXXNODG-UHFFFAOYSA-N,CCT128930,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18345609.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1(CC2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,4.301029995663981,NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1
32656,CHEMBL263664,RZIDZIGAXXNODG-UHFFFAOYSA-N,CCT128930,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20151677.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomal preparation,"Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).",J. Med. Chem.,PUBLICATION,,C1CN(CCC1(CC2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,5.0,NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1
32664,CHEMBL489095,RZKDEGZIFSJVNA-IBGZPJMESA-N,CAMICINAL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,4.585026652029182,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
32665,CHEMBL489095,RZKDEGZIFSJVNA-IBGZPJMESA-N,CAMICINAL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,69000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,4.161150909262744,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
32667,CHEMBL523933,RZKDEGZIFSJVNA-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,4.5376020021010435,C[C@@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
32668,CHEMBL523933,RZKDEGZIFSJVNA-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,69000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,4.161150909262744,C[C@@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
32672,CHEMBL536086,RZNQLFINCJHZDT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276063.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(C(CN1C2=NC=NC(=C2)C3=CSC=C3)N)C4=CC(=C(C=C4F)F)F.Cl,5.0,NC1CN(c2cc(-c3ccsc3)ncn2)CC1c1cc(F)c(F)cc1F
32703,CHEMBL2017107,RZUAZHYCHPHTPG-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)C1=C(ON=C1[C@H]2CNCC[C@@]2(C3=CC(=C(C=C3)F)F)O)C4=CC=CC=C4CCNC(=O)C,5.096910013008056,CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1C(C)=O
32707,CHEMBL2380648,RZUKTDWPBQOSBE-PQFSURCISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)N1CCN(CC1)C2=CN=C(C=C2)N3CCN(C4=CC=CC=C43)C(=O)NC5C6CC7CC5CC(C7)(C6)C(=O)N,4.301029995663981,CC(C)(C)N1CCN(c2ccc(N3CCN(C(=O)NC4C5CC6CC4CC(C(N)=O)(C6)C5)c4ccccc43)nc2)CC1
32723,CHEMBL10604,RZYAVBJCTLMHKS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CN(C(=NC1=O)SCC2=CC=C(C=C2)F)CC(=O)N(CCN(CC)CC)CC3=CC=C(C=C3)C4=CC=C(C=C4)C(F)(F)F,4.958607314841775,CCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O
32735,CHEMBL557329,SABBBCPABFDZNM-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,20600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC(=O)N[C@H](CO)C2=CC=CC=C2)CC3=CN(C=C3)C4=CC=C(C=C4)C(F)(F)F,4.686132779630847,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N[C@H](CO)c1ccccc1
32738,CHEMBL3114968,SACAPSNGZVETHL-OEWRPIJISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24461352.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)S(=O)(=O)N2C[C@@H]3[C@H](C2)C3(CNC(=O)C4=CC=CC=C4C(F)(F)F)C5=CC=CC=N5,4.522878745280337,Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)C3(CNC(=O)c2ccccc2C(F)(F)F)c2ccccn2)c1
32761,CHEMBL1214394,SAJCBJSFCCCGCI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC1=NC(=C(C=C1)C2=CC3=C(CC(C3)NS(=O)(=O)C(C)C)C=C2)C,5.0,Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)c(C)n1
32762,CHEMBL2380639,SAJCFTZASJAEDN-KISMBWHLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)C2=CN=C(N=C2)N3CCN(C4=CC=CC=C43)C(=O)NC5C6CC7CC5CC(C7)(C6)C(=O)N,5.0,COc1ccc(-c2cnc(N3CCN(C(=O)NC4C5CC6CC4CC(C(N)=O)(C6)C5)c4ccccc43)nc2)cc1
32770,CHEMBL121405,SAMLUEXYGUANPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177482.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)NC2=NC=CC(=C2)C3=C(N=C(O3)C4(CCNCC4)O)C5=CC=C(C=C5)F,5.698970004336019,OC1(c2nc(-c3ccc(F)cc3)c(-c3ccnc(NC4CCCCC4)c3)o2)CCNCC1
32796,CHEMBL193647,SAUCOGITCIJPAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC3=NNN=N3)CCO)C4=C(C=CC(=C4)Cl)O,4.886056647693163,O=c1c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc2n1Cc1nn[nH]n1
32797,CHEMBL193647,SAUCOGITCIJPAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC3=NNN=N3)CCO)C4=C(C=CC(=C4)Cl)O,4.522878745280337,O=c1c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc2n1Cc1nn[nH]n1
32823,CHEMBL2151926,SBBKINLPXCJMBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1C2=CC(=O)NC(=N2)CC(=O)NC3=CC(=C(C=C3)F)Cl,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Cl)c1
32824,CHEMBL3115191,SBBZCSSPXOWAMS-RRURFNPQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,7.045757490560675,CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
32825,CHEMBL3115184,SBBZCSSPXOWAMS-RWSVXVLSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.920818753952375,CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
32827,CHEMBL1271428,SBCGRJJTBCEEND-PIPWKQLISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,=,8500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@H]1NC2=C(C=CC=N2)C(F)(F)F)C(=O)OC3C4CC5CC3CC(C5)(C4)C(=O)N,5.070581074285707,NC(=O)C12CC3CC(C1)C(OC(=O)N1CC[C@H](Nc4ncccc4C(F)(F)F)C1)C(C3)C2
32828,CHEMBL1271218,SBCGRJJTBCEEND-PYEGBPRMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1NC2=C(C=CC=N2)C(F)(F)F)C(=O)OC3C4CC5CC3CC(C5)(C4)C(=O)N,5.481486060122113,NC(=O)C12CC3CC(C1)C(OC(=O)N1CC[C@@H](Nc4ncccc4C(F)(F)F)C1)C(C3)C2
32841,CHEMBL3084581,SBJLPUIBYIEHFY-PBROBROCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18752960.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.,Bioorg. Med. Chem.,PUBLICATION,,C1CCN(CC1)C(=O)C2=C(C=C[N+](=C2)[O-])C(=O)NC3C[C@H]4CC[C@@H](C3)N4CC5=CC6=C(C=C5)C=C(C=C6)F,4.3979400086720375,O=C(NC1C[C@@H]2CC[C@H](C1)N2Cc1ccc2cc(F)ccc2c1)c1cc[n+]([O-])cc1C(=O)N1CCCCC1
32845,CHEMBL3260745,SBLRGVQPPNSJQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=CC=C(C=C4)C#N)C5=CC=C(C=C5)Cl,4.3979400086720375,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccc(C#N)cc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
32846,CHEMBL89750,SBMHFUHIBLNLAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CC4=CC=C(C=C4)C5=CC=C(C=C5)C(F)(F)F)CC(=O)O,4.508638306165727,Cn1cc(Cc2cn(CC(=O)N(CC(=O)O)Cc3ccc(-c4ccc(C(F)(F)F)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
32847,CHEMBL2316379,SBMZVMAQHHRTLR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,=,610.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,C1COCCC1CNC(=O)C2=C(C=CC=N2)NC(=O)C3=CC=C(C4=CC=CC=C43)CN5C=CN=N5,6.214670164989233,O=C(NCC1CCOCC1)c1ncccc1NC(=O)c1ccc(Cn2ccnn2)c2ccccc12
32873,CHEMBL2409707,SBVAXUGOISPYPX-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810497.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Hydantoin based inhibitors of MMP13-Discovery of AZD6605.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@]1(C(=O)NC(=O)N1)CS(=O)(=O)N2CCC(CC2)OC3=CC=C(C=C3)OC(C(F)F)(F)F,5.0,C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(OC(F)(F)C(F)F)cc3)CC2)NC(=O)NC1=O
32883,CHEMBL3699316,SCCIUWBTSOHVEK-VYQNARHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8=CN=C(C=C8)OC,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccc(OC)nc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
32885,CHEMBL3259928,SCEGQLOWLADTKA-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CN1CCC[C@](C1)(C2=CC=CC=C2)NC(=O)C3=C(C=C(C=C3SC)C(F)(F)F)OC,4.301029995663981,COc1cc(C(F)(F)F)cc(SC)c1C(=O)N[C@@]1(c2ccccc2)CCCN(C)C1
32887,CHEMBL2058663,SCFKYKHATMFMTK-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,37.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)C(C)C,7.431798275933005,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(C(C)C)oc2c1
32890,CHEMBL2325697,SCGCBAAYLFTIJU-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23394205.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)S(=O)(=O)C)C4=C5C=CNC5=CC=C4,5.0,C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1
32893,CHEMBL1667935,SCJMHNYQTKWNRD-NDQYQSCMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CC1(CC(C1)C2=NC(=C3N2N=CN=C3N)C4=C(C5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)F)O,4.6020599913279625,CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3F)c3c(N)ncnn23)C1
32911,CHEMBL562285,SCNLJQQVOVIBKB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,3220.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC(=O)NC(CC2=NC=CN=C2)C3=CC=CC=C3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,5.492144128304169,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cc1cnccn1)c1ccccc1
32917,CHEMBL1077781,SCQHVECWBAHHHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CC(=O)O)C3=CC=CC=C3,5.0,O=C(O)CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
32919,CHEMBL3414926,SCRRRLBPWUHHER-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in absence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,CC1=NOC(=C1)C2=CN3C(=NN=C3[C@@H](C)C4=CC5=CC(=CN=C5C=C4)OCCOC)C(=C2)F,4.301029995663981,COCCOc1cnc2ccc([C@H](C)c3nnc4c(F)cc(-c5cc(C)no5)cn34)cc2c1
32920,CHEMBL3414926,SCRRRLBPWUHHER-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,CC1=NOC(=C1)C2=CN3C(=NN=C3[C@@H](C)C4=CC5=CC(=CN=C5C=C4)OCCOC)C(=C2)F,4.301029995663981,COCCOc1cnc2ccc([C@H](C)c3nnc4c(F)cc(-c5cc(C)no5)cn34)cc2c1
32924,CHEMBL3632719,SCUGTCMSRMQNNQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=CC=C1)NC2=NC3=C(N2C)C=CC(=C3)OC4=CC(=NC=C4)C5=NC=C(N5)C(F)(F)F,5.0,Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
32940,CHEMBL1651532,SCXPFFTVFSPORD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng testosterone substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,CC1=NC=C(C=C1)NC(=O)N2CCC(=CC3=CC(=CC=C3)OC4=NC=C(C=C4)C(F)(F)F)CC2,5.522878745280337,Cc1ccc(NC(=O)N2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1
32941,CHEMBL1651532,SCXPFFTVFSPORD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,11800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng midazolam substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,CC1=NC=C(C=C1)NC(=O)N2CCC(=CC3=CC(=CC=C3)OC4=NC=C(C=C4)C(F)(F)F)CC2,4.928117992693875,Cc1ccc(NC(=O)N2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1
32942,CHEMBL212689,SCXSQUUTGCWHFU-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16631366.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of P450 3A4,Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C1CCN(CC1)CC[C@H](C2=CC=C(C=C2)S(=O)(=O)C)C3=CC(=CC(=C3)F)F)C(=O)CC4=CC=C(C=C4)S(=O)(=O)C,5.0,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@H](c2ccc(S(C)(=O)=O)cc2)c2cc(F)cc(F)c2)CC1
32947,CHEMBL246322,SDCAYDSIXAYUNR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276063.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1S(=O)(=O)C2=CC=CC(=C2)C3=CC(=NC=N3)N4CC(C(C4)N)C5=CC(=C(C=C5F)F)F,5.0,NC1CN(c2cc(-c3cccc(S(=O)(=O)N4CCOCC4)c3)ncn2)CC1c1cc(F)c(F)cc1F
32951,CHEMBL551347,SDEZSIUXMXPOCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2C=CC=N2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,5.301029995663981,Fc1ccc(Cn2c(N3CCC(n4cccn4)CC3)nc3ccccc32)cc1
32967,CHEMBL377085,SDMLKCQDZJOSDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,CC1=CC(=NC2=C1C(=C(S2)C(=O)N)N)C,4.522878745280337,Cc1cc(C)c2c(N)c(C(N)=O)sc2n1
32970,CHEMBL1829782,SDPGWJVXVCTHJY-HMILPKGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCCNS(=O)(=O)C)C4=CC=C(C=C4)F,5.154901959985743,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCNS(C)(=O)=O)(c2ccc(F)cc2)OC1=O
32971,CHEMBL1778481,SDPOAFSISKXZLC-XMHGGMMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550240.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C(=O)NC1=CC=C(C=C1)/C=C/C(=O)O)NC(=O)C2=CC3=C(C=C2)C(=C(N3C)C4=CC=CC=N4)C5CCCCC5,5.050609993355088,Cn1c(-c2ccccn2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21
32983,CHEMBL96347,SDXSGUVLSFVWRF-BHYZAODMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15139756.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC(=C1)O[C@H](C(=O)O)[C@@]2(C3=CC=CC=C3N(C(=O)CN2)CC4=C(C=C(C=C4F)F)F)C5=CC=CC=C5)C,4.853871964321762,Cc1cc(C)cc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1
33004,CHEMBL495787,SECCFJLAASGLAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,5.142667503568732,Cc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
33005,CHEMBL495787,SECCFJLAASGLAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,4.769551078621726,Cc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
33018,CHEMBL2409667,SEFFUKHXSNXXNA-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810497.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Hydantoin based inhibitors of MMP13-Discovery of AZD6605.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)S(=O)(=O)C[C@H](CCCC3=NC=CC=N3)N(C=O)O,6.0,O=CN(O)[C@@H](CCCc1ncccn1)CS(=O)(=O)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
33028,CHEMBL2017102,SEGYVZKSGPIGLE-KOSHJBKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)[C@H]3CNCC[C@@]3(C4=CC(=C(C=C4)F)F)O)Br,4.481486060122112,CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br
33045,CHEMBL2018914,SEPBORGDHRCCDG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCCCC(=O)O,4.301029995663981,COc1ccc2nc(SCCCC(=O)O)[nH]c2c1
33057,CHEMBL1271544,SEUYCXXZPFOTNT-RRIIRSAJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,0.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H]1COC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CC5CCC(C4)N5,9.301029995663981,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC4CCC(C3)N4)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
33064,CHEMBL447591,SEXSHORPOJSDHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672861.0,IC50,=,1913.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)C=C(C=C2)C3=CC(=CN=C3)OC,5.718285029972704,COc1cncc(-c2ccc3cc(OC)ccc3c2)c1
33065,CHEMBL578579,SEXWHEGZWUEBDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)N4CCOCC4,5.301029995663981,CC1(CC(=O)NCc2ccc(N3CCOCC3)cc2)CC2(CCCCC2)OO1
33075,CHEMBL1371684,SEZPRMPVJMVCBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)CSC2=NC3=C(CCC3)C(=O)N2,4.698970004336019,Cc1ccc(CSc2nc3c(c(=O)[nH]2)CCC3)cc1
33076,CHEMBL1371684,SEZPRMPVJMVCBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)CSC2=NC3=C(CCC3)C(=O)N2,4.698970004336019,Cc1ccc(CSc2nc3c(c(=O)[nH]2)CCC3)cc1
33077,CHEMBL1080975,SFAHBRRRIPXYTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NCC2=CC=C(C=C2)C3=CC(=CC=C3)Cl)C4=CC=CC=C4,5.0,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3cccc(Cl)c3)cc2)C1
33082,CHEMBL1760206,SFBJQTXZKXTYKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=CC(=N1)C(=O)N2CCN(CC2)C3=CC=CC=C3OC)C4=CC=C(C=C4)Cl,4.698970004336019,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n(C)n2)CC1
33089,CHEMBL1173260,SFFLHOMUFWFHRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,896.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)F,6.047691990337875,Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1F
33090,CHEMBL1173260,SFFLHOMUFWFHRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,896.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)F,6.047691990337875,Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1F
33093,CHEMBL399283,SFICTTTWDKGKCQ-BAGYTPMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@H](N([C@H](C1)C2(CC2)CC3=NC(=NO3)CN4CC[C@H](C4)O)S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,6.221848749616356,O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2nc(CN3CC[C@@H](O)C3)no2)CC1
33105,CHEMBL2043437,SFNSLLSYNZWZQG-VQIMIIECSA-N,GLASDEGIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CN1CC[C@H](C[C@@H]1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N,4.522878745280337,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
33110,CHEMBL2347410,SFPNGRVNEZGBGX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)F)C(=N1)C3=CN=C4C(=N3)C(=CN4)C(=O)NC5CC(COC5)N,4.301029995663981,Cn1nc(-c2cnc3[nH]cc(C(=O)NC4COCC(N)C4)c3n2)c2ccc(F)cc21
33111,CHEMBL10769,SFPOPEFEUFHEAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)Cl,4.5376020021010435,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cl)c(=O)nc1SCc1ccc(F)cc1
33113,CHEMBL2382415,SFQBQYYGWHSCJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23628336.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2CN(CC1N2C(=O)OCC(F)(F)F)C3=NC=C(C=N3)OCC4=C(C=NC=C4)C#N,4.522878745280337,N#Cc1cnccc1COc1cnc(N2CC3CCC(C2)N3C(=O)OCC(F)(F)F)nc1
33115,CHEMBL567911,SFQQUBOFNDDLMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19743867.0,IC50,=,48000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.",J. Med. Chem.,PUBLICATION,,CC1=CNC2=C1C(=CN=C2NC3=CC(=CC=C3)Cl)C(=O)N4CCOCC4,4.318758762624412,Cc1c[nH]c2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c12
33126,CHEMBL3084778,SFVKVHVOODTRCH-QKDCVEJESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1[C@@H]2CCC[C@H]1CC(C2)NC(=O)C3=C4C(=CC=C3)OC(=N4)C5CC5,4.301029995663981,CN1[C@H]2CCC[C@@H]1CC(NC(=O)c1cccc3oc(C4CC4)nc13)C2
33139,CHEMBL500394,SGBOBLSELUHWRG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672861.0,IC50,=,3540.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC4=CC=CC=C43,5.450996737974212,COc1ccc2cc(-c3cncc4ccccc34)ccc2c1
33154,CHEMBL405565,SGDGSDPRWPCTHO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)CC1=CC(=NC(=N1)C2=CC=NC=C2)N3CCCC3,5.886056647693163,CS(=O)(=O)Cc1cc(N2CCCC2)nc(-c2ccncc2)n1
33155,CHEMBL2043004,SGDWPIDXMHBDQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,=,69000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)C6=CC=CC=C6,4.161150909262744,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccccc3)cc1)C(=O)N2c1cc(=O)[nH]cn1
33169,CHEMBL3115181,SGJYFRAVXMHBRK-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.920818753952375,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
33170,CHEMBL2178221,SGKCFBSHEIOVRA-XPYDGVJRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061376.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,PUBLICATION,,C1[C@@H]([C@H](CN1CCO)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=C(C=C3)/C=C/C(=O)NC4=CC=CC=C4N,5.698970004336019,Nc1ccccc1NC(=O)/C=C/c1ccc([C@H]2CN(CCO)C[C@@H]2C(=O)Nc2ccc(Cl)cc2)cc1
33187,CHEMBL2059803,SGQSLILVTRDLTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3)NC=C4)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,5.6020599913279625,O=C(NC(Cc1ccc2[nH]ccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
33205,CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,5.327902142064283,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
33206,CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,76032.63,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,4.11899998682835,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
33212,CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,17600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,4.7544873321858505,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
33213,CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,4.920818753952375,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
33275,CHEMBL3702784,SHLJOEBOAVNKSW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2530.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCCN8CCCCC8,5.5968794788241825,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
33280,CHEMBL1080076,SHOBDCUSXYTMQM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3)C4=CC=CC=C4,5.0,CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(-c3ccccc3)cc2)C1
33296,CHEMBL1835153,SHSWWKAPCSHSHG-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21942426.0,IC50,>,75000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-Amino-5H-pyrido[4,3-b]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative Disorders.",J. Med. Chem.,PUBLICATION,,C1CC1[C@H](C(F)(F)F)NC2=NC=C(C3=C2C4=C(N3)C=C(C=C4)C5=CN=C(N=C5)N)C(=O)N,4.1249387366083,NC(=O)c1cnc(N[C@H](C2CC2)C(F)(F)F)c2c1[nH]c1cc(-c3cnc(N)nc3)ccc12
33300,CHEMBL2165502,SHTICQDOCLQFOS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CCC1=NC2=CC=CC=C2N1C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCN(CC6(C)C)C7COC7,5.0,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C4COC4)CC3(C)C)cc2n1
33304,CHEMBL2403816,SHTNULLAAVPXRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23773153.0,IC50,=,14800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-Hydroxymidazolam after 7 mins by LC-MS/MS analysis,Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=CC=C(C=C2)NC3=NC=NC4=CC=CC=C43)C5=CC=CC(=C5)N,4.8297382846050425,CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4ccccc34)cc2)n(-c2cccc(N)c2)n1
33310,CHEMBL2113177,SHUVSCHNMZHWMV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16302826.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4 isoform,"Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.",J. Med. Chem.,PUBLICATION,,C1COCCN1CCNC2=CC=C(C=C2)S(=O)(=O)N(CC(=O)N=NC3=C(NC4=CC=CC=C43)O)C5=CC=C(C=C5)Cl,6.508638306165727,O=C(CN(c1ccc(Cl)cc1)S(=O)(=O)c1ccc(NCCN2CCOCC2)cc1)N=Nc1c(O)[nH]c2ccccc12
33334,CHEMBL1081779,SIDLHXXVIBTSJZ-UHFFFAOYSA-N,7-BENZYLOXYQUINOLINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19891474.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)COC2=CC3=C(C=CC=N3)C=C2,4.6020599913279625,c1ccc(COc2ccc3cccnc3c2)cc1
33335,CHEMBL1081779,SIDLHXXVIBTSJZ-UHFFFAOYSA-N,7-BENZYLOXYQUINOLINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20839775.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Exploration of the amine terminus in a novel series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)COC2=CC3=C(C=CC=N3)C=C2,4.6020599913279625,c1ccc(COc2ccc3cccnc3c2)cc1
33365,CHEMBL47955,SIMWTRCFFSTNMG-AWEZNQCLSA-N,EPEREZOLID,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23584544.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,PUBLICATION,,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCN(CC3)C(=O)CO)F,4.698970004336019,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1
33381,CHEMBL1929238,SIUIQMQVKUUQQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22014550.0,IC50,=,550.0,NM,,inhibition,biochemical,functional,enzyme_activity,non_competitive_inhibitor,radiometry,,30,UM,ATP, =,1,UM,Inhibition of CYP3A4,Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).,Bioorg. Med. Chem. Lett.,PUBLICATION,HOTSPOT FILTRATION ASSAY,CC(C)(C)C1=CC(=C(S1)NC(=O)NC2=C(C(=CC=C2)Cl)Cl)C(=O)N3CCC(=O)N(CC3)CCN(C)C,6.259637310505756,CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O
33388,CHEMBL2403820,SIXVDPYFTBZLMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23773153.0,IC50,=,1950.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-Hydroxymidazolam after 7 mins by LC-MS/MS analysis,Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=CC=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)NC(=O)CCN5CCN(CC5)C)C6=CC=CC(=C6)N,5.709965388637482,CN1CCN(CCC(=O)Nc2ccc3ncnc(Nc4ccc(NC(=O)Nc5cc(C(C)(C)C)nn5-c5cccc(N)c5)cc4)c3c2)CC1
33389,CHEMBL2171124,SIXVRXARNAVBTC-UHFFFAOYSA-N,GSK2606414,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F,5.0,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21
33390,CHEMBL2171124,SIXVRXARNAVBTC-UHFFFAOYSA-N,GSK2606414,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F,4.886056647693163,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21
33391,CHEMBL2171124,SIXVRXARNAVBTC-UHFFFAOYSA-N,GSK2606414,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,,10000.0,NM,,inhibition,tissue,functional,,,,,0.01-30,UM,,=,0.1-0.5,MG-ML,,,ACS MED. CHEM. LETT.,PUBLICATION,,CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F,5.0,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21
33392,CHEMBL2171124,SIXVRXARNAVBTC-UHFFFAOYSA-N,GSK2606414,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,,13000.0,NM,,inhibition,tissue,functional,,,,,0.01-30,UM,,=,0.1-0.5,MG-ML,,,ACS MED. CHEM. LETT.,PUBLICATION,,CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F,4.886056647693163,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21
33396,CHEMBL1760205,SIYPEYKSXSWWFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=CC(=N1)C2=CC=C(C=C2)Cl)C(=O)N3CCN(CC3)C4=CC=CC=C4OC,4.920818753952375,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)nn2C)CC1
33403,CHEMBL1257706,SJBVKVDGVANGJA-DOACRVLCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20729082.0,IC50,=,22680.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CN3[C@H]([C@@H]2C4=CC=C(C=C4)F)[C@@H]5C[C@](C[C@@H]5C3=O)(C)O,4.644356949779131,C[C@@H](O[C@H]1CN2C(=O)[C@H]3C[C@@](C)(O)C[C@H]3[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
33406,CHEMBL3702687,SJDMIRPKIHYUCM-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2920.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCC(CC1)NC(=O)NC2=NC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.534617148551582,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
33413,CHEMBL270996,SJDOZKJTMVUAKV-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,160.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)CN)C,6.795880017344075,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)CN)c(C)c34)ccc2[nH]1
33414,CHEMBL270996,SJDOZKJTMVUAKV-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)CN)C,6.508638306165727,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)CN)c(C)c34)ccc2[nH]1
33418,CHEMBL270515,SJFBTAPEPRWNKH-CCKFTAQKSA-N,DELANZOMIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18247547.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.",J. Med. Chem.,PUBLICATION,,B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O,5.455931955649724,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(-c2ccccc2)n1)[C@@H](C)O)B(O)O
33426,CHEMBL552402,SJIHFYQHTFWHTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC3=CC=CC=C3O2)C(=O)NC4CC4C5=CC=CC=C5,5.0,O=C(NC1CC1c1ccccc1)N1CCC(c2nc3ccccc3o2)CC1
33430,CHEMBL3313969,SJOFEHGUJFUHSO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25711516.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using midazolam substrate by LC-MS/MS method,"Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.",J. Med. Chem.,PUBLICATION,,CC1=C(C=NC=C1)C2=CC3=C(C(=C2)F)N4C(=NN=C4CC3)C,4.301029995663981,Cc1ccncc1-c1cc(F)c2c(c1)CCc1nnc(C)n1-2
33431,CHEMBL263179,SJOJFTCKJRUNRE-MBEDZMRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)COC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](CN3CCN(C[C@H]3C(=O)NC(C)(C)C)CC4=CN=CS4)O,4.823908740944319,CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cncs3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1
33440,CHEMBL1269687,SJSGQQBOEMCRGY-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)C)Cl)C5CC5)Cl,5.292429823902063,CC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
33441,CHEMBL1269687,SJSGQQBOEMCRGY-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)C)Cl)C5CC5)Cl,5.075720713938118,CC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
33443,CHEMBL2387599,SJSIOPWZUMWNBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=CC=CC=C5Cl,4.522878745280337,O=c1[nH]c2cc(-c3ccccc3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
33447,CHEMBL206545,SJTJWXRSXLQPEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCCNS(=O)(=O)C)C,6.0,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCNS(C)(=O)=O)c(C)c34)ccc2[nH]1
33474,CHEMBL207831,SJXXIFKOMSEXRL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16495056.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C=CCC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,5.259637310505756,C=CCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
33504,CHEMBL3260744,SKEJACPDEDIHNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=C(C=NC=C4)C)C5=CC=C(C=C5)Cl,4.3979400086720375,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3C)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
33510,CHEMBL1241641,SKGSBVPKDPLIEF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,<,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=C(N=C6CO5)C(F)(F)F,5.3979400086720375,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nc(C(F)(F)F)cn4-5)CC3)cccc2n1
33513,CHEMBL2448737,SKHSDXFQRUQZAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CC1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(N=C3)C4=CC=CC=C4,5.0,Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
33540,CHEMBL1277935,SKOALCKWENTDHG-TUXUZCGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,C1CN(CC(=C1)C(=O)O)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35,5.0,O=C(O)C1=CCCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1
33545,CHEMBL2017290,SKRNOPQLHIMWNG-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@H](C1=CC=CC=C1)N2C3=C(C=NC4=CC(=C(C=C43)OC)C5=C(ON=C5C)C)NC2=O,5.619788758288394,CC[C@H](c1ccccc1)n1c(=O)[nH]c2cnc3cc(-c4c(C)noc4C)c(OC)cc3c21
33569,CHEMBL1093469,SLAGVDVFVOTFNB-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by P450-Glo method,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=CC=CC=C4,5.0,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3)CC2)C1
33572,CHEMBL520648,SLAWODYHZHIDLN-NBEIKUQISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=N1)S(=O)(=O)C2CCC(CC2)(CC3CC3)CNC(=O)C4=C(C=C(C=C4)Cl)Cl,5.0,Cn1cc(S(=O)(=O)C2CCC(CNC(=O)c3ccc(Cl)cc3Cl)(CC3CC3)CC2)nn1
33577,CHEMBL231383,SLBLVSSPDCNCSA-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,=,10700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,CC1=CN=C(N1CC(=O)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4C[C@@H](OC4=O)CN5C=CN=N5)F)C,4.97061622231479,Cc1cnc(C)n1CC(=O)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1
33591,CHEMBL1209553,SLIFTHAOQMHZDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)Cl,7.167491087293763,CC(C)CC1n2cncc2CN(Cc2ccc(Cl)cc2)S1(=O)=O
33592,CHEMBL1209553,SLIFTHAOQMHZDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,87.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)Cl,7.060480747381382,CC(C)CC1n2cncc2CN(Cc2ccc(Cl)cc2)S1(=O)=O
33601,CHEMBL1777976,SLOODFDSRINSMM-JWQCQUIFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]3CCCC4=C3C=CC(=C4)CNC(C)(C)C,4.522878745280337,Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNC(C)(C)C)ccc32)cc1
33602,CHEMBL1777976,SLOODFDSRINSMM-JWQCQUIFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]3CCCC4=C3C=CC(=C4)CNC(C)(C)C,4.522878745280337,Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNC(C)(C)C)ccc32)cc1
33605,CHEMBL270666,SLPRBNYHIRCQPB-RTBURBONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18282707.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyresorufin as a substrate,Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C2=NN=NN2[C@H](CC#N)COC3=CC=CC=C3O)N,5.259637310505756,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccc1O
33606,CHEMBL270666,SLPRBNYHIRCQPB-RTBURBONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18282707.0,IC50,=,9800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate,Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C2=NN=NN2[C@H](CC#N)COC3=CC=CC=C3O)N,5.008773924307505,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccc1O
33619,CHEMBL1829763,SLSMHOGJKAPYQU-QLXKLKPCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CC[C@](OC3=O)(CCO)C4=CC=C(C=C4)F,4.920818753952375,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O
33624,CHEMBL490672,SLVAPEZTBDBAPI-GDLZYMKVSA-N,FILIBUVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19209845.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.",J. Med. Chem.,PUBLICATION,,CCC1=CC(=CC(=N1)CC)CC[C@@]2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5,4.522878745280337,CCc1cc(CC[C@]2(C3CCCC3)CC(O)=C(Cc3nc4nc(C)cc(C)n4n3)C(=O)O2)cc(CC)n1
33638,CHEMBL3403986,SLZAUJBJBWFYSU-BHDXBOSCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25754490.0,IC50,<=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate,"trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: Prime site exploration using an oxygen linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1OCC2=CC(=CC=C2)C3=CC=CC=C3)C(=O)C4=CC(=C(C=C4)OC)OCCCOC,6.698970004336019,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OCc2cccc(-c3ccccc3)c2)C(C)C)ccc1OC
33643,CHEMBL30008,SMANXXCATUTDDT-QPJJXVBHSA-N,FLUNARIZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,4.301029995663981,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1
33662,CHEMBL1829433,SMFXSYMLJDHGIE-UHFFFAOYSA-N,AZD-4877,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21899292.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of (+)-N-(3-Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent.",J. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=NC3=C(C(=NS3)C)C(=O)N2CC4=CC=CC=C4)C(C)C,5.0,Cc1ccc(C(=O)N(CCCN)C(c2nc3snc(C)c3c(=O)n2Cc2ccccc2)C(C)C)cc1
33663,CHEMBL399507,SMIMGTZNUUPWTH-ACIOBRDBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,19500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)[C@H]3C[C@H](C[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5)O,4.709965388637482,CC(C)(CO)N1CCN(C(=O)OC2([C@H]3C[C@@H](O)C[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
33664,CHEMBL399507,SMIMGTZNUUPWTH-ACIOBRDBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,19500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)[C@H]3C[C@H](C[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5)O,4.709965388637482,CC(C)(CO)N1CCN(C(=O)OC2([C@H]3C[C@@H](O)C[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
33671,CHEMBL570639,SMLNDPGQWMLXAK-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,87000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)O,4.060480747381382,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(C(=O)O)nc3)ccc2o1
33673,CHEMBL3702753,SMMMLQJKBCIERQ-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2480.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC1=NC=CN1CCN(C)C(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.605548319173784,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCn5ccnc5C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
33674,CHEMBL1099323,SMNCEXHPBATBIT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=CC(=CC(=C2)OCCCCCCC3=C(C(=CC=C3)OCCCC(=O)O)CCC(=O)O)C4=CC=CC=C4,5.1249387366083,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccccc3)cc(-c3ccccc3)c2)c1CCC(=O)O
33685,CHEMBL568012,SMSTUWNNYWFKMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,2030.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC(=O)C1=CC(=CC=C1)NC(=O)COC2=CC=C(C=C2)C34CC5CC(C3)CC(C5)(C4)C(=O)N6CCN(CC6)CC7=CC=C(C=C7)C(F)(F)F,5.692503962086787,COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7ccc(C(F)(F)F)cc7)CC6)(C5)C3)C4)cc2)c1
33686,CHEMBL2407717,SMTXKVURUPJKNQ-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829483.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using vivid green as substrate,"Discovery of Potent, Isoform-Selective Inhibitors of Histone Deacetylase Containing Chiral Heterocyclic Capping Groups and a N-(2-Aminophenyl)benzamide Binding Unit.",J. Med. Chem.,PUBLICATION,,C1[C@@H](NC(=NCC2=CC=C(C=C2)C(=O)NC3=CC=CC=C3N)S1)C4=CC=CC=C4,4.795880017344075,Nc1ccccc1NC(=O)c1ccc(CN=C2N[C@@H](c3ccccc3)CS2)cc1
33687,CHEMBL2407717,SMTXKVURUPJKNQ-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829483.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using vivid red as substrate,"Discovery of Potent, Isoform-Selective Inhibitors of Histone Deacetylase Containing Chiral Heterocyclic Capping Groups and a N-(2-Aminophenyl)benzamide Binding Unit.",J. Med. Chem.,PUBLICATION,,C1[C@@H](NC(=NCC2=CC=C(C=C2)C(=O)NC3=CC=CC=C3N)S1)C4=CC=CC=C4,4.6020599913279625,Nc1ccccc1NC(=O)c1ccc(CN=C2N[C@@H](c3ccccc3)CS2)cc1
33688,CHEMBL3114717,SMWGYCRIYRMWHW-HFASVGIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23746300.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,,,,,,CCC[C@@H](CC[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)NC(=O)N(C)CC2=CSC(=N2)C(C)C)NC(=O)OCC3=CN=CS3,5.552841968657781,CCC[C@@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1
33690,CHEMBL3114717,SMWGYCRIYRMWHW-HFASVGIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC[C@@H](CC[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)NC(=O)N(C)CC2=CSC(=N2)C(C)C)NC(=O)OCC3=CN=CS3,6.886056647693163,CCC[C@@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1
33696,CHEMBL1642913,SNDGNPRZZZPUAX-BLLLJJGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1[C@H](CC2=CC=CC=C2[C@H]1C3=CC(=C(C=C3)Cl)Cl)CCN,4.6020599913279625,NCC[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
33697,CHEMBL1642912,SNDGNPRZZZPUAX-WBMJQRKESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1[C@@H](CC2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)CCN,4.6020599913279625,NCC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
33699,CHEMBL227676,SNDYOAGMAZLRJN-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC3=C(C=C(C=C3)Br)C(=O)N2CC4=CC=CC=C4C#N)N,6.6020599913279625,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(Br)cc2c1=O
33701,CHEMBL564845,SNFXVJPZRORJQP-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(N3C=CC=CC3=C2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.958607314841775,CN([C@@H]1CCc2c(c3ccccn3c2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1
33711,CHEMBL440464,SNICXCGAKADSCV-UHFFFAOYSA-N,(+/-)NICOTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,142400.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,CN1CCCC1C2=CN=CC=C2,3.8464900106991626,CN1CCCC1c1cccnc1
33718,CHEMBL3318998,SNLIVOYLVZGJOY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25050172.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C#N)N=C(N2)N3CCN(CC3)CCN4C(=O)C=CC5=C4C=C(C=N5)OC,4.698970004336019,COc1cnc2ccc(=O)n(CCN3CCN(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1
33723,CHEMBL2386162,SNNRWIBSGBMYRF-ZFWWWQNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=N1)OC)O[C@@H](CC(C)C)[C@H]2CCNC2,5.0,COc1ccc(O[C@@H](CC(C)C)[C@H]2CCNC2)c(C)n1
33725,CHEMBL597211,SNNUMARRAFQOGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20151677.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomal preparation,"Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).",J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC=C(C=C1)CC2(CCN(CC2)C3=NC=NC4=C3C=CN4)N,5.0,CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1
33742,CHEMBL178474,SNSYASMKLBWRLR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C(=O)OC)N4C=CN=C4)N(C)C,8.0,COC(=O)c1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1
33743,CHEMBL178474,SNSYASMKLBWRLR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C(=O)OC)N4C=CN=C4)N(C)C,7.3979400086720375,COC(=O)c1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1
33756,CHEMBL2181629,SNWJTLNFUDCRNX-XNTDXEJSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=CC=NC=C5)C6CCCC6,5.366531544420414,Cn1c(-c2ccncc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21
33760,CHEMBL1668114,SNZZAHRDXCGWEM-CKFHNAJUSA-N,TAXIRESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,85600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,COC1=C(C=CC(=C1)C[C@H]2CO[C@@H]([C@H]2CO)C3=CC(=C(C=C3)O)O)O,4.0675262353228465,COc1cc(C[C@H]2CO[C@H](c3ccc(O)c(O)c3)[C@H]2CO)ccc1O
33767,CHEMBL479701,SOCNBZCAGNYAED-OKFXBHNASA-N,(-)-CLUSIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,830.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,COC1=CC(=CC(=C1OC)OC)C[C@@H]2[C@H](COC2O)CC3=CC4=C(C=C3)OCO4,6.080921907623926,COc1cc(C[C@H]2C(O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC
33778,CHEMBL1910124,SOFQOASLSXGZBR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCOCC3)C4=C(C=C(C=C4)Cl)Cl)CN,4.769551078621726,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCOCC1)C2=O
33790,CHEMBL3112865,SONKMXSQGHFTFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,CC1(CN(C2=CC=CC=C21)C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4)C,4.3979400086720375,CC1(C)CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21
33793,CHEMBL3114727,SOOCSEFIXRGIQQ-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,1260.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)NCCCNC(=O)OCC2=CN=CS2,5.8996294548824375,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCCNC(=O)OCc2cncs2)C(C)C)cs1
33809,CHEMBL240528,SOSLMHZOJATCCP-AEIZVZFYSA-N,AFZELIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)O)O,4.0,C[C@@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@H](O)[C@H]1O
33813,CHEMBL448253,SOUIZGJPJARRHY-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)N)C4=CC(=CC=C4)OCCCC(=O)O,5.0,Cc1c(-c2cccc(OCCCC(=O)O)c2)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F
33815,CHEMBL1951778,SOUKAJZEGIHVAV-VXBHWDOESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,COC1=NC=C(C=C1)C2(CCC(CC2)N3CC[C@H](C3)NC(=O)CNC(=O)C4=CC(=CC=C4)C(F)(F)F)O.CS(=O)(=O)O,4.6020599913279625,COc1ccc(C2(O)CCC(N3CC[C@@H](NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1
33816,CHEMBL467079,SOUYYRXENUITFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19364658.0,IC50,=,8600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C(C(=O)N)NC2=C(C(=O)C2=O)NC3=CC=NC=C3,5.0655015487564325,NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1
33838,CHEMBL1200633,SPBDXSGPUHCETR-JFUDTMANSA-N,IVERMECTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)O[C@@H]1C(C)C,4.301029995663981,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
33839,CHEMBL1200633,SPBDXSGPUHCETR-JFUDTMANSA-N,IVERMECTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)O[C@@H]1C(C)C,4.522878745280337,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
33843,CHEMBL2040894,SPCSFCKHCIOCTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)C6=NOC(=N6)COC,4.301029995663981,COCc1nc(-c2ccc(N3C(=O)N(c4cc(=O)[nH]cn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)no1
33862,CHEMBL1796293,SPHCZZBTYLIKMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C#N)OC2=CC=C(C=C2)C(=O)NCC3=CC=NC=C3,6.0,N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccncc2)cc1
33879,CHEMBL3702711,SPNMGKKKLSOOCQ-SAGRBAIFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)(C)OC(=O)N1CCN2CCN(CC2C1)C(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.657577319177793,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C(=O)OC(C)(C)C)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
33882,CHEMBL3702727,SPRRJSDCKXRUNI-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)C2CN(C2)C(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCN(C)CC6)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
33883,CHEMBL10271,SPSIJFFRJLVTRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)Br,4.4089353929735005,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Br)c(=O)nc1SCc1ccc(F)cc1
33885,CHEMBL1949939,SPTLTOMHDUZGDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC(=NC=C4)F)O)OC,6.221848749616356,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccnc(F)c3)c2c1
33886,CHEMBL1949939,SPTLTOMHDUZGDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC(=NC=C4)F)O)OC,5.376750709602099,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccnc(F)c3)c2c1
33887,CHEMBL231147,SPUNALFSCHUGOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)N5C=CC=C5)N(C2=O)CC6=CC=CC=C6F,5.0,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-n5cccc5)cc4)CC3)C2=O)c1
33890,CHEMBL477204,SPVRNTZJWSWACV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18809327.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=N1)C2=CC=C(C=C2)F)C(=O)NC3=CC4=C(C=CC=N4)C=C3,5.0,Cc1nc(-c2ccc(F)cc2)ccc1C(=O)Nc1ccc2cccnc2c1
33896,CHEMBL1255837,SPXACGZWWVIDGR-SPZWACKZSA-N,DIHYDROERGOCRISTINE MESYLATE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,5.522878745280337,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O
33903,CHEMBL2158227,SPZDCHRXPBSIHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)CCN1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4,5.0,CS(=O)(=O)CCN1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1
33909,CHEMBL2441847,SQBQWLJQRMPESE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CCN(CC)C(=O)CCN1CC2=NC(=C(C(=C2C1=O)C3=C(C=C(C=C3)Cl)Cl)CN)C,5.080921907623926,CCN(CC)C(=O)CCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
33910,CHEMBL87792,SQCCCUOOWHMPBF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCN(C)C)CC4=CC=C(C=C4)C5=CC=C(C=C5)C(F)(F)F,4.522878745280337,CN(C)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
33915,CHEMBL3326577,SQDHZRJWYDAANI-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CCC1(C[C@H](C2=C(O1)C=CC(=C2)F)NC(=O)NC3=CC=CC4=C3C=CN=C4)CC,5.552841968657781,CCC1(CC)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2cc(F)ccc2O1
33926,CHEMBL1669411,SQGLQUFJVYRVPS-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCC(F)(F)F,5.301029995663981,C[C@H](C1=C(CCN(C)CCC(F)(F)F)Cc2ccccc21)c1cnccn1
33931,CHEMBL2313764,SQIBVAVXYSKQBW-FZFRBNDOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23182090.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CO[C@@H]1COCC[C@@H]1N[C@@H]2C[C@H]3CCC[C@]3(C2)C(=O)N4CCC5=C(C4)C=C(C=N5)C(F)(F)F,5.1249387366083,CO[C@@H]1COCC[C@@H]1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1
33936,CHEMBL1079140,SQMRZYILEJFWLA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCC1(CCCN(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3,5.0,CN(C)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
33943,CHEMBL3586436,SQOCEMCKYDVLMM-IYBDPMFKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26087021.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NC(=N1)N2C[C@@H]3CN(C[C@@H]3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C,5.0,Cc1cc(C)nc(N2C[C@H]3CN(C(=O)c4c(F)cccc4-n4nccn4)C[C@H]3C2)n1
33950,CHEMBL3702823,SQSHFUZAFRGGRD-JSXFGMRASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCOC(=O)NC(=S)NC1=NC=C(C=C1)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=S)NC(=O)OCC)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
33951,CHEMBL3702766,SQSKPCJVGCVCQY-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6870.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7CCN(CC7)C(=O)CCO,5.16304326294045,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
33981,CHEMBL605833,SREGRCFSXVBPIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19700331.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C2C=C(C=CC2=C1)CCOC3=C(C=CC(=C3)CN4C=CC=N4)CCC(=O)O,4.522878745280337,O=C(O)CCc1ccc(Cn2cccn2)cc1OCCc1ccc2ccccc2c1
33984,CHEMBL2347991,SRGSOSLNVCMQMS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)F)CCC(CO)O,4.301029995663981,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCC(O)CO)c4cc(F)ccc34)nc12
33988,CHEMBL1929387,SRIIFFBJIKZICS-RSAXXLAASA-N,ANAGLIPTIN HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22019046.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N.Cl,5.0,Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1
34012,CHEMBL1091069,SROGIGROUAOOFN-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)OC,5.0,COc1cccnc1[C@H](C)c1c(CCN(C)C)sc2ccccc12
34013,CHEMBL1098560,SRPFDFNVILUDAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,C1OC2=C(O1)C=C(C=C2)C3=CC(=CC(=C3)OCCCCCCC4=C(C(=CC=C4)OCCCC(=O)O)CCC(=O)O)C5=CSC=C5,5.1249387366083,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccsc3)cc(-c3ccc4c(c3)OCO4)c2)c1CCC(=O)O
34016,CHEMBL2105423,SRRHGTUDJFMQIV-UHFFFAOYSA-N,SABIPORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=CN3,5.154901959985743,NC(N)=NC(=O)c1ccc(N2CCN(C(=O)c3ccc[nH]3)CC2)c(C(F)(F)F)c1
34049,CHEMBL567582,SSCCINNDXPYQQI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC4=C(C=C3)OC=CCO4,5.301029995663981,CC1(CC(=O)NCc2ccc3c(c2)OCC=CO3)CC2(CCCCC2)OO1
34050,CHEMBL240364,SSCJBDJJWLFQLZ-ZBLYBZFDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@H](C)CC3=CC=C(C=C3)Cl)[C@H](C(C)C)NC(=O)CCN,5.0,Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](NC(=O)CCN)C(C)C)c1
34059,CHEMBL3422012,SSHIUOSPXKCYNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,CC1=NC(=CS1)C2=NN=C3N2CCN(C3)C(=O)C4=CC=C(C=C4)C5=CC=CS5,4.522878745280337,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3)cs1
34066,CHEMBL594755,SSMMEOSYEUOMIT-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OC[C@H](CC5=CC=CC=C5)N,5.494850021680094,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2ccccc2)cc1-c1cnc2n[nH]c(C)c2n1
34080,CHEMBL3355474,SSPHMGCXSJLCMP-ZIAGYGMSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589928.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H]1COCCN1C2=C3C(=CC(=N2)C4=CN=CC5=C4C=CN5)N(C=N3)[C@@H](C)S(=O)(=O)C,4.3979400086720375,C[C@@H]1COCCN1c1nc(-c2cncc3[nH]ccc23)cc2c1ncn2[C@@H](C)S(C)(=O)=O
34097,CHEMBL503705,SSTWFLYMZFXJLL-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,69000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)N(C)CCCC(=O)O)C4=C(C(=CC=C4)OC)F,4.161150909262744,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@@H](c3ccccc3)N(C)CCCC(=O)O)c2=O)c1F
34103,CHEMBL2041191,SSVPMKGPRCBPJY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CN=C4)C5=CN=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1
34110,CHEMBL257150,STALPJWOKWGXGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CC2C(CCCN2C(=O)CN3C4=C(C=CC(=C4)Cl)OC3=O)C5=CC=CC=C5,5.6777807052660805,O=C(Cn1c(=O)oc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1
34115,CHEMBL1808631,STCUWCYDLVMFEY-GQCTYLIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=C(CN1S(=O)(=O)C3=CC=CS3)C=C(C=C2)/C=C/C(=O)NO,4.301029995663981,O=C(/C=C/c1ccc2c(c1)CN(S(=O)(=O)c1cccs1)C2)NO
34120,CHEMBL2272118,STEPQTYSZVCJPV-UHFFFAOYSA-N,METAZACHLOR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,CC1=C(C(=CC=C1)C)N(CN2C=CC=N2)C(=O)CCl,5.0,Cc1cccc(C)c1N(Cn1cccn1)C(=O)CCl
34121,CHEMBL2272118,STEPQTYSZVCJPV-UHFFFAOYSA-N,METAZACHLOR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CC1=C(C(=CC=C1)C)N(CN2C=CC=N2)C(=O)CCl,5.0,Cc1cccc(C)c1N(Cn1cccn1)C(=O)CCl
34123,CHEMBL1172847,STFAHYUUOLTNDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,464.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,CC(=C(C1=CC=C(C=C1)C2=CC(=C(C=C2)O)O)C3=CC=NC=C3)C,6.333482019445119,CC(C)=C(c1ccncc1)c1ccc(-c2ccc(O)c(O)c2)cc1
34125,CHEMBL569862,STFVOGWUKNAWOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19831396.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC(=C1)C2=CSC(=C2)C3=CC(=CC=C3)O)O,5.823908740944319,Cc1cc(-c2csc(-c3cccc(O)c3)c2)ccc1O
34130,CHEMBL193306,STINDBVFOPRZHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15943473.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against human cytochrome P450 3A4,"Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.",J. Med. Chem.,PUBLICATION,,CC1=CN=C(O1)C2=CN3C(=C2C(C)C)C(=NC=N3)NC4=C(C=C(C(=C4)C(=O)NOC)F)F,5.292429823902063,CONC(=O)c1cc(Nc2ncnn3cc(-c4ncc(C)o4)c(C(C)C)c23)c(F)cc1F
34134,CHEMBL560579,STJLVHWMYQXCPB-UHFFFAOYSA-N,PROPICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,1039.92,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CCCC1COC(O1)(CN2C=NC=N2)C3=C(C=C(C=C3)Cl)Cl,5.983000069254019,CCCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1
34140,CHEMBL2436627,STNAHDQLZLCSLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2CCC3=CC=CC=C3C2)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,4.522878745280337,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCc5ccccc5C4)CC3)CC2)ccn1
34157,CHEMBL2396661,STUWGJZDJHPWGZ-LBPRGKRZSA-N,ALPELISIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,5.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1
34160,CHEMBL1910292,STXFMRGIISYYJC-IRPSRAIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)[C@H]3CNCC[C@@]3(C4=CC(=C(C=C4)F)F)O,6.045757490560675,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)C2CC2)cc(OCCOC)c1
34161,CHEMBL1910294,STXFMRGIISYYJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21641209.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)C3CNCCC3(C4=CC(=C(C=C4)F)F)O,6.045757490560675,COCCCc1cc(CN(C(=O)C2CNCCC2(O)c2ccc(F)c(F)c2)C2CC2)cc(OCCOC)c1
34163,CHEMBL2070146,STZWTQUFIPPPOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=C3F)C4=CC=CC=C4,5.180456064458132,CCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)c3F)[nH]c2c1
34167,CHEMBL1503,SUBDBMMJDZJVOS-UHFFFAOYSA-N,OMEPRAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,77983.01,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,4.108000005860498,COc1ccc2nc([S+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2c1
34182,CHEMBL2387502,SUERHDHTNGFCPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)[N+](=O)[O-],4.522878745280337,O=c1[nH]c2cc(-c3ccccc3)ccc2c2nc(-c3c(Cl)cccc3[N+](=O)[O-])[nH]c12
34185,CHEMBL1272152,SUGZFIXSMJJZIS-FYYLOGMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)[C@H]3COC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)CC5CC5,7.522878745280337,CC(C)(CO)N1CCN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
34203,CHEMBL559061,SULKMHQPINMVTR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,5.301029995663981,CN(C)CCN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
34205,CHEMBL2018903,SUMJDTVJSTZJFC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CCCCSC1=NC2=C(N1)C=C(C=C2)OC,4.301029995663981,CCCCSc1nc2ccc(OC)cc2[nH]1
34215,CHEMBL3313972,SUODWKMMJQIJQB-GZOQVGHDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24422519.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)C[C@@H](C4=CC=CC=C4)O,7.167491087293763,C[C@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@H](O)c2ccccc2)S1(=O)=O
34216,CHEMBL1209696,SUODWKMMJQIJQB-XABNSEFBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)C[C@@H](C4=CC=CC=C4)O,7.167491087293763,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@H](O)c2ccccc2)S1(=O)=O
34217,CHEMBL1209696,SUODWKMMJQIJQB-XABNSEFBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,1920.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)C[C@@H](C4=CC=CC=C4)O,5.716698771296451,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@H](O)c2ccccc2)S1(=O)=O
34218,CHEMBL1209695,SUODWKMMJQIJQB-XDJLXXALSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)C[C@H](C4=CC=CC=C4)O,7.0,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@@H](O)c2ccccc2)S1(=O)=O
34219,CHEMBL1209695,SUODWKMMJQIJQB-XDJLXXALSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)C[C@H](C4=CC=CC=C4)O,6.045757490560675,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@@H](O)c2ccccc2)S1(=O)=O
34222,CHEMBL390526,SUQCZNPRHQYYQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC(=C3)F)F,4.0,O=C(NCC1CCOCC1)c1cnc(Nc2cc(F)cc(F)c2)nc1C(F)(F)F
34242,CHEMBL495786,SUVHLBHXIPQGAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC(=O)C=C4,4.795880017344075,Cc1cccc(C)c1CNc1cc(-n2ccc(=O)cc2)cn2c(C)c(C)nc12
34243,CHEMBL495786,SUVHLBHXIPQGAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC(=O)C=C4,4.552841968657781,Cc1cccc(C)c1CNc1cc(-n2ccc(=O)cc2)cn2c(C)c(C)nc12
34244,CHEMBL227356,SUVWKEOODLERME-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,790.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC3=CC(=C(C=C3C(=O)N2CC4=CC=CC=C4C#N)F)N5CCOCC5)N,6.102372908709558,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cc(N3CCOCC3)c(F)cc2c1=O
34253,CHEMBL568444,SUYWBFYEHQMEKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)[N+](=O)[O-],5.301029995663981,CC1(CC(=O)NCc2ccc([N+](=O)[O-])cc2)CC2(CCCCC2)OO1
34255,CHEMBL1223236,SVBRTHGICYDAAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)N2CCCN(CC2)C(C3=CC=C(C=C3)CN4C=NC=N4)C5=NN=NN5CC6=CC=CC=C6,4.920818753952375,c1ccc(Cn2nnnc2C(c2ccc(Cn3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1
34281,CHEMBL460997,SVKIVWVOFVHFNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,19500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)C5CCN(CC5)CCOC,4.709965388637482,COCCN1CCC(c2cc(C)c3nc(-c4c(NCCn5cc(Cl)cn5)cc[nH]c4=O)[nH]c3c2)CC1
34288,CHEMBL1766175,SVOSCUAPCVQCPN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=C(C=C1)C2=CC=C(C=C2)Cl)(C3=CN=CN3)O,5.119186407719209,CC(C)C(O)(c1ccc(-c2ccc(Cl)cc2)cc1)c1cnc[nH]1
34298,CHEMBL1269697,SVSUEWKNQNMUNQ-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,5900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=NC(=C4)CCCOC)Cl)C5CC5)Cl,5.229147988357856,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c(Cl)cn1
34308,CHEMBL2448712,SVVUFNZMTNZJNC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4500.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1=CC=C(C=C1)C2=NC=C(S2)C(=O)NC3=C(C=CC(=C3)C#N)N4C=CN=C4,5.346787486224656,N#Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1
34309,CHEMBL3702726,SVVWQNVWSAFJNO-LQJZCPKCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CC(C7)O,4.73754891026957,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(O)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
34313,CHEMBL1909987,SVXNNKHVIMXUBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,340.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(CC2=N1)CC3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,6.468521082957745,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2
34314,CHEMBL1909987,SVXNNKHVIMXUBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,770.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(CC2=N1)CC3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,6.113509274827518,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2
34316,CHEMBL438699,SVZZYOGCUPHRBU-ZDTVFLJBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CC5CCC(C4)N5C,5.327902142064283,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC4CCC(C3)N4C)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
34317,CHEMBL552338,SWADTMSKMJUFBO-ZDUSSCGKSA-N,PF-3409409,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19616432.0,IC50,=,12200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)CN([C@H]2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F,4.913640169325252,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1
34318,CHEMBL552338,SWADTMSKMJUFBO-ZDUSSCGKSA-N,PF-3409409,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19616432.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using felodipine as substrate,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)CN([C@H]2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F,4.657577319177793,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1
34319,CHEMBL552338,SWADTMSKMJUFBO-ZDUSSCGKSA-N,PF-3409409,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19616432.0,IC50,=,31200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C1)CN([C@H]2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F,4.505845405981558,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1
34320,CHEMBL197202,SWCLDFSCLHXNAM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,74000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,CC(C1=CC(=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)O)F)C(=O)O,4.130768280269024,CC(C(=O)O)c1ccc(-c2ccc(-c3ccc(O)cc3)cc2)c(F)c1
34321,CHEMBL465289,SWCSHYFRURDRBU-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CCC1=CC=CC=C1)C(=O)C2=CC=CC=C2C3=CC=C(C=C3)CN4C[C@H](N[C@H](C4)C)C,6.045757490560675,CCN(CCc1ccccc1)C(=O)c1ccccc1-c1ccc(CN2C[C@H](C)N[C@H](C)C2)cc1
34322,CHEMBL465289,SWCSHYFRURDRBU-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CCC1=CC=CC=C1)C(=O)C2=CC=CC=C2C3=CC=C(C=C3)CN4C[C@H](N[C@H](C4)C)C,5.823908740944319,CCN(CCc1ccccc1)C(=O)c1ccccc1-c1ccc(CN2C[C@H](C)N[C@H](C)C2)cc1
34324,CHEMBL1935447,SWDWBOARDFBZAD-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2[C@H]4CNCCS4,5.236572006437063,COc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1
34325,CHEMBL1935448,SWDWBOARDFBZAD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,15800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,4.801342913045577,COc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
34327,CHEMBL496189,SWEAYHBSAXRXDZ-MOPGFXCFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC12CC(=O)C3=CC=CC=C3O2)C(=O)N[C@H]4C[C@@H]4C5=CC=CC=C5,5.0,O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2ccccc21
34331,CHEMBL3142316,SWEQJWJHTNSSDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21923116.0,IC50,=,74800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of N-(3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a Selective Inhibitor of Human Neuronal Nitric Oxide Synthase (nNOS) for the Treatment of Pain.",J. Med. Chem.,PUBLICATION,,CN1CCC(=CC1)C2=CNC3=C2C=CC(=C3)N=C(C4=CC=CS4)N.Cl.Cl,4.126098402135539,CN1CC=C(c2c[nH]c3cc(N=C(N)c4cccs4)ccc23)CC1
34332,CHEMBL3142316,SWEQJWJHTNSSDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21923116.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BQ as substrate,"Discovery of N-(3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a Selective Inhibitor of Human Neuronal Nitric Oxide Synthase (nNOS) for the Treatment of Pain.",J. Med. Chem.,PUBLICATION,,CN1CCC(=CC1)C2=CNC3=C2C=CC(=C3)N=C(C4=CC=CS4)N.Cl.Cl,4.0,CN1CC=C(c2c[nH]c3cc(N=C(N)c4cccs4)ccc23)CC1
34335,CHEMBL1935446,SWFSQSZMVIJILA-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,15600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CS[C@H](CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,4.806875401645538,Fc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1
34336,CHEMBL1935445,SWFSQSZMVIJILA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,10600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CSC(CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,4.97469413473523,Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
34337,CHEMBL1935445,SWFSQSZMVIJILA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,16700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CSC(CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,4.777283528852417,Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
34361,CHEMBL276081,SWPBTKCAQDJKSO-KRXYOAFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CN(C=C2)C3=CC(=CC=C3)Cl)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CN=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,7.096910013008056,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3cccc(Cl)c3)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
34362,CHEMBL2158302,SWPGDCRPXQMSIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)NCCO)NC(=O)C4=NC=C(N4)C#N,5.1938200260161125,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)NCCO)CC3)cc2C2=CCCCC2)[nH]1
34363,CHEMBL1813114,SWQLTIWVDZKVMH-SWYRRKHMSA-N,MK-5710,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21737263.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@]12CN(CCN1C(=O)N(C2=O)[C@H]3C[C@@H]3C4=CC=CC=C4)C(=O)NC5=CC=NN5C6=CC=CC=C6,4.3979400086720375,C[C@@]12CN(C(=O)Nc3ccnn3-c3ccccc3)CCN1C(=O)N([C@H]1C[C@@H]1c1ccccc1)C2=O
34373,CHEMBL442086,SWSPTEWZUSYXHL-FQEVSTJZSA-N,SR-902,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)[C@@H]4CC5=CC=CC=C5CN4,5.0,O=C([C@@H]1Cc2ccccc2CN1)N1CCN(c2ccc3[nH]ncc3c2)CC1
34383,CHEMBL3427277,SWWRPROUTDGFFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25941547.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)CCC1=C(N=C2N1C=CC(=C2)Cl)CN3C4=C(C=CN=C4)N(C3=O)C5CC5,4.301029995663981,CCS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12
34394,CHEMBL3353342,SXAOLYUXAFWLCI-UXFRTJKQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,C1[C@H]([C@@]12C3=CC=CC=C3NC2=O)C4=CC5=C(C=C4)C(=NN5)/C=C/C6=CN=CC=C6,6.0,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3cccnc3)n[nH]c2c1
34403,CHEMBL1270362,SXBWNENFIQGMLK-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20833041.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of NADPH,Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N[C@@H](CC1=CC(=CC(=C1)F)F)[C@@H](CNC2(CC2)C3=CC(=CC=C3)C(C)(C)C(F)F)O,8.397940008672037,CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1
34404,CHEMBL1270362,SXBWNENFIQGMLK-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20833041.0,IC50,=,46.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N[C@@H](CC1=CC(=CC(=C1)F)F)[C@@H](CNC2(CC2)C3=CC(=CC=C3)C(C)(C)C(F)F)O,7.337242168318426,CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1
34405,CHEMBL1270362,SXBWNENFIQGMLK-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20833041.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 by competitive inhibition assay,Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N[C@@H](CC1=CC(=CC(=C1)F)F)[C@@H](CNC2(CC2)C3=CC(=CC=C3)C(C)(C)C(F)F)O,6.958607314841775,CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1
34415,CHEMBL394993,SXIQBPDOSGYNFP-UHFFFAOYSA-N,SR-890,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Cl)O,5.522878745280337,O=C(C(O)c1ccc(Cl)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
34431,CHEMBL3673959,SXMVDOWLRVXGBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320628,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=NC=C(C=C1)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl,5.0,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
34432,CHEMBL3673959,SXMVDOWLRVXGBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320672,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=NC=C(C=C1)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl,5.0,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
34441,CHEMBL240954,SXOZSDJHGMAEGZ-IGKKHSBFSA-N,SL-0101,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,20600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)OC(=O)C)OC(=O)C,4.686132779630847,CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H]1OC(C)=O
34443,CHEMBL1951339,SXQGGECXWPMBCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C(C)C)C(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,7.221848749616356,CC(C)N(C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1)C(C)C
34445,CHEMBL498026,SXRFIFLANPJWQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=N4,5.42021640338319,Cc1ccccc1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12
34446,CHEMBL498026,SXRFIFLANPJWQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=N4,4.769551078621726,Cc1ccccc1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12
34448,CHEMBL2425160,SXSHRCRPTWSWQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CN=C(C=C4)OC,5.0,COc1ccc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)cn1
34452,CHEMBL2163827,SXVPPLOMCQSJMY-CRHVVPOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,C1C[C@H]2CC(C[C@@H]1N2C(=O)[C@H](CC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4(CC4)C5=CC=C(C=C5)OC(F)(F)F)N,5.619788758288394,NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(OC(F)(F)F)cc2)CC1
34458,CHEMBL1910125,SXXTUZFVBVFYTQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)NC3=CC=NN3C)C4=C(C=C(C=C4)Cl)Cl)CN,4.769551078621726,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)Nc1ccnn1C)C2=O
34465,CHEMBL583867,SXYMVJZFEUONDV-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=C2C=CN=C3)C(=O)C4=CC=CC=C4,4.3979400086720375,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cnccc12
34466,CHEMBL583867,SXYMVJZFEUONDV-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=C2C=CN=C3)C(=O)C4=CC=CC=C4,4.3979400086720375,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cnccc12
34471,CHEMBL509903,SXZFQYPWEANJGQ-SKCUWOTOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20731374.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Direct renin inhibitors as a new therapy for hypertension.,J. Med. Chem.,PUBLICATION,,C1CC1N(CC2=C(C(=CC=C2)Cl)Cl)C(=O)C3=C(C[C@@H]4CNC[C@H]3N4)C5=CC=C(C=C5)CCCOC6=C(C=CC(=C6Cl)F)F,5.0,O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)C[C@@H]2CNC[C@H]1N2)N(Cc1cccc(Cl)c1Cl)C1CC1
34484,CHEMBL478037,SYBPXZBWAAAJAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C(C2=NC=CS2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1nccs1
34486,CHEMBL499307,SYBXHLIANYBTCO-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,670.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)COC(=O)CN)N,6.173925197299173,NCC(=O)OCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1
34489,CHEMBL3236654,SYEJHQQRLZNDAL-GXAGMUTGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC5=NC=C(S5)C(=O)CO,6.096910013008056,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ncc(C(=O)CO)s2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
34490,CHEMBL153741,SYEUUCQERNUTBQ-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698201.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(S1)C=CC(=C2)OC[C@@H](CN3CCN(CC3)CC(=O)NC4=CC=C(C=C4)C5=CC=CC=C5)O,5.102372908709558,Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4ccc(-c5ccccc5)cc4)CC3)ccc2s1
34498,CHEMBL255509,SYNTYRNKHJSTLL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CC2C(CCCN2C(=O)CN3C(=O)COC4=CC(=C(C=C43)Cl)Cl)C5=CC=CC=C5,5.7447274948966935,O=C1COc2cc(Cl)c(Cl)cc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1
34512,CHEMBL3673940,SYSOKYYRVIKDBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320651,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CN=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)C)F,5.301029995663981,Cc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)nc1
34513,CHEMBL3673940,SYSOKYYRVIKDBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320695,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CN=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)C)F,5.0,Cc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)nc1
34524,CHEMBL484029,SYVLRDXITUYNAK-USACIQFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15568772.0,IC50,=,120000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa.",J. Nat. Prod.,PUBLICATION,,CC(C)CC(=O)C1=C(C=C(C=C1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O,3.9208187539523753,CC(C)CC(=O)c1c(O)cc(O)cc1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
34540,CHEMBL3608741,SZEYAOKHLPDWFZ-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC1=NSC(=N1)C2=NN=C3N2CCN([C@@H]3CCO)C(=O)C4=CC=C(C=C4)F,4.0,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3CCO)n1
34551,CHEMBL1951454,SZKGHXMOYDKXPX-IRXDYDNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264487.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using midazolam as substrate by LC-MS/MS analysis,A ß-tryptase inhibitor with a tropanylamide scaffold to improve in vitro stability and to lower hERG channel binding affinity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCOC1=C(C(=C(S1)C(=O)N2[C@H]3CC[C@H]2CC(C3)C4=C(C=CC(=C4)CN)F)C)Br,5.275724130399211,CCCOc1sc(C(=O)N2[C@H]3CC[C@H]2CC(c2cc(CN)ccc2F)C3)c(C)c1Br
34552,CHEMBL1214396,SZKJWXCCFDRJTF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,CC1=C(C=NC=C1)C2=CC3=C(CC(C3)NS(=O)(=O)C(C)C)C=C2,5.045757490560675,Cc1ccncc1-c1ccc2c(c1)CC(NS(=O)(=O)C(C)C)C2
34554,CHEMBL1669405,SZKXEXNSYILRKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3,5.0,CCN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1
34564,CHEMBL1950090,SZMWOWPIZBQHLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CN4C)O)Cl,6.522878745280337,Cc1cc(Cl)cc2c(C(O)c3cncn3C)c3c(C)[nH]nc3nc12
34565,CHEMBL1950090,SZMWOWPIZBQHLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CN4C)O)Cl,6.096910013008056,Cc1cc(Cl)cc2c(C(O)c3cncn3C)c3c(C)[nH]nc3nc12
34572,CHEMBL1076245,SZPJAZAOTADHKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCCC4=O)C(=C(N3)C)C,6.0,Cc1cccc(C)c1CNc1nc(N2CCCC2=O)cc2c(C)c(C)[nH]c12
34573,CHEMBL1076245,SZPJAZAOTADHKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCCC4=O)C(=C(N3)C)C,5.7447274948966935,Cc1cccc(C)c1CNc1nc(N2CCCC2=O)cc2c(C)c(C)[nH]c12
34574,CHEMBL3702783,SZPKRLIHOZBLQB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5350.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCN(CC)CCN(CCN(CC)CC)C1=NC=C(C=C1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.2716462179787715,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(CCN(CC)CC)CCN(CC)CC)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
34576,CHEMBL152968,SZRMSHBRXJWBFG-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698201.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(S1)C=CC(=C2)OC[C@@H](CN3CCN(CC3)CC(=O)NC4=CC=CC(=C4)C5=CC=CC=C5)O,4.431798275933005,Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4cccc(-c5ccccc5)c4)CC3)ccc2s1
34584,CHEMBL2415095,SZSKTZXFLXPROO-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23890837.0,IC50,=,6940.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design and synthesis of bicyclic heterocycles as potent ¿-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)F)[C@@H]2CCCN3C2=NC(=N3)C4=CC(=C(C=C4)N5C=C(N=C5)C)OC,5.158640529545145,COc1cc(-c2nc3n(n2)CCC[C@H]3c2ccc(F)cc2C)ccc1-n1cnc(C)c1
34590,CHEMBL2413881,SZTUUDCVQNNFRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23896611.0,IC50,=,6.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 20 mins by LCMS analysis,"Tetrazole-based deoxyamodiaquines: Synthesis, ADME/PK profiling and pharmacological evaluation as potential antimalarial agents.",Bioorg. Med. Chem.,PUBLICATION,,CCN(CC)C(C1=CC(=CC=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)C4=NN=NN4C(C)(C)C,8.221848749616356,CCN(CC)C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)c1nnnn1C(C)(C)C
34606,CHEMBL2178254,TTWJUJRTJUODCG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,CN1C=C(C(=N1)C2=CC(=CC=C2)Cl)NC(=O)C3=C4N=C(C=CN4N=C3)N,5.0,Cn1cc(NC(=O)c2cnn3ccc(N)nc23)c(-c2cccc(Cl)c2)n1
34627,CHEMBL2163828,TUDINUHHPSENND-VYTWWXLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,C1C[C@H]2CC(C[C@@H]1N2C(=O)[C@H](CC3=CC=C(C=C3)Br)NC(=O)C4(CC4)C5=CC=C(C=C5)OC(F)(F)F)N,5.5376020021010435,NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(OC(F)(F)F)cc2)CC1
34637,CHEMBL379834,TUFFUEHRXNGQLP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,COC1=CC=CC=C1OC2=CC=CC(=C2)CN3CCC(CC3)(C(=O)O)NC(=O)C4(CCNCC4)C5=CC=CC=C5,5.0,COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccccc4)CCNCC3)(C(=O)O)CC2)c1
34639,CHEMBL3291118,TUGLCXDNPZXHHN-ZMRSBPIZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1250.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CC=CC=N4)C,5.903089986991944,C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
34640,CHEMBL3291118,TUGLCXDNPZXHHN-ZMRSBPIZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1360.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CC=CC=N4)C,5.866461091629782,C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
34641,CHEMBL2181621,TUHQBDDCFFEKIR-LICLKQGHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,10700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=NC=C(C=C5)Cl)C6CCCC6,4.97061622231479,Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21
34647,CHEMBL246970,TUJUZVJICDSNLY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BFC substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CCC1CN)CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,6.154901959985743,NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1
34648,CHEMBL246970,TUJUZVJICDSNLY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BQ substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CCC1CN)CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,5.853871964321762,NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1
34651,CHEMBL2057514,TUMOCTIPKNLFSX-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,84.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,7.075720713938118,CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
34655,CHEMBL410414,TUOSYWCFRFNJBS-BHVANESWSA-N,DIRLOTAPIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276061.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"In vitro and in vivo profile of 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C2=C(C=C(C=C2)NC(=O)C3=CC=CC=C3C4=CC=C(C=C4)C(F)(F)F)C=C1C(=O)N[C@@H](C5=CC=CC=C5)C(=O)N(C)CC6=CC=CC=C6,4.522878745280337,CN(Cc1ccccc1)C(=O)[C@@H](NC(=O)c1cc2cc(NC(=O)c3ccccc3-c3ccc(C(F)(F)F)cc3)ccc2n1C)c1ccccc1
34657,CHEMBL476302,TUOXXRMLFZBSTB-UHFFFAOYSA-N,GSK8062,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621523.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled human liver microsome using atrovastatin substrate,Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)COC3=CC=C(C=C3)C4=CC5=C(C=C4)C(=CC=C5)C(=O)O,5.337242168318426,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1
34658,CHEMBL476302,TUOXXRMLFZBSTB-UHFFFAOYSA-N,GSK8062,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621523.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled human liver microsome using midazolam substrate,Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)COC3=CC=C(C=C3)C4=CC5=C(C=C4)C(=CC=C5)C(=O)O,5.142667503568732,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1
34659,CHEMBL476302,TUOXXRMLFZBSTB-UHFFFAOYSA-N,GSK8062,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621523.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled human liver microsome using nifedipine substrate,Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)COC3=CC=C(C=C3)C4=CC5=C(C=C4)C(=CC=C5)C(=O)O,5.055517327849831,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1
34664,CHEMBL403998,TUQYNUMCKKHFKS-SIRJMXRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CC5CCC(C4)N5CCO,5.657577319177793,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC4CCC(C3)N4CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
34694,CHEMBL205808,TVFMBJYYWFCDRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1CCN(CC1)CC2=CC(=CC=C2)OC3=CC=CC=C3,5.0,CCOC(=O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1
34706,CHEMBL2448730,TVJSHFZBWQHJFF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1=CC=C2C(=C1)N=C(S2)C3=CC(=CC(=C3)F)N(CC4=CN=CC=C4)C(=O)CN.Cl,6.0,NCC(=O)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1
34707,CHEMBL2448730,TVJSHFZBWQHJFF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1010.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1=CC=C2C(=C1)N=C(S2)C3=CC(=CC(=C3)F)N(CC4=CN=CC=C4)C(=O)CN.Cl,5.995678626217358,NCC(=O)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1
34710,CHEMBL558663,TVKCCIBAUDHHBL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)OC,5.301029995663981,COc1ccc(Cn2c(N3CCC(N(C)CC4CCOCC4)CC3)nc3ccccc32)cc1
34715,CHEMBL1269686,TVMDRXNOEWPGJS-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC(=O)CC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,5.6777807052660805,CCNC(=O)Cc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
34716,CHEMBL1269686,TVMDRXNOEWPGJS-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC(=O)CC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,5.1487416512809245,CCNC(=O)Cc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
34724,CHEMBL1078715,TVNCLEMLTQVHDY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=C(C=C3)C(F)(F)F,5.0,O=C(O)CCC1(c2ccc(C(F)(F)F)cc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
34746,CHEMBL2418954,TVUPSIBSWDXJGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23820386.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NC1=CN2C=C(C=CC2=N1)C3=CC(=C(N=C3)N)C(F)(F)F,4.6020599913279625,CC(=O)Nc1cn2cc(-c3cnc(N)c(C(F)(F)F)c3)ccc2n1
34754,CHEMBL149750,TVVGACWXAKCONN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,70600.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CC=NN2,4.151195298948196,CCCCOc1ccc(-c2ccn[nH]2)cc1
34755,CHEMBL456390,TVVPAZUMRVMIFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,<,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,C1CC(=O)NC2=C1C=C(C=C2)C3=CN=CC4=CC=CC=C43,4.301029995663981,O=C1CCc2cc(-c3cncc4ccccc34)ccc2N1
34765,CHEMBL3125394,TVZPBIBWLNLUKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N)C=CC=C2Cl,4.3979400086720375,CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O
34772,CHEMBL2070160,TWDJYRDXTHJMHU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)N2C=C(C=CC2=O)C3=NC4=C(N3)C=C(C=C4)S(=O)(=O)C(F)(F)F,5.292429823902063,O=c1ccc(-c2nc3ccc(S(=O)(=O)C(F)(F)F)cc3[nH]2)cn1-c1ccccc1
34778,CHEMBL3137475,TWGGJXLRMIHURH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CN1C(=CC(=N1)C2CC2)N3CCC(CC3)N(C4=CC=C(C=C4)C(F)(F)F)C5=CN=CC=C5,4.698970004336019,Cn1nc(C2CC2)cc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
34783,CHEMBL2070140,TWKAGABGOWTMNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=C3)C4=CC=CC=C4,5.221848749616356,CCCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)c3)[nH]c2c1
34792,CHEMBL486130,TWPKWYDANODGCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CN=C3)O)C,4.7447274948966935,CC(=O)Nc1cc(-c2cncc(O)c2)nc(-n2nc(C)cc2C)n1
34793,CHEMBL3422102,TWPZRFZCHZSVKG-XQOXSZQVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,330.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1CCC(C1)[C@H](C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6[C@@H]7CC(C[C@@H]6COC7)O,6.481486060122113,O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5COC[C@H]4CC(O)C5)cc3)c2c1
34795,CHEMBL556849,TWQRVSJZLRCHNE-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C1)C3=NC=CN=C3N2CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.522878745280337,CN([C@@H]1CCc2c(c3nccnc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1
34796,CHEMBL225411,TWQYWUXBZHPIIV-UHFFFAOYSA-N,GW842166X,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C=C(C=C3)Cl)Cl,4.0,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)nc1C(F)(F)F
34810,CHEMBL3706613,TWZWSIXDZUIEIJ-BEILRLPOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852969.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=NC=C(O1)C2=CN=CC=C2)N3CCN([C@@H](C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,6.958607314841775,CC(C)(c1ncc(-c2cccnc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1
34811,CHEMBL191053,TXAXHAIICLKOKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,CCC1=NC(=C(N1)C2=CC=C(C=C2)F)C3=CC4=C(C=C3)N=C(N4S(=O)(=O)C(C)C)N.CS(=O)(=O)O,5.356547323513812,CCc1nc(-c2ccc3nc(N)n(S(=O)(=O)C(C)C)c3c2)c(-c2ccc(F)cc2)[nH]1
34819,CHEMBL2069843,TXDCCDZUBCMPHL-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ß-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)S(=O)(=O)N,6.0,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(S(N)(=O)=O)cc2)CC1)Cc1cc(F)c(F)cc1F
34821,CHEMBL497828,TXDIMDCQMFKIQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CC2)CCN(CC3)C(=O)C4=CC=C(C=C4)C(F)(F)F,5.0,CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)c3ccc(C(F)(F)F)cc3)CC1)O2
34822,CHEMBL380492,TXEFMFGXKKPZEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)O)N1CCC(CC1)(C2=CC=CC=C2)C(=O)NC3CCN(CC3)CC4=CC(=CC=C4)OC5=CC=CC=C5Cl,5.0,CC(C)(C(=O)O)N1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1
34824,CHEMBL2177736,TXGKRVFSSHPBAJ-JKSUJKDBSA-N,PRT-2607,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,C1CC[C@H]([C@H](C1)N)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)N4N=CC=N4)C(=O)N,4.6020599913279625,NC(=O)c1cnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc(-n2nccn2)c1
34827,CHEMBL3664668,TXIQSUUSOLWWTP-WRONEBCDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,48000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CCN1C=C(C=CC1=O)C2=CC=C(C=C2)[C@H](C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=C(C=C4)F,4.318758762624412,CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccc(F)cc4)OC3=O)cc2)ccc1=O
34844,CHEMBL3664717,TXNPQZGSVXLGGP-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
34857,CHEMBL2437424,TXRQOKKFUWBRKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1C2=C(C=CC(=C2)F)N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC(=NC=C5)N,4.522878745280337,CC(C)Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccnc(N)c4)CC3)CC2)c2ccc(F)cc21
34883,CHEMBL2387312,TXYHNJMNQMYNTO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23591110.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1CCCN1C2CCN(C2)C3=CC(=C(C=C3)NC(=O)NC4=CC(=CC(=C4)Cl)Cl)C,4.886056647693163,Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)Nc1cc(Cl)cc(Cl)c1
34885,CHEMBL2163832,TYAVMDLBFYORIC-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,1030.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C(=O)[C@H](CC2=C(C=C(C=C2)Cl)Cl)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,5.987162775294828,CN1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
34889,CHEMBL1951608,TYCXZEWCOHIARO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=NC=CC5=CC=CC=C54)C)C,5.522878745280337,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C
34895,CHEMBL1761521,TYDNACGHSINKSF-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCCNS(=O)(=O)C)C5CC5)Cl,5.795880017344075,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCNS(C)(=O)=O)c1
34896,CHEMBL1761521,TYDNACGHSINKSF-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,27600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCCNS(=O)(=O)C)C5CC5)Cl,4.559090917934783,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCNS(C)(=O)=O)c1
34899,CHEMBL1829766,TYERBRGKZKGLIN-UZTOHYMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CC[C@](OC3=O)(CCCO)C4=CC(=CC=C4)F,5.154901959985743,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2cccc(F)c2)OC1=O
34902,CHEMBL485612,TYHGSJHFMYWTNJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,CC1=C(C(N=C(N1)C2=CC(=NC=C2)OC)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=C(C=C5C(=C4)C=NN5)F,5.275724130399211,COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3cc4cn[nH]c4cc3F)=C(C)N2)ccn1
34903,CHEMBL3702767,TYIDCPRIOTUDSB-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6150.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7CCN(CC7)C(=O)C8=CC=C(C=C8)N(C)C,5.211124884224583,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)c6ccc(N(C)C)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
34904,CHEMBL3403815,TYIUULJYLSZQJM-VPNNIMDCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)C)C)C)O)C)C(C)(C)O,4.6020599913279625,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
34905,CHEMBL3403815,TYIUULJYLSZQJM-VPNNIMDCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)C)C)C)O)C)C(C)(C)O,4.6020599913279625,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
34913,CHEMBL2205045,TYKBKDLIAKRVRZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)SC2=CC=CC=C2N3CCNCC3.Cl,4.795880017344075,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1
34916,CHEMBL3114720,TYLOVNGZCFIJOG-WFXMLNOXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23746300.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,C[C@@H](CC[C@H](C)NC(=O)OCC1=CN=CS1)NC(=O)[C@H](C(C)C)NC(=O)N(C)CC2=CSC(=N2)C(C)C,5.0,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](C)CC[C@H](C)NC(=O)OCc2cncs2)C(C)C)cs1
34919,CHEMBL3114720,TYLOVNGZCFIJOG-WFXMLNOXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](CC[C@H](C)NC(=O)OCC1=CN=CS1)NC(=O)[C@H](C(C)C)NC(=O)N(C)CC2=CSC(=N2)C(C)C,6.292429823902063,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](C)CC[C@H](C)NC(=O)OCc2cncs2)C(C)C)cs1
34924,CHEMBL1951330,TYMZTIRSSWUYPG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,6.698970004336019,COc1ccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)cc1
34925,CHEMBL1682892,TYNRBNIVUWDJAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)N)(C3=CN=CN3)O,5.431798275933005,CC(C)C(O)(c1ccc2cc(C(N)=O)ccc2c1)c1cnc[nH]1
34927,CHEMBL3358930,TYOOOSONZFYFLZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)C(=O)N)(C(F)(F)F)O,5.698970004336019,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C(N)=O)ncc2[nH]1)C(F)(F)F
34929,CHEMBL1208966,TYQDNFSUWCTPOC-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=NC(=NC=C5)NC6CCN(CC6)C)C(=O)N,6.0,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)n4)ccc32)sc1C(N)=O)c1ccccc1Cl
34930,CHEMBL1208966,TYQDNFSUWCTPOC-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=NC(=NC=C5)NC6CCN(CC6)C)C(=O)N,4.823908740944319,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)n4)ccc32)sc1C(N)=O)c1ccccc1Cl
34931,CHEMBL2180528,TYQNFWIJWOXJPV-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23075267.0,IC50,>,40000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect cells using fluorogeinc substrate,Discovery and Lead Optimization of a Novel Series of CC Chemokine Receptor 1 (CCR1)-Selective Piperidine Antagonists via Parallel Synthesis.,J. Med. Chem.,PUBLICATION,,CC(C)[C@H](C(=O)N1CCC(CC1)C2=CC=C(C=C2)Cl)NC(=O)C3=CC=CC=C3,4.3979400086720375,CC(C)[C@@H](NC(=O)c1ccccc1)C(=O)N1CCC(c2ccc(Cl)cc2)CC1
34937,CHEMBL2018905,TYVFYXGXKSBOIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,27100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CCCSC1=NC2=C(N1)C=C(C=C2)OC,4.567030709125595,CCCSc1nc2ccc(OC)cc2[nH]1
34939,CHEMBL3627894,TYWWABBJXVGGPH-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25978966.0,IC50,=,33260.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NN(C=N1)C2=CC(=C(C(=C2)Cl)C(=O)NC[C@@H](C3=CC(=CC=C3)F)C4=NC5=CC(=C(C=C5N4)Cl)OC)Cl,4.4780777551165,COc1cc2nc([C@@H](CNC(=O)c3c(Cl)cc(-n4cnc(C)n4)cc3Cl)c3cccc(F)c3)[nH]c2cc1Cl
34949,CHEMBL126,TYZROVQLWOKYKF-ZDUSSCGKSA-N,LINEZOLID,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23584544.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,PUBLICATION,,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,4.698970004336019,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
34951,CHEMBL126,TYZROVQLWOKYKF-ZDUSSCGKSA-N,LINEZOLID,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,4.698970004336019,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
34953,CHEMBL556927,TZAVEMGJPFYKKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC(=O)NC(CN2C=CC=N2)C3=CC=CC=C3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,5.356547323513812,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1cccn1)c1ccccc1
34977,CHEMBL3115174,TZHVWGUJONDDOT-WUNLWTINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.886056647693163,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
34986,CHEMBL466555,TZNQLVLILPGVRT-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,84.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CSC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,7.075720713938118,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
34987,CHEMBL466555,TZNQLVLILPGVRT-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,870.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CSC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,6.060480747381382,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
35001,CHEMBL400261,TZRWXVQERJBYNA-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1(C2=CC=CC=C2)N3C(=NC4=C3N=CC=C4)CNC(=O)[C@@H](CC5=CC=CC=C5C(F)(F)F)NC(=O)C6(CC6)C(F)(F)F,5.721246399047171,O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1ccccc1C(F)(F)F)NC(=O)C1(C(F)(F)F)CC1
35006,CHEMBL2170632,TZUIJGLTRUKCJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=CC=C(C=C1)C(=O)N2CCC(CC2)C3=C(C=C(C=C3)C(=O)N=C(N)N)C(F)(F)F,4.823908740944319,CS(=O)(=O)c1ccc(C(=O)N2CCC(c3ccc(C(=O)N=C(N)N)cc3C(F)(F)F)CC2)cc1
35034,CHEMBL2436620,UADYGGCZODNWRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NN=C2N1C3=C(CN(C2)C4CCN(CC4)C(=O)C5(CCN(CC5)CC6=CC(=NC=C6)N)F)C=CS3,4.522878745280337,Cc1nnc2n1-c1sccc1CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2
35038,CHEMBL3422236,UAFMDFJKXYVYRS-IXBGWNDUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=COC(=N1)[C@H]2C[C@H]3CSC(=N[C@]3(CO2)C4=C(C=C(C=C4)F)F)N,4.522878745280337,Cc1coc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1
35042,CHEMBL2381074,UAGIOQUVPZGBMF-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535328.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=C(C=C1)C2=NC=CC=N2)C(=O)N3CC4(CC4)C[C@H]3CNC5=NC=C(C=C5)C(F)(F)F,4.0,Cc1ccc(-c2ncccn2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)n1
35048,CHEMBL1951453,UAGMQELKQICEOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264487.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using midazolam as substrate by LC-MS/MS analysis,A ß-tryptase inhibitor with a tropanylamide scaffold to improve in vitro stability and to lower hERG channel binding affinity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCOC1=C(C(=C(S1)C(=O)N2CCC(CC2)C3=CC=CC(=C3)CN)C)Br,5.327902142064283,CCCOc1sc(C(=O)N2CCC(c3cccc(CN)c3)CC2)c(C)c1Br
35053,CHEMBL2036212,UAHVGQVTFGOJQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,CCCCC(=O)N(CC1=CC(=CC=C1)OC(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)F,5.0,CCCCC(=O)N(Cc1cccc(OC(F)(F)F)c1)c1cc(F)cc(-c2nn[nH]n2)c1
35078,CHEMBL1682890,UARNBGAVALRVSI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)NC(=O)NC)(C3=CN=CN3)O,6.0,CNC(=O)Nc1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
35094,CHEMBL3112867,UAXHPOBBKRWJGA-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CC2=CC=CC=C2N1C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1
35095,CHEMBL3112866,UAXHPOBBKRWJGA-ZDUSSCGKSA-N,SAR-260301,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C[C@H]1CC2=CC=CC=C2N1C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1
35098,CHEMBL239496,UAXNNGUDPWZOKX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,1140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(C)C4=CC(=CC(=C4)F)F,5.943095148663527,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1cc(F)cc(F)c1)O2
35099,CHEMBL3358947,UAYXTLWPZTYJEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=C(C=C(C=C3)Cl)C(=O)N,4.823908740944319,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(Cl)cc1C(N)=O
35121,CHEMBL583442,UBCWZOKKGDETJW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)OC(F)F,5.301029995663981,CC1(CC(=O)NCc2ccc(OC(F)F)cc2)CC2(CCCCC2)OO1
35125,CHEMBL2316386,UBFBCNIBTXDRJO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,=,5500.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,CS(=O)CC1=CC=C(C2=CC=CC=C12)C(=O)NC3=C(N=C(C=C3)OCCOCCO)C(=O)NCC4CCC4,5.259637310505756,C[S+]([O-])Cc1ccc(C(=O)Nc2ccc(OCCOCCO)nc2C(=O)NCC2CCC2)c2ccccc12
35139,CHEMBL1951596,UBKXEHHBQTWHJR-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C2=C(C(=O)N(C1=O)CC3=NC=CC4=CC=CC=C43)N(C(=C2C#N)N5CCC[C@@H](C5)N)CC6=CC=CC=C6,5.522878745280337,Cn1c(=O)n(Cc2nccc3ccccc23)c(=O)c2c1c(C#N)c(N1CCC[C@H](N)C1)n2Cc1ccccc1
35147,CHEMBL2431460,UBNVHIMTEMQRJP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC(=CC(=C1OC)CCN2CCC(CC2)NS(=O)(=O)C)C3=CC=CNC3=O,4.301029995663981,COc1c(CCN2CCC(NS(C)(=O)=O)CC2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C
35154,CHEMBL3260755,UBRBDDDFBPVEQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=CC=C(C=C3)C#N)C4=CN(N=C4)C)C5=CC=C(C=C5)Cl,5.468521082957745,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnn(C)c3)c(=O)n(Cc3ccc(C#N)cc3)n2c1=O
35174,CHEMBL1668261,UBXGEZISKCURBV-RPPIVITFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=NC(=C(C=C1)C2=NC3=CC(=C(C=C3N2[C@@H](C4CCCCC4)C(=O)NC5CCC(CC5)C(=O)O)F)F)OC,4.301029995663981,COc1ccc(-c2nc3cc(F)c(F)cc3n2[C@H](C(=O)NC2CCC(C(=O)O)CC2)C2CCCCC2)c(OC)n1
35186,CHEMBL3291394,UCALKYGDSCLCAF-POJKVFINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1080.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)NC(=O)CN5CCCC(C5)O)C,5.966576244513051,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCCC(O)C3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
35187,CHEMBL3291394,UCALKYGDSCLCAF-POJKVFINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1240.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)NC(=O)CN5CCCC(C5)O)C,5.906578314837765,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCCC(O)C3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
35189,CHEMBL3702819,UCAOZUWAXDBCRB-VYXSRHMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2630.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CC8=C(C=C7)OCCO8,5.580044251510242,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc6c(c5)OCCO6)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
35191,CHEMBL521860,UCBHJGKWEAXEKC-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,C[C@H]1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC(=O)C)C,4.6020599913279625,CC(=O)Nc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(C)ccc12
35200,CHEMBL189942,UCDZIPQDLFQWSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16107158.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-4-(trifluoromethyl)coumarin (BFC) as fluorogenic substrate,Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.,J. Med. Chem.,PUBLICATION,,CCN1C2=C(C=CC(=N2)F)N(C(=O)C3=C1N=CC(=C3)CCOC4=C(C=C(C=C4)C(=O)O)C)C,5.0,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2ccc(F)nc21
35201,CHEMBL189942,UCDZIPQDLFQWSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16107158.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-quinoline (BQ) as fluorogenic substrate,Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.,J. Med. Chem.,PUBLICATION,,CCN1C2=C(C=CC(=N2)F)N(C(=O)C3=C1N=CC(=C3)CCOC4=C(C=C(C=C4)C(=O)O)C)C,4.522878745280337,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2ccc(F)nc21
35204,CHEMBL84,UCFGDBYHRUNTLO-QHCPKHFHSA-N,TOPOTECAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1521.1,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,5.8178422336652185,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1
35207,CHEMBL3288028,UCFLPCZZROQSNW-AQOUDTPCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24785301.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD.,J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C)C(=O)NC2CCC(CC2)NC(=O)C3=C(N=CC(=C3)F)OC4=CC=CC(=C4)C5=CC=C(C=C5)CCN6CCC(CC6)N7CCCC7,6.0,Cc1cc(C(=O)NC2CCC(NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(CCN5CCC(N6CCCC6)CC5)cc4)c3)CC2)nn1C
35208,CHEMBL481575,UCGDJSGANNJRLB-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)NC5=CC=C(C=C5)Cl,5.455931955649724,C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccc(Cl)cc4)CC3)cc2)C[C@@H](C)N1
35209,CHEMBL481575,UCGDJSGANNJRLB-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)NC5=CC=C(C=C5)Cl,5.2839966563652006,C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccc(Cl)cc4)CC3)cc2)C[C@@H](C)N1
35226,CHEMBL1950351,UCMNIYFDRVBMFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22284817.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,¿-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)N1C2=C(CN(CC2)C3CCOCC3)C4=C1C=CC(=C4)C(=O)N5CCC(CC5)C,4.698970004336019,CCS(=O)(=O)n1c2c(c3cc(C(=O)N4CCC(C)CC4)ccc31)CN(C1CCOCC1)CC2
35242,CHEMBL2070137,UCTMDJGIDNKBDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=C3)C4=CC=CC=C4,5.045757490560675,CCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)c3)[nH]c2c1
35248,CHEMBL1090209,UCUHPRBZQBMMNA-MVBJNABHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20236824.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,Design and synthesis of tricyclic sulfones as gamma-secretase inhibitors with greatly reduced Notch toxicity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@@]2([C@H](C[C@@H]1NS(=O)(=O)C(F)(F)F)COC3=C(C=CC(=C32)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl,4.522878745280337,O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F
35249,CHEMBL1090209,UCUHPRBZQBMMNA-MVBJNABHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@@]2([C@H](C[C@@H]1NS(=O)(=O)C(F)(F)F)COC3=C(C=CC(=C32)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl,5.455931955649724,O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F
35250,CHEMBL1090209,UCUHPRBZQBMMNA-MVBJNABHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1C[C@@]2([C@H](C[C@@H]1NS(=O)(=O)C(F)(F)F)COC3=C(C=CC(=C32)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl,5.017728766960431,O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F
35255,CHEMBL1682904,UCYQUZAJMGMKEU-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)[C@](C1=CC2=C(C=C1)C3=C(C=C2)C(=O)N(C3)C)(C4=CN=CN4)O,5.0,CC(C)[C@](O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1cnc[nH]1
35256,CHEMBL1682905,UCYQUZAJMGMKEU-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)[C@@](C1=CC2=C(C=C1)C3=C(C=C2)C(=O)N(C3)C)(C4=CN=CN4)O,5.0,CC(C)[C@@](O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1cnc[nH]1
35257,CHEMBL1682901,UCYQUZAJMGMKEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C3=C(C=C2)C(=O)N(C3)C)(C4=CN=CN4)O,5.0,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1cnc[nH]1
35264,CHEMBL2043168,UDDLGZQDALRQID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)O,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
35273,CHEMBL401122,UDIQMHOHOCRKGM-CTNGQTDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@@H](N([C@@H](C1)C2CC2)S(=O)(=O)C3=CC=C(C=C3)Cl)COC(=O)N4CCN(CC4)CCO,6.522878745280337,O=C(OC[C@H]1CCC[C@@H](C2CC2)N1S(=O)(=O)c1ccc(Cl)cc1)N1CCN(CCO)CC1
35303,CHEMBL399719,UDXAWWYJIGJLRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCN(CC3)CC4=CC5=C(C=C4)OCC(=O)N5C,4.698970004336019,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(C)C(=O)CO5)CC3)cccc2n1
35304,CHEMBL3702704,UDYNSGNOZYBHLA-YATWDLPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5530.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCN8CCCCC8,5.257274868695301,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCN6CCCCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
35312,CHEMBL2170618,UEDSNYYBBFEFCG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,CN1C=NC=C1C(=O)N2CCC(CC2)C3=C(C=C(C=C3)C(=O)N=C(N)N)C(F)(F)F,5.522878745280337,Cn1cncc1C(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
35313,CHEMBL3137467,UEFAKJDYSQUQOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1500.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CC1C(=O)N2CCC(CC2)N(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,5.823908740944319,O=C(C1CC1)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1
35329,CHEMBL1643514,UEPBVWIBDNMJPA-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21095126.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)[C@@H]1CCN(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,4.6020599913279625,CN(C)[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
35345,CHEMBL241663,UERMDDSMFCIPGD-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)O[C@@](C(=O)N3CCCC(F)(F)F)(C)C4=CC(=CC(=C4)F)F,5.769551078621726,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCC(F)(F)F)C(=O)[C@](C)(c1cc(F)cc(F)c1)O2
35353,CHEMBL3314850,UEUUWJVQGWZIJY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24969015.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled human liver microsomes in presence of NADPH,Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CN=C(C=C1Cl)C(=O)NC2=CN=CC(=N2)OC3=CN=CN=C3,4.522878745280337,O=C(Nc1cncc(Oc2cncnc2)n1)c1cc(Cl)ccn1
35354,CHEMBL3702791,UEWPLDOHKHENQG-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2210.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC(CC8)OC,5.655607726314889,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(OC)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
35367,CHEMBL446054,UFAYJVYELGRGFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC(=CC=C4)Cl,5.522878745280337,O=S(=O)(c1cccc(Cl)c1)n1ccc2cc3c(cc21)CCNCC3
35368,CHEMBL446054,UFAYJVYELGRGFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC(=CC=C4)Cl,5.154901959985743,O=S(=O)(c1cccc(Cl)c1)n1ccc2cc3c(cc21)CCNCC3
35384,CHEMBL3303792,UFFYJUZFFYYLGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NOC(=C1)CNC(=O)C2=CC(=C(C=C2)OC)OCCN3CCCCC3,4.522878745280337,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OCCN1CCCCC1
35388,CHEMBL2069316,UFIJMRPHGQWUEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=C(C=C3)C)C4=CC=CC=C4,5.2441251443275085,CCS(=O)(=O)c1ccc2nc(-c3ccc(C)c(-c4ccccc4)c3)[nH]c2c1
35389,CHEMBL2158288,UFIPENMOPMVCOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)CNCCO)NC(=O)C4=NC=C(N4)C#N,5.292429823902063,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)CNCCO)CC3)cc2C2=CCCCC2)[nH]1
35390,CHEMBL2086687,UFJZVFBUUIBTHV-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23628336.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(CCN1C2=NC=C(C=N2)OCC3=C(C=NC=C3)C#N)C(=O)OCC(F)(F)F,4.522878745280337,C[C@@H]1CN(C(=O)OCC(F)(F)F)CCN1c1ncc(OCc2ccncc2C#N)cn1
35392,CHEMBL1210423,UFKVTMVFNCOIKU-UHFFFAOYSA-M,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20566292.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN=C(C=C1)COC2=CC3=C(C=C2)N(C(=C3SC(C)(C)C)CC(C)(C)C(=O)[O-])CC4=CC=C(C=C4)C5=NC=C(C=N5)OC.[Na+],5.055517327849831,COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)[O-])c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1
35396,CHEMBL2437330,UFLCSYKVIUPYKK-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044938.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Synthesis and in vitro/in vivo antibacterial activity of oxazolidinones having thiocarbamate at C-5 on the A-ring and an amide- or urea-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane as the C-ring.",Eur. J. Med. Chem.,PUBLICATION,,COC(=S)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCNN(CC3)C(=O)C(F)F)F,4.698970004336019,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)C(F)F)CC3)c(F)c2)C(=O)O1
35416,CHEMBL2425146,UFUDJJBHRBMKDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=CN=C4,5.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3ccnc3)cc2)cc1
35421,CHEMBL498220,UFWOHRJEMMPVKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)NCC3=C(C=C(C=C3)F)Cl)N4C=CC=CC4=O)C,5.468521082957745,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3ccccc3=O)cn2c1C
35422,CHEMBL498220,UFWOHRJEMMPVKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)NCC3=C(C=C(C=C3)F)Cl)N4C=CC=CC4=O)C,4.886056647693163,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3ccccc3=O)cn2c1C
35435,CHEMBL3673943,UFYPFASIUYPWBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320618,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,C1=CC(=NC(=C1CC2=CNC3=C2C=C(C=N3)Cl)F)NCC4=CC(=CN=C4)F,5.301029995663981,Fc1cncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)c1
35436,CHEMBL3673943,UFYPFASIUYPWBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320662,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,C1=CC(=NC(=C1CC2=CNC3=C2C=C(C=N3)Cl)F)NCC4=CC(=CN=C4)F,5.301029995663981,Fc1cncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)c1
35443,CHEMBL2435853,UFZMURFKAOEOKB-PMERELPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24090135.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC(=N1)OC2=CC=C(C=C2)C(=O)O)CN3CCC(CC3)N4[C@@H](CN(C4=O)C5CCOCC5)C6=CC(=CC=C6)Cl,4.0,Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2cccc(Cl)c2)CC1
35444,CHEMBL2057517,UFZSWPKCQNDLNT-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,41.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)NC,7.3872161432802645,CNc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
35452,CHEMBL1969102,UGEJLCNSVIVALC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 µL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 µg/mL) were incubated with 5 concentrations of test compound (from 0.1 µM to 10 µM), 1 mM NADPH (Sigma), and 2 µM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,CC1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CNN=C5)N,6.522878745280337,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1
35453,CHEMBL1969102,UGEJLCNSVIVALC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,760.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 µL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 µg/mL) were incubated with 5 concentrations of test compound (from 0.1 µM to 10 µM), 1 mM NADPH (Sigma), and 2 µM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,CC1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CNN=C5)N,6.119186407719209,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1
35455,CHEMBL389433,UGFHIPBXIWJXNA-UHFFFAOYSA-N,LIAROZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,<,100.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4,7.0,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1
35456,CHEMBL389433,UGFHIPBXIWJXNA-UHFFFAOYSA-N,LIAROZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,<,100.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4,7.0,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1
35457,CHEMBL389433,UGFHIPBXIWJXNA-UHFFFAOYSA-N,LIAROZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26365710.0,IC50,=,690.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay,"Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4,6.161150909262744,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1
35470,CHEMBL115876,UGLPVHLKYTWQRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,252.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=NC(=C1)CCCOC2=CC=C(C=C2)N3C=CN=C3,6.598599459218456,c1ccc(CCCOc2ccc(-n3ccnc3)cc2)nc1
35472,CHEMBL3326570,UGNRNJDBLIKGQC-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,660.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1(C[C@H](C2=C(O1)C=C(C=C2)F)NC(=O)NC3=CC=CC4=C3C=CN=C4)C,6.180456064458132,CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2ccc(F)cc2O1
35476,CHEMBL238866,UGOGQLRJKMMHMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,920.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(C)C4=CC(=C(C=C4)F)F,6.036212172654444,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1ccc(F)c(F)c1)O2
35486,CHEMBL2397316,UGTHQAXCCBBNQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)C(C)(C)CC(F)(F)F)C2=CN=C(C=C2)N,4.769551078621726,Cc1nc(NC(=O)C(C)(C)CC(F)(F)F)sc1-c1ccc(N)nc1
35490,CHEMBL2059802,UGVTUQAEJUZTMQ-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C2=CC=CC=C21)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,7.0,Cn1cc(C[C@@H](NC(=O)N2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c2ccccc21
35493,CHEMBL2448722,UGXFQEUACCBNIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1520.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CC(=O)N(CC1=CN=CC=C1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4S3,5.818156412055227,CC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1
35494,CHEMBL2448722,UGXFQEUACCBNIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2900.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CC(=O)N(CC1=CN=CC=C1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4S3,5.5376020021010435,CC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1
35495,CHEMBL1098125,UGXRUMNFAKOITP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4CCCO4,5.301029995663981,CN1CCCC(c2nc3ccccc3n2CC2CCCO2)C1
35502,CHEMBL1951607,UHCGBYNFQULPRR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC(=O)C4=CC(=CC=C4)OC)C)C,5.522878745280337,COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCCNCC4)n3CC=C(C)C)n(C)c2=O)c1
35522,CHEMBL487554,UHHRYINUVNKFTA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CC(C4)OC)C,4.958607314841775,COC1CN(c2cccc(-c3cc(NC(C)=O)nc(-n4nc(C)cc4C)n3)n2)C1
35523,CHEMBL231510,UHIYZXSEOHGEBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=O)NC5CC5,5.0,Cc1cc(C(=O)NC2CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
35524,CHEMBL1911819,UHJLPAVCVVEQGP-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)C(=O)[C@@H](COCC2=CC=C(C=C2)F)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,5.200659450546418,CN1CCN(C(=O)[C@@H](COCc2ccc(F)cc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
35529,CHEMBL550868,UHMQYWPLWZKMOS-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C1)C3=C(N2CC(=O)O)C=NC=C3)S(=O)(=O)C4=CC=C(C=C4)F,4.522878745280337,CN([C@@H]1CCc2c(c3ccncc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1
35531,CHEMBL2057790,UHNGMTOQQDUDOW-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,31.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)NCCCN5C=CN=C5,7.508638306165727,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCCn3ccnc3)oc2c1
35533,CHEMBL3608684,UHNVQJPBRBMNNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC1=NSC(=N1)C2=NN=C3N2CCN(C3)C(=O)C4=CC=C(C=C4)F,4.0,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3)n1
35534,CHEMBL205807,UHNVWCCKBJDIGZ-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CC3=CNC4=CC=CC=C43)C(=O)N5CC[C@H](C5)O)C(=O)N(C1=O)C,6.0,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3c[nH]c4ccccc34)sc21
35537,CHEMBL1092649,UHPLDFSEISHDBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NC=CN=C3,5.0,CN(C)CCC1=C(Cc2cnccn2)c2ccc(F)cc2C1
35554,CHEMBL1649683,UHTWSBHKNUALPU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,C1CCN(C1)C(=O)C2=CC=C(C=C2)N3C4=C(CCOC4)C(=N3)C(F)(F)F,5.0,O=C(c1ccc(-n2nc(C(F)(F)F)c3c2COCC3)cc1)N1CCCC1
35555,CHEMBL2426677,UHUCZYJVWVZKAH-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25699143.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)CC(=O)N2CCC3(CC2)CN(C3)[C@@H]4CCC5=C4C=CC(=C5)C6=NC=CC=N6,5.6020599913279625,COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5ncccn5)ccc42)C3)cc1
35571,CHEMBL38958,UHYGTCSPRAOTBE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,=,11.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)Cl)CC(C)(C)C(=O)O,7.939302159646388,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccccn3)cc12
35580,CHEMBL1428,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,NIMODIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,1780.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,5.749579997691106,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1
35588,CHEMBL1224197,UIASTQRXRWRHSW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709552.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=CSC(=N3)C(=O)N)OC(F)(F)F,4.7447274948966935,NC(=O)c1nc(-c2cccc(-c3ccccc3OC(F)(F)F)c2)cs1
35594,CHEMBL1813472,UIBIRCANCAKLIN-RISCZKNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,12800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,C1CC[C@]2(CNC[C@H]2C1)C3=CC(=C(C=C3)Cl)Cl,4.892790030352131,Clc1ccc([C@@]23CCCC[C@@H]2CNC3)cc1Cl
35595,CHEMBL1813471,UIBIRCANCAKLIN-SMDDNHRTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,8390.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,C1CC[C@@]2(CNC[C@@H]2C1)C3=CC(=C(C=C3)Cl)Cl,5.0762380391713,Clc1ccc([C@]23CCCC[C@H]2CNC3)cc1Cl
35599,CHEMBL2058908,UICZFGBRBAVNHU-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,410.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CCN(C)C)C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,6.3872161432802645,CCN(C)c1nc2ccc(C(=O)N(CCN(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
35600,CHEMBL258394,UIDGLYUNOUKLBM-GEBJFKNCSA-N,NARCISSIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16562853.0,IC50,>,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)OC)O)O)O)O)O)O,4.096910013008056,COc1cc(-c2oc3cc(O)cc(O)c3c(=O)c2O[C@@H]2O[C@H](CO[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)ccc1O
35608,CHEMBL1008,UIEATEWHFDRYRU-UHFFFAOYSA-N,BEPRIDIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3,4.522878745280337,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1
35609,CHEMBL1008,UIEATEWHFDRYRU-UHFFFAOYSA-N,BEPRIDIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,23600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3,4.627087997029894,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1
35620,CHEMBL3601190,UIGJXMQBTZRJST-MJKPMQHNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1OC2=NC=CC(=C2)NC3=NC=C(C(=N3)N[C@@H]4C[C@@H]([C@H]([C@H]4O)O)CO)C5=NC6=CC=CC=C6C=C5,4.301029995663981,OC[C@H]1C[C@@H](Nc2nc(Nc3ccnc(OC4CC4)c3)ncc2-c2ccc3ccccc3n2)[C@H](O)[C@@H]1O
35623,CHEMBL480016,UIILMPGHICZFBB-LRDNONRASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19014886.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 red,"Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)C[C@@]34CC[C@@H](C3(C)C)CC4=O,6.494850021680094,C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](CC2=O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F
35636,CHEMBL236939,UINUKESLPATVPH-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)[C@H](CC(C)C)N,5.721246399047171,Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@@H](N)CC(C)C)c1
35642,CHEMBL2086757,UIPHWSFCVAAJDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=C3C(=C4N=C5C=CC=CC5=N4)C6=CC(=CC(=C6)F)F)O,5.221848749616356,CCN1CCC(Nc2ccc3[nH]c(O)c(C(=C4N=c5ccccc5=N4)c4cc(F)cc(F)c4)c3c2)CC1
35654,CHEMBL1097357,UIUYQDFIVJOTTH-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCNCC5,5.522878745280337,Cc1cc(N2CCNCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
35655,CHEMBL1097357,UIUYQDFIVJOTTH-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCNCC5,5.522878745280337,Cc1cc(N2CCNCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
35672,CHEMBL1955989,UJDYXOAGLLGCSW-JLHYYAGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22330635.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)/C=C/C2=NC3=C(N2)C=C(C=C3)C4=CC=CC=C4C(F)(F)F,5.455931955649724,FC(F)(F)c1ccccc1-c1ccc2nc(/C=C/C3CCCCC3)[nH]c2c1
35673,CHEMBL1955989,UJDYXOAGLLGCSW-JLHYYAGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22330635.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)/C=C/C2=NC3=C(N2)C=C(C=C3)C4=CC=CC=C4C(F)(F)F,4.522878745280337,FC(F)(F)c1ccccc1-c1ccc2nc(/C=C/C3CCCCC3)[nH]c2c1
35675,CHEMBL179005,UJFDLQZAPFUWOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,114000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=NC=C1C2=CSC=C2)F,3.9430951486635273,Fc1ccc(-c2ccsc2)cn1
35676,CHEMBL179005,UJFDLQZAPFUWOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,114000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,C1=CC(=NC=C1C2=CSC=C2)F,3.9430951486635273,Fc1ccc(-c2ccsc2)cn1
35681,CHEMBL1089501,UJIBXDMNCMEJAY-UHFFFAOYSA-N,BMS-687453,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20218621.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=C(C=C2)Cl)COC3=CC=CC(=C3)CN(CC(=O)O)C(=O)OC,4.3979400086720375,COC(=O)N(CC(=O)O)Cc1cccc(OCc2nc(-c3ccc(Cl)cc3)oc2C)c1
35688,CHEMBL221959,UJLAWZDWDVHWOW-YPMHNXCESA-N,TOFACITINIB,PFE-PKIS 25,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21105711.0,IC50,>,52000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Discovery of CP-690,550: a potent and selective Janus Kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,4.2839966563652006,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
35692,CHEMBL3288448,UJONHAQOJCHCJU-BRMBYNPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,<,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)[C@@]3(CCCN([C@@H]3CC=C)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,6.522878745280337,C=CC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ccccc2OCCOC)CC1
35693,CHEMBL3288448,UJONHAQOJCHCJU-BRMBYNPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)[C@@]3(CCCN([C@@H]3CC=C)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,5.6777807052660805,C=CC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ccccc2OCCOC)CC1
35698,CHEMBL2017281,UJPOOIUOVCPCTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC5=C4N=CC=C5)C(=O)N)OC,5.4089353929735005,COc1cc2c(Nc3cccc4cccnc34)c(C(N)=O)cnc2cc1-c1c(C)noc1C
35699,CHEMBL2017281,UJPOOIUOVCPCTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC5=C4N=CC=C5)C(=O)N)OC,5.4089353929735005,COc1cc2c(Nc3cccc4cccnc34)c(C(N)=O)cnc2cc1-c1c(C)noc1C
35701,CHEMBL2016639,UJQWCBANYGKWRO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22260203.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=NOC(=N2)CSC3=NN=C(N3C4=CC=CC=C4)C5=CC=C(C=C5)F,4.301029995663981,Fc1ccc(-c2nnc(SCc3nc(-c4ccccc4)no3)n2-c2ccccc2)cc1
35714,CHEMBL3702769,UJSWDPBCBIORIG-LRHLLKFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2970.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)F,5.527243550682788,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(F)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
35720,CHEMBL3112592,UJUIPZRMKOMRCU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=C1C=C(C=C2)Cl)C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(Cl)ccc21
35723,CHEMBL2448715,UJWMCTCIJSSLTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,790.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CCN(CC1=CN=CC=C1)C2=CN=CC(=C2)C3=NC4=CC=CC=C4S3,6.102372908709558,CCN(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1
35726,CHEMBL1385840,UJYGDMFEEDNVBF-OGGGUQDZSA-N,ERGOCORNINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,500.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,6.301029995663981,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
35732,CHEMBL2425895,UKAKHNHDUXRYCO-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,14080.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=CC=CC=C3C(=C2)Cl)N4CCC[C@H](C4)N,4.851397345193907,CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2cc(Cl)c3ccccc3n2)c1=O
35741,CHEMBL3234569,UKDXGNZPPKPUKO-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC(=NC(=C2)N3CCNCC3)C(F)(F)F)C(=O)NCCC4=CC=C(C=C4)C#N,7.0,N#Cc1ccc(CCNC(=O)[C@@H]2CCCN(c3cc(N4CCNCC4)nc(C(F)(F)F)n3)C2)cc1
35745,CHEMBL256712,UKGCAEYEQULSSN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4,5.0,CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1
35767,CHEMBL1081514,UKPPSZQPJMMBGE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,88.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC(CC(=O)OC)NC(=O)OCC1=CN=CS1)CC(CC(=O)OC)NC(=O)OCC2=NC=CS2,7.055517327849832,CCN(CC(CC(=O)OC)NC(=O)OCc1cncs1)CC(CC(=O)OC)NC(=O)OCc1nccs1
35768,CHEMBL1257336,UKPYAHVTVCYHSG-FNLKRUPLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20839775.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Exploration of the amine terminus in a novel series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3[C@@H]4CC[C@H]3CC(C4)C5=CC=C(C=C5)C(F)(F)F,5.0,Cc1ncoc1-c1nnc(SCCCN2[C@H]3CC[C@@H]2CC(c2ccc(C(F)(F)F)cc2)C3)n1C
35784,CHEMBL2059125,UKVVUPPPZVSRBB-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,230.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,6.638272163982407,CN(C)CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
35790,CHEMBL3297762,UKZRGBUTBINTPD-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139169.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.",Bioorg. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C[C@H](C2CCCCC2)NC(=O)C[C@H]3CNC(=O)C4=CC(=CN34)C5=CC(=CC=C5)Cl,5.0,CN1CCN(C[C@@H](NC(=O)C[C@H]2CNC(=O)c3cc(-c4cccc(Cl)c4)cn32)C2CCCCC2)CC1
35793,CHEMBL1668239,ULCPSNSFZVTANO-RLSLOFABSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)[C@@H](C(=O)NC2CCC(CC2)O)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,4.481486060122112,O=C(NC1CCC(O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21
35803,CHEMBL230205,ULETZFIZUULMSQ-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)N[C@@H](CC4=CC=CC=C4)CO)C5=CC=CC=C5,5.443697499232713,Cc1cc(-c2ccccc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12
35810,CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,4.481486060122112,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
35817,CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,132129.56,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,3.8790000112367293,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
35818,CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,190.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 25 to 30 mins by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,6.721246399047171,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
35819,CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 0 to 5 mins by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,5.721246399047171,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
35842,CHEMBL513491,ULMVHDYUXBTTIU-UHFFFAOYSA-M,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19332369.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using DEF substrate,Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC(=C1)C(=O)[O-])CC2=C(C=CC(=C2)Cl)OCC3=C(C=C(C=C3)F)Cl.[Na+],4.455931955649724,O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(F)cc2Cl)n1
35843,CHEMBL513491,ULMVHDYUXBTTIU-UHFFFAOYSA-M,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19332369.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using PPR substrate,Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC(=C1)C(=O)[O-])CC2=C(C=CC(=C2)Cl)OCC3=C(C=C(C=C3)F)Cl.[Na+],4.0,O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(F)cc2Cl)n1
35845,CHEMBL1923108,ULNHETKFDOYNPV-VEEOACQBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC=CC=C5CCO4,5.1938200260161125,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCCc2ccccc23)C2CC2)cc(OCCOC)c1
35847,CHEMBL2017273,ULNHSRPVGJEURD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4F)C(=O)N)OC,5.327902142064283,COc1cc2c(Nc3ccccc3F)c(C(N)=O)cnc2cc1-c1c(C)noc1C
35848,CHEMBL2017273,ULNHSRPVGJEURD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4F)C(=O)N)OC,5.327902142064283,COc1cc2c(Nc3ccccc3F)c(C(N)=O)cnc2cc1-c1c(C)noc1C
35855,CHEMBL168563,ULSCNHRBLXYHIC-WUXOVTSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)[C@H](C)CNCCC6=CC7=NNN=C7C=C6)C,5.1249387366083,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3n[nH]nc3c2)c1
35856,CHEMBL398387,ULSULMMOPVCYQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC4(CC4)C(=O)N3CCNC(=O)C,4.522878745280337,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C1(CC1)O2
35859,CHEMBL1923983,ULTCRVJUAZCGPP-UHFFFAOYSA-N,BMS-066,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22018461.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CNC1=C2C(=C3C=C(NC3=N1)C4=CC=CC(=N4)CNC(=O)COC)N(C=N2)C,4.3979400086720375,CNc1nc2[nH]c(-c3cccc(CNC(=O)COC)n3)cc2c2c1ncn2C
35860,CHEMBL252404,ULUAOKMJKCFHDN-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)N(C)CC1=NOC(=N1)CC2(CC2)[C@H]3CCC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,6.522878745280337,CN(Cc1noc(CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)n1)C(C)(C)CO
35865,CHEMBL604085,ULXYUIOTBNWJFH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3CCNCC3)OC,4.522878745280337,COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC
35866,CHEMBL604085,ULXYUIOTBNWJFH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3CCNCC3)OC,4.522878745280337,COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC
35892,CHEMBL1079436,UMIBNFDCUFYJCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCOCC4=O)C(=C(N3)C)C,4.657577319177793,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)[nH]c12
35893,CHEMBL1079436,UMIBNFDCUFYJCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCOCC4=O)C(=C(N3)C)C,4.657577319177793,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)[nH]c12
35918,CHEMBL3264596,UMTRREIEFFNJMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CNN=C3)O,4.568636235841013,COc1cc2ccc(C(O)(c3cn[nH]c3)C(C)C)cc2cc1OC
35925,CHEMBL1271821,UMWLKNMSOMCHSO-VWNXMTODSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,1.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC1)[C@@H]2COC[C@@H](N2S(=O)(=O)C3=CC=C(C=C3)Cl)COC(=O)N4CCC(CC4)N5CCCCC5,8.823908740944319,CC1([C@@H]2COC[C@H](COC(=O)N3CCC(N4CCCCC4)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1
35945,CHEMBL2151927,UNDRYPNXYPXVPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=CC(=C1)NC(=O)CC2=NC(=CC(=O)N2)N3CCOCC3)F,4.3979400086720375,COc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F
35946,CHEMBL2163831,UNDSHGMDHIMJOM-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,1360.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,5.866461091629782,CN1CCN(C(=O)[C@H](Cc2ccccc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
35951,CHEMBL567374,UNGALHHMDYBABX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCCC3=CC(=CC=C3)NC(=O)OC(C)(C)C,6.0,CC(C)(C)OC(=O)Nc1cccc(CCNC(=O)CC2(C)CC3(CCCCC3)OO2)c1
35954,CHEMBL2086690,UNGZTVLHLKAKQE-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22545772.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 by high-throughput fluorescence assay,Use of small-molecule crystal structures to address solubility in a novel series of g protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C2=NC=C(C=N2)OCC3=C(C=NC=C3)C#N)C4=NOC(=N4)C(C)C,4.522878745280337,CC(C)c1nc(N2CCN(c3ncc(OCc4ccncc4C#N)cn3)[C@H](C)C2)no1
35963,CHEMBL3236637,UNKIPWCTGDLSKY-MMYUMUNASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC5=CC=CC=N5,6.154901959985743,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ccccn2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
35967,CHEMBL246530,UNKYYGBTNCKVGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276063.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC=CC(=C1)C2=NC(=NC=N2)N3CC(C(C3)N)C4=CC(=C(C=C4F)F)F,5.0,CS(=O)(=O)c1cccc(-c2ncnc(N3CC(N)C(c4cc(F)c(F)cc4F)C3)n2)c1
35974,CHEMBL3664719,UNNIETXFEWYLRH-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CNC(=O)C=C2)N3CC[C@](OC3=O)(CC(C)(C)C#C)C4=CC=CC=C4,5.221848749616356,C#CC(C)(C)C[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccc(=O)[nH]c3)cc2)C(=O)O1
35983,CHEMBL1243335,UNQMLUWBMWGIRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20690643.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC=C(C=C1)SCC(C2=CC=CC=N2)C3=CN=CN3,6.568636235841013,CC(C)(C)c1ccc(SCC(c2ccccn2)c2cnc[nH]2)cc1
35984,CHEMBL3125383,UNRKTJKQLXZCJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C2=C1C(=CC=C2)Br)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O,4.3979400086720375,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21
36013,CHEMBL1683571,UOCHFMVPMIYRHJ-QWRGUYRKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21324688.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1=O)[C@H]2CN(C[C@@H]2N)C3=NC=NC(=N3)N4CCC(C4)(F)F)(F)F,4.823908740944319,N[C@H]1CN(c2ncnc(N3CCC(F)(F)C3)n2)C[C@@H]1N1CC(F)(F)CCC1=O
36038,CHEMBL399568,UONIUQQOOBARAF-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,2430.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1C(F)(F)F)C(=O)NCC2=NC3=C(N2CC4CC4)N=CC=C3,5.614393726401688,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1CC1CC1
36047,CHEMBL3702718,UOSYPEJGZRITSC-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7650.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)NC(=O)CCO,5.116338564846382,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
36054,CHEMBL2338481,UOVZAVLNUTTZBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1Cl)Cl)S(=O)(=O)NC2=CC(=C(C(=C2)Cl)OC3=CN=CC(=C3)C(=O)N)Cl,7.522878745280337,NC(=O)c1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1
36058,CHEMBL3597017,UOWQGZGDOQIXHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26544629.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents.,Eur. J. Med. Chem.,PUBLICATION,,CC(C)CC1=CC(=C(C(=O)N1)C2=CC=CC=C2)O,4.698970004336019,CC(C)Cc1cc(O)c(-c2ccccc2)c(=O)[nH]1
36081,CHEMBL3359927,UPBRYBJZTWHUQK-RISCZKNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25453808.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@]1(CCC[C@H]1NC2=C(C=NN3C2=CC=C3)C(=O)N)F,4.698970004336019,C[C@]1(F)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12
36083,CHEMBL3422072,UPBYKYBKDRDENP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1CC1C(C2=CC=CC=C2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)OC6CCN(CC6)C=O,5.823908740944319,O=CN1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc2)CC1
36093,CHEMBL3394868,UPGJLYYUAKKKAD-JVGMIBGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25577041.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1C[C@H](N(C1)C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=C(C=C3)C4=CC=C(C=C4)C5=CC=C(C=C5)C6=CN=C(N6)[C@@H]7C[C@@H](CN7C(=O)[C@H](C(C)C)NC(=O)OC)C,4.522878745280337,COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1ncc(-c2ccc(-c3ccc(-c4ccc5nc([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c5c4)cc3)cc2)[nH]1)C(C)C
36102,CHEMBL271876,UPJVOWNSAUCCBH-RTBURBONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18282707.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyresorufin as a substrate,Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C2=NN=NN2[C@H](CC#N)COC3=CC=CC=N3)N,4.958607314841775,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccn1
36103,CHEMBL271876,UPJVOWNSAUCCBH-RTBURBONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18282707.0,IC50,=,59000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate,Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C2=NN=NN2[C@H](CC#N)COC3=CC=CC=N3)N,4.229147988357856,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccn1
36120,CHEMBL1222884,UPMYXXWLKPRNBD-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673718.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome preincubated for 30 mins,"Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C[C@H](CN)C(=O)N(CC3=C(C=CC(=C3)CCCOC)Cl)C4CC4)Cl,6.920818753952375,COCCCc1ccc(Cl)c(CN(C(=O)[C@@H](CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
36121,CHEMBL1222884,UPMYXXWLKPRNBD-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673718.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,"Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C[C@H](CN)C(=O)N(CC3=C(C=CC(=C3)CCCOC)Cl)C4CC4)Cl,4.853871964321762,COCCCc1ccc(Cl)c(CN(C(=O)[C@@H](CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
36126,CHEMBL29631,UPNGEDJHCUNSGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3N(C5=C4C(=CC=C5)[N+](=O)[O-])CC6=CN=CC=C6,5.0915149811213505,O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1cccnc1
36139,CHEMBL2380647,UPRHNSFKNOMQKG-FYDKXEAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1S(=O)(=O)N2CCN(CC2)C3=CN=C(C=C3)N4CCN(C5=CC=CC=C54)C(=O)NC6C7CC8CC6CC(C8)(C7)O,5.0,O=C(NC1C2CC3CC1CC(O)(C3)C2)N1CCN(c2ccc(N3CCN(S(=O)(=O)C4CC4)CC3)cn2)c2ccccc21
36140,CHEMBL2016936,UPRILTGQBKRVGC-ODXCJYRJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNC[C@@H]([C@]1(C2=CC(=C(C=C2)F)F)O)C3=CC(=NO3)C4=C(C=CC=C4Cl)Cl,5.096910013008056,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2c(Cl)cccc2Cl)no1
36148,CHEMBL1271935,UPTFCSZWKUUGCL-HNYUPJOQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1C2CCC1CN(C2)C(=O)OC3(CC3)[C@H]4COC[C@H](N4S(=O)(=O)C5=CC=C(C=C5)Cl)CC6CC6,7.522878745280337,CC(=O)N1C2CCC1CN(C(=O)OC1([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2
36159,CHEMBL207987,UPWLRKVVLBSIPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=NC(=C(O2)N)C(=O)N,4.522878745280337,NC(=O)c1nc(-c2ccccc2)oc1N
36164,CHEMBL1778388,UPZGABGQGJFIDG-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21515053.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)C(=O)C4(CCCC4)C5=CC=C(C=C5)F,4.431798275933005,CN(C(=O)C1(c2ccc(F)cc2)CCCC1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1
36165,CHEMBL1761674,UQAYVLAYSNHNRH-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC6=NNN=N6)C7CC7)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(Cc3nn[nH]n3)CC2)c1
36166,CHEMBL1761674,UQAYVLAYSNHNRH-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC6=NNN=N6)C7CC7)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(Cc3nn[nH]n3)CC2)c1
36170,CHEMBL2070153,UQCBLTGPBKOQCM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=C(C=CC(=C3)C4=CC=CC=C4)C,5.229147988357856,CCS(=O)(=O)c1ccc2nc(-c3cc(-c4ccccc4)ccc3C)[nH]c2c1
36175,CHEMBL1835706,UQECZBVIJKOGTA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C2=CC=CC=C2C(=N1)C3=CC=C(C=C3)OCCCN4CCCCC4,4.522878745280337,Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2ccccc2c1=O
36182,CHEMBL2397304,UQGXIBZKHFGPLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)CN(CC(=O)NC2=NC=C(S2)C3=CN=C(C=C3)N)C(=O)C4=CC=NC=C4,5.7447274948966935,Nc1ccc(-c2cnc(NC(=O)CN(Cc3ccccc3)C(=O)c3ccncc3)s2)cn1
36186,CHEMBL2436980,UQHKXSZPEUNUDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,COC1=CC(=CC(=C1OC)OC)C2=CC3=C(NC=C3C4=CC5=C(C=C4)NC=C5)N=C2,4.522878745280337,COc1cc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cc(OC)c1OC
36187,CHEMBL239085,UQHQDWYHACOCCN-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,530.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)O[C@](C(=O)N3CCNC(=O)C)(C)C4=CC=CC=C4,6.275724130399211,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@@](C)(c1ccccc1)O2
36188,CHEMBL391463,UQHQDWYHACOCCN-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)O[C@@](C(=O)N3CCNC(=O)C)(C)C4=CC=CC=C4,4.522878745280337,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@](C)(c1ccccc1)O2
36189,CHEMBL391463,UQHQDWYHACOCCN-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20731374.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Direct renin inhibitors as a new therapy for hypertension.,J. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)O[C@@](C(=O)N3CCNC(=O)C)(C)C4=CC=CC=C4,4.522878745280337,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@](C)(c1ccccc1)O2
36191,CHEMBL218834,UQKFKOGOHFMDDR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16908150.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCN(CC1)C(=O)N2CCC(CC2)C(=O)N3CC4CCC(C3)CC4,4.6020599913279625,CC(C)N1CCN(C(=O)N2CCC(C(=O)N3CC4CCC(CC4)C3)CC2)CC1
36192,CHEMBL236902,UQKHQHYWAJFGDY-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17761416.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1CN(CCN1C(=O)OCC2=CC=CC=C2)C3=NC=C(C=C3)C(=O)NC4=CC=CC=C4N,4.301029995663981,C[C@H]1CN(c2ccc(C(=O)Nc3ccccc3N)cn2)CCN1C(=O)OCc1ccccc1
36201,CHEMBL1094165,UQNVJOYCOQUVLD-XMMPIXPASA-N,BMS-577098,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCOC,5.5376020021010435,COCCN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
36210,CHEMBL3422000,UQPULIPFKDYVSO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,CC1=NC(=CC=C1)C2=NN=C3N2CCN(C3)C(=O)C4=CC=C(C=C4)F,4.0,Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3)n1
36211,CHEMBL3622939,UQRBPKDDLLIVLG-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26384287.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1OCCO)C)NC2=NC=CC(=N2)N3C=C(C(=C3)CN4CC[C@H](C4)O)C,5.0,Cc1cn(-c2ccnc(Nc3cc(C)c(OCCO)c(C)c3)n2)cc1CN1CC[C@@H](O)C1
36215,CHEMBL2057786,UQSOMQDTFBVVRY-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,39.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)C,7.4089353929735005,CCc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
36234,CHEMBL2425886,UQXZWOAEVRHHOF-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,97900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=CC=CC=C3C=C2)N4CCC[C@H](C4)N,4.009217308196862,CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccccc3n2)c1=O
36240,CHEMBL3092421,URBPETAAWZXGNX-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,C1[C@@H](OC(=O)N1C2=CC(=C(C=C2)C3=CC4=NC=CN4C=C3)F)CN5C=CN=N5,4.823908740944319,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccn3ccnc3c2)c(F)c1
36246,CHEMBL1671917,URDDZDCIBYBQCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,CCCCC(=O)NC1=CC=C(C=C1)C(=O)NC2=NC=CS2,4.3979400086720375,CCCCC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
36248,CHEMBL384467,UREBDLICKHMUKA-CXSFZGCWSA-N,DEXAMETHASONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,4.301029995663981,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
36282,CHEMBL3114894,URGKJLUZLWQADG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412066.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC=C(C=C1)OC2=NC=NC3=C2C=NN3C4CCN(CC4)CC5=CC=C(C=C5)C(F)(F)F,5.7447274948966935,CS(=O)(=O)c1ccc(Oc2ncnc3c2cnn3C2CCN(Cc3ccc(C(F)(F)F)cc3)CC2)cc1
36283,CHEMBL2397199,URGNTPNJBQTGQN-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=NC(=NC=C3)C4(CC4)C,5.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2(C)CC2)n1
36286,CHEMBL2448713,URGZQOIBTDTZPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CN(C)S(=O)(=O)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(S3)C4=CC=CC=C4,5.0,CN(C)S(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1
36288,CHEMBL1649681,URIDIEFPWLZYEF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,C1CC(=O)N(C1)CC2=CC=C(C=C2)N3C4=C(COCC4)C(=N3)C(F)(F)F,5.096910013008056,O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1
36292,CHEMBL471195,URJAQUYCRCFSSV-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,870.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC=C1Cl)C2=CC(=O)N(C3=C2C=C(C=C3)[C@](C4=CC=C(C=C4)Cl)(C5=CN=CN5C)OC)C,6.060480747381382,CO[C@](c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1cccc(Cl)c1C)cc(=O)n2C)c1cncn1C
36305,CHEMBL2436217,URLHXBBEIISVEY-FXXKCHFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@H]1[C@@H](C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=C(C=CC4=C3C=CC=C4Br)OC)NC(=O)[C@H](C)NC.Cl,5.769551078621726,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3c(Br)cccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C
36334,CHEMBL396431,URXRYNAIWUJHTJ-MFMCTBQISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCN(C)C,4.494850021680094,CC(C)C[C@H](NCCN(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
36338,CHEMBL394864,URZMJARQWGKHCG-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,C1[C@@H](OC(=O)N1C2=CC(=C(C=C2)C3=CN=CC=C3)F)CN4C=CN=N4,5.167491087293763,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2cccnc2)c(F)c1
36343,CHEMBL2158287,USCISWISWCWWPX-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)[C@@H](CO)O)NC(=O)C4=NC=C(N4)C#N,5.086186147616283,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)[C@H](O)CO)CC3)cc2C2=CCCCC2)[nH]1
36349,CHEMBL2437428,USFZHGOWALHXMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)CN2C3=C(C=CC(=C3)F)N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC(=NC=C6)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC5CCCCC5)c5cc(F)ccc54)CC3)CC2)ccn1
36350,CHEMBL403525,USHUMFPTMMCHJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NN1C2=NC(=NC(=C2)NC(=O)CC3=CC(=CC(=C3)OC)OC)C4=CC=CC=N4)C,5.886056647693163,COc1cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc(OC)c1
36359,CHEMBL2348857,USLKIBNDGILVSI-XYPYZODXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)F)C(=N1)C3=CN=C4C(=N3)C(=CN4)C(=O)NC5CC(C5)O,4.301029995663981,Cn1nc(-c2cnc3[nH]cc(C(=O)NC4CC(O)C4)c3n2)c2ccc(F)cc21
36362,CHEMBL3664667,USNQWJSXGPOIQH-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CC1=CC(=CN(C1=O)C)C2=CC=C(C=C2)[C@H](C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn(C)c1=O
36366,CHEMBL3601323,USOMPACWXVKBTM-NYRHXDHDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26181851.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.,J. Med. Chem.,PUBLICATION,,CC(C)OC1=C(C=C2CC(=O)N([C@H](C2=C1)C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)N(C)CC5CCC(CC5)N(C)C)OC,5.026872146400302,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)CC3CCC(N(C)C)CC3)cc1)C(=O)C2
36367,CHEMBL1671965,USOPBKQVIILZGG-CHHVJCJISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)/C=C\2/C(=O)NC(=O)S2)OC3=C(C=C(C=C3)C(F)(F)F)Cl,5.0,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C(F)(F)F)cc1Cl
36369,CHEMBL53821,USPFJPDEADLGIG-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CN2C3=CC=CC4=C3C=C(C=C4)OC5=C(C=CC(=C5)CN6C=NC=C6CN[C@@H]1C2=O)C#N,5.301029995663981,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CC[C@H](NCc3cncn3C2)C1=O
36370,CHEMBL53821,USPFJPDEADLGIG-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CN2C3=CC=CC4=C3C=C(C=C4)OC5=C(C=CC(=C5)CN6C=NC=C6CN[C@@H]1C2=O)C#N,5.096910013008056,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CC[C@H](NCc3cncn3C2)C1=O
36375,CHEMBL513510,USSLQUIVSMCVBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18625554.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C(C=C1)CC2=NNC(=O)N2C)F)OC3=CC(=CC(=C3)C#N)Cl,4.920818753952375,Cc1ccc(Cc2n[nH]c(=O)n2C)c(F)c1Oc1cc(Cl)cc(C#N)c1
36377,CHEMBL1957816,USTBGZUJKCBYAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22325948.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Identification of fused bicyclic heterocycles as potent and selective 5-HT(2A) receptor antagonists for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1CCC2=C(C=C(C=C2)F)F)C(=O)C3=CC=CN4C3=NC=C4,4.3979400086720375,O=C(c1cccn2ccnc12)N1CCN(CCc2ccc(F)cc2F)CC1
36382,CHEMBL476116,USUPIRYFHGUVOR-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621528.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,5.522878745280337,CC(C)C(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
36396,CHEMBL1951343,UTAKVGKVXLTUNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,290.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1C(=O)C2=CC(=CC=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,6.537602002101044,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(C(=O)N2CCOCC2)c1
36397,CHEMBL3601186,UTAVZGFTYULZRM-OJWCNPDFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CC(=C1)NC2=NC=C(C(=N2)N[C@@H]3C[C@@H]([C@H]([C@H]3O)O)CO)C4=NC(=CS4)C5=CC=CC=C5,4.301029995663981,Cc1cc(Nc2ncc(-c3nc(-c4ccccc4)cs3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1
36403,CHEMBL1080603,UTFRBPAGKUDDNY-NSOVKSMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,741.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CC=CS2)C[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CC=CS4,6.130181792020672,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cccs1)C[C@H](Cc1ccccc1)NC(=O)OCc1cccs1
36426,CHEMBL599264,UTNWHVZSHUCJTA-REPLKXPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)OC1=CC=CC(=C1)CN(C2C[C@@H]3CNC[C@@H]3C2)C(=O)C4=CN(C=N4)C,5.0,CC(C)Oc1cccc(CN(C(=O)c2cn(C)cn2)C2C[C@@H]3CNC[C@@H]3C2)c1
36429,CHEMBL236184,UTPYURSIXIVBEJ-IFMALSPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)C(C)(C)CO,5.657577319177793,CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
36430,CHEMBL236184,UTPYURSIXIVBEJ-IFMALSPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)C(C)(C)CO,5.657577319177793,CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
36431,CHEMBL236184,UTPYURSIXIVBEJ-IFMALSPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19694467.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.,J. Med. Chem.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)C(C)(C)CO,5.698970004336019,CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
36435,CHEMBL1761844,UTSIHHDNMUZNMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21439819.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11ß-hydroxysteroid-dehydrogenase type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2=CC=CC=C2N(C1)C(=O)N3CCC(CC3)C4=CN=CN4,6.0,O=C(N1CCC(c2cnc[nH]2)CC1)N1CCCc2ccccc21
36438,CHEMBL2018331,UTTKPRISWKRTNJ-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22429469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active ¿-secretase modulators.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(C=N1)C2=C(N=C(C=C2)C(=O)N[C@H]3COC4=C3C(=C(C=C4)Cl)F)OC,4.522878745280337,COc1nc(C(=O)N[C@H]2COc3ccc(Cl)c(F)c32)ccc1-n1cnc(C)c1
36452,CHEMBL10532,UTZKWISWBRTAEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)C,4.769551078621726,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(C)c(=O)nc1SCc1ccc(F)cc1
36457,CHEMBL3673974,UUANLLGTKSTXOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320654,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,5.301029995663981,COc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1
36458,CHEMBL3673974,UUANLLGTKSTXOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320698,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,5.301029995663981,COc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1
36472,CHEMBL1092259,UUEDQZRCAVWNIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NC=CN=C3,5.0,CN(C)CCC1=C(Cc2cnccn2)c2ccc(Cl)cc2C1
36489,CHEMBL1077780,UUJAMNFWDAPMSE-MFCMXAAESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CCCN(C1)C(=O)N[C@H]2C[C@@H]2C3=CC=CC=C3)C4=CC=CC=C4,5.0,CC1(c2ccccc2)CCCN(C(=O)N[C@H]2C[C@@H]2c2ccccc2)C1
36498,CHEMBL1650652,UUOAAGDQRNIMNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21189020.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17ß-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=C(C=C3)O)C4=CC(=CC=C4)O,7.3979400086720375,Oc1cccc(-c2ccc3c(-c4cccc(O)c4)c(O)ccc3c2)c1
36512,CHEMBL3309278,UUTCNLFZEMSWPT-BJOHPYRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,46000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=NC=C1F)[C@](CN2N=CN=N2)(C3=C(C=C(C=C3)F)F)O,4.337242168318426,C[C@@H](c1ncncc1F)[C@](O)(Cn1ncnn1)c1ccc(F)cc1F
36514,CHEMBL3702773,UUTYIEWFDWBJML-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7620.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)OCCOC,5.1180450286604,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCOC)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
36516,CHEMBL520915,UUUXPUGZNDRYSV-GCKMJXCFSA-N,ALPHA-METHYLCUBEBIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,CO[C@H]1[C@@H]([C@H](CO1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,5.113509274827518,CO[C@@H]1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2
36533,CHEMBL450829,UUZQHDNTPXKEID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,74000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,CC(=O)C(=O)C1=CC(=C(C=C1OC)OC)OC,4.130768280269024,COc1cc(OC)c(C(=O)C(C)=O)cc1OC
36547,CHEMBL1987518,UVCJGUGAGLDPAA-UHFFFAOYSA-N,ENSULIZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)S(=O)(=O)O,5.0,O=S(=O)(O)c1ccc2nc(-c3ccccc3)[nH]c2c1
36548,CHEMBL1987518,UVCJGUGAGLDPAA-UHFFFAOYSA-N,ENSULIZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)S(=O)(=O)O,5.0,O=S(=O)(O)c1ccc2nc(-c3ccccc3)[nH]c2c1
36549,CHEMBL3422095,UVHDAKLRGJSVKQ-MOMDTQCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,940.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1CCC(C1)[C@@H](C2=NC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6[C@H]7CC[C@H]6CC(C7)O,6.026872146400302,O=C(N[C@H](c1ncccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1
36561,CHEMBL2441838,UVLAIQGSAPXWHH-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)C[C@H]3CCCO3)C4=C(C=C(C=C4)Cl)Cl)CN,4.853871964321762,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@H]1CCCO1)C2
36562,CHEMBL2441839,UVLAIQGSAPXWHH-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)C[C@@H]3CCCO3)C4=C(C=C(C=C4)Cl)Cl)CN,4.823908740944319,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCO1)C2
36570,CHEMBL3398175,UVPQQVIBGBMPDZ-YKSBVNFPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655723.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC=C1C2=CC=C3N2N=C(N=C3)NC4=C(C=C(C=C4)[C@H]5CCN(C[C@@H]5O)CCO)OC,4.920818753952375,COc1cc([C@H]2CCN(CCO)C[C@@H]2O)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1
36590,CHEMBL392642,UVZVWLFSZNPMBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BFC substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CSC1=CC=CC=C1CNC2=NC=C(C(=N2)NCC3CCC(CC3)CN)[N+](=O)[O-],5.161150909262744,CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1
36591,CHEMBL392642,UVZVWLFSZNPMBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BQ substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CSC1=CC=CC=C1CNC2=NC=C(C(=N2)NCC3CCC(CC3)CN)[N+](=O)[O-],4.522878745280337,CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1
36607,CHEMBL3702804,UWFLXEHFFLOHAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(=O)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,4.6020599913279625,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)=O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
36618,CHEMBL3261486,UWHBCOHEASCLEA-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@@H](C2)N3CCN4C5=C(C3=O)C=CC=C5NC4=O,4.301029995663981,O=C1c2cccc3[nH]c(=O)n(c23)CCN1[C@@H]1CN2CCC1CC2
36619,CHEMBL2037511,UWHCWRQFNKUYCG-QUZACWSFSA-N,EPELSIBAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239250.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(N=C(C=C2)C)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4,4.0,CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C
36620,CHEMBL2037511,UWHCWRQFNKUYCG-QUZACWSFSA-N,EPELSIBAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239250.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using diethoxyfluorescein as substrate,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(N=C(C=C2)C)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4,4.0,CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C
36627,CHEMBL3115821,UWIHILLUGAWUQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24354316.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Substituted 2-phenylimidazopyridines: a new class of drug leads for human african trypanosomiasis.,J. Med. Chem.,PUBLICATION,,C1CCN(C1)C(=O)NC2=CC(=C(C=C2)F)C3=NC4=C(N3)C=C(C=N4)C5=CC=CC=C5,5.823908740944319,O=C(Nc1ccc(F)c(-c2nc3ncc(-c4ccccc4)cc3[nH]2)c1)N1CCCC1
36648,CHEMBL2059852,UWQDLKXMRMJIJF-HKBQPEDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@H](CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.136677139879544,O=C(N[C@@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
36649,CHEMBL454751,UWQDLKXMRMJIJF-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.3979400086720375,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
36650,CHEMBL454751,UWQDLKXMRMJIJF-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.3979400086720375,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
36651,CHEMBL454751,UWQDLKXMRMJIJF-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.3979400086720375,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
36652,CHEMBL454751,UWQDLKXMRMJIJF-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.3979400086720375,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
36655,CHEMBL1923114,UWRLQDKZLAIUGI-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=C(C=C(C=C2)Cl)Cl)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F,5.721246399047171,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccc(Cl)cc1Cl)C1CC1
36657,CHEMBL1836317,UWSBTSAJZMIHBL-HDJSIYSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21782428.0,IC50,=,4100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)NCC1CCC(CC1)NC2=NC3=C(S2)CCSC4=CC=CC=C43,5.3872161432802645,CS(=O)(=O)NCC1CCC(Nc2nc3c(s2)CCSc2ccccc2-3)CC1
36674,CHEMBL537424,UXAMBBJHHKLTIB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,=,19700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)CC(C)C.Cl,4.705533773838407,CCCCN1C(=O)C(CC(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
36680,CHEMBL2441833,UXBUGZAYDAHAQU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CC3=NN(C=C3)C)C4=C(C=C(C=C4)Cl)Cl)CN,5.102372908709558,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ccn(C)n1)C2
36683,CHEMBL465451,UXDNAIXKDXHQMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C(=C1)Cl)C(=O)N(CCO)CC(CNC(=O)C2=C(N(N=C2)C3=CC=C(C=C3)F)N)(C(F)(F)F)O)Cl,4.0,Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(Cl)cccc2Cl)C(F)(F)F)cnn1-c1ccc(F)cc1
36687,CHEMBL225464,UXFAKWBTPNUZRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,68000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C=CC(=C3)Cl)F,4.167491087293763,O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)ccc2F)nc1C(F)(F)F
36689,CHEMBL1831092,UXFHVEVFSFZCGS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21838328.0,IC50,=,330.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26).",J. Med. Chem.,PUBLICATION,,CC(C)(C(C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2)N4C=NC=N4)C(=O)OC,6.481486060122113,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1cncn1
36691,CHEMBL1098712,UXGODHMBZZMTNL-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C(=O)COC,6.096910013008056,COCC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
36710,CHEMBL3088172,UXRSVTXAGGLLHU-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,J. Med. Chem.,PUBLICATION,,CC1=CSC(=N1)[C@@](C)(C2=NN=C(S2)NC3=NN(C=C3)CC4=C(C=CC=C4F)F)O,5.721246399047171,Cc1csc([C@](C)(O)c2nnc(Nc3ccn(Cc4c(F)cccc4F)n3)s2)n1
36722,CHEMBL512339,UXYYOHOTPOQJPD-OEPOZYLCSA-N,ZERUMBONE EPOXIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,48400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C/C/1=C\CC[C@@]2([C@H](O2)CC(/C=C/C1=O)(C)C)C,4.315154638355588,C/C1=C\CC[C@@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O
36727,CHEMBL327705,UYBIRMFTNJZIJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)CCCN(CC2=CC=C(C=C2)C3=CC=C(C=C3)Cl)C(=O)CN4C=C(C(=O)N=C4SCC5=CC=C(C=C5)F)CC6=CN(N=C6)C,5.0,CN1CCN(CCCN(Cc2ccc(-c3ccc(Cl)cc3)cc2)C(=O)Cn2cc(Cc3cnn(C)c3)c(=O)nc2SCc2ccc(F)cc2)CC1
36737,CHEMBL1698322,UYGDCIXFYIWDMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21966889.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,PUBLICATION,,C1C(C(=O)N(C1=O)C2=C(C=C(C=C2)NC(=O)C3=CC=CC=N3)Cl)C4=CC=CC=C4,4.522878745280337,O=C(Nc1ccc(N2C(=O)CC(c3ccccc3)C2=O)c(Cl)c1)c1ccccn1
36747,CHEMBL201094,UYJUZNLFJAWNEZ-UHFFFAOYSA-N,FUBERIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC=C2C(=C1)NC(=N2)C3=CC=CO3,5.0,c1coc(-c2nc3ccccc3[nH]2)c1
36748,CHEMBL201094,UYJUZNLFJAWNEZ-UHFFFAOYSA-N,FUBERIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CC=C2C(=C1)NC(=N2)C3=CC=CO3,5.0,c1coc(-c2nc3ccccc3[nH]2)c1
36772,CHEMBL1923131,UYULRDAPYWFIRZ-SJHOIFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=C(C(=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F)Cl)CCCN6CCS(=O)(=O)CC6,5.619788758288394,COCCCc1cc(CCCN2CCS(=O)(=O)CC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1
36779,CHEMBL3408948,UYYCHKFCCDPBMQ-AFYCESQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)N(C6=O)C,5.0,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2C
36780,CHEMBL3408948,UYYCHKFCCDPBMQ-AFYCESQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)N(C6=O)C,6.0,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2C
36784,CHEMBL483401,UYYWLFZGFMIWIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,CC1=C(C(N=C(N1)C2=CC(=NC=C2)Cl)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=CC5=C(C=C4)NN=C5,5.259637310505756,CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1
36793,CHEMBL1928092,UZBOQGXUHIEDSC-LQKURTRISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22100140.0,IC50,=,33200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.,Eur. J. Med. Chem.,PUBLICATION,,CC1=C(SC(=C1C#N)/N=C/C2=CC=C(C=C2)N(C)CCC#N)C3=CC(=C(C=C3)OC)OC,4.478861916295964,COc1ccc(-c2sc(/N=C/c3ccc(N(C)CCC#N)cc3)c(C#N)c2C)cc1OC
36816,CHEMBL2057521,UZHUXAQEJDDGHJ-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,7.221848749616356,CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
36829,CHEMBL1829767,UZLJFYGNQAZWLF-UZTOHYMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CC[C@](OC3=O)(CCCO)C4=CC=C(C=C4)F,5.096910013008056,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O
36848,CHEMBL3092124,UZVPIJMLVISXHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24252545.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after compound pre-incubation,Discovery of an irreversible HCV NS5B polymerase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1F)N(C(=C2C3=CC=CNC3=O)C(=O)O)CC4=CC5=CC=CC=C5N=C4Cl,4.301029995663981,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)O)n(Cc3cc4ccccc4nc3Cl)c2cc1F
36849,CHEMBL3092124,UZVPIJMLVISXHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24252545.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after concurrent incubation,Discovery of an irreversible HCV NS5B polymerase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1F)N(C(=C2C3=CC=CNC3=O)C(=O)O)CC4=CC5=CC=CC=C5N=C4Cl,4.301029995663981,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)O)n(Cc3cc4ccccc4nc3Cl)c2cc1F
36854,CHEMBL1096789,UZWZCPWLKKLXON-HOTGVXAUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,580.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)[C@H](C)NP(=O)(COC1=C2C(=C(C(=C1)C)C)CC3=C2N=CS3)N[C@@H](C)C(=O)OCC,6.236572006437063,CCOC(=O)[C@H](C)NP(=O)(COc1cc(C)c(C)c2c1-c1ncsc1C2)N[C@@H](C)C(=O)OCC
36859,CHEMBL1090210,VAAPJDSRZCMKSZ-QCPUYCGNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20236824.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,Design and synthesis of tricyclic sulfones as gamma-secretase inhibitors with greatly reduced Notch toxicity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@@]2([C@H](C[C@@H]1NS(=O)(=O)C3CC3)COC4=C(C=CC(=C42)F)F)S(=O)(=O)C5=CC=C(C=C5)Cl,4.522878745280337,O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C1CC1
36862,CHEMBL161,VAAUVRVFOQPIGI-SPQHTLEESA-N,CEFTRIAXONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)O,4.301029995663981,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1
36870,CHEMBL1191,VACCAVUAMIDAGB-UHFFFAOYSA-N,SULFAMETHIZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,835603.02,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,3.0779999990807125,Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1
36875,CHEMBL204419,VACZJUIZGZSWET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,CCN1CCC(CC1)(C2=CC=CC=C2)C(=O)NC3CCN(CC3)CC4=CC(=CC=C4)OC5=CC=CC=C5Cl,5.0,CCN1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1
36879,CHEMBL3702772,VAFLWJDQDRVGLV-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,19100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)(C)OC1=CC=C(C=C1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,4.718966632752273,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OC(C)(C)C)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
36892,CHEMBL2380646,VANVYRKGPFYCRZ-RLOPOPLLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CN=C(C=C2)N3CCN(C4=CC=CC=C43)C(=O)NC5C6CC7CC5CC(C7)(C6)O,4.522878745280337,CC(=O)N1CCN(c2ccc(N3CCN(C(=O)NC4C5CC6CC4CC(O)(C6)C5)c4ccccc43)nc2)CC1
36896,CHEMBL402813,VAPFYVRZDCWUAW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCN(CC(=O)N1CCCC(C1CN2CCOCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,6.318758762624412,COCCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1
36899,CHEMBL567292,VARGWBUXBMFVJN-UHFFFAOYSA-N,GSK554418A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19743867.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.",J. Med. Chem.,PUBLICATION,,CN1C=CC2=C1C(=CN=C2NC3=CC(=CC=C3)Cl)C(=O)N4CCOCC4,4.619788758288394,Cn1ccc2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c21
36905,CHEMBL2436215,VASRIQFKJJZKID-ZLLYMXMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)CS(=O)(=O)C)NC.Cl,5.0,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CS(C)(=O)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
36909,CHEMBL3664672,VATASNGCLCGJEL-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)CC(F)(F)F)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.7447274948966935,C[C@@H](c1ccc(-c2ccn(CC(F)(F)F)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
36911,CHEMBL607982,VAVBDQVWHLBYKB-FICVDOATSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)C(=O)N(CC2=CC(=C(C=C2)F)C(F)(F)F)C3C[C@@H]4CNC[C@@H]4C3,5.086186147616283,Cn1cnc(C(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)C2C[C@@H]3CNC[C@@H]3C2)c1
36912,CHEMBL596699,VAVBDQVWHLBYKB-QDMKHBRRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)C(=O)N(CC2=CC(=C(C=C2)F)C(F)(F)F)C3C[C@@H]4CNC[C@@H]4C3,5.0,Cn1cnc(C(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)C2C[C@@H]3CNC[C@@H]3C2)c1
36917,CHEMBL1289053,VAXDISKYVOZCHP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20961756.0,IC50,=,38000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN=C(N1)CN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5)C=N2,4.42021640338319,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CC2=NCCN2)c1
36918,CHEMBL237578,VAYCDIWDIOSEFX-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=CC=CC=C1N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCCN,5.468521082957745,CC(C)C[C@H](NCCCN)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
36921,CHEMBL2436632,VBAGFAWQNDYXGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C2=C(CCN(CC2)C3CCN(CC3)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F)C6=CC=CC=C61,4.522878745280337,Cn1c2c(c3ccccc31)CCN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CC2
36923,CHEMBL1818291,VBCGLTJYUOQZMW-MEMLXQNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21515056.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.,Bioorg. Med. Chem.,PUBLICATION,,CC(C)(C)OC(=O)NCC1CCC(CC1)CNC(=O)C2=CC(=NC3=CC=CC=C32)C4=CC=CC(=C4)CN,5.619788758288394,CC(C)(C)OC(=O)NCC1CCC(CNC(=O)c2cc(-c3cccc(CN)c3)nc3ccccc23)CC1
36943,CHEMBL3427276,VBHUDCXGFXRLFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25941547.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)CCC1=C(N=C2N1C=CC(=C2)Cl)CN3C4=C(C=CN=C4)N(C3=O)C5CC5,4.301029995663981,CS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12
36945,CHEMBL3087040,VBKISNMTKAPFLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CC(=C1)C2=CC(=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)OC,5.657577319177793,COc1cc(-c2ccnc(C)c2)ccc1NS(=O)(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
36966,CHEMBL2402572,VBUOSAKACWCALS-IOOJMYGHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23808489.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways.",J. Med. Chem.,PUBLICATION,,CC1=CC=CC=C1[C@@H]2[C@H](CC[C@H]3[C@H]2CN(C3)C4=NC(=O)CO4)O[C@H](CO)C5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F,4.823908740944319,Cc1ccccc1[C@@H]1[C@@H](O[C@H](CO)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H]2CN(C3=NC(=O)CO3)C[C@H]21
36969,CHEMBL3354553,VBVSLBXYPFYZIR-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25575658.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=NO1)NC(=O)[C@@H]2CCCCN2C(=O)N3CCS(=O)(=O)CC3,4.522878745280337,CC(C)(C)c1cc(NC(=O)[C@@H]2CCCCN2C(=O)N2CCS(=O)(=O)CC2)no1
36970,CHEMBL585487,VBVWWMHZQQUOKJ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=C2N=CC=C3)C(=O)C4=CC=CC=C4,4.3979400086720375,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccnc12
36971,CHEMBL585487,VBVWWMHZQQUOKJ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=C2N=CC=C3)C(=O)C4=CC=CC=C4,4.3979400086720375,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccnc12
36983,CHEMBL240646,VBZRXOXVUUYQOV-GOSISDBHSA-N,SR-1357,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)[C@@H](CC4=CC=CC=C4)N,5.154901959985743,N[C@H](Cc1ccccc1)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1
36992,CHEMBL3608683,VCDLSNHPAIHNNG-LLVKDONJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NO4)C(C)C,4.0,CC(C)c1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1
36995,CHEMBL392465,VCENFKCGBAWAEQ-FTJBHMTQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)F)[C@H]2CN(C[C@@H]2C3=NOC(=N3)C(C)(C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C(=O)C5CCN(CC5)C(=O)C,4.0,CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](c3noc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)C2)CC1
37009,CHEMBL2048183,VCLQAHLNTRBSNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=CC=CC=C3N2CC(=O)O,4.431798275933005,COc1ccc(C(C)=O)cc1CSc1nc2ccccc2n1CC(=O)O
37010,CHEMBL2048183,VCLQAHLNTRBSNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=CC=CC=C3N2CC(=O)O,4.301029995663981,COc1ccc(C(C)=O)cc1CSc1nc2ccccc2n1CC(=O)O
37011,CHEMBL1277678,VCLTUEPMXZBALZ-FHZUCYEKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,C1C[C@@]2(CC1N3CCC(CC3)(C(=O)O)F)CC4=CC=CC=C4CC5=CC=CC=C25,5.0,O=C(O)C1(F)CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CC1
37018,CHEMBL444533,VCNRITFCECGWNQ-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,430.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC=C(O2)C3=CC=CC=C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CN=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,6.366531544420414,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
37019,CHEMBL444533,VCNRITFCECGWNQ-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,430.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC=C(O2)C3=CC=CC=C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CN=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,6.366531544420414,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
37037,CHEMBL1097165,VCTMBHZQYKYSTO-RBSBEOHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,650.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OC[P@@]4(=O)OCC[C@H](O4)C5=CC=C(C=C5)Cl,6.187086643357144,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccc(Cl)cc3)O2)c2c(c1C)Cc1scnc1-2
37038,CHEMBL1097180,VCTMBHZQYKYSTO-YRVHBCJASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,730.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OC[P@]4(=O)OCC[C@H](O4)C5=CC=C(C=C5)Cl,6.136677139879544,Cc1cc(OC[P@]2(=O)OCC[C@@H](c3ccc(Cl)cc3)O2)c2c(c1C)Cc1scnc1-2
37042,CHEMBL1762808,VCUDJYYRRWZBSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21411321.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as a substrate,"Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(CCO)CC1=CSC(=N1)C2=CN(C3=C2C=CC=C3Cl)CC4CCOCC4,4.0,CC(C)N(CCO)Cc1csc(-c2cn(CC3CCOCC3)c3c(Cl)cccc23)n1
37043,CHEMBL1762808,VCUDJYYRRWZBSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21411321.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using dibenzylfluorescein as a substrate,"Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(CCO)CC1=CSC(=N1)C2=CN(C3=C2C=CC=C3Cl)CC4CCOCC4,4.0,CC(C)N(CCO)Cc1csc(-c2cn(CC3CCOCC3)c3c(Cl)cccc23)n1
37052,CHEMBL3121694,VCYDWWJWQPVMIA-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1F)C(=C(N2C3=NC=C(C=N3)F)C4=NC=C(C=C4)S(=O)(=O)N[C@@H](C)C(F)(F)F)C#N,5.0,Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncc(F)cn1
37053,CHEMBL2178807,VCZAFUUQQIEMKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=NN(C(=C1)NC(=O)C2=C3N=C(C=CN3N=C2)N)C4=CC(=CC=C4)Cl,5.0,Cc1cc(NC(=O)c2cnn3ccc(N)nc23)n(-c2cccc(Cl)c2)n1
37078,CHEMBL400642,VDKRGTBLHFOGSC-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=C(C=CC=C1F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,5.214670164989233,CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
37079,CHEMBL2425603,VDLAKWBRPSVZBP-XPLIUGCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)OC1=CC=CC(=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F,6.045757490560675,COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(OC(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F
37089,CHEMBL3702762,VDQAOEVDXCKSBE-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6800.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NNC7=CC=CC=C7,5.167491087293763,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NNc5ccccc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
37096,CHEMBL3109802,VDRYGTNDKXIPSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCCO)N=C1,4.301029995663981,COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc32)c1C
37098,CHEMBL3358937,VDSMZEJGVOMCGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=CC=C4S(=O)(=O)C,8.0,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O
37102,CHEMBL3702747,VDUNEFAIXQBADT-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2860.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(C)CCN7CCOCC7,5.543633966870957,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
37118,CHEMBL1093294,VDXIBLBHDRKGBK-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(N=CC=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,COc1ncccc1[C@@H](C)c1c(CCN(C)C)sc2ccccc12
37132,CHEMBL2420681,VEDXLNFHAQEVMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CC(=CN=C3)OC,5.0,COc1cncc(-c2ccc3ccc(OC)cc3c2Cl)c1
37145,CHEMBL319754,VEMZPXZQLOLLKQ-ILFWFZRHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15139756.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NC(=N1)O[C@H](C(=O)O)[C@@]2(C3=CC=CC=C3N(C(=O)CN2)CC4=C(C=C(C=C4F)F)F)C5=CC=CC(=C5)C6=CC=CC=C6)C,5.154901959985743,Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3cccc(-c4ccccc4)c3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1
37157,CHEMBL119385,VEPKQEUBKLEPRA-UHFFFAOYSA-N,VX-745,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl,4.3979400086720375,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl
37165,CHEMBL2165499,VEPWTRQLXLDABP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC1=NC2=CC=CC=C2N1C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCN(CC6)C(C)(C)C(=O)N,5.0,Cc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C(C)(C)C(N)=O)CC3)cc2n1
37191,CHEMBL1269684,VETZEDDIBGTLQT-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCNC(=O)CC(F)(F)F)Cl)C5CC5)Cl,5.552841968657781,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CCNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
37192,CHEMBL1269684,VETZEDDIBGTLQT-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCNC(=O)CC(F)(F)F)Cl)C5CC5)Cl,5.346787486224656,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CCNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
37216,CHEMBL3581145,VFDUENSNKFWMNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=CC(=NC=C3)Cl,5.443697499232713,COc1cccc(CC(=O)Nc2nc(-c3ccnc(Cl)c3)cs2)c1
37229,CHEMBL3115178,VFJGSZLCNCKFER-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCNC)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.886056647693163,CNCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
37254,CHEMBL1921978,VFQVXPOUVYTBQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,CC1(CN2C=NC=C2C1(C3=CC4=C(C=C3)C=C(C=C4)C(=O)NC)O)C,5.494850021680094,CNC(=O)c1ccc2cc(C3(O)c4cncn4CC3(C)C)ccc2c1
37314,CHEMBL494630,VGGVRYBMGLIVTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=CC(=C5)F)F,5.080921907623926,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1
37315,CHEMBL494630,VGGVRYBMGLIVTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=CC(=C5)F)F,4.301029995663981,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1
37317,CHEMBL10921,VGIQUSQBXZXBGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN(N=C5)C,5.0,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
37318,CHEMBL10921,VGIQUSQBXZXBGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN(N=C5)C,5.0,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
37319,CHEMBL1241548,VGJMSZYBBPAAOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,<,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C(=C(N=C6CO5)C)C,5.3979400086720375,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nc(C)c(C)n4-5)CC3)cccc2n1
37324,CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,6.096910013008056,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
37327,CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,13600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,4.866461091629782,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
37340,CHEMBL550465,VGQBIBJVDNWZRI-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C1)C3=C(N2CC(=O)O)C=CC=N3)S(=O)(=O)C4=CC=C(C=C4)F,4.522878745280337,CN([C@@H]1CCc2c(c3ncccc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1
37353,CHEMBL1243333,VGVKTKUHIJKMHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20690643.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC=C(C=C1)SCC(C2CCNCC2)C3=CN=CN3,5.187086643357144,CC(C)(C)c1ccc(SCC(c2cnc[nH]2)C2CCNCC2)cc1
37354,CHEMBL1080604,VGWCZAIIXZBYSZ-NSOVKSMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,>,300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CNN=C2)C[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CNN=C4,6.522878745280337,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cn[nH]c1)C[C@H](Cc1ccccc1)NC(=O)OCc1cn[nH]c1
37379,CHEMBL377931,VHHPNELKVATLRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C(=O)O)CC2=CC(=CC=C2)OC3=CC=CC=C3,5.0,O=C(O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1
37382,CHEMBL2205054,VHKBDODTXKHVJR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,CC1=C(C=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C.Cl,4.958607314841775,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1C
37388,CHEMBL1829485,VHKZHZYOGPESQF-JKSUJKDBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21782432.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1C[C@H](C)COC2=CC=C(C=C2)C3=NN(C(=O)C=C3)C,4.522878745280337,C[C@H](COc1ccc(-c2ccc(=O)n(C)n2)cc1)CN1CCC[C@H]1C
37397,CHEMBL391189,VHOKSFYGSMXMTN-GOSISDBHSA-N,SR-1349,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)[C@@H](C4=CC=CC=C4)N,6.327902142064283,N[C@@H](C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccccc1
37398,CHEMBL1270910,VHQZXUBTPDOCIZ-GGSCPBHOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@@H]1CCN(C1)C(=O)OC2C3CC4CC2CC(C4)(C3)C(=O)N,4.522878745280337,CC(C)(C)OC(=O)N[C@@H]1CCN(C(=O)OC2C3CC4CC2CC(C(N)=O)(C4)C3)C1
37413,CHEMBL1761523,VHSIEYYFBUUDJV-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC(C)(C)O)C5CC5)Cl,5.251811972993799,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)O)c1
37414,CHEMBL1761523,VHSIEYYFBUUDJV-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC(C)(C)O)C5CC5)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)O)c1
37416,CHEMBL3702824,VHTAZBLWIMFABR-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=S)NC(=O)C8=CC=CC=C8,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=S)NC(=O)c6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
37424,CHEMBL1835949,VHVPQPYKVGDNFY-ARROIKNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,CC[C@H](C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@@H]5CO[C@@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,8.397940008672037,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37428,CHEMBL1835951,VHVPQPYKVGDNFY-DFMJLFEVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,CC[C@@H](C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,8.397940008672037,CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37432,CHEMBL454471,VHVPQPYKVGDNFY-DKYCYSLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,CC[C@@H](C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@@H]5CO[C@@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,8.397940008672037,CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37433,CHEMBL1835954,VHVPQPYKVGDNFY-MZPAXQNMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,CC[C@H](C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7.698970004336019,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37438,CHEMBL1835953,VHVPQPYKVGDNFY-OPVGUIJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,16.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,CC[C@@H](C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7.795880017344075,CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37448,CHEMBL1835952,VHVPQPYKVGDNFY-PGTZCRIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,17.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,CC[C@H](C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7.769551078621726,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37457,CHEMBL1835950,VHVPQPYKVGDNFY-TUJWMRSMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,CC[C@H](C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,8.397940008672037,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37458,CHEMBL64391,VHVPQPYKVGDNFY-UHFFFAOYSA-N,ITRAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27955926.0,IC50,=,32.6,NM,,inhibition,tissue,,,,,,,,,,,,,,,,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7.486782399932061,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37459,CHEMBL64391,VHVPQPYKVGDNFY-UHFFFAOYSA-N,ITRAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27014922.0,IC50,=,50.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins by LC/MS/MS analysis,Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.,J. Med. Chem.,PUBLICATION,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7.297569463554475,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37460,CHEMBL1835955,VHVPQPYKVGDNFY-VKHSVWCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,CC[C@@H](C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7.585026652029182,CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37465,CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,6.154901959985743,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37467,CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,70.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,7.154901959985743,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37470,CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,900.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,6.045757490560675,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
37475,CHEMBL195217,VHWBXEUHUQDHDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324762.0,IC50,=,1580.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.",J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C=C(C=C3)O,5.801342913045578,Oc1cccc(-c2ccc3cc(O)ccc3c2)c1
37496,CHEMBL1957676,VIEBGHIBCUYPNE-VWNXMTODSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCC1=CC=CC=C1C2=CC(=C(C=C2)[C@H]3CNCC[C@@H]3C4=CC(=C(C=C4)F)F)Cl,4.698970004336019,CC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)c(Cl)c1
37520,CHEMBL1087493,VILNAIPEYFWQQH-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOCCN1C2=CC=CC=C2N=C1N3CC[C@@H](C3)N(C)C,5.301029995663981,CCOCCn1c(N2CC[C@H](N(C)C)C2)nc2ccccc21
37521,CHEMBL285343,VIMSJHBPSQABPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,11790.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3N(C5=C4C(=CC=C5)[N+](=O)[O-])CCC6=CC=CC=C6,4.928486194904911,O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2CCc1ccccc1
37522,CHEMBL3702690,VINDQDYEPNHNKQ-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,4.913640169325252,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
37523,CHEMBL204684,VINGQXPBSLYVAK-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(COC1=CC2=C(C=C1)C=C(C=C2)[C@H](CN(C)C)N3C=CN=C3)C(=O)O,4.698970004336019,CN(C)C[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
37538,CHEMBL221044,VIVBCFKGUVZCLT-LRDJCYRESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17274610.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CCCC1=C(C=CC(=C1)C2=NC3C(S2)CCCO3)OCCCOC4=CC5=C(C=C4)[C@@H](CC5)CC(=O)O,5.0,CCCc1cc(C2=NC3OCCCC3S2)ccc1OCCCOc1ccc2c(c1)CC[C@H]2CC(=O)O
37546,CHEMBL1095681,VIYHZEAFVCWOMU-YMGMXPECSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OC[P@@]4(=O)OCC[C@H](O4)C5=CC=NC=C5,5.657577319177793,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccncc3)O2)c2c(c1C)Cc1scnc1-2
37548,CHEMBL401323,VIYNQEBUNVSDPK-GUDVDZBRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1C[C@H](C[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)CCO)O,4.522878745280337,CC[C@@H]1C[C@@H](O)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
37549,CHEMBL249086,VIYNQEBUNVSDPK-QRVBRYPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,15600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1C[C@@H](C[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)CCO)O,4.806875401645538,CC[C@@H]1C[C@H](O)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
37550,CHEMBL3645225,VIZKFHFQFJRUES-RUDMXATFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2250.0,NM,221149,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. Inhibition assay using P450 CYP enzymes.,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,PATENT,,CNC(=O)/C=C/C1=CC(=CC(=C1)OC)C2=CC3=C(C=C2)C=C(C=C3)OC,5.647817481888637,CNC(=O)/C=C/c1cc(OC)cc(-c2ccc3cc(OC)ccc3c2)c1
37554,CHEMBL564757,VJCACPMAAVZCPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC(=NO2)C3=CN=CC=C3)C(=O)NC4CC4C5=CC=CC=C5,5.0,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cccnc3)no2)CC1
37568,CHEMBL3706619,VJEYRJGOROCIKW-NKDCNHMZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852968.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC=C(O2)C3=CC=CC=N3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,5.2839966563652006,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccn3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
37575,CHEMBL3326588,VJJGAJAUECQWSZ-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4)Cl)(CF)CF)C=N1,4.698970004336019,Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4cc(Cl)ccc43)cccc2cn1
37579,CHEMBL44657,VJJPUSNTGOMMGY-MRVIYFEKSA-N,ETOPOSIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,4.301029995663981,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
37592,CHEMBL165064,VJJZJBUCDWKPLC-UHFFFAOYSA-N,ISOKAEMPFERIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,36200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,COC1=C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O,4.441291429466834,COc1c(-c2ccc(O)cc2)oc2cc(O)cc(O)c2c1=O
37605,CHEMBL513023,VJOBNGRIBLNUKN-ITZZLVQVSA-N,MEDIORESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,13700.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,COC1=CC(=CC(=C1O)OC)C2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C=C4)O)OC,4.863279432843593,COc1cc([C@H]2OC[C@@H]3C(c4cc(OC)c(O)c(OC)c4)OC[C@H]23)ccc1O
37611,CHEMBL389810,VJVGNLWFBAMJAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)C5=CC=CC(=C5)C#N)N(C2=O)CC6=CC=CC=C6F,5.0,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cccc(C#N)c5)cc4)CC3)C2=O)c1
37612,CHEMBL1834663,VJVZPGBCTGRTJD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC(=CC=C1)NC2=CC(=NC=N2)N(C)C(=O)NC3=C(C(=CC(=C3Cl)OC)OC)Cl,7.0,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN(C)C)c3)ncn2)c1Cl
37613,CHEMBL1834663,VJVZPGBCTGRTJD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC(=CC=C1)NC2=CC(=NC=N2)N(C)C(=O)NC3=C(C(=CC(=C3Cl)OC)OC)Cl,5.6020599913279625,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN(C)C)c3)ncn2)c1Cl
37623,CHEMBL3646210,VKBFHTIUXUCYRQ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 µL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 µg/mL) were incubated with 5 concentrations of test compound (from 0.1 µM to 10 µM), 1 mM NADPH (Sigma), and 2 µM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,CC1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)C[C@H](C)O)N,5.0,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](C)O)c5)cnc(N)c34)cc2)c1
37633,CHEMBL2170643,VKFYSQSTERJHNR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=C(C=C3)F,5.221848749616356,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccc(F)cc3)CC2)c(C(F)(F)F)c1
37634,CHEMBL539168,VKGRHANZJPGGQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,3364.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C(CC3)(C4=CC=NC=C4)O)F,5.473144012874125,COc1ccc(-c2ccc3c(c2)CCC3(O)c2ccncc2)cc1F
37673,CHEMBL1215552,VKOYHMBQGJRYAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20672820.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C(C(=C(N1)CN2C=CN=C2)C(=O)OC)C3=C(C=C(C=C3)F)Cl)C#N,6.698970004336019,COC(=O)C1=C(Cn2ccnc2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl
37692,CHEMBL1949940,VKSDHNUDPMJHKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=NC=CO4)O)OC,5.356547323513812,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ncco3)c2c1
37693,CHEMBL1949940,VKSDHNUDPMJHKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=NC=CO4)O)OC,5.107905397309519,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ncco3)c2c1
37700,CHEMBL1951332,VKUPYUAAOPDZKP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,44.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,7.356547323513813,CCOC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
37702,CHEMBL1269674,VKUUNUNXIVLQGO-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNC)Cl)C5CC5)Cl,4.823908740944319,CNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
37703,CHEMBL1269674,VKUUNUNXIVLQGO-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNC)Cl)C5CC5)Cl,4.769551078621726,CNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
37711,CHEMBL2375587,VKZMICHNLVMXRJ-UAPYVXQJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535326.0,IC50,=,30300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel and highly potent histamine H3 receptor ligands. Part 3: An alcohol function to improve the pharmacokinetic profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)CCCOC2=CC=C(C=C2)C3CCC(CC3)O,4.518557371497695,OC1CCC(c2ccc(OCCCN3CCCCC3)cc2)CC1
37713,CHEMBL2041180,VLBBPWTZWIHQLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CN=C(C=C5)C6=CC=C(C=C6)C(=O)O,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
37731,CHEMBL2425615,VLHAYZZEMIYRND-PVRJFLCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC[C@H](C(F)(F)F)OC1=C(C(=CC(=C1)C[C@@H]2CS(=O)C[C@@H]([C@H]2O)N)F)N,5.0,COC[C@@H](Oc1cc(C[C@@H]2C[S+]([O-])C[C@H](N)[C@H]2O)cc(F)c1N)C(F)(F)F
37738,CHEMBL2181331,VLNBTEQPYIXIMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21604762.0,IC50,=,370.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.",J. Med. Chem.,PUBLICATION,,C1CCN(CC1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,6.431798275933005,C1=CCOCc2cc(ccc2OCCN2CCCCC2)Nc2nccc(n2)-c2cccc(c2)COC1
37748,CHEMBL3672576,VLNZCNIBUVLVDW-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,160.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CS(=O)(=O)C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.795880017344075,CC(C)c1nc(CN(C)C(=O)N2CS(=O)(=O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
37749,CHEMBL3672576,VLNZCNIBUVLVDW-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,260.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CS(=O)(=O)C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.585026652029182,CC(C)c1nc(CN(C)C(=O)N2CS(=O)(=O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
37757,CHEMBL2420615,VLPQNEWDWXCJON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859074.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II.,J. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)C2=NN(C3=NC(=O)N(C(=O)C3=N2)C)C,6.0,CCc1ccc(-c2nc3c(=O)n(C)c(=O)nc-3n(C)n2)cc1
37758,CHEMBL3403823,VLPSRHJLJIZUBN-HRANHPEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)C9CCC9)C)C)O)C)C(C)(C)O,5.113509274827518,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
37759,CHEMBL3403823,VLPSRHJLJIZUBN-HRANHPEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)C9CCC9)C)C)O)C)C(C)(C)O,4.886056647693163,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
37763,CHEMBL3114787,VLRZGIHSKGUGTB-FICVDOATSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24461352.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C[C@@H]2[C@H](C1)C2CN(CC3=CC(=C(C=C3)Cl)F)C(=O)C4=CN(C=N4)C,5.0,CN1C[C@@H]2C(CN(Cc3ccc(Cl)c(F)c3)C(=O)c3cn(C)cn3)[C@@H]2C1
37774,CHEMBL3112850,VLUJVXBQLNFVKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=C1C(=CC=C2)Br)C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Br)cccc21
37788,CHEMBL1667925,VLZBNNUEXCARSV-JCMHNJIXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21211972.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC(=O)C1=C(C2=C(O1)C=NC=C2)NC3=CC4=C(C=C3)/C(=N\O)/CC4,5.080921907623926,CCOC(=O)c1oc2cnccc2c1Nc1ccc2c(c1)CC/C2=N/O
37807,CHEMBL2323775,VMJFTOSOFDEKTM-UHFFFAOYSA-N,MK-8033,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23379595.0,IC50,=,11580.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS-MS analysis,"Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met.",J. Med. Chem.,PUBLICATION,,CN1C=C(C=N1)C2=CC3=C(C=CC4=C(C3=O)C=C(C=C4)CS(=O)(=O)NCC5=CC=CC=N5)N=C2,4.936291440608582,Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1
37813,CHEMBL347303,VMKNDIQDOBATQU-UHFFFAOYSA-O,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CC=[N+](N2)C,4.0,CCCCOc1ccc(-c2cc[n+](C)[nH]2)cc1
37814,CHEMBL557262,VMMGFPNGNCDEDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,570.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1NC(=O)NC(CN2C=NC=N2)C3=CC=CC=C3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,6.2441251443275085,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1cncn1)c1ccccc1
37820,CHEMBL259922,VMOVZKURWYNTLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18359226.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)C(=O)NC2=NOC=C2)NC3=C4C=NN(C4=NC=N3)C5=CC=CC=C5,4.3979400086720375,Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1
37823,CHEMBL3633321,VMQJQZZJFVZNTF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26363868.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human Liver microsomes after 5 mins by LC-MS/MS method,3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.,Eur. J. Med. Chem.,PUBLICATION,,C1CN(CCN1CC2=CC(=C(C=C2)Cl)Cl)C(=O)CN3C=NC(=N3)[N+](=O)[O-],4.698970004336019,O=C(Cn1cnc([N+](=O)[O-])n1)N1CCN(Cc2ccc(Cl)c(Cl)c2)CC1
37828,CHEMBL497137,VMTCAWWXUQDLPT-DFEHQXHXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,73500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,CCC1=CC(=CC(=C1O)CC)/C=C\2/C(=O)/C(=C/C3=CC(=C(C(=C3)CC)O)CC)/CC2,4.133712660915805,CCc1cc(/C=C2\CC/C(=C\c3cc(CC)c(O)c(CC)c3)C2=O)cc(CC)c1O
37829,CHEMBL497137,VMTCAWWXUQDLPT-DFEHQXHXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,73451386.82,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,CCC1=CC(=CC(=C1O)CC)/C=C\2/C(=O)/C(=C/C3=CC(=C(C(=C3)CC)O)CC)/CC2,1.1339999999746435,CCc1cc(/C=C2\CC/C(=C\c3cc(CC)c(O)c(CC)c3)C2=O)cc(CC)c1O
37832,CHEMBL439727,VMVGGLFKABPLBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,31310.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=CC=CC(=C2C3=C1C(=NC(=N3)CN4CCOCC4)N5CCN(CC5)CCC6=CC(=C(C=C6)F)F)C(=O)N,4.504316932383085,Cn1c2cccc(C(N)=O)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
37841,CHEMBL120067,VMXIUTUFHIFDKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177483.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(N1)C=C(C(=C2)OC)C(=O)C3=CC=C(C=C3)NC4=C(C=C(C=C4)F)F,5.698970004336019,COc1cc2nc(C)[nH]c2cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1
37843,CHEMBL1790041,VMXUWOKSQNHOCA-UHFFFAOYSA-N,RANITIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,4.301029995663981,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
37849,CHEMBL499007,VMXXQQUNEIDJSC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,COC1=CN=CC(=C1)C2=CC3=C(CC(=O)CC3)C=C2,5.42021640338319,COc1cncc(-c2ccc3c(c2)CCC(=O)C3)c1
37853,CHEMBL1093044,VMZBJCIUNPGQKF-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCNC,5.0,CNCCc1sc2ccccc2c1[C@@H](C)c1ccccn1
37875,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,300.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,6.522878745280337,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
37876,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,500000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,3.3010299956639813,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
37877,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,20.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,7.698970004336019,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
37879,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,7.301029995663981,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
37880,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,7.0,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
37886,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,7.795880017344075,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
37897,CHEMBL2397187,VNGAUNCZCLFPCA-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C,5.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)c1
37906,CHEMBL231409,VNHSWSVUHFYHIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=O)NC,5.431798275933005,CNC(=O)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1
37915,CHEMBL598215,VNJFIBFHISUZRV-ZACQAIPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,COC[C@@H]1[C@@H]2[C@]1(CNC2)C3=CC4=CC=CC=C4C=C3,5.3979400086720375,COC[C@@H]1[C@H]2CNC[C@]21c1ccc2ccccc2c1
37917,CHEMBL2163823,VNJOULOPKZCEMY-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1N)C(=O)[C@H](CC2=CC=C(C=C2)Br)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,5.096910013008056,NC1CCN(C(=O)[C@H](Cc2ccc(Br)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
37950,CHEMBL499588,VNZZTXDBRSOFHQ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)COCC(=O)O)N,4.698970004336019,N[C@@H](Cn1c(=O)c(-c2ccc(COCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
37952,CHEMBL3116156,VOCAUMUELJMEHG-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@](C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=CC=CC=C5N4,4.886056647693163,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3ccccc3[nH]2)c2ccc(Cl)cn2)c1
37953,CHEMBL3116156,VOCAUMUELJMEHG-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C[C@](C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=CC=CC=C5N4,4.3979400086720375,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3ccccc3[nH]2)c2ccc(Cl)cn2)c1
37958,CHEMBL231609,VOEZJKBTZPTQLU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=O)NC5CCCC5,5.795880017344075,Cc1cc(C(=O)NC2CCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
37981,CHEMBL2057776,VORKZGMPBYXFTH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22749871.0,IC50,<,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CPY3A4,Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2CN(CC2CN1C3=CC=NC=C3)C(=O)C4CN(C4)S(=O)(=O)C5=CC=CC6=C5C=CN=C6,5.6020599913279625,O=C(C1CN(S(=O)(=O)c2cccc3cnccc23)C1)N1CC2CN(c3ccncc3)CC2C1
37992,CHEMBL1949942,VOUAUMKVLOMARH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CS4)O)OC,6.698970004336019,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cncs3)c2c1
37993,CHEMBL1949942,VOUAUMKVLOMARH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CS4)O)OC,6.154901959985743,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cncs3)c2c1
37998,CHEMBL1911818,VOUTUZMXSRIFMF-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCN(CC1)C(=O)[C@@H](COCC2=CC3=C(C=C2)OCCO3)NC(=O)C4=C(N=CC=C4)OC5=C(C=C(C=C5)C(F)(F)F)Cl,5.481486060122113,CN1CCN(C(=O)[C@@H](COCc2ccc3c(c2)OCCO3)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
38019,CHEMBL1923121,VOVWPJYRKUBSTK-JOMNFKBKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC2=CC=CC=C2C(=C1)CN(C3CC3)C(=O)[C@H]4CNCC[C@]45C6=CC(=C(C=C6CO5)F)F,5.795880017344075,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c2ccccc2c1
38025,CHEMBL2069805,VOXSTMJILMNHJT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,C1CCC(CC1)NC(=O)C2=NC(=NO2)CS(=O)(=O)C3=CC=CC=C3,4.698970004336019,O=C(NC1CCCCC1)c1nc(CS(=O)(=O)c2ccccc2)no1
38028,CHEMBL2017283,VOXWVXCIJOFLCE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C5=CC=CC=C5C(C)(C)C)OC,5.769551078621726,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3C(C)(C)C)c12
38029,CHEMBL2017283,VOXWVXCIJOFLCE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C5=CC=CC=C5C(C)(C)C)OC,5.769551078621726,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3C(C)(C)C)c12
38040,CHEMBL502341,VPAUFXIBDRBNIX-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2Cl)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F,4.958607314841775,COc1cccc(-c2c(C)n(Cc3c(F)cccc3Cl)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F
38041,CHEMBL239299,VPAXWNMEGKLSOJ-GMUIIQOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O,4.0,C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1
38042,CHEMBL239299,VPAXWNMEGKLSOJ-GMUIIQOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O,4.0,C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1
38043,CHEMBL239299,VPAXWNMEGKLSOJ-GMUIIQOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using diethoxyfluorescein substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O,4.0,C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1
38048,CHEMBL3702763,VPECJBKJBLKBNM-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5650.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)(C)OC(=O)N1CCC(CC1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.247951552180561,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)OC(C)(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
38051,CHEMBL2401818,VPGLBWRUBBOYIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23773865.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CP3A4 (unknown origin),"Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C#CCC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C3C(=CN=C2N)C(=CO3)C4=CN(N=C4)C5CCNCC5,5.795880017344075,C#CCC(Oc1c(N)ncc2c(-c3cnn(C4CCNCC4)c3)coc12)c1c(Cl)ccc(F)c1Cl
38055,CHEMBL1208965,VPGSHWKKZVAVBK-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN=C(C=C5)NC6CCN(CC6)C)C(=O)N,5.468521082957745,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccc(NC5CCN(C)CC5)nc4)ccc32)sc1C(N)=O)c1ccccc1Cl
38056,CHEMBL1208965,VPGSHWKKZVAVBK-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN=C(C=C5)NC6CCN(CC6)C)C(=O)N,4.795880017344075,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccc(NC5CCN(C)CC5)nc4)ccc32)sc1C(N)=O)c1ccccc1Cl
38057,CHEMBL443065,VPGTXENSHDCTLV-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)N(C)CC1=NC(=NO1)CC2(CC2)[C@H]3CCC[C@H](N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,5.508638306165727,CN(Cc1nc(CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)no1)C(C)(C)CO
38058,CHEMBL1910108,VPGYQTGJKYIUMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,670.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=C(C=C3)C#N)C4=C(C=C(C=C4)Cl)Cl)CN,6.173925197299173,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(C#N)cc1)C2=O
38059,CHEMBL3702686,VPIPGPIOBMSQSI-HHDOLNPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6400.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=O)N8CCN(CC8)S(=O)(=O)C,5.1938200260161125,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
38060,CHEMBL3702818,VPIPGPIOBMSQSI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6400.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=O)N8CCN(CC8)S(=O)(=O)C,5.1938200260161125,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
38071,CHEMBL1949938,VPLAJHSHSVVJEM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=CC=N4)O)OC,5.337242168318426,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccccn3)c2c1
38072,CHEMBL1949938,VPLAJHSHSVVJEM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,10600.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=CC=N4)O)OC,4.97469413473523,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccccn3)c2c1
38074,CHEMBL252636,VPLYLBCWMYERNA-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=C(C(=CC=C1)F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,5.337242168318426,CC(C)(C)OC(=O)N[C@H](Cc1cccc(F)c1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
38101,CHEMBL561932,VPYHMFOFGLWNPN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19574047.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C=C(C2=C1N(N=C2)C3=CC=C(C=C3)F)NC4=C(C=CC(=C4)C(=O)NC5CC5)Cl,4.522878745280337,Cn1c(=O)cc(Nc2cc(C(=O)NC3CC3)ccc2Cl)c2cnn(-c3ccc(F)cc3)c21
38110,CHEMBL2431456,VQCSFAUVYAVXEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,=,340.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC(=CC(=C1OC)CCC2=CC=C(C=C2)NS(=O)(=O)C)C3=CC=CNC3=O,6.468521082957745,COc1c(CCc2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C
38111,CHEMBL2334764,VQCWJZWGHDLXCC-ZAAXVRCTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C[C@@H]4CC[C@H]3N4S(=O)(=O)C)C(=N2)N5CCOC[C@@H]5C,5.301029995663981,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)C[C@@H]2CC[C@H]3N2S(C)(=O)=O)cc1
38116,CHEMBL2170609,VQGJOZLBMBECDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,CCC(=O)N1CCC(CC1)C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F,4.585026652029182,CCC(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
38148,CHEMBL3702721,VQOICHPDWXYAPI-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2230.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)N(C)C,5.651695136951839,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
38149,CHEMBL1271704,VQOLUEFEGFCAIH-CTNGQTDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,23.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)[C@@H]1COC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)C(C)(C)CO,7.623423042943488,CC(C)(C)[C@@H]1COC[C@H](COC(=O)N2CCN(C(C)(C)CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
38157,CHEMBL2012951,VQQZSOVXMSWVFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using midazolam as substrate after 5 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(N1C3=CC=C(S3)C(=O)NC4CC4)C=CC=C2OC(F)F,5.0,Cc1nc2c(OC(F)F)cccc2n1-c1ccc(C(=O)NC2CC2)s1
38165,CHEMBL193055,VQVKHCWYXCFZSE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,31800.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)N1C2=C(C=CC(=C2)C3=C(NC(=N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O,4.497572880015567,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3nc(C(C)(C)C)[nH]c3-c3ccc(F)cc3)cc21
38170,CHEMBL478871,VQWUSTLVSKKFKL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C2=C1C=C3CCNCCC3=C2)S(=O)(=O)C4=CC=CC=C4,5.107905397309519,Cn1cc(S(=O)(=O)c2ccccc2)c2cc3c(cc21)CCNCC3
38171,CHEMBL478871,VQWUSTLVSKKFKL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C2=C1C=C3CCNCCC3=C2)S(=O)(=O)C4=CC=CC=C4,4.886056647693163,Cn1cc(S(=O)(=O)c2ccccc2)c2cc3c(cc21)CCNCC3
38187,CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,5.0,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
38188,CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,5.0,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
38190,CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22409598.0,IC50,=,15.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks.,J. Med. Chem.,PUBLICATION,,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,7.823908740944319,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
38191,CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22409598.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Competitive inhibition of CYP3A4 in human liver microsomes,Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks.,J. Med. Chem.,PUBLICATION,,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,5.823908740944319,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
38237,CHEMBL3640286,VRRVVCOABSEJKG-UGZDLDLSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC(=N1)N2C[C@H]3C(=O)N(C(=N[C@]3(C2)C4=C(C=CC(=C4F)F)F)N)C)OC)F,4.698970004336019,COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)ccc(F)c3F)C2)nc(C)c1F
38250,CHEMBL207071,VRUAXQODZDRLMI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1C2=CC(=C(S2)C(=O)N)N)F,5.698970004336019,NC(=O)c1sc(-c2ccc(F)cc2)cc1N
38254,CHEMBL560377,VRWJZGHUCOFGPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19630403.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=C(C=C3)C4=C(C=NN4)C5=CC=NC=C5,5.0,c1ccc2nc(COc3ccc(-c4[nH]ncc4-c4ccncc4)cc3)ccc2c1
38259,CHEMBL1235,VRXFDHAGFYWGHT-UHFFFAOYSA-N,DESETHYL AMODIAQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,"Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate","Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,CCNCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,4.619788758288394,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
38260,CHEMBL1235,VRXFDHAGFYWGHT-UHFFFAOYSA-N,DESETHYL AMODIAQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,CCNCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,4.0,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
38261,CHEMBL1235,VRXFDHAGFYWGHT-UHFFFAOYSA-N,DESETHYL AMODIAQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using DEF substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,CCNCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,4.619788758288394,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
38262,CHEMBL1235,VRXFDHAGFYWGHT-UHFFFAOYSA-N,DESETHYL AMODIAQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using PPR substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,CCNCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,4.0,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
38266,CHEMBL518142,VRZJRRFRFQRESG-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)OC5=CC=C(C=C5)F,5.075720713938118,C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Oc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
38267,CHEMBL518142,VRZJRRFRFQRESG-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)OC5=CC=C(C=C5)F,4.853871964321762,C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Oc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
38270,CHEMBL2347408,VSAIMZAFUWHQMD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC1(CCNCC1)NC(=O)C2=CNC3=NC=C(N=C23)C4=NN(C5=C4C=CC(=C5)F)C,4.301029995663981,Cn1nc(-c2cnc3[nH]cc(C(=O)NC4(C)CCNCC4)c3n2)c2ccc(F)cc21
38277,CHEMBL3125270,VSEJBALUHIPEBF-PBHICJAKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24450589.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.,J. Med. Chem.,PUBLICATION,,CCC1=NN(C(=C1)C(=O)N[C@@H]2C[C@H](N(C2)C(=O)C3=COC4=CC=CC=C43)C(=O)N)CC,4.301029995663981,CCc1cc(C(=O)N[C@@H]2C[C@@H](C(N)=O)N(C(=O)c3coc4ccccc34)C2)n(CC)n1
38281,CHEMBL252414,VSGMPHWPOWPCHF-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C[C@H](N([C@H](C1)C2(CC2)CC(=O)N3CCC4(CCN4)CC3)S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,5.154901959985743,O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC2(CCN2)CC1
38286,CHEMBL3702707,VSHMJRDIOFZVNT-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3630.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.440093374963888,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
38288,CHEMBL1668115,VSJGYMSTWHUFMX-OALUTQOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,54200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,COC1=C(C=CC(=C1)[C@H]2[C@@H](OC3=C(O2)C=C(C=C3)CCCO)CO)O,4.266000713461613,COc1cc([C@@H]2Oc3cc(CCCO)ccc3O[C@H]2CO)ccc1O
38295,CHEMBL2386653,VSKQOMHTMYZRLK-ZJUUUORDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1[C@H]4CCCOC4)C=CN3)O,5.0,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CCCOC1
38296,CHEMBL2386653,VSKQOMHTMYZRLK-ZJUUUORDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,C[C@H](C1=NC2=CN=C3C(=C2N1[C@H]4CCCOC4)C=CN3)O,5.0,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CCCOC1
38298,CHEMBL2057520,VSKXCMMQATYJBE-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,79.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC)C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,7.102372908709558,CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)CC)oc2c1
38302,CHEMBL2204445,VSLWUPHHCFQTDB-LJQANCHMSA-N,(R)-VU0463597,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22607673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu(3)) NAM probe (ML289) derived from a closely related mGlu(5) PAM.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)C#CC2=CC=C(C=C2)C(=O)N3CCC[C@H](C3)CO,4.522878745280337,COc1ccc(C#Cc2ccc(C(=O)N3CCC[C@@H](CO)C3)cc2)cc1
38303,CHEMBL1650511,VSMFCZZEKTVDHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128593.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,PUBLICATION,,C1CCC2(CC1)CC(=NO2)C3=NC4=C(C=C(C=C4N3)C5=CC=CC=C5C(F)(F)F)C(F)(F)F,5.0,FC(F)(F)c1ccccc1-c1cc(C(F)(F)F)c2nc(C3=NOC4(CCCCC4)C3)[nH]c2c1
38309,CHEMBL3338865,VSOUDUXMPUHJEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25248679.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 (unknown origin),Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CN=C1)C2=NC=C(C(=C2)C(=O)NCC3=NC(=C(C=C3)OC)OC)C4=NC=CS4,4.769551078621726,COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC
38314,CHEMBL469292,VSPZMUAUSBZZJK-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=C(C=C4)OC)Cl)O)C5CCN(CC5)CCCF,5.0,COc1ccc([C@H](O)CNc2cc[nH]c(=O)c2-c2nc3c(C)cc(C4CCN(CCCF)CC4)cc3[nH]2)cc1Cl
38317,CHEMBL2448717,VSTCTLPTEFNPSS-CVKSISIWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1400.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C/C(=N\OC)/C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(C=C3)C4=CC=CS4,5.853871964321762,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3cccs3)nc2)c1
38332,CHEMBL151170,VSYIEXFPNPTQGT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,883.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CN=CN2,6.054039296422431,CCCCOc1ccc(-c2cnc[nH]2)cc1
38337,CHEMBL552567,VSYWLXSRFUTNAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,=,15.1,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)C5=NN=C(C=C5)OC)CC(C)(C)C(=O)O,7.82102305270683,COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)nn1
38350,CHEMBL1916288,VTFOIOURAFZEDM-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21955939.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of pyrazoles as novel FPR1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NN(C(=C1C(=O)N[C@@H](C)C(C)(C)C)NS(=O)(=O)C2=CC=C(C=C2)C#N)C3=CC=C(C=C3)F,5.0,Cc1nn(-c2ccc(F)cc2)c(NS(=O)(=O)c2ccc(C#N)cc2)c1C(=O)N[C@@H](C)C(C)(C)C
38352,CHEMBL2387503,VTGCIWWYBFGGNJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F,4.522878745280337,O=c1[nH]c2cc(-c3ccccc3)ccc2c2nc(-c3c(F)cccc3Cl)[nH]c12
38353,CHEMBL1258035,VTGDLGOSPAKXEA-WMISUKIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20839775.0,IC50,>,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Exploration of the amine terminus in a novel series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN[C@@H]3CC[C@]4(C3C4)C5=CC=C(C=C5)C(F)(F)F,5.3979400086720375,Cc1ncoc1-c1nnc(SCCCN[C@@H]2CC[C@]3(c4ccc(C(F)(F)F)cc4)CC23)n1C
38362,CHEMBL2181643,VTIJLRPGYFSCQT-NTEUORMPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,10600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=NC=CN=C5)C6CCCC6,4.97469413473523,Cn1c(-c2cnccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21
38376,CHEMBL446793,VTMXWIGCCDHWKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18632268.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC(=C1)Cl)C(=O)C2=C3C(=CC(=C2)CC4=NNC(=O)C=C4)C=CO3,6.221848749616356,O=C(c1cccc(Cl)c1)c1cc(Cc2ccc(=O)[nH]n2)cc2ccoc12
38387,CHEMBL3087351,VTPLTXZKMKTFBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,15300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CC=NN2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,4.815308569182402,O=S(=O)(Nc1ccc(-c2ccn[nH]2)cc1)c1cc(Cl)cc(Cl)c1
38391,CHEMBL1272135,VTQGIZQKCPGUNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20926294.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)NC(=O)NC2=CC=CN(C2=O)CC3=C(C=CC=C3Cl)F,4.6020599913279625,COc1cccc(NC(=O)Nc2cccn(Cc3c(F)cccc3Cl)c2=O)c1
38396,CHEMBL2448742,VTTSFAQAAYHUOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CC(=O)N(CC1=CN=CN1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4S3,5.0,CC(=O)N(Cc1cnc[nH]1)c1ccc(-c2nc3ccccc3s2)cc1
38408,CHEMBL3422094,VTWYCQYMWJLMTC-AKOVUPKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,230.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1CCC(C1)[C@H](C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6[C@H]7CC[C@H]6CC(C7)O,6.638272163982407,O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1
38409,CHEMBL3422093,VTWYCQYMWJLMTC-WBXFWKJNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1CCC(C1)[C@@H](C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6[C@H]7CC[C@H]6CC(C7)O,6.096910013008056,O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1
38410,CHEMBL3422093,VTWYCQYMWJLMTC-WBXFWKJNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,820.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,C1CCC(C1)[C@@H](C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6[C@H]7CC[C@H]6CC(C7)O,6.086186147616283,O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1
38411,CHEMBL3623823,VTXPPXZJCHEWPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26403853.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,PUBLICATION,,CC(=O)NC1CCCC2=C1C=NC=C2C3=CC=C(C=C3)C#N,4.301029995663981,CC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21
38418,CHEMBL472757,VUDLFYRSWDHZSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24461352.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)N1CCC(CC1)(CC2CC2)CNC(=O)C3=C(C=C(C=C3)Cl)Cl,5.0,CCS(=O)(=O)N1CCC(CNC(=O)c2ccc(Cl)cc2Cl)(CC2CC2)CC1
38420,CHEMBL1818451,VUEZBOYAXGKAME-ZYMOGRSISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550808.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC1=NN(C=C1)CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,5.0,Cc1ccn(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
38427,CHEMBL454774,VUFHHJKMMITIBF-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)N)C4=C(C(=CC=C4)OCCCCC(=O)O)F,4.552841968657781,Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F
38432,CHEMBL2385902,VUKXPPCLOKSGNR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)CC4=CNC5=CC=CC=C54,4.301029995663981,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)Cc1c[nH]c3ccccc13)CC2
38436,CHEMBL479314,VUNCHONBJWJYID-DLBZAZTESA-N,(-)-CUBEBININOLIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,14900.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,COC1=CC(=CC(=C1OC)OC)C[C@H]2COC(=O)[C@@H]2CC3=CC(=C(C(=C3)OC)OC)OC,4.826813731587726,COc1cc(C[C@H]2COC(=O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC
38438,CHEMBL2409676,VUNVHTRIAQAVIJ-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810497.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Hydantoin based inhibitors of MMP13-Discovery of AZD6605.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@]1(C(=O)NC(=O)N1)CS(=O)(=O)N2CCN(CC2)C3=NC=C(C=N3)OCC4=CC=C(O4)C(F)(F)F,5.0,C[C@]1(CS(=O)(=O)N2CCN(c3ncc(OCc4ccc(C(F)(F)F)o4)cn3)CC2)NC(=O)NC1=O
38451,CHEMBL1094458,VUVAXIBXIAPBBM-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCCF,6.346787486224656,Cc1cc(N2CCN(CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
38458,CHEMBL3640263,VUVKLOMPJFHDFF-ORAYPTAESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,=,34100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,CC1=C(C(=NC(=N1)N2C[C@H]3C(=O)N(C(=N[C@]3(C2)C4=CC=C(C=C4)F)N)C)OC)F,4.467245621007502,COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3)C2)nc(C)c1F
38460,CHEMBL2017291,VUVUVNZRUGEAHB-CYBMUJFWSA-N,GSK1210151A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,9700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)[C@H](C)C5=CC=CC=N5)OC,5.013228265733755,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12
38461,CHEMBL2017291,VUVUVNZRUGEAHB-CYBMUJFWSA-N,GSK1210151A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,9700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)[C@H](C)C5=CC=CC=N5)OC,5.013228265733755,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12
38469,CHEMBL512079,VUXLKOATKUTQHW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19341281.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)C4=NC(=NO4)CN,5.508638306165727,NCc1noc(-c2nn(Cc3ccccc3)c3ccccc23)n1
38470,CHEMBL576093,VUXWOZNVRFWGIQ-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)N,4.7447274948966935,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(C(N)=O)nc3)ccc2o1
38478,CHEMBL479575,VVAHJSXAXRVBPR-NZQKXSOJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18583127.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,"Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@@](O3)(C)C4=C(C=C(C=C4)F)F,4.3979400086720375,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@@](C)(c4ccc(F)cc4F)O3)cc2)CC1
38479,CHEMBL411082,VVATYHJETCAAEJ-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1CN(C1)C2CC(C2)C3=NC(=C4N3C=CN=C4N)C5=CC6=C(C=C5)C=CC(=N6)C7=CC=CC=C7,4.698970004336019,Nc1nccn2c(C3CC(N4CCC4)C3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12
38483,CHEMBL3358926,VVCVRVUPFSJFRH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)N)(C(F)(F)F)O,6.301029995663981,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N)ncc2[nH]1)C(F)(F)F
38492,CHEMBL1669419,VVGNEGYIOFKVTA-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,1826.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CS4,5.73849922680172,C[C@H](C1=C(CCN(C)Cc2cccs2)Cc2ccccc21)c1cnccn1
38495,CHEMBL502092,VVICOEQHILEAPE-PHVLTXCSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,3.1,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](O1)C)C2CCN(CC2)C3=CC4=C(C(=C3)C)N=C(N4)C5=C(C=CNC5=O)NC[C@H](C6=CC(=CC=C6)Cl)O,8.508638306165727,Cc1cc(N2CCC(N3C[C@H](C)O[C@H](C)C3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
38499,CHEMBL1094164,VVIPLSCLYCWUQT-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCC#N,5.958607314841775,Cc1cc(N2CCN(CCC#N)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
38501,CHEMBL1091792,VVIWSBGDDVESJJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1=NC(=CC=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,COc1cccc(C(C)c2c(CCN(C)C)sc3ccccc23)n1
38502,CHEMBL240645,VVJKDHDXWRSOBK-UHFFFAOYSA-N,SR-1353,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC(=CC=C4)Cl)N,6.6020599913279625,NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1
38517,CHEMBL2152613,VVRUXFPJOVUDCV-UHFFFAOYSA-N,2-((3-PHENETHOXYPHENYL)AMINO)BENZAMIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22642300.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.",J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)CCOC2=CC=CC(=C2)NC3=CC=CC=C3C(=O)N,5.0,NC(=O)c1ccccc1Nc1cccc(OCCc2ccccc2)c1
38520,CHEMBL507691,VVSAPIDRRVMKFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CNC(=O)C1=CC=CC(=C1)C2=CC=C(C=C2)C(CN3CCOCC3)N(C)C(=O)CN4C5=CC(=C(C=C5N=CC4=O)Cl)Cl,5.301029995663981,CNC(=O)c1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)Cn3c(=O)cnc4cc(Cl)c(Cl)cc43)cc2)c1
38523,CHEMBL3126382,VVUGQHSQCFTHGT-CZCBIWLKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24359185.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein as substrate,"Discovery of a rapidly metabolized, long-acting ß(2) adrenergic receptor agonist with a short onset time incorporating a sulfone group suitable for once-daily dosing.",J. Med. Chem.,PUBLICATION,,CC(=O)O.C1CCC(C1)S(=O)(=O)C2=CC=CC(=C2)CCCCOCCCCCCNC[C@@H](C3=CC(=C(C=C3)O)CO)O,5.795880017344075,O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CCCC1
38524,CHEMBL3126382,VVUGQHSQCFTHGT-CZCBIWLKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24359185.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7-benzyloxyquinoline as substrate,"Discovery of a rapidly metabolized, long-acting ß(2) adrenergic receptor agonist with a short onset time incorporating a sulfone group suitable for once-daily dosing.",J. Med. Chem.,PUBLICATION,,CC(=O)O.C1CCC(C1)S(=O)(=O)C2=CC=CC(=C2)CCCCOCCCCCCNC[C@@H](C3=CC(=C(C=C3)O)CO)O,5.42021640338319,O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CCCC1
38525,CHEMBL3137446,VVUMTHNDTDZGCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10700.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)CC4=CC(=CC=C4)C(F)(F)F,4.97061622231479,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1
38526,CHEMBL3137446,VVUMTHNDTDZGCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)CC4=CC(=CC=C4)C(F)(F)F,4.7447274948966935,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1
38528,CHEMBL3137446,VVUMTHNDTDZGCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)CC4=CC(=CC=C4)C(F)(F)F,4.0,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1
38534,CHEMBL1208894,VVYUVUVFTYVYIG-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCNCC6)C(=O)N,5.853871964321762,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCNCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
38535,CHEMBL1208894,VVYUVUVFTYVYIG-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,5900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCNCC6)C(=O)N,5.229147988357856,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCNCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
38538,CHEMBL3393291,VWAWBZYBSWVMRW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1C(=O)NCC2=CC=NC=C2)OC3=CC=C(C=C3)F,6.0,O=C(NCc1ccncc1)c1ccc(Oc2ccc(F)cc2)cc1
38546,CHEMBL459729,VWELCPLMPPEKOL-UHFFFAOYSA-N,BMS-695735,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)C5CCN(CC5)CCCF,4.585026652029182,Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12
38548,CHEMBL2018925,VWGACEKTAOFWMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,2490.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC(=CC=C3)OC4=CC=CC=C4,5.603800652904264,COc1ccc2nc(SCc3cccc(Oc4ccccc4)c3)[nH]c2c1
38549,CHEMBL1092258,VWGHJDXVTAUEQY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)OC)CC3=NC=CN=C3,5.0,COc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1
38550,CHEMBL255460,VWGHPHKDTXAJJF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,680.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(C(N(C1)C(=O)CN2C3=C(C=CC(=C3)Cl)SC2=O)CN4CCOCC4)C5=CC=CC=C5,6.167491087293763,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1
38552,CHEMBL1222969,VWGSYATZAOMKDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673729.0,IC50,>,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 30 mins,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,PUBLICATION,,C1CC(C1)(C2=NN=C(S2)C3=NN(C(=C3CN4C=NC=N4)C5=CC=C(C=C5)Cl)C6=C(C=C(C=C6)Cl)Cl)C(F)(F)F,7.698970004336019,FC(F)(F)C1(c2nnc(-c3nn(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)c3Cn3cncn3)s2)CCC1
38554,CHEMBL3422008,VWHSUJREXZPXOB-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=NC(=CN=C5)C,5.698970004336019,Cc1cncc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1
38556,CHEMBL3137474,VWJAPQXRZIFGME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)Cl)C3=CN=CC=C3)C4=C(C=C(C=C4)C(F)(F)F)C#N,4.698970004336019,N#Cc1cc(C(F)(F)F)ccc1N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1
38560,CHEMBL1095031,VWKIIEUSSJXADS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOCCN1C2=CC=CC=C2N=C1C3CCCN(C3)C,5.301029995663981,CCOCCn1c(C2CCCN(C)C2)nc2ccccc21
38576,CHEMBL471074,VWQNZPASHLNLEM-WKSZPJAWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,31600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)OC(=O)C)O)OC(=O)C,4.500312917381596,CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](OC(C)=O)[C@@H]1O
38587,CHEMBL561259,VWTOOZUTLQWOPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NOC=N2)C(=O)NC3CC3C4=CC=CC=C4,5.0,O=C(NC1CC1c1ccccc1)N1CCC(c2ncon2)CC1
38612,CHEMBL2386075,VXAZUHZNPMCSLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CS4,4.301029995663981,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccs1)CC2
38613,CHEMBL1944698,VXBAJLGYBMTJCY-NSCUHMNNSA-N,TG-02,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22148278.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,"Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.",J. Med. Chem.,PUBLICATION,,CN1C/C=C/CCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1,4.6020599913279625,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
38618,CHEMBL364925,VXCUSFSWRIJJDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,CC(C)C1=NC(=C(N1)C2=CC=C(C=C2)F)C3=CC4=C(C=C3)N=C(N4S(=O)(=O)C(C)C)N.CS(=O)(=O)O,5.214670164989233,CC(C)c1nc(-c2ccc3nc(N)n(S(=O)(=O)C(C)C)c3c2)c(-c2ccc(F)cc2)[nH]1
38624,CHEMBL2382414,VXEVEBMHWZDNOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23628336.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=NC=C(C=N2)OCC3=C(C=NC=C3)C#N)C(=O)OCC(F)(F)F,4.522878745280337,N#Cc1cnccc1COc1cnc(N2CCN(C(=O)OCC(F)(F)F)CC2)nc1
38625,CHEMBL282365,VXFHXZLPYZXJKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,19300.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)N=CC=C2,4.714442690992226,Cn1c2cccnc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
38632,CHEMBL3702722,VXHCTCQAIMFHGE-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8550.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCC(CC1)N2CCN(CC2)C(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.068033885271827,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C6CCN(C)CC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
38633,CHEMBL2018907,VXHDUQXXAHZWMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,5330.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CCCCCCSC1=NC2=C(N1)C=C(C=C2)OC,5.273272790973428,CCCCCCSc1nc2ccc(OC)cc2[nH]1
38634,CHEMBL3234565,VXHHIPNHNBMMJV-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=NC(=NC(=C2)C(F)(F)F)N3CCC[C@H](C3)C(=O)NCCC4=CC=C(C=C4)C#N,5.698970004336019,CN1CCN(c2cc(C(F)(F)F)nc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)cc4)C3)n2)CC1
38658,CHEMBL362412,VXPLIKXVYZZBFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)OCC(=O)OC)N4C=CN=C4)N(C)C,6.853871964321762,COC(=O)COc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1
38659,CHEMBL362412,VXPLIKXVYZZBFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)OCC(=O)OC)N4C=CN=C4)N(C)C,6.657577319177793,COC(=O)COc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1
38676,CHEMBL1951432,VXTXSTJYACXQSO-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=CCN1C2=C(C(=C1N3CCC[C@@H](C3)N)C#N)N=CN(C2=O)CC4=NC=CC5=CC=CC=C54)C,5.769551078621726,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2ncn(Cc3nccc4ccccc34)c(=O)c21
38683,CHEMBL3116157,VXVXUOCSXHINSV-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(S1)N[C@@](CC2=CC=CC=C2)(C3=NC=C(C=C3)Cl)C4=CC(=CC(=C4)F)OC(C(F)F)(F)F)C(F)(F)F,4.3979400086720375,Cc1sc(N[C@](Cc2ccccc2)(c2cc(F)cc(OC(F)(F)C(F)F)c2)c2ccc(Cl)cn2)nc1C(F)(F)F
38684,CHEMBL3116157,VXVXUOCSXHINSV-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(S1)N[C@@](CC2=CC=CC=C2)(C3=NC=C(C=C3)Cl)C4=CC(=CC(=C4)F)OC(C(F)F)(F)F)C(F)(F)F,4.3979400086720375,Cc1sc(N[C@](Cc2ccccc2)(c2cc(F)cc(OC(F)(F)C(F)F)c2)c2ccc(Cl)cn2)nc1C(F)(F)F
38687,CHEMBL3128188,VXXIYUBYYXZZOE-FCJDFRRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24437735.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective ß3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,PUBLICATION,,C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=CC=NN34)[C@@H](C5=CN=CC=C5)O,4.0,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2ccnn21
38688,CHEMBL3128188,VXXIYUBYYXZZOE-FCJDFRRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26709102.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,PUBLICATION,,C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=CC=NN34)[C@@H](C5=CN=CC=C5)O,4.0,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2ccnn21
38694,CHEMBL2151048,VYALMGYTNFNPPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCN1C2=CC(=O)NC(=N2)CC(=O)NC3=CC(=C(C=C3)F)Br,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Br)c1
38705,CHEMBL3237560,VYFZIPUVTIMYCJ-NWDGAFQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24520947.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,PUBLICATION,,CC1=C(C=CC(=N1)NC2=CC(=NN=C2C(=O)N)N[C@@H]3CCCC[C@@H]3N)F,4.301029995663981,Cc1nc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)ccc1F
38713,CHEMBL3291357,VYKHHRFZDHVGDQ-KUHUBIRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@]12CC[C@@H](C1(C)C)C3=C2N(N(C3=O)CC4=CC=CC=C4C(F)(F)F)C,5.318758762624412,Cn1c2c(c(=O)n1Cc1ccccc1C(F)(F)F)[C@H]1CC[C@]2(C)C1(C)C
38716,CHEMBL312137,VYLMFRUDZGQCNT-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,C1CN(C(=O)[C@H]1NCC2=CN=CN2CC3=CC=C(C=C3)C#N)CC4=CC(=CC=C4)Cl,6.0,N#Cc1ccc(Cn2cncc2CN[C@H]2CCN(Cc3cccc(Cl)c3)C2=O)cc1
38718,CHEMBL592709,VYLVEERKOLDJOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by LCMS/MS assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,CN(C)CC1=CC=C(C=C1)NC(=O)C2=CC=CC(=C2)CNC(=O)C3=CC(=C(C=C3)OC)Cl,4.522878745280337,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1Cl
38736,CHEMBL3422028,VYSGWFCGFKTGQC-WCWDXBQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25751283.0,IC50,=,1880.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay,Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.,J. Med. Chem.,PUBLICATION,,CC/C(=C(/C1=CC=C(C=C1)O)\C2=CC=C(C=C2)OCCN)/C3=CC=C(C=C3)O,5.72584215073632,CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccc(O)cc1
38748,CHEMBL2017285,VYWGWQXJWULHNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)CC5=CC=CC=C5)OC,5.431798275933005,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccc3)c12
38749,CHEMBL2017285,VYWGWQXJWULHNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)CC5=CC=CC=C5)OC,5.431798275933005,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccc3)c12
38754,CHEMBL595092,VYXWHVDEWWHDLH-LJAQVGFWSA-N,AM-679,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19914828.0,IC50,=,16700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1[C@@H](CC2=CC=CC=C21)COC3=CC4=C(C=C3)N(C(=C4SC(C)(C)C)CC(C)(C)C(=O)O)CC5=CC=C(C=C5)C6=NC=C(C=N6)OC,4.777283528852417,COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OC[C@@H]5Cc6ccccc6N5C(C)=O)ccc43)cc2)nc1
38762,CHEMBL3673963,VYZQJQZLBIQWTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320631,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=C(C=N4)OC)F)F)N=C1,5.0,COc1cnc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cc1F
38763,CHEMBL3673963,VYZQJQZLBIQWTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320675,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=C(C=N4)OC)F)F)N=C1,5.0,COc1cnc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cc1F
38766,CHEMBL2448736,VZAGCRQJRXHJNZ-VULFUBBASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C/C(=N\OC)/C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(S3)C4=CC=CC=N4,5.522878745280337,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccn3)s2)c1
38769,CHEMBL207638,VZAYORFJMPOFKB-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]([C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCCCC3)C(=O)O)N4C=CN=C4)N(C)C,5.096910013008056,C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCCCC3)ccc2c1)n1ccnc1)N(C)C
38777,CHEMBL3601401,VZDNISKFMYZWGF-YFMCWZQFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26181851.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.,J. Med. Chem.,PUBLICATION,,CC(C)OC1=C(C=C2CC(=O)N([C@H](C2=C1)C3=CC=C(C=C3)Cl)C4=CN=C(C=C4)N(C)CC5CCC(CC5)N6CCN(C(=O)C6)C)OC,4.698970004336019,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)CC3CCC(N4CCN(C)C(=O)C4)CC3)nc1)C(=O)C2
38782,CHEMBL521271,VZGOJYYBQQYRJE-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)NC(=O)OC,9.301029995663981,COC(=O)NC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
38805,CHEMBL1208964,VZQLEKQMCOAWNB-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NC6CCN(CC6)C)C(=O)N,5.958607314841775,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
38806,CHEMBL1208964,VZQLEKQMCOAWNB-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NC6CCN(CC6)C)C(=O)N,5.327902142064283,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
38810,CHEMBL1271879,VZTDQEWJIVUVPC-FLQRSKGTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,0.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C[C@@H]2COC[C@@H](N2S(=O)(=O)C3=CC=C(C=C3)Cl)C4(CC4)OC(=O)N5CC6CCC(C5)N6,9.096910013008056,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2
38828,CHEMBL3236635,VZZITKBMNYFVPR-OQZRLNFTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)N5CC[C@H](C5)C(=O)O,4.568636235841013,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)N2CC[C@@H](C(=O)O)C2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
38829,CHEMBL3236636,VZZITKBMNYFVPR-RHWDBWQKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)N5CC[C@@H](C5)C(=O)O,4.568636235841013,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)N2CC[C@H](C(=O)O)C2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
38841,CHEMBL2436628,WAEWFNQGFKVNEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2CCC3=C(C2)C=C(C=C3)C#N)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,4.522878745280337,N#Cc1ccc2c(c1)CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CC2
38842,CHEMBL98,WAEXFXRVDQXREF-UHFFFAOYSA-N,VORINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17107790.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,4.920818753952375,O=C(CCCCCCC(=O)Nc1ccccc1)NO
38843,CHEMBL98,WAEXFXRVDQXREF-UHFFFAOYSA-N,VORINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,5.0,O=C(CCCCCCC(=O)Nc1ccccc1)NO
38847,CHEMBL1079257,WAFKWVRPHCVAGK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=CC=C3C(F)(F)F,5.0,O=C(O)CCC1(c2ccccc2C(F)(F)F)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
38850,CHEMBL536636,WAFZISBSKUIZLT-PDIZPCIFSA-N,OZ-209,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19962893.0,IC50,=,9700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The comparative antimalarial properties of weak base and neutral synthetic ozonides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2(CCC1CN)OC3(C4CC5CC(C4)CC3C5)OO2,5.013228265733755,NCC1CCC2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3
38854,CHEMBL2170747,WAIPUKHVRXNDDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22277094.0,IC50,=,54000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17ß-HSD1.,J. Med. Chem.,PUBLICATION,,C1=CC2=C(C=C1O)SC(=N2)NC(=O)C3=C(C=CC(=C3F)O)F,4.267606240177032,O=C(Nc1nc2ccc(O)cc2s1)c1c(F)ccc(O)c1F
38857,CHEMBL453169,WAIWXNYKRBBVSH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672861.0,IC50,=,21070.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)C=C(C=C2)C3=C(C=CN=C3)N,4.6763354643919,COc1ccc2cc(-c3cnccc3N)ccc2c1
38862,CHEMBL3087042,WAKFEUQVWCWZCS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,12200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=NC=CC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,4.913640169325252,CCc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
38870,CHEMBL240813,WAMCIKGNVJZNAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,2180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNS(=O)(=O)C)(C)C4=CC(=CC(=C4)F)F,5.661543506395395,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNS(C)(=O)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2
38873,CHEMBL1209017,WAMWLVAINQIUBS-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)CCCN(C)C)C(=O)N,6.045757490560675,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
38874,CHEMBL1209017,WAMWLVAINQIUBS-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)CCCN(C)C)C(=O)N,5.301029995663981,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
38881,CHEMBL258199,WAPPDJVNPDRYEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18462938.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NN1CC2=C(C=CC(=C2)Cl)OCC3=CC=CC=C3)NC(=O)OC(C)(C)C,4.0,Cc1cc(NC(=O)OC(C)(C)C)nn1Cc1cc(Cl)ccc1OCc1ccccc1
38887,CHEMBL231306,WASNZPFVELUKFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134929.0,IC50,<,18.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BFC in vitro by 50%,Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5C=CN=C5,7.7447274948966935,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
38888,CHEMBL231306,WASNZPFVELUKFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134929.0,IC50,<,18.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BzRes in vitro by 50%,Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5C=CN=C5,7.7447274948966935,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
38889,CHEMBL231306,WASNZPFVELUKFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,<,46.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5C=CN=C5,7.337242168318426,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
38895,CHEMBL3672573,WAWNWRVGWKZVLT-CFTUFJLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,170.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,6.769551078621726,CC(C)c1nc(CN(C)C(=O)N2C[C@@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
38896,CHEMBL3672573,WAWNWRVGWKZVLT-CFTUFJLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,240.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,6.619788758288394,CC(C)c1nc(CN(C)C(=O)N2C[C@@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
38897,CHEMBL3672572,WAWNWRVGWKZVLT-HYHVOXATSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,160.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,6.795880017344075,CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
38898,CHEMBL3672572,WAWNWRVGWKZVLT-HYHVOXATSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,230.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,6.638272163982407,CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
38899,CHEMBL3672574,WAWNWRVGWKZVLT-YUXCJTBFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,120.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@H](CC[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,6.920818753952375,CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
38900,CHEMBL3672574,WAWNWRVGWKZVLT-YUXCJTBFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@H](CC[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,6.522878745280337,CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
38909,CHEMBL1766185,WAXZAJPOBWYNFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)C(C3CC3)(C4=CN=CN4)O,5.259637310505756,CC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C3CC3)cc2)c1
38912,CHEMBL3086078,WBARVJREQICCOV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24157370.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by NADPH and substrate addition measured after 5 mins by LC/MS/MS analysis,The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)OC2=CC(=C(C=C12)F)OC(=O)N(C)C)CC3=C(C(=CC=C3)NS(=O)(=O)N)F,4.853871964321762,Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12
38913,CHEMBL3086078,WBARVJREQICCOV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24157370.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins post NADPH addition followed by substrate addition measured after 5 mins by LC/MS/MS analysis,The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)OC2=CC(=C(C=C12)F)OC(=O)N(C)C)CC3=C(C(=CC=C3)NS(=O)(=O)N)F,4.7447274948966935,Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12
38918,CHEMBL2159131,WBDMEXWZCXEWGM-ISHVPQBTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NCCCN(C)C)O4)C)(C)OC)C)C)O)(C)O,6.154901959985743,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NCCCN(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
38919,CHEMBL2159131,WBDMEXWZCXEWGM-ISHVPQBTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NCCCN(C)C)O4)C)(C)OC)C)C)O)(C)O,5.096910013008056,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NCCCN(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
38930,CHEMBL3304438,WBLVOWHFRUAMCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NOC(=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC3CCN(CC3)C,4.522878745280337,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C)CC1
38931,CHEMBL3112855,WBLYYZMOJFRKFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=CC=CC(=C21)C3=CC=CC=C3)C(=O)CC4=NC(=CC(=O)N4)N5CCOCC5,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccc3)cccc21
38940,CHEMBL408962,WBQCKUNNRLRPOG-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18217703.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.,J. Med. Chem.,PUBLICATION,,CN(C)C(=O)C(=O)N(C)[C@H]1CCCCN2C1=NC(=C(C2=O)O)C(=O)NCC3=CC=C(C=C3)F,4.0,CN(C)C(=O)C(=O)N(C)[C@H]1CCCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O
38970,CHEMBL156339,WCERJEZPIONOJU-LHEXPUQLSA-N,MAGNOSALIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,85400.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,C[C@@H]1[C@H]([C@H]([C@@H]1C2=CC(=C(C=C2OC)OC)OC)C3=CC(=C(C=C3OC)OC)OC)C,4.068542129310995,COc1cc(OC)c([C@@H]2[C@H](C)[C@@H](C)[C@H]2c2cc(OC)c(OC)cc2OC)cc1OC
38979,CHEMBL1923123,WCHSAUILSYDXQD-RLWLMLJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=NC=CC3=CC=CC=C32)C(=O)[C@H]4CNCC[C@]45C6=CC(=C(C=C6CO5)F)F,5.031517051446065,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1nccc2ccccc12)C1CC1
38987,CHEMBL502778,WCIIYKWDVLHGIY-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,3.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)COCCOC,8.522878745280337,COCCOCC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
38995,CHEMBL2058909,WCLGDMOUQNNCRI-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CCN3CCOCC3)C[C@H]([C@H](CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5)O,6.853871964321762,CCN(C)c1nc2ccc(C(=O)N(CCN3CCOCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
38997,CHEMBL3645215,WCLQUDCFQAVYPS-ACCUITESSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1580.0,NM,221146,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. Inhibition assay using P450 CYP enzymes.,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,PATENT,,CCOC(=O)/C=C/C1=C(C=CC2=C1C=CC(=C2)C3=CC(=CC=C3)OC)OC,5.801342913045578,CCOC(=O)/C=C/c1c(OC)ccc2cc(-c3cccc(OC)c3)ccc12
39009,CHEMBL2158890,WCUGLWYOYKWQOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,Adamantyl carboxamides and acetamides as potent human 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CN(CC1=CC=CS1)C(=O)CC23CC4CC(C2)CC(C4)C3,6.823908740944319,CN(Cc1cccs1)C(=O)CC12CC3CC(CC(C3)C1)C2
39012,CHEMBL2387605,WCVGPCAQEVCGQB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CN=CC=C5)Cl,4.619788758288394,O=c1[nH]c2cc(-c3cccnc3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
39018,CHEMBL377300,WCWUXEGQKLTGDX-LLVKDONJSA-N,BRIVANIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C,4.7447274948966935,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
39019,CHEMBL377300,WCWUXEGQKLTGDX-LLVKDONJSA-N,BRIVANIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C,4.7447274948966935,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
39020,CHEMBL377300,WCWUXEGQKLTGDX-LLVKDONJSA-N,BRIVANIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C,4.3979400086720375,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
39027,CHEMBL427202,WCWUXEGQKLTGDX-NSHDSACASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@H](C)O)C,5.3979400086720375,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@H](C)O)c(C)c34)ccc2[nH]1
39028,CHEMBL495995,WCYAHHRDZBUIGB-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2(CCN(CC2)C(=O)N[C@H]3C[C@@H]3C4=CC=CC=C4)OC5=CC=CC=C51,5.0,O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3ccccc3O2)CC1
39036,CHEMBL478036,WDADGFYGRSIPGG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2=CC=CC=C2C(C3=CC=CC=C31)CNC(=O)CNC(=O)C4=CC=C(C=C4)F,4.301029995663981,O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2CCc2ccccc21
39040,CHEMBL401352,WDDRUCUWAOFJED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17937987.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and structure-activity relationships of thieno[2,3-b]pyrroles as antagonists of the GnRH receptor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)C2=C(C3=C(N2)SC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)CCN6CCN(CC6)CC(CN7CCN(CC7)C(=O)C)O)C,5.221848749616356,CC(=O)N1CCN(CC(O)CN2CCN(CCc3c(-c4cc(C)cc(C)c4)[nH]c4sc(C(C)(C)C(=O)N5C6CCC5CC6)cc34)CC2)CC1
39052,CHEMBL26039,WDEYYJCTUQWQCT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CCOC(=O)CN1C2=C(C=C(C=C2)[N+](=O)[O-])C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,4.823908740944319,CCOC(=O)Cn1c2ccc([N+](=O)[O-])cc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
39080,CHEMBL1818543,WDNOUFVJCUYSDQ-ZYMOGRSISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550808.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC1=NN(C(=N1)C)CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,4.6020599913279625,Cc1nc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
39088,CHEMBL204021,WDPFJWLDPVQCAJ-UHFFFAOYSA-N,DARAPLADIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,4.568636235841013,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2
39089,CHEMBL1099314,WDPFLACZLYWILA-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C(=O)OC(C)(C)C,5.721246399047171,Cc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
39095,CHEMBL3409870,WDQKCMWGNYOTEG-OALUTQOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)OC)[C@@H]2C[C@@H](C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)F,5.055517327849831,COc1cccc(OC)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc2oc3ccccc3c2c1
39114,CHEMBL3527048,WDWIMDKOXZZYHH-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22645092.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A4 harboring human P450 oxidoreductase and b5,,Drug Metab. Dispos.,PUBLICATION,,CC1=CC=C(C=C1)C2=C(C=NN2C)C3=NN(C4=C3C(=NC=N4)N5CC[C@@H](C5)N6CCCCC6)C,6.522878745280337,Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1
39115,CHEMBL3527048,WDWIMDKOXZZYHH-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22645092.0,IC50,=,690.0,NM,,,,,,,,,,,,,,,Reversible inhibition of testosterone 6beta-hydroxylase activity of human recombinant CYP3A4 in presence of human P450 oxidoreductase and b5,,Drug Metab. Dispos.,PUBLICATION,,CC1=CC=C(C=C1)C2=C(C=NN2C)C3=NN(C4=C3C(=NC=N4)N5CC[C@@H](C5)N6CCCCC6)C,6.161150909262744,Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1
39143,CHEMBL372199,WDZVWDXOIGQJIO-UJKQEGAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1CC(CCC1NS(=O)(=O)C(F)(F)F)(C2=C(C=CC(=C2)F)F)S(=O)(=O)C3=CC=C(C=C3)Cl,5.031517051446065,O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F
39144,CHEMBL372199,WDZVWDXOIGQJIO-UJKQEGAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,16600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1CC(CCC1NS(=O)(=O)C(F)(F)F)(C2=C(C=CC(=C2)F)F)S(=O)(=O)C3=CC=C(C=C3)Cl,4.779891911959945,O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F
39155,CHEMBL2159084,WECXXIXHKMZMPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,Adamantyl carboxamides and acetamides as potent human 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CN1C=CC=C1CN(C)C(=O)C23CC4CC(C2)CC(C4)C3,4.7447274948966935,CN(Cc1cccn1C)C(=O)C12CC3CC(CC(C3)C1)C2
39156,CHEMBL2159084,WECXXIXHKMZMPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,Adamantyl carboxamides and acetamides as potent human 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CN1C=CC=C1CN(C)C(=O)C23CC4CC(C2)CC(C4)C3,4.721246399047171,CN(Cc1cccn1C)C(=O)C12CC3CC(CC(C3)C1)C2
39174,CHEMBL2436206,WEHMXUQKHFVNFA-DZGIFAGBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=C(C=C5)C(=O)C)NC.Cl,5.7447274948966935,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C(C)=O)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
39190,CHEMBL2069842,WEOYJEAONRLZTP-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ß-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)C(F)(F)F,6.0,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(C(F)(F)F)cc2)CC1)Cc1cc(F)c(F)cc1F
39198,CHEMBL2448720,WERADNQQDSSVCI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1120.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1CC1C(=O)N(CC2=CN=CC=C2)C3=CN=CC(=C3)C4=NC5=CC=CC=C5S4,5.950781977329818,O=C(C1CC1)N(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1
39203,CHEMBL10759,WESWMZAUSGJQRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C(=C(C(=O)N=C3SCC4=CC=C(C=C4)F)C)C,4.657577319177793,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c(C)c1C
39228,CHEMBL1951614,WFBDTIOQYJHWJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,>=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC#CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=C(C=NC5=CC=CC=C54)C#N)C,5.0,CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1c(C#N)cnc3ccccc13)c(=O)n2C
39235,CHEMBL2177836,WFDHLKUQFQCHKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22533986.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins,"Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(=O)NC1=CC=CC(=C1)C2=NC3=C(C=C2)N=C(N3C4=CC=C(C=C4)CNC(=O)C5=CC(=CC=C5)F)C6=C(N=CC=C6)N,5.0,CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1
39251,CHEMBL1079061,WFKBKGKEWUKRGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)OC(F)(F)F)(CCC(=O)O)C3=CC=C(C=C3)C4=CC=CC=C4,5.0,O=C(O)CCC1(c2ccc(-c3ccccc3)cc2)CCCN(C(=O)Nc2ccc(OC(F)(F)F)cc2)C1
39255,CHEMBL3673950,WFKFRFWYVHBMNZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320615,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=NC=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)F)F,5.301029995663981,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(F)cc34)c(F)n2)cn1
39256,CHEMBL3673950,WFKFRFWYVHBMNZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320661,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=NC=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)F)F,5.301029995663981,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(F)cc34)c(F)n2)cn1
39261,CHEMBL2158228,WFLCXRISIXFCBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)CC(=O)N)NC(=O)C4=NC=C(N4)C#N,5.0,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CC(N)=O)CC3)cc2C2=CCCCC2)[nH]1
39274,CHEMBL2165512,WFNROQCVMLIPMS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=CN=CC5=C4C=CN5)N6CCOCC6,5.494850021680094,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cncc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
39292,CHEMBL2163829,WFRXEZYSVYRRFE-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)C4(CC4)C5=C(C=C(C=C5)Cl)Cl,5.0,CN1CCN(C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
39294,CHEMBL283253,WFSCZQNQFUCKDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,CC(C)OC1=NC=CC2=C1C3=C(N2C)C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,4.0,CC(C)Oc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C
39348,CHEMBL3422074,WGEHOPBYUQXTMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,CN(C)CC(=O)N1CCC(CC1)OC2=CC=C(C=C2)C3=NNC4=C3C=C(C=C4)C(=O)NC(C5CC5)C6=CC=CC=C6,6.0,CN(C)CC(=O)N1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc2)CC1
39352,CHEMBL3403995,WGHJKYWWSVIRLL-JYFHCDHNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25754490.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate,"trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: Prime site exploration using an oxygen linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1OC(=O)NCC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,5.3979400086720375,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OC(=O)NCc2ccccc2)C(C)C)ccc1OC
39368,CHEMBL2059905,WGJMVERMPFJOTM-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22732695.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CSC4=CC=CC=C43)NC(=O)N5CCC6(CC5)C7=CC=CC=C7NC(=O)O6,6.0,O=C1Nc2ccccc2C2(CCN(C(=O)N[C@H](Cc3csc4ccccc34)C(=O)N3CCC(N4CCCCC4)CC3)CC2)O1
39372,CHEMBL1800774,WGKXETUOZHHSRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21644570.0,IC50,>,8900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP 3A4,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N1CCN2C(=NC(=C2NC3=CC(=C(C=C3)F)F)C4=CC=C(C=C4)F)C1)N,5.050609993355088,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)c(F)c2)C1
39376,CHEMBL495331,WGLILLWPZIBWTQ-UHFFFAOYSA-N,L-900525,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763751.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.",J. Med. Chem.,PUBLICATION,,CC(C)(C1=NC(=C(C(=O)N1C)O)C(=O)NCC2=CC=C(C=C2)F)NC(=O)C(=O)N(C)C,4.301029995663981,CN(C)C(=O)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C
39380,CHEMBL3358941,WGPUIGWWPPLBBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC(=CC=C4)S(=O)(=O)N,5.698970004336019,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(N)(=O)=O)c1
39381,CHEMBL425819,WGPYWDLNUPWWNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=NC)N,4.823908740944319,CN=C(N)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1
39383,CHEMBL1222651,WGQSWRLDQGXUQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CCO)CC5=CC=NC=C5,4.522878745280337,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCO)c3ccccc32)CC1
39390,CHEMBL517438,WGVPSTQRQHGEEP-QRWLVFNGSA-N,R-116010,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21428449.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26): Synthesis and Biological Evaluation of Imidazole Methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.,J. Med. Chem.,PUBLICATION,,C[C@H]([C@@H](C1=CC=C(C=C1)NC2=NC3=CC=CC=C3S2)N4C=CN=C4)N(C)C,4.958607314841775,C[C@H]([C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C
39391,CHEMBL517438,WGVPSTQRQHGEEP-QRWLVFNGSA-N,R-116010,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21838328.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26).",J. Med. Chem.,PUBLICATION,,C[C@H]([C@@H](C1=CC=C(C=C1)NC2=NC3=CC=CC=C3S2)N4C=CN=C4)N(C)C,6.455931955649724,C[C@H]([C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C
39392,CHEMBL1095040,WGVVIVGNBSSANI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20189807.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCC(=O)NC1=NNC2=CC(=C(C=C21)C3=CC=CC=C3)Cl,5.0,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12
39395,CHEMBL1916697,WGXIPXHUOIQNGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958540.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of a biphenylacetic acid series of prostaglandin D(2) receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C(C=C1)CC(=O)O)C2=C(C=C(C=C2)C(F)(F)F)CN(CC3=CC=CC=C3)C(=O)OC,4.522878745280337,COC(=O)N(Cc1ccccc1)Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC
39412,CHEMBL2425618,WHGCVYRLVFZOSN-JUZXMZQFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=CC=CC(=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F,6.154901959985743,COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F
39414,CHEMBL1081687,WHGLFZPJAYDODK-WMZHIEFXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19891474.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,PUBLICATION,,CC1=C(C=CC=N1)C2=NN=C(N2C)SCCCN3C[C@@H]4C[C@@]4(C3)C5=CC=C(C=C5)C(F)(F)F,5.0,Cc1ncccc1-c1nnc(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3)C2)n1C
39418,CHEMBL495794,WHHQPBQWWSSETM-QUCCMNQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CCN(CC3)C(=O)N[C@H]4C[C@@H]4C5=CC=CC=C5)CC2=O,5.0,CS(=O)(=O)c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2
39431,CHEMBL1210614,WHOZDXFLKLSAJU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC(=CC=C5)S(F)(F)(F)(F)F,5.0,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C
39432,CHEMBL1210614,WHOZDXFLKLSAJU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC(=CC=C5)S(F)(F)(F)(F)F,5.0,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C
39438,CHEMBL388590,WHQCHUCQKNIQEC-UHFFFAOYSA-N,BENZBROMARONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,29200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br,4.534617148551582,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1
39446,CHEMBL76,WHTVZRBIWZFKQO-UHFFFAOYSA-N,CHLOROQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,349945.17,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,3.455999996312085,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12
39483,CHEMBL402279,WICCBBOVLJSUTQ-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)O[C@H]4CCNC4)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,5.318758762624412,CC(C)c1c(-c2nnc(O[C@H]3CCNC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
39494,CHEMBL230080,WIFGAYBFSSWCPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,35.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)N5C=CN=C5)N(C2=O)CC6=CC=CC=C6F,7.455931955649724,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-n5ccnc5)cc4)CC3)C2=O)c1
39513,CHEMBL1091793,WIKAXVDAJYMGCT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1=NC(=CC=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,CC(c1cccc(F)n1)c1c(CCN(C)C)sc2ccccc12
39517,CHEMBL2070949,WIKIUJMLESFHCO-HZPDHXFCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22858142.0,IC50,>,31622.78,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC[C@H]([C@@H](C1)C(=O)NC2(CC2)C#N)C(=O)N3CCN(CC3)C4=NC5=C(S4)N=CC=C5,4.499999953328896,N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4cccnc4s3)CC2)CC1
39535,CHEMBL3664674,WILRFGPGSCIZNX-CHJDUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,43000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C(C)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.366531544420414,CC(C)n1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O
39547,CHEMBL1949936,WIPFOPZHWMUVDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)O)OC,5.5376020021010435,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccncc3)c2c1
39548,CHEMBL1949936,WIPFOPZHWMUVDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)O)OC,5.522878745280337,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccncc3)c2c1
39549,CHEMBL1078218,WIPOZGZUHPTZTR-ACHIHNKUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CC=C2)C[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CC=C4,5.522878745280337,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cccnc1)C[C@H](Cc1ccccc1)NC(=O)OCc1cccnc1
39554,CHEMBL341089,WIUDTZXSQKGXHD-ZUHKWECKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CN(C=C2)C3=CC=CC=C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CN=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,6.3979400086720375,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3ccccc3)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
39555,CHEMBL446083,WIUTZMQRXHUOSJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,<,200000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,CN1C(=O)CCC2=C1C=CC(=C2)C3=CN=CC=C3,3.6989700043360187,CN1C(=O)CCc2cc(-c3cccnc3)ccc21
39559,CHEMBL1232887,WIXHEGLMUQGJCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19772287.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli by fluorimetric assay,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,PUBLICATION,,CC1=C(C=C(C=C1)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC4CC4,4.0,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cn1
39593,CHEMBL3311226,WJGQBRYSRQIYNV-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,54000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)C(F)(F)F,4.267606240177032,O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1
39594,CHEMBL3311224,WJGQBRYSRQIYNV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,>,60000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)C(F)(F)F,4.221848749616356,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1
39595,CHEMBL3311224,WJGQBRYSRQIYNV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,60000.0,NM,253315,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",Metalloenzyme inhibitor compounds,,PATENT,,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)C(F)(F)F,4.221848749616356,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1
39605,CHEMBL2070147,WJKJOKNERLASNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=C(C=CC(=C3)C4=CC=CC=C4)F,4.853871964321762,CCS(=O)(=O)c1ccc2nc(-c3cc(-c4ccccc4)ccc3F)[nH]c2c1
39608,CHEMBL3699328,WJLYZJUAZGDOJF-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6530.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC(=CC=C8)OC,5.185086818724926,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OC)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
39619,CHEMBL1951443,WJTBCUZNVGPRTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)NC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=CC=NC=C3,6.886056647693163,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccncc3)cc2)c1
39623,CHEMBL1813067,WJUJICMNSMPLLG-PFEQFJNWSA-N,IRDABISANT HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634396.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3.Cl,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1
39624,CHEMBL3702756,WJUKAGADXSWIEY-ACHIHNKUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2330.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CNN(C)C(=O)C1=CN(C2=C(C=CC=C12)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C,5.632644078973981,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)NC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
39686,CHEMBL2048496,WKVPTVMGLXDFTB-OTBWLPETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,25700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2OC)OC)[C@@H]3C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO,4.590066876668706,CCc1ccc(Cc2cc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1
39687,CHEMBL2048496,WKVPTVMGLXDFTB-OTBWLPETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,40300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2OC)OC)[C@@H]3C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO,4.394694953858891,CCc1ccc(Cc2cc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1
39708,CHEMBL1631876,WLGXHFREMLNUDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20971004.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC=CC(=C3)C4=CN=CC=C4,5.7447274948966935,Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-c3cccnc3)c1)=N2
39709,CHEMBL3261482,WLINCFBAKQHMPZ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@@H](C2)N3CCN4C5=C(C=C(C=C5C3=O)F)C=N4,4.301029995663981,O=C1c2cc(F)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
39714,CHEMBL2159136,WLKGGVSOAWMXIY-WCXMYULTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](NC(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NC5=CC=C(C=C5)OC)O4)C)(C)OC)C)C)O)(C)O,6.154901959985743,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=Nc2ccc(OC)cc2)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O
39715,CHEMBL2159136,WLKGGVSOAWMXIY-WCXMYULTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](NC(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NC5=CC=C(C=C5)OC)O4)C)(C)OC)C)C)O)(C)O,5.327902142064283,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=Nc2ccc(OC)cc2)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O
39731,CHEMBL2334756,WLQPHPRJRBGPBN-XWFZLUIHSA-N,6-AZA-PAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C([C@H]4CC[C@@H](C3)N4C5COC5)C(=N2)N6CCOC[C@@H]6C,5.0,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)[C@H]2CC[C@@H](C3)N2C2COC2)cc1
39733,CHEMBL3264602,WLSFHVCGANYCRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC=NC=C1)(C2=CC3=CC(=C(C=C3C=C2)OC)OC)O,5.346787486224656,COc1cc2ccc(C(O)(c3ccncc3)C(C)C)cc2cc1OC
39737,CHEMBL1094852,WLXTZKAROJEVMI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CCCN(C4)C5CCOCC5,5.301029995663981,COc1ccc(Cn2c(C3CCCN(C4CCOCC4)C3)nc3ccccc32)cc1
39742,CHEMBL1834658,WMASPOZRAFIGIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC=CC(=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,5.958607314841775,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(N4CCN(C)CC4)c3)ncn2)c1Cl
39743,CHEMBL1834658,WMASPOZRAFIGIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC=CC(=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,5.0,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(N4CCN(C)CC4)c3)ncn2)c1Cl
39752,CHEMBL360072,WMGCLEIKLXKKON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,357.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)N(C)C)N4C=CN=C4)N(C)C,6.447331783887807,CC(C(c1ccc2cc(OCc3cccc(C(=O)N(C)C)c3)ccc2c1)n1ccnc1)N(C)C
39753,CHEMBL3664665,WMGGVACWNSZZQE-RPLLCQBOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CC[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CC[C@](OC3=O)(CC)C4=CC=CC=C4,5.096910013008056,CC[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC)(c2ccccc2)OC1=O
39769,CHEMBL2315239,WMLLWXCYJMFXSU-LTJSBYPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294255.0,IC50,>,22000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Trichoplusia ni BTI-TN-5B1-4 cells preincubated for 15 mins measured after 30 mins by spectrofluorimetry,Development of new cyclic plasmin inhibitors with excellent potency and selectivity.,J. Med. Chem.,PUBLICATION,,C1CN2CCN1CC(=O)NC3=CC=C(C[C@H](C(=O)N[C@@H](CC4=CC=C(C=C4)NC(=O)C2)C(=O)NCC5=CC=C(C=C5)C(=N)N)NS(=O)(=O)CC6=CC=CC=C6)C=C3.C(=O)(C(F)(F)F)O,4.657577319177793,N=C(N)c1ccc(CNC(=O)[C@@H]2Cc3ccc(cc3)NC(=O)CN3CCN(CC3)CC(=O)Nc3ccc(cc3)C[C@@H](NS(=O)(=O)Cc3ccccc3)C(=O)N2)cc1
39770,CHEMBL252438,WMLNCGYLJNOXEB-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=CC(=CC=C1)Cl)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,5.619788758288394,CC(C)(C)OC(=O)N[C@H](Cc1cccc(Cl)c1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
39772,CHEMBL3403820,WMMVSZKVXZQWAL-UZIYNMEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)CC(C)(C)O)C)C)O)C)C(C)(C)O,5.568636235841013,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
39773,CHEMBL3403820,WMMVSZKVXZQWAL-UZIYNMEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)CC(C)(C)O)C)C)O)C)C(C)(C)O,5.522878745280337,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
39776,CHEMBL192848,WMNVYPIDBPUURP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)N1C2=C(C=CC(=C2)C3=C(NC=N3)C4=CC=CC=C4)N=C1N,5.795880017344075,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3nc[nH]c3-c3ccccc3)cc21
39781,CHEMBL3400440,WMOLSILQHXYKNV-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NC(=O)C2CCOCC2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,5.0,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)C2CCOCC2)C(C)C)ccc1OC
39797,CHEMBL79236,WMTSGCIMPPZQLI-LZVMDTAVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12161148.0,IC50,,30.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=CC2=C(O1)C=CN=C2)N3CCN([C@@H](C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,7.522878745280337,CC(C)(c1cc2cnccc2o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1
39798,CHEMBL495290,WMURFNLBNNBFQO-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,C[C@H]1CN(CCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC6CC6)C)C(=O)C,5.376750709602099,CC(=O)N1CCN(c2nncc3cc(-c4c(C)ccc5c(NC6CC6)noc45)ccc23)[C@@H](C)C1
39807,CHEMBL1800911,WMXJYEDCJIDCNY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21696951.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Indolin-2-one p38a inhibitors I: design, profiling and crystallographic binding mode.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)C(=O)NC2CC2)C3=CC4=C(C=C3)C5(CCCC5)C(=O)N4,4.6020599913279625,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(c1)NC(=O)C21CCCC1
39811,CHEMBL1094349,WMYNTTGGSSIVHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,C1OC2=C(O1)C=C(C=C2)C3=CC(=CC(=C3)OCCCCCCC4=C(C(=CC=C4)OCCCC(=O)O)CCC(=O)O)C5=CC=CC=C5F,5.1249387366083,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccc4c(c3)OCO4)cc(-c3ccccc3F)c2)c1CCC(=O)O
39827,CHEMBL3436346,WNJHNFPCLVLFKX-LREBCSMRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23006002.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,CC1=NN(C2=C1C=C(C=C2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,5.0,COc1ccc(S(=O)(=O)n2nc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1
39832,CHEMBL3115172,WNKJULKGXFIBJE-XRRFYDIFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](COCC2=CC=CC=C2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.769551078621726,CC(C)c1nc(CN(C)C(=O)N[C@@H](COCc2ccccc2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
39838,CHEMBL207345,WNMJTTIGNYLSJY-VGSWGCGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]([C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCC3)C(=O)O)N4C=CN=C4)N(C)C,5.154901959985743,C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCC3)ccc2c1)n1ccnc1)N(C)C
39844,CHEMBL249243,WNOWXHZXFDFPBC-IWQLRFKPSA-N,EPI-FIBRAURETINOSIDE A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,C[C@@]12C[C@H](OC(=O)[C@]1(C[C@@H]3[C@@]4([C@H]2CC=C[C@]4(C(=O)O3)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)O)C6=COC=C6,4.0,C[C@@]12[C@H]3CC=C[C@@]1(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)O[C@@H]2C[C@]1(O)C(=O)O[C@H](c2ccoc2)C[C@@]31C
39845,CHEMBL400494,WNOWXHZXFDFPBC-WEYSNVRMSA-N,FIBRAURETINOSIDE A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,C[C@@]12C[C@H](OC(=O)[C@]1(C[C@@H]3[C@@]4([C@H]2CC=C[C@@]4(C(=O)O3)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)O)C6=COC=C6,4.0,C[C@@]12C[C@@H](c3ccoc3)OC(=O)[C@@]1(O)C[C@H]1OC(=O)[C@@]3(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=CC[C@@H]2[C@@]13C
39865,CHEMBL2397309,WNWFDHLMCZOQPH-BJHJDKERSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)C2CCC(CC2)OC)C3=CN=C(C=C3)N,4.522878745280337,COC1CCC(C(=O)Nc2nc(C)c(-c3ccc(N)nc3)s2)CC1
39868,CHEMBL2418946,WNYMKNYCLRXAIM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23820386.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NC1=NC2=C(S1)C=C(C=C2)C3=CN=C(C=C3)N,7.301029995663981,CC(=O)Nc1nc2ccc(-c3ccc(N)nc3)cc2s1
39874,CHEMBL3318469,WOBNNXBIQRYYDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2Cl)C3=C(C=CC=C3Cl)Cl,5.301029995663981,O=C1CC(c2c(Cl)cccc2Cl)CC(O)=C1Sc1ccccc1Cl
39880,CHEMBL398160,WOCKQPIYHQRKEQ-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,C1[C@@H](OC(=O)N1C2=CC(=C(C=C2)C3=CN=C(C=C3)CO)F)CN4C=CN=N4,4.698970004336019,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccc(CO)nc2)c(F)c1
39884,CHEMBL1079256,WODRVGVVTPASNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=CC=C3,5.0,O=C(O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
39885,CHEMBL1079256,WODRVGVVTPASNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=CC=C3,4.0,O=C(O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
39889,CHEMBL2041170,WOFLYJYTODVGLV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)C6=CC=C(C=C6)N7CCOCC7,4.301029995663981,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(N4CCOCC4)cc3)cc1)C(=O)N2c1cc(=O)[nH]cn1
39897,CHEMBL3104477,WOGNYOHGZLVUOP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CS(=O)(=O)C1=CC=C(C=C1)N2CCC(CC2)N(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,5.698970004336019,CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1
39900,CHEMBL218547,WOIDDZSLDVWACJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1CNC2=NC=CS2)C(=O)OCC3=CC=CC=C3,5.0,O=C(OCc1ccccc1)N1CCC(CNc2nccs2)CC1
39903,CHEMBL3686863,WOJKYHBOHSQZDW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27020304.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(C=C1)N2CCC(CC2)O)C(=O)NC3=C(C=C(C=C3C)C(=O)O)C,5.0,Cc1ccc(N2CCC(O)CC2)nc1C(=O)Nc1c(C)cc(C(=O)O)cc1C
39909,CHEMBL1951328,WOLVVZYIMHOLRF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,61.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC(=C1)[N+](=O)[O-])NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,7.214670164989233,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc([N+](=O)[O-])c1
39911,CHEMBL453587,WOLXSMOIVRMEIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C(CN1CCCC1)C2=CC=C(C=C2)C3=CC(=CC=C3)C(=O)N)C(=O)CN(CC#N)C4=CC(=C(C=C4)Cl)Cl,5.657577319177793,CN(C(=O)CN(CC#N)c1ccc(Cl)c(Cl)c1)C(CN1CCCC1)c1ccc(-c2cccc(C(N)=O)c2)cc1
39915,CHEMBL2064346,WOQUVNKDDWFSGT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,C1COCCN1C2=CC(=O)NC(=N2)CC3=NC4=C(C=CC=C4N3)C5=CC=CC=C5,4.3979400086720375,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)cccc3[nH]2)[nH]1
39936,CHEMBL400431,WPAPODFGOZXFLG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(C)C,4.522878745280337,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(C)O2
39937,CHEMBL1096103,WPASHFXVTJYQPC-LBEKAKSKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OC[P@]4(=O)OCC[C@@H](O4)C5=C(N=CC=C5)C,5.236572006437063,Cc1cc(OC[P@]2(=O)OCC[C@H](c3cccnc3C)O2)c2c(c1C)Cc1scnc1-2
39938,CHEMBL1096105,WPASHFXVTJYQPC-RBSBEOHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OC[P@@]4(=O)OCC[C@H](O4)C5=C(N=CC=C5)C,4.823908740944319,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccnc3C)O2)c2c(c1C)Cc1scnc1-2
39942,CHEMBL541483,WPBLHQJDLOPHGT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19524437.0,IC50,>,41000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)C=C(C=C3)C(=O)N4CCOCC4,4.3872161432802645,CC(C)N1CCC(Oc2ccc3cc(C(=O)N4CCOCC4)ccc3c2)CC1
39952,CHEMBL3237564,WPELTQURDISYSR-GXTWGEPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24520947.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,PUBLICATION,,C1CC[C@H]([C@H](C1)N)NC2=NN=C(C(=C2)NC3=NC4=C(CCC4)C=C3)C(=O)N,4.301029995663981,NC(=O)c1nnc(N[C@@H]2CCCC[C@@H]2N)cc1Nc1ccc2c(n1)CCC2
39961,CHEMBL1980297,WPHKIQPVPYJNAX-UHFFFAOYSA-N,ILORASERTIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22465635.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC(=C1)F)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)CCO)N,4.522878745280337,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
39964,CHEMBL1980297,WPHKIQPVPYJNAX-UHFFFAOYSA-N,ILORASERTIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 µL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 µg/mL) were incubated with 5 concentrations of test compound (from 0.1 µM to 10 µM), 1 mM NADPH (Sigma), and 2 µM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,C1=CC(=CC(=C1)F)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)CCO)N,5.0,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
39966,CHEMBL3358922,WPHQTOKGVMHYCJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=C(N2)C=NC=C3C)(C(F)(F)F)O,5.698970004336019,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2c(C)cncc2[nH]1)C(F)(F)F
39987,CHEMBL442398,WPQGTFWRUQZWSD-XREYCITQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,120000.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=CS1)COC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](CN3CCN(C[C@H]3C(=O)NC(C)(C)C)CC4=CC(=C(C=C4)OC)OC)O,3.9208187539523753,COc1ccc(CN2CCN(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)OCc3csc(C)n3)C(C)C)[C@H](C(=O)NC(C)(C)C)C2)cc1OC
39990,CHEMBL3582481,WPQXLUHKXSHBCJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26005536.0,IC50,=,8235.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C=NC=C1C2=NC3=CC(=C(C=C3N2C4CC4)F)F)F,5.084336396494227,Cc1c(F)cncc1-c1nc2cc(F)c(F)cc2n1C1CC1
39998,CHEMBL3401541,WPSURGXSNWIBBJ-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NS(=O)(=O)CC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,5.356547323513812,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)Cc2ccccc2)C(C)C)ccc1OC
39999,CHEMBL3401541,WPSURGXSNWIBBJ-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NS(=O)(=O)CC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,4.522878745280337,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)Cc2ccccc2)C(C)C)ccc1OC
40004,CHEMBL2017104,WPTSXGNZZOZOLL-KOSHJBKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,45000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCC1=C(C=CC(=C1)F)C2=C(C(=NO2)[C@H]3CNCC[C@@]3(C4=CC(=C(C=C4)F)F)O)Br,4.346787486224656,CC(=O)NCCc1cc(F)ccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br
40011,CHEMBL3409875,WPUHSUHTXPVKAB-MUMRKEEXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,46000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)F)C2C[C@H](C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)O,4.337242168318426,COc1cccc(F)c1C1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1
40012,CHEMBL3409876,WPUHSUHTXPVKAB-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)F)[C@@H]2C[C@H](C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)O,4.301029995663981,COc1cccc(F)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1
40013,CHEMBL3409876,WPUHSUHTXPVKAB-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)F)[C@@H]2C[C@H](C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)O,4.301029995663981,COc1cccc(F)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1
40026,CHEMBL1170725,WPZKKCHLDQPKDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20627722.0,IC50,=,19498.45,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC=N1)OC2=C(C=C(C=N2)Cl)NS(=O)(=O)C3=CC(=C(C=C3)Cl)Cl,4.709999910852971,Cc1ncccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1
40032,CHEMBL2181522,WQBAZXIQANTUOY-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,900.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4=NC=CC=N4)C(=N2)N5CCOC[C@@H]5C,6.045757490560675,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ncccn2)C3)cc1
40037,CHEMBL3260741,WQCVKQKJPUHDNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC(=N1)C(F)(F)F)CN2C(=O)C(=C(C3=NN(C(=O)N32)C)C4=CC=C(C=C4)Cl)C5=CC=NC=C5,5.167491087293763,Cc1nc(C(F)(F)F)ccc1Cn1c(=O)c(-c2ccncc2)c(-c2ccc(Cl)cc2)c2nn(C)c(=O)n21
40047,CHEMBL1271246,WQGSTVFPWRFZTI-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ß-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)[C@@](N=C1N)(C2=CC=C(C=C2)OC(F)F)C3=CC=CC(=C3)C#CC4CC4,7.0,CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2cccc(C#CC3CC3)c2)N=C1N
40053,CHEMBL481659,WQKGOLGYPXZSSX-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18539454.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines as VLA-4 integrin antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC2(CC1)C(=C(C2=O)Br)N[C@@H](CC3=CC=C(C=C3)N4C5=C(C=CC=N5)N=C4C6=CN=CC=C6)C(=O)O,4.207608310501746,O=C(O)[C@H](Cc1ccc(-n2c(-c3cccnc3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2
40054,CHEMBL3702705,WQKONMWIFWSSSD-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6090.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCN8CCOCC8,5.215382707367125,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCN6CCOCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
40058,CHEMBL2181765,WQNYJRIRCUZJJO-NTEUORMPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,9200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=COC=C5)C6CCCC6,5.036212172654444,Cn1c(-c2ccoc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21
40060,CHEMBL1095510,WQOMZYPBVOXQJY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOCCN1C2=CC=CC=C2N=C1C3CCCN(C3)C4CCOCC4,5.301029995663981,CCOCCn1c(C2CCCN(C3CCOCC3)C2)nc2ccccc21
40071,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,5.568636235841013,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40072,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,5.5376020021010435,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40073,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,5.2839966563652006,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40074,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,5700.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,5.2441251443275085,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40075,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,5.154901959985743,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40076,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,5.096910013008056,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40077,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,5.080921907623926,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40078,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,9200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,5.036212172654444,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40079,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,4.698970004336019,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40080,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,4.6777807052660805,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40081,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,4.657577319177793,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40082,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,4.6020599913279625,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40083,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,4.585026652029182,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40084,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,4.568636235841013,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40085,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,4.522878745280337,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40086,CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,4.522878745280337,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
40107,CHEMBL1271991,WQUXILRTVPBVCS-HNYUPJOQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC(=O)N1C2CCC1CN(C2)C(=O)OC3(CC3)[C@H]4COC[C@H](N4S(=O)(=O)C5=CC=C(C=C5)Cl)CC6CC6,7.522878745280337,CCNC(=O)N1C2CCC1CN(C(=O)OC1([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2
40110,CHEMBL151449,WQYJPEHBLXPHHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=CC(=C1)C2=CC=NO2,4.0,CCCCOc1cccc(-c2ccno2)c1
40117,CHEMBL2386558,WRBFPGYDKJBYBI-SJORKVTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CN1C=NC(=C1SC2=NC=C(C=C2)Cl)C3=CC=C(C=C3)[C@H]4C[C@@H]4C(=O)N(C)C,4.301029995663981,CN(C)C(=O)[C@H]1C[C@@H]1c1ccc(-c2ncn(C)c2Sc2ccc(Cl)cn2)cc1
40119,CHEMBL1951348,WRCCQNZGVMRARX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)NC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CNC4=NC=N3)Cl,4.853871964321762,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]cc(Cl)c34)cc2)c1
40149,CHEMBL576138,WRRGABWWSIAMMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19902954.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists.,J. Med. Chem.,PUBLICATION,,CC1=C(C=C(C=C1)N(C)C(=O)C2=C(ON=C2C3=CC=CC=C3Cl)C)Cl,5.899998417198648,Cc1ccc(N(C)C(=O)c2c(-c3ccccc3Cl)noc2C)cc1Cl
40165,CHEMBL3259868,WRXRPPQRURPMPT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,81000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C3=CC=CS3)(C4=NNN=C4)O,4.0915149811213505,CC(C)C(O)(c1ccc2cc(-c3cccs3)ccc2c1)c1cn[nH]n1
40168,CHEMBL401960,WRYKATOCEQATEA-UEVCKROQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=CC=C(O2)C(F)(F)F)C(=O)NC(C)C)C3CC4=CC=CC=C4C3,5.522878745280337,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(C(F)(F)F)o1
40174,CHEMBL1269681,WSBCYTMHZZVDOP-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNCC(F)F)Cl)C5CC5)Cl,5.508638306165727,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCC(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
40175,CHEMBL1269681,WSBCYTMHZZVDOP-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CNCC(F)F)Cl)C5CC5)Cl,5.318758762624412,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCC(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
40182,CHEMBL3319549,WSCXEOSPTMGMGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25001129.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket.,J. Med. Chem.,PUBLICATION,,C1CN(CCN1C2=C(C=C(C=N2)C(C(F)(F)F)(C(F)(F)F)O)C3=CN=CC=C3)S(=O)(=O)C4=CN=C(C=C4)N,4.568636235841013,Nc1ccc(S(=O)(=O)N2CCN(c3ncc(C(O)(C(F)(F)F)C(F)(F)F)cc3-c3cccnc3)CC2)cn1
40192,CHEMBL502335,WSFARKDYYPRFAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,3110.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC4=CC=CC=C4C=C3,5.507239610973163,COc1ccc2nc(SCc3ccc4ccccc4c3)[nH]c2c1
40195,CHEMBL2336412,WSIDSJAOLGDFPK-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C=C3Br)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,5.638272163982407,O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Br)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
40196,CHEMBL2336412,WSIDSJAOLGDFPK-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC4=C(C=C3Br)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.7447274948966935,O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Br)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
40203,CHEMBL168471,WSJWUIDLGZAXID-ZBFHGGJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12593666.0,IC50,=,81000.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 as BFC substrate,Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor.,J. Med. Chem.,PUBLICATION,,CC(C)C[C@H](C=O)NC(=O)[C@H](C(C)C)NS(=O)(=O)C1=CC=C(C=C1)F,4.0915149811213505,CC(C)C[C@H](C=O)NC(=O)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(C)C
40204,CHEMBL168471,WSJWUIDLGZAXID-ZBFHGGJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12593666.0,IC50,=,531000.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 as BQ substrate,Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor.,J. Med. Chem.,PUBLICATION,,CC(C)C[C@H](C=O)NC(=O)[C@H](C(C)C)NS(=O)(=O)C1=CC=C(C=C1)F,3.274905478918531,CC(C)C[C@H](C=O)NC(=O)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(C)C
40209,CHEMBL2070148,WSLDJBIBBVFJHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=C(C=C3)F)C4=CC=CC=C4,5.251811972993799,CCS(=O)(=O)c1ccc2nc(-c3ccc(F)c(-c4ccccc4)c3)[nH]c2c1
40214,CHEMBL281743,WSLYVCYLWXBOKX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,1790.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,COC1=C(C2=C(C=C1)C3=C(N2)C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)[N+](=O)[O-],5.747146969020107,COc1ccc2c([nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc32)c1[N+](=O)[O-]
40217,CHEMBL480501,WSMJMACKNHBKSD-XUTJKUGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18539028.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent, orally active benzimidazole glucagon receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1CCC(CC1)N(CC2=CC=C(C=C2)C(=O)NC3=NNN=N3)C4=NC5=C(N4C)C=CC(=C5)C(F)(F)F,5.0,Cn1c(N(Cc2ccc(C(=O)Nc3nn[nH]n3)cc2)C2CCC(C(C)(C)C)CC2)nc2cc(C(F)(F)F)ccc21
40221,CHEMBL1923117,WSNYMUSQZWXVNZ-YKSBVNFPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC=C1C(F)(F)F)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F,5.638272163982407,Cc1c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)cccc1C(F)(F)F
40226,CHEMBL2380643,WSPHZWFOMITWJU-RLOPOPLLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)N3CCN(C4=CC=CC=C43)C(=O)NC5C6CC7CC5CC(C7)(C6)O,5.0,CS(=O)(=O)N1CCN(c2ccc(N3CCN(C(=O)NC4C5CC6CC4CC(O)(C6)C5)c4ccccc43)cc2)CC1
40231,CHEMBL2070151,WSRNACDNBXDTGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=C(C=C3)Cl)C4=CC=CC=C4,5.585026652029182,CCS(=O)(=O)c1ccc2nc(-c3ccc(Cl)c(-c4ccccc4)c3)[nH]c2c1
40239,CHEMBL209244,WSTSJUHYFOKDQM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16503138.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)COC2=C(C=C(C=C2)Cl)C3=C(C=CN=C3)C4=CC(=CC=C4)C(=O)O,5.853871964321762,O=C(O)c1cccc(-c2ccncc2-c2cc(Cl)ccc2OCc2ccccc2)c1
40252,CHEMBL1934810,WTAIERVWPQNXDM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)Br)Cl,4.619788758288394,O=c1[nH]c2cc(Br)ccc2c2nc(-c3ccccc3Cl)[nH]c12
40254,CHEMBL1089202,WTCGMGACKXOKHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20236824.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,Design and synthesis of tricyclic sulfones as gamma-secretase inhibitors with greatly reduced Notch toxicity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2(C(CC1=O)COC3=C(C=CC(=C32)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl,5.920818753952375,O=C1CCC2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC2C1
40257,CHEMBL225465,WTDJZXIANMNOOX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C=C(C=C3)Cl)F,4.0,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2F)nc1C(F)(F)F
40258,CHEMBL1837041,WTDORPHQLSCAEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21885275.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)N1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCN(CC4)C5=CC=CC=N5)C1,4.522878745280337,CS(=O)(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1
40267,CHEMBL3702774,WTHIVYAJBCYSSM-QARUCVQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)OCCN(C)C,4.995678626217358,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
40286,CHEMBL178681,WTPRWIIKNCIYOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,77500.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CC=C(S2)CN.C1=CC(=CN=C1)C2=CC=C(S2)C=N.C1=CC(=CN=C1)C2=CC=C(S2)C=N,4.110698297493689,NCc1ccc(-c2cccnc2)s1
40288,CHEMBL468672,WTQDFMWCMKSXGH-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)C5CCN(CC5)CCCF,4.552841968657781,Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
40290,CHEMBL411118,WTRWFOXPPRLKFP-BDYUSTAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)OC)C(=O)O,4.585026652029182,COc1ccc(N2C(=O)[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@H]2C(=O)O)cc1
40291,CHEMBL411118,WTRWFOXPPRLKFP-BDYUSTAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)OC)C(=O)O,4.481486060122112,COc1ccc(N2C(=O)[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@H]2C(=O)O)cc1
40303,CHEMBL1089525,WTXUIYHQKGABGR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20236824.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,Design and synthesis of tricyclic sulfones as gamma-secretase inhibitors with greatly reduced Notch toxicity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2(C(CC1O)COC3=C(C=CC(=C32)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl,5.040958607678906,O=S(=O)(c1ccc(Cl)cc1)C12CCC(O)CC1COc1c(F)ccc(F)c12
40327,CHEMBL429743,WUBFAXNVDMCVIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=C(C=C5)Cl,4.301029995663981,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccc(Cl)cc5)cccc4c3)c2cc1OC
40337,CHEMBL2418948,WUEXEUOEWYMTKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23820386.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NC1=NC2=C(S1)C=C(C=C2)C3=CC(=C(N=C3)N)C(F)(F)F,6.096910013008056,CC(=O)Nc1nc2ccc(-c3cnc(N)c(C(F)(F)F)c3)cc2s1
40338,CHEMBL2178253,WUGATYAZBCNSNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)Cl)C2=C(C=NN2)NC(=O)C3=C4N=CC=CN4N=C3,5.142667503568732,O=C(Nc1cn[nH]c1-c1cccc(Cl)c1)c1cnn2cccnc12
40344,CHEMBL1808624,WUGRYAJUCLYESW-VQHVLOKHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C2=C(CN1C(=O)CC3=CC=CC=C3)C=C(C=C2)/C=C/C(=O)NO,4.301029995663981,O=C(/C=C/c1ccc2c(c1)CN(C(=O)Cc1ccccc1)C2)NO
40347,CHEMBL334379,WUIIVYZPUDLMGE-OTTPZFKLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CN(C=C2)C3=C(C(=C(C=C3)F)F)F)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CN=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,7.301029995663981,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3ccc(F)c(F)c3F)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
40364,CHEMBL3699334,WUQQGTBJNNXQJA-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3410.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC(C)(C)NNC(=O)C1=CC=C(C=C1)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.467245621007502,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NNC(C)(C)C)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
40369,CHEMBL520897,WURBVZBTWMNKQT-UHFFFAOYSA-N,TRIADIMEFON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,9289.66,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC(C)(C)C(=O)C(N1C=NC=N1)OC2=CC=C(C=C2)Cl,5.032000180820781,CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1cncn1
40374,CHEMBL229176,WUSUIPCZTUWOIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17500511.0,IC50,>,22000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.,J. Med. Chem.,PUBLICATION,,CCC(C)COC1=CC=C(C=C1)C(CC(=O)O)C2=CC=CC=C2,4.657577319177793,CCC(C)COc1ccc(C(CC(=O)O)c2ccccc2)cc1
40392,CHEMBL2441842,WVAJNEZWLOLVEH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CNC2=O)C3=C(C=C(C=C3)Cl)Cl)CN,4.3979400086720375,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)NC2
40394,CHEMBL376722,WVBVFBWFVVPNPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15566305.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.",J. Med. Chem.,PUBLICATION,,CC1=C(C=CN=C1NC2=NC=C(S2)C#N)CN3CCN(CC3)C(=O)NC,4.0,CNC(=O)N1CCN(Cc2ccnc(Nc3ncc(C#N)s3)c2C)CC1
40401,CHEMBL3673939,WVCIKWIWVGCIOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320650,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4)F)F)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(F)c4)nc3F)c2c1
40402,CHEMBL3673939,WVCIKWIWVGCIOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320694,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4)F)F)N=C1,5.0,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(F)c4)nc3F)c2c1
40411,CHEMBL258951,WVDATIVEQWYJIH-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,C1CSCCN1C2CC(C2)C3=NC(=C4N3C=CN=C4N)C5=CC6=C(C=C5)C=CC(=N6)C7=CC=CC=C7,5.107905397309519,Nc1nccn2c(C3CC(N4CCSCC4)C3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12
40415,CHEMBL271202,WVDKULPCDHAQIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18307292.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents.,J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=NC(=C2)NC(=O)CN3CCN(CC3)C)C4=NC=CS4)C,4.886056647693163,Cc1cc(C)n(-c2cc(NC(=O)CN3CCN(C)CC3)nc(-c3nccs3)n2)n1
40416,CHEMBL271202,WVDKULPCDHAQIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24164628.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Adenosine A2A receptor as a drug discovery target.,J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=NC(=C2)NC(=O)CN3CCN(CC3)C)C4=NC=CS4)C,4.886056647693163,Cc1cc(C)n(-c2cc(NC(=O)CN3CCN(C)CC3)nc(-c3nccs3)n2)n1
40442,CHEMBL2251445,WVQBLGZPHOPPFO-LBPRGKRZSA-N,S-METOLACHLOR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CCC1=CC=CC(=C1N([C@@H](C)COC)C(=O)CCl)C,5.0,CCc1cccc(C)c1N(C(=O)CCl)[C@@H](C)COC
40446,CHEMBL2177831,WVQVQQXBOHNXQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22533986.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins,"Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors.",J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C(=O)NCC2=CC=C(C=C2)N3C4=C(C=C(C=N4)C5=CN=CC=C5)N=C3C6=C(N=CC=C6)N,5.0,Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1
40453,CHEMBL3215850,WVTAOBVWAHTAMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21823597.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by luceferin-based assay,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)CN6C=NC=N6.Cl.Cl.Cl,4.698970004336019,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2Cn2cncn2)CC1
40472,CHEMBL1915563,WVWJNRQKNPFRGF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21924610.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aminothiazoles as ¿-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C(C=C1)Br)C2=CSC(=N2)NC3=CC=C(C=C3)N4C=CN=C4,6.698970004336019,COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3ccnc3)cc2)n1
40479,CHEMBL596583,WVXVZSIOYIMDMF-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,630.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)N=CC(=N2)C3=C(N=CC(=C3)OC[C@H](CC4=CNC5=CC=CC=C54)N)C6=C(OC=C6)C,6.200659450546418,Cc1occc1-c1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2n1
40510,CHEMBL505033,WWIQHIRTDVHNNM-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)N)C4=C(C(=CC=C4)OCCCCCC(=O)O)F,5.086186147616283,Cc1c(-c2cccc(OCCCCCC(=O)O)c2F)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F
40522,CHEMBL3604717,WWQZYHBACWHPRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,3981.07,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,CC1=CC(=C2C=CC=C(C2=N1)C(=O)N)NCC3=C(C(=CC=C3)Cl)Cl,5.40000018605658,Cc1cc(NCc2cccc(Cl)c2Cl)c2cccc(C(N)=O)c2n1
40524,CHEMBL3628591,WWSWXUCLNZWXKO-IZCXSWDTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@](C)(C1=CN(N=N1)C(CCS(=O)(=O)C)C(=O)COC2=C(C(=CC(=C2F)F)F)F)NCC3=CC4=C(C=C3)N=CC=C4,5.920818753952375,CC(C)[C@](C)(NCc1ccc2ncccc2c1)c1cn(C(CCS(C)(=O)=O)C(=O)COc2c(F)c(F)cc(F)c2F)nn1
40539,CHEMBL478902,WWYOUXCBBIIJAP-AQTBWJFISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19321349.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,PUBLICATION,,CC1=NN(C=C1)C2=CC(=C(C=C2)C(=O)N3CCC(/C(=C\C(=O)O)/C4=CC=CC=C43)(F)F)Cl,4.0,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)O)c4ccccc43)c(Cl)c2)n1
40545,CHEMBL2159134,WXAHYADQZARZEO-UTZFUXNDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NC(C)C)O4)C)(C)O)C)C)O)(C)O,5.958607314841775,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NC(C)C)N3C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
40546,CHEMBL2159134,WXAHYADQZARZEO-UTZFUXNDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,=,9800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@H]4[C@H](C[C@H](O3)C)N(C(=NC(C)C)O4)C)(C)O)C)C)O)(C)O,5.008773924307505,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2OC(=NC(C)C)N3C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
40552,CHEMBL2036208,WXCYUCDZYGCZKX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,CCC(=O)N(CC1=CC(=CC=C1)C(F)(F)F)C2=CC=CC(=C2)C3=NNN=N3,5.0,CCC(=O)N(Cc1cccc(C(F)(F)F)c1)c1cccc(-c2nn[nH]n2)c1
40562,CHEMBL488400,WXFIODYGMHZQAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,720.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC(=CC(=C3)OC)OC,6.142667503568732,COc1cc(CSc2nc3ccc(OC)cc3[nH]2)cc(OC)c1
40566,CHEMBL2163838,WXGCKASPTGCGFN-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,1530.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,CN(C)CCN(C)C(=O)[C@H](CC1=C(C=C(C=C1)Cl)Cl)NC(=O)C2(CC2)C3=C(C=C(C=C3)Cl)Cl,5.815308569182402,CN(C)CCN(C)C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1
40572,CHEMBL3702749,WXJJFQFWJXJCNS-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7800.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)CCN(C)C(=O)C2=CN(C3=C(C=CC=C23)CN4C[C@H]5N([C@H](C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,5.107905397309519,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
40578,CHEMBL450471,WXJLFSUTNCMCGA-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,15848.93,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=CC=C4Cl)NCCCC(=O)O,4.800000052738446,O=C(O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
40579,CHEMBL450471,WXJLFSUTNCMCGA-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=CC=C4Cl)NCCCC(=O)O,4.769551078621726,O=C(O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
40590,CHEMBL2436623,WXNHTAGZWUGZCQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2=CC=CC=C2CN(C1)C3CCN(CC3)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,4.522878745280337,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCCc5ccccc5C4)CC3)CC2)ccn1
40606,CHEMBL3422005,WXTKQYNUESPTFK-SNVBAGLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,63000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=CSC(=N4)C,4.200659450546418,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)cs1
40614,CHEMBL1258517,WXUUCRLKXQMWRY-UHFFFAOYSA-N,PKI-179,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20797855.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2COCC1N2C3=NC(=NC(=N3)N4CCOCC4)C5=CC=C(C=C5)NC(=O)NC6=CC=NC=C6,4.522878745280337,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1
40616,CHEMBL371613,WXUZGCQTOVWUDO-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)C1=CC=CC(=C1CN2C=C(C(=O)N(C2=O)C[C@@H](C3=CC=CC=C3)N)C4=CC=CC=C4Cl)F,6.7447274948966935,CS(=O)(=O)c1cccc(F)c1Cn1cc(-c2ccccc2Cl)c(=O)n(C[C@H](N)c2ccccc2)c1=O
40619,CHEMBL3104534,WXWZTJHZVPXAHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,CC1=CC=CC=C1CN2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,4.7447274948966935,Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
40620,CHEMBL3104534,WXWZTJHZVPXAHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC1=CC=CC=C1CN2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,4.7447274948966935,Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
40621,CHEMBL3104534,WXWZTJHZVPXAHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC1=CC=CC=C1CN2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,4.698970004336019,Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
40662,CHEMBL3702806,WYJMFZPMALWDGM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2370.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC(CC8)N9CCCCC9,5.6252516539898965,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCCCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
40663,CHEMBL1911194,WYJRHMPICZARGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958544.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Indolin-2-one p38a inhibitors III: Bioisosteric amide replacement.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(C=C1)C2=NNC(=N2)C)C3=CC4=C(C=C3)C5(CCOCC5)C(=O)N4,4.6020599913279625,Cc1nc(-c2ccc(C)c(-c3ccc4c(c3)NC(=O)C43CCOCC3)c2)n[nH]1
40665,CHEMBL2170630,WYKRFGYHTDMMFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=CC(=C3)C#N,4.657577319177793,N#Cc1cccc(C(=O)N2CCC(c3ccc(C(=O)N=C(N)N)cc3C(F)(F)F)CC2)c1
40668,CHEMBL2070157,WYLTXXROXQGYPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=NC=C3)C4=CC=CC=C4,5.060480747381382,CCS(=O)(=O)c1ccc2nc(-c3ccnc(-c4ccccc4)c3)[nH]c2c1
40670,CHEMBL150614,WYMUHCAWPDYRJQ-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698201.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C2=C(C=C(C=C2)NC(=O)CN3CCN(CC3)C[C@H](COC4=CC5=C(C=C4)SC(=N5)C)O)C6=CC=CC=C61,4.4089353929735005,CCn1c2ccccc2c2cc(NC(=O)CN3CCN(C[C@@H](O)COc4ccc5sc(C)nc5c4)CC3)ccc21
40690,CHEMBL2048204,WYTXJLWGOIYXTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C(C=C1)C(=O)N2CCC3=CC=CC=C32)CSC4=NC5=C(N4CC(=O)O)C=CC(=C5)F,5.301029995663981,COc1ccc(C(=O)N2CCc3ccccc32)cc1CSc1nc2cc(F)ccc2n1CC(=O)O
40691,CHEMBL2048204,WYTXJLWGOIYXTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=C(C=C1)C(=O)N2CCC3=CC=CC=C32)CSC4=NC5=C(N4CC(=O)O)C=CC(=C5)F,4.886056647693163,COc1ccc(C(=O)N2CCc3ccccc32)cc1CSc1nc2cc(F)ccc2n1CC(=O)O
40728,CHEMBL2036210,WZEGCAWKLRVSGX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,CCC(=O)N(CC1=CC=C(C=C1)C(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)F,5.0,CCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cc(F)cc(-c2nn[nH]n2)c1
40745,CHEMBL3422016,WZHKQWSHHGMARO-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=NC(=CS5)C,4.958607314841775,Cc1csc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1
40767,CHEMBL2336421,WZSCJOMKGFGYAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,6.346787486224656,CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
40768,CHEMBL2336421,WZSCJOMKGFGYAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,4.6020599913279625,CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
40782,CHEMBL3137452,XAACDTNCWKPUDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1700.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=CS4,5.769551078621726,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3nccs3)CC2)cc1
40787,CHEMBL597127,XAAZBMINIBYRPX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3CCCNC3)OC,4.522878745280337,COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC
40788,CHEMBL597127,XAAZBMINIBYRPX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3CCCNC3)OC,4.522878745280337,COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC
40792,CHEMBL3393483,XACWBNSEGIFUIV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(C=CC=C6N5)N,7.096910013008056,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(N)cccc3[nH]2)o1
40795,CHEMBL1208960,XAEATFZFGRMBDN-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCOCC6)C(=O)N,5.552841968657781,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
40796,CHEMBL1208960,XAEATFZFGRMBDN-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCOCC6)C(=O)N,4.698970004336019,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
40813,CHEMBL2152525,XAMJZICIEQIVJK-FGZHOGPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12589.25,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli,,ACS Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)[C@H](C2=CC=CC=C2)[C@@H](C3=CC=CC=C3)N4CCCC4,4.900000142057633,c1ccc([C@H]([C@@H](c2ccccc2)N2CCCC2)N2CCCC2)cc1
40814,CHEMBL2152524,XAMJZICIEQIVJK-VXKWHMMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12589.25,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli,,ACS Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)[C@@H](C2=CC=CC=C2)[C@H](C3=CC=CC=C3)N4CCCC4,4.900000142057633,c1ccc([C@@H]([C@H](c2ccccc2)N2CCCC2)N2CCCC2)cc1
40815,CHEMBL3125395,XAMUUSXIEMJRLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N)C=CC=C2Br,4.6020599913279625,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O
40816,CHEMBL3125395,XAMUUSXIEMJRLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N)C=CC=C2Br,4.3979400086720375,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O
40819,CHEMBL1257567,XAPFGEPPWZRGFN-UHFFFAOYSA-N,DIETHOXYFLOURESCEIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20839775.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Exploration of the amine terminus in a novel series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,CCOC1=CC2=C(C=C1)C3(C4=C(O2)C=C(C=C4)OCC)C5=CC=CC=C5C(=O)O3,6.0,CCOc1ccc2c(c1)Oc1cc(OCC)ccc1C21OC(=O)c2ccccc21
40823,CHEMBL1907089,XAPVAKKLQGLNOY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23445448.0,IC50,=,17600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Development of Dual PLD1/2 and PLD2 Selective Inhibitors from a Common 1,3,8-Triazaspiro[4.5]decane Core: Discovery of ML298 and ML299 That Decrease Invasive Migration in U87-MG Glioblastoma Cells.",J. Med. Chem.,PUBLICATION,,C1CN(CCC12C(=O)NCN2C3=CC(=CC=C3)F)CCNC(=O)C4=CC(=C(C=C4)F)F,4.7544873321858505,O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc(F)c(F)c1
40827,CHEMBL1615150,XAVJTYOBWCSWFJ-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC(=C1)C(=O)O)NC(=O)[C@H](C2CCCCC2)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,4.301029995663981,Cc1cc(C(=O)O)ccc1NC(=O)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21
40835,CHEMBL1784357,XAXGZPUPBCYAIE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1COCCC1(CS(=O)(=O)N2CCN(CC2)C3=CC=C(C=C3)F)N(C=O)O,5.0,O=CN(O)C1(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)CCOCC1
40836,CHEMBL2069840,XAXKWKHCLDUGSC-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ß-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)O,6.0,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(O)cc2)CC1)Cc1cc(F)c(F)cc1F
40847,CHEMBL404621,XBAKWGXDYRBWJH-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1Cl)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,5.0,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
40859,CHEMBL3664685,XBFPHNXOOORGNO-YYONYHEJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)CC(C)COC)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,COCC(C)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O
40873,CHEMBL1079229,XBOFJPSCQGVLPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)CN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,6.958607314841775,CC(C)(C)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1
40874,CHEMBL1079230,XBOFJPSCQGVLPB-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)CN(C[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)C[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,7.0,CC(C)(C)CN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1
40882,CHEMBL1923642,XBPLNMSLGBYKCW-UFKXBGGNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106937.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.,J. Med. Chem.,PUBLICATION,,C[C@@H]1C(=O)N[C@@H](C(=O)NCCCC2=C(C=C(C=C2)F)OCCN[C@H](C(=O)N1C)C3CC3)CC4=CC=C(C=C4)F,5.920818753952375,C[C@@H]1C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccc(F)cc2OCCN[C@@H](C2CC2)C(=O)N1C
40884,CHEMBL1834793,XBPRBIMQCWCMJS-KDYLLFBJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21917454.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C2=C(C=C(C=C2)C(F)(F)F)C(=N1)NCC(=O)NC3CN(C3)C4CCC(CC4)C5=CN=CS5,5.167491087293763,Cn1nc(NCC(=O)NC2CN(C3CCC(c4cncs4)CC3)C2)c2cc(C(F)(F)F)ccc21
40888,CHEMBL592646,XBQOGPRXCCTYMI-AKWYTYQQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,260.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC(C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=C(N=N2)[C@](C)(C3CCCC3)NCC4=CC5=C(C=C4)N=CC=C5,6.585026652029182,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncccc3c2)C2CCCC2)nn1
40896,CHEMBL498471,XBVDRLSPKAFNGG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC(C2=C1C=C(C=C2)C3=CC=C(C=C3)F)(C4=CN=CC=C4)O,4.698970004336019,OC1(c2cccnc2)CCc2cc(-c3ccc(F)cc3)ccc21
40906,CHEMBL1911823,XBXQAGKJALZGRX-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)COC[C@H](C(=O)N1CCN(CC1)C)NC(=O)C2=C(N=CC=C2)OC3=C(C=C(C=C3)C(F)(F)F)Cl,4.920818753952375,CN1CCN(C(=O)[C@@H](COCC(C)(C)C)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
40924,CHEMBL3545252,XCDIRYDKECHIPE-QHEQPUDQSA-N,DOCETAXEL HYDRATE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O,5.698970004336019,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C
40927,CHEMBL211204,XCFCFGDFIJDQNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,=,19200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,CCOC1(C2=NOC(=O)N2C(=CS1)C)C3=CC=C(C=C3)Br,4.716698771296451,CCOC1(c2ccc(Br)cc2)SC=C(C)n2c1noc2=O
40928,CHEMBL211204,XCFCFGDFIJDQNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,CCOC1(C2=NOC(=O)N2C(=CS1)C)C3=CC=C(C=C3)Br,4.698970004336019,CCOC1(c2ccc(Br)cc2)SC=C(C)n2c1noc2=O
40935,CHEMBL442,XCGSFFUVFURLIX-VFGNJEKYSA-N,ERGOTAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,6.0,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
40946,CHEMBL3401127,XCJBWBMTIYUPEB-GHMZBOCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,=,485000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3ß inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1[C@H](OCCN1C2=NC(=CC(=O)N2C)C3=C(C=NC=C3)F)C,3.3142582613977365,C[C@H]1OCCN(c2nc(-c3ccncc3F)cc(=O)n2C)[C@@H]1C
40947,CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24047900.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,,,,,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,4.698970004336019,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
40948,CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,4.698970004336019,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
40949,CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,5.221848749616356,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
40950,CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12100.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,4.91721462968355,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
40952,CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,4.698970004336019,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
40953,CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,4.0,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
40967,CHEMBL3702803,XCMBYAPIZRSJSM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CC1(CC(CC(N1C)(C)C)NC2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C)C,5.1487416512809245,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NC6CC(C)(C)N(C)C(C)(C)C6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
40970,CHEMBL3355480,XCOKOJKTXOLUTM-LLVKDONJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589928.0,IC50,>,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H]1COCCN1C2=C3C(=CC(=N2)C4=C5C=CNC5=CN=N4)N(C=N3)C,4.619788758288394,C[C@@H]1COCCN1c1nc(-c2nncc3[nH]ccc23)cc2c1ncn2C
40985,CHEMBL3236640,XCRGKBIGLYHHMI-HEBVPBOISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,C[C@@]1(C[C@@H]([C@H](N(C1=O)[C@H](CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC5=NC(=CS5)CC(=O)O,4.568636235841013,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2nc(CC(=O)O)cs2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
40988,CHEMBL1819090,XCTNLNITUUOHNO-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21865048.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.",Bioorg. Med. Chem.,PUBLICATION,,C[C@]1(CCCN(C1)C2=CC3=C(N2CC4=C(C=CC(=C4)F)C#N)C(=O)N(C(=O)N3C)C)N,4.301029995663981,Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O
40994,CHEMBL1270269,XCVJGPONRKMMGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843687.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C(=O)N)NCCCC1=CC(=NC(=N1)C#N)C2=CC(=CC=C2)C(F)(F)F,4.455931955649724,CC(C)(NCCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1)C(N)=O
40997,CHEMBL2347992,XCYCRDIMKXBEOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(CO)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)F)CCCS(=O)(=O)C,4.301029995663981,CC(C)(CO)NC(=O)c1c[nH]c2ncc(-c3nn(CCCS(C)(=O)=O)c4cc(F)ccc34)nc12
41001,CHEMBL271121,XCYJXGREMGRASS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,71.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CC1=CN=C(N=C1)CNC2=NC(=NC(=C2)C3=CC=CC=C3)C4=CC=NC=C4,7.1487416512809245,Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3ccncc3)n2)nc1
41026,CHEMBL3261485,XDJFTOOYWJXAAZ-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=C3C(=C1)C(=O)N(CCN3N=C2)[C@@H]4CN5CCC4CC5,4.301029995663981,COc1cc2c3c(cnn3CCN([C@@H]3CN4CCC3CC4)C2=O)c1
41030,CHEMBL3358951,XDLANRATEHYNAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)S(=O)(=O)C1=NC=C2C(=C1)C=C(N2)CC(CC(C)(C)C3=C(C=C(C=C3)F)C(=O)N)(C(F)(F)F)O,5.3979400086720375,CC(C)S(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1
41040,CHEMBL1515648,XDOXZFXJIASILF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,COC(=O)C1=CC=C(C=C1)CSC2=NC3=C(CCC3)C(=O)N2,4.698970004336019,COC(=O)c1ccc(CSc2nc3c(c(=O)[nH]2)CCC3)cc1
41041,CHEMBL1515648,XDOXZFXJIASILF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,COC(=O)C1=CC=C(C=C1)CSC2=NC3=C(CCC3)C(=O)N2,4.698970004336019,COC(=O)c1ccc(CSc2nc3c(c(=O)[nH]2)CCC3)cc1
41058,CHEMBL220407,XDVGYCLZBOMGDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16908150.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCN(CC1)C(=O)N2CCC(CC2)NC(=O)C3CCCC3,4.6020599913279625,CC(C)N1CCN(C(=O)N2CCC(NC(=O)C3CCCC3)CC2)CC1
41075,CHEMBL1760200,XDXNXAQKAHUCSV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC=C1N2CCN(CC2)C(=O)C3=CC(=NN3)C4=CC=CC=C4,4.823908740944319,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccccc3)n[nH]2)CC1
41079,CHEMBL3114971,XDYVFXBZMZMEHY-RMFSNUHRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24461352.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)S(=O)(=O)N2C[C@@H]3[C@H](C2)C3(CC4CC4)CNC(=O)C5=CC=CC=C5C(F)(F)F,4.522878745280337,Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)C3(CNC(=O)c2ccccc2C(F)(F)F)CC2CC2)c1
41080,CHEMBL516551,XDZZEIOBAUKKMP-OYRHEFFESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CC4=CC(=NO4)C,4.3979400086720375,Cc1cc(CC(=O)N(C)Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)on1
41081,CHEMBL516551,XDZZEIOBAUKKMP-OYRHEFFESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CC4=CC(=NO4)C,4.0,Cc1cc(CC(=O)N(C)Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)on1
41095,CHEMBL2178742,XEDMJQGYEUEUJR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23006002.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,CN1CCC(CC1)NC2=C(C=CC(=C2)S(=O)(=O)N3CCOC4=C3C=C(C=C4)Cl)OC,5.552841968657781,COc1ccc(S(=O)(=O)N2CCOc3ccc(Cl)cc32)cc1NC1CCN(C)CC1
41098,CHEMBL172,XEEQGYMUWCZPDN-DOMZBBRYSA-N,"(S,R)-MEFLOQUINE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,667.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,C1CCN[C@H](C1)[C@H](C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O,6.175874166083451,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1
41107,CHEMBL422858,XEKAEMQSBUSNIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CC(=NO2)C,4.0,CCCCOc1ccc(-c2cc(C)no2)cc1
41110,CHEMBL3112611,XEKWGMXLJBVYET-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,1670.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)NC2CCN(CC2)C(=O)OCC3=CN=CS3,5.777283528852417,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NC2CCN(C(=O)OCc3cncs3)CC2)C(C)C)cs1
41112,CHEMBL1779013,XEKZQVZQOZRWEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21524576.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Iinhibition of CYP3A4,"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=CC(=C1)F)C2=CN=CC(=C2)CNC(=O)C3=CC=CC=N3,4.698970004336019,COc1cc(F)ccc1-c1cncc(CNC(=O)c2ccccn2)c1
41132,CHEMBL551813,XEOSTBFUCNZKGS-UHFFFAOYSA-N,ACTIMIS,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C1=C(C(=NC(=N1)CC2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C(F)(F)F)N(C)C)CC(=O)O,4.522878745280337,CN(C)c1nc(Cc2ccc(NC(=O)c3ccc(C(F)(F)F)cc3)cc2)nc(N(C)C)c1CC(=O)O
41133,CHEMBL240572,XEPRNTQLEBCAFA-HLADLETHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@H](C)CC3=C(C=C(C=C3)Cl)C)[C@H](C(C)C)NC(=O)CCN(C)C,5.167491087293763,Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3C)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1
41142,CHEMBL397581,XEURJRGOGLBXPG-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,5400.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCN,5.267606240177032,CC(C)C[C@H](NC(=O)CCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
41144,CHEMBL229008,XEVJUIZOZCFECP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17585753.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2- fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419).",J. Med. Chem.,PUBLICATION,,CCN1CCN(CC1)C2=NC=C(C=C2)C(C)(C)NC(=O)C3=C(C=C4C(=C3)NC5=CC=CC=C5C4=O)F,4.886056647693163,CCN1CCN(c2ccc(C(C)(C)NC(=O)c3cc4[nH]c5ccccc5c(=O)c4cc3F)cn2)CC1
41157,CHEMBL1921975,XEYZCKZMDNQROP-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)[C@](C1=CC2=C(C=C1)C=C(C=C2)C(=O)NC)(C3=CN=CN3)O,5.107905397309519,CNC(=O)c1ccc2cc([C@](O)(c3cnc[nH]3)C(C)C)ccc2c1
41158,CHEMBL1682893,XEYZCKZMDNQROP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)NC)(C3=CN=CN3)O,5.443697499232713,CNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
41159,CHEMBL1682893,XEYZCKZMDNQROP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)NC)(C3=CN=CN3)O,5.443697499232713,CNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
41160,CHEMBL3114886,XEYZWQDXEHTOKO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412066.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CC(=O)N1CCC(CC1)N2C3=C(C=N2)C(=NC=N3)OC4=CC=C(C=C4)S(=O)(=O)C,4.6020599913279625,CC(C)CC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1
41190,CHEMBL1761519,XFJSBMXXKPHIIX-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCOC)C5CC5)Cl,5.619788758288394,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1
41191,CHEMBL1761519,XFJSBMXXKPHIIX-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,21600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCOC)C5CC5)Cl,4.665546248849069,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1
41225,CHEMBL1935442,XFQZALCRWJDNNK-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CO[C@H](CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,4.698970004336019,Fc1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1
41240,CHEMBL2347328,XFVVLCBORWIGHO-GOTSBHOMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23466233.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C(F)(F)F)NC(=O)OC,5.187086643357144,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)[nH]1)C(C)C
41242,CHEMBL453329,XFWGEKHPBVFSFW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C(CN1CCOCC1)C2=CC=C(C=C2)C3=CC(=CC=C3)OC)C(=O)CN4C(=O)COC5=CC(=C(C=C54)Cl)Cl,6.0,COc1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)CN3C(=O)COc4cc(Cl)c(Cl)cc43)cc2)c1
41243,CHEMBL1825089,XFWNXRYYGPIPLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798738.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxy-4(trifluoromethyl)-coumarin,"Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)N(CCN1CCOCC1)C2=CC=C(C=C2)NC3=NC=C4C=NN(C4=N3)C5CCCCCC5,7.3979400086720375,CS(=O)(=O)N(CCN1CCOCC1)c1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cc1
41244,CHEMBL1825089,XFWNXRYYGPIPLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798738.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxyquinoline,"Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)N(CCN1CCOCC1)C2=CC=C(C=C2)NC3=NC=C4C=NN(C4=N3)C5CCCCCC5,7.3979400086720375,CS(=O)(=O)N(CCN1CCOCC1)c1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cc1
41248,CHEMBL1821735,XFXOOLLVYYZWQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21859094.0,IC50,=,14600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC=C(C=C2)NC3=NN4C(=CC=C4C5=CC=CC=C5N(C)S(=O)(=O)C)C=N3,4.835647144215563,CN1CCN(c2ccc(Nc3ncc4ccc(-c5ccccc5N(C)S(C)(=O)=O)n4n3)cc2)CC1
41250,CHEMBL529220,XFZDFYYRUDDKBS-HZPDHXFCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18462007.0,IC50,>,65000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara.,J. Nat. Prod.,PUBLICATION,,CCCCC[C@@H]1[C@@H](C2=C(C=CC(=C2)OC)C(=O)O1)OC(=O)C,4.187086643357144,CCCCC[C@H]1OC(=O)c2ccc(OC)cc2[C@H]1OC(C)=O
41270,CHEMBL263004,XGDYFBGSSSIIDK-WDEPAJCISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)[C@H](C)CNCCC6=CC7=C(C=C6)N=CO7)C,6.0,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3ncoc3c2)c1
41273,CHEMBL487569,XGFRRYAZOMJDQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,380.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CC(=C3)OC)OC)C,6.42021640338319,COc1cc(OC)cc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1
41279,CHEMBL1672054,XGGTZCKQRWXCHW-WMTVXVAQSA-N,CASOPITANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21149541.0,IC50,=,9720.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine substrate by HPLC-MS/MS method,Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.,Drug Metab. Dispos.,PUBLICATION,,CC1=C(C=CC(=C1)F)[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C,5.012333735073725,CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1
41280,CHEMBL1672054,XGGTZCKQRWXCHW-WMTVXVAQSA-N,CASOPITANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21149541.0,IC50,=,9860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method,Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.,Drug Metab. Dispos.,PUBLICATION,,CC1=C(C=CC(=C1)F)[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C,5.006123085058789,CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1
41299,CHEMBL255462,XGRAVLAUZKWSQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CC2C(CCCN2C(=O)CN3C4=C(C=CC(=C4)Cl)SC3=O)C5=CC=CC=C5,6.0,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1
41302,CHEMBL1076461,XGUNBNDCDWFBAF-SETSBSEESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19853442.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New classes of potent and bioavailable human renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC=C1OC)CN(C2CC2)C(=O)C3=C(C[C@H]4COC[C@H]3N4)C5=CC=C(C=C5)CCCOC6=C(C=CC(=C6Cl)F)F,6.0,COc1cccc(CN(C(=O)C2=C(c3ccc(CCCOc4c(F)ccc(F)c4Cl)cc3)C[C@H]3COC[C@H]2N3)C2CC2)c1C
41321,CHEMBL1289313,XGYYVDZJWSDWDE-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21036042.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PK.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C(=O)C1=NC=C2C(=C1)C(=CN2CC3=CC=C(C=C3)F)CN4CCC[C@H]4C(=O)N)O,4.522878745280337,CN(O)C(=O)c1cc2c(CN3CCC[C@H]3C(N)=O)cn(Cc3ccc(F)cc3)c2cn1
41325,CHEMBL240780,XHASNPJPTJYEPD-DFHRPNOPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)[C@H](C)CC3=CC=C(C=C3)Cl)[C@H](C(C)C)NC(=O)CCNC,5.221848749616356,CNCCC(=O)N[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1)C(C)C
41326,CHEMBL254080,XHAUDRHLRBFHDL-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(C1)CC2=NOC(=N2)CC3(CC3)[C@H]4CCC[C@H](N4S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,6.522878745280337,O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2nc(CN3CCCC3)no2)CC1
41330,CHEMBL2086760,XHCPCYVQXFHJAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC=C(C=C4)Cl)C5=NC=CN5,4.301029995663981,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(Cl)cc2)c2ncc[nH]2)C(=O)N3)CC1
41350,CHEMBL394016,XHILZVTVIKVPKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C(F)(F)F,4.657577319177793,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(C(F)(F)F)O2
41356,CHEMBL2441565,XHJPFLSAHTYUNW-ONEGZZNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 20 mins by LC/MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CN(C)C/C=C/C(=O)N1CCOC2=C1C=C3C(=C2)N=CN=C3NC4=CC(=C(C=C4)F)Cl,5.0,CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21
41373,CHEMBL2448716,XHNSUZALLCTOAT-CVKSISIWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C/C(=N\OC)/C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(S3)C4=CC=CC=C4,6.0,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1
41386,CHEMBL565360,XHQRQWJOOLSDNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=CC=C3SC4=CC=CC=C4CO,5.920818753952375,CC1(CC(=O)NCc2ccccc2Sc2ccccc2CO)CC2(CCCCC2)OO1
41393,CHEMBL2420685,XHTUSXVMRHUIGE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CN=CN=C3,5.0,COc1ccc2ccc(-c3cncnc3)c(Cl)c2c1
41403,CHEMBL498114,XHVSEFQNZWHSNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CCC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,5.0,Cc1cccc(C)c1CCc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
41404,CHEMBL498114,XHVSEFQNZWHSNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CCC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,4.508638306165727,Cc1cccc(C)c1CCc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
41405,CHEMBL389908,XHWIJMYLOJKSST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)Cl)NC2=NC=C(C(=N2)C(F)(F)F)C(=O)NCC3=CC=C(C=C3)F,5.301029995663981,O=C(NCc1ccc(F)cc1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
41423,CHEMBL1079957,XIHFOOAKDQNZGJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCNC4=O)C(=C(N3)C)C,5.795880017344075,Cc1cccc(C)c1CNc1nc(N2CCNC2=O)cc2c(C)c(C)[nH]c12
41424,CHEMBL1079957,XIHFOOAKDQNZGJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCNC4=O)C(=C(N3)C)C,5.795880017344075,Cc1cccc(C)c1CNc1nc(N2CCNC2=O)cc2c(C)c(C)[nH]c12
41435,CHEMBL151354,XIJNLZJHRREJKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,22900.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)C2=CC=NS2,4.640164517660112,CCCCOc1ccc(-c2ccns2)cc1
41438,CHEMBL330354,XIKMSNPORKHQQQ-FJQKOURKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15139756.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,PUBLICATION,,CCCCC1=CC(=CC=C1)[C@]2(C3=CC=CC=C3N(C(=O)CN2)CC4=C(C=C(C=C4F)F)F)[C@@H](C(=O)O)OC5=NC(=CC(=N5)C)C,5.301029995663981,CCCCc1cccc([C@]2([C@H](Oc3nc(C)cc(C)n3)C(=O)O)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1
41455,CHEMBL1229205,XIPYFDKZPWWWGS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22059882.0,IC50,=,8.8,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,PUBLICATION,,CC1=CN=C(C=C1)COC2=CC3=C(C=C2)N(C(=C3SC(C)(C)C)CC(C)(C)C(=O)O)CC4=CC=C(C=C4)C5=NC=C(C=N5)OC,8.05551732784983,COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1
41468,CHEMBL1923125,XITVKUPYTCBIOT-RLWLMLJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=CC=CC3=C2N=CC=C3)C(=O)[C@H]4CNCC[C@]45C6=CC(=C(C=C6CO5)F)F,5.050609993355088,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc2cccnc12)C1CC1
41471,CHEMBL3125391,XITZHALCAXQXME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C2=C1C=C(C=C2)F)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N,4.3979400086720375,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21
41475,CHEMBL3121800,XIYFVTRDXPGMEW-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,CCC1=CC2=C(C=C1F)C(=C(N2C3=CC=CC=N3)C4=NC=C(C=C4)S(=O)(=O)N[C@@H](C)C(F)(F)F)C#N,5.0,CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ccccn1
41476,CHEMBL523563,XIZBFDTZSLSHTR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=CC4=O,5.6777807052660805,Cc1cccc(C)c1CNc1cc(-n2cnccc2=O)cn2c(C)c(C)nc12
41477,CHEMBL523563,XIZBFDTZSLSHTR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=CC4=O,5.318758762624412,Cc1cccc(C)c1CNc1cc(-n2cnccc2=O)cn2c(C)c(C)nc12
41478,CHEMBL2441954,XIZQTPHCQYNKEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)N3CCCC3)C4=C(C=C(C=C4)Cl)Cl)CN,4.638272163982407,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N1CCCC1)C2
41480,CHEMBL1095511,XJANDYKKEVAKFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CSC(=N1)CN2C3=CC=CC=C3N=C2C4CCCN(C4)C5CCCCC5,5.301029995663981,Cc1csc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)n1
41486,CHEMBL3702689,XJCPULIHXFIZOP-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3900.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCOCC7,5.4089353929735005,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
41487,CHEMBL2058664,XJCYZAUSMGGIRP-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,24.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)C5=CC=NC=C5,7.619788758288394,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(-c3ccncc3)oc2c1
41488,CHEMBL2441950,XJDKGHMEFQVYDZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)N)C3=C(C=C(C=C3)Cl)Cl)CN,4.3979400086720375,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(N)=O)C2
41492,CHEMBL483402,XJEJCCXXTNIOJF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,CC1=C(C(N=C(N1)C2=CC(=NC=C2)OC)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=CC5=C(C=C4)NN=C5,5.366531544420414,COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)ccn1
41525,CHEMBL419396,XJPWYIFOSHVNSZ-RMERSUQASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN([C@@H](CN1CC2=CC3C=CSC3S2)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CN=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,6.508638306165727,O=C(NCC(F)(F)F)[C@@H]1CN(CC2=CC3C=CSC3S2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O
41547,CHEMBL3115166,XJTLAMHFTBREAR-KAYWLYCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC1=CN=CS1)C(=O)NCCC(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.886056647693163,CN(Cc1cncs1)C(=O)NCCC(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
41549,CHEMBL3264606,XJVOQAFXKZKDRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OCC(F)(F)F)OCC(F)(F)F)(C3=NNN=C3)O,4.6020599913279625,CC(C)C(O)(c1ccc2cc(OCC(F)(F)F)c(OCC(F)(F)F)cc2c1)c1cn[nH]n1
41558,CHEMBL3680983,XJXWVRYXVARTIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1400.0,NM,253316,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",Metalloenzyme inhibitor compounds,,PATENT,,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)F,5.853871964321762,OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)cc2)cn1
41561,CHEMBL3237561,XJZVCDVZCRLIKN-QWHCGFSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24520947.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,PUBLICATION,,CC1=C(N=C(C=C1)NC2=CC(=NN=C2C(=O)N)N[C@@H]3CCCC[C@@H]3N)C,4.301029995663981,Cc1ccc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)nc1C
41570,CHEMBL3702810,XKDFAVCCGODROP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,21520.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)CC9=CC=C(C=C9)OC,4.667157733005649,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(Cc7ccc(OC)cc7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
41592,CHEMBL594523,XKNDLPMAXNMALL-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,630.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=COC=C4)C)OC[C@H](CC5=CNC6=CC=CC=C65)N,6.200659450546418,Cc1nc(-c2ccoc2)c(-c2cnc3n[nH]c(C)c3n2)cc1OC[C@@H](N)Cc1c[nH]c2ccccc12
41601,CHEMBL1829768,XKUYBHWZCQUCGO-QYBDOPJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CC[C@](OC3=O)(CCO)C4=CC=C(C=C4)F,4.6777807052660805,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O
41611,CHEMBL478283,XKZZIPLEGIRBDK-HKWRFOASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19321349.0,IC50,=,47000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,PUBLICATION,,CC1=NN(C=C1)C2=CC(=C(C=C2)C(=O)N3CCC(/C(=C\C(=O)NCCO)/C4=CC=CC=C43)(F)F)Cl,4.327902142064283,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCCO)c4ccccc43)c(Cl)c2)n1
41615,CHEMBL2019026,XLAHUVMRXXMPOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,520.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,C1=CC=NC(=C1)CSC2=NC3=C(N2)C=C(C=C3)N,6.2839966563652006,Nc1ccc2nc(SCc3ccccn3)[nH]c2c1
41625,CHEMBL2064330,XLESLWHDVUIEMT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kß Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,CN1C2=CC=CC=C2N=C1CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21
41636,CHEMBL566683,XLJQUFRVZDFEAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,4.301029995663981,COc1ccc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
41637,CHEMBL566683,XLJQUFRVZDFEAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC2=NC=CC(=C2C=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,4.301029995663981,COc1ccc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
41643,CHEMBL465244,XLNMHVBRWVMJDC-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)COC4=CC=CC=C4,5.154901959985743,C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccccc3)cc2)C[C@@H](C)N1
41644,CHEMBL465244,XLNMHVBRWVMJDC-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)COC4=CC=CC=C4,4.619788758288394,C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccccc3)cc2)C[C@@H](C)N1
41655,CHEMBL2070143,XLSXASRFKWCYKL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=CC=C3)OC(F)(F)F,5.0,CCCS(=O)(=O)c1ccc2nc(-c3cccc(OC(F)(F)F)c3)[nH]c2c1
41663,CHEMBL3112690,XLUFPHQRHPTDJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3Kß Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,C1CN(C2=CC=CC=C21)C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4,4.3979400086720375,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
41686,CHEMBL328863,XMAYWYJOQHXEEK-BVAGGSTKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,1495014.0,IC50,=,897.0,NM,,,,,,,,,,,,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Stereoisomers of ketoconazole: preparation and biological activity.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.047207556955908,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41687,CHEMBL319160,XMAYWYJOQHXEEK-JYFHCDHNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,1495014.0,IC50,=,570.0,NM,,,,,,,,,,,,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Stereoisomers of ketoconazole: preparation and biological activity.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.2441251443275085,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41689,CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,12.0,NM,,,,binding,,,,,,,,,,,,,,,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.920818753952375,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41690,CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27789139.0,IC50,=,133.0,NM,,inhibition,,,,,,,,,,,,,,,,,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.876148359032914,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41691,CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.0,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41696,CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23355637.0,IC50,=,9.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 activity in human liver microsomes assessed as dibenzo fluuorescene oxidation up to 40 uM,,Drug Metab. Dispos.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,8.008773924307505,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41700,CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26204510.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model.",Eur. J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.7447274948966935,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41701,CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26900658.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 by luminescence -based microplate reader assay,"Rational design in search for 5-phenylhydantoin selective 5-HT7R antagonists. Molecular modeling, synthesis and biological evaluation.",Eur. J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.853871964321762,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41702,CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,9.0,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41703,CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,8.397940008672037,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41705,CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27105029.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate incubated for 30 mins by fluorimetry,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",Eur. J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.552841968657781,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41706,CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27145071.0,IC50,=,240.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay,2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.619788758288394,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41709,CHEMBL157101,XMAYWYJOQHXEEK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,150.0,NM,291613,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",Metalloenzyme inhibitor compounds,,PATENT,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.823908740944319,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41711,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27789139.0,IC50,=,146.0,NM,,inhibition,,,,,,,,,,,,,,,,,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.835647144215563,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41712,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,1495014.0,IC50,=,786.0,NM,,,,,,,,,,,,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Stereoisomers of ketoconazole: preparation and biological activity.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.104577453960592,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41713,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,1495014.0,IC50,=,1260.0,NM,,,,,,,,,,,,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Stereoisomers of ketoconazole: preparation and biological activity.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,5.8996294548824375,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41714,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.301029995663981,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41715,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,13.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.886056647693163,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41716,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,16.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.795880017344075,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41717,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,17.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.769551078621726,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41718,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,22.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.657577319177793,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41719,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,245.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.610833915635467,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41720,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,720.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.142667503568732,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41721,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16220979.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against human hepatic cytochrome P450 3A4 enzyme,Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.301029995663981,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41722,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570918.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.301029995663981,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41726,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.6777807052660805,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41731,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324762.0,IC50,=,54.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.",J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.267606240177032,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41732,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18583127.0,IC50,=,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,"Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.698970004336019,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41734,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672861.0,IC50,=,57.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.2441251443275085,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41735,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,72.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.142667503568732,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41737,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763754.0,IC50,=,57.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.2441251443275085,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41738,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,=,57000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,4.2441251443275085,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41739,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,199.99,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.698991719603,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41740,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19211174.0,IC50,=,72.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,"Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.",Eur. J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.142667503568732,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41741,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.3979400086720375,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41744,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,8.397940008672037,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41749,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.958607314841775,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41750,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,57.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.2441251443275085,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41751,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,7.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,8.10790539730952,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41752,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21189020.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17ß-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.301029995663981,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41753,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21384875.0,IC50,=,57.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in baculovirus-infected insect microsomes,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.2441251443275085,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41754,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497764.0,IC50,=,70.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in liver microsomes,"Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.154901959985743,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41760,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24328103.0,IC50,=,24.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Discovery of a non-estrogenic irreversible inhibitor of 17ß-hydroxysteroid dehydrogenase type 1 from 3-substituted-16ß-(m-carbamoylbenzyl)-estradiol derivatives.,J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.619788758288394,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41761,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24793360.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Investigation of a Novel Series of 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as Human Immunodeficiency Virus Type 1 Integrase Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.552841968657781,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41764,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25082126.0,IC50,<,62.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.2076083105017466,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41765,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,5.6020599913279625,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41767,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25300820.0,IC50,=,25.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using AMMC by fluorescence assay,"Chemical synthesis, cytotoxicity, selectivity and bioavailability of 5a-androstane-3a,17ß-diol derivatives.",Bioorg. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.6020599913279625,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41768,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25499431.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay,Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.698970004336019,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41772,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25868743.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 assessed as effect on conversion of beetle D-luciferin derivative into D-luciferin by firefly luciferase based luminescence assay,"Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.",Bioorg. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.853871964321762,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41773,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26052884.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 assessed as remaining enzyme activity by measuring conversion of luciferin-PPXE into D-luciferin by luminescence CYP3A4 P450-Glo assay relative to untreated control,"Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides.",J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.853871964321762,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41776,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26355532.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition,Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).,Eur. J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.221848749616356,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41777,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26360048.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 assessed as conversion of luciferin-PPXE to D-luciferin by luminescence Glo assay,"(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands.",Eur. J. Med. Chem.,PUBLICATION,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,6.853871964321762,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41782,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,7.795880017344075,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
41800,CHEMBL3087347,XMEWECBJZOPGCV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CN=CO2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,5.795880017344075,O=S(=O)(Nc1ccc(-c2cnco2)cc1)c1cc(Cl)cc(Cl)c1
41810,CHEMBL3353341,XMHCFCMVNKTYOH-ZBVNWKHZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=NC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O,5.6777807052660805,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2
41811,CHEMBL3353341,XMHCFCMVNKTYOH-ZBVNWKHZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=NC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O,5.251811972993799,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2
41812,CHEMBL3353341,XMHCFCMVNKTYOH-ZBVNWKHZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=NC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O,5.0,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2
41819,CHEMBL462093,XMIVJNDWTQQRAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,=,6210.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,C1CC2=C(CC1=O)C=CC(=C2)C3=CN=CC=C3,5.20690839982342,O=C1CCc2cc(-c3cccnc3)ccc2C1
41823,CHEMBL2164422,XMLJHUDPEAJQOK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22801646.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,inhibition of CYP3A4,"4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C2=CC3=C(C=CN=C3N2)C4=CC=C(C=C4)S(=O)(=O)NCCO,5.0,O=S(=O)(NCCO)c1ccc(-c2ccnc3[nH]c(C4CC4)cc23)cc1
41825,CHEMBL469917,XMLWGUKRPGLJGA-CABCVRRESA-N,(-)-THUJAPLICATINTRIMETHYL ETHER,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,COC1=CC(=CC(=C1O)OC)C[C@H]2[C@@H](COC2=O)CC3=CC(=C(C=C3)O)OC,5.958607314841775,COc1cc(C[C@@H]2COC(=O)[C@H]2Cc2cc(OC)c(O)c(OC)c2)ccc1O
41830,CHEMBL593813,XMNABEGDUNNDFW-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OC[C@H](CC5=C(NC6=CC=CC=C65)Cl)N,6.301029995663981,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(Cl)[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2n1
41831,CHEMBL425483,XMOSOHDOZCRMML-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC3=C(C=C(C=C3)F)C(=O)N2CC4=CC=CC=C4C#N)N,5.6020599913279625,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(F)cc2c1=O
41832,CHEMBL425483,XMOSOHDOZCRMML-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19217790.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC3=C(C=C(C=C3)F)C(=O)N2CC4=CC=CC=C4C#N)N,5.6020599913279625,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(F)cc2c1=O
41887,CHEMBL180856,XNPARDFAECDMGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=CC=C3)N4C=CN=C4)N(C)C,6.698970004336019,CC(C(c1ccc2cc(OCc3ccccc3)ccc2c1)n1ccnc1)N(C)C
41889,CHEMBL2059804,XNPPAPISIBTENR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,4.769551078621726,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
41890,CHEMBL262320,XNPVNWIDDNEPTG-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCCC(=O)O,4.6020599913279625,CC(C)C[C@H](NCCCC(=O)O)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
41910,CHEMBL3594232,XODSGAMMDBEEFN-ZSOGYDGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26181715.0,IC50,>,34000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease.,J. Med. Chem.,PUBLICATION,,CC1=CC(=NC(=N1)N2C[C@H]3CC(C[C@H]3C2)C4=CC=CC=C4C(F)(F)F)C(=O)O,4.468521082957745,Cc1cc(C(=O)O)nc(N2C[C@H]3CC(c4ccccc4C(F)(F)F)C[C@H]3C2)n1
41926,CHEMBL2031470,XOHLGPHQMURXNY-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22617490.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H(3) receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC3=C(C=C2)C4=NN(C(=O)C=C4CC3)C,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc2c(c1)CCc1cc(=O)n(C)nc1-2
41934,CHEMBL2063494,XOHMICFWUQPTNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,C1=CC(=C(C=C1Cl)Cl)C(=O)CN2C=NC=N2,4.823908740944319,O=C(Cn1cncn1)c1ccc(Cl)cc1Cl
41945,CHEMBL2387600,XOMUBBMQPXUGME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)CC2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=CC=CC=C5Cl,4.522878745280337,O=c1[nH]c2cc(Cc3ccccc3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
41946,CHEMBL593490,XONRTPBYDAFIRW-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C=C(C=CC2=NN1)C3=C(N=CC(=C3)OC[C@H](CC4=CNC5=CC=CC=C54)N)C6=COC=C6,7.301029995663981,Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12
41947,CHEMBL3092195,XONVFTCAGXZIPY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=CC=C4)NS(=O)(=O)NC)F,4.958607314841775,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F
41948,CHEMBL3092195,XONVFTCAGXZIPY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=CC=C4)NS(=O)(=O)NC)F,4.585026652029182,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F
41952,CHEMBL2436209,XOTGKSFDRNMNQY-FEINMWSASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CN=CC=C5)NC.Cl,5.920818753952375,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cccnc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
41956,CHEMBL3581148,XOVHPPILLSHRPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,CS(=O)(=O)NC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)Cl,5.1249387366083,CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1
41974,CHEMBL1921981,XPDAYTAXTQFSDQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,C1CN2C=NC=C2C1(C3=CC4=C(C=C3)C=C(C=C4)C(=O)N)O,5.0,NC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
41975,CHEMBL582806,XPEAOXGBRVOUMK-GAJHUEQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19632830.0,IC50,=,2030.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]([C@@H](CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)NC3=NC=C(C=C3)C(F)(F)F,5.692503962086787,C[C@H](NC(=O)C(C)(C)Nc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1
41999,CHEMBL401766,XPPPFLDICCXGSJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)N5CCOCC5,5.6777807052660805,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12
42009,CHEMBL477386,XPTXBBCZWWFNRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC(=CC=C1)S(=O)(=O)N2C=CC3=CC4=C(CCNCC4)C=C32,4.769551078621726,COc1cccc(S(=O)(=O)n2ccc3cc4c(cc32)CCNCC4)c1
42010,CHEMBL477386,XPTXBBCZWWFNRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC(=CC=C1)S(=O)(=O)N2C=CC3=CC4=C(CCNCC4)C=C32,4.568636235841013,COc1cccc(S(=O)(=O)n2ccc3cc4c(cc32)CCNCC4)c1
42029,CHEMBL248880,XQDQWKMHQLOKBQ-CTNGQTDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)CCO,6.522878745280337,CC(C)[C@@H]1CCC[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
42049,CHEMBL101180,XQHGYIOMSIVJMT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=CC=C(C=C1)N=CNO,4.0,CC(C)c1ccc(N=CNO)cc1
42050,CHEMBL2036213,XQIZEBWLPMOVGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,CCC(=O)N(CC1=CC=C(C=C1)OC(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)F,5.0,CCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(F)cc(-c2nn[nH]n2)c1
42064,CHEMBL2397196,XQOYOWADRSYAQH-NSHDSACASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=NC=CC(=C1)C2=CN=C(S2)NC(=O)N3CCC[C@H]3C(=O)N)C(F)(F)F,5.0,CC(C)(c1cc(-c2cnc(NC(=O)N3CCC[C@H]3C(N)=O)s2)ccn1)C(F)(F)F
42066,CHEMBL598194,XQPFDQVEBGYLHB-UHFFFAOYSA-N,CCT129524,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20151677.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomal preparation,"Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).",J. Med. Chem.,PUBLICATION,,C1CN(CCC1(C(=O)NCC2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,5.0,NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1
42074,CHEMBL2059800,XQQODFXEFSPXTA-UUWRZZSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2CCN(CC2)C(=O)[C@@H](CC3=CC=C(C=C3)C4=CC=CC=C4)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,5.886056647693163,O=C(N[C@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
42077,CHEMBL408443,XQSGLDYOIWDBIR-CRAIPNDOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,95.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@@H](CC(C)C)N)C,7.022276394711152,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](N)CC(C)C)c(C)c34)ccc2[nH]1
42078,CHEMBL408443,XQSGLDYOIWDBIR-CRAIPNDOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,370.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@@H](CC(C)C)N)C,6.431798275933005,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](N)CC(C)C)c(C)c34)ccc2[nH]1
42079,CHEMBL564109,XQTARQNQIVVBRX-UHFFFAOYSA-N,TAZANOLAST,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,289734.36,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CCCCOC(=O)C(=O)NC1=CC=CC(=C1)C2=NNN=N2,3.537999998156502,CCCCOC(=O)C(=O)Nc1cccc(-c2nn[nH]n2)c1
42082,CHEMBL1222939,XQUSGRXUDTVJOI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CC5=CC=CC=C5Cl)CC6=CC=NC=C6,6.301029995663981,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3Cl)c3ccccc32)CC1
42103,CHEMBL3422097,XRBFZYFJBUZBIE-MOMDTQCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,CC(C)C[C@@H](C1=CC=CC=N1)NC(=O)C2=CC3=C(C=C2)NN=C3C4=CC=C(C=C4)N5[C@H]6CC[C@H]5CC(C6)O,6.494850021680094,CC(C)C[C@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1)c1ccccn1
42104,CHEMBL3422098,XRBFZYFJBUZBIE-NDIVSWGXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,290.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,CC(C)C[C@H](C1=CC=CC=N1)NC(=O)C2=CC3=C(C=C2)NN=C3C4=CC=C(C=C4)N5[C@H]6CC[C@H]5CC(C6)O,6.537602002101044,CC(C)C[C@@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1)c1ccccn1
42111,CHEMBL2179222,XRDVQWJPAZZLKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23006002.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,CC1=CN(C2=C1C=C(C=N2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C,5.0,COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)cnc32)cc1NC1CCN(C)CC1
42142,CHEMBL3403822,XROVVBKXTANRKV-CTYWIBQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)C(C)C)C)C)O)C)C(C)(C)O,4.823908740944319,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
42143,CHEMBL3403822,XROVVBKXTANRKV-CTYWIBQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)C(C)C)C)C)O)C)C(C)(C)O,4.795880017344075,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
42170,CHEMBL272963,XRVNSFDHOMAYDC-XRKRLSELSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=CC(=C3)C[C@@H]4[C@@H](N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,4.698970004336019,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)c1
42171,CHEMBL255389,XRVNSFDHOMAYDC-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=CC(=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,4.769551078621726,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1
42172,CHEMBL255389,XRVNSFDHOMAYDC-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=CC(=C3)C[C@H]4[C@H](N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,4.721246399047171,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1
42178,CHEMBL1761848,XRXOWLSSJZUJBB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21439819.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11ß-hydroxysteroid-dehydrogenase type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2=CC=CC=C2N(C1)C(=O)N3CCC(CC3)C4=CNN=C4,5.0,O=C(N1CCC(c2cn[nH]c2)CC1)N1CCCc2ccccc21
42179,CHEMBL2012958,XRXYHTFKWSMTFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using midazolam as substrate after 5 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=NC2=C(C=CC=C2N1C3=CC=C(S3)C(=O)NC4CC4)C#N,5.0,Cc1nc2c(C#N)cccc2n1-c1ccc(C(=O)NC2CC2)s1
42190,CHEMBL2419493,XSAIJRMURHASGT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)C)C,4.769551078621726,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(C)cc3)CC2)nc1C
42193,CHEMBL459118,XSBPOCYYAOOLIV-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,19.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)N7CCOCC7,7.721246399047171,Cc1cc(N2CCC(N3CCN(C(=O)N4CCOCC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
42225,CHEMBL3265032,XSMSNFMDVXXHGJ-UHFFFAOYSA-N,ENTOSPLETINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24779514.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.",J. Med. Chem.,PUBLICATION,,C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6,5.0,c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1
42228,CHEMBL397114,XSNHZCBRIHYDIF-SNVBAGLBSA-N,SR-1360,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C(=O)N1CCN(CC1)C2=CC3=C(C=C2)NN=C3)N,5.0,C[C@@H](N)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1
42234,CHEMBL496386,XSQBHUDKEMPJMV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=C(C=CC4=O)C(=O)N,5.142667503568732,Cc1cccc(C)c1CNc1cc(-n2cc(C(N)=O)ccc2=O)cn2c(C)c(C)nc12
42235,CHEMBL496386,XSQBHUDKEMPJMV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=C(C=CC4=O)C(=O)N,4.853871964321762,Cc1cccc(C)c1CNc1cc(-n2cc(C(N)=O)ccc2=O)cn2c(C)c(C)nc12
42265,CHEMBL317798,XTFQDUYGGZGGLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCOC1=CC=C(C=C1)N=CNO,4.0,CCCOc1ccc(N=CNO)cc1
42276,CHEMBL3127525,XTJBCFNMRKMFGP-ZYKFHVCXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1CC2CN(CC1O2)S(=O)(=O)C3=CC=C(C=C3)NC(=O)[C@@H]4C[C@H]4C5=CN=CC=C5,5.6020599913279625,O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)[C@@H]1C[C@H]1c1cccnc1
42277,CHEMBL3127525,XTJBCFNMRKMFGP-ZYKFHVCXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1CC2CN(CC1O2)S(=O)(=O)C3=CC=C(C=C3)NC(=O)[C@@H]4C[C@H]4C5=CN=CC=C5,5.050609993355088,O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)[C@@H]1C[C@H]1c1cccnc1
42286,CHEMBL1222863,XTLNKZYASKPMLL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)CCN2C3=CC=CC=C3N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC=NC=C6,4.522878745280337,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCCCC3)c3ccccc32)CC1
42304,CHEMBL3422078,XTULNCWAJUYUIA-PNTNLKMUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,410.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,CC(C)CC(C1=CC=CC=N1)NC(=O)C2=CC3=C(C=C2)NN=C3C4=CC=C(C=C4)OC5C[C@H]6CC[C@@H](C5)N6C=O,6.3872161432802645,CC(C)CC(NC(=O)c1ccc2[nH]nc(-c3ccc(OC4C[C@@H]5CC[C@H](C4)N5C=O)cc3)c2c1)c1ccccn1
42305,CHEMBL3627955,XTURHBZXAJOBEO-AXHNFQJDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,21400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1CO[C@H]([C@H]2[C@@]1(C3=C(C=CC(=C3OC2)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl)CNS(=O)(=O)C(F)(F)F,4.669586226650809,O=S(=O)(NC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C(F)(F)F
42306,CHEMBL3627955,XTURHBZXAJOBEO-AXHNFQJDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ¿-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,C1CO[C@H]([C@H]2[C@@]1(C3=C(C=CC(=C3OC2)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl)CNS(=O)(=O)C(F)(F)F,4.522878745280337,O=S(=O)(NC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C(F)(F)F
42307,CHEMBL381076,XTVVJSSQHZOGSY-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3[C@H](CNCC3=O)COC4=CC5=C(C=C4)OCC(=O)N5CC(=O)O,4.6020599913279625,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CC(=O)O)C(=O)CO3)cc1
42311,CHEMBL1777861,XTXMTBWPTJUGRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC#CC(CC(=O)O)C1=CC=C(C=C1)OC2=C(C=C(C=C2)C(F)(F)F)OC(F)F,4.301029995663981,CC#CC(CC(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1
42349,CHEMBL1487,XUKUURHRXDUEBC-KAYWLYCHSA-N,ATORVASTATIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256005.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,5.292429823902063,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
42357,CHEMBL2205043,XUMDENDMRHWGGR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,C1CN(CCN1)C2=CC=CC=C2SC3=CC=C(C=C3)Cl.Cl,5.167491087293763,Clc1ccc(Sc2ccccc2N2CCNCC2)cc1
42359,CHEMBL1951340,XUOFRIRHKXSQDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,53.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)NC(=O)C2=CC(=CC=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,7.275724130399211,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(C(=O)Nc2ccccc2)c1
42363,CHEMBL2048047,XUPJXTGHHHIDNH-WVBUVRCRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ß-peptides.,J. Med. Chem.,PUBLICATION,,CC(C)(C)C1=CC=CC(=C1)CN[C@H]2CS(=O)(=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,6.522878745280337,CC(C)(C)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1
42365,CHEMBL2436222,XUSGYCMAJIJBII-ULLKZFKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@H]1[C@@H](C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=NN(C4=CC=CC=C43)C5=CC=CC=C5C#N)NC(=O)[C@H](C)NC.Cl,4.431798275933005,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2nn(-c3ccccc3C#N)c3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C
42380,CHEMBL1672627,XUYURJQIMYCWBB-UHFFFAOYSA-N,LAS101057,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CN=CC=C3)C4=C(C=NC=C4)F,5.301029995663981,O=C(Nc1cnc(-c2ccncc2F)c(-c2cccnc2)n1)C1CC1
42382,CHEMBL192850,XVALFXOLDAVCKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,CC(C)S(=O)(=O)N1C2=C(C=CC(=C2)C3=C(NC=N3)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O,6.096910013008056,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3nc[nH]c3-c3ccc(F)cc3)cc21
42395,CHEMBL2448747,XVEIEUIURLFUMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CC(C)CC1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(S3)C4=CC=CC=C4,6.0,CC(C)Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1
42401,CHEMBL271620,XVESHLWLQJLGGM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)CC1=CC(=NC(=N1)C2=CC=CC=C2)N3CCCC3,4.3979400086720375,CS(=O)(=O)Cc1cc(N2CCCC2)nc(-c2ccccc2)n1
42405,CHEMBL1098766,XVMSTDBLFRGHSD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,5.301029995663981,CC(C)N1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1
42408,CHEMBL397582,XVNQYSVVZUWFTA-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=CC=CC=C1N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCNC,5.886056647693163,CNCCC(=O)N[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
42412,CHEMBL1682896,XVSPNIQMNAPNKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)NC(C)C)(C3=CN=CN3)O,5.031517051446065,CC(C)NC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
42424,CHEMBL1077324,XWAXDNIZFDHSSU-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)NC(=O)OC(C)(C)C,4.795880017344075,Cc1cc(N2CCC(NC(=O)OC(C)(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
42426,CHEMBL146826,XWBLHPDICBKAEX-UHFFFAOYSA-N,DESETHYL ISOQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,"Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate","Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,CCNCC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,4.0,CCNCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O
42427,CHEMBL146826,XWBLHPDICBKAEX-UHFFFAOYSA-N,DESETHYL ISOQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>=,55000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,CCNCC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,4.259637310505756,CCNCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O
42450,CHEMBL1951446,XWIQRYXCWXJXRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5)N,6.698970004336019,Nc1ccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5nc[nH]c45)cc3)cc2)cc1
42455,CHEMBL239150,XWMMNGXDPDSMBN-UHFFFAOYSA-N,SR-899,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Br)O,5.3979400086720375,O=C(C(O)c1ccc(Br)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
42459,CHEMBL2448728,XWOSNQDOEDQYOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1110.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C1CC1C(=O)N(CC2=CN=CC=C2)C3=CC(=CC(=C3)C4=NC5=CC=CC=C5S4)F,5.954677021213342,O=C(C1CC1)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1
42468,CHEMBL168726,XWSMFYRZZIFQGL-WUXOVTSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)[C@H](C)CNCCC6=CC7=C(C=C6)N=C(N7)C(F)(F)F)C,5.0,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3nc(C(F)(F)F)[nH]c3c2)c1
42478,CHEMBL1209018,XWUCTSMJFVUKTR-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCN(CC1)CCCN2C=C(C=N2)C3=CC4=C(C=C3)N(C=N4)C5=CC(=C(S5)C(=O)N)O[C@H](C)C6=CC=CC=C6Cl,6.0,CCN1CCN(CCCn2cc(-c3ccc4c(c3)ncn4-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)cn2)CC1
42479,CHEMBL1209018,XWUCTSMJFVUKTR-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1CCN(CC1)CCCN2C=C(C=N2)C3=CC4=C(C=C3)N(C=N4)C5=CC(=C(S5)C(=O)N)O[C@H](C)C6=CC=CC=C6Cl,5.346787486224656,CCN1CCN(CCCn2cc(-c3ccc4c(c3)ncn4-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)cn2)CC1
42481,CHEMBL505652,XWUXNFBFVBWTFY-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,1.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)OCCO,8.744727494896694,Cc1cc(N2CCC(N3CCN(C(=O)OCCO)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
42508,CHEMBL3115169,XXFQAQQBFPSMAQ-GEBXHLAXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC1=CN=CS1)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.769551078621726,CN(Cc1cncs1)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
42512,CHEMBL1096104,XXGHMIJYQJJVNZ-RBSBEOHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=C(C=C1)[C@@H]2CCO[P@@](=O)(O2)COC3=C4C(=C(C(=C3)C)C)CC5=C4N=CS5,5.2839966563652006,Cc1ccc([C@@H]2CCO[P@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)cn1
42515,CHEMBL512414,XXHBZSGXGMJSEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19339177.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC2CC(CC1N2C(C3=CC=CC=C3Cl)C4=CC=CC=C4Cl)(C5=CC=CC=C5)C(=O)N,4.522878745280337,NC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
42517,CHEMBL237577,XXHJASVEYUQRFO-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCNC,4.958607314841775,CNCCN[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
42520,CHEMBL3402641,XXKSMVQSCWXLCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25701253.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Synthesis and SAR studies of analogues of 4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-N-thiazol-2-yl-benzamide (Lu AA41063) as adenosine A2A receptor ligands with improved aqueous solubility.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(CCN1CCOCC1)CC(=O)NC2=CC=C(C=C2)C(=O)NC3=NC=CS3,4.3979400086720375,CC(CCN1CCOCC1)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
42529,CHEMBL1080982,XXODNTBQCNWAAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCOCC4=O)C(=C(N3CCO)C)C,5.221848749616356,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)n(CCO)c12
42530,CHEMBL1080982,XXODNTBQCNWAAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCOCC4=O)C(=C(N3CCO)C)C,4.958607314841775,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)n(CCO)c12
42550,CHEMBL2069803,XXTHMVRJMJIERU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,=,10200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,C1CCC(CC1)C2=NC(=NO2)C3=CC=NC=C3,4.991399828238082,c1cc(-c2noc(C3CCCCC3)n2)ccn1
42576,CHEMBL237146,XYHMIFWCJKCCQZ-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)[C@@H](CC(C)C)C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O,5.568636235841013,CCN(CC)[C@@H](CC(C)C)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
42582,CHEMBL578594,XYJYINJWXKGOJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)SC,5.301029995663981,CSc1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1
42595,CHEMBL1829765,XYMFJLWCTXMXHU-UZTOHYMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,C[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CC[C@](OC3=O)(CCCO)C4=CC=CC=C4F,5.221848749616356,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2F)OC1=O
42605,CHEMBL3092189,XYPITQNKWLZVKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)OC2=C1C=CC(=C2)OC(=O)N(C)C)CC3=CC(=CC=C3)NS(=O)(=O)NC,5.251811972993799,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1
42606,CHEMBL3092189,XYPITQNKWLZVKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=O)OC2=C1C=CC(=C2)OC(=O)N(C)C)CC3=CC(=CC=C3)NS(=O)(=O)NC,4.886056647693163,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1
42619,CHEMBL1923130,XYRCXXGEWXZMCD-NEEKEDPPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=C(C(=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F)Cl)CCCNS(=O)(=O)C,5.698970004336019,COCCCc1cc(CCCNS(C)(=O)=O)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1
42631,CHEMBL494917,XYVMIKBYRGFIJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,CC1=C(C2=C(C=C1)C(=NO2)NC)C3=CC4=CN=NC(=C4C=C3)OC(C)C,4.6020599913279625,CNc1noc2c(-c3ccc4c(OC(C)C)nncc4c3)c(C)ccc12
42635,CHEMBL2017106,XYWQJJVDYDCQKB-KOSHJBKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)[C@H]3CNCC[C@@]3(C4=CC(=C(C=C4)F)F)O)Cl,4.301029995663981,CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Cl
42643,CHEMBL1641613,XZCPNRFCLBNHOY-BAOGCXAUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21134748.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Stereospecific synthesis and structure-activity relationships of unsymmetrical 4,4-diphenylbut-3-enyl derivatives of nipecotic acid as GAT-1 inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1/C(=C\CCN2CCC[C@H](C2)C(=O)O)/C3=CC=CC=C3F,5.0,Cc1ccccc1/C(=C\CCN1CCC[C@@H](C(=O)O)C1)c1ccccc1F
42656,CHEMBL3137458,XZGXLRPOTMAXIV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,600.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC1=CC(=CN=C1)N2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,6.221848749616356,Cc1cncc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)c1
42661,CHEMBL207012,XZIZYTUIRQMBPN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,C1=CC2=C(N=C1)SC(=C2N)C(=O)N,4.522878745280337,NC(=O)c1sc2ncccc2c1N
42662,CHEMBL3400435,XZJFCCNTHXFRPO-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NCC2=CC3=CC=CC=C3C=C2)C(=O)C4=CC(=C(C=C4)OC)OCCCOC,5.853871964321762,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NCc2ccc3ccccc3c2)C(C)C)ccc1OC
42663,CHEMBL3400435,XZJFCCNTHXFRPO-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NCC2=CC3=CC=CC=C3C=C2)C(=O)C4=CC(=C(C=C4)OC)OCCCOC,5.6020599913279625,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NCc2ccc3ccccc3c2)C(C)C)ccc1OC
42675,CHEMBL2165510,XZQRCJXLCKQEIT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=CN(C5=CC=C4)C)N6CCOCC6,5.0,Cn1ccc2c(-c3nc(N4CCOCC4)c4sc(CN5CCN(C(C)(C)C(N)=O)CC5)cc4n3)cccc21
42680,CHEMBL381619,XZSLPXJGQLDVET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,C1CN(CCC1NC(=O)C2(CCNC2)C3=CC=CC=C3)CC4=CC(=CC=C4)OC5=CC=CC=C5Cl,5.0,O=C(NC1CCN(Cc2cccc(Oc3ccccc3Cl)c2)CC1)C1(c2ccccc2)CCNC1
42709,CHEMBL558752,YABJJWZLRMPFSI-UHFFFAOYSA-N,CHIR-265,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F,4.3979400086720375,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
42721,CHEMBL3403827,YAEUHXARFVDSAM-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)CCO)C)C)O)C)C(C)(C)O,4.769551078621726,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
42722,CHEMBL3403827,YAEUHXARFVDSAM-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)CC8CN(C8)CCO)C)C)O)C)C(C)(C)O,4.769551078621726,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
42731,CHEMBL1950081,YAGLFTIBFQFZJH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C#N)C4=CC=C(C=C4)OC)OC,6.522878745280337,COc1ccc(C(C#N)c2c3cc(OC)cc(C)c3nc3n[nH]c(C)c23)cc1
42732,CHEMBL1950081,YAGLFTIBFQFZJH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,12900.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C#N)C4=CC=C(C=C4)OC)OC,4.889410289700751,COc1ccc(C(C#N)c2c3cc(OC)cc(C)c3nc3n[nH]c(C)c23)cc1
42749,CHEMBL249292,YAMNDFFLOPYHJZ-WIYYLYMNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)C(C)(C)CO,6.096910013008056,C[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
42753,CHEMBL1767164,YANGEESWIGIKOP-UUWRZZSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21381763.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl,6.522878745280337,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
42757,CHEMBL1672622,YAPJZGXRIHUBAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CC=NC=C3)C4=CC=NC=C4,6.0,O=C(Nc1cnc(-c2ccncc2)c(-c2ccncc2)n1)C1CC1
42764,CHEMBL2059119,YARFTVQMCHDCQY-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,53.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N(C)C,7.275724130399211,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)C)oc2c1
42814,CHEMBL2048497,YBDASUYOOMCJRA-ASDZUOGYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2OC)OC)[C@@]3(C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO)O,4.5376020021010435,CCc1ccc(Cc2cc([C@]3(O)C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1
42815,CHEMBL2048497,YBDASUYOOMCJRA-ASDZUOGYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2OC)OC)[C@@]3(C[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO)O,4.301029995663981,CCc1ccc(Cc2cc([C@]3(O)C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1
42817,CHEMBL3664657,YBDFPAYNZHIEFN-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,32000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)C#N)C4=CC=CC=C4,4.494850021680094,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O
42819,CHEMBL1669422,YBDNLKCSUIZMPU-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,4416.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN4,5.354970935278858,C[C@H](C1=C(CCN(C)Cc2ncc[nH]2)Cc2ccccc21)c1cnccn1
42826,CHEMBL1951341,YBIKJBVQOXSYEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,70.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(C1)NC(=O)C2=CC(=CC=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,7.154901959985743,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(C(=O)NC2CCCC2)c1
42830,CHEMBL3114733,YBLOSHNBIZTDHF-NQVJXQQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,340.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(CC3=CC=CC=C3Cl)C(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.468521082957745,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccccc2Cl)C(=O)OCc2cncs2)Cc2ccccc2)cs1
42834,CHEMBL3236359,YBMODFWQBWSTTG-FIULFVJVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1[C@@H]([C@H](C[C@](C1=O)(C)CC2=NOC(=O)N2)C3=CC(=CC=C3)Cl)C4=CC=C(C=C4)Cl,5.920818753952375,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(Cc2noc(=O)[nH]2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
42840,CHEMBL3115183,YBPGJLVCLREDGV-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCNS(=O)(=O)C)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.920818753952375,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCNS(C)(=O)=O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
42841,CHEMBL2010816,YBPKUYHMTYRITD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22306122.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SAR.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1NC2=NC(=CN=C2)N)OC3=CC=C(C=C3)OC(F)(F)F,4.568636235841013,Nc1cncc(Nc2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)n1
42863,CHEMBL496606,YCAMYJGGAXTJHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=N4,5.173925197299173,Cc1cccc(C)c1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12
42864,CHEMBL496606,YCAMYJGGAXTJHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=N4,4.769551078621726,Cc1cccc(C)c1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12
42865,CHEMBL3393730,YCBGAHFPRWRCEG-VDNLBMKXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25597006.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]1C[C@H](N(C1)C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=C(S3)C4=CC=C(S4)C5=CC=C(C=C5)C6=CN=C(N6)[C@@H]7C[C@@H](CN7C(=O)[C@H](C(C)C)NC(=O)OC)C,4.522878745280337,COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5s4)s3)cc2)[nH]1)C(C)C
42870,CHEMBL426851,YCHYUPBHYYIHNM-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN1C2=C(C(=C(S2)CN3C4=CC=CC=C4N=C3NC)C(=O)N5CC[C@H](C5)O)C(=O)N(C1=O)C,4.301029995663981,CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C
42879,CHEMBL1641811,YCLHCCNXVIOFPI-RHSMWYFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21185722.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azaindoles as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=CC=C(C=C1)F)C(=O)N(C)[C@@H]2CCC3=C(C4=C(N3C2)N=CC=C4)CC(=O)O,4.301029995663981,C[C@@H](C(=O)N(C)[C@@H]1CCc2c(CC(=O)O)c3cccnc3n2C1)c1ccc(F)cc1
42880,CHEMBL3672575,YCLPMWDXYKCXAX-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CSC[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.698970004336019,CC(C)c1nc(CN(C)C(=O)N2CSC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
42881,CHEMBL3672575,YCLPMWDXYKCXAX-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CSC[C@H]2C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.522878745280337,CC(C)c1nc(CN(C)C(=O)N2CSC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
42884,CHEMBL218068,YCMQHZLCRNKFNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1CNC2=NC=NC=C2)C(=O)OCC3=CC=CC=C3,5.292429823902063,O=C(OCc1ccccc1)N1CCC(CNc2ccncn2)CC1
42885,CHEMBL1085107,YCNCXQNUXCHRRX-ZHPDPMBESA-N,AMG-221,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20465278.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).",J. Med. Chem.,PUBLICATION,,CC(C)[C@]1(C(=O)NC(=N[C@H]2C[C@@H]3CC[C@H]2C3)S1)C,4.823908740944319,CC(C)[C@]1(C)SC(=N[C@H]2C[C@@H]3CC[C@H]2C3)NC1=O
42888,CHEMBL403999,YCOGAHGFEYEAQE-SJLPKXTDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,<,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NC=CO4,7.522878745280337,CC[C@@H]1CCC[C@H](C2(Cc3ncco3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
42894,CHEMBL2386285,YCQBLTPGQSYLHD-WCWDXBQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25751283.0,IC50,=,285.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay,Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.,J. Med. Chem.,PUBLICATION,,CC/C(=C(/C1=CC=C(C=C1)O)\C2=CC=C(C=C2)OCCN)/C3=CC=CC=C3,6.54515513999149,CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccccc1
42922,CHEMBL1834659,YCXMKEVLJQGEKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CN(C1=NC=NC(=C1)NC2=CC=C(C=C2)OCCN3CCCC3)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,5.6020599913279625,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(OCCN4CCCC4)cc3)ncn2)c1Cl
42923,CHEMBL1834659,YCXMKEVLJQGEKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CN(C1=NC=NC(=C1)NC2=CC=C(C=C2)OCCN3CCCC3)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,5.0,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(OCCN4CCCC4)cc3)ncn2)c1Cl
42944,CHEMBL2425610,YDLJWZHCJHGQOV-MMIABTCFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC=CC(=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)OC,6.522878745280337,COc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N
42945,CHEMBL3087035,YDNYPKDLLNMZPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,16200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CN=C(N=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,4.790484985457369,O=S(=O)(Nc1ccc(-c2ncccn2)cc1)c1cc(Cl)cc(Cl)c1
42949,CHEMBL1403281,YDOTUXAWKBPQJW-NSLWYYNWSA-N,ERGOCRYPTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,600.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,6.221848749616356,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
42956,CHEMBL3400445,YDPUZUFPFFYPHY-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N(C[C@@H]1CNC[C@H]1NC(=O)CCC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,5.508638306165727,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)CCc2ccccc2)C(C)C)ccc1OC
42981,CHEMBL1650404,YEBKYXHNDLEMKJ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21186796.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.,J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC=C(C(=O)N2CC3=CC=CC=C3C#N)F)N,5.0,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)ncc(F)c1=O
42995,CHEMBL2041171,YEDDTSUKSZDINS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CC(=O)NN7,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5cc(=O)[nH][nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
42997,CHEMBL2158299,YEEBLJFZYXYIOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)CN4CCOCC4)NC(=O)C5=NC=C(N5)C#N,5.7447274948966935,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)CN4CCOCC4)CC3)cc2C2=CCCCC2)[nH]1
43011,CHEMBL280981,YEHNDLQWKSUNTD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998323.0,IC50,=,9730.0,NM,,,,,,,,,,,,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CCN2C(=C(C3=C2C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=O)NC6=CN=CC=C6)C1,5.011887159731648,O=C(Nc1cccnc1)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2
43013,CHEMBL3422004,YEIDLEQRGTVNQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C1CN2C(=NN=C2C3=NC(=CC=C3)C(F)(F)F)CN1C(=O)C4=CC=C(C=C4)F,4.0,O=C(c1ccc(F)cc1)N1CCn2c(nnc2-c2cccc(C(F)(F)F)n2)C1
43026,CHEMBL2041190,YEMQCJMGXORROI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CN=C4)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1
43032,CHEMBL3634394,YEPBUHWNLNKZBW-FDVAVYTKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26410074.0,IC50,>=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=CC2=C1N=C(C=C2O[C@H]3CCN4[C@@H](C3)C(=O)N[C@@]5(C[C@H]5/C=C/CCCCN(C4=O)C)C(=O)NS(=O)(=O)C6(CC6)C)C7=NC(=CS7)C(F)(F)F)OC,5.0,COc1ccc2c(O[C@H]3CCN4C(=O)N(C)CCCC/C=C/[C@@H]5C[C@@]5(C(=O)NS(=O)(=O)C5(C)CC5)NC(=O)[C@@H]4C3)cc(-c3nc(C(F)(F)F)cs3)nc2c1C
43034,CHEMBL1923106,YEQCXSBSFLRJJT-DGPALRBDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC=CC=C5CO4,5.221848749616356,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2ccccc23)C2CC2)cc(OCCOC)c1
43041,CHEMBL3127521,YERMBKYNILMCNC-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1[C@@H]([C@H]1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=CC=C4,7.045757490560675,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1
43042,CHEMBL3127521,YERMBKYNILMCNC-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,680.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1[C@@H]([C@H]1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=CC=C4,6.167491087293763,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1
43045,CHEMBL3127520,YERMBKYNILMCNC-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1[C@H]([C@@H]1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=CC=C4,6.958607314841775,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1
43046,CHEMBL3127520,YERMBKYNILMCNC-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1[C@H]([C@@H]1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=CC=C4,5.920818753952375,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1
43064,CHEMBL3699318,YEYJQOPIRCXAMH-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1760.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)N8CCSCC8,5.7544873321858505,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCSCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
43086,CHEMBL3310483,YFFZLXAPKOKACC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)Cl,6.221848749616356,Fc1cc(C(CC2CNC2)Oc2cccc(Cl)c2)ccc1Cl
43105,CHEMBL1909991,YFKUZVBMNGNFRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=CC=C3OC)C4=C(C=C(C=C4)Cl)Cl)CN,5.886056647693163,COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
43106,CHEMBL1909991,YFKUZVBMNGNFRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=CC=C3OC)C4=C(C=C(C=C4)Cl)Cl)CN,5.823908740944319,COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
43107,CHEMBL1909991,YFKUZVBMNGNFRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=CC=C3OC)C4=C(C=C(C=C4)Cl)Cl)CN,5.657577319177793,COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
43112,CHEMBL178516,YFOKBFRTGLSZLU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,139900.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CN=CN2,3.8541822855081724,c1cncc(-c2cnc[nH]2)c1
43120,CHEMBL248867,YFVOIZOCKPSNFU-GMKZXUHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1C[C@H](C[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCC(CC3)N4CCCCC4)OC,5.468521082957745,CC[C@@H]1C[C@@H](OC)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
43121,CHEMBL248866,YFVOIZOCKPSNFU-JRFVFWCSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1C[C@@H](C[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCC(CC3)N4CCCCC4)OC,5.301029995663981,CC[C@@H]1C[C@H](OC)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
43122,CHEMBL3702795,YFWPXVZAAUNARU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6940.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCCN1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,5.158640529545145,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CCC)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
43127,CHEMBL1916559,YGAMOUONCVBLTE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21852130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C2=C1C=C(C=C2)C3=NOC(=N3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C(=O)CCC(=O)O,4.301029995663981,O=C(O)CCC(=O)N1CCc2cc(-c3noc(-c4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)ccc21
43139,CHEMBL3353862,YGFQBPYOYXCHSZ-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556092.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)C1=CC(=NO1)NC(=O)[C@@H]2CCCN2C3=CC=C(C=C3)C(F)(F)F,4.301029995663981,CC(C)(C)c1cc(NC(=O)[C@@H]2CCCN2c2ccc(C(F)(F)F)cc2)no1
43149,CHEMBL496456,YGKYXFALHGAEIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC(C2=C(C1)C=C(C=C2)C3=CC(=C(C=C3)F)F)C4=CC=NC=C4.Cl,5.638272163982407,Fc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1F
43165,CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,5.301029995663981,Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1
43166,CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,5.301029995663981,Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1
43167,CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,5.301029995663981,Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1
43172,CHEMBL479418,YGTZEUKLDBWBIS-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)CC5=CC=C(C=C5)F,6.301029995663981,C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
43173,CHEMBL479418,YGTZEUKLDBWBIS-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)CC5=CC=C(C=C5)F,6.221848749616356,C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1
43175,CHEMBL1643780,YGUQHAZHYUGNIM-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106375.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN([C@@H]1CCC2=C(C3=C(N2C1)C(=C(C=C3)F)F)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,4.301029995663981,CN([C@@H]1CCc2c(CC(=O)O)c3ccc(F)c(F)c3n2C1)S(=O)(=O)c1ccc(F)cc1
43185,CHEMBL2207081,YGWURLOZYUXZKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23079519.0,IC50,=,3981.07,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,In vivo activity of an azole series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1S(=O)(=O)NC2=C(C=CC(=C2)Cl)CN3C=CN=N3)Cl)Cl,5.40000018605658,O=S(=O)(Nc1cc(Cl)ccc1Cn1ccnn1)c1ccc(Cl)c(Cl)c1
43190,CHEMBL436753,YGYLUOKAHBFLCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,CCN1CCC(CC1)(C2=CC=CC=C2)C(=O)NC3(CCN(CC3)CC4=CC(=CC=C4)OC5=CC=CC=C5Cl)C(=O)O,5.0,CCN1CCC(C(=O)NC2(C(=O)O)CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1
43206,CHEMBL1169994,YHEVMXYWTAZKST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20627722.0,IC50,=,436.52,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1S(=O)(=O)NC2=C(N=CC(=C2)Cl)OC3=CC(=CN=C3)Cl)Cl)Cl,6.359995853468939,O=S(=O)(Nc1cc(Cl)cnc1Oc1cncc(Cl)c1)c1ccc(Cl)c(Cl)c1
43226,CHEMBL2403317,YHNQBDQWYZKMDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23768906.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: Discovery of a quinazolinone chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=NC=C1)OC2=CC3=C(C=C2)N(C=NC3=O)CC4=C(C=C(C=C4F)F)F)C(F)(F)F,4.7447274948966935,COc1ccnc(Oc2ccc3c(c2)c(=O)ncn3Cc2c(F)cc(F)cc2F)c1C(F)(F)F
43227,CHEMBL1923128,YHNTXMADPCPYPH-SJHOIFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCCC1=C(C(=CC(=C1)CCCOC)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F)Cl,5.236572006437063,CCN(CC)CCCc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1Cl
43246,CHEMBL240598,YHWFSBOTUBZNFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,160.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCC(=O)NC)(C)C4=CC(=CC(=C4)F)F,6.795880017344075,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCC(=O)NC)C(=O)C(C)(c1cc(F)cc(F)c1)O2
43260,CHEMBL1778865,YICPRNFRCVOHKV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21524576.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Iinhibition of CYP3A4,"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C=CC(=C1)F)C2=NC(=CN=C2)CNCC3CC3,4.698970004336019,COc1cc(F)ccc1-c1cncc(CNCC2CC2)n1
43264,CHEMBL2041167,YIDRPJAESDFDSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)C6=CNC(=O)N=C6,4.301029995663981,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3cnc(=O)[nH]c3)cc1)C(=O)N2c1cc(=O)[nH]cn1
43274,CHEMBL178781,YIGMADWICHWLTQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,109000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,CC1=CN(C=N1)C2=CN=CC=C2,3.962573502059376,Cc1cn(-c2cccnc2)cn1
43275,CHEMBL1086754,YIHQDWZWZRGAIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20149649.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,4.698970004336019,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C
43278,CHEMBL1076210,YIIXUMVWJVOYNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2NC(=C3C)C,5.045757490560675,Cc1cccc(C)c1CNc1nccc2c(C)c(C)[nH]c12
43279,CHEMBL1076210,YIIXUMVWJVOYNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2NC(=C3C)C,5.017728766960431,Cc1cccc(C)c1CNc1nccc2c(C)c(C)[nH]c12
43282,CHEMBL466191,YIJJJJWZXATIQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,=,58000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=CC(=NC=C1C(=O)NCC2CCOCC2)NC3=C(C=C(C=C3)Cl)Cl,4.236572006437063,CC(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1
43285,CHEMBL3092130,YIJWSWGNFRVEHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24252546.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)C2=C(C(=NN2C3=NC(=CS3)C(=O)O)C4=CC=CC=C4)N,5.0,Nc1c(-c2ccccc2)nn(-c2nc(C(=O)O)cs2)c1-c1ccccc1
43299,CHEMBL534723,YIQFFQJVNKNCNB-FSRHSHDFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16750363.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC1=CC=CC=C1C[C@H](C2=CC=CC=C2)N3CCNCC3.Cl,4.522878745280337,CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1
43300,CHEMBL540107,YIQFFQJVNKNCNB-FYZYNONXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16750363.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC1=CC=CC=C1C[C@@H](C2=CC=CC=C2)N3CCNCC3.Cl,5.0,CCOc1ccccc1C[C@@H](c1ccccc1)N1CCNCC1
43314,CHEMBL3260756,YIYAOMUUXPETBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=CC=C(C=C3)C#N)C4=CN=C(N=C4)N(C)C)C5=CC=C(C=C5)Cl,4.3979400086720375,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnc(N(C)C)nc3)c(=O)n(Cc3ccc(C#N)cc3)n2c1=O
43316,CHEMBL3702764,YIYNUEAQYFZKKF-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9710.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7CCN(CC7)CCCO,5.012780770091995,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(CCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
43319,CHEMBL3699317,YIZDDSJUVVICBC-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=O)NC8=CC=CC=C8,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
43327,CHEMBL489500,YJFULAYRAKPBCY-CXAGYDPISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19181519.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(CCN1S(=O)(=O)C2=CC=C(C=C2)[C@](C)(C(F)(F)F)O)CC3(CC3)C(=O)N,4.0,C[C@@H]1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc([C@@](C)(O)C(F)(F)F)cc1
43328,CHEMBL460962,YJFULAYRAKPBCY-DYVFJYSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19181519.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(CCN1S(=O)(=O)C2=CC=C(C=C2)[C@@](C)(C(F)(F)F)O)CC3(CC3)C(=O)N,4.0,C[C@@H]1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc([C@](C)(O)C(F)(F)F)cc1
43329,CHEMBL465955,YJFULAYRAKPBCY-FWJOYPJLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19181519.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(CCN1S(=O)(=O)C2=CC=C(C=C2)C(C)(C(F)(F)F)O)CC3(CC3)C(=O)N,4.0,C[C@@H]1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1
43342,CHEMBL61,YJGVMLPVUAXIQN-XVVDYKMHSA-N,PODOFILOX,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,600.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,6.221848749616356,COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC
43352,CHEMBL2059120,YJLFMPGHIVLBOD-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,38.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCOCC5,7.42021640338319,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCOCC3)oc2c1
43353,CHEMBL3326585,YJLGMMODESAVMW-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4)OC(F)(F)F)(C)C)C=N1,4.698970004336019,Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4cc(OC(F)(F)F)ccc43)cccc2cn1
43370,CHEMBL3669001,YJRASZMPGGZLLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320643,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CN=C(C=C4)Cl)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(Cl)nc4)nc3)c2c1
43371,CHEMBL3669001,YJRASZMPGGZLLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320687,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CN=C(C=C4)Cl)N=C1,5.0,Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(Cl)nc4)nc3)c2c1
43375,CHEMBL436137,YJSFAHMGDRBZGH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17113292.0,IC50,=,42000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)C2=CC3=C(C(=C2)C)N=C(N=N3)NC4=CC=C(C=C4)OCCN5CCCC5,4.376750709602099,Cc1cccc(C)c1-c1cc(C)c2nc(Nc3ccc(OCCN4CCCC4)cc3)nnc2c1
43388,CHEMBL1923129,YKCXEFNZNYQXHC-ZUKKLESISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCC1=CC(=C(C(=C1)CN(C2CC2)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F)Cl)CCCCNS(=O)(=O)C,5.657577319177793,COCCCc1cc(CCCCNS(C)(=O)=O)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1
43390,CHEMBL3237444,YKDDWNDRNJMVDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,C1CCC(C1)N2C3=C(C=CN=C3Cl)C4=CN=C(N=C42)NC5=NC=C(C=C5)N6CCNCC6,5.0,Clc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12
43392,CHEMBL3601189,YKDGQNXRKZSZOG-ICYYRSKXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=NC=CC(=C1)NC2=NC=C(C(=N2)N[C@@H]3C[C@@H]([C@H]([C@H]3O)O)CO)C4=NC5=CC=CC=C5C=C4,4.301029995663981,COc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1
43395,CHEMBL1079228,YKGANGZPZGMFOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,65.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)CC(CN(CC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC(CC4=CC=CC=C4)NC(=O)OCC5=NC=CS5)NC(=O)OCC6=CN=CS6,7.187086643357144,O=C(NC(Cc1ccccc1)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
43411,CHEMBL1766186,YKJRYOUVLGHMHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)C(C3=CN=CN3)O,5.0,CC(=O)Nc1cccc(-c2ccc(C(O)c3cnc[nH]3)cc2)c1
43417,CHEMBL26485,YKLMGVJEZXDKGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998323.0,IC50,=,30150.0,NM,,,,,,,,,,,,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.,J. Med. Chem.,PUBLICATION,,C1CCN2C(=C(C3=C2C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=O)NCC6=CC=CC=N6)C1,4.52071268352383,O=C(NCc1ccccn1)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2
43458,CHEMBL255590,YKTUSHSSKIWDRY-UHFFFAOYSA-N,JNJ-27390467,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18272363.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC12COC3=C2C=C(C=C3)CN)C(=O)C4=CC=C(O4)C#CC5=CC=CC=C5,4.698970004336019,NCc1ccc2c(c1)C1(CCN(C(=O)c3ccc(C#Cc4ccccc4)o3)CC1)CO2
43465,CHEMBL3394736,YKTUZLHYXSJRBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC=C1S(=O)C2=CC(=CC(=C2)F)F)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,O=C(NCc1ccc([S+]([O-])c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1
43466,CHEMBL3394736,YKTUZLHYXSJRBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=NC=C1S(=O)C2=CC(=CC(=C2)F)F)CNC(=O)C3=CC4=C(O3)C=NC=C4,5.0,O=C(NCc1ccc([S+]([O-])c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1
43473,CHEMBL498371,YKVPDUWONPUOHW-ASIDMNOUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,77600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,CC(C1=CC(=CC(=C1O)C(C)C)/C=C\2/C(=O)/C(=C/C3=CC(=C(C(=C3)C(C)C)O)C(C)C)/CC2)C,4.110138278741812,CC(C)c1cc(/C=C2\CC/C(=C\c3cc(C(C)C)c(O)c(C(C)C)c3)C2=O)cc(C(C)C)c1O
43474,CHEMBL498371,YKVPDUWONPUOHW-ASIDMNOUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,77624711.66,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,CC(C1=CC(=CC(=C1O)C(C)C)/C=C\2/C(=O)/C(=C/C3=CC(=C(C(=C3)C(C)C)O)C(C)C)/CC2)C,1.1100000000160524,CC(C)c1cc(/C=C2\CC/C(=C\c3cc(C(C)C)c(O)c(C(C)C)c3)C2=O)cc(C(C)C)c1O
43480,CHEMBL3702679,YLAPRUSAFZVMFL-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8520.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8=NC=CC=N8,5.0695604052333,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ncccn6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
43481,CHEMBL467187,YLBKDRAXARKXCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18625554.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1C(=O)NN=C(O1)CC2=C(C(=C(C=C2)Cl)OC3=CC(=CC(=C3)C#N)Cl)F,6.568636235841013,CC1OC(Cc2ccc(Cl)c(Oc3cc(Cl)cc(C#N)c3)c2F)=NNC1=O
43482,CHEMBL2178806,YLBXBHSEZZNJPX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=NN(C(=C1)NC(=O)C2=C3N=CC=CN3N=C2)C4=CC(=CC=C4)Cl,5.337242168318426,Cc1cc(NC(=O)c2cnn3cccnc23)n(-c2cccc(Cl)c2)n1
43489,CHEMBL1094851,YLEDBIZRBVHBJQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CCCN(C4)C5CCCCC5,5.481486060122113,COc1ccc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)cc1
43495,CHEMBL2070154,YLESIDOZBVSZQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=N3)C4=CC=CC=C4,5.113509274827518,CCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)n3)[nH]c2c1
43534,CHEMBL208154,YLMRCYCGLCIPMC-IERDGZPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H]([C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N(C)C,5.200659450546418,C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C
43535,CHEMBL360771,YLMRCYCGLCIPMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,1488.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N(C)C,5.82739706879014,CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C
43536,CHEMBL360771,YLMRCYCGLCIPMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N(C)C,5.200659450546418,CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C
43540,CHEMBL3695713,YLPZTDCVMOWRPZ-CVEARBPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26602277.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)CNC2=CC(=NC3=CC=NN32)OC[C@H]4C[C@@H]4C5=CC=CC=N5,4.301029995663981,Cn1cc(CNc2cc(OC[C@H]3C[C@@H]3c3ccccn3)nc3ccnn23)cn1
43546,CHEMBL570867,YLSKCQOVDOZHTQ-VWLOTQADSA-N,BMS-344577,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)N(C)C,4.4089353929735005,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(C(=O)N(C)C)nc3)ccc2o1
43547,CHEMBL570867,YLSKCQOVDOZHTQ-VWLOTQADSA-N,BMS-344577,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BZR as substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)N(C)C,4.3979400086720375,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(C(=O)N(C)C)nc3)ccc2o1
43548,CHEMBL570867,YLSKCQOVDOZHTQ-VWLOTQADSA-N,BMS-344577,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 by HHA assay,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)N(C)C,3.6989700043360187,Cc1cc2cc(NC(=N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(C(=O)N(C)C)nc3)ccc2o1
43549,CHEMBL3702780,YLWKSJWNDNVJRD-QARUCVQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6750.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCCN(C)C,5.170696227168975,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
43555,CHEMBL3409873,YLZAYQGWWQGQAW-OALUTQOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=C(C(=CC=C1)F)[C@@H]2C[C@@H](C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)F,4.6777807052660805,COc1cccc(F)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc2oc3ccccc3c2c1
43568,CHEMBL116,YMARZQAQMVYCKC-OEMFJLHTSA-N,AMPRENAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,6.0,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1
43570,CHEMBL492661,YMBFUJAHKNUKLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,CC1=C(C2=C(C=C1)C(=NO2)NC)C3=CC4=CN=NC(=C4C=C3)C(C)C,4.6020599913279625,CNc1noc2c(-c3ccc4c(C(C)C)nncc4c3)c(C)ccc12
43575,CHEMBL3121951,YMCAVGXTSCNFDE-BBACVFHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24568313.0,IC50,>,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.,J. Med. Chem.,PUBLICATION,,CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CC7(CN6C(=O)[C@H](C(C)C)NC(=O)OC)OCCO7)NC(=O)OC,4.481486060122112,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CC6(CN5C(=O)[C@@H](NC(=O)OC)C(C)C)OCCO6)[nH]4)cc3)cc2)[nH]1)C(C)C
43577,CHEMBL3417511,YMEFXAYUHCDQHO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25671290.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,PUBLICATION,,CC(C)(CN1C=C(C=N1)C2=NC(=NO2)C3(CCC3)C4=CC=C(C=C4)C5=CN=C(N=C5)N)O,4.522878745280337,CC(C)(O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CCC3)no2)cn1
43578,CHEMBL496035,YMEJDVRSUORBRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C(=NC=N4)CO,4.795880017344075,Cc1cccc(C)c1CNc1cc(-n2ncnc2CO)cn2c(C)c(C)nc12
43579,CHEMBL496035,YMEJDVRSUORBRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C(=NC=N4)CO,4.6777807052660805,Cc1cccc(C)c1CNc1cc(-n2ncnc2CO)cn2c(C)c(C)nc12
43583,CHEMBL3234568,YMFDSPVIOOOQTH-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCC[C@H](C3)C(=O)NCCC4=CC=C(C=C4)C#N,6.0,CN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)cc4)C3)nc(C(F)(F)F)n2)CC1
43586,CHEMBL2448721,YMGUXTBLOJPLDX-CVKSISIWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1400.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,C/C(=N\OC)/C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN(N=C3)C4=CC=CC=N4,5.853871964321762,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnn(-c3ccccn3)c2)c1
43616,CHEMBL2048187,YMSMSUFAXNUPLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=C(N2CC(=O)O)C=CC(=C3)F,5.0,COc1ccc(C(C)=O)cc1CSc1nc2cc(F)ccc2n1CC(=O)O
43617,CHEMBL2048187,YMSMSUFAXNUPLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=C(N2CC(=O)O)C=CC(=C3)F,4.823908740944319,COc1ccc(C(C)=O)cc1CSc1nc2cc(F)ccc2n1CC(=O)O
43634,CHEMBL2431173,YMYCVXPMSMNWEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050755.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).,J. Med. Chem.,PUBLICATION,,CC1(COC1)NC(=O)C2=NC=C(C=C2)C#CC3=CC(=CC=C3)F,4.522878745280337,CC1(NC(=O)c2ccc(C#Cc3cccc(F)c3)cn2)COC1
43637,CHEMBL3087038,YMYLYYGGKKEUPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,4.568636235841013,Cc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
43643,CHEMBL1271763,YNBKEKSKMRNJDI-QUCCMNQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,5.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC1)[C@@H]2COC[C@@H](N2S(=O)(=O)C3=CC=C(C=C3)Cl)COC(=O)N4CCC(CC4)CO,8.259637310505756,CC1([C@@H]2COC[C@H](COC(=O)N3CCC(CO)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1
43654,CHEMBL1705230,YNDMAMUBWKKHPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21966889.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,PUBLICATION,,C1CCC2(CC1)CC(=O)N(C2=O)C3=C(C=C(C=C3)NC(=O)C4=CC=CC=N4)Cl,4.522878745280337,O=C(Nc1ccc(N2C(=O)CC3(CCCCC3)C2=O)c(Cl)c1)c1ccccn1
43663,CHEMBL1834184,YNFDIGJKJPNFFD-SJORKVTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21873051.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC(=O)N[C@H]1CC[C@H](C1)C(=O)N(C)C2=CC=C(C=C2)C3=NC4=CC=CC=C4O3,5.0,CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1
43665,CHEMBL2163834,YNGDZADJXARDMA-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C(=O)[C@H](CC2=CC=C(C=C2)Br)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,6.318758762624412,CN1CCN(C(=O)[C@H](Cc2ccc(Br)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
43672,CHEMBL3234572,YNLLKLRKSASFQV-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,<,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,C1C[C@H](CN(C1)C2=NC(=NC(=C2)N3CCNCC3)C(F)(F)F)C(=O)NCCC4=CN=C(C=C4)C#N,6.522878745280337,N#Cc1ccc(CCNC(=O)[C@@H]2CCCN(c3cc(N4CCNCC4)nc(C(F)(F)F)n3)C2)cn1
43690,CHEMBL396884,YNRLVFCAEWMMDT-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCO,4.455931955649724,CC(C)C[C@H](NCCO)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
43696,CHEMBL1796298,YNSKBMXZDCLQIV-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21669521.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selective non zinc binding inhibitors of MMP13.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@@](C2)(C#CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)NCC5=NC=NC=C5)O,5.0,O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1
43697,CHEMBL1796298,YNSKBMXZDCLQIV-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21669521.0,IC50,>,50118.72,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Selective non zinc binding inhibitors of MMP13.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@@](C2)(C#CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)NCC5=NC=NC=C5)O,4.300000029139089,O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1
43698,CHEMBL1796298,YNSKBMXZDCLQIV-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153941.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN2CCC1[C@@](C2)(C#CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)NCC5=NC=NC=C5)O,5.0,O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1
43699,CHEMBL443928,YNSVZSPFLAGJJY-MHZHKKNFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19441819.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.",J. Med. Chem.,PUBLICATION,,CCOC(=O)[C@H](CC1=CC=C(C=C1)NC(=O)C2=C(C=NC=C2Cl)Cl)NC(=O)[C@@H]3C[C@H](CN3S(=O)(=O)C4=CC=CC(=C4)C#N)NC5CCC5,5.769551078621726,CCOC(=O)[C@H](Cc1ccc(NC(=O)c2c(Cl)cncc2Cl)cc1)NC(=O)[C@@H]1C[C@@H](NC2CCC2)CN1S(=O)(=O)c1cccc(C#N)c1
43735,CHEMBL1668238,YOGIUKKDKOWWHX-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)[C@@H](C(=O)NC2CCCCC2)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,5.119186407719209,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21
43756,CHEMBL1222940,YOMZERRKMCWALK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CC5=CC(=CC=C5)Cl)CC6=CC=NC=C6,6.522878745280337,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3cccc(Cl)c3)c3ccccc32)CC1
43760,CHEMBL400404,YONIHIOBDIZSOE-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17239589.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and preliminary evaluation of 5-(4-phenylbenzyl)oxazole-4-carboxamides as prostacyclin receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)CC3=C(N=CO3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O,4.698970004336019,CC(=O)Nc1cccc(-c2ccc(Cc3ocnc3C(=O)N[C@@H](Cc3ccccc3)C(=O)O)cc2)c1
43766,CHEMBL2442750,YOPFAMROKXHVCQ-UHFFFAOYSA-N,QAV680,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24021582.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.",Bioorg. Med. Chem.,PUBLICATION,,CC1=C(C2=C(N1CC3=CC=C(C=C3)S(=O)(=O)C)N=CC=C2)CC(=O)O,4.0,Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1
43775,CHEMBL2407936,YOTOLLDMPKUKJI-ZNTNEXAZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)C1=CC=C(C=C1)C(C/C(=N\O)/C2=CC=NC=C2)C3=CC=CC=C3,6.698970004336019,CN(C)c1ccc(C(C/C(=N\O)c2ccncc2)c2ccccc2)cc1
43776,CHEMBL2387506,YOUUXSOSPBCMRE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,CC1=CC=C(C=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F,4.522878745280337,Cc1ccc(-c2ccc3c(c2)[nH]c(=O)c2[nH]c(-c4c(F)cccc4Cl)nc23)cc1
43777,CHEMBL3318957,YOVGCKBDPOHLAV-CNIHBODFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25050166.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CCOC[C@@H](CC(C)C)NC(=O)[C@@H]1CNC[C@@H]([C@@H]1O)C(=O)N(C2CC2)C3=NC=C(C=C3)C(C)C,4.522878745280337,CCOC[C@@H](CC(C)C)NC(=O)[C@@H]1CNC[C@H](C(=O)N(c2ccc(C(C)C)cn2)C2CC2)[C@@H]1O
43778,CHEMBL1909985,YOVGURDWRKRWGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,5.853871964321762,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2=O
43779,CHEMBL1909985,YOVGURDWRKRWGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,5.552841968657781,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2=O
43788,CHEMBL362702,YOYYBAFJQXCJDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,CC(=O)C1=CC=C(S1)C2=CN=CC=C2,4.568636235841013,CC(=O)c1ccc(-c2cccnc2)s1
43789,CHEMBL362702,YOYYBAFJQXCJDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,26900.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,CC(=O)C1=CC=C(S1)C2=CN=CC=C2,4.570247719997592,CC(=O)c1ccc(-c2cccnc2)s1
43790,CHEMBL1170878,YOZKWQSSNGTVAW-JMAPEOGHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,=,24900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCN1C(=O)[C@@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)CC5CCCCC5.Cl,4.603800652904264,CCCCN1C(=O)[C@H](CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
43793,CHEMBL498840,YPDJKJWWTFDCSB-UNMCSNQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)N[C@@H]3[C@H](CC4=CC=CC=C34)O)N5C=CC=CC5=O)C,4.207608310501746,Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3ccccc3=O)cn2c1C
43794,CHEMBL498840,YPDJKJWWTFDCSB-UNMCSNQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C=C(C2=N1)N[C@@H]3[C@H](CC4=CC=CC=C34)O)N5C=CC=CC5=O)C,4.0,Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3ccccc3=O)cn2c1C
43797,CHEMBL60889,YPELFRMCRYSPKZ-UHFFFAOYSA-N,MOSAPRIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,700.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N,6.154901959985743,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1
43827,CHEMBL605325,YPQGHFUUPYKNGV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045645.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCC1=C(OC(=N1)C2=CC=CC=C2)C(=O)NC(C)CN3CCN(CC3)C4=NC=CC=N4,5.0,CCCc1nc(-c2ccccc2)oc1C(=O)NC(C)CN1CCN(c2ncccn2)CC1
43831,CHEMBL1935114,YPQYVVMLRSSTFW-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22142542.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"4,5-dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C(C3)(C)C,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)C(C)(C)C2)cc1
43842,CHEMBL567376,YPYOVOMTRUTQLX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=CC=C3N,5.721246399047171,CC1(CC(=O)NCc2ccccc2N)CC2(CCCCC2)OO1
43846,CHEMBL456279,YPZFFAQSKANNPU-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)[C@H](CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CNCCC(=O)O)N,4.508638306165727,N[C@@H](Cn1c(=O)c(-c2ccc(CNCCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
43854,CHEMBL1684059,YQDMPWIZQSYQGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21310612.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C1(CCCCC1)C2=CC3=CC=CC=C3C=C2)N(C)C.Cl,5.301029995663981,CC(N(C)C)C1(c2ccc3ccccc3c2)CCCCC1
43888,CHEMBL403080,YQRYFSQPEXVGIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18417343.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C=N1)CN(C)C)OC2=C(C=C(C=C2)Cl)OC,5.0,COc1cc(Cl)ccc1Oc1cc(C)ncc1CN(C)C
43911,CHEMBL358880,YQZHYXJLJOBTSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,116.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,CCCCOC1=CC=C(C=C1)N2C=NC=C2C,6.935542010773082,CCCCOc1ccc(-n2cncc2C)cc1
43912,CHEMBL3092423,YQZRXRDKNNOEBQ-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,C1[C@@H](OC(=O)N1C2=CC(=C(C=C2)C3=CC4=NC=NN4C=C3)F)CN5C=CN=N5,4.698970004336019,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccn3ncnc3c2)c(F)c1
43932,CHEMBL2017100,YRFOMLDHCYGMMU-KOSHJBKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CNC[C@@H]([C@]1(C2=CC(=C(C=C2)F)F)O)C3=C(C(=NO3)C4=CC=CC5=CC=CC=C54)Br,4.301029995663981,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2cccc3ccccc23)c1Br
43942,CHEMBL3702720,YRIWHMGNXZETGH-ZYBCLOSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6020.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3CCN(CC3)C(=O)C4=CN(C5=C(C=CC=C45)CN6C[C@H]7N([C@H](C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,5.220403508742176,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)c6ccc(N7CCN(C)CC7)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
43954,CHEMBL251672,YROXDMYKXGMKSM-MVKHKFTQSA-N,EPI-12-PALMATOSIDE G,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,C[C@@]12C[C@@H](OC(=O)[C@@H]1CC[C@@]3([C@H]2CC=CC3=O)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=COC=C5,4.0,C[C@@]12C[C@H](c3ccoc3)OC(=O)[C@@H]1CC[C@@]1(CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(=O)C=CC[C@@H]21
43973,CHEMBL182438,YRZCYALYRQWTET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,397.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)NC)N4C=CN=C4)N(C)C,6.401209493236885,CNC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1
43974,CHEMBL2041168,YRZWSLXIHSDILJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CC=NN7,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5ccn[nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
43989,CHEMBL398811,YSDAMWLCNDERLC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CC(=O)NCC)(C)C4=CC(=CC(=C4)F)F,4.522878745280337,CCNC(=O)CN1C(=O)C(C)(c2cc(F)cc(F)c2)Oc2ccc(-c3c(N)nc(N)nc3CC)cc21
43998,CHEMBL452101,YSEMBYWAAKOCKW-JOBJLJCHSA-N,"2,5-BIS(4-HYDROXYBENZYLIDENE)CYCLOPENTANONE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,C1/C(=C\C2=CC=C(C=C2)O)/C(=O)/C(=C/C3=CC=C(C=C3)O)/C1,5.292429823902063,O=C1/C(=C/c2ccc(O)cc2)CC/C1=C\c1ccc(O)cc1
43999,CHEMBL452101,YSEMBYWAAKOCKW-JOBJLJCHSA-N,"2,5-BIS(4-HYDROXYBENZYLIDENE)CYCLOPENTANONE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,5105050.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,C1/C(=C\C2=CC=C(C=C2)O)/C(=O)/C(=C/C3=CC=C(C=C3)O)/C1,2.291999999979078,O=C1/C(=C/c2ccc(O)cc2)CC/C1=C\c1ccc(O)cc1
44015,CHEMBL1277770,YSGLQQUCJIOYSX-TUXUZCGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,C1C[C@@]2(CC1N3CCC(CC3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,5.0,O=C(O)C1CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CC1
44016,CHEMBL3702750,YSGWJWDNJCCXOX-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCN7CCOCC7,5.958607314841775,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
44025,CHEMBL3702734,YSOJTTZJKQKHPW-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3840.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCOC,5.4156687756324695,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCOC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
44048,CHEMBL1951595,YSWYESAJMAXMOW-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C2=C(C(=O)N(C1=O)CC(=O)C3=CC(=CC=C3)OC)N(C(=C2C#N)N4CCC[C@@H](C4)N)CC5=CC=CC=C5,5.522878745280337,COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCC[C@H](N)C4)n3Cc3ccccc3)n(C)c2=O)c1
44056,CHEMBL3664680,YSYKNPFUILIGKX-UGDMGKLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)CC3CC3)N4CC[C@](OC4=O)(CC(C)(C)O)C5=CC=CC=C5,5.0,C[C@@H](c1ccc(-c2ccc(=O)n(CC3CC3)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O
44058,CHEMBL1615186,YSYXAGMNRKARQB-HJPURHCSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21300546.0,IC50,>,10.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C[C@@](C)(CS(=O)(=O)N1CCC(CC1)OCC2=C(C=C(C=C2)Cl)Cl)N(C=O)O)C3=NC=C(C=N3)F,8.0,C[C@@H](C[C@@](C)(CS(=O)(=O)N1CCC(OCc2ccc(Cl)cc2Cl)CC1)N(O)C=O)c1ncc(F)cn1
44071,CHEMBL1078565,YTDWKPSJWUXUKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCCC(=O)O)C3=CC=CC=C3,5.0,O=C(O)CCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
44081,CHEMBL254497,YTHVKXJUOMIOFP-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,980.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1C(F)(F)F)C(=O)NCC2=NC3=C(N2CC4=CC=CC=C4)N=CC=C3,6.008773924307505,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1Cc1ccccc1
44089,CHEMBL3622445,YTLROJLEAFXNIK-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288685.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CC1=NN=C2N1C3=C(CC2)C=C(C=C3)C4=CC(=CN=C4)[C@@](C)(C(F)(F)F)O,4.301029995663981,Cc1nnc2n1-c1ccc(-c3cncc([C@](C)(O)C(F)(F)F)c3)cc1CC2
44096,CHEMBL1269682,YTMFZHXRZWNDFQ-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCNC(=O)C)Cl)C5CC5)Cl,5.619788758288394,CC(=O)NCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
44097,CHEMBL1269682,YTMFZHXRZWNDFQ-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCNC(=O)C)Cl)C5CC5)Cl,5.221848749616356,CC(=O)NCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
44110,CHEMBL429642,YTQRMQYHTODFGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCC#N)(C)C4=CC(=CC(=C4)F)F,4.522878745280337,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCC#N)C(=O)C(C)(c1cc(F)cc(F)c1)O2
44119,CHEMBL271087,YTYBFVQRVOHAAA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCC(C)(C)N)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,4.3979400086720375,CC(C)c1c(-c2nnc(NCC(C)(C)N)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
44127,CHEMBL3092197,YUAUQYXSYMIINF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(C1CCN(CC1)C(=O)C2=C(C=C(C=C2)S(=O)(=O)C)OC(F)(F)F)S(=O)(=O)C3=CC=CC(=C3)C(F)(F)F,5.0,CC(C)(C1CCN(C(=O)c2ccc(S(C)(=O)=O)cc2OC(F)(F)F)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1
44131,CHEMBL1923112,YUCWSJHYTURXJL-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1N(CC2=CC=CC=C2Cl)C(=O)[C@H]3CNCC[C@]34C5=CC(=C(C=C5CO4)F)F,5.301029995663981,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccccc1Cl)C1CC1
44151,CHEMBL3358962,YUMJYMLVVGYABE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,74000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=C(C=C1F)F)C(CN2C=NN=N2)(C(C3=NC=C(C=C3)Cl)(F)F)O,4.130768280269024,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(Cl)cn1
44156,CHEMBL3407822,YUNJDRCKQFFCDE-KQKCUOLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25489882.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,"Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.",J. Med. Chem.,PUBLICATION,,C1[C@H]([C@@H]1NCCC2=NC(=NC=C2)N3C=CN=C3)CC4=CC(=CC=C4)F.Cl,6.522878745280337,Fc1cccc(C[C@@H]2C[C@H]2NCCc2ccnc(-n3ccnc3)n2)c1
44166,CHEMBL2021577,YUSAYELUMYRKMP-CIUDSAMLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,CCOC[C@H]1[C@H]2[C@@]1(CNC2)C,5.045757490560675,CCOC[C@H]1[C@@H]2CNC[C@@]21C
44168,CHEMBL3672584,YUTMPZJGRVRLLE-USIGKAAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC3=C(C[C@H]2C(=O)N[C@H](CC[C@H](CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5)CC6=CC=CC=C6)N=CN3,6.721246399047171,CC(C)c1nc(CN(C)C(=O)N2Cc3[nH]cnc3C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
44169,CHEMBL3672584,YUTMPZJGRVRLLE-USIGKAAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,370.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC3=C(C[C@H]2C(=O)N[C@H](CC[C@H](CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5)CC6=CC=CC=C6)N=CN3,6.431798275933005,CC(C)c1nc(CN(C)C(=O)N2Cc3[nH]cnc3C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
44184,CHEMBL496227,YUXJYSUSUASGKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC(=N4)CO,4.886056647693163,Cc1cccc(C)c1CNc1cc(-n2cnc(CO)n2)cn2c(C)c(C)nc12
44185,CHEMBL496227,YUXJYSUSUASGKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC(=N4)CO,4.823908740944319,Cc1cccc(C)c1CNc1cc(-n2cnc(CO)n2)cn2c(C)c(C)nc12
44202,CHEMBL1092662,YVEWHDHDFNFTCD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NN=CC=C3,5.0,CN(C)CCC1=C(Cc2cccnn2)c2ccc(F)cc2C1
44203,CHEMBL1092662,YVEWHDHDFNFTCD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20800486.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NN=CC=C3,5.0,CN(C)CCC1=C(Cc2cccnn2)c2ccc(F)cc2C1
44206,CHEMBL1835786,YVEZLENKSRCDCK-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NN(C(=O)C4=C3CCCC4)C,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(-c2nn(C)c(=O)c3c2CCCC3)cc1
44213,CHEMBL1289396,YVHQUIYMYRZMIX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20952195.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCC2=C(C1)N(C3=C2C=CC(=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5)C,4.619788758288394,CN1CCc2c(n(C)c3cc(-n4ccc(OCc5ccccc5)cc4=O)ccc23)C1
44218,CHEMBL2316378,YVITVABZYDPMHU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,=,360.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,COC1=NC(=C(C=C1)NC(=O)C2=CC=C(C3=CC=CC=C32)CN4C=CN=N4)C(=O)NCC5CCOCC5,6.443697499232713,COc1ccc(NC(=O)c2ccc(Cn3ccnn3)c3ccccc23)c(C(=O)NCC2CCOCC2)n1
44220,CHEMBL2070156,YVJHUNTXORFZSN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CN=CC(=C3)C4=CC=CC=C4,5.107905397309519,CCS(=O)(=O)c1ccc2nc(-c3cncc(-c4ccccc4)c3)[nH]c2c1
44223,CHEMBL2436981,YVKIJUOXNIWLHR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,C1=CC2=C(C=CN2)C=C1C3=CNC4=C3C=C(C=N4)C5=CN=C(C=C5)N,5.376750709602099,Nc1ccc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1
44227,CHEMBL2380642,YVNBAAQRRIKOJV-DCEOMTHXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11ß-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CS(=O)(=O)N1CCN(CC1)C2=CN=C(C=C2)N3CCN(C4=CC=CC=C43)C(=O)NC5C6CC7CC5CC(C7)(C6)O,4.522878745280337,CS(=O)(=O)N1CCN(c2ccc(N3CCN(C(=O)NC4C5CC6CC4CC(O)(C6)C5)c4ccccc43)nc2)CC1
44235,CHEMBL2018571,YVPVVMYVUCYNPA-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,C1[C@H](CN([C@@H]1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CN4C=CN=N4)CC5=CC=C(C=C5)F,4.698970004336019,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1ccnn1
44241,CHEMBL2347993,YVQSMIMOPKDASQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1)C(=NN2CCCN(C)C)C3=CN=C4C(=N3)C(=CN4)C(=O)NC(C)(C)CO,4.301029995663981,Cc1ccc2c(-c3cnc4[nH]cc(C(=O)NC(C)(C)CO)c4n3)nn(CCCN(C)C)c2c1
44243,CHEMBL2158294,YVQZJJDQRBMAQM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,CN1C=C(N=C1)CC(=O)N2CCC(CC2)C3=CC(=C(C=C3)NC(=O)C4=NC=C(N4)C#N)C5=CCCCC5,5.638272163982407,Cn1cnc(CC(=O)N2CCC(c3ccc(NC(=O)c4ncc(C#N)[nH]4)c(C4=CCCCC4)c3)CC2)c1
44248,CHEMBL3137480,YVSDMZMKZZKBMX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CN=C3)C4=CN=C(C=C4)C(F)(F)F,5.045757490560675,FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1
44249,CHEMBL2180905,YVSHQGAIDXNKCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23098566.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aminopiperidine Sulfonamide Ca(v)2.2 Channel Inhibitors for the Treatment of Chronic Pain.,J. Med. Chem.,PUBLICATION,,CS(=O)(=O)C1=C(C=C(C=C1)F)C(=O)N2CCC(CC2)N(C3CC3)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F,5.292429823902063,CS(=O)(=O)c1ccc(F)cc1C(=O)N1CCC(N(C2CC2)S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1
44255,CHEMBL1423,YVUQSNJEYSNKRX-UHFFFAOYSA-N,PIMOZIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,9700.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,5.013228265733755,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
44257,CHEMBL1423,YVUQSNJEYSNKRX-UHFFFAOYSA-N,PIMOZIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,4.522878745280337,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
44266,CHEMBL1829477,YVXDOSIKSIZMGR-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21782432.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=C(C=C(C=C2)C3=NN(C(=O)C=C3)C)F,4.522878745280337,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)n2)cc1F
44268,CHEMBL1079291,YVZSCJHEMPRIEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCCO)C3=CC=CC=C3,5.0,O=C(Nc1ccc(Cl)cc1)N1CCCC(CCCO)(c2ccccc2)C1
44288,CHEMBL281284,YWGVRSZHUVTQKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,1530.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)C3=C(N2)C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,5.815308569182402,COc1ccc2c(c1)[nH]c1c(N3CCN(CCc4ccc(F)c(F)c4)CC3)ncnc12
44291,CHEMBL381751,YWJCZGDVJQLZET-GGHFOJMISA-N,MDL-73811,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19289530.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,PUBLICATION,,CN(C/C=C\CN)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O,5.301029995663981,CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O
44305,CHEMBL427844,YWMJHCFRFHOSCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17098427.0,IC50,>=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists: Structure-activity relationships of 4- and 5-substituted benzoic acid derivatives.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(N1C2=CC(=CC(=C2)NC(=O)C)C(=O)O)C3=C(C=CC(=C3)Br)OCC4=C(C=C(C=C4)F)F,4.7447274948966935,CC(=O)Nc1cc(C(=O)O)cc(-n2c(C)ccc2-c2cc(Br)ccc2OCc2ccc(F)cc2F)c1
44313,CHEMBL1078628,YWSWCOZFNGPLJG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)C(=O)CCC1(CCCN(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3,5.0,CCN(CC)C(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
44328,CHEMBL103320,YXBJKUHHCYVRFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(C=C1)N=CNO,4.0,Cc1ccc(N=CNO)cc1
44332,CHEMBL1949937,YXCQTGMZPHHUAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CC=C4)O)OC,6.698970004336019,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cccnc3)c2c1
44333,CHEMBL1949937,YXCQTGMZPHHUAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CC=C4)O)OC,5.568636235841013,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cccnc3)c2c1
44334,CHEMBL1241825,YXCVIEZEXGTOJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C#N,5.3979400086720375,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C#N)ncn4-5)CC3)cccc2n1
44338,CHEMBL1243367,YXEZVHWJNRFKSI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20690643.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,C1=CC(=CC=C1C(F)(F)F)SCC(C2=CC=NC=C2)C3=CN=CN3,6.455931955649724,FC(F)(F)c1ccc(SCC(c2ccncc2)c2cnc[nH]2)cc1
44339,CHEMBL2178953,YXFNPRHZMOGREC-SHTZXODSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23116186.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and Optimization of Pyrazinecarboxamide-Based Inhibitors of Diacylglycerol Acyltransferase 1 (DGAT1) Leading to a Clinical Candidate Dimethylpyrazinecarboxamide Phenylcyclohexylacetic Acid (AZD7687).,J. Med. Chem.,PUBLICATION,,CC1=C(N=C(C(=N1)C)C(=O)N)C2=CC=C(C=C2)C3CCC(CC3)CC(=O)O,4.522878745280337,Cc1nc(C)c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nc1C(N)=O
44347,CHEMBL600002,YXKHZYNSINIHQT-FZNWDQQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCC(C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=C(N=N2)[C@](C)(C(C)C)NCC3=CC4=C(C=C3)N=CC=C4,5.42021640338319,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncccc3c2)C(C)C)nn1
44359,CHEMBL236940,YXPCHDOWVWAKKP-AZGAKELHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,49000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N,4.309803919971486,CC(C)C[C@H](N)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
44376,CHEMBL3326224,YXTDUJJMGWZGOC-FBGQUBCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25147602.0,IC50,>=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=CC=CC=C4N3)C5=CC=CC=C5.Cl,5.301029995663981,CN(C)C1(c2ccccc2)CCC2(CC1)OCCc1c2[nH]c2ccccc12
44377,CHEMBL271512,YXVBGKJDCKGSED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCNC)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,4.3979400086720375,CNCCCNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1
44383,CHEMBL325429,YXXLYPOJAQBHAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCOC1=CC=C(C=C1)N2C=CN=C2,4.0,CN(C)CCOc1ccc(-n2ccnc2)cc1
44390,CHEMBL2397193,YYBIDABQEDHOBB-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=NC(=NC=C3)C(C)C,5.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)C)n1
44395,CHEMBL3702814,YYESOUKOMYBOTJ-ITSSNUEISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7640.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCC2C1CN(C2)C3=NC=C(C=C3)NC(=O)C4=CN(C5=C(C=CC=C45)CN6C[C@H]7N([C@H](C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,5.11690664142431,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC7CCN(C)C7C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
44398,CHEMBL400345,YYFOFDHQVIODOQ-UHFFFAOYSA-O,COLUMBAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,=,30600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)OC)O)OC,4.51427857351842,COc1cc2c(cc1O)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2
44411,CHEMBL1093286,YYIOQINMOGBBMF-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20206513.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCCC2=CC=C(C=C2)C[C@@H](CN)C(=O)N(CC3=C(C=CC(=C3)CCCOC)Cl)C4CC4)Cl,6.886056647693163,COCCCc1ccc(Cl)c(CN(C(=O)[C@H](CN)Cc2ccc(CCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
44432,CHEMBL578968,YYQFCQMYJKFEBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCOC1=CC=CC=C1CNC(=O)CC2(CC3(CCCCC3)OO2)C,5.301029995663981,CCOc1ccccc1CNC(=O)CC1(C)CC2(CCCCC2)OO1
44446,CHEMBL1093623,YYRVJJWBIQUZNR-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(CC2=C1C=CC(=C2)OC)CCN(C)C)C3=NC=CS3,5.0,COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccs1
44447,CHEMBL2017109,YYTAVUDZQYYPJI-MJGOQNOKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)[C@H]3CNCC[C@@H]3C4=CC(=C(C=C4)F)F)Br,4.886056647693163,CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)c1Br
44450,CHEMBL3702719,YYVFUVDTBBIBHS-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)NC(=O)C8=CC=C(C=C8)N(C)C,4.6020599913279625,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)c6ccc(N(C)C)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
44454,CHEMBL205304,YYYKGWKTHWSOEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,CCNC(=O)C1CCN(CC1)CC2=CC(=CC=C2)OC3=CC=CC=C3,5.0,CCNC(=O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1
44456,CHEMBL3331469,YYZODXXLBSUZSX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,1330.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,C1C(CN1)N(CC2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4.Cl,5.876148359032914,c1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1
44487,CHEMBL421841,YZMDGUHXAPIFCJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C(C=CN=C41)C,5.795880017344075,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)ccnc21
44488,CHEMBL421841,YZMDGUHXAPIFCJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C(C=CN=C41)C,5.0,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)ccnc21
44508,CHEMBL551921,YZQWPJWDFKAQSN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,C1CN(CCC1C2=NC(=NO2)C3=NC4=CC=CC=C4C=C3)C(=O)NC5CC5C6=CC=CC=C6,5.0,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
44517,CHEMBL154751,YZXYDKIBYWKPNU-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698201.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)C[C@H](COC3=CC4=C(C=C3)SC(=N4)C)O,4.638272163982407,Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4c(C)cccc4C)CC3)ccc2s1
44527,CHEMBL486179,ZAALQOFZFANFTF-UHFFFAOYSA-N,PROTOPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16562853.0,IC50,>,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,CN1CCC2=CC3=C(C=C2C(=O)CC4=CC5=C(C=C4C1)OCO5)OCO3,4.096910013008056,CN1CCc2cc3c(cc2C(=O)Cc2cc4c(cc2C1)OCO4)OCO3
44528,CHEMBL248879,ZAAVDSHTZRRHIN-MZYLBHOOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,24300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@@H]1C[C@@H](C[C@@H](N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCC(CC3)N4CCCCC4)O,4.614393726401688,CC[C@@H]1C[C@H](O)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
44529,CHEMBL3664660,ZABDLBFFXBIVLQ-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,CCN1C=C(C=CC1=O)C2=CC=C(C=C2)[C@H](C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O
44539,CHEMBL527199,ZAFTWOVROZMXTK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(CC(=O)N(C)C(CN1CCCC1)C2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl,5.481486060122113,CN(CC(=O)N(C)C(CN1CCCC1)c1ccccc1)c1ccc(Cl)c(Cl)c1
44551,CHEMBL1951450,ZAHXGOCQYQTQGH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,360.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC(=CC=C1C2=CC=NC=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,6.443697499232713,O=C(Nc1ccc(-c2ccncc2)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
44564,CHEMBL1078891,ZAKBVBOEYCRZJE-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCF,6.096910013008056,Cc1cc(N2CCN(CCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
44565,CHEMBL1078891,ZAKBVBOEYCRZJE-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCF,5.657577319177793,Cc1cc(N2CCN(CCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
44567,CHEMBL3403818,ZAKFKUPJKWHOLD-VJVWWPDYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)C9COC9)C)C)O)C)C(C)(C)O,5.795880017344075,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
44568,CHEMBL3403818,ZAKFKUPJKWHOLD-VJVWWPDYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]([C@H]1C[C@H]([C@H]2[C@H](O1)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7CN(CCO7)C8CN(C8)C9COC9)C)C)O)C)C(C)(C)O,4.920818753952375,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O
44578,CHEMBL1829762,ZASJMILIAPSNCZ-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,CC[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CC[C@](OC3=O)(CCCO)C4=CC=CC=C4,5.823908740944319,CC[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O
44580,CHEMBL3114725,ZATFGROOAKZLGK-RDGATRHJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,630.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CCNNC(=O)OCC2=CN=CS2)CC3=CC=CC=C3,6.200659450546418,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCNNC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
44584,CHEMBL2425601,ZAUGVKYIEPVOOO-CGBBJANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ß-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(CO)C1=CC=CC(=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F,6.0,COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)CO)c3)[C@H]2O)cc(F)c1N)C(F)(F)F
44594,CHEMBL377531,ZBADYPWHOVIUSC-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,12.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCCN1CCCC2=C1C=C(C=C2)OC[C@H]3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,7.920818753952375,COCCCN1CCCc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21
44604,CHEMBL1484,ZBBHBTPTTSWHBA-UHFFFAOYSA-N,NICARDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,420.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,6.376750709602099,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1
44605,CHEMBL1484,ZBBHBTPTTSWHBA-UHFFFAOYSA-N,NICARDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,4.522878745280337,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1
44606,CHEMBL1484,ZBBHBTPTTSWHBA-UHFFFAOYSA-N,NICARDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,380.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,6.42021640338319,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1
44612,CHEMBL1173326,ZBBONVVBPSZXJW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,1330.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,CC(=C(C1=CC=C(C=C1)C2=CC(=CC=C2)N)C3=CC=NC=C3)C,5.876148359032914,CC(C)=C(c1ccncc1)c1ccc(-c2cccc(N)c2)cc1
44616,CHEMBL2018919,ZBCSNQSIGXWJKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,4860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=C(C=C3)Cl,5.313363730737707,COc1ccc2nc(SCc3ccc(Cl)cc3)[nH]c2c1
44653,CHEMBL3669003,ZBJOFNRBXVLOMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320645,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=NC(=CC=C4)N5CCOCC5)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCOCC5)n4)nc3)c2c1
44654,CHEMBL3669003,ZBJOFNRBXVLOMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320689,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=NC(=CC=C4)N5CCOCC5)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCOCC5)n4)nc3)c2c1
44695,CHEMBL3264605,ZBRAJOQFSNYJMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC(F)F)OC(F)F)(C3=NNN=C3)O,4.638272163982407,CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cn[nH]n1
44696,CHEMBL3264605,ZBRAJOQFSNYJMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23000.0,NM,233066,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4. ",Metalloenzyme inhibitor compounds,,PATENT,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC(F)F)OC(F)F)(C3=NNN=C3)O,4.638272163982407,CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cn[nH]n1
44703,CHEMBL2387591,ZBUKSUSOANBWHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=C(C=C4)Br)Cl,4.522878745280337,O=c1[nH]c2ccc(Br)cc2c2nc(-c3ccccc3Cl)[nH]c12
44705,CHEMBL2347184,ZBUUPRZMJYAPQF-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23586711.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.,J. Med. Chem.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CO3)CC4=CC=CC=C4,5.468521082957745,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnco2)Cc2ccccc2)C(C)C)cs1
44713,CHEMBL1667948,ZBWFGEZHUGGSNJ-YHBQERECSA-N,OSI-971,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21251824.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC(CCC1C2=NC(=C3N2C=CN=C3N)C4=C(C5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)F)C(=O)NC7=NC8=CC=CC=C8N7,4.698970004336019,Nc1nccn2c(C3CCC(C(=O)Nc4nc5ccccc5[nH]4)CC3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3F)c12
44715,CHEMBL514681,ZBWMUFAKPSHRGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C=C1)CCC(=O)NCC(=O)NC(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,4.301029995663981,O=C(CCc1ccccc1)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1
44723,CHEMBL121550,ZBYUCNDWIVKTRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1=CC=C(C(=C1)C2=NC(C3=CN=CN3C4=C2C=C(C=C4)Cl)O)F,5.0,OC1N=C(c2ccccc2F)c2cc(Cl)ccc2-n2cncc21
44728,CHEMBL3264597,ZBZKIRAMMFHRIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,57000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=NNN=C3)O,4.2441251443275085,COc1cc2ccc(C(O)(c3cn[nH]n3)C(C)C)cc2cc1OC
44729,CHEMBL3264597,ZBZKIRAMMFHRIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,57000.0,NM,233064,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4. ",Metalloenzyme inhibitor compounds,,PATENT,,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=NNN=C3)O,4.2441251443275085,COc1cc2ccc(C(O)(c3cn[nH]n3)C(C)C)cc2cc1OC
44742,CHEMBL3217198,ZCBRBLDHBXTQSQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21699209.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,PUBLICATION,,C1CC2=C(C=CC(=C2)N=C(C3=CC=CS3)N)N(C1)C4CCNCC4.Cl.Cl,4.0,NC(=Nc1ccc2c(c1)CCCN2C1CCNCC1)c1cccs1
44750,CHEMBL1970317,ZCCJKVBTHCOISJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22465635.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 15 mins,Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)C2=CN=C(C3=C2SC=C3C4=CC=C(C=C4)NC(=O)NC5=CC(=CC=C5)F)N,5.568636235841013,Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1
44751,CHEMBL1970317,ZCCJKVBTHCOISJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22465635.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)C2=CN=C(C3=C2SC=C3C4=CC=C(C=C4)NC(=O)NC5=CC(=CC=C5)F)N,5.102372908709558,Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1
44757,CHEMBL410333,ZCDQMYGMUJCSPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18318469.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.",J. Med. Chem.,PUBLICATION,,C1C(=O)N(C(=O)C12C3=C(C=CC(=C3)Cl)N(C2=O)CC(=O)O)CC4=CC=CC=C4,5.0,O=C(O)CN1C(=O)C2(CC(=O)N(Cc3ccccc3)C2=O)c2cc(Cl)ccc21
44762,CHEMBL180348,ZCFKCDRXDKIAQV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)CC(=O)O)N4C=CN=C4)N(C)C,8.397940008672037,CC(C(c1ccc2cc(OCc3ccc(CC(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C
44765,CHEMBL2095208,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,COBICISTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.823908740944319,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
44766,CHEMBL3115180,ZCIGNRJZKPOIKD-KIGLDFBWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.823908740944319,CC(C)c1nc(CN(C)C(=O)N[C@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
44767,CHEMBL208443,ZCIYBFFBVPVYLH-FGZHOGPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC[C@H]([C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N(C)C,5.481486060122113,CC[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C
44776,CHEMBL564840,ZCNKPALYFZNAFQ-DBKRXAPLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19537798.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of testosterone 6-beta-hydroxylation,"Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate.",J. Med. Chem.,PUBLICATION,,C1C[C@@H]2C[C@H]1[C@@H](C23CC3)CN4CCC(CC4)N5C6=CC=CC=C6N(C5=O)C[C@H](CO)O.Cl,4.0,O=c1n(C[C@@H](O)CO)c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1
44778,CHEMBL1087367,ZCRCTVHOBQJBNB-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)[C@@H]1CCN(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC,5.301029995663981,COc1ccc(Cn2c(N3CC[C@@H](N(C)C)C3)nc3ccccc32)cc1
44788,CHEMBL14189,ZCUJYXPAKHMBAZ-UHFFFAOYSA-N,2-PHENYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC=C(C=C1)C2=NC=CN2,5.0,c1ccc(-c2ncc[nH]2)cc1
44789,CHEMBL14189,ZCUJYXPAKHMBAZ-UHFFFAOYSA-N,2-PHENYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C1=CC=C(C=C1)C2=NC=CN2,5.0,c1ccc(-c2ncc[nH]2)cc1
44790,CHEMBL14189,ZCUJYXPAKHMBAZ-UHFFFAOYSA-N,2-PHENYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,500000.0,NM,,,,binding,,,,,,,,,,,,,,,,C1=CC=C(C=C1)C2=NC=CN2,3.3010299956639813,c1ccc(-c2ncc[nH]2)cc1
44801,CHEMBL10663,ZCWOGLIPVLGIOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,4.7447274948966935,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2
44802,CHEMBL3582472,ZCWSKWSPXNSPLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26005536.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C1CC1N2C3=CC(=C(C=C3N=C2C4=CC(=CN=C4)F)F)F,4.301029995663981,Fc1cncc(-c2nc3cc(F)c(F)cc3n2C2CC2)c1
44819,CHEMBL3358940,ZDCRSQSGCDAAAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC(=CC=C4)S(=O)(=O)C,6.154901959985743,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(C)(=O)=O)c1
44820,CHEMBL1272153,ZDDBSJXDOTZFGP-IFMALSPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,11.3,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C[C@@H]2COC[C@@H](N2S(=O)(=O)C3=CC=C(C=C3)Cl)C4(CC4)OC(=O)N5CCC6(CCN6)CC5,7.94692155651658,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC2(CCN2)CC1
44830,CHEMBL1097079,ZDJZIVFLUPLDLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,1628.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC=C(C=C5)F)C)OC,5.788345599446817,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccc(F)cc1)cc(=O)n2C)c1cncn1C
44837,CHEMBL3357635,ZDRUKZASWZMRRR-GXHLCREISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25409491.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method,A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles.,J. Med. Chem.,PUBLICATION,,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C(=C/CN4CCCCC4)/F,5.0,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN1CCCCC1
44838,CHEMBL3358936,ZDRXNMVEXXVGIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC(=CC=C4)O,5.3979400086720375,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(O)c1
44845,CHEMBL1761535,ZDTOKBCZSLOGNR-AARKOHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCC5(CCCC5)C(=O)O)C6CC6)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC2(C(=O)O)CCCC2)c1
44846,CHEMBL1761535,ZDTOKBCZSLOGNR-AARKOHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCC5(CCCC5)C(=O)O)C6CC6)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC2(C(=O)O)CCCC2)c1
44857,CHEMBL3326583,ZDWYNWDEQXOWGK-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=C(C=C4F)F)(C)C)C=N1,4.698970004336019,Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4c(F)cc(F)cc43)cccc2cn1
44861,CHEMBL930,ZDXPYRJPNDTMRX-VKHMYHEASA-N,GLUTAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,C(CC(=O)N)[C@@H](C(=O)O)N,5.0,NC(=O)CC[C@H](N)C(=O)O
44862,CHEMBL930,ZDXPYRJPNDTMRX-VKHMYHEASA-N,GLUTAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,C(CC(=O)N)[C@@H](C(=O)O)N,5.0,NC(=O)CC[C@H](N)C(=O)O
44889,CHEMBL2018909,ZEGLOXZHHNZQFC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CC(C)CSC1=NC2=C(N1)C=C(C=C2)OC,4.301029995663981,COc1ccc2nc(SCC(C)C)[nH]c2c1
44891,CHEMBL3331507,ZEIUBTWYEVLKJP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,C1C(CN1)N(CC2=CC3=CC=CC=C3C=C2)C4=CC(=CC=C4)Cl,6.301029995663981,Clc1cccc(N(Cc2ccc3ccccc3c2)C2CNC2)c1
44911,CHEMBL2441208,ZENSLLXCLNJAMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated prior to substrate addition,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2=NC(=C(O2)C(=O)NC3=CN=C(C=C3)N4CCN(CC4)C(=O)NC5=CC=CC=C5Cl)C(F)(F)F,5.301029995663981,O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F
44912,CHEMBL2441208,ZENSLLXCLNJAMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2D6 (unknown origin) coincubated with substrate,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2=NC(=C(O2)C(=O)NC3=CN=C(C=C3)N4CCN(CC4)C(=O)NC5=CC=CC=C5Cl)C(F)(F)F,4.698970004336019,O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F
44913,CHEMBL2441208,ZENSLLXCLNJAMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) coincubated with substrate,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCN(CC1)C2=NC(=C(O2)C(=O)NC3=CN=C(C=C3)N4CCN(CC4)C(=O)NC5=CC=CC=C5Cl)C(F)(F)F,4.698970004336019,O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F
44924,CHEMBL14460,ZETBBVYSBABLHL-UHFFFAOYSA-N,SB-243213,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,10737744.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human cytochrome P450 3A4,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,PUBLICATION,,CC1=CC2=C(C=C1C(F)(F)F)N(CC2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C,4.0,Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2
44931,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,6.356547323513812,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
44932,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,6.356547323513812,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
44935,CHEMBL3237704,ZEWPRVBMQMQROZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,=,9500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,CC1(CCC(CC1)N2C3=C(C=CN=C3)C4=CN=C(N=C42)NC5=NC=C(C=C5)N6CCNCC6)C,5.022276394711152,CC1(C)CCC(n2c3cnccc3c3cnc(Nc4ccc(N5CCNCC5)cn4)nc32)CC1
44945,CHEMBL2437433,ZEYMAJZOUSDWDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)C5=NC=CN=C5)CC6=CC(=NC=C6)N,4.522878745280337,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5cnccn5)c5cc(F)ccc54)CC3)CC2)ccn1
44946,CHEMBL452864,ZEZPDHKACVMMCD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19053768.0,IC50,=,3860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.,J. Med. Chem.,PUBLICATION,,C1CCC(CC1)NC(=NC2CCCCC2)SCC3=CSC4=NCCN34,5.413412695328245,C1=C(CSC(=NC2CCCCC2)NC2CCCCC2)N2CCN=C2S1
44950,CHEMBL3407810,ZFCKGWSPRRORFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25489882.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,"Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.",J. Med. Chem.,PUBLICATION,,C1=CC(=CC(=C1)F)CCCNCCC2=NC(=NC=C2)N3C=CN=C3.Cl,5.6020599913279625,Fc1cccc(CCCNCCc2ccnc(-n3ccnc3)n2)c1
44958,CHEMBL584886,ZFHIOYANRKWHPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC4=C(CCO4)C=C3,5.585026652029182,CC1(CC(=O)NCc2ccc3c(c2)OCC3)CC2(CCCCC2)OO1
44959,CHEMBL3702815,ZFJGYPUDHCXOCY-WSQZCZOMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3910.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CCN1CCC2(C1)CCN(C2)C3=NC=C(C=C3)NC(=O)C4=CN(C5=C(C=CC=C45)CN6CC7N([C@H](C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,5.407823242604133,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCC7(CCN(CC)C7)C6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
44976,CHEMBL3702760,ZFNMWMGBWJLLBH-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,22290.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NN7CCOCC7,4.651889931519762,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
44978,CHEMBL1909994,ZFPIDBLQXYWDHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,390.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)CN,6.4089353929735005,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(Cl)cc1)C2=O
44992,CHEMBL190,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,THEOPHYLLINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5.0,Cn1c(=O)c2[nH]cnc2n(C)c1=O
44993,CHEMBL190,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,THEOPHYLLINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5.0,Cn1c(=O)c2[nH]cnc2n(C)c1=O
45001,CHEMBL498252,ZGALKRMWGKUOEJ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C3=C(C2=N1)N[C@@H](CC3)C4=CC=CC=C4)N5C=NC=N5)C,6.154901959985743,Cc1nc2c3c(c(-n4cncn4)cn2c1C)CC[C@@H](c1ccccc1)N3
45002,CHEMBL498252,ZGALKRMWGKUOEJ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(N2C=C(C3=C(C2=N1)N[C@@H](CC3)C4=CC=CC=C4)N5C=NC=N5)C,5.585026652029182,Cc1nc2c3c(c(-n4cncn4)cn2c1C)CC[C@@H](c1ccccc1)N3
45015,CHEMBL256937,ZGGCVDLJPIVYGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCN(CC(=O)N1CCCC(C1CN2CCCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,5.920818753952375,COCCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1
45042,CHEMBL3699324,ZGSOWIAWZLPMBJ-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8070.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC(=CC=C8)O,5.09312646527793,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(O)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
45053,CHEMBL3673941,ZGVRUEHWRJFEDB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320659,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CCS(=O)(=O)NC1=CC=CC=C1CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)C)F,5.301029995663981,CCS(=O)(=O)Nc1ccccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1
45062,CHEMBL3699329,ZGYCWFMKMMGTNI-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,19500.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC=C(C=C8)OC,4.709965388637482,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(OC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
45064,CHEMBL2057518,ZGYNRHPMXDOXFV-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,28.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCNC1=NC2=C(O1)C=C(C=C2)C(=O)N(C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)C,7.552841968657781,CCNc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
45067,CHEMBL179618,ZHBLIWDUZHFSJW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,57000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,C1=CC(=CN=C1)C2=CC=CS2,4.2441251443275085,c1cncc(-c2cccs2)c1
45070,CHEMBL3358944,ZHDQJPLHDTXEKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=CC=CC=C3S(=O)(=O)C,4.522878745280337,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O
45082,CHEMBL3706622,ZHHNHYJWRCZSIY-JJCSDTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852969.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C1=NC=C(O1)C2=C(C=CN=C2)Cl)N3CCN([C@@H](C3)C(=O)NCC(F)(F)F)C[C@H](C[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H]5[C@@H](COC6=CC=CC=C56)O)O,7.3979400086720375,CC(C)(c1ncc(-c2cnccc2Cl)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1
45084,CHEMBL597032,ZHIFBXYCMMXVQR-BCDXTJNWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)C(=O)N(CC2=CC(=CC=C2)OC(F)(F)F)C3C[C@@H]4CN(C[C@@H]4C3)CCC(F)(F)F,5.060480747381382,Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)C2C[C@@H]3CN(CCC(F)(F)F)C[C@@H]3C2)c1
45087,CHEMBL3298905,ZHKYFXNJJRCRFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,=,11540.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCN(CC4)C5=CC=C(C=C5)OC(F)(F)F,4.937794191180288,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)cc1
45089,CHEMBL3137448,ZHLMDGGVEXYXHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)CC4=CC=C(C=C4)C(F)(F)F,5.0,FC(F)(F)c1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
45101,CHEMBL1077933,ZHOHXFLPKBOXJU-FQLXRVMXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CCN(C[C@@H](CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)C[C@@H](CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,7.301029995663981,CC(C)CCN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1
45109,CHEMBL3115171,ZHRJGVGXVBKWCG-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](COC)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,6.823908740944319,COC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
45124,CHEMBL1222717,ZHXRHBJNZARCMY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,4.958607314841775,COCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
45125,CHEMBL604249,ZHYPMHNQQRIWRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,13500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by LCMS/MS assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,CC1=C(C=CC(=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NC3=CC=C(C=C3)CN(C)C)OC,4.869666231504994,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C
45139,CHEMBL252239,ZIBFWTNGDIVMTK-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,5.221848749616356,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
45141,CHEMBL3422246,ZIBHVERILBHVJF-AAJLLMFJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,CN1C=C(C=N1)[C@H]2C[C@H]3[C@H](SC(=N[C@]3(CO2)C4=C(C=C(C=C4)F)F)N)CF,4.522878745280337,Cn1cc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)cn1
45153,CHEMBL3318423,ZIIOGYPKQIDCAA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2C#N)C3=CC=CC=C3,5.301029995663981,N#Cc1ccccc1SC1=C(O)CC(c2ccccc2)CC1=O
45158,CHEMBL2413882,ZIJAFBZNFLICHW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23896611.0,IC50,=,1450.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 20 mins by LCMS analysis,"Tetrazole-based deoxyamodiaquines: Synthesis, ADME/PK profiling and pharmacological evaluation as potential antimalarial agents.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)(C)N1C(=NN=N1)C(C2=CC(=CC=C2)NC3=C4C=CC(=CC4=NC=C3)Cl)N5CCCC5,5.838631997765025,CC(C)(C)n1nnnc1C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)N1CCCC1
45169,CHEMBL1649685,ZIPGXLPLMWBESM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,CN1CCC2=C(C1)N(N=C2C(F)(F)F)C3=CC=C(C=C3)CN4CCCC4=O,5.0,CN1CCc2c(C(F)(F)F)nn(-c3ccc(CN4CCCC4=O)cc3)c2C1
45171,CHEMBL3114734,ZIPRFFCNESKMRB-PPTMTGTBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)CN(CC[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCN2CCOCC2)NC(=O)N(C)CC3=CSC(=N3)C(C)C)C(=O)OCC4=CN=CS4,6.455931955649724,CC(C)CN(CC[C@H](Cc1ccccc1)NC(=O)[C@H](CCN1CCOCC1)NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)OCc1cncs1
45177,CHEMBL258324,ZISAHLADKQRRPH-NTCNTBNZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18061443.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@H](C1=C(C=C(C=N1)C2=C(C(=CC(=C2)Cl)F)C3=NN(N=N3)C)F)NC(=O)[C@](C)(C(F)(F)F)O,5.0,C[C@@H](NC(=O)[C@@](C)(O)C(F)(F)F)c1ncc(-c2cc(Cl)cc(F)c2-c2nnn(C)n2)cc1F
45182,CHEMBL116438,ZIUSSTSXXLLKKK-KOBPDPAPSA-N,CURCUMIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,16300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,COC1=C(C=CC(=C1)/C=C/C(=C/C(=O)/C=C/C2=CC(=C(C=C2)O)OC)/O)O,4.787812395596042,COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O
45188,CHEMBL3127526,ZJADCXIYQQSUTG-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1COCCC1S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@@H]3C[C@H]3C4=CN=CC=C4,5.0,O=C(Nc1ccc(S(=O)(=O)C2CCOCC2)cc1)[C@@H]1C[C@H]1c1cccnc1
45189,CHEMBL3127526,ZJADCXIYQQSUTG-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,C1COCCC1S(=O)(=O)C2=CC=C(C=C2)NC(=O)[C@@H]3C[C@H]3C4=CN=CC=C4,5.0,O=C(Nc1ccc(S(=O)(=O)C2CCOCC2)cc1)[C@@H]1C[C@H]1c1cccnc1
45194,CHEMBL451331,ZJATUHGFXPEBQJ-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,2.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C,8.619788758288394,Cc1cc(N2CCC(N3CCN(C)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
45196,CHEMBL382574,ZJCPXNRESMOODE-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)(COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C(C)(C)N(C)C)N3C=CN=C3)C(=O)O,5.6777807052660805,CN(C)C(C)(C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
45197,CHEMBL1952142,ZJDHFPFSTLUYKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22266039.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by luminescent assay,"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC(=NC2=C1N=NN2C3=CC(=CC=C3)OC(F)(F)F)NCC4CCNCC4,5.346787486224656,COc1cc(NCC2CCNCC2)nc2c1nnn2-c1cccc(OC(F)(F)F)c1
45200,CHEMBL3310993,ZJDSMAHFPFFPMR-BJOHPYRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,32000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NN=N2)(C3=C(C=C(C=C3)F)F)O,4.494850021680094,C[C@@H](c1ncncc1F)[C@](O)(Cn1cnnn1)c1ccc(F)cc1F
45208,CHEMBL1073,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,GLIPIZIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,7447.32,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,5.127999984783137,Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1
45244,CHEMBL479072,ZJRBVCCQUXNYDM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,COC1=CC=C(C=C1)C(C2=CC=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,4.301029995663981,COc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)cc1
45270,CHEMBL1766183,ZKDHBAXMHDLJPU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)C(C)(C3=CN=CN3)O,5.0,CC(=O)Nc1cccc(-c2ccc(C(C)(O)c3cnc[nH]3)cc2)c1
45278,CHEMBL270654,ZKEREZNJKGRMFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=NN1C2=NC(=NC(=C2)NC(=O)CC3=CC=C(C=C3)S(=O)(=O)C)C4=CC=CC=N4)C,5.0,Cc1cc(C)n(-c2cc(NC(=O)Cc3ccc(S(C)(=O)=O)cc3)nc(-c3ccccn3)n2)n1
45290,CHEMBL483574,ZKNOJWWMOBXREH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,CC1=C(C(N=C(N1)C2=CN=C(C=C2)OC)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=CC5=C(C=C4)NN=C5,5.6020599913279625,COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cn1
45293,CHEMBL496262,ZKPQJJRSNGTTFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,13841.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,C1CC2=C(C=CC(=C2)C3=CC(=C(C=C3)F)F)C(C1)(C4=CC=NC=C4)O,4.858832531353768,OC1(c2ccncc2)CCCc2cc(-c3ccc(F)c(F)c3)ccc21
45301,CHEMBL2158291,ZKTXNDLMIQBAIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)C4=C[N+](=CC=C4)[O-])NC(=O)C5=NC=C(N5)C#N,5.721246399047171,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)c4ccc[n+]([O-])c4)CC3)cc2C2=CCCCC2)[nH]1
45308,CHEMBL3702729,ZKWHQYDCQFSQAF-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11800.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CC(C7)N8CCC(CC8)OC,4.928117992693875,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCC(OC)CC6)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
45309,CHEMBL1834660,ZKXNIXASIHIFMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CN(C)CCCC1=CC=C(C=C1)NC2=CC(=NC=N2)N(C)C(=O)NC3=C(C(=CC(=C3Cl)OC)OC)Cl,6.0,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(CCCN(C)C)cc3)ncn2)c1Cl
45310,CHEMBL1834660,ZKXNIXASIHIFMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,CN(C)CCCC1=CC=C(C=C1)NC2=CC(=NC=N2)N(C)C(=O)NC3=C(C(=CC(=C3Cl)OC)OC)Cl,5.0,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(CCCN(C)C)cc3)ncn2)c1Cl
45337,CHEMBL3702789,ZLGADOMKEUBDTC-DWQLLFNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,21060.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3CC4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCOCC8,4.676541633150532,C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCOCC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1
45371,CHEMBL2181088,ZLRQBYKTDVAMPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21604762.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.",J. Med. Chem.,PUBLICATION,,CC1=CN=C2NC3=CC(=C(C=C3)OCCN4CCCC4)COCC=CCOCC5=CC(=CC=C5)C1=N2,5.6020599913279625,Cc1cnc2nc1-c1cccc(c1)COCC=CCOCc1cc(ccc1OCCN1CCCC1)N2
45372,CHEMBL1224382,ZLRRLSAVNUFCQT-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20724153.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NN(N=N1)[C@@H](CCNC)C2=CC(=C(C=C2)Cl)Cl,5.0,CNCC[C@@H](c1ccc(Cl)c(Cl)c1)n1nnc(C)n1
45377,CHEMBL3604722,ZLSZDEARRQRWGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,7943.28,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,CC1=CC(=C2C=CC=C(C2=N1)C(=O)N)NCC3=C(C=CC=C3Cl)Cl,5.100000128334196,Cc1cc(NCc2c(Cl)cccc2Cl)c2cccc(C(N)=O)c2n1
45405,CHEMBL1688243,ZMCJFJZOSKEMOM-DNKZPPIMSA-N,INCB-9471,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,CCO[C@@H]1CC2=C([C@H]1N3CCN(C[C@@H]3C)C4(CCN(CC4)C(=O)C5=C(N=CN=C5C)C)C)C=CC(=C2)C(F)(F)F,4.6020599913279625,CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C
45412,CHEMBL3699081,ZMHFHDVAVPEGFF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11000.0,NM,273497,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",Metalloenzyme inhibitor compounds,,PATENT,,C1=CC(=C(C=C1F)F)C(CN2C=NN=C2)(C(C3=NC4=C(C=C3)C=C(C=C4)Br)(F)F)O,4.958607314841775,OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1ccc2cc(Br)ccc2n1
45413,CHEMBL3608687,ZMIOQWILBZBCHW-SECBINFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)Cl)C4=NC(=NS4)C,4.0,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(Cl)cc2)[C@@H]3C)n1
45415,CHEMBL1258873,ZMIWBFCFIBJHCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCN(C(=O)C4=C3)C,4.301029995663981,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(C)C2=O)CC1
45440,CHEMBL10600,ZMQFSABOKCOPMT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)SC,4.823908740944319,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(SC)c(=O)nc1SCc1ccc(F)cc1
45446,CHEMBL2017275,ZMSXXNUUWMPXGF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4CCN5CCOCC5)C(=O)N)OC,5.721246399047171,COc1cc2c(Nc3ccccc3CCN3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C
45459,CHEMBL1669417,ZMXXHEQIAQJFTR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CC1F)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,5.0,FC1CCN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
45467,CHEMBL3298835,ZNBAXIPHEFMSPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,=,2070.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,CCC1=C(N2C=CC(=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)F,5.684029654543083,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(F)cc3)CC2)cc1
45475,CHEMBL2436333,ZNEDXNJVZVHOKQ-GYUFFBBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=CC=C5F)NC.Cl,6.0655015487564325,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccccc2F)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
45477,CHEMBL3699320,ZNEQYXFNVWWCOJ-MVRBIKRMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7040.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1CCN(CC1)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C4=CN(C5=C(C=CC=C45)CN6C[C@H]7N([C@H](C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,5.152427340857888,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCN(C)CC7)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
45483,CHEMBL257670,ZNHZMFMDDLFSPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=C(O1)C2=NC(=CC(=N2)N3C(=CC(=N3)C)C)NC(=O)CC4=CC(=CC(=C4)OC)OC,5.301029995663981,COc1cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)cc(OC)c1
45488,CHEMBL593763,ZNILTQJFNAYPDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19810674.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor.",J. Med. Chem.,PUBLICATION,,CNCC1=CC(=O)OC2=C1C=CC(=C2)OCC3=CC(=CC=C3)Cl.CS(=O)(=O)O,5.301029995663981,CNCc1cc(=O)oc2cc(OCc3cccc(Cl)c3)ccc12
45501,CHEMBL429585,ZNNAAXZOLAOTRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,COC1=CC2=C(C=CN=C2C=C1OC)OC3=C(C4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=C(C=C5)Cl)F,4.301029995663981,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccc(Cl)cc5)cccc4c3F)c2cc1OC
45524,CHEMBL2029422,ZNSVOHSYDRPBGI-LXWOLXCRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@H]1NC2CCC(CC2)(C3=NC=C(C=C3)C4=NC=CC=N4)O)C(=O)CNC(=O)C5=CC(=CC=C5)C(F)(F)F,4.522878745280337,O=C(NCC(=O)N1CC[C@H](NC2CCC(O)(c3ccc(-c4ncccn4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1
45557,CHEMBL2316383,ZOHCTKDFWBPLPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,>,20000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,CS(=O)CC1=CC=C(C2=CC=CC=C12)C(=O)NC3=C(N=CC=C3)C(=O)NCC4CCOCC4,4.698970004336019,C[S+]([O-])Cc1ccc(C(=O)Nc2cccnc2C(=O)NCC2CCOCC2)c2ccccc12
45559,CHEMBL2407952,ZOISCDMRVZOZGO-YYDJUVGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC=CC=C1C(C/C(=N\O)/C2=CC(=NC=C2)C)C3=CC=C(C=C3)C(=O)O,4.301029995663981,Cc1cc(/C(CC(c2ccc(C(=O)O)cc2)c2ccccc2C)=N/O)ccn1
45568,CHEMBL3137456,ZOLYPCMRQHGHCV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1800.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=CC=N4,5.7447274948966935,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ncccn3)CC2)cc1
45570,CHEMBL85080,ZOLZTTFIWWNGSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,>,500.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CC4=CC=C(C=C4)C5=CC=C(C=C5)Cl)CC(=O)N(C)C,6.301029995663981,CN(C)C(=O)CN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
45575,CHEMBL445691,ZOMSEVOHXDVESY-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,COC(=O)CCCN[C@@H](CN1C(=O)C(=CN(C1=O)CC2=C(C=CC=C2F)C(F)(F)F)C3=CC=CC=C3Cl)C4=CC=CC=C4,6.886056647693163,COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
45584,CHEMBL3664687,ZORFLCOGTJKNGG-UDNBHOFDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)CC(C)(C)OC)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4,4.301029995663981,COC(C)(C)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O
45586,CHEMBL1813474,ZOSQXAHBYHMVCA-GXFFZTMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,9170.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,C1C[C@H]2CNC[C@]2(C1)C3=CC(=C(C=C3)Cl)Cl,5.037630664329979,Clc1ccc([C@]23CCC[C@H]2CNC3)cc1Cl
45587,CHEMBL1813475,ZOSQXAHBYHMVCA-MFKMUULPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,C1C[C@@H]2CNC[C@@]2(C1)C3=CC(=C(C=C3)Cl)Cl,5.301029995663981,Clc1ccc([C@@]23CCC[C@@H]2CNC3)cc1Cl
45589,CHEMBL2040854,ZOSVRRQXIOFCKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CN=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,4.301029995663981,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(=O)[nH]cn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1
45606,CHEMBL521523,ZOZCBLGQKDOWFZ-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18798607.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of biphenyl piperazines as novel and long acting muscarinic acetylcholine receptor antagonists.,J. Med. Chem.,PUBLICATION,,C[C@H]1CN(CCN1)CC2=CC(=CC=C2)C3=C(C=CC(=C3)CNC(=O)C4=CC=CC(=C4)CC5CCNCC5)F,5.0,C[C@H]1CN(Cc2cccc(-c3cc(CNC(=O)c4cccc(CC5CCNCC5)c4)ccc3F)c2)CCN1
45622,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,23300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,4.632644078973981,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
45632,CHEMBL3673938,ZPELTGPUSIGURF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320649,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)F)F)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4F)nc3F)c2c1
45633,CHEMBL3673938,ZPELTGPUSIGURF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320693,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)F)F)N=C1,5.301029995663981,Cc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4F)nc3F)c2c1
45643,CHEMBL2036653,ZPGZREGNFRDDSM-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450133.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C(=O)CN3CCN(CC3)C(=O)OC,4.522878745280337,COC(=O)N1CCN(CC(=O)c2ccc(OCCCN3CCC[C@H]3C)cc2)CC1
45656,CHEMBL1910111,ZPJLWUGRTVIDEI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)OC)C3=C(C=C(C=C3)Cl)Cl)CN,4.769551078621726,COC(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
45658,CHEMBL2338472,ZPKQAKFFLWOJGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C=C(C=N2)OC3=C(C=C(C=C3)NS(=O)(=O)C4=C(C=C(C=C4)Cl)Cl)Cl,5.585026652029182,O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl
45664,CHEMBL458242,ZPOFECDYIXUBJD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CN=C3)OC)C,4.7447274948966935,COc1cncc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1
45674,CHEMBL2179217,ZPUAIXYROPYWKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23006002.0,IC50,=,6460.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,CC1=CN(C2=C1C=C(C=C2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C,5.189767482004916,COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1
45677,CHEMBL1761530,ZPWZLFQVLHYFSM-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC(=O)O)C6CC6)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC(=O)O)CC2)c1
45678,CHEMBL1761530,ZPWZLFQVLHYFSM-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC(=O)O)C6CC6)Cl,4.301029995663981,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC(=O)O)CC2)c1
45688,CHEMBL1092495,ZQADELCMZHYIPT-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H](C1=NC=C(C=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C,5.0,C[C@@H](c1ccc(F)cn1)c1c(CCN(C)C)sc2ccccc12
45692,CHEMBL1651219,ZQBPXBADOJMCRU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23009245.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,C1CCC(C1)N2C(=O)C3=C(S2)C=C(C=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O,4.6020599913279625,O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl
45695,CHEMBL479419,ZQBXYQUUWVYTEK-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)NC5=CC=CC=C5,4.920818753952375,C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccccc4)CC3)cc2)C[C@@H](C)N1
45696,CHEMBL479419,ZQBXYQUUWVYTEK-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C[C@@H]1CN(C[C@@H](N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)NC5=CC=CC=C5,4.769551078621726,C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccccc4)CC3)cc2)C[C@@H](C)N1
45710,CHEMBL1095439,ZQLGJARKBUVURE-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCCO,5.721246399047171,Cc1cc(N2CCN(CCCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
45716,CHEMBL3289806,ZQMUEFCLRDQIPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914738.0,IC50,=,14100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,PUBLICATION,,CN1CCN(CC1)C2=NC3=C(C=C2)N=C(N3CC(C4=C(C=C(C=C4)C(F)(F)F)Cl)O)N,4.85078088734462,CN1CCN(c2ccc3nc(N)n(CC(O)c4ccc(C(F)(F)F)cc4Cl)c3n2)CC1
45718,CHEMBL1271427,ZQNGHWKIWRZPIR-GUIVANKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(C[C@@H]1NC2=CC=CC(=N2)C(F)(F)F)C(=O)OC3C4CC5CC3CC(C5)(C4)C(=O)N,5.318758762624412,NC(=O)C12CC3CC(C1)C(OC(=O)N1CC[C@@H](Nc4cccc(C(F)(F)F)n4)C1)C(C3)C2
45727,CHEMBL3137464,ZQRDCRBEVYHLGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CCC(C(=O)C)N1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3,5.0,CCC(C(C)=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
45735,CHEMBL2070138,ZQSONULFAWDAJO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC=C3,4.698970004336019,CCCS(=O)(=O)c1ccc2nc(-c3ccccc3)[nH]c2c1
45736,CHEMBL514209,ZQSUXBCZQKUSDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(C1)C(=O)NCC(=O)NC(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,4.301029995663981,O=C(CNC(=O)C1CCCC1)NC(c1ccccc1)c1ccc(Cl)cc1
45741,CHEMBL556449,ZQXPNWSXFWKXRZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,=,72000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC1N2C=CN=C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,4.142667503568732,Fc1ccc(Cn2c(N3CCC(n4ccnc4)CC3)nc3ccccc32)cc1
45745,CHEMBL2151164,ZQYDYFCAHHBFKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22650177.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent ¿-Secretase Modulators.,J. Med. Chem.,PUBLICATION,,CC1=CN(C=N1)C2=C(N=C(C=C2)NC3=C4C(=CC=C3)N(C(=N4)C5=CC=C(C=C5)F)C)OC,5.5376020021010435,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1
45746,CHEMBL2151164,ZQYDYFCAHHBFKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22650177.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent ¿-Secretase Modulators.,J. Med. Chem.,PUBLICATION,,CC1=CN(C=N1)C2=C(N=C(C=C2)NC3=C4C(=CC=C3)N(C(=N4)C5=CC=C(C=C5)F)C)OC,5.060480747381382,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1
45747,CHEMBL2151164,ZQYDYFCAHHBFKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25454273.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Anilinotriazoles as potent gamma secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(C=N1)C2=C(N=C(C=C2)NC3=C4C(=CC=C3)N(C(=N4)C5=CC=C(C=C5)F)C)OC,5.5376020021010435,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1
45748,CHEMBL2151164,ZQYDYFCAHHBFKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25454273.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Anilinotriazoles as potent gamma secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CN(C=N1)C2=C(N=C(C=C2)NC3=C4C(=CC=C3)N(C(=N4)C5=CC=C(C=C5)F)C)OC,5.060480747381382,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1
45751,CHEMBL3110076,ZRAMOXHZLIIJGI-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24294923.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Piperazine oxadiazole inhibitors of acetyl-CoA carboxylase.,J. Med. Chem.,PUBLICATION,,CCOC1=CC(=C(C=C1)N2CCN([C@H](C2)C)C3=NOC(=N3)C4(CCC4)NC(=O)C)C,4.6020599913279625,CCOc1ccc(N2CCN(c3noc(C4(NC(C)=O)CCC4)n3)[C@@H](C)C2)c(C)c1
45752,CHEMBL1078595,ZRAVHLYAOHIXOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC2=C1C=CC(=C2)NS(=O)(=O)C3=CN=C(C=C3)N4CCOCC4)CC5=CC=NN5,5.096910013008056,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1ccn[nH]1)CC2)c1ccc(N2CCOCC2)nc1
45753,CHEMBL1078595,ZRAVHLYAOHIXOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CN(CCC2=C1C=CC(=C2)NS(=O)(=O)C3=CN=C(C=C3)N4CCOCC4)CC5=CC=NN5,5.096910013008056,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1ccn[nH]1)CC2)c1ccc(N2CCOCC2)nc1
45755,CHEMBL478229,ZRBPKVXRBNGQTN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCC(C1=CC=CC=C1)NC(=O)CNC(=O)C2=CC=C(C=C2)F,4.301029995663981,CCC(NC(=O)CNC(=O)c1ccc(F)cc1)c1ccccc1
45756,CHEMBL2448729,ZRBUGCYDIVWFQV-JFLMPSFJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,CC1=C(SC(=N1)C2=CC=CC=C2)C(=O)NC3=C(C=CC(=C3)/C(=N/OC)/C)N4C=CN=C4,6.0,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2sc(-c3ccccc3)nc2C)c1
45762,CHEMBL2043327,ZREIKOVBKPAVMW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)NC=N4)C5=CC=C(C=C5)C6CCCCC6,4.3979400086720375,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(C3CCCCC3)cc1)C(=O)N2c1cc(=O)[nH]cn1
45777,CHEMBL3331508,ZRNXFPVASWCYKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,C1C(CN1)CN(CC2=CC=CC=C2Cl)C3=CC=CC=C3.C(=O)(C(F)(F)F)O,6.920818753952375,Clc1ccccc1CN(CC1CNC1)c1ccccc1
45789,CHEMBL3699325,ZRSYWCIWUUCJFJ-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7630.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC=CC=C8,5.117475462045119,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
45790,CHEMBL3318472,ZRTNLOXFIFZGMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2Cl)C3=C(C=CC=C3Cl)C(F)(F)F,5.301029995663981,O=C1CC(c2c(Cl)cccc2C(F)(F)F)CC(O)=C1Sc1ccccc1Cl
45817,CHEMBL376359,ZSBOMTDTBDDKMP-OAHLLOKOSA-N,ALOGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21186796.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.,J. Med. Chem.,PUBLICATION,,CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N,5.0,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O
45819,CHEMBL376359,ZSBOMTDTBDDKMP-OAHLLOKOSA-N,ALOGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N,4.522878745280337,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O
45834,CHEMBL270902,ZSEJKLXYMYILHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,C1=CC(=C(C=C1Cl)Cl)C(CN2C=CN=C2)OC3=C(C=C(C=C3)Cl)Cl,7.221848749616356,Clc1ccc(OC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
45835,CHEMBL2387601,ZSFXNHSRMWAYAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)CCC2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=CC=CC=C5Cl,4.522878745280337,O=c1[nH]c2cc(CCc3ccccc3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
45841,CHEMBL3422009,ZSIQAOCNFRWDNJ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C6=C(C=C(C=C6)F)F,4.721246399047171,C[C@@H]1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1
45842,CHEMBL3422009,ZSIQAOCNFRWDNJ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C6=C(C=C(C=C6)F)F,4.721246399047171,C[C@@H]1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1
45843,CHEMBL1270835,ZSIZOKHLIKKQIV-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ß-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)[C@@](N=C1N)(C2=CC=C(C=C2)OC(F)F)C3=CC(=C(C=C3)F)C#CCCCF,6.045757490560675,CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2ccc(F)c(C#CCCCF)c2)N=C1N
45860,CHEMBL2181890,ZSKDOJWDZUSTHX-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)C[C@@H]2NC[C@H]([C@H](CC4=CC(=CC=C4)C5=NC=CO5)NC(=O)COC)O,7.0,COCC(=O)N[C@@H](Cc1cccc(-c2ncco2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
45884,CHEMBL2087639,ZSUZJBBHPTXKIV-SFHVURJKSA-N,ARMENIASPIROLE A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22921279.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Armeniaspiroles, a new class of antibacterials: antibacterial activities and total synthesis of 5-chloro-Armeniaspirole A.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCCCCCC1=C(C=CC2=C1O[C@]3(C2=O)C(=C(C(=O)N3C)Cl)Cl)O,5.0,CCCCCCc1c(O)ccc2c1O[C@]1(C2=O)C(Cl)=C(Cl)C(=O)N1C
45885,CHEMBL2158297,ZSVFWIDDNJEWEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)CC4=CC=NC=C4)NC(=O)C5=NC=C(N5)C#N,6.0,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccncc4)CC3)cc2C2=CCCCC2)[nH]1
45902,CHEMBL2338473,ZTGVHNBZFLSODQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,C1=CC=C2C(=C1)C=C(C=N2)OC3=C(C=C(C=C3)NS(=O)(=O)C4=C(C=C(C=C4)Cl)Cl)F,5.0,O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)c(F)c1)c1ccc(Cl)cc1Cl
45906,CHEMBL2348856,ZTKGGBYPPJDSRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,CC(C)(CO)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)Cl)C,5.154901959985743,Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)CO)c3n2)c2ccc(Cl)cc21
45910,CHEMBL1631859,ZTMGYWMZJBHXBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20971004.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC=CC(=C3)C4=CC(=NC=C4)C,5.721246399047171,Cc1cc(-c2cccc(C3=Nc4cc(C)c(C(F)(F)F)cc4NC(=O)C3)c2)ccn1
45911,CHEMBL3645217,ZTMKPXUZAMIYCW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,221.0,NM,221145,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. Inhibition assay using P450 CYP enzymes.,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,PATENT,,C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=C(C=C3)O)C4=CC=C(C=C4)NC(=O)CCC(=O)O,6.655607726314889,O=C(O)CCC(=O)Nc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cc1
45916,CHEMBL2204469,ZTPOWDSDKMQVBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22651823.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Diazine Indole Acetic Acids as Potent, Selective, and Orally Bioavailable Antagonists of Chemoattractant Receptor Homologous Molecule Expressed on Th2 Cells (CRTH2) for the Treatment of Allergic Inflammatory Diseases.",J. Med. Chem.,PUBLICATION,,CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)CC3=NN(C(=O)C=C3)CC4=C(C=C(C=C4)F)F,4.795880017344075,Cc1c(Cc2ccc(=O)n(Cc3ccc(F)cc3F)n2)c2cc(F)ccc2n1CC(=O)O
45922,CHEMBL231620,ZTSJUQOBFLZJMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,360.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C5=NC=C(N5)C,6.443697499232713,Cc1cnc(-c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)[nH]1
45923,CHEMBL1272208,ZTSMFALKIKFNQE-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ¿-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1C[C@@H]2COC[C@@H](N2S(=O)(=O)C3=CC=C(C=C3)Cl)C4(CC4)OC(=O)N5CCC6(CC5)CC(=O)N6,7.522878745280337,O=C1CC2(CCN(C(=O)OC3([C@H]4COC[C@@H](CC5CC5)N4S(=O)(=O)c4ccc(Cl)cc4)CC3)CC2)N1
45924,CHEMBL3126842,ZTTKEBYSXUCBSE-VSBZUFFNSA-N,BECLABUVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24397558.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.",J. Med. Chem.,PUBLICATION,,CN1CC2CCC(C1)N2C(=O)[C@]34C[C@H]3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8,4.3979400086720375,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21
45931,CHEMBL3581146,ZTXPZKBYVPEULR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,COC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)F,5.42021640338319,COc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1
45932,CHEMBL1080473,ZTYNKXLNXRQPMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)C4=CC=CC=C4)C(=C(N3)C)C,5.180456064458132,Cc1cccc(C)c1CNc1nc(-c2ccccc2)cc2c(C)c(C)[nH]c12
45933,CHEMBL1080473,ZTYNKXLNXRQPMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)C4=CC=CC=C4)C(=C(N3)C)C,5.113509274827518,Cc1cccc(C)c1CNc1nc(-c2ccccc2)cc2c(C)c(C)[nH]c12
45939,CHEMBL376487,ZUDPNSAXFSEWCD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19945870.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of human liver CYP3A4,Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)N[C@@H](CC4=CNC5=C4C=C(C=C5)O)C6=CSC=N6)N=C2C7=COC=C7,6.3979400086720375,O=C(N[C@@H](Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1
45940,CHEMBL376487,ZUDPNSAXFSEWCD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20185309.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)N[C@@H](CC4=CNC5=C4C=C(C=C5)O)C6=CSC=N6)N=C2C7=COC=C7,6.356547323513812,O=C(N[C@@H](Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1
45947,CHEMBL3699322,ZUEWAKQVCILIJO-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2130.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,CN1C=C(C2=CC=CC(=C21)CN3C[C@H]4N([C@H](C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC(=CC=C7)C(=O)NC8=CC=CC=C8,5.671620396561262,C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cccc(C(=O)Nc6ccccc6)c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1
45948,CHEMBL603197,ZUFPYCGWUXYDBH-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C2C(=NN1)C=NC(=N2)C3=C(N=CC(=C3)OC[C@H](CC4=CNC5=CC=CC=C54)N)C6=COC=C6,5.886056647693163,Cc1[nH]nc2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12
45953,CHEMBL2436224,ZULRMJWNHUYYOE-DYRPNGKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,C[C@H]1[C@@H](C(=O)N(C2=C(N1C(=O)CS(=O)(=O)C)C=C(C=C2)C#N)CC3=C(C=CC4=CC=CC=C43)C)NC(=O)[C@H](C)NC.Cl,4.301029995663981,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)[C@H]1C
45960,CHEMBL2440626,ZUOJEWXMTBAQSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC(=CC=C1)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CN=C3,5.366531544420414,Cc1cccc(NC(=O)c2cc(Cl)cc(Oc3cncnc3)c2)n1
45967,CHEMBL168538,ZURGVSINFPSAAI-WPCLDFDBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)[C@H](C)CNCCC6=CC7=C(C=C6)N=CN7)C,7.0,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3nc[nH]c3c2)c1
45971,CHEMBL3359019,ZURQJVZWXQJVGJ-ZSOGYDGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25210858.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2CN(C[C@@H]2CC1C3=CC=CC=C3C(F)(F)F)C(=O)NC4=C(C=C(C=C4)Cl)C(=O)O,4.301029995663981,O=C(O)c1cc(Cl)ccc1NC(=O)N1C[C@H]2CC(c3ccccc3C(F)(F)F)C[C@H]2C1
45972,CHEMBL3318415,ZUUIXGIFVWOUQU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2Cl)C3=CC=CC=C3,5.301029995663981,O=C1CC(c2ccccc2)CC(O)=C1Sc1ccccc1Cl
45980,CHEMBL204772,ZUXHCWNSICPUJO-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC2=CC=CC=C2N1CC3=C(C4=C(S3)N(C(=O)N(C4=O)C)CC(C)C)C(=O)N5CC[C@H](C5)O,4.301029995663981,Cc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C
45989,CHEMBL3219283,ZUZXFEFLTIBJAB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,MedChemComm,PUBLICATION,,CN(C)CC1=CC2=C(S1)NC(=O)C3=C2C(=CC=C3)O.Br,3.6989700043360187,CN(C)Cc1cc2c([nH]c(=O)c3cccc(O)c32)s1
45990,CHEMBL2013052,ZVASRANJKNGBRB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22365751.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C(=O)N1CCC(CC1)OC2=CC3=C(C=C2)OC4(CC3)CCN(CC4)C5CCC5,4.522878745280337,CC(C)C(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
45995,CHEMBL2041164,ZVCMQZNPBWGCEG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CSC(=C6)C(=O)O,4.301029995663981,COc1cc(N2C(=O)N(c3ccc(-c4csc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
46003,CHEMBL270272,ZVJJJFLRYHVRLN-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,COC(=O)[C@H](CC1=CN=CN1)NCC2=CC=CC=C2,5.823908740944319,COC(=O)[C@H](Cc1cnc[nH]1)NCc1ccccc1
46009,CHEMBL147806,ZVMMVSSEAMUNGI-UHFFFAOYSA-N,GSK369796,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,CC(C)(C)NCC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,4.0,CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O
46024,CHEMBL524054,ZVSBBBUKPZBFMP-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,C[C@H]1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4SN=C5N)C,5.3979400086720375,Cc1ccc2c(N)nsc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1
46033,CHEMBL441136,ZVXDTQBHPOHGTP-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CNC,5.187086643357144,CNCC(=O)N[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
46040,CHEMBL3217125,ZVZMRARBCRQHQT-COZJCMDMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045321.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C=C(N=C1)C(=O)N(CC2=CC(=CC=C2)Cl)C3CCC(CC3)N.Cl.Cl.Cl,5.0,Cn1cnc(C(=O)N(Cc2cccc(Cl)c2)C2CCC(N)CC2)c1
46049,CHEMBL270193,ZWBUEQUTXFJDFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCCN)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,4.6020599913279625,CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
46050,CHEMBL270193,ZWBUEQUTXFJDFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCCN)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,4.6020599913279625,CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
46051,CHEMBL270193,ZWBUEQUTXFJDFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCCN)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,4.568636235841013,CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
46059,CHEMBL2018910,ZWFGREILWFKZPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,CC(C)(C)CSC1=NC2=C(N1)C=C(C=C2)OC,4.301029995663981,COc1ccc2nc(SCC(C)(C)C)[nH]c2c1
46063,CHEMBL585498,ZWGZFELFBFJIHY-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=C2C=NC=C3)C(=O)C4=CC=CC=C4,5.031517051446065,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccncc12
46064,CHEMBL585498,ZWGZFELFBFJIHY-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,C[C@@H]1CN(CCN1C(=O)C(=O)C2=CNC3=C2C=NC=C3)C(=O)C4=CC=CC=C4,4.7447274948966935,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccncc12
46070,CHEMBL1923502,ZWIXEQBDJMFCMN-DHHNQDMHSA-N,ULIMORELIN HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106937.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.,J. Med. Chem.,PUBLICATION,,C[C@@H]1CN[C@H](C(=O)N([C@@H](C(=O)N[C@@H](C(=O)NCCCC2=CC=CC=C2O1)CC3=CC=C(C=C3)F)C)C)C4CC4.O.Cl,5.619788758288394,C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1
46075,CHEMBL549595,ZWLGQCPYBKFAIX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,2020.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CN1CC(C2=CC=CC=C2)NC(=O)NC3CCN(CC3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,5.694648630553377,Cc1nccn1CC(NC(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)c1ccccc1
46083,CHEMBL494305,ZWPJNBTUVZEJGC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,CC1=C(C2=C(C=C1)C(=NO2)NC)C3=CC4=CN=NC(=C4C=C3)NC(C)C,4.6020599913279625,CNc1noc2c(-c3ccc4c(NC(C)C)nncc4c3)c(C)ccc12
46091,CHEMBL1784172,ZWQSPUPMQMBACD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19772287.0,IC50,>,63095.73,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli by fluorimetric assay,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,PUBLICATION,,CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC4CC4,4.200000030616179,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cn1
46097,CHEMBL1082158,ZWVCUFJZBBAOFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20138761.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.",Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC1NC(=O)C2=CC(=C(C=C2)Cl)NC3=C4C=NN(C4=CN=N3)C5=C(C=CC=C5F)F,4.568636235841013,O=C(NC1CC1)c1ccc(Cl)c(Nc2nncc3c2cnn3-c2c(F)cccc2F)c1
46098,CHEMBL1835785,ZWVLHXRFHSCJTO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C(=O)C2CCCC2C(=N1)C3=CC=C(C=C3)OCCCN4CCCCC4,4.522878745280337,CN1N=C(c2ccc(OCCCN3CCCCC3)cc2)C2CCCC2C1=O
46099,CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134929.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BFC in vitro by 50%,Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCOCC5,6.301029995663981,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
46100,CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134929.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BzRes in vitro by 50%,Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCOCC5,5.275724130399211,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
46101,CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCOCC5,9.301029995663981,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
46102,CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCOCC5,7.301029995663981,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
46103,CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BzRes as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCOCC5,5.275724130399211,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
46104,CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCOCC5,6.301029995663981,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
46105,CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCOCC5,6.301029995663981,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
46111,CHEMBL559251,ZWZGWXZGAUJLHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3,5.0,CN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1
46116,CHEMBL1289395,ZXGHIZDLSIWWGJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20952195.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1C2=C(CCNC2)C3=C1C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5,4.920818753952375,Cn1c2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc31)CCNC2
46122,CHEMBL64894,ZXJXZNDDNMQXFV-UHFFFAOYSA-M,GENTIAN VIOLET,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3633.7,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],5.439650931106894,CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1
46128,CHEMBL1766172,ZXKRGWHSNSRDIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,CC(C)C(C1=CC=C(C=C1)C2=CC=CC=C2)(C3=CN=CN3)O,5.431798275933005,CC(C)C(O)(c1ccc(-c2ccccc2)cc1)c1cnc[nH]1
46130,CHEMBL352806,ZXKTYOLDPJDWSF-DCWSAZFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)[C@H](C)CNCCC6=CC7=C(N=C6)N=CN7)C,5.3979400086720375,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2cnc3nc[nH]c3c2)c1
46132,CHEMBL3137481,ZXMMFXLTPVVJOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CC(C)C(CN1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)O,4.698970004336019,CC(C)C(O)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
46133,CHEMBL2048487,ZXMWWEOFNKCIIA-LILXYRQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,C1CC1C2=CC=C(C=C2)CC3=CC(=CC=C3)[C@@H]4C[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO,4.481486060122112,OC[C@H]1C[C@@H](c2cccc(Cc3ccc(C4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O
46134,CHEMBL2048487,ZXMWWEOFNKCIIA-LILXYRQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,76000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,C1CC1C2=CC=C(C=C2)CC3=CC(=CC=C3)[C@@H]4C[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO,4.119186407719209,OC[C@H]1C[C@@H](c2cccc(Cc3ccc(C4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O
46138,CHEMBL3137466,ZXNRMVMIMUJMGG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2600.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,CS(=O)(=O)N1CCC(CC1)N(C2=CC=C(C=C2)Cl)C3=CN=CC=C3,5.585026652029182,CS(=O)(=O)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1
46144,CHEMBL393788,ZXOJJZQNCXSKSG-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C[C@@H](C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)[C@@H](CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCCN,4.795880017344075,CC(C)C[C@H](NCCCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
46149,CHEMBL210780,ZXPSJDOWBKNEAW-VGSWGCGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CCN(C)[C@H](C)[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3,5.769551078621726,CCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
46161,CHEMBL1094509,ZXUHVJGJAIGPRR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC,5.301029995663981,COc1ccc(Cn2c(C3CCCN(C)C3)nc3ccccc32)cc1
46191,CHEMBL2170617,ZXZKBUDCPJISJW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,CN1C=CN=C1C(=O)N2CCC(CC2)C3=C(C=C(C=C3)C(=O)N=C(N)N)C(F)(F)F,4.585026652029182,Cn1ccnc1C(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
46194,CHEMBL181385,ZYAKTISGGAZUDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)OC(C)(C)C)N4C=CN=C4)N(C)C,7.3979400086720375,CC(C(c1ccc2cc(OCc3ccc(OC(C)(C)C)cc3)ccc2c1)n1ccnc1)N(C)C
46195,CHEMBL181385,ZYAKTISGGAZUDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,580.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)OC(C)(C)C)N4C=CN=C4)N(C)C,6.236572006437063,CC(C(c1ccc2cc(OCc3ccc(OC(C)(C)C)cc3)ccc2c1)n1ccnc1)N(C)C
46218,CHEMBL1631858,ZYGZDPKEZBLAHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20971004.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC=CC(=C3)C4=CC=NC=C4,6.698970004336019,Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-c3ccncc3)c1)=N2
46224,CHEMBL3289034,ZYKFIVCTYFMUFH-WGSAOQKQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24794746.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.",Bioorg. Med. Chem.,PUBLICATION,,C1CC(CCC1C(=O)NC2=CC(=CC(=C2)OC3=CC=C(C=C3)C(=N)N)OC4=CC=C(C=C4)C(=N)N)N,4.522878745280337,N=C(N)c1ccc(Oc2cc(NC(=O)C3CCC(N)CC3)cc(Oc3ccc(C(=N)N)cc3)c2)cc1
46240,CHEMBL469227,ZYOIQICRHUXCRL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21189020.0,IC50,=,2770.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17ß-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,PUBLICATION,,C1=CC=C(C=C1)C2=C(C=CC3=C2C=CC(=C3)C4=CC(=CC=C4)O)O,5.557520230935552,Oc1cccc(-c2ccc3c(-c4ccccc4)c(O)ccc3c2)c1
46256,CHEMBL2348780,ZYTXTXAMMDTYDQ-DGEXFFLYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23498916.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"VBP15: Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.",Bioorg. Med. Chem.,PUBLICATION,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@]1(C(=O)CO)O)C)C,4.301029995663981,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO
46262,CHEMBL3673978,ZYUJERAVFWUVMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320656,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=C(C=C(C=N1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)Cl)F)F,5.0,COc1ncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)cc1F
46263,CHEMBL3673978,ZYUJERAVFWUVMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320700,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,COC1=C(C=C(C=N1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)Cl)F)F,5.0,COc1ncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)cc1F
46270,CHEMBL3664706,ZYZZURDCHBXQIE-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,C[C@@H](C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4F,4.301029995663981,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O
46271,CHEMBL3601185,ZZAHNCINSQBRFG-TYFWRSTJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=CC(=CC(=N1)C)NC2=NC=C(C(=N2)N[C@@H]3C[C@@H]([C@H]([C@H]3O)O)CO)C4=NC(=CS4)C5=CC=CC=C5,4.301029995663981,Cc1cc(Nc2ncc(-c3nc(-c4ccccc4)cs3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)cc(C)n1
46284,CHEMBL2070937,ZZFJAPGUVYMXSJ-IAGOWNOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22858142.0,IC50,>,31622.78,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,C1CC[C@H]([C@@H](C1)C(=O)NC2(CC2)C#N)C(=O)N3CCN(CC3)C4=NC5=CC=CC=C5S4,4.499999953328896,N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4ccccc4s3)CC2)CC1
46286,CHEMBL3577447,ZZFWSQSQNZHVSP-TWPACSSBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25990761.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins by LC-MS/MS method,Novel Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) from Natural Product Anabaenopeptin.,J. Med. Chem.,PUBLICATION,,CC1(C2CCC1(CC2NC(=O)[C@@H](CC3CCCCC3)NC(=O)N[C@@H](CCCCN)C(=O)O)C)C.Cl,5.187086643357144,CC12CCC(C(NC(=O)[C@@H](CC3CCCCC3)NC(=O)N[C@@H](CCCCN)C(=O)O)C1)C2(C)C
46287,CHEMBL3577447,ZZFWSQSQNZHVSP-TWPACSSBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25990761.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate incubated for 30 mins by LC-MS/MS method,Novel Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) from Natural Product Anabaenopeptin.,J. Med. Chem.,PUBLICATION,,CC1(C2CCC1(CC2NC(=O)[C@@H](CC3CCCCC3)NC(=O)N[C@@H](CCCCN)C(=O)O)C)C.Cl,4.823908740944319,CC12CCC(C(NC(=O)[C@@H](CC3CCCCC3)NC(=O)N[C@@H](CCCCN)C(=O)O)C1)C2(C)C
46288,CHEMBL3115161,ZZGMOZUZSAJAML-MCQSSSDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C)C1=NC(=CS1)CN(C2CC2)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,6.6777807052660805,CC(C)c1nc(CN(C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)C2CC2)cs1
46289,CHEMBL180805,ZZGVWUSRXVYCSC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C)N3C=CN=C3)N(C)C,6.657577319177793,CC(C(c1ccc2cc(OCC(C)(C)C)ccc2c1)n1ccnc1)N(C)C
46290,CHEMBL180805,ZZGVWUSRXVYCSC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C)N3C=CN=C3)N(C)C,6.154901959985743,CC(C(c1ccc2cc(OCC(C)(C)C)ccc2c1)n1ccnc1)N(C)C
46293,CHEMBL1076536,ZZHNYWHADLVCEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)COC2=CC=CN3C2=NC(=C3C)C,5.259637310505756,Cc1cccc(C)c1COc1cccn2c(C)c(C)nc12
46294,CHEMBL1076536,ZZHNYWHADLVCEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=C(C(=CC=C1)C)COC2=CC=CN3C2=NC(=C3C)C,4.7447274948966935,Cc1cccc(C)c1COc1cccn2c(C)c(C)nc12
46314,CHEMBL3087341,ZZNSTCGBKYJVKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ¿-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,CC1=NC=CC(=C1)C2=CC=C(C=C2)NC(=O)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,4.568636235841013,Cc1cc(-c2ccc(NC(=O)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
46356,CHEMBL2181641,ZZYHXFCSTOMZNZ-LICLKQGHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)/C=C/C(=O)O)C(=C1C5=CN=C(C=C5)OC)C6CCCC6,5.823908740944319,COc1ccc(-c2c(C3CCCC3)c3ccc(C(=O)NC4(C(=O)Nc5ccc(/C=C/C(=O)O)cc5)CCC4)cc3n2C)cn1
46359,CHEMBL3359014,ZZZMLSGWZAFWHA-QKDCVEJESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25210858.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,PUBLICATION,,C1[C@@H]2CN(C[C@@H]2CC1C3=CC=CC=C3C(F)(F)F)C(=O)NC4=CC=CC=C4C(=O)O,4.552841968657781,O=C(O)c1ccccc1NC(=O)N1C[C@H]2CC(c3ccccc3C(F)(F)F)C[C@H]2C1
